10150268.xml	DDI-MedLine.d78.s0	NO_SECTION	NO_SETID	9
The fluoroquinolones for urinary tract infections: a review.
1	0	2	O	The
2	4	19	U-UNK	fluoroquinolones
3	21	23	O	for
4	25	31	O	urinary
5	33	37	O	tract
6	39	48	O	infections
7	49	49	O	:
8	51	51	O	a
9	53	58	O	review
NULL

10150268.xml	DDI-MedLine.d78.s1	NO_SECTION	NO_SETID	24
The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
1	0	2	O	The
2	4	19	U-UNK	fluoroquinolones
3	21	23	O	are
4	25	25	O	a
5	27	33	O	rapidly
6	35	41	O	growing
7	43	47	O	class
8	49	50	O	of
9	52	62	U-UNK	antibiotics
10	64	67	O	with
11	69	69	O	a
12	71	75	O	broad
13	77	84	O	spectrum
14	86	87	O	of
15	89	96	O	activity
16	98	104	O	against
17	106	109	O	gram
18	111	118	O	negative
19	120	122	O	and
20	124	127	O	some
21	129	132	O	gram
22	134	141	O	positive
23	143	149	O	aerobic
24	151	158	O	bacteria
NULL

10150268.xml	DDI-MedLine.d78.s2	NO_SECTION	NO_SETID	45
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
1	0	4	O	These
2	6	11	O	agents
3	12	12	O	,
4	14	22	O	including
5	24	34	U-UNK	norfloxacin
6	35	35	O	,
7	37	49	U-UNK	ciprofloxacin
8	50	50	O	,
9	52	60	U-UNK	ofloxacin
10	61	61	O	,
11	63	70	U-UNK	enoxacin
12	71	71	O	,
13	73	75	O	and
14	77	88	U-UNK	lomefloxacin
15	89	89	O	,
16	91	94	O	have
17	96	99	O	been
18	101	111	O	extensively
19	113	119	O	studied
20	121	123	O	and
21	125	128	O	have
22	130	141	O	demonstrated
23	143	150	O	efficacy
24	152	154	O	and
25	156	161	O	safety
26	163	170	O	profiles
27	172	181	O	comparable
28	183	184	O	to
29	186	190	O	those
30	192	193	O	of
31	195	199	O	other
32	201	211	O	traditional
33	213	218	O	agents
34	220	222	O	for
35	224	226	O	the
36	228	236	O	treatment
37	238	239	O	of
38	241	251	O	complicated
39	253	254	O	or
40	256	268	O	uncomplicated
41	270	276	O	urinary
42	278	282	O	tract
43	284	293	O	infections
44	295	297	O	and
45	299	309	O	prostatitis
NULL

10150268.xml	DDI-MedLine.d78.s3	NO_SECTION	NO_SETID	27
Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used.
1	0	9	O	Advantages
2	11	17	O	offered
3	19	20	O	by
4	22	25	O	this
5	27	31	O	class
6	33	34	O	of
7	36	46	U-UNK	antibiotics
8	48	54	O	include
9	56	62	O	optimal
10	64	79	O	pharmacokinetics
11	80	80	O	,
12	82	94	O	effectiveness
13	96	102	O	against
14	104	112	O	multidrug
15	114	122	O	resistant
16	124	132	O	organisms
17	133	133	O	,
18	135	137	O	and
19	139	142	O	oral
20	144	157	O	administration
21	159	162	O	even
22	164	167	O	when
23	169	178	O	parenteral
24	180	190	U-UNK	antibiotics
25	192	194	O	are
26	196	204	O	generally
27	206	209	O	used
NULL

10150268.xml	DDI-MedLine.d78.s4	NO_SECTION	NO_SETID	9
The fluoroquinolones are also extensively used in urologic surgery.
1	0	2	O	The
2	4	19	U-UNK	fluoroquinolones
3	21	23	O	are
4	25	28	O	also
5	30	40	O	extensively
6	42	45	O	used
7	47	48	O	in
8	50	57	O	urologic
9	59	65	O	surgery
NULL

10226677.xml	DDI-MedLine.d80.s0	NO_SECTION	NO_SETID	8
Progestin-only oral contraception: a comprehensive review.
1	0	8	O	Progestin
2	10	13	O	only
3	15	18	O	oral
4	20	32	O	contraception
5	33	33	O	:
6	35	35	O	a
7	37	49	O	comprehensive
8	51	56	O	review
NULL

10226677.xml	DDI-MedLine.d80.s1	NO_SECTION	NO_SETID	42
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	18	O	provide
5	20	30	O	information
6	32	34	O	for
7	36	38	O	the
8	40	50	O	appropriate
9	52	58	O	package
10	60	65	O	insert
11	67	74	O	labeling
12	76	77	O	of
13	79	87	B-UNK	progestin
14	89	92	I-UNK	only
15	94	97	I-UNK	oral
16	99	112	L-UNK	contraceptives
17	115	117	U-UNK	POC
18	120	121	O	in
19	123	125	O	the
20	127	128	O	US
21	129	129	O	,
22	131	131	O	a
23	133	145	O	comprehensive
24	147	152	O	review
25	154	156	O	was
26	158	161	O	made
27	163	164	O	of
28	166	175	U-UNK	norgestrel
29	178	182	O	0.075
30	184	185	O	mg
31	188	190	O	and
32	192	204	U-UNK	norethindrone
33	207	210	O	0.35
34	212	213	O	mg
35	215	215	O	,
36	217	220	O	with
37	222	224	O	the
38	226	233	O	clinical
39	235	245	O	differences
40	247	255	O	indicated
41	257	261	O	where
42	263	272	O	applicable
NULL

10226677.xml	DDI-MedLine.d80.s2	NO_SECTION	NO_SETID	19
The goal of this review was to cite primary sources for virtually all research specific to POPs since 1975.
1	0	2	O	The
2	4	7	O	goal
3	9	10	O	of
4	12	15	O	this
5	17	22	O	review
6	24	26	O	was
7	28	29	O	to
8	31	34	O	cite
9	36	42	O	primary
10	44	50	O	sources
11	52	54	O	for
12	56	64	O	virtually
13	66	68	O	all
14	70	77	O	research
15	79	86	O	specific
16	88	89	O	to
17	91	94	O	POPs
18	96	100	O	since
19	102	105	O	1975
NULL

10226677.xml	DDI-MedLine.d80.s3	NO_SECTION	NO_SETID	16
Conclusions and the types of studies which support these conclusions are given for each major section.
1	0	10	O	Conclusions
2	12	14	O	and
3	16	18	O	the
4	20	24	O	types
5	26	27	O	of
6	29	35	O	studies
7	37	41	O	which
8	43	49	O	support
9	51	55	O	these
10	57	67	O	conclusions
11	69	71	O	are
12	73	77	O	given
13	79	81	O	for
14	83	86	O	each
15	88	92	O	major
16	94	100	O	section
NULL

10226677.xml	DDI-MedLine.d80.s4	NO_SECTION	NO_SETID	18
The introductory chapter discusses the advantages and disadvantages of POCs and the magnitude and prevalence of their use.
1	0	2	O	The
2	4	15	O	introductory
3	17	23	O	chapter
4	25	33	O	discusses
5	35	37	O	the
6	39	48	O	advantages
7	50	52	O	and
8	54	66	O	disadvantages
9	68	69	O	of
10	71	74	U-UNK	POCs
11	76	78	O	and
12	80	82	O	the
13	84	92	O	magnitude
14	94	96	O	and
15	98	107	O	prevalence
16	109	110	O	of
17	112	116	O	their
18	118	120	O	use
NULL

10226677.xml	DDI-MedLine.d80.s5	NO_SECTION	NO_SETID	5
Future trends are also predicted.
1	0	5	O	Future
2	7	12	O	trends
3	14	16	O	are
4	18	21	O	also
5	23	31	O	predicted
NULL

10226677.xml	DDI-MedLine.d80.s6	NO_SECTION	NO_SETID	11
Chapter 2 considers the mode of action, including ovulation prevention;
1	0	6	O	Chapter
2	8	8	O	2
3	10	18	O	considers
4	20	22	O	the
5	24	27	O	mode
6	29	30	O	of
7	32	37	O	action
8	38	38	O	,
9	40	48	O	including
10	50	58	O	ovulation
11	60	69	O	prevention
NULL

10226677.xml	DDI-MedLine.d80.s7	NO_SECTION	NO_SETID	5
suppression of midcycle gonadotropin peaks;
1	0	10	O	suppression
2	12	13	O	of
3	15	22	O	midcycle
4	24	35	O	gonadotropin
5	37	41	O	peaks
NULL

10226677.xml	DDI-MedLine.d80.s8	NO_SECTION	NO_SETID	12
changes in cervical mucus, the endometrium, and the fallopian tubes;
1	0	6	O	changes
2	8	9	O	in
3	11	18	O	cervical
4	20	24	O	mucus
5	25	25	O	,
6	27	29	O	the
7	31	41	O	endometrium
8	42	42	O	,
9	44	46	O	and
10	48	50	O	the
11	52	60	O	fallopian
12	62	66	O	tubes
NULL

10226677.xml	DDI-MedLine.d80.s9	NO_SECTION	NO_SETID	3
and clinical implications.
1	0	2	O	and
2	4	11	O	clinical
3	13	24	O	implications
NULL

10226677.xml	DDI-MedLine.d80.s10	NO_SECTION	NO_SETID	13
Chapter 3 covers pharmacology (pharmacokinetics, pharmacodynamics and potency, and clinical implications).
1	0	6	O	Chapter
2	8	8	O	3
3	10	15	O	covers
4	17	28	O	pharmacology
5	31	46	O	pharmacokinetics
6	47	47	O	,
7	49	64	O	pharmacodynamics
8	66	68	O	and
9	70	76	O	potency
10	77	77	O	,
11	79	81	O	and
12	83	90	O	clinical
13	92	103	O	implications
NULL

10226677.xml	DDI-MedLine.d80.s11	NO_SECTION	NO_SETID	36
The next chapter presents information on efficacy and pregnancy outcomes in terms of pregnancy rates, compliance and efficacy, ectopic pregnancies, the outcome of pregnancies conceived while using POCs, and fertility following discontinuation.
1	0	2	O	The
2	4	7	O	next
3	9	15	O	chapter
4	17	24	O	presents
5	26	36	O	information
6	38	39	O	on
7	41	48	O	efficacy
8	50	52	O	and
9	54	62	O	pregnancy
10	64	71	O	outcomes
11	73	74	O	in
12	76	80	O	terms
13	82	83	O	of
14	85	93	O	pregnancy
15	95	99	O	rates
16	100	100	O	,
17	102	111	O	compliance
18	113	115	O	and
19	117	124	O	efficacy
20	125	125	O	,
21	127	133	O	ectopic
22	135	145	O	pregnancies
23	146	146	O	,
24	148	150	O	the
25	152	158	O	outcome
26	160	161	O	of
27	163	173	O	pregnancies
28	175	183	O	conceived
29	185	189	O	while
30	191	195	O	using
31	197	200	U-UNK	POCs
32	201	201	O	,
33	203	205	O	and
34	207	215	O	fertility
35	217	225	O	following
36	227	241	O	discontinuation
NULL

10226677.xml	DDI-MedLine.d80.s12	NO_SECTION	NO_SETID	22
Chapter 5 focuses on metabolic effects, specifically lipid metabolism, carbohydrate metabolism and diabetes, coagulation factors, and blood pressure.
1	0	6	O	Chapter
2	8	8	O	5
3	10	16	O	focuses
4	18	19	O	on
5	21	29	O	metabolic
6	31	37	O	effects
7	38	38	O	,
8	40	51	O	specifically
9	53	57	O	lipid
10	59	68	O	metabolism
11	69	69	O	,
12	71	82	O	carbohydrate
13	84	93	O	metabolism
14	95	97	O	and
15	99	106	O	diabetes
16	107	107	O	,
17	109	119	O	coagulation
18	121	127	O	factors
19	128	128	O	,
20	130	132	O	and
21	134	138	O	blood
22	140	147	O	pressure
NULL

10226677.xml	DDI-MedLine.d80.s13	NO_SECTION	NO_SETID	26
Cardiovascular disease is considered in the next chapter, and chapter 7 presents findings on endometrial, ovarian, cervical, breast, and other cancers.
1	0	13	O	Cardiovascular
2	15	21	O	disease
3	23	24	O	is
4	26	35	O	considered
5	37	38	O	in
6	40	42	O	the
7	44	47	O	next
8	49	55	O	chapter
9	56	56	O	,
10	58	60	O	and
11	62	68	O	chapter
12	70	70	O	7
13	72	79	O	presents
14	81	88	O	findings
15	90	91	O	on
16	93	103	O	endometrial
17	104	104	O	,
18	106	112	O	ovarian
19	113	113	O	,
20	115	122	O	cervical
21	123	123	O	,
22	125	130	O	breast
23	131	131	O	,
24	133	135	O	and
25	137	141	O	other
26	143	149	O	cancers
NULL

10226677.xml	DDI-MedLine.d80.s14	NO_SECTION	NO_SETID	16
A host of other medical considerations are discussed in chapter 8, including persistent ovarian follicles;
1	0	0	O	A
2	2	5	O	host
3	7	8	O	of
4	10	14	O	other
5	16	22	O	medical
6	24	37	O	considerations
7	39	41	O	are
8	43	51	O	discussed
9	53	54	O	in
10	56	62	O	chapter
11	64	64	O	8
12	65	65	O	,
13	67	75	O	including
14	77	86	O	persistent
15	88	94	O	ovarian
16	96	104	O	follicles
NULL

10226677.xml	DDI-MedLine.d80.s15	NO_SECTION	NO_SETID	3
reproductive tract infections;
1	0	11	O	reproductive
2	13	17	O	tract
3	19	28	O	infections
NULL

10226677.xml	DDI-MedLine.d80.s16	NO_SECTION	NO_SETID	3
abnormal vaginal bleeding;
1	0	7	O	abnormal
2	9	15	O	vaginal
3	17	24	O	bleeding
NULL

10226677.xml	DDI-MedLine.d80.s18	NO_SECTION	NO_SETID	3
gestational trophoblastic disease;
1	0	10	O	gestational
2	12	24	O	trophoblastic
3	26	32	O	disease
NULL

10226677.xml	DDI-MedLine.d80.s19	NO_SECTION	NO_SETID	3
benign breast disease;
1	0	5	O	benign
2	7	12	O	breast
3	14	20	O	disease
NULL

10226677.xml	DDI-MedLine.d80.s20	NO_SECTION	NO_SETID	9
diseases of the liver, gallbladder, and bowel;
1	0	7	O	diseases
2	9	10	O	of
3	12	14	O	the
4	16	20	O	liver
5	21	21	O	,
6	23	33	O	gallbladder
7	34	34	O	,
8	36	38	O	and
9	40	44	O	bowel
NULL

10226677.xml	DDI-MedLine.d80.s21	NO_SECTION	NO_SETID	2
endocrine dysfunction;
1	0	8	O	endocrine
2	10	20	O	dysfunction
NULL

10226677.xml	DDI-MedLine.d80.s24	NO_SECTION	NO_SETID	3
sickle cell disease;
1	0	5	O	sickle
2	7	10	O	cell
3	12	18	O	disease
NULL

10226677.xml	DDI-MedLine.d80.s28	NO_SECTION	NO_SETID	24
The last 4 chapters cover interactions with drugs and laboratory tests, common side effects, breast feeding, and effective use of POCs.
1	0	2	O	The
2	4	7	O	last
3	9	9	O	4
4	11	18	O	chapters
5	20	24	O	cover
6	26	37	O	interactions
7	39	42	O	with
8	44	48	O	drugs
9	50	52	O	and
10	54	63	O	laboratory
11	65	69	O	tests
12	70	70	O	,
13	72	77	O	common
14	79	82	O	side
15	84	90	O	effects
16	91	91	O	,
17	93	98	O	breast
18	100	106	O	feeding
19	107	107	O	,
20	109	111	O	and
21	113	121	O	effective
22	123	125	O	use
23	127	128	O	of
24	130	133	U-UNK	POCs
NULL

10226677.xml	DDI-MedLine.d80.s29	NO_SECTION	NO_SETID	22
Information on precautions and contraindications, indications, use instructions, and instructions for appropriate actions after missing a pill is appended.
1	0	10	O	Information
2	12	13	O	on
3	15	25	O	precautions
4	27	29	O	and
5	31	47	O	contraindications
6	48	48	O	,
7	50	60	O	indications
8	61	61	O	,
9	63	65	O	use
10	67	78	O	instructions
11	79	79	O	,
12	81	83	O	and
13	85	96	O	instructions
14	98	100	O	for
15	102	112	O	appropriate
16	114	120	O	actions
17	122	126	O	after
18	128	134	O	missing
19	136	136	O	a
20	138	141	O	pill
21	143	144	O	is
22	146	153	O	appended
NULL

10319155.xml	DDI-MedLine.d84.s0	NO_SECTION	NO_SETID	13
Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
1	0	12	O	Antimicrobial
2	14	21	O	activity
3	23	24	O	of
4	26	34	B-UNK	Ganoderma
5	36	42	I-UNK	lucidum
6	44	50	L-UNK	extract
7	52	56	O	alone
8	58	60	O	and
9	62	63	O	in
10	65	75	O	combination
11	77	80	O	with
12	82	85	O	some
13	87	97	U-UNK	antibiotics
NULL

10319155.xml	DDI-MedLine.d84.s1	NO_SECTION	NO_SETID	42
Antimicrobial activity of GL (the aqueous extract from the carpophores of Ganoderma lucidum (FR)KARST) was tested in vitro against Gram positive and Gram negative bacteria by serial broth dilution method, and the antimicrobial activity was expressed by minimal inhibitory concentration (MIC).
1	0	12	O	Antimicrobial
2	14	21	O	activity
3	23	24	O	of
4	26	27	U-UNK	GL
5	30	32	O	the
6	34	40	O	aqueous
7	42	48	O	extract
8	50	53	O	from
9	55	57	O	the
10	59	69	O	carpophores
11	71	72	O	of
12	74	82	O	Ganoderma
13	84	90	O	lucidum
14	93	100	O	FR)KARST
15	103	105	O	was
16	107	112	O	tested
17	114	115	O	in
18	117	121	O	vitro
19	123	129	O	against
20	131	134	O	Gram
21	136	143	O	positive
22	145	147	O	and
23	149	152	O	Gram
24	154	161	O	negative
25	163	170	O	bacteria
26	172	173	O	by
27	175	180	O	serial
28	182	186	O	broth
29	188	195	O	dilution
30	197	202	O	method
31	203	203	O	,
32	205	207	O	and
33	209	211	O	the
34	213	225	O	antimicrobial
35	227	234	O	activity
36	236	238	O	was
37	240	248	O	expressed
38	250	251	O	by
39	253	259	O	minimal
40	261	270	O	inhibitory
41	272	284	O	concentration
42	287	289	O	MIC
NULL

10319155.xml	DDI-MedLine.d84.s2	NO_SECTION	NO_SETID	25
Among fifteen species of bacteria tested, the antimicrobial activity of GL was the most potent against Micrococcus luteus (MIC, 0.75 mg/ml).
1	0	4	O	Among
2	6	12	O	fifteen
3	14	20	O	species
4	22	23	O	of
5	25	32	O	bacteria
6	34	39	O	tested
7	40	40	O	,
8	42	44	O	the
9	46	58	O	antimicrobial
10	60	67	O	activity
11	69	70	O	of
12	72	73	U-UNK	GL
13	75	77	O	was
14	79	81	O	the
15	83	86	O	most
16	88	93	O	potent
17	95	101	O	against
18	103	113	O	Micrococcus
19	115	120	O	luteus
20	123	125	O	MIC
21	126	126	O	,
22	128	131	O	0.75
23	133	134	O	mg
24	135	135	O	/
25	136	137	O	ml
NULL

10319155.xml	DDI-MedLine.d84.s3	NO_SECTION	NO_SETID	36
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
1	0	1	O	To
2	3	13	O	investigate
3	15	17	O	the
4	19	25	O	effects
5	27	28	O	of
6	30	42	O	antimicrobial
7	44	55	O	combinations
8	57	58	O	of
9	60	61	U-UNK	GL
10	63	66	O	with
11	68	71	O	four
12	73	77	O	kinds
13	79	80	O	of
14	82	92	U-UNK	antibiotics
15	95	104	U-UNK	ampicillin
16	105	105	O	,
17	107	115	U-UNK	cefazolin
18	116	116	O	,
19	118	132	U-UNK	oxytetracycline
20	134	136	O	and
21	138	152	U-UNK	chloramphenicol
22	154	154	O	,
23	156	158	O	the
24	160	169	O	fractional
25	171	180	O	inhibitory
26	182	194	O	concentration
27	196	200	O	index
28	203	206	O	FICI
29	209	211	O	was
30	213	222	O	determined
31	224	225	O	by
32	227	238	O	checkerboard
33	240	244	O	assay
34	246	248	O	for
35	250	253	O	each
36	255	260	O	strain
NULL

10319155.xml	DDI-MedLine.d84.s4	NO_SECTION	NO_SETID	26
The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
1	0	2	O	The
2	4	16	O	antimicrobial
3	18	29	O	combinations
4	31	32	O	of
5	34	35	U-UNK	GL
6	37	40	O	with
7	42	45	O	four
8	47	57	U-UNK	antibiotics
9	59	66	O	resulted
10	68	69	O	in
11	71	78	O	additive
12	80	85	O	effect
13	87	88	O	in
14	90	93	O	most
15	95	103	O	instances
16	104	104	O	,
17	106	114	O	synergism
18	116	117	O	in
19	119	121	O	two
20	123	131	O	instances
21	132	132	O	,
22	134	136	O	and
23	138	147	O	antagonism
24	149	150	O	in
25	152	154	O	two
26	156	164	O	instances
NULL

10319155.xml	DDI-MedLine.d84.s5	NO_SECTION	NO_SETID	15
Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
1	0	8	O	Synergism
2	10	12	O	was
3	14	21	O	observed
4	23	26	O	when
5	28	29	U-UNK	GL
6	31	33	O	was
7	35	42	O	combined
8	44	47	O	with
9	49	57	U-UNK	cefazolin
10	59	65	O	against
11	67	74	O	Bacillus
12	76	83	O	subtilis
13	85	87	O	and
14	89	98	O	Klebsiella
15	100	106	O	oxytoca
NULL

1089034.xml	DDI-MedLine.d13.s0	NO_SECTION	NO_SETID	8
Death in amphetamine users: causes and rates.
1	0	4	O	Death
2	6	7	O	in
3	9	19	U-UNK	amphetamine
4	21	25	O	users
5	26	26	O	:
6	28	33	O	causes
7	35	37	O	and
8	39	43	O	rates
NULL

1089034.xml	DDI-MedLine.d13.s1	NO_SECTION	NO_SETID	17
The world medical literature contains 43 reports of deaths associated with amphetamines in a 35-year period.
1	0	2	O	The
2	4	8	O	world
3	10	16	O	medical
4	18	27	O	literature
5	29	36	O	contains
6	38	39	O	43
7	41	47	O	reports
8	49	50	O	of
9	52	57	O	deaths
10	59	68	O	associated
11	70	73	O	with
12	75	86	U-UNK	amphetamines
13	88	89	O	in
14	91	91	O	a
15	93	94	O	35
16	96	99	O	year
17	101	106	O	period
NULL

1089034.xml	DDI-MedLine.d13.s2	NO_SECTION	NO_SETID	30
These included seven cerebrovascular accidents, six sudden cardiac deaths, three cases of hyperpyrexia, eight poisonings of uncertain mechanism and seven cases of medical complications of intravenous injection;
1	0	4	O	These
2	6	13	O	included
3	15	19	O	seven
4	21	35	O	cerebrovascular
5	37	45	O	accidents
6	46	46	O	,
7	48	50	O	six
8	52	57	O	sudden
9	59	65	O	cardiac
10	67	72	O	deaths
11	73	73	O	,
12	75	79	O	three
13	81	85	O	cases
14	87	88	O	of
15	90	101	O	hyperpyrexia
16	102	102	O	,
17	104	108	O	eight
18	110	119	O	poisonings
19	121	122	O	of
20	124	132	O	uncertain
21	134	142	O	mechanism
22	144	146	O	and
23	148	152	O	seven
24	154	158	O	cases
25	160	161	O	of
26	163	169	O	medical
27	171	183	O	complications
28	185	186	O	of
29	188	198	O	intravenous
30	200	208	O	injection
NULL

1089034.xml	DDI-MedLine.d13.s3	NO_SECTION	NO_SETID	6
the remainder were of uncertain cause.
1	0	2	O	the
2	4	12	O	remainder
3	14	17	O	were
4	19	20	O	of
5	22	30	O	uncertain
6	32	36	O	cause
NULL

1089034.xml	DDI-MedLine.d13.s4	NO_SECTION	NO_SETID	29
In contrast, in Ontario alone, in 1972 and 1973 there were 26 deaths in amphetamine users, of which 16 were due to accident suicide or homicide.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	in
5	16	22	O	Ontario
6	24	28	O	alone
7	29	29	O	,
8	31	32	O	in
9	34	37	O	1972
10	39	41	O	and
11	43	46	O	1973
12	48	52	O	there
13	54	57	O	were
14	59	60	O	26
15	62	67	O	deaths
16	69	70	O	in
17	72	82	U-UNK	amphetamine
18	84	88	O	users
19	89	89	O	,
20	91	92	O	of
21	94	98	O	which
22	100	101	O	16
23	103	106	O	were
24	108	110	O	due
25	112	113	O	to
26	115	122	O	accident
27	124	130	O	suicide
28	132	133	O	or
29	135	142	O	homicide
NULL

1089034.xml	DDI-MedLine.d13.s5	NO_SECTION	NO_SETID	18
Of the remaining cases, two were cardiac, two hepatic and the rest were mixed drug overdose.
1	0	1	O	Of
2	3	5	O	the
3	7	15	O	remaining
4	17	21	O	cases
5	22	22	O	,
6	24	26	O	two
7	28	31	O	were
8	33	39	O	cardiac
9	40	40	O	,
10	42	44	O	two
11	46	52	O	hepatic
12	54	56	O	and
13	58	60	O	the
14	62	65	O	rest
15	67	70	O	were
16	72	76	O	mixed
17	78	81	O	drug
18	83	90	O	overdose
NULL

1089034.xml	DDI-MedLine.d13.s6	NO_SECTION	NO_SETID	18
Pulmonary granulomata, subacute hepatitis and other lesions resulting from intravenous drug use were common findings at autopsy.
1	0	8	O	Pulmonary
2	10	20	O	granulomata
3	21	21	O	,
4	23	30	O	subacute
5	32	40	O	hepatitis
6	42	44	O	and
7	46	50	O	other
8	52	58	O	lesions
9	60	68	O	resulting
10	70	73	O	from
11	75	85	O	intravenous
12	87	90	O	drug
13	92	94	O	use
14	96	99	O	were
15	101	106	O	common
16	108	115	O	findings
17	117	118	O	at
18	120	126	O	autopsy
NULL

1089034.xml	DDI-MedLine.d13.s7	NO_SECTION	NO_SETID	49
On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	18	O	the
6	20	28	O	estimated
7	30	35	O	number
8	37	38	O	of
9	40	46	O	regular
10	48	52	O	users
11	54	55	O	of
12	57	67	O	intravenous
13	69	79	U-UNK	amphetamine
14	81	82	O	in
15	84	90	O	Ontario
16	91	91	O	,
17	93	95	O	the
18	97	105	O	mortality
19	107	110	O	rate
20	112	113	O	in
21	115	118	O	such
22	120	124	O	users
23	126	127	O	is
24	129	130	O	at
25	132	136	O	least
26	138	141	O	four
27	143	147	O	times
28	149	150	O	as
29	152	155	O	high
30	157	158	O	as
31	160	161	O	in
32	163	165	O	the
33	167	173	O	general
34	175	184	O	population
35	186	187	O	of
36	189	191	O	the
37	193	196	O	same
38	198	200	O	age
39	201	201	O	,
40	203	205	O	and
41	207	208	O	is
42	210	219	O	comparable
43	221	222	O	to
44	224	227	O	that
45	229	230	O	in
46	232	241	O	alcoholics
47	243	245	O	and
48	247	252	U-UNK	heroin
49	254	260	O	addicts
NULL

1089034.xml	DDI-MedLine.d13.s8	NO_SECTION	NO_SETID	22
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	20	O	absolute
5	22	27	O	number
6	29	30	O	of
7	32	38	U-UNK	alcohol
8	40	46	O	related
9	48	53	O	deaths
10	55	56	O	is
11	58	60	O	far
12	62	68	O	greater
13	70	73	O	than
14	75	77	O	the
15	79	84	O	number
16	86	87	O	of
17	89	94	O	deaths
18	96	97	O	in
19	99	109	U-UNK	amphetamine
20	111	112	O	or
21	114	119	U-UNK	heroin
22	121	125	O	users
NULL

1089817.xml	DDI-MedLine.d50.s0	NO_SECTION	NO_SETID	6
Ascorbic acid and the common cold.
1	0	7	B-UNK	Ascorbic
2	9	12	L-UNK	acid
3	14	16	O	and
4	18	20	O	the
5	22	27	O	common
6	29	32	O	cold
NULL

1089817.xml	DDI-MedLine.d50.s1	NO_SECTION	NO_SETID	6
Evaluation of its efficacy and toxicity.
1	0	9	O	Evaluation
2	11	12	O	of
3	14	16	O	its
4	18	25	O	efficacy
5	27	29	O	and
6	31	38	O	toxicity
NULL

1089817.xml	DDI-MedLine.d50.s2	NO_SECTION	NO_SETID	26
We reviewed the clinical data relating to the efficacy and safety of pharmacologic doses of ascorbic acid in the prevention and treatment of the common cold.
1	0	1	O	We
2	3	10	O	reviewed
3	12	14	O	the
4	16	23	O	clinical
5	25	28	O	data
6	30	37	O	relating
7	39	40	O	to
8	42	44	O	the
9	46	53	O	efficacy
10	55	57	O	and
11	59	64	O	safety
12	66	67	O	of
13	69	81	O	pharmacologic
14	83	87	O	doses
15	89	90	O	of
16	92	99	B-UNK	ascorbic
17	101	104	L-UNK	acid
18	106	107	O	in
19	109	111	O	the
20	113	122	O	prevention
21	124	126	O	and
22	128	136	O	treatment
23	138	139	O	of
24	141	143	O	the
25	145	150	O	common
26	152	155	O	cold
NULL

1089817.xml	DDI-MedLine.d50.s3	NO_SECTION	NO_SETID	48
Although one study tentatively supports the hypothesis that such doses of ascorbic acid may be efficacious, a second study by the same group did not confirm the significant findings, and no clear, reproducible pattern of efficacy has emerged from the review of all the evidence.
1	0	7	O	Although
2	9	11	O	one
3	13	17	O	study
4	19	29	O	tentatively
5	31	38	O	supports
6	40	42	O	the
7	44	53	O	hypothesis
8	55	58	O	that
9	60	63	O	such
10	65	69	O	doses
11	71	72	O	of
12	74	81	B-UNK	ascorbic
13	83	86	L-UNK	acid
14	88	90	O	may
15	92	93	O	be
16	95	105	O	efficacious
17	106	106	O	,
18	108	108	O	a
19	110	115	O	second
20	117	121	O	study
21	123	124	O	by
22	126	128	O	the
23	130	133	O	same
24	135	139	O	group
25	141	143	O	did
26	145	147	O	not
27	149	155	O	confirm
28	157	159	O	the
29	161	171	O	significant
30	173	180	O	findings
31	181	181	O	,
32	183	185	O	and
33	187	188	O	no
34	190	194	O	clear
35	195	195	O	,
36	197	208	O	reproducible
37	210	216	O	pattern
38	218	219	O	of
39	221	228	O	efficacy
40	230	232	O	has
41	234	240	O	emerged
42	242	245	O	from
43	247	249	O	the
44	251	256	O	review
45	258	259	O	of
46	261	263	O	all
47	265	267	O	the
48	269	276	O	evidence
NULL

1089817.xml	DDI-MedLine.d50.s4	NO_SECTION	NO_SETID	33
Similarly, there is currently little adequate evidence on either the presence or the absence of serious adverse reactions to such doses of ascorbic acid, although many such reactions have been hypothesized.
1	0	8	O	Similarly
2	9	9	O	,
3	11	15	O	there
4	17	18	O	is
5	20	28	O	currently
6	30	35	O	little
7	37	44	O	adequate
8	46	53	O	evidence
9	55	56	O	on
10	58	63	O	either
11	65	67	O	the
12	69	76	O	presence
13	78	79	O	or
14	81	83	O	the
15	85	91	O	absence
16	93	94	O	of
17	96	102	O	serious
18	104	110	O	adverse
19	112	120	O	reactions
20	122	123	O	to
21	125	128	O	such
22	130	134	O	doses
23	136	137	O	of
24	139	146	B-UNK	ascorbic
25	148	151	L-UNK	acid
26	152	152	O	,
27	154	161	O	although
28	163	166	O	many
29	168	171	O	such
30	173	181	O	reactions
31	183	186	O	have
32	188	191	O	been
33	193	204	O	hypothesized
NULL

1089817.xml	DDI-MedLine.d50.s5	NO_SECTION	NO_SETID	20
The unrestricted use of ascorbic acid for these purposes cannot be advocated on the basis of the evidence currently available.
1	0	2	O	The
2	4	15	O	unrestricted
3	17	19	O	use
4	21	22	O	of
5	24	31	B-UNK	ascorbic
6	33	36	L-UNK	acid
7	38	40	O	for
8	42	46	O	these
9	48	55	O	purposes
10	57	62	O	cannot
11	64	65	O	be
12	67	75	O	advocated
13	77	78	O	on
14	80	82	O	the
15	84	88	O	basis
16	90	91	O	of
17	93	95	O	the
18	97	104	O	evidence
19	106	114	O	currently
20	116	124	O	available
NULL

10959916.xml	DDI-MedLine.d26.s0	NO_SECTION	NO_SETID	12
Optimal designs for the individual and joint exposure general logistic regression models.
1	0	6	O	Optimal
2	8	14	O	designs
3	16	18	O	for
4	20	22	O	the
5	24	33	O	individual
6	35	37	O	and
7	39	43	O	joint
8	45	52	O	exposure
9	54	60	O	general
10	62	69	O	logistic
11	71	80	O	regression
12	82	87	O	models
NULL

10959916.xml	DDI-MedLine.d26.s1	NO_SECTION	NO_SETID	17
Interest in administering compounds in combination lies both in enhancing efficacious effects and in limiting adverse effects.
1	0	7	O	Interest
2	9	10	O	in
3	12	24	O	administering
4	26	34	O	compounds
5	36	37	O	in
6	39	49	O	combination
7	51	54	O	lies
8	56	59	O	both
9	61	62	O	in
10	64	72	O	enhancing
11	74	84	O	efficacious
12	86	92	O	effects
13	94	96	O	and
14	98	99	O	in
15	101	108	O	limiting
16	110	116	O	adverse
17	118	124	O	effects
NULL

10959916.xml	DDI-MedLine.d26.s2	NO_SECTION	NO_SETID	31
Although much statistical work has focused on developing mathematical functions to model the joint dose-response curves, relatively little work exists in regard to designing experiments for assessing joint action.
1	0	7	O	Although
2	9	12	O	much
3	14	24	O	statistical
4	26	29	O	work
5	31	33	O	has
6	35	41	O	focused
7	43	44	O	on
8	46	55	O	developing
9	57	68	O	mathematical
10	70	78	O	functions
11	80	81	O	to
12	83	87	O	model
13	89	91	O	the
14	93	97	O	joint
15	99	102	O	dose
16	104	111	O	response
17	113	118	O	curves
18	119	119	O	,
19	121	130	O	relatively
20	132	137	O	little
21	139	142	O	work
22	144	149	O	exists
23	151	152	O	in
24	154	159	O	regard
25	161	162	O	to
26	164	172	O	designing
27	174	184	O	experiments
28	186	188	O	for
29	190	198	O	assessing
30	200	204	O	joint
31	206	211	O	action
NULL

10959916.xml	DDI-MedLine.d26.s3	NO_SECTION	NO_SETID	22
A variety of parametric dose-response models based on either the normal or logistic probability distribution have been proposed in the literature.
1	0	0	O	A
2	2	8	O	variety
3	10	11	O	of
4	13	22	O	parametric
5	24	27	O	dose
6	29	36	O	response
7	38	43	O	models
8	45	49	O	based
9	51	52	O	on
10	54	59	O	either
11	61	63	O	the
12	65	70	O	normal
13	72	73	O	or
14	75	82	O	logistic
15	84	94	O	probability
16	96	107	O	distribution
17	109	112	O	have
18	114	117	O	been
19	119	126	O	proposed
20	128	129	O	in
21	131	133	O	the
22	135	144	O	literature
NULL

10959916.xml	DDI-MedLine.d26.s4	NO_SECTION	NO_SETID	28
These models are typically nonlinear in the parameters, and as such, a nonlinear weighted least squares approach can be employed for the purpose of designing experiments.
1	0	4	O	These
2	6	11	O	models
3	13	15	O	are
4	17	25	O	typically
5	27	35	O	nonlinear
6	37	38	O	in
7	40	42	O	the
8	44	53	O	parameters
9	54	54	O	,
10	56	58	O	and
11	60	61	O	as
12	63	66	O	such
13	67	67	O	,
14	69	69	O	a
15	71	79	O	nonlinear
16	81	88	O	weighted
17	90	94	O	least
18	96	102	O	squares
19	104	111	O	approach
20	113	115	O	can
21	117	118	O	be
22	120	127	O	employed
23	129	131	O	for
24	133	135	O	the
25	137	143	O	purpose
26	145	146	O	of
27	148	156	O	designing
28	158	168	O	experiments
NULL

10959916.xml	DDI-MedLine.d26.s5	NO_SECTION	NO_SETID	31
The approach is applicable across a wide variety of settings commonly associated with joint action data, including continuous and discrete responses, alternative error structures, and nonzero background response.
1	0	2	O	The
2	4	11	O	approach
3	13	14	O	is
4	16	25	O	applicable
5	27	32	O	across
6	34	34	O	a
7	36	39	O	wide
8	41	47	O	variety
9	49	50	O	of
10	52	59	O	settings
11	61	68	O	commonly
12	70	79	O	associated
13	81	84	O	with
14	86	90	O	joint
15	92	97	O	action
16	99	102	O	data
17	103	103	O	,
18	105	113	O	including
19	115	124	O	continuous
20	126	128	O	and
21	130	137	O	discrete
22	139	147	O	responses
23	148	148	O	,
24	150	160	O	alternative
25	162	166	O	error
26	168	177	O	structures
27	178	178	O	,
28	180	182	O	and
29	184	190	O	nonzero
30	192	201	O	background
31	203	210	O	response
NULL

10959916.xml	DDI-MedLine.d26.s6	NO_SECTION	NO_SETID	30
Further, designs can be expressed in terms of proportionate responses associated with the individual compounds rather than dose levels, thereby providing for results that are applicable across compounds.
1	0	6	O	Further
2	7	7	O	,
3	9	15	O	designs
4	17	19	O	can
5	21	22	O	be
6	24	32	O	expressed
7	34	35	O	in
8	37	41	O	terms
9	43	44	O	of
10	46	58	O	proportionate
11	60	68	O	responses
12	70	79	O	associated
13	81	84	O	with
14	86	88	O	the
15	90	99	O	individual
16	101	109	O	compounds
17	111	116	O	rather
18	118	121	O	than
19	123	126	O	dose
20	128	133	O	levels
21	134	134	O	,
22	136	142	O	thereby
23	144	152	O	providing
24	154	156	O	for
25	158	164	O	results
26	166	169	O	that
27	171	173	O	are
28	175	184	O	applicable
29	186	191	O	across
30	193	201	O	compounds
NULL

10959916.xml	DDI-MedLine.d26.s7	NO_SECTION	NO_SETID	26
As a precursor to this effort, optimal and minimal experimental designs for the case in which a single compound is administered have also been developed.
1	0	1	O	As
2	3	3	O	a
3	5	13	O	precursor
4	15	16	O	to
5	18	21	O	this
6	23	28	O	effort
7	29	29	O	,
8	31	37	O	optimal
9	39	41	O	and
10	43	49	O	minimal
11	51	62	O	experimental
12	64	70	O	designs
13	72	74	O	for
14	76	78	O	the
15	80	83	O	case
16	85	86	O	in
17	88	92	O	which
18	94	94	O	a
19	96	101	O	single
20	103	110	O	compound
21	112	113	O	is
22	115	126	O	administered
23	128	131	O	have
24	133	136	O	also
25	138	141	O	been
26	143	151	O	developed
NULL

10959916.xml	DDI-MedLine.d26.s8	NO_SECTION	NO_SETID	45
Although the proposed methodology for deriving experimental designs can be applied to any nonlinear regression model, primary focus is given to the additive and nonadditive independent joint action (IJA) models for individual and combined exposures proposed by Barton, Braunberg, and Friedman (1).
1	0	7	O	Although
2	9	11	O	the
3	13	20	O	proposed
4	22	32	O	methodology
5	34	36	O	for
6	38	45	O	deriving
7	47	58	O	experimental
8	60	66	O	designs
9	68	70	O	can
10	72	73	O	be
11	75	81	O	applied
12	83	84	O	to
13	86	88	O	any
14	90	98	O	nonlinear
15	100	109	O	regression
16	111	115	O	model
17	116	116	O	,
18	118	124	O	primary
19	126	130	O	focus
20	132	133	O	is
21	135	139	O	given
22	141	142	O	to
23	144	146	O	the
24	148	155	O	additive
25	157	159	O	and
26	161	171	O	nonadditive
27	173	183	O	independent
28	185	189	O	joint
29	191	196	O	action
30	199	201	O	IJA
31	204	209	O	models
32	211	213	O	for
33	215	224	O	individual
34	226	228	O	and
35	230	237	O	combined
36	239	247	O	exposures
37	249	256	O	proposed
38	258	259	O	by
39	261	266	O	Barton
40	267	267	O	,
41	269	277	O	Braunberg
42	278	278	O	,
43	280	282	O	and
44	284	291	O	Friedman
45	294	294	O	1
NULL

10978746.xml	DDI-MedLine.d69.s0	NO_SECTION	NO_SETID	21
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.
1	0	11	O	Differential
2	13	22	O	regulation
3	24	25	O	of
4	27	34	O	tyrosine
5	36	50	O	phosphorylation
6	52	53	O	in
7	55	59	O	tumor
8	61	65	O	cells
9	67	68	O	by
10	70	84	U-UNK	contortrostatin
11	85	85	O	,
12	87	87	O	a
13	89	99	O	homodimeric
14	101	111	O	disintegrin
15	112	112	O	,
16	114	116	O	and
17	118	126	O	monomeric
18	128	139	O	disintegrins
19	141	150	U-UNK	echistatin
20	152	154	O	and
21	156	165	U-UNK	flavoridin
NULL

10978746.xml	DDI-MedLine.d69.s1	NO_SECTION	NO_SETID	25
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
1	0	2	O	The
2	4	14	O	homodimeric
3	16	26	O	disintegrin
4	28	42	U-UNK	contortrostatin
5	44	46	O	was
6	48	55	O	compared
7	57	64	O	directly
8	66	67	O	to
9	69	71	O	the
10	73	81	O	monomeric
11	83	94	O	disintegrins
12	96	105	U-UNK	echistatin
13	107	109	O	and
14	111	120	U-UNK	flavoridin
15	122	124	O	for
16	126	128	O	the
17	130	136	O	ability
18	138	139	O	to
19	141	146	O	affect
20	148	154	O	protein
21	156	163	O	tyrosine
22	165	179	O	phosphorylation
23	181	182	O	in
24	184	188	O	tumor
25	190	194	O	cells
NULL

10978746.xml	DDI-MedLine.d69.s2	NO_SECTION	NO_SETID	38
It was observed that contortrostatin had a dramatic effect on the tyrosine phosphorylation status of several proteins in T24 human bladder cancer cells, including robust induction of phosphorylation of proteins in the range of 120-140 kDa.
1	0	1	O	It
2	3	5	O	was
3	7	14	O	observed
4	16	19	O	that
5	21	35	U-UNK	contortrostatin
6	37	39	O	had
7	41	41	O	a
8	43	50	O	dramatic
9	52	57	O	effect
10	59	60	O	on
11	62	64	O	the
12	66	73	O	tyrosine
13	75	89	O	phosphorylation
14	91	96	O	status
15	98	99	O	of
16	101	107	O	several
17	109	116	O	proteins
18	118	119	O	in
19	121	123	O	T24
20	125	129	O	human
21	131	137	O	bladder
22	139	144	O	cancer
23	146	150	O	cells
24	151	151	O	,
25	153	161	O	including
26	163	168	O	robust
27	170	178	O	induction
28	180	181	O	of
29	183	197	O	phosphorylation
30	199	200	O	of
31	202	209	O	proteins
32	211	212	O	in
33	214	216	O	the
34	218	222	O	range
35	224	225	O	of
36	227	229	O	120
37	231	233	O	140
38	235	237	O	kDa
NULL

10978746.xml	DDI-MedLine.d69.s3	NO_SECTION	NO_SETID	25
Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
1	0	9	U-UNK	Echistatin
2	11	15	O	alone
3	17	19	O	had
4	21	22	O	no
5	24	29	O	effect
6	31	32	O	on
7	34	41	O	tyrosine
8	43	57	O	phosphorylation
9	59	60	O	in
10	62	64	O	T24
11	66	70	O	cells
12	71	71	O	,
13	73	75	O	but
14	77	80	O	dose
15	82	92	O	dependently
16	94	101	O	inhibits
17	103	105	O	the
18	107	113	O	effects
19	115	116	O	of
20	118	132	U-UNK	contortrostatin
21	134	137	O	when
22	139	142	O	both
23	144	146	O	are
24	148	152	O	added
25	154	167	O	simultaneously
NULL

10978746.xml	DDI-MedLine.d69.s4	NO_SECTION	NO_SETID	24
Among the proteins that undergo tyrosine phosphorylation in response to contortrostatin treatment is CAS, a 130 kDa adapter protein involved in integrin signaling.
1	0	4	O	Among
2	6	8	O	the
3	10	17	O	proteins
4	19	22	O	that
5	24	30	O	undergo
6	32	39	O	tyrosine
7	41	55	O	phosphorylation
8	57	58	O	in
9	60	67	O	response
10	69	70	O	to
11	72	86	U-UNK	contortrostatin
12	88	96	O	treatment
13	98	99	O	is
14	101	103	O	CAS
15	104	104	O	,
16	106	106	O	a
17	108	110	O	130
18	112	114	O	kDa
19	116	122	O	adapter
20	124	130	O	protein
21	132	139	O	involved
22	141	142	O	in
23	144	151	O	integrin
24	153	161	O	signaling
NULL

10978746.xml	DDI-MedLine.d69.s5	NO_SECTION	NO_SETID	26
Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
1	0	9	U-UNK	Flavoridin
2	11	15	O	alone
3	17	19	O	was
4	21	25	O	found
5	27	28	O	to
6	30	33	O	have
7	35	36	O	no
8	38	43	O	effect
9	45	46	O	on
10	48	50	O	CAS
11	51	51	O	,
12	53	55	O	but
13	57	59	O	can
14	61	70	O	completely
15	72	76	O	block
16	78	92	U-UNK	contortrostatin
17	94	100	O	induced
18	102	116	O	phosphorylation
19	118	119	O	of
20	121	124	O	this
21	126	132	O	protein
22	134	135	O	in
23	137	139	O	MDA
24	141	142	O	MB
25	144	146	O	435
26	148	152	O	cells
NULL

10978746.xml	DDI-MedLine.d69.s6	NO_SECTION	NO_SETID	21
These observations strongly suggest that the homodimeric structure of contortrostatin functionally distinguishes it from other monomeric members of the disintegrin family.
1	0	4	O	These
2	6	17	O	observations
3	19	26	O	strongly
4	28	34	O	suggest
5	36	39	O	that
6	41	43	O	the
7	45	55	O	homodimeric
8	57	65	O	structure
9	67	68	O	of
10	70	84	U-UNK	contortrostatin
11	86	97	O	functionally
12	99	111	O	distinguishes
13	113	114	O	it
14	116	119	O	from
15	121	125	O	other
16	127	135	O	monomeric
17	137	143	O	members
18	145	146	O	of
19	148	150	O	the
20	152	162	O	disintegrin
21	164	169	O	family
NULL

10978751.xml	DDI-MedLine.d48.s0	NO_SECTION	NO_SETID	14
Modification of surface histidine residues abolishes the cytotoxic activity of Clostridium difficile toxin A.
1	0	11	O	Modification
2	13	14	O	of
3	16	22	O	surface
4	24	32	O	histidine
5	34	41	O	residues
6	43	51	O	abolishes
7	53	55	O	the
8	57	65	O	cytotoxic
9	67	74	O	activity
10	76	77	O	of
11	79	89	B-UNK	Clostridium
12	91	99	I-UNK	difficile
13	101	105	I-UNK	toxin
14	107	107	L-UNK	A
NULL

10978751.xml	DDI-MedLine.d48.s1	NO_SECTION	NO_SETID	10
Clostridium difficile toxin A displays both cytotoxic and enterotoxic activities.
1	0	10	B-UNK	Clostridium
2	12	20	I-UNK	difficile
3	22	26	I-UNK	toxin
4	28	28	L-UNK	A
5	30	37	O	displays
6	39	42	O	both
7	44	52	O	cytotoxic
8	54	56	O	and
9	58	68	O	enterotoxic
10	70	79	O	activities
NULL

10978751.xml	DDI-MedLine.d48.s2	NO_SECTION	NO_SETID	25
It has recently been demonstrated that toxin A exerts its cytotoxic effect by the glucosylation of the small GTP-binding proteins of the Rho family.
1	0	1	O	It
2	3	5	O	has
3	7	14	O	recently
4	16	19	O	been
5	21	32	O	demonstrated
6	34	37	O	that
7	39	43	B-UNK	toxin
8	45	45	L-UNK	A
9	47	52	O	exerts
10	54	56	O	its
11	58	66	O	cytotoxic
12	68	73	O	effect
13	75	76	O	by
14	78	80	O	the
15	82	94	O	glucosylation
16	96	97	O	of
17	99	101	O	the
18	103	107	O	small
19	109	111	O	GTP
20	113	119	O	binding
21	121	128	O	proteins
22	130	131	O	of
23	133	135	O	the
24	137	139	O	Rho
25	141	146	O	family
NULL

10978751.xml	DDI-MedLine.d48.s3	NO_SECTION	NO_SETID	18
Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A.
1	0	6	B-UNK	Diethyl
2	8	20	L-UNK	pyrocarbonate
3	21	21	O	,
4	23	24	O	at
5	26	27	O	pH
6	29	31	O	7.0
7	32	32	O	,
8	34	36	O	was
9	38	41	O	used
10	43	44	O	to
11	46	55	O	chemically
12	57	62	O	modify
13	64	70	O	exposed
14	72	80	O	histidine
15	82	89	O	residues
16	91	92	O	on
17	94	98	B-UNK	toxin
18	100	100	L-UNK	A
NULL

10978751.xml	DDI-MedLine.d48.s4	NO_SECTION	NO_SETID	23
Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
1	0	11	O	Modification
2	13	14	O	of
3	16	20	B-UNK	toxin
4	22	22	L-UNK	A
5	24	27	O	with
6	29	35	B-UNK	diethyl
7	37	49	L-UNK	pyrocarbonate
8	51	59	O	abolished
9	61	64	O	both
10	66	68	O	its
11	70	78	O	cytotoxic
12	80	87	O	activity
13	89	91	O	and
14	93	95	O	the
15	97	103	O	ability
16	105	106	O	of
17	108	110	O	the
18	112	116	O	toxin
19	118	119	O	to
20	121	124	O	bind
21	126	127	O	Zn
22	129	137	O	Sepharose
23	139	141	O	gel
NULL

10978751.xml	DDI-MedLine.d48.s5	NO_SECTION	NO_SETID	19
Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules.
1	0	8	O	Treatment
2	10	11	O	of
3	13	17	B-UNK	toxin
4	19	19	L-UNK	A
5	21	24	O	with
6	28	31	O	14)C
7	34	40	B-UNK	diethyl
8	42	54	L-UNK	pyrocarbonate
9	56	63	O	revealed
10	65	77	O	concentration
11	79	87	O	dependent
12	89	97	O	labelling
13	99	100	O	of
14	102	110	O	histidine
15	112	119	O	residues
16	121	122	O	on
17	124	126	O	the
18	128	132	O	toxin
19	134	142	O	molecules
NULL

10978751.xml	DDI-MedLine.d48.s6	NO_SECTION	NO_SETID	11
The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	B-UNK	diethyl
5	23	35	L-UNK	pyrocarbonate
6	37	41	O	could
7	43	44	O	be
8	46	53	O	reversed
9	55	56	O	by
10	58	70	U-UNK	hydroxylamine
11	72	80	O	treatment
NULL

10978751.xml	DDI-MedLine.d48.s7	NO_SECTION	NO_SETID	16
These data suggest the modified histidine residues on toxin A are critical to its cytotoxic activity.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	21	O	the
5	23	30	O	modified
6	32	40	O	histidine
7	42	49	O	residues
8	51	52	O	on
9	54	58	B-UNK	toxin
10	60	60	L-UNK	A
11	62	64	O	are
12	66	73	O	critical
13	75	76	O	to
14	78	80	O	its
15	82	90	O	cytotoxic
16	92	99	O	activity
NULL

10978751.xml	DDI-MedLine.d48.s8	NO_SECTION	NO_SETID	14
Histidine modification had no effect on the glucosyl transferase enzyme activity of toxin A.
1	0	8	O	Histidine
2	10	21	O	modification
3	23	25	O	had
4	27	28	O	no
5	30	35	O	effect
6	37	38	O	on
7	40	42	O	the
8	44	51	O	glucosyl
9	53	63	O	transferase
10	65	70	O	enzyme
11	72	79	O	activity
12	81	82	O	of
13	84	88	B-UNK	toxin
14	90	90	L-UNK	A
NULL

10978751.xml	DDI-MedLine.d48.s9	NO_SECTION	NO_SETID	26
However, modification abolished the 'cold' binding of toxin to bovine thyroglobulin in an ELISA and reduced ligand binding activity in a rabbit erythrocyte haemagglutination assay.
1	0	6	O	However
2	7	7	O	,
3	9	20	O	modification
4	22	30	O	abolished
5	32	34	O	the
6	36	41	O	'cold'
7	43	49	O	binding
8	51	52	O	of
9	54	58	O	toxin
10	60	61	O	to
11	63	68	O	bovine
12	70	82	O	thyroglobulin
13	84	85	O	in
14	87	88	O	an
15	90	94	O	ELISA
16	96	98	O	and
17	100	106	O	reduced
18	108	113	O	ligand
19	115	121	O	binding
20	123	130	O	activity
21	132	133	O	in
22	135	135	O	a
23	137	142	O	rabbit
24	144	154	O	erythrocyte
25	156	172	O	haemagglutination
26	174	178	O	assay
NULL

10978751.xml	DDI-MedLine.d48.s10	NO_SECTION	NO_SETID	18
The data suggest that the histidine residues may be crucial to the receptor-binding activity of toxin A.
1	0	2	O	The
2	4	7	O	data
3	9	15	O	suggest
4	17	20	O	that
5	22	24	O	the
6	26	34	O	histidine
7	36	43	O	residues
8	45	47	O	may
9	49	50	O	be
10	52	58	O	crucial
11	60	61	O	to
12	63	65	O	the
13	67	74	O	receptor
14	76	82	O	binding
15	84	91	O	activity
16	93	94	O	of
17	96	100	B-UNK	toxin
18	102	102	L-UNK	A
NULL

10978751.xml	DDI-MedLine.d48.s11	NO_SECTION	NO_SETID	31
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.
1	0	6	O	Exposed
2	8	17	O	histidines
3	19	20	O	on
4	22	26	B-UNK	toxin
5	28	28	L-UNK	A
6	30	32	O	are
7	34	42	O	available
8	44	46	O	for
9	48	51	U-UNK	zinc
10	53	61	O	chelation
11	62	62	O	,
12	64	66	O	and
13	68	72	O	these
14	74	77	O	have
15	79	82	O	been
16	84	92	O	exploited
17	94	95	O	in
18	97	99	O	the
19	101	111	O	development
20	113	114	O	of
21	116	116	O	a
22	118	122	O	novel
23	124	135	O	purification
24	137	144	O	protocol
25	146	148	O	for
26	150	154	B-UNK	toxin
27	156	156	L-UNK	A
28	158	162	O	using
29	164	167	U-UNK	zinc
30	169	177	O	chelating
31	179	192	O	chromatography
NULL

11064383.xml	DDI-MedLine.d18.s0	NO_SECTION	NO_SETID	15
Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
1	0	3	O	Note
2	4	4	O	:
3	6	16	O	dissolution
4	18	19	O	of
5	21	27	O	aerosol
6	29	37	O	particles
7	39	40	O	of
8	42	51	U-UNK	budesonide
9	53	54	O	in
10	56	63	O	XXXXXXXX
11	64	64	O	,
12	66	66	O	a
13	68	72	O	model
14	74	77	B-UNK	lung
15	79	88	L-UNK	surfactant
NULL

11064383.xml	DDI-MedLine.d18.s1	NO_SECTION	NO_SETID	24
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	14	O	a
5	16	24	B-UNK	pulmonary
6	26	35	L-UNK	surfactant
7	37	43	O	extract
8	45	48	O	from
9	50	55	O	bovine
10	57	60	O	lung
11	61	61	O	,
12	63	70	O	XXXXXXXX
13	71	71	O	,
14	73	74	O	on
15	76	78	O	the
16	80	90	O	dissolution
17	92	95	O	rate
18	97	98	O	of
19	100	106	O	aerosol
20	108	116	O	particles
21	118	119	O	of
22	121	130	U-UNK	budesonide
23	132	134	O	was
24	136	145	O	determined
NULL

11064383.xml	DDI-MedLine.d18.s2	NO_SECTION	NO_SETID	29
Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.
1	0	6	O	Aerosol
2	8	16	O	particles
3	18	19	O	of
4	21	30	U-UNK	budesonide
5	32	35	O	were
6	37	45	O	generated
7	47	50	O	from
8	52	53	O	an
9	55	61	U-UNK	ethanol
10	63	70	O	solution
11	71	71	O	,
12	73	77	O	dried
13	78	78	O	,
14	80	82	O	and
15	84	92	O	collected
16	94	95	O	by
17	97	97	O	a
18	99	105	O	cascade
19	107	114	O	impactor
20	116	118	O	for
21	120	135	O	characterization
22	137	138	O	or
23	140	141	O	by
24	143	143	O	a
25	145	150	O	liquid
26	152	159	O	impinger
27	161	163	O	for
28	165	175	O	dissolution
29	177	187	O	experiments
NULL

11064383.xml	DDI-MedLine.d18.s3	NO_SECTION	NO_SETID	27
Powder x-ray diffraction, differential scanning calorimetry, differential thermal analysis, and scanning electron microscopy were used to characterize the aerosol particles and starting material.
1	0	5	O	Powder
2	7	7	O	x
3	9	11	O	ray
4	13	23	O	diffraction
5	24	24	O	,
6	26	37	O	differential
7	39	46	O	scanning
8	48	58	O	calorimetry
9	59	59	O	,
10	61	72	O	differential
11	74	80	O	thermal
12	82	89	O	analysis
13	90	90	O	,
14	92	94	O	and
15	96	103	O	scanning
16	105	112	O	electron
17	114	123	O	microscopy
18	125	128	O	were
19	130	133	O	used
20	135	136	O	to
21	138	149	O	characterize
22	151	153	O	the
23	155	161	O	aerosol
24	163	171	O	particles
25	173	175	O	and
26	177	184	O	starting
27	186	193	O	material
NULL

11064383.xml	DDI-MedLine.d18.s4	NO_SECTION	NO_SETID	16
No change in phase was detected, although the aerosol particles appeared to contain residual solvent.
1	0	1	O	No
2	3	8	O	change
3	10	11	O	in
4	13	17	O	phase
5	19	21	O	was
6	23	30	O	detected
7	31	31	O	,
8	33	40	O	although
9	42	44	O	the
10	46	52	O	aerosol
11	54	62	O	particles
12	64	71	O	appeared
13	73	74	O	to
14	76	82	O	contain
15	84	91	O	residual
16	93	99	U-UNK	solvent
NULL

11064383.xml	DDI-MedLine.d18.s5	NO_SECTION	NO_SETID	13
The dissolution rate of the aerosol particles in saline was low and variable.
1	0	2	O	The
2	4	14	O	dissolution
3	16	19	O	rate
4	21	22	O	of
5	24	26	O	the
6	28	34	O	aerosol
7	36	44	O	particles
8	46	47	O	in
9	49	54	O	saline
10	56	58	O	was
11	60	62	O	low
12	64	66	O	and
13	68	75	O	variable
NULL

11064383.xml	DDI-MedLine.d18.s6	NO_SECTION	NO_SETID	23
Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies.
1	0	7	O	XXXXXXXX
2	9	17	O	increased
3	19	21	O	the
4	23	28	O	extent
5	30	31	O	of
6	33	43	O	dissolution
7	45	46	O	of
8	48	57	U-UNK	budesonide
9	59	60	O	in
10	62	71	O	proportion
11	73	74	O	to
12	76	78	O	the
13	80	84	O	added
14	86	98	O	concentration
15	99	99	O	,
16	101	105	O	which
17	107	109	O	was
18	111	114	O	also
19	116	123	O	verified
20	125	126	O	by
21	128	138	O	equilibrium
22	140	153	O	solubilization
23	155	161	O	studies
NULL

11064383.xml	DDI-MedLine.d18.s7	NO_SECTION	NO_SETID	15
Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate.
1	0	7	O	XXXXXXXX
2	9	12	O	also
3	14	22	O	increased
4	24	27	O	rate
5	29	30	O	of
6	32	42	O	dissolution
7	43	43	O	,
8	45	46	O	in
9	48	48	O	a
10	50	55	O	manner
11	57	63	O	similar
12	65	66	O	to
13	68	73	B-UNK	sodium
14	75	81	I-UNK	dodecyl
15	83	89	L-UNK	sulfate
NULL

11064383.xml	DDI-MedLine.d18.s8	NO_SECTION	NO_SETID	22
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
1	0	7	O	Analysis
2	9	10	O	of
3	12	14	O	the
4	16	28	O	concentration
5	30	31	O	of
6	33	42	U-UNK	budesonide
7	44	52	O	following
8	54	72	O	ultracentrifugation
9	74	82	O	indicated
10	84	87	O	that
11	89	93	O	there
12	95	96	O	is
13	98	102	O	rapid
14	104	116	O	equilibration
15	118	119	O	of
16	121	130	U-UNK	budesonide
17	132	138	O	between
18	140	142	O	the
19	144	151	O	XXXXXXXX
20	153	155	O	and
21	157	163	O	aqueous
22	165	169	O	phase
NULL

11064383.xml	DDI-MedLine.d18.s9	NO_SECTION	NO_SETID	23
These results show that lung surfactant has the potential of enhancing the rate and extent of dissolution of drugs administered to the lung.
1	0	4	O	These
2	6	12	O	results
3	14	17	O	show
4	19	22	O	that
5	24	27	B-UNK	lung
6	29	38	L-UNK	surfactant
7	40	42	O	has
8	44	46	O	the
9	48	56	O	potential
10	58	59	O	of
11	61	69	O	enhancing
12	71	73	O	the
13	75	78	O	rate
14	80	82	O	and
15	84	89	O	extent
16	91	92	O	of
17	94	104	O	dissolution
18	106	107	O	of
19	109	113	O	drugs
20	115	126	O	administered
21	128	129	O	to
22	131	133	O	the
23	135	138	O	lung
NULL

11085305.xml	DDI-MedLine.d62.s0	NO_SECTION	NO_SETID	10
Activation of an effector immediate-early gene arc by methamphetamine.
1	0	9	O	Activation
2	11	12	O	of
3	14	15	O	an
4	17	24	O	effector
5	26	34	O	immediate
6	36	40	O	early
7	42	45	O	gene
8	47	49	O	arc
9	51	52	O	by
10	54	68	U-UNK	methamphetamine
NULL

11085305.xml	DDI-MedLine.d62.s1	NO_SECTION	NO_SETID	43
As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects.
1	0	1	O	As
2	3	11	O	immediate
3	13	17	O	early
4	19	23	O	genes
5	26	29	O	IEGs
6	32	34	O	are
7	36	42	O	thought
8	44	45	O	to
9	47	50	O	play
10	52	52	O	a
11	54	61	O	critical
12	63	66	O	role
13	68	69	O	in
14	71	79	O	mediating
15	81	88	O	stimulus
16	90	96	O	induced
17	98	103	O	neural
18	105	114	O	plasticity
19	115	115	O	,
20	117	119	O	IEG
21	121	128	O	response
22	130	136	O	induced
23	138	139	O	by
24	141	155	U-UNK	methamphetamine
25	158	161	U-UNK	METH
26	164	166	O	has
27	168	171	O	been
28	173	185	O	characterized
29	187	188	O	to
30	190	195	O	define
31	197	199	O	the
32	201	207	O	changes
33	209	210	O	in
34	212	215	O	gene
35	217	226	O	expression
36	228	231	O	that
37	233	235	O	may
38	237	244	O	underlie
39	246	248	O	its
40	250	253	O	long
41	255	261	O	lasting
42	263	272	O	behavioral
43	274	280	O	effects
NULL

11085305.xml	DDI-MedLine.d62.s2	NO_SECTION	NO_SETID	17
Although activation of several transcription factor IEGs has been described, little is known about effector IEGs.
1	0	7	O	Although
2	9	18	O	activation
3	20	21	O	of
4	23	29	O	several
5	31	43	O	transcription
6	45	50	O	factor
7	52	55	O	IEGs
8	57	59	O	has
9	61	64	O	been
10	66	74	O	described
11	75	75	O	,
12	77	82	O	little
13	84	85	O	is
14	87	91	O	known
15	93	97	O	about
16	99	106	O	effector
17	108	111	O	IEGs
NULL

11085305.xml	DDI-MedLine.d62.s3	NO_SECTION	NO_SETID	28
Here, we have examined whether METH administration affects expression of an effector IEG arc (activity-regulated, cytoskeleton-associated) that encodes a protein with homology to spectrin.
1	0	3	O	Here
2	4	4	O	,
3	6	7	O	we
4	9	12	O	have
5	14	21	O	examined
6	23	29	O	whether
7	31	34	U-UNK	METH
8	36	49	O	administration
9	51	57	O	affects
10	59	68	O	expression
11	70	71	O	of
12	73	74	O	an
13	76	83	O	effector
14	85	87	O	IEG
15	89	91	O	arc
16	94	101	O	activity
17	103	111	O	regulated
18	112	112	O	,
19	114	125	O	cytoskeleton
20	127	136	O	associated
21	139	142	O	that
22	144	150	O	encodes
23	152	152	O	a
24	154	160	O	protein
25	162	165	O	with
26	167	174	O	homology
27	176	177	O	to
28	179	186	O	spectrin
NULL

11085305.xml	DDI-MedLine.d62.s4	NO_SECTION	NO_SETID	47
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
1	0	4	O	Using
2	6	7	O	in
3	9	12	O	situ
4	14	26	O	hybridization
5	27	27	O	,
6	29	30	O	we
7	32	39	O	observed
8	41	44	O	that
9	46	49	U-UNK	METH
10	51	56	O	caused
11	58	58	O	a
12	60	64	O	rapid
13	66	68	O	and
14	70	78	O	transient
15	80	83	O	dose
16	85	93	O	dependent
17	95	102	O	increase
18	104	105	O	in
19	107	109	O	arc
20	111	114	O	mRNA
21	116	120	O	level
22	122	123	O	in
23	125	127	O	the
24	129	136	O	striatum
25	138	140	O	and
26	142	147	O	cortex
27	149	152	O	that
28	154	156	O	was
29	158	166	O	abolished
30	168	169	O	by
31	171	182	O	pretreatment
32	184	187	O	with
33	189	191	O	the
34	193	200	O	specific
35	202	209	O	dopamine
36	211	212	O	D1
37	214	221	O	receptor
38	223	232	O	antagonist
39	234	236	B-UNK	SCH
40	238	242	L-UNK	23390
41	244	246	O	but
42	248	250	O	not
43	252	253	O	by
44	255	256	O	an
45	258	265	B-UNK	atypical
46	267	277	L-UNK	neuroleptic
47	279	287	U-UNK	clozapine
NULL

11085305.xml	DDI-MedLine.d62.s5	NO_SECTION	NO_SETID	18
METH induced arc mRNA in layers IV and VI of the cortex which dopamine receptor are localized to.
1	0	3	U-UNK	METH
2	5	11	O	induced
3	13	15	O	arc
4	17	20	O	mRNA
5	22	23	O	in
6	25	30	O	layers
7	32	33	O	IV
8	35	37	O	and
9	39	40	O	VI
10	42	43	O	of
11	45	47	O	the
12	49	54	O	cortex
13	56	60	O	which
14	62	69	O	dopamine
15	71	78	O	receptor
16	80	82	O	are
17	84	92	O	localized
18	94	95	O	to
NULL

11085305.xml	DDI-MedLine.d62.s6	NO_SECTION	NO_SETID	29
These results suggest that D1 receptors are coupled to activation of arc gene, which may be involved in functional or structural alterations underlying neural plasticity triggered by METH.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	28	O	D1
6	30	38	O	receptors
7	40	42	O	are
8	44	50	O	coupled
9	52	53	O	to
10	55	64	O	activation
11	66	67	O	of
12	69	71	O	arc
13	73	76	O	gene
14	77	77	O	,
15	79	83	O	which
16	85	87	O	may
17	89	90	O	be
18	92	99	O	involved
19	101	102	O	in
20	104	113	O	functional
21	115	116	O	or
22	118	127	O	structural
23	129	139	O	alterations
24	141	150	O	underlying
25	152	157	O	neural
26	159	168	O	plasticity
27	170	178	O	triggered
28	180	181	O	by
29	183	186	U-UNK	METH
NULL

11085328.xml	DDI-MedLine.d104.s0	NO_SECTION	NO_SETID	19
The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	17	B-UNK	DCG
5	19	20	L-UNK	IV
6	22	24	O	and
7	26	26	B-UNK	L
8	28	30	I-UNK	CCG
9	32	32	L-UNK	1
10	34	37	O	upon
11	39	51	U-UNK	phencyclidine
12	54	56	U-UNK	PCP
13	59	65	O	induced
14	67	76	O	locomotion
15	78	80	O	and
16	82	91	O	behavioral
17	93	99	O	changes
18	101	102	O	in
19	104	107	O	mice
NULL

11085328.xml	DDI-MedLine.d104.s1	NO_SECTION	NO_SETID	11
The behavioral changes of mice induced by acute and repeated i.p.
1	0	2	O	The
2	4	13	O	behavioral
3	15	21	O	changes
4	23	24	O	of
5	26	29	O	mice
6	31	37	O	induced
7	39	40	O	by
8	42	46	O	acute
9	48	50	O	and
10	52	59	O	repeated
11	61	63	O	i.p
NULL

11085328.xml	DDI-MedLine.d104.s2	NO_SECTION	NO_SETID	13
injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior.
1	0	8	O	injection
2	10	11	O	of
3	13	25	U-UNK	phencyclidine
4	28	30	U-UNK	PCP
5	33	36	O	were
6	38	45	O	observed
7	47	48	O	by
8	50	58	O	measuring
9	60	68	O	locomotor
10	70	77	O	activity
11	79	81	O	and
12	83	93	O	stereotyped
13	95	102	O	behavior
NULL

11085328.xml	DDI-MedLine.d104.s3	NO_SECTION	NO_SETID	28
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found.
1	0	3	O	Then
2	4	4	O	,
3	6	8	O	the
4	10	16	O	effects
5	18	19	O	of
6	21	32	O	metabotropic
7	34	42	O	glutamate
8	44	51	O	receptor
9	54	58	O	mGluR
10	61	68	O	agonists
11	69	69	O	,
12	71	73	B-UNK	DCG
13	75	76	L-UNK	IV
14	78	80	O	and
15	82	82	B-UNK	L
16	84	86	I-UNK	CCG
17	88	88	L-UNK	1
18	89	89	O	,
19	91	92	O	on
20	94	96	O	the
21	98	102	O	above
22	104	113	O	behavioral
23	115	121	O	changes
24	123	129	O	induced
25	131	132	O	by
26	134	136	U-UNK	PCP
27	138	141	O	were
28	143	147	O	found
NULL

11085328.xml	DDI-MedLine.d104.s4	NO_SECTION	NO_SETID	15
The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	17	B-UNK	DCG
5	19	20	L-UNK	IV
6	22	25	O	were
7	27	30	O	very
8	32	37	O	strong
9	39	41	O	and
10	43	52	O	completely
11	54	62	O	depressed
12	64	66	O	the
13	68	70	U-UNK	PCP
14	72	78	O	induced
15	80	94	O	hyperlocomotion
NULL

11085328.xml	DDI-MedLine.d104.s5	NO_SECTION	NO_SETID	10
The effects of L-CCG-1 were not so strong.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	15	B-UNK	L
5	17	19	I-UNK	CCG
6	21	21	L-UNK	1
7	23	26	O	were
8	28	30	O	not
9	32	33	O	so
10	35	40	O	strong
NULL

11085328.xml	DDI-MedLine.d104.s6	NO_SECTION	NO_SETID	19
Repeated injection of PCP for 20 days into mice induced lower locomotor activity than that in acutely injected mice.
1	0	7	O	Repeated
2	9	17	O	injection
3	19	20	O	of
4	22	24	U-UNK	PCP
5	26	28	O	for
6	30	31	O	20
7	33	36	O	days
8	38	41	O	into
9	43	46	O	mice
10	48	54	O	induced
11	56	60	O	lower
12	62	70	O	locomotor
13	72	79	O	activity
14	81	84	O	than
15	86	89	O	that
16	91	92	O	in
17	94	100	O	acutely
18	102	109	O	injected
19	111	114	O	mice
NULL

11085328.xml	DDI-MedLine.d104.s7	NO_SECTION	NO_SETID	12
These behavioral changes may be related with the negative symptoms of schizophrenia.
1	0	4	O	These
2	6	15	O	behavioral
3	17	23	O	changes
4	25	27	O	may
5	29	30	O	be
6	32	38	O	related
7	40	43	O	with
8	45	47	O	the
9	49	56	O	negative
10	58	65	O	symptoms
11	67	68	O	of
12	70	82	O	schizophrenia
NULL

11085328.xml	DDI-MedLine.d104.s8	NO_SECTION	NO_SETID	39
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	18	O	examine
5	20	23	O	some
6	25	33	O	molecular
7	35	44	O	mechanisms
8	46	47	O	of
9	49	51	U-UNK	PCP
10	53	59	O	induced
11	61	70	O	behavioral
12	72	78	O	changes
13	79	79	O	,
14	81	88	O	Northern
15	90	93	O	blot
16	95	102	O	analysis
17	104	105	O	of
18	107	111	O	total
19	113	115	O	RNA
20	117	120	O	from
21	122	131	O	prefrontal
22	133	140	O	cortical
23	142	148	O	tissues
24	150	151	O	of
25	153	156	O	mice
26	158	164	O	treated
27	166	169	O	with
28	171	173	U-UNK	PCP
29	174	174	O	,
30	176	178	B-UNK	DCG
31	180	181	L-UNK	IV
32	182	182	O	,
33	184	186	O	and
34	188	188	B-UNK	L
35	190	192	I-UNK	CCG
36	194	194	L-UNK	1
37	196	198	O	was
38	200	206	O	carried
39	208	210	O	out
NULL

11085333.xml	DDI-MedLine.d98.s0	NO_SECTION	NO_SETID	15
Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
1	0	9	O	Behavioral
2	11	19	O	responses
3	21	22	O	to
4	24	31	O	repeated
5	33	39	U-UNK	cocaine
6	41	48	O	exposure
7	50	51	O	in
8	53	56	O	mice
9	58	68	O	selectively
10	70	73	O	bred
11	75	77	O	for
12	79	90	O	differential
13	92	102	O	sensitivity
14	104	105	O	to
15	107	119	U-UNK	pentobarbital
NULL

11085333.xml	DDI-MedLine.d98.s1	NO_SECTION	NO_SETID	40
Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization.
1	0	3	O	Mice
2	5	8	O	from
3	10	12	O	the
4	14	17	O	20th
5	19	28	O	generation
6	30	31	O	of
7	33	37	O	three
8	39	43	O	lines
9	45	55	O	divergently
10	57	64	O	selected
11	66	68	O	for
12	70	77	O	response
13	79	80	O	to
14	82	94	U-UNK	pentobarbital
15	96	102	O	induced
16	104	111	O	sedation
17	113	117	O	times
18	120	123	O	long
19	125	132	O	sedation
20	134	137	O	time
21	140	142	O	LST
22	144	144	O	,
23	146	150	O	short
24	152	159	O	sedation
25	161	164	O	time
26	167	169	O	SST
27	171	171	O	,
28	173	175	O	and
29	177	184	O	randomly
30	186	189	O	bred
31	191	197	O	control
32	200	202	O	RBC
33	206	209	O	were
34	211	214	O	used
35	216	217	O	to
36	219	223	O	study
37	225	231	U-UNK	cocaine
38	233	239	O	induced
39	241	250	O	behavioral
40	252	264	O	sensitization
NULL

11085333.xml	DDI-MedLine.d98.s2	NO_SECTION	NO_SETID	12
These lines showed variable degrees of locomotor activities in response to cocaine.
1	0	4	O	These
2	6	10	O	lines
3	12	17	O	showed
4	19	26	O	variable
5	28	34	O	degrees
6	36	37	O	of
7	39	47	O	locomotor
8	49	58	O	activities
9	60	61	O	in
10	63	70	O	response
11	72	73	O	to
12	75	81	U-UNK	cocaine
NULL

11085333.xml	DDI-MedLine.d98.s3	NO_SECTION	NO_SETID	33
At a low cocaine dose and long withdrawal period (10 mg/kg, twice a day for 5 days followed by a 14-day withdrawal), the LST mice showed tolerance development.
1	0	1	O	At
2	3	3	O	a
3	5	7	O	low
4	9	15	U-UNK	cocaine
5	17	20	O	dose
6	22	24	O	and
7	26	29	O	long
8	31	40	O	withdrawal
9	42	47	O	period
10	50	51	O	10
11	53	54	O	mg
12	55	55	O	/
13	56	57	O	kg
14	58	58	O	,
15	60	64	O	twice
16	66	66	O	a
17	68	70	O	day
18	72	74	O	for
19	76	76	O	5
20	78	81	O	days
21	83	90	O	followed
22	92	93	O	by
23	95	95	O	a
24	97	98	O	14
25	100	102	O	day
26	104	113	O	withdrawal
27	115	115	O	,
28	117	119	O	the
29	121	123	O	LST
30	125	128	O	mice
31	130	135	O	showed
32	137	145	O	tolerance
33	147	157	O	development
NULL

11085333.xml	DDI-MedLine.d98.s4	NO_SECTION	NO_SETID	19
In response to cocaine, the locomotor activities of the SST were not significantly different from the RBC group.
1	0	1	O	In
2	3	10	O	response
3	12	13	O	to
4	15	21	U-UNK	cocaine
5	22	22	O	,
6	24	26	O	the
7	28	36	O	locomotor
8	38	47	O	activities
9	49	50	O	of
10	52	54	O	the
11	56	58	O	SST
12	60	63	O	were
13	65	67	O	not
14	69	81	O	significantly
15	83	91	O	different
16	93	96	O	from
17	98	100	O	the
18	102	104	O	RBC
19	106	110	O	group
NULL

11085333.xml	DDI-MedLine.d98.s5	NO_SECTION	NO_SETID	45
At a higher dose and a shorter withdrawal period (20 mg/kg, daily for 7 days followed by a 3-day withdrawal), the SST mice showed behavioral sensitization similar to the RBC mice, but the LST mice did not develop sensitization.
1	0	1	O	At
2	3	3	O	a
3	5	10	O	higher
4	12	15	O	dose
5	17	19	O	and
6	21	21	O	a
7	23	29	O	shorter
8	31	40	O	withdrawal
9	42	47	O	period
10	50	51	O	20
11	53	54	O	mg
12	55	55	O	/
13	56	57	O	kg
14	58	58	O	,
15	60	64	O	daily
16	66	68	O	for
17	70	70	O	7
18	72	75	O	days
19	77	84	O	followed
20	86	87	O	by
21	89	89	O	a
22	91	91	O	3
23	93	95	O	day
24	97	106	O	withdrawal
25	108	108	O	,
26	110	112	O	the
27	114	116	O	SST
28	118	121	O	mice
29	123	128	O	showed
30	130	139	O	behavioral
31	141	153	O	sensitization
32	155	161	O	similar
33	163	164	O	to
34	166	168	O	the
35	170	172	O	RBC
36	174	177	O	mice
37	178	178	O	,
38	180	182	O	but
39	184	186	O	the
40	188	190	O	LST
41	192	195	O	mice
42	197	199	O	did
43	201	203	O	not
44	205	211	O	develop
45	213	225	O	sensitization
NULL

11085333.xml	DDI-MedLine.d98.s6	NO_SECTION	NO_SETID	26
The different responses in locomotor activity induced by cocaine suggest that genetic factors may play a role in determining the magnitude of response to this drug.
1	0	2	O	The
2	4	12	O	different
3	14	22	O	responses
4	24	25	O	in
5	27	35	O	locomotor
6	37	44	O	activity
7	46	52	O	induced
8	54	55	O	by
9	57	63	U-UNK	cocaine
10	65	71	O	suggest
11	73	76	O	that
12	78	84	O	genetic
13	86	92	O	factors
14	94	96	O	may
15	98	101	O	play
16	103	103	O	a
17	105	108	O	role
18	110	111	O	in
19	113	123	O	determining
20	125	127	O	the
21	129	137	O	magnitude
22	139	140	O	of
23	142	149	O	response
24	151	152	O	to
25	154	157	O	this
26	159	162	O	drug
NULL

11085333.xml	DDI-MedLine.d98.s7	NO_SECTION	NO_SETID	26
Dopamine (DA) levels did not differ significantly in either striatum (STR) or nucleus accumbens (NAC) for the cocaine-treated animals to their corresponding saline-treated controls.
1	0	7	O	Dopamine
2	10	11	O	DA
3	14	19	O	levels
4	21	23	O	did
5	25	27	O	not
6	29	34	O	differ
7	36	48	O	significantly
8	50	51	O	in
9	53	58	O	either
10	60	67	O	striatum
11	70	72	O	STR
12	75	76	O	or
13	78	84	O	nucleus
14	86	94	O	accumbens
15	97	99	O	NAC
16	102	104	O	for
17	106	108	O	the
18	110	116	U-UNK	cocaine
19	118	124	O	treated
20	126	132	O	animals
21	134	135	O	to
22	137	141	O	their
23	143	155	O	corresponding
24	157	162	O	saline
25	164	170	O	treated
26	172	179	O	controls
NULL

11085333.xml	DDI-MedLine.d98.s8	NO_SECTION	NO_SETID	25
The affinity (Kd) of D2 in the NAC decreased significantly, without changes in density (Bmax), in the cocaine-treated SST and RBC mice.
1	0	2	O	The
2	4	11	O	affinity
3	14	15	O	Kd
4	18	19	O	of
5	21	22	O	D2
6	24	25	O	in
7	27	29	O	the
8	31	33	O	NAC
9	35	43	O	decreased
10	45	57	O	significantly
11	58	58	O	,
12	60	66	O	without
13	68	74	O	changes
14	76	77	O	in
15	79	85	O	density
16	88	91	O	Bmax
17	93	93	O	,
18	95	96	O	in
19	98	100	O	the
20	102	108	U-UNK	cocaine
21	110	116	O	treated
22	118	120	O	SST
23	122	124	O	and
24	126	128	O	RBC
25	130	133	O	mice
NULL

11085333.xml	DDI-MedLine.d98.s9	NO_SECTION	NO_SETID	32
On the other hand, the density of D2 binding sites in the SST and the RBC mice in the STR was significantly increased in cocaine-treated groups without change in Kd.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	other
4	13	16	O	hand
5	17	17	O	,
6	19	21	O	the
7	23	29	O	density
8	31	32	O	of
9	34	35	O	D2
10	37	43	O	binding
11	45	49	O	sites
12	51	52	O	in
13	54	56	O	the
14	58	60	O	SST
15	62	64	O	and
16	66	68	O	the
17	70	72	O	RBC
18	74	77	O	mice
19	79	80	O	in
20	82	84	O	the
21	86	88	O	STR
22	90	92	O	was
23	94	106	O	significantly
24	108	116	O	increased
25	118	119	O	in
26	121	127	U-UNK	cocaine
27	129	135	O	treated
28	137	142	O	groups
29	144	150	O	without
30	152	157	O	change
31	159	160	O	in
32	162	163	O	Kd
NULL

11085333.xml	DDI-MedLine.d98.s10	NO_SECTION	NO_SETID	20
The LST mice did not show any changes in the Kd and Bmax in either the STR or the NAC.
1	0	2	O	The
2	4	6	O	LST
3	8	11	O	mice
4	13	15	O	did
5	17	19	O	not
6	21	24	O	show
7	26	28	O	any
8	30	36	O	changes
9	38	39	O	in
10	41	43	O	the
11	45	46	O	Kd
12	48	50	O	and
13	52	55	O	Bmax
14	57	58	O	in
15	60	65	O	either
16	67	69	O	the
17	71	73	O	STR
18	75	76	O	or
19	78	80	O	the
20	82	84	O	NAC
NULL

11085333.xml	DDI-MedLine.d98.s11	NO_SECTION	NO_SETID	40
Taken together, these findings suggest that the changes in the Kd of D2 in the NAC and the Bmax of D2 in the STR may contribute to the differences in locomotor responses to cocaine exposure in these mouse lines.
1	0	4	O	Taken
2	6	13	O	together
3	14	14	O	,
4	16	20	O	these
5	22	29	O	findings
6	31	37	O	suggest
7	39	42	O	that
8	44	46	O	the
9	48	54	O	changes
10	56	57	O	in
11	59	61	O	the
12	63	64	O	Kd
13	66	67	O	of
14	69	70	O	D2
15	72	73	O	in
16	75	77	O	the
17	79	81	O	NAC
18	83	85	O	and
19	87	89	O	the
20	91	94	O	Bmax
21	96	97	O	of
22	99	100	O	D2
23	102	103	O	in
24	105	107	O	the
25	109	111	O	STR
26	113	115	O	may
27	117	126	O	contribute
28	128	129	O	to
29	131	133	O	the
30	135	145	O	differences
31	147	148	O	in
32	150	158	O	locomotor
33	160	168	O	responses
34	170	171	O	to
35	173	179	U-UNK	cocaine
36	181	188	O	exposure
37	190	191	O	in
38	193	197	O	these
39	199	203	O	mouse
40	205	209	O	lines
NULL

11085336.xml	DDI-MedLine.d110.s0	NO_SECTION	NO_SETID	18
18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
1	0	1	B-UNK	18
2	3	21	L-UNK	Methoxycoronaridine
3	24	25	B-UNK	18
4	27	28	L-UNK	MC
5	31	33	O	and
6	35	42	U-UNK	ibogaine
7	43	43	O	:
8	45	54	O	comparison
9	56	57	O	of
10	59	71	O	antiaddictive
11	73	80	O	efficacy
12	81	81	O	,
13	83	90	O	toxicity
14	91	91	O	,
15	93	95	O	and
16	97	106	O	mechanisms
17	108	109	O	of
18	111	116	O	action
NULL

11085336.xml	DDI-MedLine.d110.s1	NO_SECTION	NO_SETID	22
18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse.
1	0	1	B-UNK	18
2	3	4	L-UNK	MC
3	5	5	O	,
4	7	7	O	a
5	9	13	O	novel
6	15	19	O	iboga
7	21	28	O	alkaloid
8	30	37	O	congener
9	38	38	O	,
10	40	41	O	is
11	43	47	O	being
12	49	57	O	developed
13	59	60	O	as
14	62	62	O	a
15	64	72	O	potential
16	74	82	O	treatment
17	84	86	O	for
18	88	95	O	multiple
19	97	101	O	forms
20	103	104	O	of
21	106	109	O	drug
22	111	115	O	abuse
NULL

11085336.xml	DDI-MedLine.d110.s2	NO_SECTION	NO_SETID	33
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;
1	0	3	O	Like
2	5	12	U-UNK	ibogaine
3	15	16	O	40
4	18	19	O	mg
5	20	20	O	/
6	21	22	O	kg
7	24	24	O	,
8	26	27	B-UNK	18
9	29	30	L-UNK	MC
10	33	34	O	40
11	36	37	O	mg
12	38	38	O	/
13	39	40	O	kg
14	43	51	O	decreases
15	53	55	O	the
16	57	67	O	intravenous
17	69	72	O	self
18	74	87	O	administration
19	89	90	O	of
20	92	99	U-UNK	morphine
21	101	103	O	and
22	105	111	U-UNK	cocaine
23	113	115	O	and
24	117	119	O	the
25	121	124	O	oral
26	126	129	O	self
27	131	144	O	administration
28	146	147	O	of
29	149	155	U-UNK	ethanol
30	157	159	O	and
31	161	168	U-UNK	nicotine
32	170	171	O	in
33	173	176	O	rats
NULL

11085336.xml	DDI-MedLine.d110.s3	NO_SECTION	NO_SETID	14
unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water).
1	0	5	O	unlike
2	7	14	U-UNK	ibogaine
3	15	15	O	,
4	17	18	B-UNK	18
5	20	21	L-UNK	MC
6	23	26	O	does
7	28	30	O	not
8	32	37	O	affect
9	39	48	O	responding
10	50	52	O	for
11	54	54	O	a
12	56	62	O	nondrug
13	64	73	O	reinforcer
14	76	80	O	water
NULL

11085336.xml	DDI-MedLine.d110.s4	NO_SECTION	NO_SETID	9
Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
1	0	3	O	Both
2	5	12	U-UNK	ibogaine
3	14	16	O	and
4	18	19	B-UNK	18
5	21	22	L-UNK	MC
6	24	33	O	ameliorate
7	35	40	U-UNK	opioid
8	42	51	O	withdrawal
9	53	57	O	signs
NULL

11085336.xml	DDI-MedLine.d110.s5	NO_SECTION	NO_SETID	27
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.
1	0	3	O	Both
2	5	12	U-UNK	ibogaine
3	14	16	O	and
4	18	19	B-UNK	18
5	21	22	L-UNK	MC
6	24	31	O	decrease
7	33	45	O	extracellular
8	47	52	O	levels
9	54	55	O	of
10	57	64	O	dopamine
11	66	67	O	in
12	69	71	O	the
13	73	79	O	nucleus
14	81	89	O	accumbens
15	90	90	O	,
16	92	94	O	but
17	96	99	O	only
18	101	108	U-UNK	ibogaine
19	110	118	O	increases
20	120	132	O	extracellular
21	134	139	O	levels
22	141	142	O	of
23	144	152	O	serotonin
24	154	155	O	in
25	157	159	O	the
26	161	167	O	nucleus
27	169	177	O	accumbens
NULL

11085336.xml	DDI-MedLine.d110.s6	NO_SECTION	NO_SETID	17
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
1	0	3	O	Both
2	5	12	U-UNK	ibogaine
3	14	16	O	and
4	18	19	B-UNK	18
5	21	22	L-UNK	MC
6	24	28	O	block
7	30	37	U-UNK	morphine
8	39	45	O	induced
9	47	49	O	and
10	51	58	U-UNK	nicotine
11	60	66	O	induced
12	68	75	O	dopamine
13	77	83	O	release
14	85	86	O	in
15	88	90	O	the
16	92	98	O	nucleus
17	100	108	O	accumbens
NULL

11085336.xml	DDI-MedLine.d110.s7	NO_SECTION	NO_SETID	9
only ibogaine enhances cocaine-induced increases in accumbal dopamine.
1	0	3	O	only
2	5	12	U-UNK	ibogaine
3	14	21	O	enhances
4	23	29	U-UNK	cocaine
5	31	37	O	induced
6	39	47	O	increases
7	49	50	O	in
8	52	59	O	accumbal
9	61	68	O	dopamine
NULL

11085336.xml	DDI-MedLine.d110.s8	NO_SECTION	NO_SETID	15
Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
1	0	3	O	Both
2	5	12	U-UNK	ibogaine
3	14	16	O	and
4	18	19	B-UNK	18
5	21	22	L-UNK	MC
6	24	30	O	enhance
7	32	34	O	the
8	36	44	O	locomotor
9	46	48	O	and
10	49	49	O	/
11	50	51	O	or
12	53	63	O	stereotypic
13	65	71	O	effects
14	73	74	O	of
15	76	85	O	stimulants
NULL

11085336.xml	DDI-MedLine.d110.s9	NO_SECTION	NO_SETID	14
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
1	0	7	U-UNK	Ibogaine
2	9	18	O	attenuates
3	19	19	O	,
4	21	23	O	but
5	25	26	B-UNK	18
6	28	29	L-UNK	MC
7	31	41	O	potentiates
8	42	42	O	,
9	44	46	O	the
10	48	52	O	acute
11	54	62	O	locomotor
12	64	70	O	effects
13	72	73	O	of
14	75	82	U-UNK	morphine
NULL

11085336.xml	DDI-MedLine.d110.s10	NO_SECTION	NO_SETID	10
both compounds attenuate morphine-induced locomotion in morphine-experienced rats.
1	0	3	O	both
2	5	13	O	compounds
3	15	23	O	attenuate
4	25	32	U-UNK	morphine
5	34	40	O	induced
6	42	51	O	locomotion
7	53	54	O	in
8	56	63	U-UNK	morphine
9	65	75	O	experienced
10	77	80	O	rats
NULL

11085336.xml	DDI-MedLine.d110.s11	NO_SECTION	NO_SETID	20
Ibogaine produces whole body tremors and, at high doses (> or = 100 mg/kg), cerebellar damage;
1	0	7	U-UNK	Ibogaine
2	9	16	O	produces
3	18	22	O	whole
4	24	27	O	body
5	29	35	O	tremors
6	37	39	O	and
7	40	40	O	,
8	42	43	O	at
9	45	48	O	high
10	50	54	O	doses
11	57	57	O	>
12	59	60	O	or
13	62	62	O	=
14	64	66	O	100
15	68	69	O	mg
16	70	70	O	/
17	71	72	O	kg
18	74	74	O	,
19	76	85	O	cerebellar
20	87	92	O	damage
NULL

11085336.xml	DDI-MedLine.d110.s12	NO_SECTION	NO_SETID	7
18-MC does not produce these effects.
1	0	1	B-UNK	18
2	3	4	L-UNK	MC
3	6	9	O	does
4	11	13	O	not
5	15	21	O	produce
6	23	27	O	these
7	29	35	O	effects
NULL

11085336.xml	DDI-MedLine.d110.s13	NO_SECTION	NO_SETID	13
Ibogaine, but not 18-MC, decreases heart rate at high doses.
1	0	7	U-UNK	Ibogaine
2	8	8	O	,
3	10	12	O	but
4	14	16	O	not
5	18	19	B-UNK	18
6	21	22	L-UNK	MC
7	23	23	O	,
8	25	33	O	decreases
9	35	39	O	heart
10	41	44	O	rate
11	46	47	O	at
12	49	52	O	high
13	54	58	O	doses
NULL

11085336.xml	DDI-MedLine.d110.s14	NO_SECTION	NO_SETID	39
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
1	0	4	O	While
2	6	7	B-UNK	18
3	9	10	L-UNK	MC
4	12	14	O	and
5	16	23	U-UNK	ibogaine
6	25	28	O	have
7	30	36	O	similar
8	38	47	O	affinities
9	49	51	O	for
10	53	57	O	kappa
11	59	64	O	opioid
12	66	68	O	and
13	70	77	O	possibly
14	79	87	O	nicotinic
15	89	97	O	receptors
16	98	98	O	,
17	100	101	B-UNK	18
18	103	104	L-UNK	MC
19	106	108	O	has
20	110	113	O	much
21	115	119	O	lower
22	121	130	O	affinities
23	132	135	O	than
24	137	144	U-UNK	ibogaine
25	146	148	O	for
26	150	153	O	NMDA
27	155	157	O	and
28	159	163	O	sigma
29	165	165	O	2
30	167	175	O	receptors
31	176	176	O	,
32	178	183	O	sodium
33	185	192	O	channels
34	193	193	O	,
35	195	197	O	and
36	199	201	O	the
37	203	203	O	5
38	205	206	O	HT
39	208	218	O	transporter
NULL

11085336.xml	DDI-MedLine.d110.s15	NO_SECTION	NO_SETID	21
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.
1	0	3	O	Both
2	5	6	B-UNK	18
3	8	9	L-UNK	MC
4	11	13	O	and
5	15	22	U-UNK	ibogaine
6	24	26	O	are
7	28	38	O	sequestered
8	40	41	O	in
9	43	45	O	fat
10	47	49	O	and
11	50	50	O	,
12	52	55	O	like
13	57	64	U-UNK	ibogaine
14	65	65	O	,
15	67	68	B-UNK	18
16	70	71	L-UNK	MC
17	73	80	O	probably
18	82	84	O	has
19	86	87	O	an
20	89	94	O	active
21	96	105	O	metabolite
NULL

11085336.xml	DDI-MedLine.d110.s16	NO_SECTION	NO_SETID	22
The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.
1	0	2	O	The
2	4	7	O	data
3	9	15	O	suggest
4	17	20	O	that
5	22	23	B-UNK	18
6	25	26	L-UNK	MC
7	28	30	O	has
8	32	32	O	a
9	34	41	O	narrower
10	43	50	O	spectrum
11	52	53	O	of
12	55	61	O	actions
13	63	65	O	and
14	67	70	O	will
15	72	75	O	have
16	77	77	O	a
17	79	91	O	substantially
18	93	99	O	greater
19	101	111	O	therapeutic
20	113	117	O	index
21	119	122	O	than
22	124	131	U-UNK	ibogaine
NULL

1109248.xml	DDI-MedLine.d106.s0	NO_SECTION	NO_SETID	8
Clinical implications of warfarin interactions with five sedatives.
1	0	7	O	Clinical
2	9	20	O	implications
3	22	23	O	of
4	25	32	U-UNK	warfarin
5	34	45	O	interactions
6	47	50	O	with
7	52	55	O	five
8	57	65	U-UNK	sedatives
NULL

1109248.xml	DDI-MedLine.d106.s1	NO_SECTION	NO_SETID	30
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
1	0	2	O	The
2	4	12	O	intensity
3	13	13	O	,
4	15	24	O	uniformity
5	26	28	O	and
6	30	33	O	time
7	35	40	O	course
8	42	43	O	of
9	45	57	U-UNK	anticoagulant
10	59	70	O	interference
11	72	73	O	by
12	75	87	U-UNK	phenobarbital
13	88	88	O	,
14	90	101	U-UNK	secobarbital
15	102	102	O	,
16	104	115	U-UNK	glutethimide
17	116	116	O	,
18	118	124	B-UNK	chloral
19	126	132	L-UNK	hydrate
20	134	136	O	and
21	138	149	U-UNK	methaqualone
22	151	154	O	were
23	156	169	O	systematically
24	171	182	O	investigated
25	184	185	O	in
26	187	188	O	16
27	190	197	O	patients
28	199	207	O	receiving
29	209	216	U-UNK	coumarin
30	218	224	O	therapy
NULL

1109248.xml	DDI-MedLine.d106.s2	NO_SECTION	NO_SETID	20
Each subject received an individualized fixed daily dose of warfarin and served as his own pre- and postsedative treatment control.
1	0	3	O	Each
2	5	11	O	subject
3	13	20	O	received
4	22	23	O	an
5	25	38	O	individualized
6	40	44	O	fixed
7	46	50	O	daily
8	52	55	O	dose
9	57	58	O	of
10	60	67	U-UNK	warfarin
11	69	71	O	and
12	73	78	O	served
13	80	81	O	as
14	83	85	O	his
15	87	89	O	own
16	91	93	O	pre
17	96	98	O	and
18	100	111	O	postsedative
19	113	121	O	treatment
20	123	129	O	control
NULL

1109248.xml	DDI-MedLine.d106.s3	NO_SECTION	NO_SETID	12
Prothrombin times were measured four times weekly during five long-term experiments.
1	0	10	O	Prothrombin
2	12	16	O	times
3	18	21	O	were
4	23	30	O	measured
5	32	35	O	four
6	37	41	O	times
7	43	48	O	weekly
8	50	55	O	during
9	57	60	O	five
10	62	65	O	long
11	67	70	O	term
12	72	82	O	experiments
NULL

1109248.xml	DDI-MedLine.d106.s4	NO_SECTION	NO_SETID	13
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide;
1	0	12	O	Anticoagulant
2	14	23	O	inhibition
3	25	27	O	was
4	29	36	O	observed
5	38	43	O	during
6	45	47	O	the
7	49	62	O	administration
8	64	65	O	of
9	67	79	U-UNK	phenobarbital
10	80	80	O	,
11	82	93	U-UNK	secobarbital
12	95	97	O	and
13	99	110	U-UNK	glutethimide
NULL

1109248.xml	DDI-MedLine.d106.s5	NO_SECTION	NO_SETID	17
there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone.
1	0	4	O	there
2	6	8	O	was
3	10	11	O	no
4	13	23	O	significant
5	25	30	O	change
6	32	33	O	in
7	35	45	O	prothrombin
8	47	50	O	test
9	52	58	O	results
10	60	65	O	during
11	67	69	O	the
12	71	76	O	trials
13	78	79	O	of
14	81	87	B-UNK	chloral
15	89	95	L-UNK	hydrate
16	97	99	O	and
17	101	112	U-UNK	methaqualone
NULL

1109248.xml	DDI-MedLine.d106.s6	NO_SECTION	NO_SETID	12
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
1	0	11	U-UNK	Barbiturates
2	13	15	O	and
3	17	28	U-UNK	glutethimide
4	30	35	O	should
5	37	39	O	not
6	41	42	O	be
7	44	55	O	administered
8	57	58	O	to
9	60	67	O	patients
10	69	77	O	receiving
11	79	86	B-UNK	coumarin
12	88	92	L-UNK	drugs
NULL

1109248.xml	DDI-MedLine.d106.s7	NO_SECTION	NO_SETID	19
The concurrent use of drugs from these groups is decreasing according to a survey of 200 hospital medical records.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	26	O	drugs
6	28	31	O	from
7	33	37	O	these
8	39	44	O	groups
9	46	47	O	is
10	49	58	O	decreasing
11	60	68	O	according
12	70	71	O	to
13	73	73	O	a
14	75	80	O	survey
15	82	83	O	of
16	85	87	O	200
17	89	96	O	hospital
18	98	104	O	medical
19	106	112	O	records
NULL

1109248.xml	DDI-MedLine.d106.s8	NO_SECTION	NO_SETID	19
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
1	0	6	B-UNK	Chloral
2	8	14	L-UNK	hydrate
3	16	18	O	and
4	20	31	U-UNK	methaqualone
5	33	40	O	interact
6	42	58	O	pharmacologically
7	60	63	O	with
8	65	70	O	orally
9	72	83	O	administered
10	85	97	B-UNK	anticoagulant
11	99	104	L-UNK	agents
12	105	105	O	,
13	107	109	O	but
14	111	113	O	the
15	115	120	O	effect
16	122	123	O	is
17	125	127	O	not
18	129	138	O	clinically
19	140	150	O	significant
NULL

1109248.xml	DDI-MedLine.d106.s9	NO_SECTION	NO_SETID	23
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	concluded
4	16	19	O	that
5	21	27	B-UNK	chloral
6	29	35	L-UNK	hydrate
7	37	39	O	and
8	41	52	U-UNK	methaqualone
9	54	56	O	may
10	58	59	O	be
11	61	72	O	administered
12	74	79	O	safely
13	81	87	O	without
14	89	98	O	additional
15	100	106	O	caution
16	108	109	O	in
17	111	121	O	prothrombin
18	123	126	O	test
19	128	137	O	monitoring
20	139	144	O	during
21	146	149	O	oral
22	151	163	U-UNK	anticoagulant
23	165	171	O	therapy
NULL

1109299.xml	DDI-MedLine.d77.s0	NO_SECTION	NO_SETID	16
Effects of low temperatures on microtubules in the non-myelinated axons of post-ganglionic sympathetic nerves.
1	0	6	O	Effects
2	8	9	O	of
3	11	13	O	low
4	15	26	O	temperatures
5	28	29	O	on
6	31	42	O	microtubules
7	44	45	O	in
8	47	49	O	the
9	51	53	O	non
10	55	64	O	myelinated
11	66	70	O	axons
12	72	73	O	of
13	75	78	O	post
14	80	89	O	ganglionic
15	91	101	O	sympathetic
16	103	108	O	nerves
NULL

1109299.xml	DDI-MedLine.d77.s1	NO_SECTION	NO_SETID	39
The effect of temperature changes on the number of microtubules in non-myelinated axons has been studied in cat inferior mesenteric ganglion/hypogastric nerve preparations incubated at various temperatures in Eagles minimal essential tissue culture medium in vitro.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	24	O	temperature
5	26	32	O	changes
6	34	35	O	on
7	37	39	O	the
8	41	46	O	number
9	48	49	O	of
10	51	62	O	microtubules
11	64	65	O	in
12	67	69	O	non
13	71	80	O	myelinated
14	82	86	O	axons
15	88	90	O	has
16	92	95	O	been
17	97	103	O	studied
18	105	106	O	in
19	108	110	O	cat
20	112	119	O	inferior
21	121	130	O	mesenteric
22	132	139	O	ganglion
23	140	140	O	/
24	141	151	O	hypogastric
25	153	157	O	nerve
26	159	170	O	preparations
27	172	180	O	incubated
28	182	183	O	at
29	185	191	O	various
30	193	204	O	temperatures
31	206	207	O	in
32	209	214	O	Eagles
33	216	222	O	minimal
34	224	232	O	essential
35	234	239	O	tissue
36	241	247	O	culture
37	249	254	O	medium
38	256	257	O	in
39	259	263	O	vitro
NULL

1109299.xml	DDI-MedLine.d77.s2	NO_SECTION	NO_SETID	15
At 37 degrees C the non-myelinated axons contained 28.4 plus or minus 0.8 S.E.M.
1	0	1	O	At
2	3	4	O	37
3	6	12	O	degrees
4	14	14	O	C
5	16	18	O	the
6	20	22	O	non
7	24	33	O	myelinated
8	35	39	O	axons
9	41	49	O	contained
10	51	54	O	28.4
11	56	59	O	plus
12	61	62	O	or
13	64	68	O	minus
14	70	72	O	0.8
15	74	78	O	S.E.M
NULL

1109299.xml	DDI-MedLine.d77.s3	NO_SECTION	NO_SETID	4
(54) microtubules per axon.
1	1	2	O	54
2	5	16	O	microtubules
3	18	20	O	per
4	22	25	O	axon
NULL

1109299.xml	DDI-MedLine.d77.s4	NO_SECTION	NO_SETID	19
After incubation at 0 degrees C for 4 h this number fell to 2.3 plus or minus 0.1 S.E.M.
1	0	4	O	After
2	6	15	O	incubation
3	17	18	O	at
4	20	20	O	0
5	22	28	O	degrees
6	30	30	O	C
7	32	34	O	for
8	36	36	O	4
9	38	38	O	h
10	40	43	O	this
11	45	50	O	number
12	52	55	O	fell
13	57	58	O	to
14	60	62	O	2.3
15	64	67	O	plus
16	69	70	O	or
17	72	76	O	minus
18	78	80	O	0.1
19	82	86	O	S.E.M
NULL

1109299.xml	DDI-MedLine.d77.s5	NO_SECTION	NO_SETID	11
(41) but returned to normal levels when the nerves were rewarmed.
1	1	2	O	41
2	5	7	O	but
3	9	16	O	returned
4	18	19	O	to
5	21	26	O	normal
6	28	33	O	levels
7	35	38	O	when
8	40	42	O	the
9	44	49	O	nerves
10	51	54	O	were
11	56	63	O	rewarmed
NULL

1109299.xml	DDI-MedLine.d77.s6	NO_SECTION	NO_SETID	17
This loss of microtubules on cooling the nerves and their reappearance on rewarming was a rapid process;
1	0	3	O	This
2	5	8	O	loss
3	10	11	O	of
4	13	24	O	microtubules
5	26	27	O	on
6	29	35	O	cooling
7	37	39	O	the
8	41	46	O	nerves
9	48	50	O	and
10	52	56	O	their
11	58	69	O	reappearance
12	71	72	O	on
13	74	82	O	rewarming
14	84	86	O	was
15	88	88	O	a
16	90	94	O	rapid
17	96	102	O	process
NULL

1109299.xml	DDI-MedLine.d77.s7	NO_SECTION	NO_SETID	18
it was independent of the influence of the nueronal cell body and of protein synthesis within the axon.
1	0	1	O	it
2	3	5	O	was
3	7	17	O	independent
4	19	20	O	of
5	22	24	O	the
6	26	34	O	influence
7	36	37	O	of
8	39	41	O	the
9	43	50	O	nueronal
10	52	55	O	cell
11	57	60	O	body
12	62	64	O	and
13	66	67	O	of
14	69	75	O	protein
15	77	85	O	synthesis
16	87	92	O	within
17	94	96	O	the
18	98	101	O	axon
NULL

1109299.xml	DDI-MedLine.d77.s8	NO_SECTION	NO_SETID	15
The preservation of the microtubules was improved when D2O was present in the incubation medium.
1	0	2	O	The
2	4	15	O	preservation
3	17	18	O	of
4	20	22	O	the
5	24	35	O	microtubules
6	37	39	O	was
7	41	48	O	improved
8	50	53	O	when
9	55	57	O	D2O
10	59	61	O	was
11	63	69	O	present
12	71	72	O	in
13	74	76	O	the
14	78	87	O	incubation
15	89	94	O	medium
NULL

1109299.xml	DDI-MedLine.d77.s9	NO_SECTION	NO_SETID	22
Reformed microtubules appeared to function normally with respect to their possible role in the transport of noradrenaline storage vesicles along the axons.
1	0	7	O	Reformed
2	9	20	O	microtubules
3	22	29	O	appeared
4	31	32	O	to
5	34	41	O	function
6	43	50	O	normally
7	52	55	O	with
8	57	63	O	respect
9	65	66	O	to
10	68	72	O	their
11	74	81	O	possible
12	83	86	O	role
13	88	89	O	in
14	91	93	O	the
15	95	103	O	transport
16	105	106	O	of
17	108	120	O	noradrenaline
18	122	128	O	storage
19	130	137	O	vesicles
20	139	143	O	along
21	145	147	O	the
22	149	153	O	axons
NULL

1109556.xml	DDI-MedLine.d127.s0	NO_SECTION	NO_SETID	17
Serum digoxin levels using an 125I-labelled antigen: Validation of method and observations on cardiac patients.
1	0	4	O	Serum
2	6	12	U-UNK	digoxin
3	14	19	O	levels
4	21	25	O	using
5	27	28	O	an
6	30	33	O	125I
7	35	42	O	labelled
8	44	50	O	antigen
9	51	51	O	:
10	53	62	O	Validation
11	64	65	O	of
12	67	72	O	method
13	74	76	O	and
14	78	89	O	observations
15	91	92	O	on
16	94	100	O	cardiac
17	102	109	O	patients
NULL

1109556.xml	DDI-MedLine.d127.s2	NO_SECTION	NO_SETID	28
Determinations of serum digoxin levels utilizing commercially available kits with an 125I-labelled antigen were precise and not materially different from results obtained with a 3H-labelled antigen.
1	0	13	O	Determinations
2	15	16	O	of
3	18	22	O	serum
4	24	30	U-UNK	digoxin
5	32	37	O	levels
6	39	47	O	utilizing
7	49	60	O	commercially
8	62	70	O	available
9	72	75	O	kits
10	77	80	O	with
11	82	83	O	an
12	85	88	O	125I
13	90	97	O	labelled
14	99	105	O	antigen
15	107	110	O	were
16	112	118	O	precise
17	120	122	O	and
18	124	126	O	not
19	128	137	O	materially
20	139	147	O	different
21	149	152	O	from
22	154	160	O	results
23	162	169	O	obtained
24	171	174	O	with
25	176	176	O	a
26	178	179	O	3H
27	181	188	O	labelled
28	190	196	O	antigen
NULL

1109556.xml	DDI-MedLine.d127.s4	NO_SECTION	NO_SETID	29
In order to approximate the steady state level, serum digoxin levels should be drawn either before or at least six hours following the administration of an oral tablet.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	22	O	approximate
5	24	26	O	the
6	28	33	O	steady
7	35	39	O	state
8	41	45	O	level
9	46	46	O	,
10	48	52	O	serum
11	54	60	U-UNK	digoxin
12	62	67	O	levels
13	69	74	O	should
14	76	77	O	be
15	79	83	O	drawn
16	85	90	O	either
17	92	97	O	before
18	99	100	O	or
19	102	103	O	at
20	105	109	O	least
21	111	113	O	six
22	115	119	O	hours
23	121	129	O	following
24	131	133	O	the
25	135	148	O	administration
26	150	151	O	of
27	153	154	O	an
28	156	159	O	oral
29	161	166	O	tablet
NULL

1109556.xml	DDI-MedLine.d127.s6	NO_SECTION	NO_SETID	15
Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin.
1	0	12	O	Concomitantly
2	14	18	O	given
3	20	27	B-UNK	thiazide
4	29	37	L-UNK	diuretics
5	39	41	O	did
6	43	45	O	not
7	47	55	O	interfere
8	57	60	O	with
9	62	64	O	the
10	66	75	O	absorption
11	77	78	O	of
12	80	80	O	a
13	82	87	O	tablet
14	89	90	O	of
15	92	98	U-UNK	digoxin
NULL

1109556.xml	DDI-MedLine.d127.s8	NO_SECTION	NO_SETID	28
In the digitalized patient, slow alterations in serum levels after oral administration appeared well correlated with, at least, the negative chronotropic effects of the drug.
1	0	1	O	In
2	3	5	O	the
3	7	17	O	digitalized
4	19	25	O	patient
5	26	26	O	,
6	28	31	O	slow
7	33	43	O	alterations
8	45	46	O	in
9	48	52	O	serum
10	54	59	O	levels
11	61	65	O	after
12	67	70	O	oral
13	72	85	O	administration
14	87	94	O	appeared
15	96	99	O	well
16	101	110	O	correlated
17	112	115	O	with
18	116	116	O	,
19	118	119	O	at
20	121	125	O	least
21	126	126	O	,
22	128	130	O	the
23	132	139	O	negative
24	141	152	O	chronotropic
25	154	160	O	effects
26	162	163	O	of
27	165	167	O	the
28	169	172	O	drug
NULL

1109556.xml	DDI-MedLine.d127.s10	NO_SECTION	NO_SETID	20
Maximal exercise testing, a maneuver often applied to cardiac patients, does not significantly alter the serum digoxin level.
1	0	6	O	Maximal
2	8	15	O	exercise
3	17	23	O	testing
4	24	24	O	,
5	26	26	O	a
6	28	35	O	maneuver
7	37	41	O	often
8	43	49	O	applied
9	51	52	O	to
10	54	60	O	cardiac
11	62	69	O	patients
12	70	70	O	,
13	72	75	O	does
14	77	79	O	not
15	81	93	O	significantly
16	95	99	O	alter
17	101	103	O	the
18	105	109	O	serum
19	111	117	U-UNK	digoxin
20	119	123	O	level
NULL

11114408.xml	DDI-MedLine.d135.s0	NO_SECTION	NO_SETID	15
Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
1	0	11	O	Combinations
2	13	14	O	of
3	16	24	U-UNK	clozapine
4	26	28	O	and
5	30	42	U-UNK	phencyclidine
6	43	43	O	:
7	45	51	O	effects
8	53	54	O	on
9	56	59	O	drug
10	61	74	O	discrimination
11	76	78	O	and
12	80	89	O	behavioral
13	91	100	O	inhibition
14	102	103	O	in
15	105	108	O	rats
NULL

11114408.xml	DDI-MedLine.d135.s1	NO_SECTION	NO_SETID	11
Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.
1	0	12	U-UNK	Phencyclidine
2	15	17	U-UNK	PCP
3	20	27	O	produces
4	29	43	O	psychotomimetic
5	45	51	O	effects
6	53	54	O	in
7	56	61	O	humans
8	63	66	O	that
9	68	75	O	resemble
10	77	89	O	schizophrenia
11	91	98	O	symptoms
NULL

11114408.xml	DDI-MedLine.d135.s2	NO_SECTION	NO_SETID	23
In an effort to screen compounds for antipsychotic activity, preclinical researchers have investigated whether these compounds block PCP-induced behaviors in animals.
1	0	1	O	In
2	3	4	O	an
3	6	11	O	effort
4	13	14	O	to
5	16	21	O	screen
6	23	31	O	compounds
7	33	35	O	for
8	37	49	O	antipsychotic
9	51	58	O	activity
10	59	59	O	,
11	61	71	O	preclinical
12	73	83	O	researchers
13	85	88	O	have
14	90	101	O	investigated
15	103	109	O	whether
16	111	115	O	these
17	117	125	O	compounds
18	127	131	O	block
19	133	135	U-UNK	PCP
20	137	143	O	induced
21	145	153	O	behaviors
22	155	156	O	in
23	158	164	O	animals
NULL

11114408.xml	DDI-MedLine.d135.s3	NO_SECTION	NO_SETID	35
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	present
4	15	19	O	study
5	20	20	O	,
6	22	24	O	the
7	26	33	B-UNK	atypical
8	35	47	L-UNK	antipsychotic
9	49	57	U-UNK	clozapine
10	59	61	O	was
11	63	68	O	tested
12	70	71	O	in
13	73	83	O	combination
14	85	88	O	with
15	90	91	O	an
16	93	98	O	active
17	100	103	O	dose
18	105	106	O	of
19	108	110	U-UNK	PCP
20	112	113	O	in
21	115	117	O	two
22	119	123	O	lever
23	125	128	O	drug
24	130	143	O	discrimination
25	145	147	O	and
26	149	153	O	mixed
27	155	163	O	signalled
28	165	175	O	unsignalled
29	177	188	O	differential
30	190	202	O	reinforcement
31	204	205	O	of
32	207	209	O	low
33	211	215	O	rates
34	218	220	O	DRL
35	223	232	O	procedures
NULL

11114408.xml	DDI-MedLine.d135.s4	NO_SECTION	NO_SETID	41
PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.
1	0	2	U-UNK	PCP
2	4	11	O	produced
3	13	23	O	distinctive
4	25	31	O	effects
5	33	34	O	in
6	36	39	O	each
7	41	44	O	task
8	45	45	O	:
9	47	48	O	it
10	50	60	O	substituted
11	62	64	O	for
12	66	68	O	the
13	70	77	O	training
14	79	82	O	dose
15	84	85	O	in
16	87	89	U-UNK	PCP
17	91	104	O	discrimination
18	106	108	O	and
19	110	111	O	it
20	113	121	O	increased
21	123	125	O	the
22	127	132	O	number
23	134	135	O	of
24	137	145	O	responses
25	147	150	O	with
26	152	156	O	short
27	159	160	O	<3
28	162	162	O	s
29	165	177	O	interresponse
30	179	183	O	times
31	185	186	O	as
32	188	191	O	well
33	193	194	O	as
34	196	205	O	increasing
35	207	213	O	overall
36	215	222	O	response
37	224	228	O	rates
38	230	231	O	in
39	233	235	O	the
40	237	239	O	DRL
41	241	248	O	schedule
NULL

11114408.xml	DDI-MedLine.d135.s5	NO_SECTION	NO_SETID	26
Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone.
1	0	4	O	Acute
2	6	11	O	dosing
3	13	16	O	with
4	18	26	U-UNK	clozapine
5	28	33	O	failed
6	35	36	O	to
7	38	42	O	alter
8	44	46	O	the
9	48	57	O	behavioral
10	59	65	O	effects
11	67	68	O	of
12	70	72	U-UNK	PCP
13	74	75	O	in
14	77	82	O	either
15	84	92	O	procedure
16	94	97	O	even
17	99	102	O	when
18	104	109	O	tested
19	111	112	O	up
20	114	115	O	to
21	117	121	O	doses
22	123	126	O	that
23	128	135	O	produced
24	137	151	O	pharmacological
25	153	159	O	effects
26	161	165	O	alone
NULL

11114408.xml	DDI-MedLine.d135.s6	NO_SECTION	NO_SETID	18
These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	31	O	acute
6	33	38	O	dosing
7	40	43	O	with
8	45	53	U-UNK	clozapine
9	55	59	O	would
10	61	63	O	not
11	65	70	O	affect
12	72	80	O	behaviors
13	82	85	O	most
14	87	93	O	closely
15	95	104	O	associated
16	106	109	O	with
17	111	113	U-UNK	PCP
18	115	126	O	intoxication
NULL

11114408.xml	DDI-MedLine.d135.s7	NO_SECTION	NO_SETID	20
Further, they bring into question the utility of using PCP combination procedures in animals to screen for antipsychotic potential.
1	0	6	O	Further
2	7	7	O	,
3	9	12	O	they
4	14	18	O	bring
5	20	23	O	into
6	25	32	O	question
7	34	36	O	the
8	38	44	O	utility
9	46	47	O	of
10	49	53	O	using
11	55	57	U-UNK	PCP
12	59	69	O	combination
13	71	80	O	procedures
14	82	83	O	in
15	85	91	O	animals
16	93	94	O	to
17	96	101	O	screen
18	103	105	O	for
19	107	119	O	antipsychotic
20	121	129	O	potential
NULL

11114408.xml	DDI-MedLine.d135.s8	NO_SECTION	NO_SETID	28
Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.
1	0	4	O	Since
2	6	12	O	chronic
3	14	19	O	dosing
4	21	22	O	is
5	24	31	O	required
6	33	35	O	for
7	37	47	O	therapeutic
8	49	56	O	efficacy
9	58	59	O	of
10	61	74	U-UNK	antipsychotics
11	75	75	O	,
12	77	82	O	future
13	84	90	O	studies
14	92	97	O	should
15	99	103	O	focus
16	105	106	O	on
17	108	120	O	investigation
18	122	123	O	of
19	125	131	O	chronic
20	133	138	O	dosing
21	140	146	O	effects
22	148	149	O	of
23	151	155	O	these
24	157	161	O	drugs
25	163	164	O	in
26	166	176	O	combination
27	178	181	O	with
28	183	185	U-UNK	PCP
NULL

11115418.xml	DDI-MedLine.d95.s0	NO_SECTION	NO_SETID	17
The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	27	U-UNK	resveratrol
5	29	35	O	induced
6	37	50	O	vasorelaxation
7	52	58	O	differs
8	60	61	O	in
9	63	65	O	the
10	67	76	O	mesenteric
11	78	87	O	resistance
12	89	96	O	arteries
13	98	99	O	of
14	101	104	O	lean
15	106	108	O	and
16	110	114	O	obese
17	116	119	O	rats
NULL

11115418.xml	DDI-MedLine.d95.s1	NO_SECTION	NO_SETID	7
Resveratrol has been shown to induce vasorelaxation.
1	0	10	U-UNK	Resveratrol
2	12	14	O	has
3	16	19	O	been
4	21	25	O	shown
5	27	28	O	to
6	30	35	O	induce
7	37	50	O	vasorelaxation
NULL

11115418.xml	DDI-MedLine.d95.s2	NO_SECTION	NO_SETID	24
In this study, we investigated the mechanism(s) of resveratrol-induced vasorelaxation in resistance mesenteric arteries from male lean and dietary-induced obese rats.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	16	O	we
6	18	29	O	investigated
7	31	33	O	the
8	35	45	O	mechanism(s
9	48	49	O	of
10	51	61	U-UNK	resveratrol
11	63	69	O	induced
12	71	84	O	vasorelaxation
13	86	87	O	in
14	89	98	O	resistance
15	100	109	O	mesenteric
16	111	118	O	arteries
17	120	123	O	from
18	125	128	O	male
19	130	133	O	lean
20	135	137	O	and
21	139	145	O	dietary
22	147	153	O	induced
23	155	159	O	obese
24	161	164	O	rats
NULL

11115418.xml	DDI-MedLine.d95.s3	NO_SECTION	NO_SETID	27
Compared with lean rats, arteries from dietary-obese rats showed significant (P<0.001) endothelial dysfunction, as indicated by a decrease (>20%) in maximal acetylcholine-induced vasorelaxation.
1	0	7	O	Compared
2	9	12	O	with
3	14	17	O	lean
4	19	22	O	rats
5	23	23	O	,
6	25	32	O	arteries
7	34	37	O	from
8	39	45	O	dietary
9	47	51	O	obese
10	53	56	O	rats
11	58	63	O	showed
12	65	75	O	significant
13	78	84	O	P<0.001
14	87	97	O	endothelial
15	99	109	O	dysfunction
16	110	110	O	,
17	112	113	O	as
18	115	123	O	indicated
19	125	126	O	by
20	128	128	O	a
21	130	137	O	decrease
22	140	143	O	>20%
23	146	147	O	in
24	149	155	O	maximal
25	157	169	O	acetylcholine
26	171	177	O	induced
27	179	192	O	vasorelaxation
NULL

11115418.xml	DDI-MedLine.d95.s4	NO_SECTION	NO_SETID	33
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
1	0	10	U-UNK	Resveratrol
2	13	13	O	5
3	15	16	O	35
4	18	25	O	micromol
5	26	26	O	/
6	27	27	O	l
7	30	36	O	induced
8	38	50	O	concentration
9	52	60	O	dependent
10	62	71	O	relaxation
11	73	74	O	of
12	76	85	O	mesenteric
13	87	94	O	arteries
14	96	109	O	preconstricted
15	111	114	O	with
16	116	128	U-UNK	noradrenaline
17	131	131	O	8
18	133	140	O	micromol
19	141	141	O	/
20	142	142	O	l
21	145	146	O	or
22	148	150	U-UNK	KCl
23	153	155	O	125
24	157	160	O	mmol
25	161	161	O	/
26	162	162	O	l
27	165	168	O	from
28	170	173	O	both
29	175	178	O	lean
30	180	182	O	and
31	184	190	O	dietary
32	192	196	O	obese
33	198	201	O	rats
NULL

11115418.xml	DDI-MedLine.d95.s5	NO_SECTION	NO_SETID	24
There were no significant differences between the two groups, achieving a maximum relaxation of >95% at a concentration of 35 micromol/l.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	24	O	significant
5	26	36	O	differences
6	38	44	O	between
7	46	48	O	the
8	50	52	O	two
9	54	59	O	groups
10	60	60	O	,
11	62	70	O	achieving
12	72	72	O	a
13	74	80	O	maximum
14	82	91	O	relaxation
15	93	94	O	of
16	96	99	O	>95%
17	101	102	O	at
18	104	104	O	a
19	106	118	O	concentration
20	120	121	O	of
21	123	124	O	35
22	126	133	O	micromol
23	134	134	O	/
24	135	135	O	l
NULL

11115418.xml	DDI-MedLine.d95.s6	NO_SECTION	NO_SETID	29
However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves.
1	0	6	O	However
2	7	7	O	,
3	9	9	B-UNK	L
4	11	14	L-UNK	NAME
5	17	19	O	100
6	21	23	O	and
7	25	27	O	300
8	29	36	O	micromol
9	37	37	O	/
10	38	38	O	l
11	41	43	O	did
12	45	47	O	not
13	49	53	O	alter
14	55	57	O	the
15	59	65	O	effects
16	67	68	O	of
17	70	81	U-UNK	reseveratrol
18	83	84	O	on
19	86	93	O	arteries
20	95	98	O	from
21	100	106	O	dietary
22	108	112	O	obese
23	114	117	O	rats
24	118	118	O	,
25	120	125	O	giving
26	127	138	O	superimposed
27	140	152	O	concentration
28	154	162	O	responses
29	164	169	O	curves
NULL

11115418.xml	DDI-MedLine.d95.s7	NO_SECTION	NO_SETID	17
Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats.
1	0	11	U-UNK	Indomethacin
2	13	15	O	was
3	17	20	O	also
4	22	32	O	ineffective
5	34	35	O	in
6	37	44	O	altering
7	46	56	U-UNK	resveratrol
8	58	65	O	activity
9	67	68	O	in
10	70	77	O	arteries
11	79	82	O	from
12	84	87	O	both
13	89	92	O	lean
14	94	96	O	and
15	98	104	O	dietary
16	106	110	O	obese
17	112	115	O	rats
NULL

11115418.xml	DDI-MedLine.d95.s8	NO_SECTION	NO_SETID	26
In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium.
1	0	1	O	In
2	3	15	U-UNK	noradrenaline
3	17	29	O	precontracted
4	31	38	O	arteries
5	40	43	O	from
6	45	51	O	dietary
7	53	57	O	obese
8	59	62	O	rats
9	63	63	O	,
10	65	73	O	responses
11	75	76	O	to
12	78	88	U-UNK	resveratrol
13	90	93	O	were
14	95	97	O	not
15	99	108	O	attenuated
16	110	111	O	by
17	113	123	O	endothelial
18	125	134	O	denudation
19	135	135	O	,
20	137	146	O	indicating
21	148	149	O	an
22	151	156	O	action
23	158	168	O	independent
24	170	171	O	of
25	173	175	O	the
26	177	187	O	endothelium
NULL

11115418.xml	DDI-MedLine.d95.s9	NO_SECTION	NO_SETID	54
This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.
1	0	3	O	This
2	5	9	O	study
3	11	19	O	indicates
4	21	24	O	that
5	25	25	O	:
6	28	28	O	a
7	31	33	O	the
8	35	41	O	maximal
9	43	49	O	effects
10	51	52	O	of
11	54	64	U-UNK	resveratrol
12	66	67	O	on
13	69	78	O	resistance
14	80	87	O	arteries
15	89	92	O	from
16	94	97	O	lean
17	99	101	O	and
18	103	109	O	dietary
19	111	115	O	obese
20	117	120	O	rats
21	122	124	O	are
22	126	128	O	not
23	130	137	O	effected
24	139	140	O	by
25	142	152	O	endothelial
26	154	164	O	dysfunction
27	165	165	O	,
28	167	169	O	and
29	172	172	O	b
30	175	177	O	the
31	179	185	O	effects
32	187	188	O	of
33	190	200	U-UNK	resveratrol
34	202	203	O	in
35	205	208	O	lean
36	210	216	O	animals
37	219	223	O	where
38	225	235	O	endothelial
39	237	244	O	function
40	246	247	O	is
41	249	251	O	not
42	253	260	O	impaired
43	262	262	O	,
44	264	266	O	but
45	268	270	O	not
46	272	273	O	in
47	275	281	O	dietary
48	283	287	O	obese
49	289	292	O	rats
50	293	293	O	,
51	295	297	O	are
52	299	306	O	mediated
53	308	310	O	via
54	312	313	O	NO
NULL

11120981.xml	DDI-MedLine.d79.s0	NO_SECTION	NO_SETID	19
If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
1	0	1	O	If
2	3	7	O	taken
3	9	9	O	1
4	11	14	O	hour
5	16	21	O	before
6	23	31	U-UNK	indinavir
7	34	36	U-UNK	IDV
8	38	38	O	,
9	40	49	U-UNK	didanosine
10	51	54	O	does
11	56	58	O	not
12	60	65	O	affect
13	67	69	U-UNK	IDV
14	71	78	O	exposure
15	79	79	O	,
16	81	87	O	despite
17	89	98	O	persistent
18	100	108	O	buffering
19	110	116	O	effects
NULL

11120981.xml	DDI-MedLine.d79.s1	NO_SECTION	NO_SETID	29
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	37	U-UNK	indinavir
5	39	41	O	and
6	43	52	U-UNK	didanosine
7	54	66	O	significantly
8	68	74	O	reduces
9	76	78	O	the
10	80	84	O	level
11	86	87	O	of
12	89	96	O	exposure
13	98	99	O	to
14	101	109	U-UNK	indinavir
15	110	110	O	,
16	112	114	O	but
17	116	117	O	it
18	119	120	O	is
19	122	128	O	unclear
20	130	132	O	how
21	134	137	O	soon
22	139	143	O	after
23	145	154	U-UNK	didanosine
24	156	169	O	administration
25	171	179	U-UNK	indinavir
26	181	183	O	may
27	185	186	O	be
28	188	192	O	given
29	194	199	O	safely
NULL

11120981.xml	DDI-MedLine.d79.s2	NO_SECTION	NO_SETID	33
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration.
1	0	1	O	We
2	3	10	O	compared
3	12	20	U-UNK	indinavir
4	22	37	O	pharmacokinetics
5	39	41	O	and
6	43	49	O	gastric
7	51	52	O	pH
8	54	55	O	in
9	57	58	O	12
10	60	64	O	human
11	66	81	O	immunodeficiency
12	83	87	O	virus
13	89	96	O	positive
14	98	105	O	patients
15	107	108	O	by
16	110	112	O	use
17	114	115	O	of
18	117	119	O	800
19	121	122	O	mg
20	124	125	O	of
21	127	135	U-UNK	indinavir
22	137	141	O	alone
23	143	148	O	versus
24	150	152	O	800
25	154	155	O	mg
26	157	158	O	of
27	160	168	U-UNK	indinavir
28	170	181	O	administered
29	183	183	O	1
30	185	185	O	h
31	187	191	O	after
32	193	202	U-UNK	didanosine
33	204	217	O	administration
NULL

11120981.xml	DDI-MedLine.d79.s3	NO_SECTION	NO_SETID	13
Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
1	0	5	O	Median
2	7	13	O	gastric
3	15	16	O	pH
4	18	20	O	was
5	22	34	O	significantly
6	36	41	O	higher
7	43	46	O	when
8	48	56	U-UNK	indinavir
9	58	60	O	was
10	62	66	O	taken
11	68	72	O	after
12	74	83	U-UNK	didanosine
13	85	98	O	administration
NULL

11120981.xml	DDI-MedLine.d79.s4	NO_SECTION	NO_SETID	27
however, no significant difference in the maximum concentration in plasma or the area under the concentration-time curve from time zero to 8 h was observed.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	no
4	12	22	O	significant
5	24	33	O	difference
6	35	36	O	in
7	38	40	O	the
8	42	48	O	maximum
9	50	62	O	concentration
10	64	65	O	in
11	67	72	O	plasma
12	74	75	O	or
13	77	79	O	the
14	81	84	O	area
15	86	90	O	under
16	92	94	O	the
17	96	108	O	concentration
18	110	113	O	time
19	115	119	O	curve
20	121	124	O	from
21	126	129	O	time
22	131	134	O	zero
23	136	137	O	to
24	139	139	O	8
25	141	141	O	h
26	143	145	O	was
27	147	154	O	observed
NULL

11120981.xml	DDI-MedLine.d79.s5	NO_SECTION	NO_SETID	18
Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
1	0	8	U-UNK	Indinavir
2	10	12	O	may
3	14	15	O	be
4	17	21	O	taken
5	23	26	O	with
6	28	28	O	a
7	30	34	O	light
8	36	39	O	meal
9	41	41	O	1
10	43	43	O	h
11	45	53	O	following
12	55	57	O	the
13	59	72	O	administration
14	74	75	O	of
15	77	79	O	400
16	81	82	O	mg
17	84	85	O	of
18	87	96	U-UNK	didanosine
NULL

11121387.xml	DDI-MedLine.d59.s0	NO_SECTION	NO_SETID	13
A proposed mechanism for the potentiation of cAMP-mediated acid secretion by carbachol.
1	0	0	O	A
2	2	9	O	proposed
3	11	19	O	mechanism
4	21	23	O	for
5	25	27	O	the
6	29	40	O	potentiation
7	42	43	O	of
8	45	48	O	cAMP
9	50	57	O	mediated
10	59	62	O	acid
11	64	72	O	secretion
12	74	75	O	by
13	77	85	U-UNK	carbachol
NULL

11121387.xml	DDI-MedLine.d59.s1	NO_SECTION	NO_SETID	14
Acid secretion in isolated rabbit gastric glands was monitored by the accumulation of [(14)C]aminopyrine.
1	0	3	O	Acid
2	5	13	O	secretion
3	15	16	O	in
4	18	25	O	isolated
5	27	32	O	rabbit
6	34	40	O	gastric
7	42	47	O	glands
8	49	51	O	was
9	53	61	O	monitored
10	63	64	O	by
11	66	68	O	the
12	70	81	O	accumulation
13	83	84	O	of
14	88	103	O	14)C]aminopyrine
NULL

11121387.xml	DDI-MedLine.d59.s2	NO_SECTION	NO_SETID	13
Stimulation of the glands with carbachol synergistically augmented the response to dibutyryl cAMP.
1	0	10	O	Stimulation
2	12	13	O	of
3	15	17	O	the
4	19	24	O	glands
5	26	29	O	with
6	31	39	U-UNK	carbachol
7	41	55	O	synergistically
8	57	65	O	augmented
9	67	69	O	the
10	71	78	O	response
11	80	81	O	to
12	83	91	O	dibutyryl
13	93	96	O	cAMP
NULL

11121387.xml	DDI-MedLine.d59.s3	NO_SECTION	NO_SETID	28
The augmentation persisted even after carbachol was washed out and was resistant to chelated extracellular Ca(2+) and to inhibitors of either protein kinase C or calmodulin kinase II.
1	0	2	O	The
2	4	15	O	augmentation
3	17	25	O	persisted
4	27	30	O	even
5	32	36	O	after
6	38	46	U-UNK	carbachol
7	48	50	O	was
8	52	57	O	washed
9	59	61	O	out
10	63	65	O	and
11	67	69	O	was
12	71	79	O	resistant
13	81	82	O	to
14	84	91	O	chelated
15	93	105	O	extracellular
16	107	111	O	Ca(2+
17	114	116	O	and
18	118	119	O	to
19	121	130	O	inhibitors
20	132	133	O	of
21	135	140	O	either
22	142	148	O	protein
23	150	155	O	kinase
24	157	157	O	C
25	159	160	O	or
26	162	171	O	calmodulin
27	173	178	O	kinase
28	180	181	O	II
NULL

11121387.xml	DDI-MedLine.d59.s4	NO_SECTION	NO_SETID	33
Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
1	0	11	B-UNK	Cytochalasin
2	13	13	L-UNK	D
3	15	16	O	at
4	18	19	O	10
5	21	26	O	microM
6	28	41	O	preferentially
7	43	49	O	blocked
8	51	53	O	the
9	55	63	O	secretory
10	65	70	O	effect
11	72	73	O	of
12	75	83	U-UNK	carbachol
13	85	87	O	and
14	89	91	O	its
15	93	101	O	synergism
16	103	106	O	with
17	108	111	O	cAMP
18	112	112	O	,
19	114	120	O	whereas
20	122	123	O	it
21	125	127	O	had
22	129	130	O	no
23	132	137	O	effect
24	139	140	O	on
25	142	150	O	histamine
26	153	154	O	or
27	156	159	O	cAMP
28	161	170	O	stimulated
29	172	175	O	acid
30	177	185	O	secretion
31	187	192	O	within
32	194	195	O	15
33	197	199	O	min
NULL

11121387.xml	DDI-MedLine.d59.s5	NO_SECTION	NO_SETID	18
Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
1	0	11	B-UNK	Cytochalasin
2	13	13	L-UNK	D
3	15	23	O	inhibited
4	25	27	O	the
5	29	37	U-UNK	carbachol
6	39	48	O	stimulated
7	50	62	O	intracellular
8	64	68	O	Ca(2+
9	71	83	O	concentration
10	87	95	O	Ca(2+)](i
11	99	106	O	increase
12	108	110	O	due
13	112	113	O	to
14	115	121	O	release
15	123	126	O	from
16	128	130	O	the
17	132	136	O	Ca(2+
18	139	143	O	store
NULL

11121387.xml	DDI-MedLine.d59.s6	NO_SECTION	NO_SETID	44
Treatment of the glands with cytochalasin D redistributed type 3 inositol 1,4,5-trisphosphate receptor (the major subtype in the parietal cell) from the fraction containing membranes of large size to the microsomal fraction, suggesting a dissociation of the store from the plasma membrane.
1	0	8	O	Treatment
2	10	11	O	of
3	13	15	O	the
4	17	22	O	glands
5	24	27	O	with
6	29	40	B-UNK	cytochalasin
7	42	42	L-UNK	D
8	44	56	O	redistributed
9	58	61	O	type
10	63	63	O	3
11	65	72	O	inositol
12	74	78	O	1,4,5
13	80	92	O	trisphosphate
14	94	101	O	receptor
15	104	106	O	the
16	108	112	O	major
17	114	120	O	subtype
18	122	123	O	in
19	125	127	O	the
20	129	136	O	parietal
21	138	141	O	cell
22	144	147	O	from
23	149	151	O	the
24	153	160	O	fraction
25	162	171	O	containing
26	173	181	O	membranes
27	183	184	O	of
28	186	190	O	large
29	192	195	O	size
30	197	198	O	to
31	200	202	O	the
32	204	213	O	microsomal
33	215	222	O	fraction
34	223	223	O	,
35	225	234	O	suggesting
36	236	236	O	a
37	238	249	O	dissociation
38	251	252	O	of
39	254	256	O	the
40	258	262	O	store
41	264	267	O	from
42	269	271	O	the
43	273	278	O	plasma
44	280	287	O	membrane
NULL

11121387.xml	DDI-MedLine.d59.s7	NO_SECTION	NO_SETID	37
These findings suggest that intracellular Ca(2+) release by cholinergic stimulation is critical for determining synergism with cAMP in parietal cell activation and that functional coupling between the Ca(2+) store and the receptor is maintained by actin microfilaments.
1	0	4	O	These
2	6	13	O	findings
3	15	21	O	suggest
4	23	26	O	that
5	28	40	O	intracellular
6	42	46	O	Ca(2+
7	49	55	O	release
8	57	58	O	by
9	60	70	O	cholinergic
10	72	82	O	stimulation
11	84	85	O	is
12	87	94	O	critical
13	96	98	O	for
14	100	110	O	determining
15	112	120	O	synergism
16	122	125	O	with
17	127	130	O	cAMP
18	132	133	O	in
19	135	142	O	parietal
20	144	147	O	cell
21	149	158	O	activation
22	160	162	O	and
23	164	167	O	that
24	169	178	O	functional
25	180	187	O	coupling
26	189	195	O	between
27	197	199	O	the
28	201	205	O	Ca(2+
29	208	212	O	store
30	214	216	O	and
31	218	220	O	the
32	222	229	O	receptor
33	231	232	O	is
34	234	243	O	maintained
35	245	246	O	by
36	248	252	O	actin
37	254	267	O	microfilaments
NULL

11121884.xml	DDI-MedLine.d75.s0	NO_SECTION	NO_SETID	16
Interference of biocytin with opioid-evoked hyperpolarization and membrane properties of rat spinal substantia gelatinosa neurons.
1	0	11	O	Interference
2	13	14	O	of
3	16	23	O	biocytin
4	25	28	O	with
5	30	35	U-UNK	opioid
6	37	42	O	evoked
7	44	60	O	hyperpolarization
8	62	64	O	and
9	66	73	O	membrane
10	75	84	O	properties
11	86	87	O	of
12	89	91	O	rat
13	93	98	O	spinal
14	100	109	O	substantia
15	111	120	O	gelatinosa
16	122	128	O	neurons
NULL

11121884.xml	DDI-MedLine.d75.s1	NO_SECTION	NO_SETID	40
In our laboratory, preliminary whole-cell, tight seal recordings of rat spinal substantia gelatinosa neurons including biocytin in the patch pipette yielded a significantly smaller proportion of neurons hyperpolarized by selective opioid agonists compared with recordings without biocytin.
1	0	1	O	In
2	3	5	O	our
3	7	16	O	laboratory
4	17	17	O	,
5	19	29	O	preliminary
6	31	35	O	whole
7	37	40	O	cell
8	41	41	O	,
9	43	47	O	tight
10	49	52	O	seal
11	54	63	O	recordings
12	65	66	O	of
13	68	70	O	rat
14	72	77	O	spinal
15	79	88	O	substantia
16	90	99	O	gelatinosa
17	101	107	O	neurons
18	109	117	O	including
19	119	126	O	biocytin
20	128	129	O	in
21	131	133	O	the
22	135	139	O	patch
23	141	147	O	pipette
24	149	155	O	yielded
25	157	157	O	a
26	159	171	O	significantly
27	173	179	O	smaller
28	181	190	O	proportion
29	192	193	O	of
30	195	201	O	neurons
31	203	216	O	hyperpolarized
32	218	219	O	by
33	221	229	B-UNK	selective
34	231	236	I-UNK	opioid
35	238	245	L-UNK	agonists
36	247	254	O	compared
37	256	259	O	with
38	261	270	O	recordings
39	272	278	O	without
40	280	287	O	biocytin
NULL

11121884.xml	DDI-MedLine.d75.s2	NO_SECTION	NO_SETID	26
Therefore, we investigated the effects of biocytin inclusion on opioid responses and other membrane properties during whole-cell, tight seal recordings of these neurons.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	we
4	14	25	O	investigated
5	27	29	O	the
6	31	37	O	effects
7	39	40	O	of
8	42	49	O	biocytin
9	51	59	O	inclusion
10	61	62	O	on
11	64	69	U-UNK	opioid
12	71	79	O	responses
13	81	83	O	and
14	85	89	O	other
15	91	98	O	membrane
16	100	109	O	properties
17	111	116	O	during
18	118	122	O	whole
19	124	127	O	cell
20	128	128	O	,
21	130	134	O	tight
22	136	139	O	seal
23	141	150	O	recordings
24	152	153	O	of
25	155	159	O	these
26	161	167	O	neurons
NULL

11121884.xml	DDI-MedLine.d75.s3	NO_SECTION	NO_SETID	22
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not <
1	0	2	O	The
2	4	13	O	percentage
3	15	16	O	of
4	18	24	O	neurons
5	26	39	O	hyperpolarized
6	41	42	O	by
7	44	45	B-UNK	mu
8	47	47	I-UNK	,
9	49	55	I-UNK	delta(1
10	58	58	I-UNK	,
11	60	62	I-UNK	and
12	64	68	I-UNK	kappa
13	70	78	I-UNK	selective
14	80	86	L-UNK	opioids
15	88	90	O	was
16	92	104	O	significantly
17	106	112	O	reduced
18	114	117	O	when
19	119	120	O	1%
20	122	124	O	but
21	126	128	O	not
22	130	130	O	<
NULL

11121884.xml	DDI-MedLine.d75.s4	NO_SECTION	NO_SETID	16
or =0.2% biocytin was included in the recording pipette, compared with neurons recorded without biocytin.
1	0	1	O	or
2	3	7	O	=0.2%
3	9	16	O	biocytin
4	18	20	O	was
5	22	29	O	included
6	31	32	O	in
7	34	36	O	the
8	38	46	O	recording
9	48	54	O	pipette
10	55	55	O	,
11	57	64	O	compared
12	66	69	O	with
13	71	77	O	neurons
14	79	86	O	recorded
15	88	94	O	without
16	96	103	O	biocytin
NULL

11121884.xml	DDI-MedLine.d75.s5	NO_SECTION	NO_SETID	23
However, a significantly higher proportion of neurons fired spontaneous action potentials with either 0.05-0.2 or 1% biocytin compared to no biocytin.
1	0	6	O	However
2	7	7	O	,
3	9	9	O	a
4	11	23	O	significantly
5	25	30	O	higher
6	32	41	O	proportion
7	43	44	O	of
8	46	52	O	neurons
9	54	58	O	fired
10	60	70	O	spontaneous
11	72	77	O	action
12	79	88	O	potentials
13	90	93	O	with
14	95	100	O	either
15	102	105	O	0.05
16	107	109	O	0.2
17	111	112	O	or
18	114	115	O	1%
19	117	124	O	biocytin
20	126	133	O	compared
21	135	136	O	to
22	138	139	O	no
23	141	148	O	biocytin
NULL

11121884.xml	DDI-MedLine.d75.s6	NO_SECTION	NO_SETID	29
Resting membrane potential, input impedance and the proportion of neurons displaying transient outward rectification were each significantly altered for neurons recorded with 1% but not 0.05-0.2% biocytin.
1	0	6	O	Resting
2	8	15	O	membrane
3	17	25	O	potential
4	26	26	O	,
5	28	32	O	input
6	34	42	O	impedance
7	44	46	O	and
8	48	50	O	the
9	52	61	O	proportion
10	63	64	O	of
11	66	72	O	neurons
12	74	83	O	displaying
13	85	93	O	transient
14	95	101	O	outward
15	103	115	O	rectification
16	117	120	O	were
17	122	125	O	each
18	127	139	O	significantly
19	141	147	O	altered
20	149	151	O	for
21	153	159	O	neurons
22	161	168	O	recorded
23	170	173	O	with
24	175	176	O	1%
25	178	180	O	but
26	182	184	O	not
27	186	189	O	0.05
28	191	194	O	0.2%
29	196	203	O	biocytin
NULL

11121884.xml	DDI-MedLine.d75.s7	NO_SECTION	NO_SETID	15
These effects may be due to a relatively specific blockade of diverse potassium channel types.
1	0	4	O	These
2	6	12	O	effects
3	14	16	O	may
4	18	19	O	be
5	21	23	O	due
6	25	26	O	to
7	28	28	O	a
8	30	39	O	relatively
9	41	48	O	specific
10	50	57	O	blockade
11	59	60	O	of
12	62	68	O	diverse
13	70	78	O	potassium
14	80	86	O	channel
15	88	92	O	types
NULL

11121884.xml	DDI-MedLine.d75.s8	NO_SECTION	NO_SETID	18
Because efficient labeling can be achieved with 0.1% biocytin with whole-cell recording, higher concentrations are contraindicated.
1	0	6	O	Because
2	8	16	O	efficient
3	18	25	O	labeling
4	27	29	O	can
5	31	32	O	be
6	34	41	O	achieved
7	43	46	O	with
8	48	51	O	0.1%
9	53	60	O	biocytin
10	62	65	O	with
11	67	71	O	whole
12	73	76	O	cell
13	78	86	O	recording
14	87	87	O	,
15	89	94	O	higher
16	96	109	O	concentrations
17	111	113	O	are
18	115	129	O	contraindicated
NULL

11125022.xml	DDI-MedLine.d117.s0	NO_SECTION	NO_SETID	15
Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation.
1	0	8	O	Increased
2	10	18	O	stability
3	20	21	O	of
4	23	35	O	nucleophosmin
5	36	36	O	/
6	37	39	O	B23
7	41	42	O	in
8	44	47	O	anti
9	49	57	O	apoptotic
10	59	64	O	effect
11	66	67	O	of
12	69	71	O	ras
13	73	78	O	during
14	80	84	O	serum
15	86	96	O	deprivation
NULL

11125022.xml	DDI-MedLine.d117.s1	NO_SECTION	NO_SETID	20
We obtained evidence that increased stability of nucleophosmin/B23 is involved in antiapoptotic effect of ras during serum deprivation.
1	0	1	O	We
2	3	10	O	obtained
3	12	19	O	evidence
4	21	24	O	that
5	26	34	O	increased
6	36	44	O	stability
7	46	47	O	of
8	49	61	O	nucleophosmin
9	62	62	O	/
10	63	65	O	B23
11	67	68	O	is
12	70	77	O	involved
13	79	80	O	in
14	82	94	O	antiapoptotic
15	96	101	O	effect
16	103	104	O	of
17	106	108	O	ras
18	110	115	O	during
19	117	121	O	serum
20	123	133	O	deprivation
NULL

11125022.xml	DDI-MedLine.d117.s2	NO_SECTION	NO_SETID	25
Nucleophosmin/B23 in serum-deprived (0% serum) NIH-3T3 cells was found to be highly unstable with a half-life less than 4 h.
1	0	12	O	Nucleophosmin
2	13	13	O	/
3	14	16	O	B23
4	18	19	O	in
5	21	25	O	serum
6	27	34	O	deprived
7	37	38	O	0%
8	40	44	O	serum
9	47	49	O	NIH
10	51	53	O	3T3
11	55	59	O	cells
12	61	63	O	was
13	65	69	O	found
14	71	72	O	to
15	74	75	O	be
16	77	82	O	highly
17	84	91	O	unstable
18	93	96	O	with
19	98	98	O	a
20	100	103	O	half
21	105	108	O	life
22	110	113	O	less
23	115	118	O	than
24	120	120	O	4
25	122	122	O	h
NULL

11125022.xml	DDI-MedLine.d117.s3	NO_SECTION	NO_SETID	28
In contrast, nucleophosmin/B23 in serum-deprived ras-transformed (RAS-3T3) cells was as stable as that in serum-supplemented NIH-3T3 or RAS-3T3 cells.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	25	O	nucleophosmin
5	26	26	O	/
6	27	29	O	B23
7	31	32	O	in
8	34	38	O	serum
9	40	47	O	deprived
10	49	51	O	ras
11	53	63	O	transformed
12	66	68	O	RAS
13	70	72	O	3T3
14	75	79	O	cells
15	81	83	O	was
16	85	86	O	as
17	88	93	O	stable
18	95	96	O	as
19	98	101	O	that
20	103	104	O	in
21	106	110	O	serum
22	112	123	O	supplemented
23	125	127	O	NIH
24	129	131	O	3T3
25	133	134	O	or
26	136	138	O	RAS
27	140	142	O	3T3
28	144	148	O	cells
NULL

11125022.xml	DDI-MedLine.d117.s4	NO_SECTION	NO_SETID	19
Treatment of RAS-3T3 cells with nucleophosmin/B23 antisense oligomer significantly potentiated the apoptosis induced by serum deprivation.
1	0	8	O	Treatment
2	10	11	O	of
3	13	15	O	RAS
4	17	19	O	3T3
5	21	25	O	cells
6	27	30	O	with
7	32	44	O	nucleophosmin
8	45	45	O	/
9	46	48	O	B23
10	50	58	O	antisense
11	60	67	O	oligomer
12	69	81	O	significantly
13	83	93	O	potentiated
14	95	97	O	the
15	99	107	O	apoptosis
16	109	115	O	induced
17	117	118	O	by
18	120	124	O	serum
19	126	136	O	deprivation
NULL

11125022.xml	DDI-MedLine.d117.s5	NO_SECTION	NO_SETID	29
Much less caspase-3 activity was noted in the lysate derived from serum-deprived RAS-3T3 cells compared with that in the lysate of serum-deprived NIH-3T3 cells.
1	0	3	O	Much
2	5	8	O	less
3	10	16	O	caspase
4	18	18	O	3
5	20	27	O	activity
6	29	31	O	was
7	33	37	O	noted
8	39	40	O	in
9	42	44	O	the
10	46	51	O	lysate
11	53	59	O	derived
12	61	64	O	from
13	66	70	O	serum
14	72	79	O	deprived
15	81	83	O	RAS
16	85	87	O	3T3
17	89	93	O	cells
18	95	102	O	compared
19	104	107	O	with
20	109	112	O	that
21	114	115	O	in
22	117	119	O	the
23	121	126	O	lysate
24	128	129	O	of
25	131	135	O	serum
26	137	144	O	deprived
27	146	148	O	NIH
28	150	152	O	3T3
29	154	158	O	cells
NULL

11125022.xml	DDI-MedLine.d117.s6	NO_SECTION	NO_SETID	26
Cell permeable caspase-3 inhibitor added in the medium blocked the decrease of nucleophosmin/B23 and apoptosis induced by serum deprivation in NIH-3T3 cells.
1	0	3	O	Cell
2	5	13	O	permeable
3	15	21	O	caspase
4	23	23	O	3
5	25	33	O	inhibitor
6	35	39	O	added
7	41	42	O	in
8	44	46	O	the
9	48	53	O	medium
10	55	61	O	blocked
11	63	65	O	the
12	67	74	O	decrease
13	76	77	O	of
14	79	91	O	nucleophosmin
15	92	92	O	/
16	93	95	O	B23
17	97	99	O	and
18	101	109	O	apoptosis
19	111	117	O	induced
20	119	120	O	by
21	122	126	O	serum
22	128	138	O	deprivation
23	140	141	O	in
24	143	145	O	NIH
25	147	149	O	3T3
26	151	155	O	cells
NULL

11125022.xml	DDI-MedLine.d117.s7	NO_SECTION	NO_SETID	22
The inhibitor, on the other hand, promoted significant decrease of nucleolin/C23 in NIH-3T3 cells during serum deprivation.
1	0	2	O	The
2	4	12	O	inhibitor
3	13	13	O	,
4	15	16	O	on
5	18	20	O	the
6	22	26	O	other
7	28	31	O	hand
8	32	32	O	,
9	34	41	O	promoted
10	43	53	O	significant
11	55	62	O	decrease
12	64	65	O	of
13	67	75	O	nucleolin
14	76	76	O	/
15	77	79	O	C23
16	81	82	O	in
17	84	86	O	NIH
18	88	90	O	3T3
19	92	96	O	cells
20	98	103	O	during
21	105	109	O	serum
22	111	121	O	deprivation
NULL

11125022.xml	DDI-MedLine.d117.s8	NO_SECTION	NO_SETID	22
Unlike nucleolin/C23, down-regulation of nucleophosmin/B23 was thus not proliferation-dependent but caspase-3- and apoptosis-dependent.
1	0	5	O	Unlike
2	7	15	O	nucleolin
3	16	16	O	/
4	17	19	O	C23
5	20	20	O	,
6	22	25	O	down
7	27	36	O	regulation
8	38	39	O	of
9	41	53	O	nucleophosmin
10	54	54	O	/
11	55	57	O	B23
12	59	61	O	was
13	63	66	O	thus
14	68	70	O	not
15	72	84	O	proliferation
16	86	94	O	dependent
17	96	98	O	but
18	100	106	O	caspase
19	108	108	O	3
20	111	113	O	and
21	115	123	O	apoptosis
22	125	133	O	dependent
NULL

11125022.xml	DDI-MedLine.d117.s9	NO_SECTION	NO_SETID	21
Our results indicate important relationships among ras, nucleophosmin/B23, activation of caspase-3, and induction of apoptosis.
1	0	2	O	Our
2	4	10	O	results
3	12	19	O	indicate
4	21	29	O	important
5	31	43	O	relationships
6	45	49	O	among
7	51	53	O	ras
8	54	54	O	,
9	56	68	O	nucleophosmin
10	69	69	O	/
11	70	72	O	B23
12	73	73	O	,
13	75	84	O	activation
14	86	87	O	of
15	89	95	O	caspase
16	97	97	O	3
17	98	98	O	,
18	100	102	O	and
19	104	112	O	induction
20	114	115	O	of
21	117	125	O	apoptosis
NULL

11125235.xml	DDI-MedLine.d133.s0	NO_SECTION	NO_SETID	17
Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
1	0	10	O	Suppression
2	12	13	O	by
3	15	23	U-UNK	verapamil
4	25	26	O	of
5	28	35	U-UNK	bombesin
6	37	44	O	enhanced
7	46	55	O	peritoneal
8	57	66	O	metastasis
9	68	69	O	of
10	71	80	O	intestinal
11	82	96	O	adenocarcinomas
12	98	104	O	induced
13	106	107	O	by
14	109	120	U-UNK	azoxymethane
15	122	123	O	in
16	125	130	O	wistar
17	132	135	O	rats
NULL

11125235.xml	DDI-MedLine.d133.s1	NO_SECTION	NO_SETID	45
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.
1	0	9	O	BACKGROUND
2	10	10	O	:
3	12	14	O	The
4	16	22	O	effects
5	24	25	O	of
6	27	34	O	combined
7	36	49	O	administration
8	51	52	O	of
9	54	61	U-UNK	bombesin
10	63	65	O	and
11	67	75	B-UNK	verapamil
12	77	89	L-UNK	hydrochloride
13	92	100	U-UNK	verapamil
14	102	102	O	,
15	104	104	O	a
16	106	112	B-UNK	calcium
17	114	120	I-UNK	channel
18	122	128	L-UNK	blocker
19	129	129	O	,
20	131	132	O	on
21	134	136	O	the
22	138	146	O	incidence
23	148	149	O	of
24	151	160	O	peritoneal
25	162	171	O	metastasis
26	173	174	O	of
27	176	185	O	intestinal
28	187	201	O	adenocarcinomas
29	203	209	O	induced
30	211	212	O	by
31	214	225	U-UNK	azoxymethane
32	228	230	U-UNK	AOM
33	233	235	O	and
34	237	239	O	the
35	241	248	O	labeling
36	250	254	O	index
37	256	257	O	of
38	259	268	O	intestinal
39	270	276	O	cancers
40	278	281	O	were
41	283	294	O	investigated
42	296	297	O	in
43	299	302	O	male
44	304	309	O	Wistar
45	311	314	O	rats
NULL

11125235.xml	DDI-MedLine.d133.s2	NO_SECTION	NO_SETID	68
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
1	0	6	O	METHODS
2	7	7	O	:
3	9	12	O	From
4	14	16	O	the
5	18	26	O	beginning
6	28	29	O	of
7	31	33	O	the
8	35	44	O	experiment
9	45	45	O	,
10	47	50	O	rats
11	52	55	O	were
12	57	61	O	given
13	63	64	O	10
14	66	71	O	weekly
15	73	84	O	subcutaneous
16	86	95	O	injections
17	97	98	O	of
18	100	102	U-UNK	AOM
19	105	107	O	7.4
20	109	110	O	mg
21	111	111	O	/
22	112	113	O	kg
23	115	118	O	body
24	120	125	O	weight
25	128	130	O	and
26	132	143	O	subcutaneous
27	145	154	O	injections
28	156	157	O	of
29	159	166	U-UNK	bombesin
30	169	170	O	40
31	172	177	O	microg
32	178	178	O	/
33	179	180	O	kg
34	182	185	O	body
35	187	192	O	weight
36	195	199	O	every
37	201	205	O	other
38	207	209	O	day
39	210	210	O	,
40	212	214	O	and
41	216	219	O	from
42	221	224	O	week
43	226	227	O	16
44	228	228	O	,
45	230	244	O	intraperitoneal
46	246	255	O	injections
47	257	258	O	of
48	260	268	U-UNK	verapamil
49	271	272	O	10
50	274	275	O	or
51	277	278	O	20
52	280	281	O	mg
53	282	282	O	/
54	283	284	O	kg
55	286	289	O	body
56	291	296	O	weight
57	299	303	O	every
58	305	309	O	other
59	311	313	O	day
60	315	319	O	until
61	321	323	O	the
62	325	327	O	end
63	329	330	O	fo
64	332	334	O	the
65	336	345	O	experiment
66	347	348	O	in
67	350	353	O	week
68	355	356	O	45
NULL

11125235.xml	DDI-MedLine.d133.s3	NO_SECTION	NO_SETID	16
RESULTS: Bombesin significantly increased the incidence of intestinal tumors and cancer metastasis to the peritoneum.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	16	U-UNK	Bombesin
4	18	30	O	significantly
5	32	40	O	increased
6	42	44	O	the
7	46	54	O	incidence
8	56	57	O	of
9	59	68	O	intestinal
10	70	75	O	tumors
11	77	79	O	and
12	81	86	O	cancer
13	88	97	O	metastasis
14	99	100	O	to
15	102	104	O	the
16	106	115	O	peritoneum
NULL

11125235.xml	DDI-MedLine.d133.s4	NO_SECTION	NO_SETID	51
Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
1	0	7	O	Although
2	9	17	U-UNK	verapamil
3	19	30	O	administered
4	32	33	O	at
5	35	40	O	either
6	42	45	O	dose
7	47	49	O	had
8	51	56	O	little
9	58	59	O	or
10	61	62	O	no
11	64	69	O	effect
12	71	72	O	on
13	74	76	O	the
14	78	88	O	enhancement
15	90	91	O	of
16	93	102	O	intestinal
17	104	117	O	carcinogenesis
18	119	120	O	by
19	122	129	U-UNK	bombesin
20	131	132	O	or
21	134	135	O	on
22	137	139	O	the
23	141	148	O	location
24	149	149	O	,
25	151	160	O	histologic
26	162	165	O	type
27	166	166	O	,
28	168	172	O	depth
29	174	175	O	of
30	177	187	O	involvement
31	188	188	O	,
32	190	197	O	labeling
33	199	203	O	index
34	204	204	O	,
35	206	214	O	apoptotic
36	216	220	O	index
37	222	223	O	or
38	225	229	O	tumor
39	231	241	O	vascularity
40	243	244	O	of
41	246	255	O	intestinal
42	257	263	O	cancers
43	264	264	O	,
44	266	267	O	it
45	269	281	O	significantly
46	283	291	O	decreased
47	293	295	O	the
48	297	305	O	incidence
49	307	308	O	of
50	310	315	O	cancer
51	317	326	O	metastasis
NULL

11125235.xml	DDI-MedLine.d133.s5	NO_SECTION	NO_SETID	17
Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
1	0	8	U-UNK	Verapamil
2	10	13	O	also
3	15	27	O	significantly
4	29	37	O	decreased
5	39	41	O	the
6	43	51	O	incidence
7	53	54	O	of
8	56	64	O	lymphatic
9	66	73	O	invasion
10	75	76	O	of
11	78	92	O	adenocarcinomas
12	93	93	O	,
13	95	99	O	which
14	101	103	O	was
15	105	112	O	enhanced
16	114	115	O	by
17	117	124	U-UNK	bombesin
NULL

11125235.xml	DDI-MedLine.d133.s6	NO_SECTION	NO_SETID	21
CONCLUSION: These findings indicate that verapamil inhibits cancer metastasis through actions that do not affect the growth of intestinal cancers.
1	0	9	O	CONCLUSION
2	10	10	O	:
3	12	16	O	These
4	18	25	O	findings
5	27	34	O	indicate
6	36	39	O	that
7	41	49	U-UNK	verapamil
8	51	58	O	inhibits
9	60	65	O	cancer
10	67	76	O	metastasis
11	78	84	O	through
12	86	92	O	actions
13	94	97	O	that
14	99	100	O	do
15	102	104	O	not
16	106	111	O	affect
17	113	115	O	the
18	117	122	O	growth
19	124	125	O	of
20	127	136	O	intestinal
21	138	144	O	cancers
NULL

1113260.xml	DDI-MedLine.d17.s0	NO_SECTION	NO_SETID	11
In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
1	0	1	O	In
2	3	7	O	vitro
3	9	19	O	interaction
4	21	22	O	of
5	24	36	B-UNK	prostaglandin
6	38	44	L-UNK	F2alpha
7	46	48	O	and
8	50	57	U-UNK	oxytocin
9	59	60	O	in
10	62	70	O	placental
11	72	78	O	vessels
NULL

1113260.xml	DDI-MedLine.d17.s1	NO_SECTION	NO_SETID	15
The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro.
1	0	2	O	The
2	4	14	O	interaction
3	16	17	O	of
4	19	31	B-UNK	prostaglandin
5	33	39	L-UNK	F2alpha
6	41	43	O	and
7	45	53	O	synthetic
8	55	62	U-UNK	oxytocin
9	64	65	O	on
10	67	75	O	placental
11	77	83	O	vessels
12	85	87	O	was
13	89	95	O	studied
14	97	98	O	in
15	100	104	O	vitro
NULL

1113260.xml	DDI-MedLine.d17.s2	NO_SECTION	NO_SETID	11
Resistance was measured near the placental margin after spontaneous term delivery.
1	0	9	O	Resistance
2	11	13	O	was
3	15	22	O	measured
4	24	27	O	near
5	29	31	O	the
6	33	41	O	placental
7	43	48	O	margin
8	50	54	O	after
9	56	66	O	spontaneous
10	68	71	O	term
11	73	80	O	delivery
NULL

1113260.xml	DDI-MedLine.d17.s3	NO_SECTION	NO_SETID	10
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha.
1	0	1	O	In
2	3	7	O	seven
3	9	19	O	experiments
4	21	29	O	reactions
5	31	32	O	to
6	34	47	U-UNK	norepinephrine
7	49	51	O	and
8	53	60	U-UNK	oxytocin
9	62	65	O	were
10	67	75	U-UNK	PGF2alpha
NULL

1113260.xml	DDI-MedLine.d17.s4	NO_SECTION	NO_SETID	11
PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
1	0	8	U-UNK	PGF2alpha
2	10	17	O	produced
3	19	31	O	significantly
4	33	41	O	increased
5	43	58	O	vasoconstriction
6	60	64	O	after
7	66	66	O	a
8	68	73	O	single
9	75	88	O	administration
10	90	91	O	of
11	93	100	U-UNK	oxytocin
NULL

1113260.xml	DDI-MedLine.d17.s5	NO_SECTION	NO_SETID	8
In eight experiments the perfusion medium contained oxytocin.
1	0	1	O	In
2	3	7	O	eight
3	9	19	O	experiments
4	21	23	O	the
5	25	33	O	perfusion
6	35	40	O	medium
7	42	50	O	contained
8	52	59	U-UNK	oxytocin
NULL

1113260.xml	DDI-MedLine.d17.s6	NO_SECTION	NO_SETID	10
There was no change after a single dose of PGF2alpha.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	18	O	change
5	20	24	O	after
6	26	26	O	a
7	28	33	O	single
8	35	38	O	dose
9	40	41	O	of
10	43	51	U-UNK	PGF2alpha
NULL

1113260.xml	DDI-MedLine.d17.s7	NO_SECTION	NO_SETID	12
The reaction after norepinephrine remained the same in both groups of experiments.
1	0	2	O	The
2	4	11	O	reaction
3	13	17	O	after
4	19	32	U-UNK	norepinephrine
5	34	41	O	remained
6	43	45	O	the
7	47	50	O	same
8	52	53	O	in
9	55	58	O	both
10	60	65	O	groups
11	67	68	O	of
12	70	80	O	experiments
NULL

1113260.xml	DDI-MedLine.d17.s8	NO_SECTION	NO_SETID	6
There is thus an enhancement effect
1	0	4	O	There
2	6	7	O	is
3	9	12	O	thus
4	14	15	O	an
5	17	27	O	enhancement
6	29	34	O	effect
NULL

1113260.xml	DDI-MedLine.d17.s9	NO_SECTION	NO_SETID	18
There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
1	0	4	O	There
2	6	7	O	is
3	9	12	O	thus
4	14	15	O	an
5	17	27	O	enhancement
6	29	34	O	effect
7	36	37	O	of
8	39	47	U-UNK	PGF2alpha
9	49	52	O	upon
10	54	56	O	the
11	58	65	O	reaction
12	67	68	O	of
13	70	78	O	placental
14	80	86	O	vessels
15	88	89	O	to
16	91	98	U-UNK	oxytocin
17	100	101	O	in
18	103	107	O	vitro
NULL

11134454.xml	DDI-MedLine.d36.s0	NO_SECTION	NO_SETID	8
Carbamazepine overdose recognized by a tricyclic antidepressant assay.
1	0	12	U-UNK	Carbamazepine
2	14	21	O	overdose
3	23	32	O	recognized
4	34	35	O	by
5	37	37	O	a
6	39	47	B-UNK	tricyclic
7	49	62	L-UNK	antidepressant
8	64	68	O	assay
NULL

11134454.xml	DDI-MedLine.d36.s1	NO_SECTION	NO_SETID	26
Altered mental status in an adolescent presents a diagnostic challenge, and the clinician depends on clinical evaluation and laboratory studies to determine therapy and prognosis.
1	0	6	O	Altered
2	8	13	O	mental
3	15	20	O	status
4	22	23	O	in
5	25	26	O	an
6	28	37	O	adolescent
7	39	46	O	presents
8	48	48	O	a
9	50	59	O	diagnostic
10	61	69	O	challenge
11	70	70	O	,
12	72	74	O	and
13	76	78	O	the
14	80	88	O	clinician
15	90	96	O	depends
16	98	99	O	on
17	101	108	O	clinical
18	110	119	O	evaluation
19	121	123	O	and
20	125	134	O	laboratory
21	136	142	O	studies
22	144	145	O	to
23	147	155	O	determine
24	157	163	O	therapy
25	165	167	O	and
26	169	177	O	prognosis
NULL

11134454.xml	DDI-MedLine.d36.s2	NO_SECTION	NO_SETID	36
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
1	0	1	O	We
2	3	8	O	report
3	10	12	O	the
4	14	17	O	case
5	19	20	O	of
6	22	23	O	an
7	25	34	O	adolescent
8	36	39	O	with
9	41	47	O	altered
10	49	61	O	consciousness
11	63	68	O	caused
12	70	71	O	by
13	73	85	U-UNK	carbamazepine
14	87	94	O	overdose
15	96	99	O	with
16	101	101	O	a
17	103	110	O	positive
18	112	120	B-UNK	tricyclic
19	122	135	L-UNK	antidepressant
20	137	141	O	level
21	143	144	O	to
22	146	150	O	alert
23	152	161	O	clinicians
24	163	164	O	to
25	166	168	O	the
26	170	174	O	cross
27	176	185	O	reactivity
28	187	188	O	of
29	190	202	U-UNK	carbamazepine
30	204	207	O	with
31	209	209	O	a
32	211	220	O	toxicology
33	222	227	O	screen
34	229	231	O	for
35	233	241	B-UNK	tricyclic
36	243	257	L-UNK	antidepressants
NULL

11137320.xml	DDI-MedLine.d126.s0	NO_SECTION	NO_SETID	16
Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
1	0	11	U-UNK	Cypermethrin
2	13	19	O	induced
3	21	29	O	oxidative
4	31	36	O	stress
5	38	39	O	in
6	41	43	O	rat
7	45	49	O	brain
8	51	53	O	and
9	55	59	O	liver
10	61	62	O	is
11	64	72	O	prevented
12	74	75	O	by
13	77	83	B-UNK	vitamin
14	85	85	L-UNK	E
15	87	88	O	or
16	90	100	U-UNK	allopurinol
NULL

11137320.xml	DDI-MedLine.d126.s1	NO_SECTION	NO_SETID	38
Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid.
1	0	10	O	Considering
2	12	15	O	that
3	17	19	O	the
4	21	31	O	involvement
5	33	34	O	of
6	36	43	O	reactive
7	45	50	O	oxygen
8	52	58	O	species
9	61	63	O	ROS
10	66	68	O	has
11	70	73	O	been
12	75	84	O	implicated
13	86	87	O	in
14	89	91	O	the
15	93	100	O	toxicity
16	102	103	O	of
17	105	111	O	various
18	113	122	O	pesticides
19	123	123	O	,
20	125	128	O	this
21	130	134	O	study
22	136	138	O	was
23	140	147	O	designed
24	149	150	O	to
25	152	162	O	investigate
26	164	166	O	the
27	168	178	O	possibility
28	180	181	O	of
29	183	191	O	oxidative
30	193	198	O	stress
31	200	208	O	induction
32	210	211	O	by
33	213	224	U-UNK	cypermethrin
34	225	225	O	,
35	227	227	O	a
36	229	232	B-UNK	Type
37	234	235	I-UNK	II
38	237	246	L-UNK	pyrethroid
NULL

11137320.xml	DDI-MedLine.d126.s2	NO_SECTION	NO_SETID	62
Either single (170 mg/kg) or repeated (75 mg/kg per day for 5 days) oral administration of cypermethrin was found to produce significant oxidative stress in cerebral and hepatic tissues of rats, as was evident by the elevation of the level of thiobarbituric acid reactive substances (TBARS) in both tissues, either 4 or 24 h after treatment.
1	0	5	O	Either
2	7	12	O	single
3	15	17	O	170
4	19	20	O	mg
5	21	21	O	/
6	22	23	O	kg
7	26	27	O	or
8	29	36	O	repeated
9	39	40	O	75
10	42	43	O	mg
11	44	44	O	/
12	45	46	O	kg
13	48	50	O	per
14	52	54	O	day
15	56	58	O	for
16	60	60	O	5
17	62	65	O	days
18	68	71	O	oral
19	73	86	O	administration
20	88	89	O	of
21	91	102	U-UNK	cypermethrin
22	104	106	O	was
23	108	112	O	found
24	114	115	O	to
25	117	123	O	produce
26	125	135	O	significant
27	137	145	O	oxidative
28	147	152	O	stress
29	154	155	O	in
30	157	164	O	cerebral
31	166	168	O	and
32	170	176	O	hepatic
33	178	184	O	tissues
34	186	187	O	of
35	189	192	O	rats
36	193	193	O	,
37	195	196	O	as
38	198	200	O	was
39	202	208	O	evident
40	210	211	O	by
41	213	215	O	the
42	217	225	O	elevation
43	227	228	O	of
44	230	232	O	the
45	234	238	O	level
46	240	241	O	of
47	243	256	O	thiobarbituric
48	258	261	O	acid
49	263	270	O	reactive
50	272	281	O	substances
51	284	288	O	TBARS
52	291	292	O	in
53	294	297	O	both
54	299	305	O	tissues
55	306	306	O	,
56	308	313	O	either
57	315	315	O	4
58	317	318	O	or
59	320	321	O	24
60	323	323	O	h
61	325	329	O	after
62	331	339	O	treatment
NULL

11137320.xml	DDI-MedLine.d126.s3	NO_SECTION	NO_SETID	30
Much higher changes were observed in liver, increasing from a level of 60% at 4 h up to nearly 4 times the control at 24 h for single dose.
1	0	3	O	Much
2	5	10	O	higher
3	12	18	O	changes
4	20	23	O	were
5	25	32	O	observed
6	34	35	O	in
7	37	41	O	liver
8	42	42	O	,
9	44	53	O	increasing
10	55	58	O	from
11	60	60	O	a
12	62	66	O	level
13	68	69	O	of
14	71	73	O	60%
15	75	76	O	at
16	78	78	O	4
17	80	80	O	h
18	82	83	O	up
19	85	86	O	to
20	88	93	O	nearly
21	95	95	O	4
22	97	101	O	times
23	103	105	O	the
24	107	113	O	control
25	115	116	O	at
26	118	119	O	24
27	121	121	O	h
28	123	125	O	for
29	127	132	O	single
30	134	137	O	dose
NULL

11137320.xml	DDI-MedLine.d126.s4	NO_SECTION	NO_SETID	34
Reduced levels (up to 20%) of total glutathione (total GSH), and elevation of conjugated dienes ( approximately 60% in liver by single dose at 4 h) also indicated the presence of an oxidative insult.
1	0	6	O	Reduced
2	8	13	O	levels
3	16	17	O	up
4	19	20	O	to
5	22	24	O	20%
6	27	28	O	of
7	30	34	O	total
8	36	46	O	glutathione
9	49	53	O	total
10	55	57	O	GSH
11	59	59	O	,
12	61	63	O	and
13	65	73	O	elevation
14	75	76	O	of
15	78	87	O	conjugated
16	89	94	O	dienes
17	98	110	O	approximately
18	112	114	O	60%
19	116	117	O	in
20	119	123	O	liver
21	125	126	O	by
22	128	133	O	single
23	135	138	O	dose
24	140	141	O	at
25	143	143	O	4
26	145	145	O	h
27	148	151	O	also
28	153	161	O	indicated
29	163	165	O	the
30	167	174	O	presence
31	176	177	O	of
32	179	180	O	an
33	182	190	O	oxidative
34	192	197	O	insult
NULL

11137320.xml	DDI-MedLine.d126.s5	NO_SECTION	NO_SETID	27
Glutathione-S-transferase (GST) activity, however, did not differ from control values for any dose or at any time point in cerebral and hepatic tissues.
1	0	10	O	Glutathione
2	12	12	O	S
3	14	24	O	transferase
4	27	29	O	GST
5	32	39	O	activity
6	40	40	O	,
7	42	48	O	however
8	49	49	O	,
9	51	53	O	did
10	55	57	O	not
11	59	64	O	differ
12	66	69	O	from
13	71	77	O	control
14	79	84	O	values
15	86	88	O	for
16	90	92	O	any
17	94	97	O	dose
18	99	100	O	or
19	102	103	O	at
20	105	107	O	any
21	109	112	O	time
22	114	118	O	point
23	120	121	O	in
24	123	130	O	cerebral
25	132	134	O	and
26	136	142	O	hepatic
27	144	150	O	tissues
NULL

11137320.xml	DDI-MedLine.d126.s6	NO_SECTION	NO_SETID	65
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
1	0	11	O	Pretreatment
2	13	14	O	of
3	16	19	O	rats
4	21	24	O	with
5	26	36	U-UNK	allopurinol
6	39	41	O	100
7	43	44	O	mg
8	45	45	O	/
9	46	47	O	kg
10	48	48	O	,
11	50	51	O	ip
12	54	55	O	or
13	57	63	B-UNK	Vitamin
14	65	65	L-UNK	E
15	68	70	O	100
16	72	73	O	mg
17	74	74	O	/
18	75	76	O	kg
19	78	80	O	per
20	82	84	O	day
21	85	85	O	,
22	87	88	O	ig
23	89	89	O	,
24	91	93	O	for
25	95	95	O	3
26	97	100	O	days
27	102	104	O	and
28	106	106	O	a
29	108	111	O	dose
30	113	114	O	of
31	116	117	O	40
32	119	120	O	mg
33	121	121	O	/
34	122	123	O	kg
35	125	126	O	on
36	128	130	O	the
37	132	134	O	4th
38	136	138	O	day
39	141	148	O	provided
40	150	160	O	significant
41	162	171	O	protection
42	173	179	O	against
43	181	183	O	the
44	185	193	O	elevation
45	195	196	O	of
46	198	202	O	TBARS
47	204	209	O	levels
48	211	212	O	in
49	214	221	O	cerebral
50	223	225	O	and
51	227	233	O	hepatic
52	235	241	O	tissues
53	242	242	O	,
54	244	250	O	induced
55	252	253	O	by
56	255	260	O	single
57	262	265	O	high
58	267	270	O	dose
59	272	273	O	of
60	275	278	O	oral
61	280	291	U-UNK	cypermethrin
62	293	306	O	administration
63	308	313	O	within
64	315	315	O	4
65	317	317	O	h
NULL

11137320.xml	DDI-MedLine.d126.s7	NO_SECTION	NO_SETID	36
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	16	O	results
5	18	24	O	suggest
6	26	29	O	that
7	31	42	U-UNK	cypermethrin
8	44	51	O	exposure
9	53	54	O	of
10	56	59	O	rats
11	61	67	O	results
12	69	70	O	in
13	72	75	O	free
14	77	83	O	radical
15	85	92	O	mediated
16	94	99	O	tissue
17	101	106	O	damage
18	107	107	O	,
19	109	110	O	as
20	112	120	O	indicated
21	122	123	O	by
22	125	132	O	elevated
23	134	141	O	cerebral
24	143	145	O	and
25	147	153	O	hepatic
26	155	159	O	lipid
27	161	172	O	peroxidation
28	173	173	O	,
29	175	179	O	which
30	181	183	O	was
31	185	193	O	prevented
32	195	196	O	by
33	198	208	U-UNK	allopurinol
34	210	212	O	and
35	214	220	B-UNK	Vitamin
36	222	222	L-UNK	E
NULL

11137351.xml	DDI-MedLine.d58.s0	NO_SECTION	NO_SETID	13
Effect of ginsenosides on voltage-dependent Ca(2+) channel subtypes in bovine chromaffin cells.
1	0	5	O	Effect
2	7	8	O	of
3	10	21	U-UNK	ginsenosides
4	23	24	O	on
5	26	32	O	voltage
6	34	42	O	dependent
7	44	48	O	Ca(2+
8	51	57	O	channel
9	59	66	O	subtypes
10	68	69	O	in
11	71	76	O	bovine
12	78	87	O	chromaffin
13	89	93	O	cells
NULL

11137351.xml	DDI-MedLine.d58.s1	NO_SECTION	NO_SETID	18
In previous reports we have shown that ginsenosides inhibit high threshold voltage-dependent Ca(2+) channels in neuronal cells.
1	0	1	O	In
2	3	10	O	previous
3	12	18	O	reports
4	20	21	O	we
5	23	26	O	have
6	28	32	O	shown
7	34	37	O	that
8	39	50	U-UNK	ginsenosides
9	52	58	O	inhibit
10	60	63	O	high
11	65	73	O	threshold
12	75	81	O	voltage
13	83	91	O	dependent
14	93	97	O	Ca(2+
15	100	107	O	channels
16	109	110	O	in
17	112	119	O	neuronal
18	121	125	O	cells
NULL

11137351.xml	DDI-MedLine.d58.s2	NO_SECTION	NO_SETID	39
However, these studies did not show whether ginsenosides-induced inhibition of Ca(2+) currents discriminates among the various Ca(2+) channel subtypes, although it is known that there are at least five different Ca(2+) channel subtypes in neuronal cells.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	these
4	15	21	O	studies
5	23	25	O	did
6	27	29	O	not
7	31	34	O	show
8	36	42	O	whether
9	44	55	U-UNK	ginsenosides
10	57	63	O	induced
11	65	74	O	inhibition
12	76	77	O	of
13	79	83	O	Ca(2+
14	86	93	O	currents
15	95	107	O	discriminates
16	109	113	O	among
17	115	117	O	the
18	119	125	O	various
19	127	131	O	Ca(2+
20	134	140	O	channel
21	142	149	O	subtypes
22	150	150	O	,
23	152	159	O	although
24	161	162	O	it
25	164	165	O	is
26	167	171	O	known
27	173	176	O	that
28	178	182	O	there
29	184	186	O	are
30	188	189	O	at
31	191	195	O	least
32	197	200	O	five
33	202	210	O	different
34	212	216	O	Ca(2+
35	219	225	O	channel
36	227	234	O	subtypes
37	236	237	O	in
38	239	246	O	neuronal
39	248	252	O	cells
NULL

11137351.xml	DDI-MedLine.d58.s3	NO_SECTION	NO_SETID	43
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	14	15	O	we
5	17	28	O	investigated
6	30	32	O	the
7	34	39	O	effect
8	41	42	O	of
9	44	55	U-UNK	ginsenosides
10	57	58	O	on
11	60	63	O	high
12	65	73	O	threshold
13	75	81	O	voltage
14	83	91	O	dependent
15	93	97	O	Ca(2+
16	100	106	O	channel
17	108	115	O	subtypes
18	117	121	O	using
19	123	127	O	their
20	129	137	B-UNK	selective
21	139	143	I-UNK	Ca(2+
22	146	152	I-UNK	channel
23	154	161	L-UNK	blockers
24	163	172	U-UNK	nimodipine
25	175	175	O	L
26	177	180	O	type
27	182	182	O	,
28	184	188	B-UNK	omega
29	190	198	I-UNK	conotoxin
30	200	203	L-UNK	GVIA
31	206	206	O	N
32	208	211	O	type
33	213	213	O	,
34	215	216	O	or
35	218	222	B-UNK	omega
36	224	231	I-UNK	agatoxin
37	233	235	L-UNK	IVA
38	238	238	O	P
39	240	243	O	type
40	246	247	O	in
41	249	254	O	bovine
42	256	265	O	chromaffin
43	267	271	O	cells
NULL

11137351.xml	DDI-MedLine.d58.s4	NO_SECTION	NO_SETID	17
We could observe that ginsenosides inhibited high threshold voltage-dependent Ca(2+) currents in a dose-dependent manner.
1	0	1	O	We
2	3	7	O	could
3	9	15	O	observe
4	17	20	O	that
5	22	33	U-UNK	ginsenosides
6	35	43	O	inhibited
7	45	48	O	high
8	50	58	O	threshold
9	60	66	O	voltage
10	68	76	O	dependent
11	78	82	O	Ca(2+
12	85	92	O	currents
13	94	95	O	in
14	97	97	O	a
15	99	102	O	dose
16	104	112	O	dependent
17	114	119	O	manner
NULL

11137351.xml	DDI-MedLine.d58.s5	NO_SECTION	NO_SETID	8
The IC(50) was about 120 microgram/ml.
1	0	2	O	The
2	4	8	O	IC(50
3	11	13	O	was
4	15	19	O	about
5	21	23	O	120
6	25	33	O	microgram
7	34	34	O	/
8	35	36	O	ml
NULL

11137351.xml	DDI-MedLine.d58.s6	NO_SECTION	NO_SETID	7
Nimodipine had no effect on ginsenosides response.
1	0	9	U-UNK	Nimodipine
2	11	13	O	had
3	15	16	O	no
4	18	23	O	effect
5	25	26	O	on
6	28	39	U-UNK	ginsenosides
7	41	48	O	response
NULL

11137351.xml	DDI-MedLine.d58.s7	NO_SECTION	NO_SETID	52
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	22	O	that
5	24	35	U-UNK	ginsenosides
6	37	39	O	are
7	41	50	O	negatively
8	52	58	O	coupled
9	60	61	O	to
10	63	67	O	three
11	69	73	O	types
12	75	76	O	of
13	78	84	O	calcium
14	86	93	O	channels
15	95	96	O	in
16	98	103	O	bovine
17	105	114	O	chromaffin
18	116	119	O	cell
19	120	120	O	,
20	122	130	O	including
21	132	133	O	an
22	135	139	B-UNK	omega
23	141	149	I-UNK	conotoxin
24	151	154	L-UNK	GVIA
25	156	164	O	sensitive
26	167	167	O	N
27	169	172	O	type
28	175	181	O	channel
29	182	182	O	,
30	184	185	O	an
31	187	191	B-UNK	omega
32	193	200	I-UNK	agatoxin
33	202	204	L-UNK	IVA
34	206	214	O	sensitive
35	217	217	O	P
36	219	222	O	type
37	225	231	O	channel
38	233	235	O	and
39	237	246	U-UNK	nimodipine
40	247	247	O	/
41	248	252	B-UNK	omega
42	254	262	I-UNK	conotoxin
43	264	267	L-UNK	GVIA
44	268	268	O	/
45	269	273	B-UNK	omega
46	275	282	I-UNK	agatoxin
47	284	286	L-UNK	VIA
48	288	296	O	resistant
49	299	309	O	presumptive
50	311	311	O	Q
51	313	316	O	type
52	319	325	O	channel
NULL

11137351.xml	DDI-MedLine.d58.s8	NO_SECTION	NO_SETID	27
Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	18	O	selective
5	20	29	O	regulation
6	31	32	O	of
7	34	40	O	voltage
8	42	50	O	dependent
9	52	56	O	Ca(2+
10	59	66	O	subtypes
11	68	69	O	by
12	71	82	U-UNK	ginsenosides
13	84	85	O	in
14	87	92	O	bovine
15	94	103	O	chromaffin
16	105	108	O	cell
17	110	114	O	could
18	116	117	O	be
19	119	121	O	the
20	123	130	O	cellular
21	132	136	O	basis
22	138	139	O	of
23	141	150	O	antistress
24	152	158	O	effects
25	160	166	O	induced
26	168	169	O	by
27	171	177	U-UNK	ginseng
NULL

11137650.xml	DDI-MedLine.d8.s0	NO_SECTION	NO_SETID	18
In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
1	0	1	O	In
2	3	7	O	vitro
3	9	16	O	activity
4	18	19	O	of
5	21	23	B-UNK	KRM
6	25	28	L-UNK	1648
7	29	29	O	,
8	31	36	O	either
9	38	43	O	singly
10	45	46	O	or
11	48	49	O	in
12	51	61	O	combination
13	63	66	O	with
14	68	76	U-UNK	ofloxacin
15	77	77	O	,
16	79	85	O	against
17	87	99	O	Mycobacterium
18	101	108	O	ulcerans
NULL

11137650.xml	DDI-MedLine.d8.s1	NO_SECTION	NO_SETID	33
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
1	0	2	O	The
2	4	16	O	antimicrobial
3	18	23	O	effect
4	25	26	O	of
5	28	28	O	a
6	30	49	U-UNK	benzoxazinorifamycin
7	50	50	O	,
8	52	54	B-UNK	KRM
9	56	59	L-UNK	1648
10	60	60	O	,
11	62	67	O	either
12	69	73	O	alone
13	75	76	O	or
14	78	79	O	in
15	81	91	O	combination
16	93	96	O	with
17	98	106	U-UNK	ofloxacin
18	107	107	O	,
19	109	111	O	was
20	113	121	O	evaluated
21	123	124	O	in
22	126	130	O	vitro
23	132	138	O	against
24	140	142	O	two
25	144	147	O	type
26	149	155	O	strains
27	157	159	O	and
28	161	163	O	six
29	165	172	O	clinical
30	174	181	O	isolates
31	183	184	O	of
32	186	198	O	Mycobacterium
33	200	207	O	ulcerans
NULL

11137650.xml	DDI-MedLine.d8.s3	NO_SECTION	NO_SETID	11
ulcerans was measured by plate counts and the BACTEC radiometric method.
1	0	7	O	ulcerans
2	9	11	O	was
3	13	20	O	measured
4	22	23	O	by
5	25	29	O	plate
6	31	36	O	counts
7	38	40	O	and
8	42	44	O	the
9	46	51	O	BACTEC
10	53	63	O	radiometric
11	65	70	O	method
NULL

11137650.xml	DDI-MedLine.d8.s4	NO_SECTION	NO_SETID	15
The minimal inhibitory concentration as well as minimal bactericidal concentration of KRM-1648 against M.
1	0	2	O	The
2	4	10	O	minimal
3	12	21	O	inhibitory
4	23	35	O	concentration
5	37	38	O	as
6	40	43	O	well
7	45	46	O	as
8	48	54	O	minimal
9	56	67	O	bactericidal
10	69	81	O	concentration
11	83	84	O	of
12	86	88	B-UNK	KRM
13	90	93	L-UNK	1648
14	95	101	O	against
15	103	103	O	M
NULL

11137650.xml	DDI-MedLine.d8.s5	NO_SECTION	NO_SETID	34
ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively.
1	0	7	O	ulcerans
2	9	11	O	was
3	13	19	O	between
4	21	25	O	0.012
5	27	29	O	and
6	31	35	O	0.025
7	37	38	O	mg
8	39	39	O	/
9	40	40	O	l
10	41	41	O	,
11	43	47	O	while
12	49	61	O	corresponding
13	63	68	O	values
14	70	72	O	for
15	74	83	U-UNK	rifampicin
16	85	87	O	and
17	89	97	U-UNK	rifabutin
18	99	102	O	were
19	104	105	O	in
20	107	109	O	the
21	111	115	O	range
22	117	118	O	of
23	120	122	O	0.1
24	124	126	O	0.8
25	128	129	O	mg
26	130	130	O	/
27	131	131	O	l
28	133	135	O	and
29	137	139	O	0.1
30	141	143	O	0.4
31	145	146	O	mg
32	147	147	O	/
33	148	148	O	l
34	150	161	O	respectively
NULL

11137650.xml	DDI-MedLine.d8.s6	NO_SECTION	NO_SETID	26
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
1	0	3	O	When
2	5	12	O	combined
3	14	17	O	with
4	19	27	U-UNK	ofloxacin
5	28	28	O	,
6	30	32	B-UNK	KRM
7	34	37	L-UNK	1648
8	39	47	O	exhibited
9	49	54	O	strong
10	56	66	O	synergistic
11	68	75	O	activity
12	77	81	O	while
13	83	86	O	only
14	88	95	O	additive
15	97	103	O	effects
16	105	108	O	were
17	110	117	O	observed
18	119	122	O	with
19	124	126	O	the
20	128	138	O	combination
21	140	141	O	of
22	143	152	U-UNK	rifampicin
23	155	156	O	or
24	158	166	U-UNK	rifabutin
25	169	171	O	and
26	173	181	U-UNK	ofloxacin
NULL

11137650.xml	DDI-MedLine.d8.s7	NO_SECTION	NO_SETID	15
These results suggest that KRM-1648 has a great potential in the treatment of M.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	29	B-UNK	KRM
6	31	34	L-UNK	1648
7	36	38	O	has
8	40	40	O	a
9	42	46	O	great
10	48	56	O	potential
11	58	59	O	in
12	61	63	O	the
13	65	73	O	treatment
14	75	76	O	of
15	78	78	O	M
NULL

11137703.xml	DDI-MedLine.d114.s0	NO_SECTION	NO_SETID	16
Inhibitory effects of ruthenium red on inositol 1,4, 5-trisphosphate-induced responses in rat megakaryocytes.
1	0	9	O	Inhibitory
2	11	17	O	effects
3	19	20	O	of
4	22	30	B-UNK	ruthenium
5	32	34	L-UNK	red
6	36	37	O	on
7	39	46	O	inositol
8	48	50	O	1,4
9	51	51	O	,
10	53	53	O	5
11	55	67	O	trisphosphate
12	69	75	O	induced
13	77	85	O	responses
14	87	88	O	in
15	90	92	O	rat
16	94	107	O	megakaryocytes
NULL

11137703.xml	DDI-MedLine.d114.s1	NO_SECTION	NO_SETID	34
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	23	B-UNK	ruthenium
5	25	27	L-UNK	red
6	30	31	U-UNK	RR
7	34	35	O	on
8	37	44	B-UNK	inositol
9	46	50	I-UNK	1,4,5
10	52	64	L-UNK	trisphosphate
11	67	72	U-UNK	InsP(3
12	76	82	O	induced
13	84	92	O	responses
14	94	97	O	were
15	99	105	O	studied
16	107	108	O	in
17	110	112	O	rat
18	114	117	O	bone
19	119	124	O	marrow
20	126	139	O	megakaryocytes
21	141	144	O	with
22	146	148	O	the
23	150	154	O	patch
24	156	160	O	clamp
25	162	166	O	whole
26	168	171	O	cell
27	173	181	O	recording
28	183	191	O	technique
29	193	194	O	in
30	196	206	O	combination
31	208	211	O	with
32	213	216	O	fura
33	218	218	O	2
34	220	235	O	microfluorometry
NULL

11137703.xml	DDI-MedLine.d114.s2	NO_SECTION	NO_SETID	18
Internal application of InsP(3) (100 microM) increased intracellular Ca(2+) concentration ([Ca(2+)](i)) and activated the Ca(2+)-dependent K(+) current.
1	0	7	O	Internal
2	9	19	O	application
3	21	22	O	of
4	24	29	U-UNK	InsP(3
5	33	35	O	100
6	37	42	O	microM
7	45	53	O	increased
8	55	67	O	intracellular
9	69	73	O	Ca(2+
10	76	88	O	concentration
11	92	100	O	Ca(2+)](i
12	104	106	O	and
13	108	116	O	activated
14	118	120	O	the
15	122	126	O	Ca(2+
16	129	137	O	dependent
17	139	141	O	K(+
18	144	150	O	current
NULL

11137703.xml	DDI-MedLine.d114.s3	NO_SECTION	NO_SETID	22
Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
1	0	12	O	Administering
2	14	19	U-UNK	InsP(3
3	22	29	O	together
4	31	34	O	with
5	36	37	U-UNK	RR
6	40	42	O	100
7	44	46	O	500
8	48	53	O	microM
9	56	64	O	inhibited
10	66	71	O	InsP(3
11	74	80	O	induced
12	82	90	O	responses
13	93	96	O	both
14	98	102	O	Ca(2+
15	105	107	O	and
16	109	115	O	current
17	117	125	O	responses
18	128	129	O	in
19	131	131	O	a
20	133	136	O	dose
21	138	146	O	dependent
22	148	154	O	fashion
NULL

11137703.xml	DDI-MedLine.d114.s4	NO_SECTION	NO_SETID	13
Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
1	0	11	O	Pretreatment
2	13	14	O	of
3	16	29	O	megakaryocytes
4	31	34	O	with
5	36	48	O	extracellular
6	50	51	U-UNK	RR
7	54	55	O	50
8	57	62	O	microM
9	65	68	O	also
10	70	78	O	inhibited
11	80	85	U-UNK	InsP(3
12	88	94	O	induced
13	96	104	O	responses
NULL

11137703.xml	DDI-MedLine.d114.s5	NO_SECTION	NO_SETID	12
Intracellular and extracellular application of RR reduced ADP-induced increases in [Ca(2+)](i).
1	0	12	O	Intracellular
2	14	16	O	and
3	18	30	O	extracellular
4	32	42	O	application
5	44	45	O	of
6	47	48	U-UNK	RR
7	50	56	O	reduced
8	58	60	O	ADP
9	62	68	O	induced
10	70	78	O	increases
11	80	81	O	in
12	84	92	O	Ca(2+)](i
NULL

11137703.xml	DDI-MedLine.d114.s6	NO_SECTION	NO_SETID	18
In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	in
5	16	23	O	isolated
6	25	30	O	single
7	32	41	O	pancreatic
8	43	48	O	acinar
9	50	54	O	cells
10	55	55	O	,
11	57	58	U-UNK	RR
12	60	62	O	had
13	64	65	O	no
14	67	72	O	effect
15	74	75	O	on
16	77	82	U-UNK	InsP(3
17	85	91	O	induced
18	93	101	O	responses
NULL

11137703.xml	DDI-MedLine.d114.s7	NO_SECTION	NO_SETID	26
Taken together, these results suggest that the site of the inhibitory action of RR is at the InsP(3) receptor, or its closely associated proteins.
1	0	4	O	Taken
2	6	13	O	together
3	14	14	O	,
4	16	20	O	these
5	22	28	O	results
6	30	36	O	suggest
7	38	41	O	that
8	43	45	O	the
9	47	50	O	site
10	52	53	O	of
11	55	57	O	the
12	59	68	O	inhibitory
13	70	75	O	action
14	77	78	O	of
15	80	81	U-UNK	RR
16	83	84	O	is
17	86	87	O	at
18	89	91	O	the
19	93	98	O	InsP(3
20	101	108	O	receptor
21	109	109	O	,
22	111	112	O	or
23	114	116	O	its
24	118	124	O	closely
25	126	135	O	associated
26	137	144	O	proteins
NULL

11137703.xml	DDI-MedLine.d114.s8	NO_SECTION	NO_SETID	23
In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	we
5	16	19	O	have
6	21	25	O	shown
7	27	30	O	that
8	32	33	U-UNK	RR
9	35	36	O	is
10	38	38	O	a
11	40	45	O	useful
12	47	61	O	pharmacological
13	63	66	O	tool
14	68	71	O	with
15	73	77	O	which
16	79	80	O	to
17	82	88	O	examine
18	90	92	O	the
19	94	99	U-UNK	InsP(3
20	102	109	O	mediated
21	111	119	O	responses
22	121	122	O	of
23	124	137	O	megakaryocytes
NULL

11144988.xml	DDI-MedLine.d109.s0	NO_SECTION	NO_SETID	11
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
1	0	5	O	Effect
2	7	8	O	of
3	10	18	U-UNK	rofecoxib
4	20	21	O	on
5	23	25	O	the
6	27	42	O	pharmacokinetics
7	44	45	O	of
8	47	53	U-UNK	digoxin
9	55	56	O	in
10	58	64	O	healthy
11	66	75	O	volunteers
NULL

11144988.xml	DDI-MedLine.d109.s1	NO_SECTION	NO_SETID	30
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects.
1	0	2	O	The
2	4	10	O	authors
3	12	19	O	examined
4	21	23	O	the
5	25	30	O	effect
6	32	33	O	of
7	35	37	O	the
8	39	52	O	cyclooxygenase
9	54	54	O	2
10	57	59	O	COX
11	61	61	O	2
12	64	72	O	inhibitor
13	73	73	O	,
14	75	83	U-UNK	rofecoxib
15	84	84	O	,
16	86	87	O	at
17	89	94	O	steady
18	96	100	O	state
19	102	103	O	on
20	105	107	O	the
21	109	124	O	pharmacokinetics
22	126	127	O	of
23	129	135	U-UNK	digoxin
24	137	145	O	following
25	147	147	O	a
26	149	154	O	single
27	156	159	O	dose
28	161	162	O	in
29	164	170	O	healthy
30	172	179	O	subjects
NULL

11144988.xml	DDI-MedLine.d109.s2	NO_SECTION	NO_SETID	30
Each healthy subject (N = 10) received rofecoxib (75 mg once daily) or placebo for 11 days in a double-blind, randomized, balanced, two-period crossover study.
1	0	3	O	Each
2	5	11	O	healthy
3	13	19	O	subject
4	22	22	O	N
5	24	24	O	=
6	26	27	O	10
7	30	37	O	received
8	39	47	U-UNK	rofecoxib
9	50	51	O	75
10	53	54	O	mg
11	56	59	O	once
12	61	65	O	daily
13	68	69	O	or
14	71	77	O	placebo
15	79	81	O	for
16	83	84	O	11
17	86	89	O	days
18	91	92	O	in
19	94	94	O	a
20	96	101	O	double
21	103	107	O	blind
22	108	108	O	,
23	110	119	O	randomized
24	120	120	O	,
25	122	129	O	balanced
26	130	130	O	,
27	132	134	O	two
28	136	141	O	period
29	143	151	O	crossover
30	153	157	O	study
NULL

11144988.xml	DDI-MedLine.d109.s3	NO_SECTION	NO_SETID	20
A single 0.5 mg oral dose of digoxin elixir was administered on the 7th day of each 11-day period.
1	0	0	O	A
2	2	7	O	single
3	9	11	O	0.5
4	13	14	O	mg
5	16	19	O	oral
6	21	24	O	dose
7	26	27	O	of
8	29	35	U-UNK	digoxin
9	37	42	O	elixir
10	44	46	O	was
11	48	59	O	administered
12	61	62	O	on
13	64	66	O	the
14	68	70	O	7th
15	72	74	O	day
16	76	77	O	of
17	79	82	O	each
18	84	85	O	11
19	87	89	O	day
20	91	96	O	period
NULL

11144988.xml	DDI-MedLine.d109.s4	NO_SECTION	NO_SETID	10
Each treatment period was separated by 14 to 21 days.
1	0	3	O	Each
2	5	13	O	treatment
3	15	20	O	period
4	22	24	O	was
5	26	34	O	separated
6	36	37	O	by
7	39	40	O	14
8	42	43	O	to
9	45	46	O	21
10	48	51	O	days
NULL

11144988.xml	DDI-MedLine.d109.s5	NO_SECTION	NO_SETID	17
Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose.
1	0	6	O	Samples
2	8	10	O	for
3	12	17	O	plasma
4	19	21	O	and
5	23	27	O	urine
6	29	42	O	immunoreactive
7	44	50	U-UNK	digoxin
8	52	65	O	concentrations
9	67	70	O	were
10	72	80	O	collected
11	82	88	O	through
12	90	92	O	120
13	94	98	O	hours
14	100	108	O	following
15	110	112	O	the
16	114	120	U-UNK	digoxin
17	122	125	O	dose
NULL

11144988.xml	DDI-MedLine.d109.s6	NO_SECTION	NO_SETID	17
No statistically significant differences between treatment groups were observed for any of the calculated digoxin pharmacokinetic parameters.
1	0	1	O	No
2	3	15	O	statistically
3	17	27	O	significant
4	29	39	O	differences
5	41	47	O	between
6	49	57	O	treatment
7	59	64	O	groups
8	66	69	O	were
9	71	78	O	observed
10	80	82	O	for
11	84	86	O	any
12	88	89	O	of
13	91	93	O	the
14	95	104	O	calculated
15	106	112	U-UNK	digoxin
16	114	128	O	pharmacokinetic
17	130	139	O	parameters
NULL

11144988.xml	DDI-MedLine.d109.s7	NO_SECTION	NO_SETID	44
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
1	0	2	O	For
2	4	10	U-UNK	digoxin
3	12	16	O	AUC(0
4	18	25	O	infinity
5	27	27	O	,
6	29	33	O	AUC(0
7	35	36	O	24
8	38	38	O	,
9	40	42	O	and
10	44	47	O	Cmax
11	48	48	O	,
12	50	52	O	the
13	54	62	O	geometric
14	64	67	O	mean
15	69	74	O	ratios
16	77	79	O	90%
17	81	90	O	confidence
18	92	99	O	interval
19	102	104	O	for
20	107	115	U-UNK	rofecoxib
21	117	117	O	+
22	119	125	U-UNK	digoxin
23	126	126	O	/
24	127	133	O	placebo
25	135	135	O	+
26	137	143	U-UNK	digoxin
27	146	149	O	were
28	151	154	O	1.04
29	157	160	O	0.94
30	161	161	O	,
31	163	166	O	1.14
32	168	168	O	,
33	170	173	O	1.02
34	176	179	O	0.94
35	180	180	O	,
36	182	185	O	1.09
37	187	187	O	,
38	189	191	O	and
39	193	196	O	1.00
40	199	202	O	0.91
41	203	203	O	,
42	205	208	O	1.10
43	210	210	O	,
44	212	223	O	respectively
NULL

11144988.xml	DDI-MedLine.d109.s8	NO_SECTION	NO_SETID	10
The digoxin median tmax was 0.5 hours for both treatments.
1	0	2	O	The
2	4	10	U-UNK	digoxin
3	12	17	O	median
4	19	22	O	tmax
5	24	26	O	was
6	28	30	O	0.5
7	32	36	O	hours
8	38	40	O	for
9	42	45	O	both
10	47	56	O	treatments
NULL

11144988.xml	DDI-MedLine.d109.s9	NO_SECTION	NO_SETID	22
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.
1	0	2	O	The
2	4	11	O	harmonic
3	13	16	O	mean
4	18	28	O	elimination
5	30	33	O	half
6	35	38	O	life
7	40	42	O	was
8	44	47	O	45.7
9	49	51	O	and
10	53	56	O	43.4
11	58	62	O	hours
12	64	66	O	for
13	68	76	U-UNK	rofecoxib
14	78	78	O	+
15	80	86	U-UNK	digoxin
16	88	90	O	and
17	92	98	O	placebo
18	100	100	O	+
19	102	108	U-UNK	digoxin
20	110	119	O	treatments
21	120	120	O	,
22	122	133	O	respectively
NULL

11144988.xml	DDI-MedLine.d109.s10	NO_SECTION	NO_SETID	4
Digoxin is eliminated renally.
1	0	6	U-UNK	Digoxin
2	8	9	O	is
3	11	20	O	eliminated
4	22	28	O	renally
NULL

11144988.xml	DDI-MedLine.d109.s11	NO_SECTION	NO_SETID	32
The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.
1	0	2	O	The
2	4	7	O	mean
3	10	11	O	SD
4	14	23	O	cumulative
5	25	31	O	urinary
6	33	41	O	excretion
7	43	44	O	of
8	46	59	O	immunoreactive
9	61	67	U-UNK	digoxin
10	69	73	O	after
11	75	84	O	concurrent
12	86	94	O	treatment
13	96	99	O	with
14	101	109	U-UNK	rofecoxib
15	111	112	O	or
16	114	120	O	placebo
17	122	124	O	was
18	126	130	O	228.2
19	133	133	O	+
20	134	134	O	/
21	137	140	O	30.8
22	143	145	O	and
23	147	151	O	235.1
24	154	154	O	+
25	155	155	O	/
26	158	161	O	39.1
27	164	173	O	micrograms
28	174	174	O	/
29	175	177	O	120
30	179	183	O	hours
31	184	184	O	,
32	186	197	O	respectively
NULL

11144988.xml	DDI-MedLine.d109.s12	NO_SECTION	NO_SETID	22
Transient and minor adverse events occurred with similar frequency on placebo and rofecoxib treatments, and no treatment-related pattern was apparent.
1	0	8	O	Transient
2	10	12	O	and
3	14	18	O	minor
4	20	26	O	adverse
5	28	33	O	events
6	35	42	O	occurred
7	44	47	O	with
8	49	55	O	similar
9	57	65	O	frequency
10	67	68	O	on
11	70	76	O	placebo
12	78	80	O	and
13	82	90	U-UNK	rofecoxib
14	92	101	O	treatments
15	102	102	O	,
16	104	106	O	and
17	108	109	O	no
18	111	119	O	treatment
19	121	127	O	related
20	129	135	O	pattern
21	137	139	O	was
22	141	148	O	apparent
NULL

11144988.xml	DDI-MedLine.d109.s13	NO_SECTION	NO_SETID	17
Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.
1	0	8	U-UNK	Rofecoxib
2	10	12	O	did
3	14	16	O	not
4	18	26	O	influence
5	28	30	O	the
6	32	37	O	plasma
7	39	54	O	pharmacokinetics
8	56	57	O	or
9	59	63	O	renal
10	65	75	O	elimination
11	77	78	O	of
12	80	80	O	a
13	82	87	O	single
14	89	92	O	oral
15	94	97	O	dose
16	99	100	O	of
17	102	108	U-UNK	digoxin
NULL

11148572.xml	DDI-MedLine.d115.s0	NO_SECTION	NO_SETID	26
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
1	0	10	O	Concomitant
2	12	27	U-UNK	cyclophosphamide
3	28	28	O	,
4	30	40	U-UNK	doxorubicin
5	41	41	O	,
6	43	53	U-UNK	vincristine
7	54	54	O	,
8	56	58	O	and
9	60	69	U-UNK	prednisone
10	71	82	O	chemotherapy
11	84	87	O	plus
12	89	94	B-UNK	highly
13	96	101	I-UNK	active
14	103	116	L-UNK	antiretroviral
15	118	124	O	therapy
16	126	127	O	in
17	129	136	O	patients
18	138	141	O	with
19	143	147	O	human
20	149	164	O	immunodeficiency
21	166	170	O	virus
22	172	178	O	related
23	179	179	O	,
24	181	183	O	non
25	185	191	O	Hodgkin
26	193	200	O	lymphoma
NULL

11148572.xml	DDI-MedLine.d115.s1	NO_SECTION	NO_SETID	27
BACKGROUND: The feasibility and efficacy of concomitant chemotherapy and highly active antiretroviral therapy (HAART) is still unknown in patients with human immunodeficiency virus (HIV)-related malignancies.
1	0	9	O	BACKGROUND
2	10	10	O	:
3	12	14	O	The
4	16	26	O	feasibility
5	28	30	O	and
6	32	39	O	efficacy
7	41	42	O	of
8	44	54	O	concomitant
9	56	67	O	chemotherapy
10	69	71	O	and
11	73	78	B-UNK	highly
12	80	85	I-UNK	active
13	87	100	L-UNK	antiretroviral
14	102	108	O	therapy
15	111	115	O	HAART
16	118	119	O	is
17	121	125	O	still
18	127	133	O	unknown
19	135	136	O	in
20	138	145	O	patients
21	147	150	O	with
22	152	156	O	human
23	158	173	O	immunodeficiency
24	175	179	O	virus
25	182	184	O	HIV
26	187	193	O	related
27	195	206	O	malignancies
NULL

11148572.xml	DDI-MedLine.d115.s2	NO_SECTION	NO_SETID	91
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
1	0	1	O	To
2	3	10	O	evaluate
3	12	14	O	the
4	16	21	O	impact
5	23	24	O	of
6	26	37	O	chemotherapy
7	39	42	O	plus
8	44	48	O	HAART
9	50	51	O	on
10	53	55	O	the
11	57	64	O	clinical
12	66	71	O	course
13	73	74	O	of
14	76	83	O	patients
15	85	88	O	with
16	90	92	O	HIV
17	94	100	O	related
18	101	101	O	,
19	103	110	O	systemic
20	111	111	O	,
21	113	115	O	non
22	117	123	O	Hodgkin
23	125	132	O	lymphoma
24	135	137	O	HIV
25	139	141	O	NHL
26	143	143	O	,
27	145	147	O	the
28	149	155	O	authors
29	157	164	O	compared
30	166	180	O	retrospectively
31	182	182	O	a
32	184	188	O	group
33	190	191	O	of
34	193	194	O	24
35	196	203	O	patients
36	205	208	O	with
37	210	212	O	HIV
38	214	216	O	NHL
39	218	220	O	who
40	222	225	O	were
41	227	233	O	treated
42	235	238	O	with
43	240	242	O	the
44	244	259	U-UNK	cyclophosphamide
45	260	260	O	,
46	262	272	U-UNK	doxorubicin
47	273	273	O	,
48	275	285	U-UNK	vincristine
49	286	286	O	,
50	288	290	O	and
51	292	301	U-UNK	prednisone
52	304	307	O	CHOP
53	310	321	O	chemotherapy
54	323	329	O	regimen
55	331	334	O	plus
56	336	340	O	HAART
57	342	345	O	with
58	347	347	O	a
59	349	353	O	group
60	355	356	O	of
61	358	359	O	80
62	361	368	O	patients
63	370	372	O	who
64	374	377	O	were
65	379	385	O	treated
66	387	390	O	with
67	392	395	O	CHOP
68	397	408	O	chemotherapy
69	410	411	O	or
70	413	413	O	a
71	415	418	O	CHOP
72	420	423	O	like
73	425	431	O	regimen
74	434	436	O	i.e
75	438	438	O	,
76	440	455	U-UNK	cyclophosphamide
77	456	456	O	,
78	458	468	U-UNK	doxorubicin
79	469	469	O	,
80	471	480	U-UNK	teniposide
81	481	481	O	,
82	483	485	O	and
83	487	496	U-UNK	prednisone
84	498	501	O	with
85	503	513	U-UNK	vincristine
86	515	518	O	plus
87	520	528	U-UNK	bleomycin
88	531	537	O	without
89	539	547	O	receiving
90	549	562	U-UNK	antiretroviral
91	564	570	O	therapy
NULL

11148572.xml	DDI-MedLine.d115.s3	NO_SECTION	NO_SETID	25
METHODS: All patients were enrolled in two sequential trials performed at the Aviano Cancer Center, Italy, from April 1988 to December 1998.
1	0	6	O	METHODS
2	7	7	O	:
3	9	11	O	All
4	13	20	O	patients
5	22	25	O	were
6	27	34	O	enrolled
7	36	37	O	in
8	39	41	O	two
9	43	52	O	sequential
10	54	59	O	trials
11	61	69	O	performed
12	71	72	O	at
13	74	76	O	the
14	78	83	O	Aviano
15	85	90	O	Cancer
16	92	97	O	Center
17	98	98	O	,
18	100	104	O	Italy
19	105	105	O	,
20	107	110	O	from
21	112	116	O	April
22	118	121	O	1988
23	123	124	O	to
24	126	133	O	December
25	135	138	O	1998
NULL

11148572.xml	DDI-MedLine.d115.s4	NO_SECTION	NO_SETID	9
HAART was included with combination therapy from January 1997.
1	0	4	O	HAART
2	6	8	O	was
3	10	17	O	included
4	19	22	O	with
5	24	34	O	combination
6	36	42	O	therapy
7	44	47	O	from
8	49	55	O	January
9	57	60	O	1997
NULL

11148572.xml	DDI-MedLine.d115.s5	NO_SECTION	NO_SETID	12
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor.
1	0	13	U-UNK	Antiretroviral
2	15	22	O	regimens
3	24	32	O	consisted
4	34	35	O	of
5	37	39	O	two
6	41	47	B-UNK	reverse
7	49	61	I-UNK	transcriptase
8	63	72	L-UNK	inhibitors
9	74	76	O	and
10	78	80	O	one
11	82	89	B-UNK	protease
12	91	99	L-UNK	inhibitor
NULL

11148572.xml	DDI-MedLine.d115.s6	NO_SECTION	NO_SETID	33
RESULTS: The two treatment groups were well matched with regard to patient demographics, NHL characteristics, HIV status, and treatment, i.e., the number of cycles and chemotherapy dose.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	11	O	The
4	13	15	O	two
5	17	25	O	treatment
6	27	32	O	groups
7	34	37	O	were
8	39	42	O	well
9	44	50	O	matched
10	52	55	O	with
11	57	62	O	regard
12	64	65	O	to
13	67	73	O	patient
14	75	86	O	demographics
15	87	87	O	,
16	89	91	O	NHL
17	93	107	O	characteristics
18	108	108	O	,
19	110	112	O	HIV
20	114	119	O	status
21	120	120	O	,
22	122	124	O	and
23	126	134	O	treatment
24	135	135	O	,
25	137	139	O	i.e
26	141	141	O	,
27	143	145	O	the
28	147	152	O	number
29	154	155	O	of
30	157	162	O	cycles
31	164	166	O	and
32	168	179	O	chemotherapy
33	181	184	O	dose
NULL

11148572.xml	DDI-MedLine.d115.s7	NO_SECTION	NO_SETID	9
The response rates were similar between the two groups.
1	0	2	O	The
2	4	11	O	response
3	13	17	O	rates
4	19	22	O	were
5	24	30	O	similar
6	32	38	O	between
7	40	42	O	the
8	44	46	O	two
9	48	53	O	groups
NULL

11148572.xml	DDI-MedLine.d115.s8	NO_SECTION	NO_SETID	38
Severe anemia (Grade 3-4 according to the World Health Organization criteria) was significantly greater in the patients who received CHOP-HAART compared with the patients who received CHOP alone (33% vs. 7%, respectively; P = 0.001).
1	0	5	O	Severe
2	7	12	O	anemia
3	15	19	O	Grade
4	21	21	O	3
5	23	23	O	4
6	25	33	O	according
7	35	36	O	to
8	38	40	O	the
9	42	46	O	World
10	48	53	O	Health
11	55	66	O	Organization
12	68	75	O	criteria
13	78	80	O	was
14	82	94	O	significantly
15	96	102	O	greater
16	104	105	O	in
17	107	109	O	the
18	111	118	O	patients
19	120	122	O	who
20	124	131	O	received
21	133	136	O	CHOP
22	138	142	O	HAART
23	144	151	O	compared
24	153	156	O	with
25	158	160	O	the
26	162	169	O	patients
27	171	173	O	who
28	175	182	O	received
29	184	187	O	CHOP
30	189	193	O	alone
31	196	198	O	33%
32	200	201	O	vs
33	204	205	O	7%
34	206	206	O	,
35	208	219	O	respectively
36	222	222	O	P
37	224	224	O	=
38	226	230	O	0.001
NULL

11148572.xml	DDI-MedLine.d115.s9	NO_SECTION	NO_SETID	34
Leukopenia was similar between the two groups, but colony stimulating factor support was significantly greater in the CHOP-HAART group than in the control group (92% vs. 66%, respectively; P = 0.03).
1	0	9	O	Leukopenia
2	11	13	O	was
3	15	21	O	similar
4	23	29	O	between
5	31	33	O	the
6	35	37	O	two
7	39	44	O	groups
8	45	45	O	,
9	47	49	O	but
10	51	56	O	colony
11	58	68	O	stimulating
12	70	75	O	factor
13	77	83	O	support
14	85	87	O	was
15	89	101	O	significantly
16	103	109	O	greater
17	111	112	O	in
18	114	116	O	the
19	118	121	O	CHOP
20	123	127	O	HAART
21	129	133	O	group
22	135	138	O	than
23	140	141	O	in
24	143	145	O	the
25	147	153	O	control
26	155	159	O	group
27	162	164	O	92%
28	166	167	O	vs
29	170	172	O	66%
30	173	173	O	,
31	175	186	O	respectively
32	189	189	O	P
33	191	191	O	=
34	193	196	O	0.03
NULL

11148572.xml	DDI-MedLine.d115.s10	NO_SECTION	NO_SETID	22
Seventeen percent of CHOP-HAART patients developed severe autonomic neurotoxicity, whereas none of the CHOP patients developed neurotoxicity (P = 0.002).
1	0	8	O	Seventeen
2	10	16	O	percent
3	18	19	O	of
4	21	24	O	CHOP
5	26	30	O	HAART
6	32	39	O	patients
7	41	49	O	developed
8	51	56	O	severe
9	58	66	O	autonomic
10	68	80	O	neurotoxicity
11	81	81	O	,
12	83	89	O	whereas
13	91	94	O	none
14	96	97	O	of
15	99	101	O	the
16	103	106	O	CHOP
17	108	115	O	patients
18	117	125	O	developed
19	127	139	O	neurotoxicity
20	142	142	O	P
21	144	144	O	=
22	146	150	O	0.002
NULL

11148572.xml	DDI-MedLine.d115.s11	NO_SECTION	NO_SETID	42
At similar median follow-up, opportunistic infection (OI) rates and mortality were significantly lower in the CHOP-HAART patients than in the CHOP patients (18% vs. 52%, respectively; P = 0.05; and 38% vs. 85%, respectively; P = 0.001).
1	0	1	O	At
2	3	9	O	similar
3	11	16	O	median
4	18	23	O	follow
5	25	26	O	up
6	27	27	O	,
7	29	41	O	opportunistic
8	43	51	O	infection
9	54	55	O	OI
10	58	62	O	rates
11	64	66	O	and
12	68	76	O	mortality
13	78	81	O	were
14	83	95	O	significantly
15	97	101	O	lower
16	103	104	O	in
17	106	108	O	the
18	110	113	O	CHOP
19	115	119	O	HAART
20	121	128	O	patients
21	130	133	O	than
22	135	136	O	in
23	138	140	O	the
24	142	145	O	CHOP
25	147	154	O	patients
26	157	159	O	18%
27	161	162	O	vs
28	165	167	O	52%
29	168	168	O	,
30	170	181	O	respectively
31	184	184	O	P
32	186	186	O	=
33	188	191	O	0.05
34	194	196	O	and
35	198	200	O	38%
36	202	203	O	vs
37	206	208	O	85%
38	209	209	O	,
39	211	222	O	respectively
40	225	225	O	P
41	227	227	O	=
42	229	233	O	0.001
NULL

11148572.xml	DDI-MedLine.d115.s12	NO_SECTION	NO_SETID	24
The median survival for CHOP-HAART patients was not reached, whereas the medial survival of CHOP patients was 7 months (P = 0.03).
1	0	2	O	The
2	4	9	O	median
3	11	18	O	survival
4	20	22	O	for
5	24	27	O	CHOP
6	29	33	O	HAART
7	35	42	O	patients
8	44	46	O	was
9	48	50	O	not
10	52	58	O	reached
11	59	59	O	,
12	61	67	O	whereas
13	69	71	O	the
14	73	78	O	medial
15	80	87	O	survival
16	89	90	O	of
17	92	95	O	CHOP
18	97	104	O	patients
19	106	108	O	was
20	110	110	O	7
21	112	117	O	months
22	120	120	O	P
23	122	122	O	=
24	124	127	O	0.03
NULL

11148572.xml	DDI-MedLine.d115.s13	NO_SECTION	NO_SETID	21
CONCLUSIONS: The combination of CHOP plus HAART is feasible and may reduce the morbidity from OIs in HIV-NHL patients.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	15	O	The
4	17	27	O	combination
5	29	30	O	of
6	32	35	O	CHOP
7	37	40	O	plus
8	42	46	O	HAART
9	48	49	O	is
10	51	58	O	feasible
11	60	62	O	and
12	64	66	O	may
13	68	73	O	reduce
14	75	77	O	the
15	79	87	O	morbidity
16	89	92	O	from
17	94	96	O	OIs
18	98	99	O	in
19	101	103	O	HIV
20	105	107	O	NHL
21	109	116	O	patients
NULL

11148572.xml	DDI-MedLine.d115.s14	NO_SECTION	NO_SETID	19
However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	careful
4	17	25	O	attention
5	27	30	O	must
6	32	33	O	be
7	35	42	O	directed
8	44	45	O	to
9	47	51	O	cross
10	53	60	O	toxicity
11	62	64	O	and
12	66	73	O	possible
13	75	89	O	pharmacokinetic
14	91	102	O	interactions
15	104	110	O	between
16	112	125	B-UNK	antiretroviral
17	127	129	I-UNK	and
18	131	144	I-UNK	antineoplastic
19	146	150	L-UNK	drugs
NULL

11148572.xml	DDI-MedLine.d115.s15	NO_SECTION	NO_SETID	20
The impact of the combined chemotherapy plus HAART treatment on patient survival needs urgently to be evaluated in prospective studies.
1	0	2	O	The
2	4	9	O	impact
3	11	12	O	of
4	14	16	O	the
5	18	25	O	combined
6	27	38	O	chemotherapy
7	40	43	O	plus
8	45	49	O	HAART
9	51	59	O	treatment
10	61	62	O	on
11	64	70	O	patient
12	72	79	O	survival
13	81	85	O	needs
14	87	94	O	urgently
15	96	97	O	to
16	99	100	O	be
17	102	110	O	evaluated
18	112	113	O	in
19	115	125	O	prospective
20	127	133	O	studies
NULL

11151029.xml	DDI-MedLine.d21.s0	NO_SECTION	NO_SETID	13
Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats.
1	0	4	O	Acute
2	6	11	O	effect
3	13	14	O	of
4	16	24	O	different
5	26	40	U-UNK	antidepressants
6	42	43	O	on
7	45	52	O	glycemia
8	54	55	O	in
9	57	64	O	diabetic
10	66	68	O	and
11	70	72	O	non
12	74	81	O	diabetic
13	83	86	O	rats
NULL

11151029.xml	DDI-MedLine.d21.s1	NO_SECTION	NO_SETID	13
Diabetic patients have a 20% higher risk of depression than the general population.
1	0	7	O	Diabetic
2	9	16	O	patients
3	18	21	O	have
4	23	23	O	a
5	25	27	O	20%
6	29	34	O	higher
7	36	39	O	risk
8	41	42	O	of
9	44	53	O	depression
10	55	58	O	than
11	60	62	O	the
12	64	70	O	general
13	72	81	O	population
NULL

11151029.xml	DDI-MedLine.d21.s2	NO_SECTION	NO_SETID	17
Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
1	0	8	O	Treatment
2	10	13	O	with
3	15	28	B-UNK	antidepressant
4	30	34	L-UNK	drugs
5	36	38	O	can
6	40	47	O	directly
7	49	57	O	interfere
8	59	62	O	with
9	64	68	O	blood
10	70	76	O	glucose
11	78	83	O	levels
12	85	86	O	or
13	88	90	O	may
14	92	99	O	interact
15	101	104	O	with
16	106	117	B-UNK	hypoglycemic
17	119	124	L-UNK	agents
NULL

11151029.xml	DDI-MedLine.d21.s3	NO_SECTION	NO_SETID	28
The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important.
1	0	2	O	The
2	4	12	O	treatment
3	14	15	O	of
4	17	26	O	depression
5	28	29	O	in
6	31	38	O	diabetic
7	40	47	O	patients
8	49	52	O	must
9	54	57	O	take
10	59	62	O	into
11	64	70	O	account
12	72	81	O	variations
13	83	84	O	of
14	86	93	O	glycemic
15	95	100	O	levels
16	102	103	O	at
17	105	113	O	different
18	115	119	O	times
19	121	123	O	and
20	125	125	O	a
21	127	136	O	comparison
22	138	139	O	of
23	141	143	O	the
24	145	153	O	available
25	155	168	B-UNK	antidepressant
26	170	175	L-UNK	agents
27	177	178	O	is
28	180	188	O	important
NULL

11151029.xml	DDI-MedLine.d21.s4	NO_SECTION	NO_SETID	20
In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	present
4	15	19	O	study
5	21	22	O	we
6	24	32	O	evaluated
7	34	36	O	the
8	38	49	O	interference
9	51	52	O	of
10	54	68	U-UNK	antidepressants
11	70	73	O	with
12	75	79	O	blood
13	81	87	O	glucose
14	89	94	O	levels
15	96	97	O	of
16	99	106	O	diabetic
17	108	110	O	and
18	112	114	O	non
19	116	123	O	diabetic
20	125	128	O	rats
NULL

11151029.xml	DDI-MedLine.d21.s5	NO_SECTION	NO_SETID	14
In a first experiment, male adult Wistar rats were fasted for 12 h.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	first
4	11	20	O	experiment
5	21	21	O	,
6	23	26	O	male
7	28	32	O	adult
8	34	39	O	Wistar
9	41	44	O	rats
10	46	49	O	were
11	51	56	O	fasted
12	58	60	O	for
13	62	63	O	12
14	65	65	O	h
NULL

11151029.xml	DDI-MedLine.d21.s6	NO_SECTION	NO_SETID	32
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.
1	0	9	U-UNK	Imipramine
2	12	12	O	5
3	14	15	O	mg
4	16	16	O	/
5	17	18	O	kg
6	20	20	O	,
7	22	32	U-UNK	moclobemide
8	35	36	O	30
9	38	39	O	mg
10	40	40	O	/
11	41	42	O	kg
12	44	44	O	,
13	46	55	U-UNK	clonazepam
14	58	61	O	0.25
15	63	64	O	mg
16	65	65	O	/
17	66	67	O	kg
18	69	69	O	,
19	71	80	U-UNK	fluoxetine
20	83	84	O	20
21	86	87	O	mg
22	88	88	O	/
23	89	90	O	kg
24	93	102	U-UNK	sertraline
25	105	106	O	30
26	108	109	O	mg
27	110	110	O	/
28	111	112	O	kg
29	115	116	O	or
30	118	124	O	vehicle
31	126	128	O	was
32	130	141	O	administered
NULL

11151029.xml	DDI-MedLine.d21.s7	NO_SECTION	NO_SETID	8
After 30 min, fasting glycemia was measured.
1	0	4	O	After
2	6	7	O	30
3	9	11	O	min
4	12	12	O	,
5	14	20	O	fasting
6	22	29	O	glycemia
7	31	33	O	was
8	35	42	O	measured
NULL

11151029.xml	DDI-MedLine.d21.s8	NO_SECTION	NO_SETID	28
An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min.
1	0	1	O	An
2	3	6	O	oral
3	8	14	U-UNK	glucose
4	16	23	O	overload
5	25	26	O	of
6	28	28	O	1
7	30	31	O	ml
8	33	34	O	of
9	36	36	O	a
10	38	40	O	50%
11	42	48	U-UNK	glucose
12	50	57	O	solution
13	59	61	O	was
14	63	67	O	given
15	69	70	O	to
16	72	75	O	rats
17	77	79	O	and
18	81	85	O	blood
19	87	93	O	glucose
20	95	97	O	was
21	99	108	O	determined
22	110	114	O	after
23	116	117	O	30
24	118	118	O	,
25	120	121	O	60
26	123	125	O	and
27	127	128	O	90
28	130	132	O	min
NULL

11151029.xml	DDI-MedLine.d21.s9	NO_SECTION	NO_SETID	10
Imipramine and clonazepam did not change fasting or overload glycemia.
1	0	9	U-UNK	Imipramine
2	11	13	O	and
3	15	24	U-UNK	clonazepam
4	26	28	O	did
5	30	32	O	not
6	34	39	O	change
7	41	47	O	fasting
8	49	50	O	or
9	52	59	O	overload
10	61	68	O	glycemia
NULL

11151029.xml	DDI-MedLine.d21.s10	NO_SECTION	NO_SETID	13
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
1	0	9	U-UNK	Fluoxetine
2	11	13	O	and
3	15	25	U-UNK	moclobemide
4	27	35	O	increased
5	37	41	O	blood
6	43	49	U-UNK	glucose
7	51	52	O	at
8	54	62	O	different
9	64	68	O	times
10	70	74	O	after
11	76	78	O	the
12	80	86	O	glucose
13	88	95	O	overload
NULL

11151029.xml	DDI-MedLine.d21.s11	NO_SECTION	NO_SETID	11
Sertraline neutralized the increase of glycemia induced by oral glucose overload.
1	0	9	U-UNK	Sertraline
2	11	21	O	neutralized
3	23	25	O	the
4	27	34	O	increase
5	36	37	O	of
6	39	46	O	glycemia
7	48	54	O	induced
8	56	57	O	by
9	59	62	O	oral
10	64	70	U-UNK	glucose
11	72	79	O	overload
NULL

11151029.xml	DDI-MedLine.d21.s12	NO_SECTION	NO_SETID	31
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload.
1	0	1	O	In
2	3	5	O	the
3	7	12	O	second
4	14	23	O	experiment
5	24	24	O	,
6	26	28	O	non
7	30	37	O	diabetic
8	39	41	O	and
9	43	56	O	streptozotocin
10	58	64	O	induced
11	66	73	O	diabetic
12	75	78	O	rats
13	80	83	O	were
14	85	90	O	fasted
15	91	91	O	,
16	93	95	O	and
17	97	99	O	the
18	101	104	O	same
19	106	115	O	procedures
20	117	120	O	were
21	122	129	O	followed
22	131	133	O	for
23	135	144	O	estimation
24	146	147	O	of
25	149	155	U-UNK	glucose
26	157	165	O	tolerance
27	167	168	O	30
28	170	172	O	min
29	174	178	O	after
30	180	186	U-UNK	glucose
31	188	195	O	overload
NULL

11151029.xml	DDI-MedLine.d21.s13	NO_SECTION	NO_SETID	18
Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats.
1	0	4	O	Again
2	5	5	O	,
3	7	16	U-UNK	sertraline
4	18	28	O	neutralized
5	30	32	O	the
6	34	41	O	increase
7	43	44	O	in
8	46	53	O	glycemia
9	55	59	O	after
10	61	67	U-UNK	glucose
11	69	76	O	overload
12	78	81	O	both
13	83	84	O	in
14	86	93	O	diabetic
15	95	97	O	and
16	99	101	O	non
17	103	110	O	diabetic
18	112	115	O	rats
NULL

11151029.xml	DDI-MedLine.d21.s14	NO_SECTION	NO_SETID	24
These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects.
1	0	4	O	These
2	6	9	O	data
3	11	15	O	raise
4	17	19	O	the
5	21	28	O	question
6	30	31	O	of
7	33	39	O	whether
8	41	50	U-UNK	sertraline
9	52	53	O	is
10	55	57	O	the
11	59	62	O	best
12	64	69	O	choice
13	71	73	O	for
14	75	83	O	prolonged
15	85	87	O	use
16	89	91	O	for
17	93	100	O	diabetic
18	102	112	O	individuals
19	113	113	O	,
20	115	121	O	because
21	123	124	O	of
22	126	128	O	its
23	130	146	O	antihyperglycemic
24	148	154	O	effects
NULL

11151029.xml	DDI-MedLine.d21.s15	NO_SECTION	NO_SETID	11
Clonazepam would be useful in cases with potential risk of hypoglycemia.
1	0	9	U-UNK	Clonazepam
2	11	15	O	would
3	17	18	O	be
4	20	25	O	useful
5	27	28	O	in
6	30	34	O	cases
7	36	39	O	with
8	41	49	O	potential
9	51	54	O	risk
10	56	57	O	of
11	59	70	O	hypoglycemia
NULL

11152438.xml	DDI-MedLine.d47.s0	NO_SECTION	NO_SETID	18
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
1	0	7	O	Activity
2	9	10	O	of
3	12	18	B-UNK	buforin
4	20	21	L-UNK	II
5	23	27	O	alone
6	29	31	O	and
7	33	34	O	in
8	36	46	O	combination
9	48	51	O	with
10	53	64	U-UNK	azithromycin
11	66	68	O	and
12	70	80	U-UNK	minocycline
13	82	88	O	against
14	90	104	O	Cryptosporidium
15	106	111	O	parvum
16	113	114	O	in
17	116	119	O	cell
18	121	127	O	culture
NULL

11152438.xml	DDI-MedLine.d47.s1	NO_SECTION	NO_SETID	19
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated.
1	0	2	O	The
2	4	5	O	in
3	7	11	O	vitro
4	13	16	O	anti
5	18	32	O	cryptosporidial
6	34	41	O	activity
7	43	44	O	of
8	46	52	B-UNK	buforin
9	54	55	L-UNK	II
10	57	61	O	alone
11	63	65	O	and
12	67	68	O	in
13	70	80	O	combination
14	82	85	O	with
15	87	98	U-UNK	azithromycin
16	100	102	O	and
17	104	114	U-UNK	minocycline
18	116	118	O	was
19	120	131	O	investigated
NULL

11152438.xml	DDI-MedLine.d47.s2	NO_SECTION	NO_SETID	19
Buforin II showed moderate activity, which increased with increasing concentration to 55.7% suppression of growth at 20 microM.
1	0	6	B-UNK	Buforin
2	8	9	L-UNK	II
3	11	16	O	showed
4	18	25	O	moderate
5	27	34	O	activity
6	35	35	O	,
7	37	41	O	which
8	43	51	O	increased
9	53	56	O	with
10	58	67	O	increasing
11	69	81	O	concentration
12	83	84	O	to
13	86	90	O	55.7%
14	92	102	O	suppression
15	104	105	O	of
16	107	112	O	growth
17	114	115	O	at
18	117	118	O	20
19	120	125	O	microM
NULL

11152438.xml	DDI-MedLine.d47.s3	NO_SECTION	NO_SETID	24
Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested.
1	0	7	O	Moreover
2	8	8	O	,
3	10	12	O	its
4	14	21	O	activity
5	23	25	O	was
6	27	34	O	enhanced
7	36	39	O	when
8	41	42	O	it
9	44	46	O	was
10	48	55	O	combined
11	57	60	O	with
12	62	67	O	either
13	69	80	U-UNK	azithromycin
14	82	83	O	or
15	85	95	U-UNK	minocycline
16	97	100	O	with
17	102	104	O	90%
18	106	113	O	parasite
19	115	123	O	reduction
20	125	126	O	at
21	128	130	O	the
22	132	138	O	highest
23	140	152	O	concentration
24	154	159	O	tested
NULL

11152438.xml	DDI-MedLine.d47.s4	NO_SECTION	NO_SETID	19
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
1	0	6	B-UNK	Buforin
2	8	9	L-UNK	II
3	11	13	O	may
4	15	16	O	be
5	18	23	O	active
6	25	26	O	in
7	28	37	O	inhibiting
8	39	53	O	Cryptosporidium
9	55	60	O	parvum
10	62	67	O	growth
11	69	70	O	in
12	72	76	O	vitro
13	78	81	O	upon
14	83	93	O	combination
15	95	98	O	with
16	100	105	O	either
17	107	118	U-UNK	azithromycin
18	120	121	O	or
19	123	133	U-UNK	minocycline
NULL

11152855.xml	DDI-MedLine.d112.s0	NO_SECTION	NO_SETID	8
Effect of dofetillide on the pharmacokinetics of digoxin.
1	0	5	O	Effect
2	7	8	O	of
3	10	20	U-UNK	dofetillide
4	22	23	O	on
5	25	27	O	the
6	29	44	O	pharmacokinetics
7	46	47	O	of
8	49	55	U-UNK	digoxin
NULL

11152855.xml	DDI-MedLine.d112.s1	NO_SECTION	NO_SETID	20
The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	U-UNK	dofetilide
5	25	26	O	on
6	28	30	O	the
7	32	37	O	steady
8	39	43	O	state
9	45	60	O	pharmacokinetics
10	62	63	O	of
11	65	71	U-UNK	digoxin
12	73	75	O	was
13	77	85	O	evaluated
14	87	88	O	in
15	90	90	O	a
16	92	101	O	randomized
17	102	102	O	,
18	104	109	O	double
19	111	115	O	blind
20	117	121	O	study
NULL

11152855.xml	DDI-MedLine.d112.s2	NO_SECTION	NO_SETID	18
Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo;
1	0	3	O	Five
2	5	8	O	days
3	10	11	O	of
4	13	22	U-UNK	dofetilide
5	24	32	O	treatment
6	34	36	O	did
7	38	40	O	not
8	42	54	O	significantly
9	56	61	O	affect
10	63	68	O	steady
11	70	74	O	state
12	76	90	O	pharmacokinetic
13	92	100	O	variables
14	102	103	O	of
15	105	111	U-UNK	digoxin
16	113	120	O	compared
17	122	125	O	with
18	127	133	O	placebo
NULL

11152855.xml	DDI-MedLine.d112.s3	NO_SECTION	NO_SETID	19
therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.
1	0	8	O	therefore
2	9	9	O	,
3	11	13	O	the
4	15	17	O	use
5	19	20	O	of
6	22	31	U-UNK	dofetilide
7	33	36	O	does
8	38	40	O	not
9	42	52	O	necessitate
10	54	55	O	an
11	57	66	O	adjustment
12	68	69	O	in
13	71	77	U-UNK	digoxin
14	79	82	O	dose
15	84	85	O	to
16	87	94	O	maintain
17	96	106	O	therapeutic
18	108	114	O	digoxin
19	116	121	O	levels
NULL

1115340.xml	DDI-MedLine.d19.s0	NO_SECTION	NO_SETID	5
Anaesthesia and the epileptic pateint.
1	0	10	O	Anaesthesia
2	12	14	O	and
3	16	18	O	the
4	20	28	O	epileptic
5	30	36	O	pateint
NULL

1115340.xml	DDI-MedLine.d19.s2	NO_SECTION	NO_SETID	19
A review is presented of some of the problems that may arise in association with anaesthesia for epileptic patients.
1	0	0	O	A
2	2	7	O	review
3	9	10	O	is
4	12	20	O	presented
5	22	23	O	of
6	25	28	O	some
7	30	31	O	of
8	33	35	O	the
9	37	44	O	problems
10	46	49	O	that
11	51	53	O	may
12	55	59	O	arise
13	61	62	O	in
14	64	74	O	association
15	76	79	O	with
16	81	91	O	anaesthesia
17	93	95	O	for
18	97	105	O	epileptic
19	107	114	O	patients
NULL

1115340.xml	DDI-MedLine.d19.s3	NO_SECTION	NO_SETID	9
There is the possibility of precipitating anticonvulsant drug toxicity.
1	0	4	O	There
2	6	7	O	is
3	9	11	O	the
4	13	23	O	possibility
5	25	26	O	of
6	28	40	O	precipitating
7	42	55	O	anticonvulsant
8	57	60	O	drug
9	62	69	O	toxicity
NULL

1115340.xml	DDI-MedLine.d19.s4	NO_SECTION	NO_SETID	22
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems.
1	0	7	O	Numerous
2	9	12	O	drug
3	14	25	O	interactions
4	27	29	O	are
5	31	38	O	possible
6	40	43	O	with
7	45	48	O	some
8	50	63	B-UNK	anticonvulsant
9	65	70	L-UNK	agents
10	71	71	O	,
11	73	76	O	such
12	78	79	O	as
13	81	94	U-UNK	phenobarbitone
14	96	98	O	and
15	100	108	U-UNK	phenytoin
16	109	109	O	,
17	111	115	O	which
18	117	122	O	affect
19	124	130	O	hepatic
20	132	141	O	microsomal
21	143	148	O	enzyme
22	150	156	O	systems
NULL

1115340.xml	DDI-MedLine.d19.s5	NO_SECTION	NO_SETID	25
There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability.
1	0	4	O	There
2	6	7	O	is
3	9	11	O	the
4	13	16	O	risk
5	18	19	O	of
6	21	31	O	convulsions
7	33	41	O	occurring
8	43	44	O	in
9	46	56	O	susceptible
10	58	65	O	patients
11	67	75	O	following
12	77	79	O	the
13	81	83	O	use
14	85	86	O	of
15	88	90	O	the
16	92	94	O	new
17	96	106	B-UNK	anaesthetic
18	108	113	L-UNK	agents
19	115	119	O	which
20	121	123	O	are
21	125	131	O	capable
22	133	134	O	of
23	136	143	O	inducing
24	145	147	O	CNS
25	149	160	O	excitability
NULL

1115367.xml	DDI-MedLine.d16.s0	NO_SECTION	NO_SETID	7
Interaction of ketamine and halothane in rats.
1	0	10	O	Interaction
2	12	13	O	of
3	15	22	U-UNK	ketamine
4	24	26	O	and
5	28	36	U-UNK	halothane
6	38	39	O	in
7	41	44	O	rats
NULL

1115367.xml	DDI-MedLine.d16.s1	NO_SECTION	NO_SETID	19
The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats.
1	0	2	O	The
2	4	14	O	interaction
3	16	17	O	of
4	19	33	O	intramuscularly
5	35	42	O	injected
6	44	51	U-UNK	ketamine
7	53	55	O	and
8	57	59	O	its
9	61	61	O	N
10	63	74	O	demethylated
11	76	85	O	metabolite
12	88	97	O	metabolite
13	99	99	O	I
14	102	105	O	with
15	107	115	U-UNK	halothane
16	117	119	O	was
17	121	129	O	evaluated
18	131	132	O	in
19	134	137	O	rats
NULL

1115367.xml	DDI-MedLine.d16.s2	NO_SECTION	NO_SETID	35
Five, 10, 20, or 50 mg/kg of ketamine alone or 20, 50, or 100 mg/kg of metabolite I alone produced less than 10 minutes of hypnosis.
1	0	3	O	Five
2	4	4	O	,
3	6	7	O	10
4	8	8	O	,
5	10	11	O	20
6	12	12	O	,
7	14	15	O	or
8	17	18	O	50
9	20	21	O	mg
10	22	22	O	/
11	23	24	O	kg
12	26	27	O	of
13	29	36	U-UNK	ketamine
14	38	42	O	alone
15	44	45	O	or
16	47	48	O	20
17	49	49	O	,
18	51	52	O	50
19	53	53	O	,
20	55	56	O	or
21	58	60	O	100
22	62	63	O	mg
23	64	64	O	/
24	65	66	O	kg
25	68	69	O	of
26	71	80	O	metabolite
27	82	82	O	I
28	84	88	O	alone
29	90	97	O	produced
30	99	102	O	less
31	104	107	O	than
32	109	110	O	10
33	112	118	O	minutes
34	120	121	O	of
35	123	130	O	hypnosis
NULL

1115367.xml	DDI-MedLine.d16.s3	NO_SECTION	NO_SETID	41
However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
1	0	6	O	However
2	7	7	O	,
3	9	17	U-UNK	halothane
4	19	28	O	anesthetic
5	30	40	O	requirement
6	43	45	O	i.e
7	47	47	O	,
8	49	51	O	MAC
9	54	56	O	was
10	58	66	O	depressed
11	68	69	O	in
12	71	71	O	a
13	73	76	O	dose
14	78	86	O	dependent
15	88	94	O	fashion
16	96	97	O	as
17	99	102	O	much
18	104	105	O	as
19	107	109	O	56%
20	111	111	O	1
21	113	113	O	2
22	115	119	O	hours
23	121	123	O	and
24	125	126	O	as
25	128	131	O	much
26	133	134	O	as
27	136	138	O	14%
28	140	140	O	5
29	142	142	O	6
30	144	148	O	hours
31	150	154	O	after
32	156	164	O	injection
33	166	167	O	of
34	169	176	U-UNK	ketamine
35	177	177	O	,
36	179	180	O	50
37	182	183	O	mg
38	184	184	O	/
39	185	186	O	kg
40	187	187	O	,
41	189	190	O	im
NULL

1115367.xml	DDI-MedLine.d16.s4	NO_SECTION	NO_SETID	23
The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1.
1	0	2	O	The
2	4	12	O	reduction
3	14	15	O	in
4	17	19	O	MAC
5	21	23	O	was
6	25	34	O	correlated
7	36	39	O	with
8	41	45	O	brain
9	47	52	O	levels
10	54	55	O	of
11	57	64	U-UNK	ketamine
12	66	67	O	or
13	69	78	O	metabolite
14	80	80	O	I
15	81	81	O	,
16	83	92	O	suggesting
17	94	94	O	a
18	96	114	O	ketamine:metabolite
19	116	116	O	I
20	118	124	O	potency
21	126	131	O	ration
22	133	134	O	of
23	136	138	O	3:1
NULL

1115367.xml	DDI-MedLine.d16.s5	NO_SECTION	NO_SETID	22
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	24	U-UNK	ketamine
6	26	27	O	in
7	29	34	O	plasma
8	36	38	O	and
9	40	44	O	brain
10	46	48	O	was
11	50	55	O	longer
12	57	58	O	in
13	60	62	O	the
14	64	71	O	presence
15	73	74	O	of
16	76	84	U-UNK	halothane
17	86	89	O	than
18	91	94	O	when
19	96	103	U-UNK	ketamine
20	105	107	O	was
21	109	113	O	given
22	115	119	O	alone
NULL

1115367.xml	DDI-MedLine.d16.s6	NO_SECTION	NO_SETID	33
It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	concluded
4	16	19	O	that
5	21	28	U-UNK	ketamine
6	30	31	O	is
7	33	35	O	not
8	37	37	O	a
9	39	43	O	short
10	45	50	O	acting
11	52	55	O	drug
12	57	59	O	and
13	61	64	O	that
14	66	76	O	concomitant
15	78	80	O	use
16	82	85	O	with
17	87	95	U-UNK	halothane
18	97	101	O	would
19	103	104	O	be
20	106	113	O	expected
21	115	116	O	to
22	118	124	O	prolong
23	126	132	O	further
24	134	136	O	the
25	138	145	O	duration
26	147	148	O	of
27	150	152	O	its
28	154	159	O	action
29	161	162	O	on
30	164	166	O	the
31	168	174	O	central
32	176	182	O	nervous
33	184	189	O	system
NULL

1115445.xml	DDI-MedLine.d116.s0	NO_SECTION	NO_SETID	7
Rifampin and warfarin: a drug interaction.
1	0	7	U-UNK	Rifampin
2	9	11	O	and
3	13	20	U-UNK	warfarin
4	21	21	O	:
5	23	23	O	a
6	25	28	O	drug
7	30	40	O	interaction
NULL

1115445.xml	DDI-MedLine.d116.s1	NO_SECTION	NO_SETID	11
The drug interaction between warfarin and rifampin is not well known.
1	0	2	O	The
2	4	7	O	drug
3	9	19	O	interaction
4	21	27	O	between
5	29	36	U-UNK	warfarin
6	38	40	O	and
7	42	49	U-UNK	rifampin
8	51	52	O	is
9	54	56	O	not
10	58	61	O	well
11	63	67	O	known
NULL

1115445.xml	DDI-MedLine.d116.s2	NO_SECTION	NO_SETID	16
Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
1	0	7	U-UNK	Rifampin
2	9	11	O	has
3	13	16	O	been
4	18	25	O	reported
5	27	28	O	to
6	30	37	O	increase
7	39	41	O	the
8	43	50	U-UNK	warfarin
9	52	63	O	requirements
10	65	66	O	in
11	68	72	O	human
12	74	81	O	subjects
13	83	91	O	ingesting
14	93	97	O	these
15	99	104	O	agents
16	106	119	O	simultaneously
NULL

1115445.xml	DDI-MedLine.d116.s3	NO_SECTION	NO_SETID	30
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	41	U-UNK	rifampin
6	43	45	O	and
7	47	54	U-UNK	warfarin
8	56	63	O	resulted
9	65	66	O	in
10	68	70	O	the
11	72	75	O	need
12	77	79	O	for
13	81	82	O	an
14	84	92	O	unusually
15	94	97	O	high
16	99	109	O	maintenance
17	111	114	O	dose
18	116	117	O	of
19	119	126	U-UNK	warfarin
20	129	130	O	20
21	132	133	O	mg
22	135	137	O	per
23	139	141	O	day
24	144	145	O	in
25	147	151	O	order
26	153	154	O	to
27	156	162	O	produce
28	164	164	O	a
29	166	176	O	therapeutic
30	178	183	O	effect
NULL

1115445.xml	DDI-MedLine.d116.s4	NO_SECTION	NO_SETID	9
Withdrawal of rifampin decreased the warfarin requirement by 50%.
1	0	9	O	Withdrawal
2	11	12	O	of
3	14	21	U-UNK	rifampin
4	23	31	O	decreased
5	33	35	O	the
6	37	44	U-UNK	warfarin
7	46	56	O	requirement
8	58	59	O	by
9	61	63	O	50%
NULL

1115445.xml	DDI-MedLine.d116.s5	NO_SECTION	NO_SETID	22
This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	may
4	16	17	O	be
5	19	26	O	mediated
6	28	29	O	by
7	31	33	O	the
8	35	41	O	ability
9	43	44	O	of
10	46	53	U-UNK	rifampin
11	55	56	O	to
12	58	63	O	induce
13	65	74	O	microsomal
14	76	82	O	enzymes
15	84	86	O	and
16	87	87	O	,
17	89	92	O	thus
18	93	93	O	,
19	95	97	O	the
20	99	108	O	catabolism
21	110	111	O	of
22	113	120	U-UNK	warfarin
NULL

1115445.xml	DDI-MedLine.d116.s6	NO_SECTION	NO_SETID	34
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	21	U-UNK	rifampin
5	23	24	O	on
6	26	28	O	the
7	30	37	U-UNK	warfarin
8	39	49	O	requirement
9	51	52	O	of
10	54	56	O	our
11	58	64	O	patient
12	66	73	O	appeared
13	75	76	O	to
14	78	79	O	be
15	81	87	O	maximal
16	89	89	O	5
17	91	92	O	to
18	94	94	O	7
19	96	99	O	days
20	101	105	O	after
21	107	109	O	the
22	111	120	O	initiation
23	122	123	O	of
24	125	132	U-UNK	rifampin
25	134	136	O	and
26	138	145	O	extended
27	147	147	O	a
28	149	155	O	similar
29	157	162	O	length
30	164	165	O	of
31	167	170	O	time
32	172	176	O	after
33	178	185	U-UNK	rifampin
34	187	196	O	withdrawal
NULL

1115445.xml	DDI-MedLine.d116.s7	NO_SECTION	NO_SETID	7
This interaction appears to be clinically significant.
1	0	3	O	This
2	5	15	O	interaction
3	17	23	O	appears
4	25	26	O	to
5	28	29	O	be
6	31	40	O	clinically
7	42	52	O	significant
NULL

11154900.xml	DDI-MedLine.d76.s0	NO_SECTION	NO_SETID	14
Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs.
1	0	8	B-UNK	Thiolated
2	10	31	L-UNK	carboxymethylcellulose
3	32	32	O	:
4	34	35	O	in
5	37	41	O	vitro
6	43	52	O	evaluation
7	54	55	O	of
8	57	59	O	its
9	61	70	O	permeation
10	72	80	O	enhancing
11	82	87	O	effect
12	89	90	O	on
13	92	98	O	peptide
14	100	104	O	drugs
NULL

11154900.xml	DDI-MedLine.d76.s1	NO_SECTION	NO_SETID	36
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
1	0	2	O	The
2	4	10	O	purpose
3	12	13	O	of
4	15	18	O	this
5	20	24	O	study
6	26	28	O	was
7	30	31	O	to
8	33	40	O	evaluate
9	42	44	O	the
10	46	51	O	effect
11	53	54	O	of
12	56	61	B-UNK	sodium
13	63	84	L-UNK	carboxymethylcellulose
14	87	91	U-UNK	NaCMC
15	94	96	O	and
16	98	119	B-UNK	carboxymethylcellulose
17	121	128	L-UNK	cysteine
18	131	133	B-UNK	CMC
19	135	137	L-UNK	Cys
20	140	149	O	conjugates
21	151	152	O	on
22	154	156	O	the
23	158	167	O	intestinal
24	169	178	O	permeation
25	180	181	O	of
26	183	188	B-UNK	sodium
27	190	200	L-UNK	fluorescein
28	203	207	U-UNK	NaFlu
29	210	212	O	and
30	214	218	O	model
31	220	226	O	peptide
32	228	232	O	drugs
33	233	233	O	,
34	235	244	U-UNK	bacitracin
35	246	248	O	and
36	250	256	U-UNK	insulin
NULL

11154900.xml	DDI-MedLine.d76.s2	NO_SECTION	NO_SETID	8
Cysteine was covalently linked to carbodiimide activated NaCMC.
1	0	7	U-UNK	Cysteine
2	9	11	O	was
3	13	22	O	covalently
4	24	29	O	linked
5	31	32	O	to
6	34	45	O	carbodiimide
7	47	55	O	activated
8	57	61	U-UNK	NaCMC
NULL

11154900.xml	DDI-MedLine.d76.s3	NO_SECTION	NO_SETID	15
Iodometric titration of the polymer conjugates was used to determine the extent of immobilised cysteine.
1	0	9	O	Iodometric
2	11	19	O	titration
3	21	22	O	of
4	24	26	O	the
5	28	34	O	polymer
6	36	45	O	conjugates
7	47	49	O	was
8	51	54	O	used
9	56	57	O	to
10	59	67	O	determine
11	69	71	O	the
12	73	78	O	extent
13	80	81	O	of
14	83	93	O	immobilised
15	95	102	U-UNK	cysteine
NULL

11154900.xml	DDI-MedLine.d76.s4	NO_SECTION	NO_SETID	15
Permeation studies were performed on guinea pig small intestinal mucosa mounted in Ussing-type chamber.
1	0	9	O	Permeation
2	11	17	O	studies
3	19	22	O	were
4	24	32	O	performed
5	34	35	O	on
6	37	42	O	guinea
7	44	46	O	pig
8	48	52	O	small
9	54	63	O	intestinal
10	65	70	O	mucosa
11	72	78	O	mounted
12	80	81	O	in
13	83	88	O	Ussing
14	90	93	O	type
15	95	101	O	chamber
NULL

11154900.xml	DDI-MedLine.d76.s5	NO_SECTION	NO_SETID	34
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
1	0	9	O	Unmodified
2	11	15	U-UNK	NaCMC
3	18	19	O	1%
4	21	21	O	m
5	22	22	O	/
6	23	23	O	v
7	26	38	O	significantly
8	40	47	O	improved
9	49	51	O	the
10	53	61	O	transport
11	63	67	O	ratio
12	70	71	O	R=
13	73	77	O	P(app
14	80	86	O	polymer
15	87	87	O	/
16	89	93	O	P(app
17	96	102	O	control
18	105	106	O	of
19	108	112	U-UNK	NaFlu
20	114	115	O	to
21	117	119	O	1.3
22	121	123	O	and
23	125	126	O	1%
24	129	129	O	m
25	130	130	O	/
26	131	131	O	v
27	134	138	U-UNK	NaCMC
28	140	149	O	conjugated
29	151	154	O	with
30	156	163	U-UNK	cysteine
31	165	171	O	further
32	173	180	O	enhanced
33	182	184	O	the
34	186	195	O	permeation
NULL

11154900.xml	DDI-MedLine.d76.s6	NO_SECTION	NO_SETID	23
Cysteine conjugation at 3.6, 5.3 and 7.3% (m/m) resulted in R-values of 1.4, 1.7 and 1.8, respectively.
1	0	7	U-UNK	Cysteine
2	9	19	O	conjugation
3	21	22	O	at
4	24	26	O	3.6
5	27	27	O	,
6	29	31	O	5.3
7	33	35	O	and
8	37	40	O	7.3%
9	43	43	O	m
10	44	44	O	/
11	45	45	O	m
12	48	55	O	resulted
13	57	58	O	in
14	60	60	O	R
15	62	67	O	values
16	69	70	O	of
17	72	74	O	1.4
18	75	75	O	,
19	77	79	O	1.7
20	81	83	O	and
21	85	87	O	1.8
22	88	88	O	,
23	90	101	O	respectively
NULL

11154900.xml	DDI-MedLine.d76.s7	NO_SECTION	NO_SETID	37
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2.
1	0	9	O	Decreasing
2	11	13	O	the
3	15	27	O	concentration
4	29	30	O	of
5	32	34	B-UNK	CMC
6	36	38	L-UNK	Cys
7	39	39	O	,
8	41	50	O	exhibiting
9	52	55	O	7.3%
10	58	58	O	m
11	59	59	O	/
12	60	60	O	m
13	63	64	O	of
14	66	76	O	immobilised
15	78	85	U-UNK	cysteine
16	88	90	O	CMC
17	92	97	O	Cys7.3
18	100	103	O	from
19	105	106	O	1%
20	109	109	O	m
21	110	110	O	/
22	111	111	O	v
23	114	115	O	to
24	117	120	O	0.5%
25	123	123	O	m
26	124	124	O	/
27	125	125	O	v
28	128	136	O	decreased
29	138	140	O	the
30	142	142	O	R
31	144	148	O	value
32	150	151	O	of
33	153	157	U-UNK	NaFlu
34	159	162	O	from
35	164	166	O	1.8
36	168	169	O	to
37	171	173	O	1.2
NULL

11154900.xml	DDI-MedLine.d76.s8	NO_SECTION	NO_SETID	26
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
1	0	4	U-UNK	NaCMC
2	6	7	O	at
3	9	10	O	1%
4	13	13	O	m
5	14	14	O	/
6	15	15	O	v
7	18	19	O	in
8	21	23	O	the
9	25	32	O	presence
10	34	35	O	of
11	37	40	O	free
12	42	49	U-UNK	cysteine
13	51	53	O	had
14	55	56	O	no
15	58	68	O	significant
16	70	75	O	effect
17	77	78	O	on
18	80	82	O	the
19	84	84	O	R
20	86	90	O	value
21	92	93	O	of
22	95	99	U-UNK	NaFlu
23	101	108	O	compared
24	110	111	O	to
25	113	117	U-UNK	NaCMC
26	119	123	O	alone
NULL

11154900.xml	DDI-MedLine.d76.s9	NO_SECTION	NO_SETID	40
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3).
1	0	10	O	Formulation
2	12	13	O	of
3	15	26	O	fluorescence
4	28	35	O	labelled
5	37	46	U-UNK	bacitracin
6	48	50	O	and
7	52	58	U-UNK	insulin
8	60	61	O	in
9	63	74	O	unconjugated
10	76	80	U-UNK	NaCMC
11	83	84	O	1%
12	86	86	O	m
13	87	87	O	/
14	88	88	O	v
15	91	93	O	did
16	95	97	O	not
17	99	111	O	significantly
18	113	119	O	improve
19	121	123	O	the
20	125	134	O	permeation
21	135	135	O	,
22	137	143	O	however
23	145	146	O	in
24	148	150	O	the
25	152	159	O	presence
26	161	162	O	of
27	164	165	O	1%
28	168	168	O	m
29	169	169	O	/
30	170	170	O	v
31	173	175	U-UNK	CMC
32	177	182	O	Cys7.3
33	184	184	O	a
34	186	198	O	significantly
35	200	207	O	improved
36	209	218	O	permeation
37	220	222	O	was
38	224	231	O	observed
39	234	235	O	R=
40	237	239	O	1.3
NULL

11154900.xml	DDI-MedLine.d76.s10	NO_SECTION	NO_SETID	42
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
1	0	10	O	Conjugation
2	12	13	O	at
3	15	19	U-UNK	NaCMC
4	21	24	O	with
5	26	33	U-UNK	cysteine
6	35	42	O	moieties
7	44	56	O	significantly
8	58	65	O	improves
9	67	69	O	the
10	71	80	O	intestinal
11	82	91	O	permeation
12	93	94	O	of
13	96	98	O	the
14	100	110	O	hydrophilic
15	112	119	O	molecule
16	121	125	U-UNK	NaFlu
17	127	129	O	and
18	131	133	O	the
19	135	139	O	model
20	141	147	O	peptide
21	149	153	O	drugs
22	155	164	U-UNK	bacitracin
23	166	168	O	and
24	170	176	U-UNK	insulin
25	178	179	O	in
26	181	185	O	vitro
27	186	186	O	,
28	188	196	O	therefore
29	198	201	O	this
30	203	212	O	conjugated
31	214	219	O	system
32	221	225	O	maybe
33	227	232	O	useful
34	234	236	O	for
35	238	244	O	peroral
36	246	259	O	administration
37	261	262	O	of
38	264	270	O	peptide
39	272	276	O	drugs
40	278	279	O	in
41	281	283	O	the
42	285	290	O	future
NULL

11155575.xml	DDI-MedLine.d92.s0	NO_SECTION	NO_SETID	3
Systemic antibiotic agents.
1	0	7	O	Systemic
2	9	18	B-UNK	antibiotic
3	20	25	L-UNK	agents
NULL

11155575.xml	DDI-MedLine.d92.s1	NO_SECTION	NO_SETID	37
Understanding the breadth of systemic antimicrobial agents available for use by the dermatologist and their associated side-effect profiles and drug interactions allows the clinician to offer patients optimal care in the management of cutaneous infectious disease.
1	0	12	O	Understanding
2	14	16	O	the
3	18	24	O	breadth
4	26	27	O	of
5	29	36	O	systemic
6	38	50	B-UNK	antimicrobial
7	52	57	L-UNK	agents
8	59	67	O	available
9	69	71	O	for
10	73	75	O	use
11	77	78	O	by
12	80	82	O	the
13	84	96	O	dermatologist
14	98	100	O	and
15	102	106	O	their
16	108	117	O	associated
17	119	122	O	side
18	124	129	O	effect
19	131	138	O	profiles
20	140	142	O	and
21	144	147	O	drug
22	149	160	O	interactions
23	162	167	O	allows
24	169	171	O	the
25	173	181	O	clinician
26	183	184	O	to
27	186	190	O	offer
28	192	199	O	patients
29	201	207	O	optimal
30	209	212	O	care
31	214	215	O	in
32	217	219	O	the
33	221	230	O	management
34	232	233	O	of
35	235	243	O	cutaneous
36	245	254	O	infectious
37	256	262	O	disease
NULL

1115721.xml	DDI-MedLine.d65.s0	NO_SECTION	NO_SETID	7
Drug interactions: How to identify them.
1	0	3	O	Drug
2	5	16	O	interactions
3	17	17	O	:
4	19	21	O	How
5	23	24	O	to
6	26	33	O	identify
7	35	38	O	them
NULL

1115721.xml	DDI-MedLine.d65.s1	NO_SECTION	NO_SETID	30
Interactions between theraputic agents have been recognized as increasingly important causes of drug at their usual recommended dose may, under certain conditions, produce toxicity of life-endangering proportions.
1	0	11	O	Interactions
2	13	19	O	between
3	21	30	O	theraputic
4	32	37	O	agents
5	39	42	O	have
6	44	47	O	been
7	49	58	O	recognized
8	60	61	O	as
9	63	74	O	increasingly
10	76	84	O	important
11	86	91	O	causes
12	93	94	O	of
13	96	99	O	drug
14	101	102	O	at
15	104	108	O	their
16	110	114	O	usual
17	116	126	O	recommended
18	128	131	O	dose
19	133	135	O	may
20	136	136	O	,
21	138	142	O	under
22	144	150	O	certain
23	152	161	O	conditions
24	162	162	O	,
25	164	170	O	produce
26	172	179	O	toxicity
27	181	182	O	of
28	184	187	O	life
29	189	199	O	endangering
30	201	211	O	proportions
NULL

1115721.xml	DDI-MedLine.d65.s2	NO_SECTION	NO_SETID	33
While the recognition of drug toxicity resulting from interactions is of importance to all physciains, it is especially so for the clinician responsible for the welfare of those in the aerospace environment.
1	0	4	O	While
2	6	8	O	the
3	10	20	O	recognition
4	22	23	O	of
5	25	28	O	drug
6	30	37	O	toxicity
7	39	47	O	resulting
8	49	52	O	from
9	54	65	O	interactions
10	67	68	O	is
11	70	71	O	of
12	73	82	O	importance
13	84	85	O	to
14	87	89	O	all
15	91	100	O	physciains
16	101	101	O	,
17	103	104	O	it
18	106	107	O	is
19	109	118	O	especially
20	120	121	O	so
21	123	125	O	for
22	127	129	O	the
23	131	139	O	clinician
24	141	151	O	responsible
25	153	155	O	for
26	157	159	O	the
27	161	167	O	welfare
28	169	170	O	of
29	172	176	O	those
30	178	179	O	in
31	181	183	O	the
32	185	193	O	aerospace
33	195	205	O	environment
NULL

1115721.xml	DDI-MedLine.d65.s3	NO_SECTION	NO_SETID	16
This paper attempts to provide a basis for the understanding and identifications of important drug interactions.
1	0	3	O	This
2	5	9	O	paper
3	11	18	O	attempts
4	20	21	O	to
5	23	29	O	provide
6	31	31	O	a
7	33	37	O	basis
8	39	41	O	for
9	43	45	O	the
10	47	59	O	understanding
11	61	63	O	and
12	65	79	O	identifications
13	81	82	O	of
14	84	92	O	important
15	94	97	O	drug
16	99	110	O	interactions
NULL

1115721.xml	DDI-MedLine.d65.s4	NO_SECTION	NO_SETID	26
Guidelines are provided to assist the clinician in his logical approach to the identification of drug interactions when serious drug toxicity is encountered in a pateint.
1	0	9	O	Guidelines
2	11	13	O	are
3	15	22	O	provided
4	24	25	O	to
5	27	32	O	assist
6	34	36	O	the
7	38	46	O	clinician
8	48	49	O	in
9	51	53	O	his
10	55	61	O	logical
11	63	70	O	approach
12	72	73	O	to
13	75	77	O	the
14	79	92	O	identification
15	94	95	O	of
16	97	100	O	drug
17	102	113	O	interactions
18	115	118	O	when
19	120	126	O	serious
20	128	131	O	drug
21	133	140	O	toxicity
22	142	143	O	is
23	145	155	O	encountered
24	157	158	O	in
25	160	160	O	a
26	162	168	O	pateint
NULL

1115721.xml	DDI-MedLine.d65.s5	NO_SECTION	NO_SETID	24
Only with knowledge of the interaction can the therapeutic regimen be altered so as to provide therapeutic levels of necessary drugs while avoiding toxicity.
1	0	3	O	Only
2	5	8	O	with
3	10	18	O	knowledge
4	20	21	O	of
5	23	25	O	the
6	27	37	O	interaction
7	39	41	O	can
8	43	45	O	the
9	47	57	O	therapeutic
10	59	65	O	regimen
11	67	68	O	be
12	70	76	O	altered
13	78	79	O	so
14	81	82	O	as
15	84	85	O	to
16	87	93	O	provide
17	95	105	O	therapeutic
18	107	112	O	levels
19	114	115	O	of
20	117	125	O	necessary
21	127	131	O	drugs
22	133	137	O	while
23	139	146	O	avoiding
24	148	155	O	toxicity
NULL

11158747.xml	DDI-MedLine.d3.s0	NO_SECTION	NO_SETID	11
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
1	0	14	O	Pharmacokinetic
2	16	26	O	Interaction
3	28	34	O	between
4	36	45	U-UNK	amprenavir
5	47	49	O	and
6	51	59	U-UNK	rifabutin
7	61	62	O	or
8	64	71	U-UNK	rifampin
9	73	74	O	in
10	76	82	O	healthy
11	84	88	O	males
NULL

11158747.xml	DDI-MedLine.d3.s1	NO_SECTION	NO_SETID	36
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
1	0	2	O	The
2	4	12	O	objective
3	14	15	O	of
4	17	20	O	this
5	22	26	O	study
6	28	30	O	was
7	32	33	O	to
8	35	43	O	determine
9	45	46	O	if
10	48	52	O	there
11	54	55	O	is
12	57	57	O	a
13	59	73	O	pharmacokinetic
14	75	85	O	interaction
15	87	90	O	when
16	92	101	U-UNK	amprenavir
17	103	104	O	is
18	106	110	O	given
19	112	115	O	with
20	117	125	U-UNK	rifabutin
21	127	128	O	or
22	130	137	U-UNK	rifampin
23	139	141	O	and
24	143	144	O	to
25	146	154	O	determine
26	156	158	O	the
27	160	166	O	effects
28	168	169	O	of
29	171	175	O	these
30	177	181	O	drugs
31	183	184	O	on
32	186	188	O	the
33	190	201	O	erythromycin
34	203	208	O	breath
35	210	213	O	test
36	216	220	O	ERMBT
NULL

11158747.xml	DDI-MedLine.d3.s2	NO_SECTION	NO_SETID	12
Twenty-four healthy male subjects were randomized to one of two cohorts.
1	0	5	O	Twenty
2	7	10	O	four
3	12	18	O	healthy
4	20	23	O	male
5	25	32	O	subjects
6	34	37	O	were
7	39	48	O	randomized
8	50	51	O	to
9	53	55	O	one
10	57	58	O	of
11	60	62	O	two
12	64	70	O	cohorts
NULL

11158747.xml	DDI-MedLine.d3.s3	NO_SECTION	NO_SETID	43
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.
1	0	2	O	All
2	4	11	O	subjects
3	13	20	O	received
4	22	31	U-UNK	amprenavir
5	34	38	O	1,200
6	40	41	O	mg
7	43	47	O	twice
8	49	49	O	a
9	51	53	O	day
10	56	58	O	for
11	60	60	O	4
12	62	65	O	days
13	66	66	O	,
14	68	75	O	followed
15	77	78	O	by
16	80	80	O	a
17	82	82	O	7
18	84	86	O	day
19	88	94	O	washout
20	96	101	O	period
21	102	102	O	,
22	104	111	O	followed
23	113	114	O	by
24	116	121	O	either
25	123	131	U-UNK	rifabutin
26	134	136	O	300
27	138	139	O	mg
28	141	144	O	once
29	146	146	O	a
30	148	150	O	day
31	153	154	O	QD
32	159	164	O	cohort
33	166	166	O	1
34	169	170	O	or
35	172	179	U-UNK	rifampin
36	182	184	O	600
37	186	187	O	mg
38	189	190	O	QD
39	194	199	O	cohort
40	201	201	O	2
41	204	206	O	for
42	208	209	O	14
43	211	214	O	days
NULL

11158747.xml	DDI-MedLine.d3.s4	NO_SECTION	NO_SETID	21
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.
1	0	5	O	Cohort
2	7	7	O	1
3	9	12	O	then
4	14	21	O	received
5	23	32	U-UNK	amprenavir
6	34	37	O	plus
7	39	47	U-UNK	rifabutin
8	49	51	O	for
9	53	54	O	10
10	56	59	O	days
11	60	60	O	,
12	62	64	O	and
13	66	71	O	cohort
14	73	73	O	2
15	75	82	O	received
16	84	93	U-UNK	amprenavir
17	95	98	O	plus
18	100	107	U-UNK	rifampin
19	109	111	O	for
20	113	113	O	4
21	115	118	O	days
NULL

11158747.xml	DDI-MedLine.d3.s5	NO_SECTION	NO_SETID	28
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.
1	0	5	O	Serial
2	7	12	O	plasma
3	14	16	O	and
4	18	22	O	urine
5	24	30	O	samples
6	32	34	O	for
7	36	46	O	measurement
8	48	49	O	of
9	51	60	U-UNK	amprenavir
10	61	61	O	,
11	63	71	U-UNK	rifabutin
12	72	72	O	,
13	74	76	O	and
14	78	85	U-UNK	rifampin
15	87	89	O	and
16	91	95	O	their
17	97	98	B-UNK	25
18	100	100	I-UNK	O
19	102	110	I-UNK	desacetyl
20	112	122	L-UNK	metabolites
21	123	123	O	,
22	125	128	O	were
23	130	137	O	measured
24	139	140	O	by
25	142	145	O	high
26	147	157	O	performance
27	159	164	O	liquid
28	166	179	O	chromatography
NULL

11158747.xml	DDI-MedLine.d3.s6	NO_SECTION	NO_SETID	7
Rifabutin did not significantly affect amprenavir's pharmacokinetics.
1	0	8	U-UNK	Rifabutin
2	10	12	O	did
3	14	16	O	not
4	18	30	O	significantly
5	32	37	O	affect
6	39	50	O	amprenavir's
7	52	67	O	pharmacokinetics
NULL

11158747.xml	DDI-MedLine.d3.s7	NO_SECTION	NO_SETID	27
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
1	0	9	U-UNK	Amprenavir
2	11	23	O	significantly
3	25	33	O	increased
4	35	37	O	the
5	39	42	O	area
6	44	48	O	under
7	50	52	O	the
8	54	58	O	curve
9	60	61	O	at
10	63	68	O	steady
11	70	74	O	state
12	77	82	O	AUC(ss
13	86	87	O	of
14	89	97	U-UNK	rifabutin
15	99	100	O	by
16	102	105	O	2.93
17	107	110	O	fold
18	112	114	O	and
19	116	118	O	the
20	120	125	O	AUC(ss
21	128	129	O	of
22	131	132	B-UNK	25
23	134	134	I-UNK	O
24	136	153	L-UNK	desacetylrifabutin
25	155	156	O	by
26	158	161	O	13.3
27	163	166	O	fold
NULL

11158747.xml	DDI-MedLine.d3.s8	NO_SECTION	NO_SETID	18
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
1	0	7	U-UNK	Rifampin
2	9	21	O	significantly
3	23	31	O	decreased
4	33	35	O	the
5	37	42	O	AUC(ss
6	45	46	O	of
7	48	57	U-UNK	amprenavir
8	59	60	O	by
9	62	64	O	82%
10	65	65	O	,
11	67	69	O	but
12	71	80	U-UNK	amprenavir
13	82	84	O	had
14	86	87	O	no
15	89	94	O	effect
16	96	97	O	on
17	99	106	U-UNK	rifampin
18	108	123	O	pharmacokinetics
NULL

11158747.xml	DDI-MedLine.d3.s9	NO_SECTION	NO_SETID	9
Amprenavir decreased the results of the ERMBT by 83%.
1	0	9	U-UNK	Amprenavir
2	11	19	O	decreased
3	21	23	O	the
4	25	31	O	results
5	33	34	O	of
6	36	38	O	the
7	40	44	O	ERMBT
8	46	47	O	by
9	49	51	O	83%
NULL

11158747.xml	DDI-MedLine.d3.s10	NO_SECTION	NO_SETID	20
The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	17	O	the
5	19	23	O	ERMBT
6	25	29	O	after
7	31	31	O	2
8	33	37	O	weeks
9	39	40	O	of
10	42	50	U-UNK	rifabutin
11	52	54	O	and
12	56	63	U-UNK	rifampin
13	65	71	O	therapy
14	73	76	O	were
15	78	86	O	increased
16	88	90	O	187
17	92	94	O	and
18	96	99	O	156%
19	100	100	O	,
20	102	113	O	respectively
NULL

11158747.xml	DDI-MedLine.d3.s11	NO_SECTION	NO_SETID	6
Amprenavir plus rifampin was well tolerated.
1	0	9	U-UNK	Amprenavir
2	11	14	O	plus
3	16	23	U-UNK	rifampin
4	25	27	O	was
5	29	32	O	well
6	34	42	O	tolerated
NULL

11158747.xml	DDI-MedLine.d3.s12	NO_SECTION	NO_SETID	14
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
1	0	9	U-UNK	Amprenavir
2	11	14	O	plus
3	16	24	U-UNK	rifabutin
4	26	28	O	was
5	30	35	O	poorly
6	37	45	O	tolerated
7	46	46	O	,
8	48	50	O	and
9	52	52	O	5
10	54	55	O	of
11	57	58	O	11
12	60	67	O	subjects
13	69	80	O	discontinued
14	82	88	O	therapy
NULL

11158747.xml	DDI-MedLine.d3.s13	NO_SECTION	NO_SETID	13
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
1	0	7	U-UNK	Rifampin
2	9	16	O	markedly
3	18	26	O	increases
4	28	30	O	the
5	32	40	O	metabolic
6	42	50	O	clearance
7	52	53	O	of
8	55	64	U-UNK	amprenavir
9	65	65	O	,
10	67	69	O	and
11	71	86	O	coadministration
12	88	89	O	is
13	91	105	O	contraindicated
NULL

11158747.xml	DDI-MedLine.d3.s14	NO_SECTION	NO_SETID	17
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
1	0	9	U-UNK	Amprenavir
2	11	23	O	significantly
3	25	33	O	decreases
4	35	43	O	clearance
5	45	46	O	of
6	48	56	U-UNK	rifabutin
7	58	60	O	and
8	62	63	B-UNK	25
9	65	65	I-UNK	O
10	67	84	L-UNK	desacetylrifabutin
11	85	85	O	,
12	87	89	O	and
13	91	93	O	the
14	95	105	O	combination
15	107	108	O	is
16	110	115	O	poorly
17	117	125	O	tolerated
NULL

11158747.xml	DDI-MedLine.d3.s15	NO_SECTION	NO_SETID	15
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.
1	0	9	U-UNK	Amprenavir
2	11	18	O	inhibits
3	20	22	O	the
4	24	28	O	ERMBT
5	29	29	O	,
6	31	33	O	and
7	35	42	U-UNK	rifampin
8	44	46	O	and
9	48	56	U-UNK	rifabutin
10	58	60	O	are
11	62	71	O	equipotent
12	73	80	O	inducers
13	82	83	O	of
14	85	87	O	the
15	89	93	O	ERMBT
NULL

11160777.xml	DDI-MedLine.d28.s0	NO_SECTION	NO_SETID	14
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
1	0	2	O	New
2	4	7	O	oral
3	9	17	O	therapies
4	19	21	O	for
5	23	26	O	type
6	28	28	O	2
7	30	37	O	diabetes
8	39	46	O	mellitus
9	47	47	O	:
10	49	51	O	The
11	53	62	U-UNK	glitazones
12	64	65	O	or
13	67	73	O	insulin
14	75	85	O	sensitizers
NULL

11160777.xml	DDI-MedLine.d28.s1	NO_SECTION	NO_SETID	19
Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world.
1	0	3	O	Type
2	5	5	O	2
3	7	14	O	diabetes
4	16	23	O	mellitus
5	25	26	O	is
6	28	28	O	a
7	30	36	O	growing
8	38	44	O	problem
9	46	48	O	not
10	50	53	O	only
11	55	56	O	in
12	58	60	O	the
13	62	67	O	United
14	69	74	O	States
15	76	78	O	but
16	80	83	O	also
17	85	90	O	across
18	92	94	O	the
19	96	100	O	world
NULL

11160777.xml	DDI-MedLine.d28.s2	NO_SECTION	NO_SETID	26
There is now strong evidence that intensive control of blood glucose can significantly reduce and retard the microvascular complications of retinopathy, nephropathy, and neuropathy.
1	0	4	O	There
2	6	7	O	is
3	9	11	O	now
4	13	18	O	strong
5	20	27	O	evidence
6	29	32	O	that
7	34	42	O	intensive
8	44	50	O	control
9	52	53	O	of
10	55	59	O	blood
11	61	67	O	glucose
12	69	71	O	can
13	73	85	O	significantly
14	87	92	O	reduce
15	94	96	O	and
16	98	103	O	retard
17	105	107	O	the
18	109	121	O	microvascular
19	123	135	O	complications
20	137	138	O	of
21	140	150	O	retinopathy
22	151	151	O	,
23	153	163	O	nephropathy
24	164	164	O	,
25	166	168	O	and
26	170	179	O	neuropathy
NULL

11160777.xml	DDI-MedLine.d28.s3	NO_SECTION	NO_SETID	15
Ultimately however, up to 80% of type 2 diabetics die from macrovascular cardiovascular disease.
1	0	9	O	Ultimately
2	11	17	O	however
3	18	18	O	,
4	20	21	O	up
5	23	24	O	to
6	26	28	O	80%
7	30	31	O	of
8	33	36	O	type
9	38	38	O	2
10	40	48	O	diabetics
11	50	52	O	die
12	54	57	O	from
13	59	71	O	macrovascular
14	73	86	O	cardiovascular
15	88	94	O	disease
NULL

11160777.xml	DDI-MedLine.d28.s4	NO_SECTION	NO_SETID	23
This increased incidence of atherosclerotic disease is intricately associated with insulin resistance, which is a major pathophysiologic abnormality in type 2 diabetes.
1	0	3	O	This
2	5	13	O	increased
3	15	23	O	incidence
4	25	26	O	of
5	28	42	O	atherosclerotic
6	44	50	O	disease
7	52	53	O	is
8	55	65	O	intricately
9	67	76	O	associated
10	78	81	O	with
11	83	89	O	insulin
12	91	100	O	resistance
13	101	101	O	,
14	103	107	O	which
15	109	110	O	is
16	112	112	O	a
17	114	118	O	major
18	120	135	O	pathophysiologic
19	137	147	O	abnormality
20	149	150	O	in
21	152	155	O	type
22	157	157	O	2
23	159	166	O	diabetes
NULL

11160777.xml	DDI-MedLine.d28.s5	NO_SECTION	NO_SETID	32
There is strong evidence that insulin resistance is involved in the development of not only hyperglycemia, but also dyslipidemia, hypertension, hypercoagulation, vasculopathy, and ultimately atherosclerotic cardiovascular disease.
1	0	4	O	There
2	6	7	O	is
3	9	14	O	strong
4	16	23	O	evidence
5	25	28	O	that
6	30	36	O	insulin
7	38	47	O	resistance
8	49	50	O	is
9	52	59	O	involved
10	61	62	O	in
11	64	66	O	the
12	68	78	O	development
13	80	81	O	of
14	83	85	O	not
15	87	90	O	only
16	92	104	O	hyperglycemia
17	105	105	O	,
18	107	109	O	but
19	111	114	O	also
20	116	127	O	dyslipidemia
21	128	128	O	,
22	130	141	O	hypertension
23	142	142	O	,
24	144	159	O	hypercoagulation
25	160	160	O	,
26	162	173	O	vasculopathy
27	174	174	O	,
28	176	178	O	and
29	180	189	O	ultimately
30	191	205	O	atherosclerotic
31	207	220	O	cardiovascular
32	222	228	O	disease
NULL

11160777.xml	DDI-MedLine.d28.s6	NO_SECTION	NO_SETID	15
This cluster of metabolic abnormalities has been termed the insulin resistance or cardiovascular dysmetabolic syndrome.
1	0	3	O	This
2	5	11	O	cluster
3	13	14	O	of
4	16	24	O	metabolic
5	26	38	O	abnormalities
6	40	42	O	has
7	44	47	O	been
8	49	54	O	termed
9	56	58	O	the
10	60	66	O	insulin
11	68	77	O	resistance
12	79	80	O	or
13	82	95	O	cardiovascular
14	97	108	O	dysmetabolic
15	110	117	O	syndrome
NULL

11160777.xml	DDI-MedLine.d28.s7	NO_SECTION	NO_SETID	17
The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers"
1	0	2	O	The
2	4	21	U-UNK	thiazolidinediones
3	24	36	U-UNK	rosiglitazone
4	38	40	O	and
5	42	53	U-UNK	pioglitazone
6	55	55	O	,
7	57	57	O	a
8	59	61	O	new
9	63	67	O	class
10	69	70	O	of
11	72	75	O	oral
12	77	88	B-UNK	antidiabetic
13	90	95	L-UNK	agents
14	96	96	O	,
15	98	100	O	are
16	102	109	O	"insulin
17	111	122	O	sensitizers"
NULL

11160777.xml	DDI-MedLine.d28.s8	NO_SECTION	NO_SETID	10
and exert direct effects on the mechanisms of insulin resistance.
1	0	2	O	and
2	4	8	O	exert
3	10	15	O	direct
4	17	23	O	effects
5	25	26	O	on
6	28	30	O	the
7	32	41	O	mechanisms
8	43	44	O	of
9	46	52	O	insulin
10	54	63	O	resistance
NULL

11160777.xml	DDI-MedLine.d28.s9	NO_SECTION	NO_SETID	29
These effects not only improve insulin sensitivity and glycemic control with reduced insulin requirements, but also have potentially favorable effects on other components of the cardiovascular dysmetabolic syndrome.
1	0	4	O	These
2	6	12	O	effects
3	14	16	O	not
4	18	21	O	only
5	23	29	O	improve
6	31	37	O	insulin
7	39	49	O	sensitivity
8	51	53	O	and
9	55	62	O	glycemic
10	64	70	O	control
11	72	75	O	with
12	77	83	O	reduced
13	85	91	O	insulin
14	93	104	O	requirements
15	105	105	O	,
16	107	109	O	but
17	111	114	O	also
18	116	119	O	have
19	121	131	O	potentially
20	133	141	O	favorable
21	143	149	O	effects
22	151	152	O	on
23	154	158	O	other
24	160	169	O	components
25	171	172	O	of
26	174	176	O	the
27	178	191	O	cardiovascular
28	193	204	O	dysmetabolic
29	206	213	O	syndrome
NULL

11160777.xml	DDI-MedLine.d28.s10	NO_SECTION	NO_SETID	28
Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death.
1	0	3	O	Long
2	5	8	O	term
3	10	16	O	studies
4	18	20	O	are
5	22	27	O	needed
6	29	30	O	to
7	32	40	O	determine
8	42	48	O	whether
9	50	52	O	the
10	54	60	O	insulin
11	62	72	O	sensitizing
12	74	80	O	effects
13	82	83	O	of
14	85	87	O	the
15	89	98	U-UNK	glitazones
16	100	102	O	can
17	104	110	O	prevent
18	112	113	O	or
19	115	119	O	delay
20	121	129	O	premature
21	131	145	O	atherosclerotic
22	147	160	O	cardiovascular
23	162	168	O	disease
24	169	169	O	,
25	171	179	O	morbidity
26	180	180	O	,
27	182	184	O	and
28	186	190	O	death
NULL

1116650.xml	DDI-MedLine.d74.s0	NO_SECTION	NO_SETID	13
Responses to arginine of the perfused pancreas of the genetically diabetic Chinese hamster.
1	0	8	O	Responses
2	10	11	O	to
3	13	20	U-UNK	arginine
4	22	23	O	of
5	25	27	O	the
6	29	36	O	perfused
7	38	45	O	pancreas
8	47	48	O	of
9	50	52	O	the
10	54	64	O	genetically
11	66	73	O	diabetic
12	75	81	O	Chinese
13	83	89	O	hamster
NULL

1116650.xml	DDI-MedLine.d74.s1	NO_SECTION	NO_SETID	20
Nonketotic, genetically diabetic Cinese hamsters show subnormal pancreatic insulin release and impaired suppression of glucagon in response to glucose.
1	0	9	O	Nonketotic
2	10	10	O	,
3	12	22	O	genetically
4	24	31	O	diabetic
5	33	38	O	Cinese
6	40	47	O	hamsters
7	49	52	O	show
8	54	62	O	subnormal
9	64	73	O	pancreatic
10	75	81	O	insulin
11	83	89	O	release
12	91	93	O	and
13	95	102	O	impaired
14	104	114	O	suppression
15	116	117	O	of
16	119	126	O	glucagon
17	128	129	O	in
18	131	138	O	response
19	140	141	O	to
20	143	149	O	glucose
NULL

1116650.xml	DDI-MedLine.d74.s2	NO_SECTION	NO_SETID	50
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM).
1	0	1	O	To
2	3	7	O	study
3	9	11	O	the
4	13	22	O	pancreatic
5	24	30	O	effects
6	32	33	O	of
7	35	39	O	other
8	41	46	O	agents
9	47	47	O	,
10	49	55	O	dynamic
11	57	63	O	insulin
12	65	67	O	and
13	69	76	O	glucagon
14	78	84	O	release
15	86	88	O	was
16	90	97	O	measured
17	99	102	O	from
18	104	106	O	the
19	108	109	O	in
20	111	115	O	vitro
21	117	124	O	perfused
22	126	135	O	pancreases
23	137	138	O	of
24	140	145	O	normal
25	147	149	O	and
26	151	158	O	diabetic
27	160	166	O	Chinese
28	168	175	O	hamsters
29	177	178	O	in
30	180	187	O	response
31	189	190	O	to
32	192	198	O	various
33	200	211	O	combinations
34	213	214	O	of
35	216	223	U-UNK	arginine
36	226	229	O	20mM
37	231	231	O	,
38	233	239	U-UNK	glucose
39	242	244	O	100
40	246	247	O	or
41	249	251	O	150
42	253	254	O	mg
43	257	259	O	per
44	261	263	O	100
45	265	266	O	ml
46	269	269	O	,
47	271	273	O	and
48	275	286	U-UNK	theophylline
49	289	290	O	10
50	292	293	O	mM
NULL

1116650.xml	DDI-MedLine.d74.s3	NO_SECTION	NO_SETID	12
Theophylline alone caused identical insulin and glucagon release in diabetics and normals.
1	0	11	U-UNK	Theophylline
2	13	17	O	alone
3	19	24	O	caused
4	26	34	O	identical
5	36	42	O	insulin
6	44	46	O	and
7	48	55	O	glucagon
8	57	63	O	release
9	65	66	O	in
10	68	76	O	diabetics
11	78	80	O	and
12	82	88	O	normals
NULL

1116650.xml	DDI-MedLine.d74.s4	NO_SECTION	NO_SETID	27
Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals.
1	0	6	U-UNK	Glucose
2	7	7	O	,
3	9	13	O	alone
4	15	17	O	and
5	19	20	O	in
6	22	24	O	the
7	26	33	O	presence
8	35	36	O	of
9	38	49	U-UNK	theophylline
10	50	50	O	,
11	52	57	O	caused
12	59	67	O	subnormal
13	69	75	O	insulin
14	77	83	O	release
15	85	87	O	and
16	89	92	O	less
17	94	104	O	suppression
18	106	107	O	of
19	109	116	O	glucagon
20	118	124	O	release
21	126	127	O	in
22	129	131	O	the
23	133	142	O	diabectics
24	144	147	O	than
25	149	150	O	in
26	152	154	O	the
27	156	162	O	normals
NULL

1116650.xml	DDI-MedLine.d74.s5	NO_SECTION	NO_SETID	22
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics.
1	0	7	U-UNK	Arginine
2	8	8	O	,
3	10	11	O	in
4	13	15	O	the
5	17	24	O	presence
6	26	27	O	of
7	29	35	U-UNK	glucose
8	37	39	O	and
9	41	52	U-UNK	theophylline
10	53	53	O	,
11	55	60	O	caused
12	62	70	O	excessive
13	72	79	O	glucagon
14	81	87	O	release
15	89	91	O	but
16	93	98	O	nearly
17	100	105	O	normal
18	107	113	O	insulin
19	115	121	O	release
20	123	124	O	in
21	126	128	O	the
22	130	138	O	diabetics
NULL

1116650.xml	DDI-MedLine.d74.s6	NO_SECTION	NO_SETID	26
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals.
1	0	7	U-UNK	Arginine
2	8	8	O	,
3	10	11	O	in
4	13	15	O	the
5	17	23	O	absence
6	25	26	O	of
7	28	34	U-UNK	glucose
8	36	37	O	or
9	39	50	U-UNK	theophylline
10	51	51	O	,
11	53	58	O	caused
12	60	68	O	excessive
13	70	77	O	glucagon
14	79	85	O	release
15	87	88	O	in
16	90	92	O	the
17	94	102	O	diabetics
18	104	106	O	and
19	108	119	O	undetectable
20	121	127	O	insulin
21	129	135	O	release
22	137	138	O	in
23	140	145	O	either
24	147	155	O	diabetics
25	157	158	O	or
26	160	166	O	normals
NULL

1116650.xml	DDI-MedLine.d74.s7	NO_SECTION	NO_SETID	11
Pancreatic content after perfusion did not correlate with release during perfusion.
1	0	9	O	Pancreatic
2	11	17	O	content
3	19	23	O	after
4	25	33	O	perfusion
5	35	37	O	did
6	39	41	O	not
7	43	51	O	correlate
8	53	56	O	with
9	58	64	O	release
10	66	71	O	during
11	73	81	O	perfusion
NULL

1116650.xml	DDI-MedLine.d74.s8	NO_SECTION	NO_SETID	14
Infusion of arginine alone markedly decreased the amount of extractable pancreatic insulin and glucagon.
1	0	7	O	Infusion
2	9	10	O	of
3	12	19	U-UNK	arginine
4	21	25	O	alone
5	27	34	O	markedly
6	36	44	O	decreased
7	46	48	O	the
8	50	55	O	amount
9	57	58	O	of
10	60	70	O	extractable
11	72	81	O	pancreatic
12	83	89	O	insulin
13	91	93	O	and
14	95	102	O	glucagon
NULL

1116650.xml	DDI-MedLine.d74.s9	NO_SECTION	NO_SETID	25
These results indicate that the pancreatic alpha cell of the diabetic Chinese hamster responds excessively to arginine, as is seen in the human diabetic.
1	0	4	O	These
2	6	12	O	results
3	14	21	O	indicate
4	23	26	O	that
5	28	30	O	the
6	32	41	O	pancreatic
7	43	47	O	alpha
8	49	52	O	cell
9	54	55	O	of
10	57	59	O	the
11	61	68	O	diabetic
12	70	76	O	Chinese
13	78	84	O	hamster
14	86	93	O	responds
15	95	105	O	excessively
16	107	108	O	to
17	110	117	U-UNK	arginine
18	118	118	O	,
19	120	121	O	as
20	123	124	O	is
21	126	129	O	seen
22	131	132	O	in
23	134	136	O	the
24	138	142	O	human
25	144	151	O	diabetic
NULL

1116650.xml	DDI-MedLine.d74.s10	NO_SECTION	NO_SETID	14
This defect is not related to acute insulin release or the presence of glucose.
1	0	3	O	This
2	5	10	O	defect
3	12	13	O	is
4	15	17	O	not
5	19	25	O	related
6	27	28	O	to
7	30	34	O	acute
8	36	42	O	insulin
9	44	50	O	release
10	52	53	O	or
11	55	57	O	the
12	59	66	O	presence
13	68	69	O	of
14	71	77	U-UNK	glucose
NULL

1116650.xml	DDI-MedLine.d74.s11	NO_SECTION	NO_SETID	25
Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.
1	0	6	O	Further
2	7	7	O	,
3	9	13	O	these
4	15	21	O	results
5	23	29	O	confirm
6	31	34	O	that
7	36	38	O	the
8	40	47	O	diabetic
9	49	55	O	Chinese
10	57	65	O	hamster's
11	67	71	O	alpha
12	73	75	O	and
13	77	80	O	beta
14	82	86	O	cells
15	88	94	O	respond
16	96	103	O	normally
17	105	106	O	to
18	108	119	U-UNK	theophylline
19	120	120	O	,
20	122	124	O	but
21	126	128	O	are
22	130	139	O	relatively
23	141	151	O	insensitive
24	153	154	O	to
25	156	162	U-UNK	glucose
NULL

11166779.xml	DDI-MedLine.d44.s0	NO_SECTION	NO_SETID	16
Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.
1	0	6	O	Effects
2	8	9	O	of
3	11	20	U-UNK	etofibrate
4	22	25	O	upon
5	27	29	O	the
6	31	40	O	metabolism
7	42	43	O	of
8	45	55	O	chylomicron
9	57	60	O	like
10	62	70	O	emulsions
11	72	73	O	in
12	75	82	O	patients
13	84	87	O	with
14	89	96	O	coronary
15	98	103	O	artery
16	105	111	O	disease
NULL

11166779.xml	DDI-MedLine.d44.s1	NO_SECTION	NO_SETID	24
Slow chylomicron intravascular catabolism has been associated with coronary artery disease and screening for drugs that can speed-up this process can be important.
1	0	3	O	Slow
2	5	15	O	chylomicron
3	17	29	O	intravascular
4	31	40	O	catabolism
5	42	44	O	has
6	46	49	O	been
7	51	60	O	associated
8	62	65	O	with
9	67	74	O	coronary
10	76	81	O	artery
11	83	89	O	disease
12	91	93	O	and
13	95	103	O	screening
14	105	107	O	for
15	109	113	O	drugs
16	115	118	O	that
17	120	122	O	can
18	124	128	O	speed
19	130	131	O	up
20	133	136	O	this
21	138	144	O	process
22	146	148	O	can
23	150	151	O	be
24	153	161	O	important
NULL

11166779.xml	DDI-MedLine.d44.s2	NO_SECTION	NO_SETID	82
In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	17	O	the
6	19	25	O	effects
7	27	28	O	of
8	30	39	U-UNK	etofibrate
9	41	44	O	upon
10	46	56	O	chylomicron
11	58	67	O	metabolism
12	69	71	O	was
13	73	78	O	tested
14	80	81	O	by
15	83	95	O	determination
16	97	98	O	of
17	100	102	O	the
18	104	109	O	plasma
19	111	118	O	kinetics
20	120	121	O	of
21	123	123	O	a
22	125	135	O	chylomicron
23	137	140	O	like
24	142	149	O	emulsion
25	151	155	O	model
26	157	158	O	in
27	160	161	O	12
28	163	170	O	patients
29	172	175	O	with
30	177	184	O	coronary
31	186	191	O	artery
32	193	199	O	disease
33	200	200	O	,
34	202	205	O	aged
35	207	209	O	59+
36	210	210	O	/
37	212	213	O	11
38	215	219	O	years
39	220	220	O	,
40	223	227	O	total
41	229	239	O	cholesterol
42	240	240	O	:
43	242	245	O	240+
44	246	246	O	/
45	248	249	O	41
46	251	252	O	mg
47	253	253	O	/
48	254	255	O	dl
49	258	270	O	triglycerides
50	271	271	O	:
51	273	276	O	188+
52	277	277	O	/
53	279	280	O	42
54	282	283	O	mg
55	284	284	O	/
56	285	286	O	dl
57	289	297	O	submitted
58	299	300	O	to
59	302	302	O	a
60	304	313	O	randomized
61	314	314	O	,
62	316	324	O	crossover
63	325	325	O	,
64	327	332	O	double
65	334	338	O	blind
66	339	339	O	,
67	341	347	O	placebo
68	349	358	O	controlled
69	360	364	O	study
70	366	369	O	with
71	371	384	O	administration
72	386	387	O	of
73	389	389	O	1
74	391	391	O	g
75	393	395	O	per
76	397	399	O	day
77	401	410	U-UNK	etofibrate
78	412	413	O	or
79	415	421	O	placebo
80	423	425	O	for
81	427	427	O	1
82	429	433	O	month
NULL

11166779.xml	DDI-MedLine.d44.s3	NO_SECTION	NO_SETID	11
A 1-month washout period was inserted between the treatment periods.
1	0	0	O	A
2	2	2	O	1
3	4	8	O	month
4	10	16	O	washout
5	18	23	O	period
6	25	27	O	was
7	29	36	O	inserted
8	38	44	O	between
9	46	48	O	the
10	50	58	O	treatment
11	60	66	O	periods
NULL

11166779.xml	DDI-MedLine.d44.s4	NO_SECTION	NO_SETID	22
Patients were intravenously injected a chylomicron-like emulsion doubly labeled with 14C-cholesteryl oleate and 3H-triolein at baseline and after treatments.
1	0	7	O	Patients
2	9	12	O	were
3	14	26	O	intravenously
4	28	35	O	injected
5	37	37	O	a
6	39	49	O	chylomicron
7	51	54	O	like
8	56	63	O	emulsion
9	65	70	O	doubly
10	72	78	O	labeled
11	80	83	O	with
12	85	87	O	14C
13	89	99	O	cholesteryl
14	101	106	O	oleate
15	108	110	O	and
16	112	113	O	3H
17	115	122	O	triolein
18	124	125	O	at
19	127	134	O	baseline
20	136	138	O	and
21	140	144	O	after
22	146	155	O	treatments
NULL

11166779.xml	DDI-MedLine.d44.s5	NO_SECTION	NO_SETID	25
After etofibrate treatment, there was decrease of total cholesterol and triglyceride plasma levels and a trend to increase high-density lipoprotein cholesterol plasma levels.
1	0	4	O	After
2	6	15	U-UNK	etofibrate
3	17	25	O	treatment
4	26	26	O	,
5	28	32	O	there
6	34	36	O	was
7	38	45	O	decrease
8	47	48	O	of
9	50	54	O	total
10	56	66	O	cholesterol
11	68	70	O	and
12	72	83	O	triglyceride
13	85	90	O	plasma
14	92	97	O	levels
15	99	101	O	and
16	103	103	O	a
17	105	109	O	trend
18	111	112	O	to
19	114	121	O	increase
20	123	126	O	high
21	128	134	O	density
22	136	146	O	lipoprotein
23	148	158	O	cholesterol
24	160	165	O	plasma
25	167	172	O	levels
NULL

11166779.xml	DDI-MedLine.d44.s6	NO_SECTION	NO_SETID	22
Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
1	0	9	U-UNK	Etofibrate
2	11	18	O	elicited
3	20	22	O	62%
4	24	34	O	enhancement
5	36	37	O	of
6	39	42	O	post
7	44	50	U-UNK	heparin
8	52	60	O	lipolytic
9	62	69	O	activity
10	71	73	O	and
11	75	78	O	100%
12	80	87	O	increase
13	89	90	O	of
14	92	93	O	3H
15	95	106	O	triglyceride
16	108	117	O	fractional
17	119	127	O	clearance
18	129	132	O	rate
19	134	141	O	compared
20	143	146	O	with
21	148	154	O	placebo
22	156	164	O	treatment
NULL

11166779.xml	DDI-MedLine.d44.s7	NO_SECTION	NO_SETID	14
14C-cholesterol ester fractional clearance rate was 260% greater after etofibrate than after placebo.
1	0	2	O	14C
2	4	14	O	cholesterol
3	16	20	O	ester
4	22	31	O	fractional
5	33	41	O	clearance
6	43	46	O	rate
7	48	50	O	was
8	52	55	O	260%
9	57	63	O	greater
10	65	69	O	after
11	71	80	U-UNK	etofibrate
12	82	85	O	than
13	87	91	O	after
14	93	99	O	placebo
NULL

11166779.xml	DDI-MedLine.d44.s8	NO_SECTION	NO_SETID	32
Therefore, a potent effect of etofibrate on both chylomicron lipolysis and remnant removal was achieved, indicating that this drug can be used to improve this metabolism in future prospective studies.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	a
4	13	18	O	potent
5	20	25	O	effect
6	27	28	O	of
7	30	39	U-UNK	etofibrate
8	41	42	O	on
9	44	47	O	both
10	49	59	O	chylomicron
11	61	69	O	lipolysis
12	71	73	O	and
13	75	81	O	remnant
14	83	89	O	removal
15	91	93	O	was
16	95	102	O	achieved
17	103	103	O	,
18	105	114	O	indicating
19	116	119	O	that
20	121	124	O	this
21	126	129	O	drug
22	131	133	O	can
23	135	136	O	be
24	138	141	O	used
25	143	144	O	to
26	146	152	O	improve
27	154	157	O	this
28	159	168	O	metabolism
29	170	171	O	in
30	173	178	O	future
31	180	190	O	prospective
32	192	198	O	studies
NULL

11170315.xml	DDI-MedLine.d125.s0	NO_SECTION	NO_SETID	18
The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
1	0	2	O	The
2	4	7	O	mode
3	9	10	O	of
4	12	16	O	toxic
5	18	23	O	action
6	25	26	O	of
7	28	30	O	the
8	32	40	O	pesticide
9	42	48	U-UNK	gliftor
10	49	49	O	:
11	51	53	O	the
12	55	64	O	metabolism
13	66	67	O	of
14	69	71	B-UNK	1,3
15	73	87	L-UNK	difluoroacetone
16	89	90	O	to
17	96	102	B-UNK	erythro
18	104	116	L-UNK	fluorocitrate
NULL

11170315.xml	DDI-MedLine.d125.s1	NO_SECTION	NO_SETID	30
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.
1	0	2	O	The
2	4	14	O	biochemical
3	16	25	O	toxicology
4	27	28	O	of
5	30	32	B-UNK	1,3
6	34	48	L-UNK	difluoroacetone
7	49	49	O	,
8	51	51	O	a
9	53	57	O	known
10	59	68	O	metabolite
11	70	71	O	of
12	73	75	O	the
13	77	81	O	major
14	83	92	O	ingredient
15	94	95	O	of
16	97	99	O	the
17	101	109	O	pesticide
18	111	117	U-UNK	Gliftor
19	120	122	B-UNK	1,3
20	124	131	I-UNK	difluoro
21	133	133	I-UNK	2
22	135	142	L-UNK	propanol
23	144	144	O	,
24	146	148	O	was
25	150	161	O	investigated
26	163	164	O	in
27	166	169	O	vivo
28	171	173	O	and
29	175	176	O	in
30	178	182	O	vitro
NULL

11170315.xml	DDI-MedLine.d125.s2	NO_SECTION	NO_SETID	22
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro.
1	0	2	O	Rat
2	4	9	O	kidney
3	11	21	O	homogenates
4	23	34	O	supplemented
5	36	39	O	with
6	41	48	O	coenzyme
7	50	50	O	A
8	51	51	O	,
9	53	55	O	ATP
10	56	56	O	,
11	58	69	O	oxaloacetate
12	70	70	O	,
13	72	74	O	and
14	76	79	O	Mg2+
15	81	89	O	converted
16	91	93	B-UNK	1,3
17	95	109	L-UNK	difluoroacetone
18	111	112	O	to
19	118	124	B-UNK	erythro
20	126	138	L-UNK	fluorocitrate
21	140	141	O	in
22	143	147	O	vitro
NULL

11170315.xml	DDI-MedLine.d125.s3	NO_SECTION	NO_SETID	37
Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.
1	0	13	O	Administration
2	15	16	O	of
3	18	20	B-UNK	1,3
4	22	36	L-UNK	difluoroacetone
5	39	41	O	100
6	43	44	O	mg
7	46	47	O	kg
8	50	50	O	1
9	53	56	O	body
10	58	63	O	weight
11	66	67	O	to
12	69	72	O	rats
13	74	75	O	in
14	77	80	O	vivo
15	82	89	O	resulted
16	91	92	O	in
17	98	104	B-UNK	erythro
18	106	118	L-UNK	fluorocitrate
19	120	128	O	synthesis
20	130	131	O	in
21	133	135	O	the
22	137	142	O	kidney
23	143	143	O	,
24	145	149	O	which
25	151	153	O	was
26	155	162	O	preceded
27	164	165	O	by
28	167	168	O	an
29	170	178	O	elevation
30	180	181	O	in
31	183	190	O	fluoride
32	192	197	O	levels
33	199	201	O	and
34	203	210	O	followed
35	212	213	O	by
36	215	221	O	citrate
37	223	234	O	accumulation
NULL

11170315.xml	DDI-MedLine.d125.s4	NO_SECTION	NO_SETID	34
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol.
1	0	6	O	Animals
2	8	12	O	dosed
3	14	17	O	with
4	19	21	B-UNK	1,3
5	23	37	L-UNK	difluoroacetone
6	39	41	O	did
7	43	45	O	not
8	47	53	O	display
9	55	57	O	the
10	59	59	O	2
11	61	61	O	3
12	63	66	O	hour
13	68	70	O	lag
14	72	76	O	phase
15	78	79	O	in
16	81	86	O	either
17	92	98	B-UNK	erythro
18	100	112	L-UNK	fluorocitrate
19	114	122	O	synthesis
20	124	125	O	or
21	127	128	O	in
22	130	136	O	citrate
23	138	140	O	and
24	142	149	O	fluoride
25	151	162	O	accumulation
26	164	177	O	characteristic
27	179	180	O	of
28	182	188	O	animals
29	190	194	O	dosed
30	196	199	O	with
31	201	203	B-UNK	1,3
32	205	212	I-UNK	difluoro
33	214	214	I-UNK	2
34	216	223	L-UNK	propanol
NULL

11170315.xml	DDI-MedLine.d125.s5	NO_SECTION	NO_SETID	38
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol.
1	0	1	O	We
2	3	13	O	demonstrate
3	15	18	O	that
4	20	22	O	the
5	24	33	O	conversion
6	35	36	O	of
7	38	40	B-UNK	1,3
8	42	49	I-UNK	difluoro
9	51	51	I-UNK	2
10	53	60	L-UNK	propanol
11	62	63	O	to
12	65	67	B-UNK	1,3
13	69	83	L-UNK	difluoroacetone
14	85	86	O	by
15	88	89	O	an
16	91	94	O	NAD+
17	96	104	O	dependent
18	106	114	O	oxidation
19	116	117	O	is
20	119	121	O	the
21	123	126	O	rate
22	128	135	O	limiting
23	137	140	O	step
24	142	143	O	in
25	145	147	O	the
26	149	157	O	synthesis
27	159	160	O	of
28	162	164	O	the
29	166	170	O	toxic
30	172	178	O	product
31	179	179	O	,
32	185	191	B-UNK	erythro
33	193	205	L-UNK	fluorocitrate
34	207	210	O	from
35	212	214	B-UNK	1,3
36	216	223	I-UNK	difluoro
37	225	225	I-UNK	2
38	227	234	L-UNK	propanol
NULL

11170315.xml	DDI-MedLine.d125.s6	NO_SECTION	NO_SETID	49
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
1	0	4	O	Prior
2	6	19	O	administration
3	21	22	O	of
4	24	24	B-UNK	4
5	26	39	L-UNK	methylpyrazole
6	42	43	O	90
7	45	46	O	mg
8	48	49	O	kg
9	52	52	O	1
10	55	58	O	body
11	60	65	O	weight
12	68	70	O	was
13	72	76	O	shown
14	78	79	O	to
15	81	87	O	prevent
16	89	91	O	the
17	93	102	O	conversion
18	104	105	O	of
19	107	109	B-UNK	1,3
20	111	118	I-UNK	difluoro
21	120	120	I-UNK	2
22	122	129	L-UNK	propanol
23	132	134	O	100
24	136	137	O	mg
25	139	140	O	kg
26	143	143	O	1
27	146	149	O	body
28	151	156	O	weight
29	159	160	O	to
30	166	172	B-UNK	erythro
31	174	186	L-UNK	fluorocitrate
32	188	189	O	in
33	191	194	O	vivo
34	196	198	O	and
35	200	201	O	to
36	203	211	O	eliminate
37	213	215	O	the
38	217	224	O	fluoride
39	226	228	O	and
40	230	236	O	citrate
41	238	247	O	elevations
42	249	252	O	seen
43	254	255	O	in
44	257	259	B-UNK	1,3
45	261	268	I-UNK	difluoro
46	270	270	I-UNK	2
47	272	279	L-UNK	propanol
48	281	291	O	intoxicated
49	293	299	O	animals
NULL

11170315.xml	DDI-MedLine.d125.s7	NO_SECTION	NO_SETID	43
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo.
1	0	6	O	However
2	7	7	O	,
3	9	22	O	administration
4	24	25	O	of
5	27	27	B-UNK	4
6	29	42	L-UNK	methylpyrazole
7	45	46	O	90
8	48	49	O	mg
9	51	52	O	kg
10	55	55	O	1
11	58	61	O	body
12	63	68	O	weight
13	71	72	O	to
14	74	77	O	rats
15	79	79	O	2
16	81	85	O	hours
17	87	91	O	prior
18	93	94	O	to
19	96	98	B-UNK	1,3
20	100	114	L-UNK	difluoroacetone
21	117	119	O	100
22	121	122	O	mg
23	124	125	O	kg
24	128	128	O	1
25	131	134	O	body
26	136	141	O	weight
27	144	146	O	was
28	148	158	O	ineffective
29	160	161	O	in
30	163	172	O	preventing
31	178	184	B-UNK	erythro
32	186	198	L-UNK	fluorocitrate
33	200	208	O	synthesis
34	210	212	O	and
35	214	216	O	did
36	218	220	O	not
37	222	229	O	diminish
38	231	238	O	fluoride
39	240	241	O	or
40	243	249	O	citrate
41	251	262	O	accumulation
42	264	265	O	in
43	267	270	O	vivo
NULL

11170315.xml	DDI-MedLine.d125.s8	NO_SECTION	NO_SETID	48
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
1	0	1	O	We
2	3	10	O	conclude
3	12	15	O	that
4	17	19	O	the
5	21	32	O	prophylactic
6	34	36	O	and
7	38	46	O	antidotal
8	48	57	O	properties
9	59	60	O	of
10	62	62	B-UNK	4
11	64	77	L-UNK	methylpyrazole
12	79	82	O	seen
13	84	85	O	in
14	87	93	O	animals
15	95	101	O	treated
16	103	106	O	with
17	108	110	B-UNK	1,3
18	112	119	I-UNK	difluoro
19	121	121	I-UNK	2
20	123	130	L-UNK	propanol
21	132	137	O	derive
22	139	142	O	from
23	144	146	O	its
24	148	155	O	capacity
25	157	158	O	to
26	160	166	O	inhibit
27	168	170	O	the
28	172	175	O	NAD+
29	177	185	O	dependent
30	187	195	O	oxidation
31	197	207	O	responsible
32	209	211	O	for
33	213	222	O	converting
34	224	226	B-UNK	1,3
35	228	235	I-UNK	difluoro
36	237	237	I-UNK	2
37	239	246	L-UNK	propanol
38	248	249	O	to
39	251	253	B-UNK	1,3
40	255	269	L-UNK	difluoroacetone
41	271	272	O	in
42	274	276	O	the
43	278	286	O	committed
44	288	291	O	step
45	293	294	O	of
46	296	298	O	the
47	300	304	O	toxic
48	306	312	O	pathway
NULL

11172561.xml	DDI-MedLine.d101.s0	NO_SECTION	NO_SETID	12
Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease.
1	0	11	O	Pharmacology
2	13	15	O	and
3	17	31	O	pharmacotherapy
4	33	34	O	of
5	36	49	O	cardiovascular
6	51	55	O	drugs
7	57	58	O	in
8	60	67	O	patients
9	69	72	O	with
10	74	80	O	chronic
11	82	86	O	renal
12	88	94	O	disease
NULL

11172561.xml	DDI-MedLine.d101.s1	NO_SECTION	NO_SETID	18
Cardiovascular disease is a common comorbidity and a major cause of mortality in patients with chronic renal disease.
1	0	13	O	Cardiovascular
2	15	21	O	disease
3	23	24	O	is
4	26	26	O	a
5	28	33	O	common
6	35	45	O	comorbidity
7	47	49	O	and
8	51	51	O	a
9	53	57	O	major
10	59	63	O	cause
11	65	66	O	of
12	68	76	O	mortality
13	78	79	O	in
14	81	88	O	patients
15	90	93	O	with
16	95	101	O	chronic
17	103	107	O	renal
18	109	115	O	disease
NULL

11172561.xml	DDI-MedLine.d101.s2	NO_SECTION	NO_SETID	20
Drug regimens in patients with cardiovascular disease are frequently complex and can be significantly affected by alterations in renal function.
1	0	3	O	Drug
2	5	12	O	regimens
3	14	15	O	in
4	17	24	O	patients
5	26	29	O	with
6	31	44	O	cardiovascular
7	46	52	O	disease
8	54	56	O	are
9	58	67	O	frequently
10	69	75	O	complex
11	77	79	O	and
12	81	83	O	can
13	85	86	O	be
14	88	100	O	significantly
15	102	109	O	affected
16	111	112	O	by
17	114	124	O	alterations
18	126	127	O	in
19	129	133	O	renal
20	135	142	O	function
NULL

11172561.xml	DDI-MedLine.d101.s3	NO_SECTION	NO_SETID	18
In addition, several cardiovascular drugs directly affect renal function and the management of patients with renal disease.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	several
5	21	34	O	cardiovascular
6	36	40	O	drugs
7	42	49	O	directly
8	51	56	O	affect
9	58	62	O	renal
10	64	71	O	function
11	73	75	O	and
12	77	79	O	the
13	81	90	O	management
14	92	93	O	of
15	95	102	O	patients
16	104	107	O	with
17	109	113	O	renal
18	115	121	O	disease
NULL

11172561.xml	DDI-MedLine.d101.s4	NO_SECTION	NO_SETID	33
This article reviews the impact of renal disease on the pharmacokinetics of cardiovascular drugs and identifies clinically important interactions between these and other drugs commonly used in the management of chronic renal disease.
1	0	3	O	This
2	5	11	O	article
3	13	19	O	reviews
4	21	23	O	the
5	25	30	O	impact
6	32	33	O	of
7	35	39	O	renal
8	41	47	O	disease
9	49	50	O	on
10	52	54	O	the
11	56	71	O	pharmacokinetics
12	73	74	O	of
13	76	89	O	cardiovascular
14	91	95	O	drugs
15	97	99	O	and
16	101	110	O	identifies
17	112	121	O	clinically
18	123	131	O	important
19	133	144	O	interactions
20	146	152	O	between
21	154	158	O	these
22	160	162	O	and
23	164	168	O	other
24	170	174	O	drugs
25	176	183	O	commonly
26	185	188	O	used
27	190	191	O	in
28	193	195	O	the
29	197	206	O	management
30	208	209	O	of
31	211	217	O	chronic
32	219	223	O	renal
33	225	231	O	disease
NULL

11172561.xml	DDI-MedLine.d101.s5	NO_SECTION	NO_SETID	22
Several classes of cardiovascular drugs are also discussed in relationship to their differential effects on the management and progression of renal disease.
1	0	6	O	Several
2	8	14	O	classes
3	16	17	O	of
4	19	32	O	cardiovascular
5	34	38	O	drugs
6	40	42	O	are
7	44	47	O	also
8	49	57	O	discussed
9	59	60	O	in
10	62	73	O	relationship
11	75	76	O	to
12	78	82	O	their
13	84	95	O	differential
14	97	103	O	effects
15	105	106	O	on
16	108	110	O	the
17	112	121	O	management
18	123	125	O	and
19	127	137	O	progression
20	139	140	O	of
21	142	146	O	renal
22	148	154	O	disease
NULL

11178969.xml	DDI-MedLine.d129.s0	NO_SECTION	NO_SETID	15
Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
1	0	4	B-UNK	Green
2	6	8	I-UNK	tea
3	10	20	L-UNK	polyphenols
4	22	23	O	as
5	25	30	O	potent
6	32	40	U-UNK	enhancers
7	42	43	O	of
8	45	58	O	glucocorticoid
9	60	66	O	induced
10	68	72	O	mouse
11	74	80	O	mammary
12	82	86	O	tumor
13	88	92	O	virus
14	94	97	O	gene
15	99	108	O	expression
NULL

11178969.xml	DDI-MedLine.d129.s1	NO_SECTION	NO_SETID	39
The effect of natural and synthetic galloyl esters on glucocorticoid-induced gene expression was evaluated by using rat fibroblast 3Y1 cells stably transfected with a luciferase reporter gene under the transcriptional regulation of the mouse mammary tumor virus promoter.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	natural
5	22	24	O	and
6	26	34	O	synthetic
7	36	42	O	galloyl
8	44	49	O	esters
9	51	52	O	on
10	54	67	O	glucocorticoid
11	69	75	O	induced
12	77	80	O	gene
13	82	91	O	expression
14	93	95	O	was
15	97	105	O	evaluated
16	107	108	O	by
17	110	114	O	using
18	116	118	O	rat
19	120	129	O	fibroblast
20	131	133	O	3Y1
21	135	139	O	cells
22	141	146	O	stably
23	148	158	O	transfected
24	160	163	O	with
25	165	165	O	a
26	167	176	O	luciferase
27	178	185	O	reporter
28	187	190	O	gene
29	192	196	O	under
30	198	200	O	the
31	202	216	O	transcriptional
32	218	227	O	regulation
33	229	230	O	of
34	232	234	O	the
35	236	240	O	mouse
36	242	248	O	mammary
37	250	254	O	tumor
38	256	260	O	virus
39	262	269	U-UNK	promoter
NULL

11178969.xml	DDI-MedLine.d129.s2	NO_SECTION	NO_SETID	12
The glucocorticoid-induced gene transcription was strongly suppressed by synthetic alkyl esters;
1	0	2	O	The
2	4	17	O	glucocorticoid
3	19	25	O	induced
4	27	30	O	gene
5	32	44	O	transcription
6	46	48	O	was
7	50	57	O	strongly
8	59	68	O	suppressed
9	70	71	O	by
10	73	81	O	synthetic
11	83	87	O	alkyl
12	89	94	O	esters
NULL

11178969.xml	DDI-MedLine.d129.s3	NO_SECTION	NO_SETID	25
n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid.
1	0	0	B-UNK	n
2	2	8	I-UNK	dodecyl
3	10	16	L-UNK	gallate
4	18	23	O	showed
5	25	27	O	the
6	29	32	O	most
7	34	39	O	potent
8	41	50	O	inhibition
9	53	55	O	66%
10	57	66	O	inhibition
11	68	69	O	at
12	71	72	O	10
13	74	79	O	microM
14	81	81	O	,
15	83	87	O	which
16	89	91	O	was
17	93	95	O	far
18	97	100	O	more
19	102	107	O	potent
20	109	112	O	than
21	114	117	O	that
22	119	120	O	of
23	122	126	O	crude
24	128	133	B-UNK	tannic
25	135	138	L-UNK	acid
NULL

11178969.xml	DDI-MedLine.d129.s4	NO_SECTION	NO_SETID	34
n-Octyl and n-cetyl gallate also showed good inhibition, while gallic acid itself was not so active, suggesting that the presence of hydrophobic side chain is important for the suppressive effect.
1	0	0	O	n
2	2	6	O	Octyl
3	8	10	O	and
4	12	12	O	n
5	14	18	O	cetyl
6	20	26	O	gallate
7	28	31	O	also
8	33	38	O	showed
9	40	43	O	good
10	45	54	O	inhibition
11	55	55	O	,
12	57	61	O	while
13	63	68	O	gallic
14	70	73	O	acid
15	75	80	O	itself
16	82	84	O	was
17	86	88	O	not
18	90	91	O	so
19	93	98	O	active
20	99	99	O	,
21	101	110	O	suggesting
22	112	115	O	that
23	117	119	O	the
24	121	128	O	presence
25	130	131	O	of
26	133	143	O	hydrophobic
27	145	148	O	side
28	150	154	O	chain
29	156	157	O	is
30	159	167	O	important
31	169	171	O	for
32	173	175	O	the
33	177	187	O	suppressive
34	189	194	O	effect
NULL

11178969.xml	DDI-MedLine.d129.s5	NO_SECTION	NO_SETID	33
On the other hand, surprisingly, green tea gallocatechins, (-)-epigallocatechin-3-O-gallate and theasinensin A, potently enhanced the promoter activity (182 and 247% activity at 1 microM, respectively).
1	0	1	O	On
2	3	5	O	the
3	7	11	O	other
4	13	16	O	hand
5	17	17	O	,
6	19	30	O	surprisingly
7	31	31	O	,
8	33	37	B-UNK	green
9	39	41	I-UNK	tea
10	43	56	L-UNK	gallocatechins
11	57	57	O	,
12	63	78	O	epigallocatechin
13	80	80	O	3
14	82	82	O	O
15	84	90	O	gallate
16	92	94	O	and
17	96	107	O	theasinensin
18	109	109	O	A
19	110	110	O	,
20	112	119	O	potently
21	121	128	O	enhanced
22	130	132	O	the
23	134	141	O	promoter
24	143	150	O	activity
25	153	155	O	182
26	157	159	O	and
27	161	164	O	247%
28	166	173	O	activity
29	175	176	O	at
30	178	178	O	1
31	180	185	O	microM
32	186	186	O	,
33	188	199	O	respectively
NULL

11178969.xml	DDI-MedLine.d129.s6	NO_SECTION	NO_SETID	25
The regulation of the level of the glucocorticoid-induced gene expression by the antioxidative gallates is of great interest from a therapeutic point of view.
1	0	2	O	The
2	4	13	O	regulation
3	15	16	O	of
4	18	20	O	the
5	22	26	O	level
6	28	29	O	of
7	31	33	O	the
8	35	48	O	glucocorticoid
9	50	56	O	induced
10	58	61	O	gene
11	63	72	O	expression
12	74	75	O	by
13	77	79	O	the
14	81	93	O	antioxidative
15	95	102	O	gallates
16	104	105	O	is
17	107	108	O	of
18	110	114	O	great
19	116	123	O	interest
20	125	128	O	from
21	130	130	O	a
22	132	142	O	therapeutic
23	144	148	O	point
24	150	151	O	of
25	153	156	O	view
NULL

11180036.xml	DDI-MedLine.d86.s0	NO_SECTION	NO_SETID	13
Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
1	0	14	O	Pharmacokinetic
2	16	26	O	interaction
3	28	34	O	between
4	36	41	O	single
5	43	46	O	oral
6	48	52	O	doses
7	54	55	O	of
8	57	65	U-UNK	diltiazem
9	67	69	O	and
10	71	79	U-UNK	sirolimus
11	81	82	O	in
12	84	90	O	healthy
13	92	101	O	volunteers
NULL

11180036.xml	DDI-MedLine.d86.s1	NO_SECTION	NO_SETID	29
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.
1	0	2	O	AIM
2	4	6	O	AND
3	8	17	O	BACKGROUND
4	18	18	O	:
5	20	22	O	The
6	24	38	O	pharmacokinetic
7	40	50	O	interaction
8	52	58	O	between
9	60	68	U-UNK	sirolimus
10	69	69	O	,
11	71	71	O	a
12	73	81	B-UNK	macrolide
13	83	99	L-UNK	immunosuppressant
14	101	111	O	metabolized
15	113	114	O	by
16	116	121	O	CYP3A4
17	122	122	O	,
18	124	126	O	and
19	128	130	O	the
20	132	138	B-UNK	calcium
21	140	146	I-UNK	channel
22	148	154	L-UNK	blocker
23	156	164	U-UNK	diltiazem
24	166	168	O	was
25	170	176	O	studied
26	178	179	O	in
27	181	182	O	18
28	184	190	O	healthy
29	192	199	O	subjects
NULL

11180036.xml	DDI-MedLine.d86.s2	NO_SECTION	NO_SETID	23
Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists.
1	0	6	O	Several
2	8	17	O	clinically
3	19	27	O	important
4	29	40	O	interactions
5	42	45	O	have
6	47	56	O	previously
7	58	61	O	been
8	63	70	O	reported
9	72	74	O	for
10	76	80	O	other
11	82	98	B-UNK	immunosuppressive
12	100	104	L-UNK	drugs
13	106	109	O	that
14	111	113	O	are
15	115	125	O	metabolized
16	127	128	O	by
17	130	132	O	the
18	134	137	O	same
19	139	144	O	enzyme
20	146	148	O	and
21	150	152	O	for
22	154	160	B-UNK	calcium
23	162	172	L-UNK	antagonists
NULL

11180036.xml	DDI-MedLine.d86.s3	NO_SECTION	NO_SETID	51
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together.
1	0	6	O	METHODS
2	7	7	O	:
3	9	15	O	Healthy
4	17	24	O	subjects
5	26	28	O	who
6	30	33	O	were
7	35	36	O	20
8	38	39	O	to
9	41	42	O	43
10	44	48	O	years
11	50	52	O	old
12	54	65	O	participated
13	67	68	O	in
14	70	71	O	an
15	73	76	O	open
16	77	77	O	,
17	79	83	O	three
18	85	90	O	period
19	91	91	O	,
20	93	102	O	randomized
21	103	103	O	,
22	105	113	O	crossover
23	115	119	O	study
24	121	122	O	of
25	124	126	O	the
26	128	143	O	pharmacokinetics
27	145	146	O	of
28	148	148	O	a
29	150	155	O	single
30	157	158	O	10
31	160	161	O	mg
32	163	166	O	oral
33	168	171	O	dose
34	173	174	O	of
35	176	184	U-UNK	sirolimus
36	185	185	O	,
37	187	187	O	a
38	189	194	O	single
39	196	199	O	oral
40	201	203	O	120
41	205	206	O	mg
42	208	211	O	dose
43	213	214	O	of
44	216	224	U-UNK	diltiazem
45	225	225	O	,
46	227	229	O	and
47	231	233	O	the
48	235	237	O	two
49	239	243	O	drugs
50	245	249	O	given
51	251	258	O	together
NULL

11180036.xml	DDI-MedLine.d86.s4	NO_SECTION	NO_SETID	12
The three study periods were separated by a 21-day washout phase.
1	0	2	O	The
2	4	8	O	three
3	10	14	O	study
4	16	22	O	periods
5	24	27	O	were
6	29	37	O	separated
7	39	40	O	by
8	42	42	O	a
9	44	45	O	21
10	47	49	O	day
11	51	57	O	washout
12	59	63	O	phase
NULL

11180036.xml	DDI-MedLine.d86.s5	NO_SECTION	NO_SETID	69
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	11	O	The
4	13	21	O	geometric
5	23	26	O	mean
6	29	31	O	90%
7	33	42	O	confidence
8	44	51	O	interval
9	54	58	O	whole
10	60	64	O	blood
11	66	74	U-UNK	sirolimus
12	76	79	O	area
13	81	85	O	under
14	87	89	O	the
15	91	96	O	plasma
16	98	110	O	concentration
17	112	115	O	time
18	117	121	O	curve
19	123	131	O	increased
20	133	135	O	60%
21	138	140	O	35%
22	142	144	O	90%
23	146	146	O	,
24	148	151	O	from
25	153	155	O	736
26	157	158	O	to
27	160	163	O	1178
28	165	166	O	ng
29	168	168	O	x
30	170	170	O	h
31	171	171	O	/
32	172	173	O	mL
33	174	174	O	,
34	176	178	O	and
35	180	186	O	maximum
36	188	200	O	concentration
37	202	210	O	increased
38	212	214	O	43%
39	217	219	O	14%
40	221	223	O	81%
41	225	225	O	,
42	227	230	O	from
43	232	233	O	67
44	235	236	O	to
45	238	239	O	96
46	241	242	O	ng
47	243	243	O	/
48	244	245	O	mL
49	246	246	O	,
50	248	251	O	with
51	253	261	U-UNK	diltiazem
52	263	278	O	coadministration
53	279	279	O	,
54	281	287	O	whereas
55	289	291	O	the
56	293	296	O	mean
57	298	308	O	elimination
58	310	313	O	half
59	315	318	O	life
60	320	321	O	of
61	323	331	U-UNK	sirolimus
62	333	341	O	decreased
63	343	350	O	slightly
64	351	351	O	,
65	353	356	O	from
66	358	359	O	79
67	361	362	O	to
68	364	365	O	67
69	367	371	O	hours
NULL

11180036.xml	DDI-MedLine.d86.s6	NO_SECTION	NO_SETID	23
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
1	0	7	O	Apparent
2	9	12	O	oral
3	14	22	O	clearance
4	24	26	O	and
5	28	33	O	volume
6	35	36	O	of
7	38	49	O	distribution
8	51	52	O	of
9	54	62	U-UNK	sirolimus
10	64	72	O	decreased
11	74	77	O	with
12	79	81	O	38%
13	83	85	O	and
14	87	89	O	45%
15	90	90	O	,
16	92	103	O	respectively
17	104	104	O	,
18	106	109	O	when
19	111	119	U-UNK	sirolimus
20	121	123	O	was
21	125	129	O	given
22	131	134	O	with
23	136	144	U-UNK	diltiazem
NULL

11180036.xml	DDI-MedLine.d86.s7	NO_SECTION	NO_SETID	47
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
1	0	2	O	The
2	4	9	O	plasma
3	11	17	O	maximum
4	19	31	O	concentration
5	33	35	O	and
6	37	40	O	area
7	42	46	O	under
8	48	50	O	the
9	52	57	O	plasma
10	59	71	O	concentration
11	73	76	O	time
12	78	82	O	curve
13	84	85	O	of
14	87	95	U-UNK	diltiazem
15	96	96	O	,
16	98	115	U-UNK	desacetyldiltiazem
17	116	116	O	,
18	118	120	O	and
19	122	139	U-UNK	desmethyldiltiazem
20	141	144	O	were
21	146	154	O	unchanged
22	156	160	O	after
23	162	177	O	coadministration
24	179	180	O	of
25	182	190	U-UNK	sirolimus
26	191	191	O	,
27	193	195	O	and
28	197	198	O	no
29	200	211	O	potentiation
30	213	214	O	of
31	216	218	O	the
32	220	226	O	effects
33	228	229	O	of
34	231	239	U-UNK	diltiazem
35	241	242	O	on
36	244	252	O	diastolic
37	254	255	O	or
38	257	264	O	systolic
39	266	270	O	blood
40	272	279	O	pressure
41	281	282	O	or
42	284	285	O	on
43	287	289	O	the
44	291	310	O	electrocardiographic
45	312	321	O	parameters
46	323	325	O	was
47	327	330	O	seen
NULL

11180036.xml	DDI-MedLine.d86.s8	NO_SECTION	NO_SETID	22
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	18	O	Single
4	20	23	O	dose
5	25	33	U-UNK	diltiazem
6	35	50	O	coadministration
7	52	56	O	leads
8	58	59	O	to
9	61	66	O	higher
10	68	76	U-UNK	sirolimus
11	78	85	O	exposure
12	86	86	O	,
13	88	97	O	presumably
14	99	100	O	by
15	102	111	O	inhibition
16	113	114	O	of
17	116	118	O	the
18	120	124	O	first
19	126	129	O	pass
20	131	140	O	metabolism
21	142	143	O	of
22	145	153	U-UNK	sirolimus
NULL

11180036.xml	DDI-MedLine.d86.s9	NO_SECTION	NO_SETID	30
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	24	O	pronounced
5	26	37	O	intersubject
6	39	49	O	variability
7	51	52	O	in
8	54	56	O	the
9	58	63	O	extent
10	65	66	O	of
11	68	70	O	the
12	72	80	U-UNK	sirolimus
13	82	90	U-UNK	diltiazem
14	92	102	O	interaction
15	103	103	O	,
16	105	109	O	whole
17	111	115	O	blood
18	117	125	U-UNK	sirolimus
19	127	140	O	concentrations
20	142	147	O	should
21	149	150	O	be
22	152	160	O	monitored
23	162	168	O	closely
24	170	171	O	in
25	173	180	O	patients
26	182	188	O	treated
27	190	193	O	with
28	195	197	O	the
29	199	201	O	two
30	203	207	O	drugs
NULL

11180037.xml	DDI-MedLine.d99.s0	NO_SECTION	NO_SETID	8
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
1	0	10	U-UNK	Fluvoxamine
2	12	19	O	inhibits
3	21	23	O	the
4	25	30	O	CYP2C9
5	32	40	O	catalyzed
6	42	58	O	biotransformation
7	60	61	O	of
8	63	73	U-UNK	tolbutamide
NULL

11180037.xml	DDI-MedLine.d99.s1	NO_SECTION	NO_SETID	19
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
1	0	8	O	OBJECTIVE
2	9	9	O	:
3	11	13	O	Our
4	15	23	O	objective
5	25	27	O	was
6	29	30	O	to
7	32	38	O	examine
8	40	42	O	the
9	44	54	O	interaction
10	56	62	O	between
11	64	74	U-UNK	fluvoxamine
12	76	78	O	and
13	80	90	U-UNK	tolbutamide
14	92	93	O	to
15	95	101	O	confirm
16	103	106	O	that
17	108	118	U-UNK	fluvoxamine
18	120	127	O	inhibits
19	129	134	O	CYP2C9
NULL

11180037.xml	DDI-MedLine.d99.s2	NO_SECTION	NO_SETID	19
METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants.
1	0	6	O	METHODS
2	7	7	O	:
3	9	11	O	The
4	13	17	O	study
5	19	21	O	was
6	23	29	O	carried
7	31	33	O	out
8	35	36	O	as
9	38	39	O	an
10	41	44	O	open
11	45	45	O	,
12	47	56	O	randomized
13	57	57	O	,
14	59	67	O	crossover
15	69	74	O	design
16	76	79	O	with
17	81	82	O	14
18	84	90	O	healthy
19	92	103	O	participants
NULL

11180037.xml	DDI-MedLine.d99.s3	NO_SECTION	NO_SETID	12
In period A, all volunteers took 500 mg of tolbutamide orally.
1	0	1	O	In
2	3	8	O	period
3	10	10	O	A
4	11	11	O	,
5	13	15	O	all
6	17	26	O	volunteers
7	28	31	O	took
8	33	35	O	500
9	37	38	O	mg
10	40	41	O	of
11	43	53	U-UNK	tolbutamide
12	55	60	O	orally
NULL

11180037.xml	DDI-MedLine.d99.s4	NO_SECTION	NO_SETID	14
In period B, the volunteers were randomly assigned to one of two groups.
1	0	1	O	In
2	3	8	O	period
3	10	10	O	B
4	11	11	O	,
5	13	15	O	the
6	17	26	O	volunteers
7	28	31	O	were
8	33	40	O	randomly
9	42	49	O	assigned
10	51	52	O	to
11	54	56	O	one
12	58	59	O	of
13	61	63	O	two
14	65	70	O	groups
NULL

11180037.xml	DDI-MedLine.d99.s5	NO_SECTION	NO_SETID	21
Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2).
1	0	3	O	Each
2	5	9	O	group
3	11	14	O	took
4	16	21	O	either
5	23	25	O	150
6	27	28	O	mg
7	30	31	O	or
8	33	34	O	75
9	36	37	O	mg
10	39	40	O	of
11	42	52	U-UNK	fluvoxamine
12	54	54	O	a
13	56	58	O	day
14	60	62	O	for
15	64	64	O	5
16	66	69	O	days
17	72	74	O	day
18	77	77	O	3
19	79	80	O	to
20	82	84	O	day
21	86	86	O	2
NULL

11180037.xml	DDI-MedLine.d99.s6	NO_SECTION	NO_SETID	14
The groups then took 500 mg of tolbutamide as a single dose (day 0).
1	0	2	O	The
2	4	9	O	groups
3	11	14	O	then
4	16	19	O	took
5	21	23	O	500
6	25	26	O	mg
7	28	29	O	of
8	31	41	U-UNK	tolbutamide
9	43	44	O	as
10	46	46	O	a
11	48	53	O	single
12	55	58	O	dose
13	61	63	O	day
14	65	65	O	0
NULL

11180037.xml	DDI-MedLine.d99.s7	NO_SECTION	NO_SETID	12
In both periods, blood and urine were sampled at regular intervals.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	periods
4	15	15	O	,
5	17	21	O	blood
6	23	25	O	and
7	27	31	O	urine
8	33	36	O	were
9	38	44	O	sampled
10	46	47	O	at
11	49	55	O	regular
12	57	65	O	intervals
NULL

11180037.xml	DDI-MedLine.d99.s8	NO_SECTION	NO_SETID	25
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.
1	0	5	O	Plasma
2	7	9	O	was
3	11	18	O	analyzed
4	20	22	O	for
5	24	34	U-UNK	tolbutamide
6	35	35	O	,
7	37	39	O	and
8	41	45	O	urine
9	47	49	O	was
10	51	58	O	analyzed
11	60	62	O	for
12	64	74	U-UNK	tolbutamide
13	76	78	O	and
14	80	82	O	its
15	84	86	O	two
16	88	98	O	metabolites
17	99	99	O	,
18	101	101	B-UNK	4
19	103	120	L-UNK	hydroxytolbutamide
20	122	124	O	and
21	126	143	U-UNK	carboxytolbutamide
22	145	146	O	by
23	148	152	O	means
24	154	155	O	of
25	157	160	O	HPLC
NULL

11180037.xml	DDI-MedLine.d99.s9	NO_SECTION	NO_SETID	43
RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	14	O	During
4	16	24	O	treatment
5	26	29	O	with
6	31	41	U-UNK	fluvoxamine
7	42	42	O	,
8	44	48	O	there
9	50	52	O	was
10	54	54	O	a
11	56	68	O	statistically
12	70	80	O	significant
13	82	89	O	decrease
14	91	92	O	in
15	94	96	O	the
16	98	103	O	median
17	105	106	O	of
18	108	110	O	the
19	112	116	O	total
20	118	126	O	clearance
21	128	129	O	of
22	131	141	U-UNK	tolbutamide
23	142	142	O	,
24	144	147	O	from
25	149	151	O	845
26	153	154	O	mL
27	155	155	O	/
28	156	156	O	h
29	158	159	O	to
30	161	163	O	688
31	165	166	O	mL
32	167	167	O	/
33	168	168	O	h
34	169	169	O	,
35	171	175	O	among
36	177	179	O	the
37	181	190	O	volunteers
38	192	194	O	who
39	196	203	O	received
40	205	206	O	75
41	208	209	O	mg
42	210	210	O	/
43	211	211	O	d
NULL

11180037.xml	DDI-MedLine.d99.s10	NO_SECTION	NO_SETID	20
There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	20	O	reduction
5	22	25	O	that
6	27	33	O	reached
7	35	44	O	borderline
8	46	56	O	statistical
9	58	69	O	significance
10	71	72	O	in
11	74	76	O	the
12	78	82	O	group
13	84	87	O	that
14	89	96	O	received
15	98	100	O	150
16	102	103	O	mg
17	104	104	O	/
18	105	105	O	d
19	107	108	O	of
20	110	120	U-UNK	tolbutamide
NULL

11180037.xml	DDI-MedLine.d99.s11	NO_SECTION	NO_SETID	60
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	by
4	17	21	O	means
5	23	24	O	of
6	26	26	B-UNK	4
7	28	45	L-UNK	hydroxytolbutamide
8	47	49	O	and
9	51	68	U-UNK	carboxytolbutamide
10	70	72	O	was
11	74	86	O	significantly
12	88	94	O	reduced
13	96	97	O	in
14	99	102	O	both
15	104	109	O	groups
16	112	113	O	ie
17	114	114	O	,
18	116	119	O	from
19	121	123	O	901
20	125	126	O	mL
21	127	127	O	/
22	128	128	O	h
23	130	131	O	to
24	133	135	O	318
25	137	138	O	mL
26	139	139	O	/
27	140	140	O	h
28	142	143	O	in
29	145	147	O	the
30	149	153	O	group
31	155	158	O	that
32	160	167	O	received
33	169	171	O	150
34	173	174	O	mg
35	176	177	O	of
36	179	189	U-UNK	tolbutamide
37	191	193	O	per
38	195	197	O	day
39	199	201	O	and
40	203	206	O	from
41	208	210	O	723
42	212	213	O	mL
43	214	214	O	/
44	215	215	O	h
45	217	218	O	to
46	220	222	O	457
47	224	225	O	mL
48	226	226	O	/
49	227	227	O	h
50	229	230	O	in
51	232	234	O	the
52	236	240	O	group
53	242	245	O	that
54	247	254	O	received
55	256	257	O	75
56	259	260	O	mg
57	262	263	O	of
58	265	275	U-UNK	tolbutamide
59	277	279	O	per
60	281	283	O	day
NULL

11180037.xml	DDI-MedLine.d99.s12	NO_SECTION	NO_SETID	37
Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant.
1	0	3	O	Thus
2	5	9	O	there
3	11	13	O	was
4	15	15	O	a
5	17	24	O	tendency
6	26	31	O	toward
7	33	33	O	a
8	35	38	O	more
9	40	49	O	pronounced
10	51	60	O	inhibition
11	62	63	O	of
12	65	67	O	the
13	69	69	O	4
14	71	83	O	hydroxylation
15	85	90	O	during
16	92	100	O	treatment
17	102	105	O	with
18	107	109	O	150
19	111	112	O	mg
20	113	113	O	/
21	114	114	O	d
22	116	117	O	of
23	119	129	U-UNK	fluvoxamine
24	131	138	O	compared
25	140	143	O	with
26	145	146	O	75
27	148	149	O	mg
28	150	150	O	/
29	151	151	O	d
30	152	152	O	,
31	154	156	O	but
32	158	160	O	the
33	162	171	O	difference
34	173	175	O	was
35	177	179	O	not
36	181	193	O	statistically
37	195	205	O	significant
NULL

11180037.xml	DDI-MedLine.d99.s13	NO_SECTION	NO_SETID	11
CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.
1	0	9	O	CONCLUSION
2	10	10	O	:
3	12	22	U-UNK	Fluvoxamine
4	24	25	O	is
5	27	27	O	a
6	29	36	O	moderate
7	38	46	O	inhibitor
8	48	49	O	of
9	51	56	O	CYP2C9
10	58	59	O	in
11	61	64	O	vivo
NULL

11180038.xml	DDI-MedLine.d140.s0	NO_SECTION	NO_SETID	27
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
1	0	11	O	Longitudinal
2	13	22	O	assessment
3	24	25	O	of
4	27	36	U-UNK	everolimus
5	38	39	O	in
6	41	42	O	de
7	44	47	O	novo
8	49	53	O	renal
9	55	64	O	transplant
10	66	75	O	recipients
11	77	80	O	over
12	82	84	O	the
13	86	90	O	first
14	92	95	O	post
15	97	106	O	transplant
16	108	111	O	year
17	112	112	O	:
18	114	129	O	pharmacokinetics
19	130	130	O	,
20	132	139	O	exposure
21	141	148	O	response
22	150	162	O	relationships
23	163	163	O	,
24	165	167	O	and
25	169	177	O	influence
26	179	180	O	on
27	182	193	U-UNK	cyclosporine
NULL

11180038.xml	DDI-MedLine.d140.s1	NO_SECTION	NO_SETID	32
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
1	0	8	O	OBJECTIVE
2	9	9	O	:
3	11	13	O	Our
4	15	23	O	objective
5	25	27	O	was
6	29	30	O	to
7	32	43	O	characterize
8	45	47	O	the
9	49	54	O	steady
10	56	60	O	state
11	62	77	O	pharmacokinetics
12	79	80	O	of
13	82	91	U-UNK	everolimus
14	93	95	O	and
15	97	108	U-UNK	cyclosporine
16	111	113	O	INN
17	114	114	O	,
18	116	126	U-UNK	ciclosporin
19	129	132	O	when
20	134	147	O	coadministered
21	149	150	O	in
22	152	153	O	de
23	155	158	O	novo
24	160	165	O	kidney
25	167	175	O	allograft
26	177	186	O	recipients
27	188	193	O	during
28	195	197	O	the
29	199	203	O	first
30	205	208	O	year
31	210	214	O	after
32	216	230	O	transplantation
NULL

11180038.xml	DDI-MedLine.d140.s2	NO_SECTION	NO_SETID	41
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone.
1	0	5	O	METHOD
2	6	6	O	:
3	8	11	O	This
4	13	17	O	study
5	19	21	O	was
6	23	23	O	a
7	25	35	O	multicenter
8	37	46	O	randomized
9	48	53	O	double
10	55	59	O	blind
11	61	65	O	study
12	67	68	O	of
13	70	72	O	101
14	74	81	O	patients
15	83	85	O	who
16	87	90	O	were
17	92	99	O	randomly
18	101	108	O	assigned
19	110	114	O	1:1:1
20	116	117	O	to
21	119	125	O	receive
22	127	136	U-UNK	everolimus
23	138	144	O	tablets
24	146	147	O	at
25	149	153	O	doses
26	155	156	O	of
27	158	160	O	0.5
28	162	163	O	mg
29	164	164	O	,
30	166	166	O	1
31	168	169	O	mg
32	170	170	O	,
33	172	173	O	or
34	175	175	O	2
35	177	178	O	mg
36	180	184	O	twice
37	186	190	O	daily
38	192	195	O	with
39	197	208	U-UNK	cyclosporine
40	210	212	O	and
41	214	223	U-UNK	prednisone
NULL

11180038.xml	DDI-MedLine.d140.s3	NO_SECTION	NO_SETID	39
Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.
1	0	4	O	Blood
2	6	13	O	sampling
3	15	17	O	for
4	19	21	O	the
5	23	38	O	pharmacokinetics
6	40	41	O	of
7	43	52	U-UNK	everolimus
8	54	56	O	and
9	58	69	U-UNK	cyclosporine
10	71	73	O	was
11	75	83	O	performed
12	85	86	O	on
13	88	90	O	day
14	92	92	O	1
15	93	93	O	,
16	95	96	O	on
17	98	102	O	weeks
18	104	104	O	1
19	105	105	O	,
20	107	107	O	2
21	108	108	O	,
22	110	110	O	3
23	111	111	O	,
24	113	115	O	and
25	117	117	O	4
26	118	118	O	,
27	120	122	O	and
28	124	125	O	on
29	127	132	O	months
30	134	134	O	2
31	135	135	O	,
32	137	137	O	3
33	138	138	O	,
34	140	140	O	6
35	141	141	O	,
36	143	143	O	9
37	144	144	O	,
38	146	148	O	and
39	150	151	O	12
NULL

11180038.xml	DDI-MedLine.d140.s4	NO_SECTION	NO_SETID	18
Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models.
1	0	9	U-UNK	Everolimus
2	11	14	O	dose
3	16	30	O	proportionality
4	32	34	O	and
5	36	44	O	stability
6	46	49	O	over
7	51	54	O	time
8	56	59	O	were
9	61	68	O	assessed
10	70	71	O	in
11	73	75	O	the
12	77	83	O	context
13	85	86	O	of
14	88	93	O	linear
15	95	104	O	regression
16	106	108	O	and
17	110	114	O	ANOVA
18	116	121	O	models
NULL

11180038.xml	DDI-MedLine.d140.s5	NO_SECTION	NO_SETID	29
Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model.
1	0	9	U-UNK	Everolimus
2	11	18	O	exposure
3	20	27	O	response
4	29	41	O	relationships
5	43	49	O	between
6	51	54	O	area
7	56	60	O	under
8	62	64	O	the
9	66	70	O	blood
10	72	84	O	concentration
11	86	89	O	time
12	91	95	O	curve
13	98	100	O	AUC
14	103	105	O	and
15	107	113	O	changes
16	115	116	O	in
17	118	126	O	platelets
18	127	127	O	,
19	129	138	O	leukocytes
20	139	139	O	,
21	141	143	O	and
22	145	150	O	lipids
23	152	155	O	were
24	157	164	O	explored
25	166	169	O	with
26	171	173	O	the
27	175	180	O	median
28	182	187	O	effect
29	189	193	O	model
NULL

11180038.xml	DDI-MedLine.d140.s6	NO_SECTION	NO_SETID	20
Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA.
1	0	8	O	Potential
2	10	20	O	differences
3	22	23	O	in
4	25	36	U-UNK	cyclosporine
5	38	43	O	dosing
6	45	47	O	and
7	49	64	O	pharmacokinetics
8	66	67	O	at
9	69	77	O	different
10	79	84	O	levels
11	86	87	O	of
12	89	98	U-UNK	everolimus
13	100	107	O	exposure
14	109	112	O	were
15	114	121	O	assessed
16	123	124	O	in
17	126	128	O	the
18	130	136	O	context
19	138	139	O	of
20	141	145	O	ANOVA
NULL

11180038.xml	DDI-MedLine.d140.s7	NO_SECTION	NO_SETID	30
RESULTS: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	18	U-UNK	Everolimus
4	20	25	O	steady
5	27	31	O	state
6	33	35	O	was
7	37	43	O	reached
8	45	46	O	on
9	48	49	O	or
10	51	56	O	before
11	58	60	O	day
12	62	62	O	7
13	63	63	O	,
14	65	68	O	with
15	70	70	O	a
16	72	77	O	median
17	79	79	O	3
18	81	84	O	fold
19	86	97	O	accumulation
20	99	100	O	of
21	102	105	O	drug
22	107	114	O	exposure
23	116	123	O	compared
24	125	128	O	with
25	130	133	O	that
26	135	139	O	after
27	141	143	O	the
28	145	149	O	first
29	151	163	O	postoperative
30	165	168	O	dose
NULL

11180038.xml	DDI-MedLine.d140.s8	NO_SECTION	NO_SETID	34
Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state.
1	0	3	O	Both
2	5	10	O	steady
3	12	16	O	state
4	18	24	O	maximum
5	26	38	O	concentration
6	40	42	O	and
7	44	46	O	AUC
8	48	51	O	were
9	53	56	O	dose
10	58	69	O	proportional
11	71	74	O	over
12	76	78	O	the
13	80	83	O	full
14	85	88	O	dose
15	90	94	O	range
16	96	99	O	when
17	101	108	O	assessed
18	110	111	O	on
19	113	115	O	day
20	117	117	O	1
21	118	118	O	,
22	120	121	O	as
23	123	126	O	well
24	128	129	O	as
25	131	133	O	for
26	135	137	O	the
27	139	142	O	full
28	144	151	O	duration
29	153	154	O	of
30	156	158	O	the
31	160	164	O	study
32	166	167	O	at
33	169	174	O	steady
34	176	180	O	state
NULL

11180038.xml	DDI-MedLine.d140.s9	NO_SECTION	NO_SETID	16
There was evidence for longitudinal stability in AUC of everolimus during the course of the study.
1	0	4	O	There
2	6	8	O	was
3	10	17	O	evidence
4	19	21	O	for
5	23	34	O	longitudinal
6	36	44	O	stability
7	46	47	O	in
8	49	51	O	AUC
9	53	54	O	of
10	56	65	U-UNK	everolimus
11	67	72	O	during
12	74	76	O	the
13	78	83	O	course
14	85	86	O	of
15	88	90	O	the
16	92	96	O	study
NULL

11180038.xml	DDI-MedLine.d140.s10	NO_SECTION	NO_SETID	15
The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%.
1	0	2	O	The
2	4	18	O	interindividual
3	20	34	O	pharmacokinetic
4	36	46	O	variability
5	48	50	O	for
6	52	54	O	AUC
7	56	58	O	was
8	60	64	O	85.4%
9	66	68	O	and
10	70	84	O	intraindividual
11	85	85	O	,
12	87	99	O	interoccasion
13	101	111	O	variability
14	113	115	O	was
15	117	121	O	40.8%
NULL

11180038.xml	DDI-MedLine.d140.s11	NO_SECTION	NO_SETID	27
Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability.
1	0	2	O	Age
2	5	9	O	range
3	10	10	O	,
4	12	13	O	17
5	15	16	O	69
6	18	22	O	years
7	24	24	O	,
8	26	31	O	weight
9	34	38	O	range
10	39	39	O	,
11	41	42	O	49
12	44	46	O	106
13	48	49	O	kg
14	51	51	O	,
15	53	55	O	and
16	57	59	O	sex
17	62	63	O	65
18	65	67	O	men
19	69	71	O	and
20	73	74	O	36
21	76	80	O	women
22	83	86	O	were
23	88	90	O	not
24	92	102	O	significant
25	104	115	O	contributors
26	117	118	O	to
27	120	130	O	variability
NULL

11180038.xml	DDI-MedLine.d140.s12	NO_SECTION	NO_SETID	21
There was an increasing incidence of transient thrombocytopenia (or =100 x 10(9)/L) with increasing everolimus AUC (P = .03).
1	0	4	O	There
2	6	8	O	was
3	10	11	O	an
4	13	22	O	increasing
5	24	32	O	incidence
6	34	35	O	of
7	37	45	O	transient
8	47	62	O	thrombocytopenia
9	65	66	O	or
10	68	71	O	=100
11	73	73	O	x
12	75	78	O	10(9
13	80	80	O	/
14	81	81	O	L
15	84	87	O	with
16	89	98	O	increasing
17	100	109	U-UNK	everolimus
18	111	113	O	AUC
19	116	116	O	P
20	118	118	O	=
21	121	122	O	03
NULL

11180038.xml	DDI-MedLine.d140.s13	NO_SECTION	NO_SETID	36
Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively).
1	0	11	U-UNK	Cyclosporine
2	13	17	O	doses
3	18	18	O	,
4	20	25	O	trough
5	27	40	O	concentrations
6	41	41	O	,
7	43	45	O	and
8	47	49	O	AUC
9	51	59	O	exhibited
10	61	67	O	similar
11	69	76	O	temporal
12	78	85	O	patterns
13	87	92	O	during
14	94	96	O	the
15	98	103	O	course
16	105	106	O	of
17	108	110	O	the
18	112	116	O	study
19	118	127	O	regardless
20	129	130	O	of
21	132	134	O	the
22	136	137	O	co
23	139	150	O	administered
24	152	161	U-UNK	everolimus
25	163	166	O	dose
26	168	172	O	level
27	175	175	O	P
28	177	177	O	=
29	180	181	O	13
30	182	182	O	,
31	185	186	O	82
32	187	187	O	,
33	189	191	O	and
34	194	195	O	76
35	196	196	O	,
36	198	209	O	respectively
NULL

11180038.xml	DDI-MedLine.d140.s14	NO_SECTION	NO_SETID	15
CONCLUSIONS: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	22	U-UNK	Everolimus
4	24	32	O	exhibited
5	34	37	O	dose
6	39	50	O	proportional
7	51	51	O	,
8	53	58	O	stable
9	60	67	O	exposure
10	69	74	O	during
11	76	78	O	the
12	80	84	O	first
13	86	89	O	post
14	91	100	O	transplant
15	102	105	O	year
NULL

11180038.xml	DDI-MedLine.d140.s15	NO_SECTION	NO_SETID	18
For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.
1	0	2	O	For
2	4	4	O	a
3	6	6	O	4
4	8	11	O	fold
5	13	17	O	range
6	19	20	O	of
7	22	31	U-UNK	everolimus
8	33	37	O	doses
9	39	43	O	there
10	45	48	O	were
11	50	51	O	no
12	53	64	O	differential
13	66	72	O	effects
14	74	75	O	on
15	77	88	U-UNK	cyclosporine
16	90	95	O	dosing
17	97	98	O	or
18	100	115	O	pharmacokinetics
NULL

11180040.xml	DDI-MedLine.d87.s0	NO_SECTION	NO_SETID	22
ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
1	0	2	B-UNK	ADL
2	4	4	I-UNK	8
3	6	9	L-UNK	2698
4	10	10	O	,
5	12	12	O	a
6	14	18	O	trans
7	20	22	O	3,4
8	24	31	O	dimethyl
9	33	33	O	4
10	36	36	O	3
11	38	50	O	hydroxyphenyl
12	53	62	O	piperidine
13	63	63	O	,
14	65	72	O	prevents
15	74	89	O	gastrointestinal
16	91	97	O	effects
17	99	100	O	of
18	102	112	O	intravenous
19	114	121	U-UNK	morphine
20	123	129	O	without
21	131	139	O	affecting
22	141	149	O	analgesia
NULL

11180040.xml	DDI-MedLine.d87.s1	NO_SECTION	NO_SETID	21
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
1	0	2	B-UNK	ADL
2	4	4	I-UNK	8
3	6	9	L-UNK	2698
4	11	12	O	is
5	14	14	O	a
6	16	20	O	novel
7	22	33	B-UNK	peripherally
8	35	44	I-UNK	restricted
9	46	51	I-UNK	opioid
10	53	62	L-UNK	antagonist
11	64	67	O	that
12	69	71	O	may
13	73	83	O	selectively
14	85	91	O	prevent
15	93	98	U-UNK	opioid
16	100	106	O	induced
17	108	123	O	gastrointestinal
18	125	131	O	effects
19	133	139	O	without
20	141	149	O	reversing
21	151	159	O	analgesia
NULL

11180040.xml	DDI-MedLine.d87.s2	NO_SECTION	NO_SETID	52
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study.
1	0	15	O	Gastrointestinal
2	17	23	O	transit
3	25	28	O	time
4	31	39	O	lactulose
5	41	48	O	hydrogen
6	50	55	O	breath
7	57	60	O	test
8	63	65	O	was
9	67	74	O	measured
10	76	77	O	in
11	79	80	O	14
12	82	91	O	volunteers
13	93	96	O	with
14	98	101	O	oral
15	103	105	O	and
16	107	117	O	intravenous
17	119	125	O	placebo
18	126	126	O	,
19	128	131	O	oral
20	133	139	O	placebo
21	141	143	O	and
22	145	155	O	intravenous
23	157	164	U-UNK	morphine
24	167	170	O	0.05
25	172	173	O	mg
26	175	175	O	x
27	177	178	O	kg
28	181	181	O	1
29	184	184	O	,
30	186	188	O	and
31	190	193	O	oral
32	195	197	B-UNK	ADL
33	199	199	I-UNK	8
34	201	204	L-UNK	2698
35	207	207	O	4
36	209	210	O	mg
37	213	215	O	and
38	217	227	O	intravenous
39	229	236	U-UNK	morphine
40	239	242	O	0.05
41	244	245	O	mg
42	247	247	O	x
43	249	250	O	kg
44	253	253	O	1
45	257	258	O	in
46	260	260	O	a
47	262	267	O	double
48	269	273	O	blind
49	274	274	O	,
50	276	280	O	cross
51	282	285	O	over
52	287	291	O	study
NULL

11180040.xml	DDI-MedLine.d87.s3	NO_SECTION	NO_SETID	13
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005);
1	0	7	U-UNK	Morphine
2	9	17	O	prolonged
3	19	34	O	gastrointestinal
4	36	42	O	transit
5	44	47	O	time
6	49	52	O	from
7	54	55	O	69
8	57	58	O	to
9	60	62	O	103
10	64	70	O	minutes
11	73	73	O	P
12	75	75	O	=
13	78	80	O	005
NULL

11180040.xml	DDI-MedLine.d87.s4	NO_SECTION	NO_SETID	23
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
1	0	7	U-UNK	Morphine
2	9	17	O	prolonged
3	19	34	O	gastrointestinal
4	36	42	O	transit
5	44	47	O	time
6	49	52	O	from
7	54	55	O	69
8	57	58	O	to
9	60	62	O	103
10	64	70	O	minutes
11	73	73	O	P
12	75	75	O	=
13	78	80	O	005
14	84	87	O	this
15	89	91	O	was
16	93	101	O	prevented
17	103	104	O	by
18	106	108	B-UNK	ADL
19	110	110	I-UNK	8
20	112	115	L-UNK	2698
21	118	118	O	P
22	120	120	O	=
23	123	125	O	004
NULL

11180040.xml	DDI-MedLine.d87.s5	NO_SECTION	NO_SETID	35
Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo.
1	0	14	O	Postoperatively
2	15	15	O	,
3	17	18	O	45
4	20	27	O	patients
5	29	32	O	were
6	34	41	O	randomly
7	43	50	O	assigned
8	52	53	O	in
9	55	55	O	a
10	57	62	O	double
11	64	68	O	blind
12	70	76	O	fashion
13	78	79	O	to
14	81	87	O	receive
15	89	91	B-UNK	ADL
16	93	93	I-UNK	8
17	95	98	L-UNK	2698
18	101	101	O	4
19	103	104	O	mg
20	107	108	O	or
21	110	116	O	placebo
22	118	120	O	and
23	122	132	O	intravenous
24	134	141	U-UNK	morphine
25	144	147	O	0.15
26	149	150	O	mg
27	151	151	O	/
28	152	153	O	kg
29	156	157	O	or
30	159	160	O	to
31	162	168	O	receive
32	170	173	O	oral
33	175	177	O	and
34	179	189	O	intravenous
35	191	197	O	placebo
NULL

11180040.xml	DDI-MedLine.d87.s6	NO_SECTION	NO_SETID	6
Analgesia and pupil constriction were measured.
1	0	8	O	Analgesia
2	10	12	O	and
3	14	18	O	pupil
4	20	31	O	constriction
5	33	36	O	were
6	38	45	O	measured
NULL

11180040.xml	DDI-MedLine.d87.s7	NO_SECTION	NO_SETID	18
Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002).
1	0	7	U-UNK	Morphine
2	9	17	O	analgesia
3	19	21	O	and
4	23	27	O	pupil
5	29	40	O	constriction
6	42	45	O	were
7	47	56	O	unaffected
8	58	59	O	by
9	61	63	B-UNK	ADL
10	65	65	I-UNK	8
11	67	70	L-UNK	2698
12	72	74	O	and
13	76	83	O	differed
14	85	88	O	from
15	90	96	O	placebo
16	99	99	O	P
17	101	101	O	<
18	104	106	O	002
NULL

11180040.xml	DDI-MedLine.d87.s8	NO_SECTION	NO_SETID	26
We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
1	0	1	O	We
2	3	10	O	conclude
3	12	15	O	that
4	17	19	B-UNK	ADL
5	21	21	I-UNK	8
6	23	26	L-UNK	2698
7	28	35	O	prevents
8	37	44	U-UNK	morphine
9	46	52	O	induced
10	54	62	O	increases
11	64	65	O	in
12	67	82	O	gastrointestinal
13	84	90	O	transit
14	92	95	O	time
15	97	98	O	by
16	100	104	O	means
17	106	107	O	of
18	109	117	O	selective
19	119	128	O	peripheral
20	130	135	O	opioid
21	137	147	O	anitagonism
22	149	155	O	without
23	157	165	O	affecting
24	167	173	O	central
25	175	180	O	opioid
26	182	190	O	analgesia
NULL

11181395.xml	DDI-MedLine.d52.s0	NO_SECTION	NO_SETID	12
Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer.
1	0	10	O	Restoration
2	12	13	O	of
3	15	24	U-UNK	vancomycin
4	26	39	O	susceptibility
5	41	42	O	in
6	44	55	O	Enterococcus
7	57	64	O	faecalis
8	66	67	O	by
9	69	82	O	antiresistance
10	84	94	O	determinant
11	96	99	O	gene
12	101	108	O	transfer
NULL

11181395.xml	DDI-MedLine.d52.s1	NO_SECTION	NO_SETID	19
We assessed the ability of gene transfer to reverse vancomycin resistance in class A (VanA) glycopeptide-resistant Enterococcus faecalis.
1	0	1	O	We
2	3	10	O	assessed
3	12	14	O	the
4	16	22	O	ability
5	24	25	O	of
6	27	30	O	gene
7	32	39	O	transfer
8	41	42	O	to
9	44	50	O	reverse
10	52	61	U-UNK	vancomycin
11	63	72	O	resistance
12	74	75	O	in
13	77	81	O	class
14	83	83	O	A
15	86	89	O	VanA
16	92	103	O	glycopeptide
17	105	113	O	resistant
18	115	126	O	Enterococcus
19	128	135	O	faecalis
NULL

11181395.xml	DDI-MedLine.d52.s2	NO_SECTION	NO_SETID	29
Recombinant shuttle vectors containing a vanH promoter-vanA antisense gene cassette fully restored vancomycin susceptibility through a combined transcriptional activator binding domain decoy and inducible vanA antisense RNA effect.
1	0	10	O	Recombinant
2	12	18	O	shuttle
3	20	26	O	vectors
4	28	37	O	containing
5	39	39	O	a
6	41	44	O	vanH
7	46	53	O	promoter
8	55	58	O	vanA
9	60	68	O	antisense
10	70	73	O	gene
11	75	82	O	cassette
12	84	88	O	fully
13	90	97	O	restored
14	99	108	U-UNK	vancomycin
15	110	123	O	susceptibility
16	125	131	O	through
17	133	133	O	a
18	135	142	O	combined
19	144	158	O	transcriptional
20	160	168	O	activator
21	170	176	O	binding
22	178	183	O	domain
23	185	189	O	decoy
24	191	193	O	and
25	195	203	O	inducible
26	205	208	O	vanA
27	210	218	O	antisense
28	220	222	O	RNA
29	224	229	O	effect
NULL

11197581.xml	DDI-MedLine.d25.s0	NO_SECTION	NO_SETID	10
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
1	0	13	O	Rhabdomyolysis
2	15	23	O	secondary
3	25	26	O	to
4	28	28	O	a
5	30	33	O	drug
6	35	45	O	interaction
7	47	53	O	between
8	55	65	U-UNK	simvastatin
9	67	69	O	and
10	71	84	U-UNK	clarithromycin
NULL

11197581.xml	DDI-MedLine.d25.s1	NO_SECTION	NO_SETID	16
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin.
1	0	8	O	OBJECTIVE
2	9	9	O	:
3	11	12	O	To
4	14	19	O	report
5	21	21	O	a
6	23	26	O	case
7	28	29	O	of
8	31	44	O	rhabdomyolysis
9	46	54	O	resulting
10	56	59	O	from
11	61	71	O	concomitant
12	73	75	O	use
13	77	78	O	of
14	80	93	U-UNK	clarithromycin
15	95	97	O	and
16	99	109	U-UNK	simvastatin
NULL

11197581.xml	DDI-MedLine.d25.s2	NO_SECTION	NO_SETID	32
CASE SUMMARY: A 64-year-old African-American man was admitted to the hospital for worsening renal failure, elevated creatine phosphokinase, diffuse muscle pain, and severe muscle weakness.
1	0	3	O	CASE
2	5	11	O	SUMMARY
3	12	12	O	:
4	14	14	O	A
5	16	17	O	64
6	19	22	O	year
7	24	26	O	old
8	28	34	O	African
9	36	43	O	American
10	45	47	O	man
11	49	51	O	was
12	53	60	O	admitted
13	62	63	O	to
14	65	67	O	the
15	69	76	O	hospital
16	78	80	O	for
17	82	90	O	worsening
18	92	96	O	renal
19	98	104	O	failure
20	105	105	O	,
21	107	114	O	elevated
22	116	123	O	creatine
23	125	137	O	phosphokinase
24	138	138	O	,
25	140	146	O	diffuse
26	148	153	O	muscle
27	155	158	O	pain
28	159	159	O	,
29	161	163	O	and
30	165	170	O	severe
31	172	177	O	muscle
32	179	186	O	weakness
NULL

11197581.xml	DDI-MedLine.d25.s3	NO_SECTION	NO_SETID	15
About three weeks prior to admission, the patient was started on clarithromycin for sinusitis.
1	0	4	O	About
2	6	10	O	three
3	12	16	O	weeks
4	18	22	O	prior
5	24	25	O	to
6	27	35	O	admission
7	36	36	O	,
8	38	40	O	the
9	42	48	O	patient
10	50	52	O	was
11	54	60	O	started
12	62	63	O	on
13	65	78	U-UNK	clarithromycin
14	80	82	O	for
15	84	92	O	sinusitis
NULL

11197581.xml	DDI-MedLine.d25.s4	NO_SECTION	NO_SETID	10
The patient had been receiving simvastatin for approximately six months.
1	0	2	O	The
2	4	10	O	patient
3	12	14	O	had
4	16	19	O	been
5	21	29	O	receiving
6	31	41	U-UNK	simvastatin
7	43	45	O	for
8	47	59	O	approximately
9	61	63	O	six
10	65	70	O	months
NULL

11197581.xml	DDI-MedLine.d25.s5	NO_SECTION	NO_SETID	13
He was treated aggressively with intravenous hydration, sodium bicarbonate, and hemodialysis.
1	0	1	O	He
2	3	5	O	was
3	7	13	O	treated
4	15	26	O	aggressively
5	28	31	O	with
6	33	43	O	intravenous
7	45	53	O	hydration
8	54	54	O	,
9	56	61	B-UNK	sodium
10	63	73	L-UNK	bicarbonate
11	74	74	O	,
12	76	78	O	and
13	80	91	O	hemodialysis
NULL

11197581.xml	DDI-MedLine.d25.s6	NO_SECTION	NO_SETID	10
A muscle biopsy revealed necrotizing myopathy secondary to a toxin.
1	0	0	O	A
2	2	7	O	muscle
3	9	14	O	biopsy
4	16	23	O	revealed
5	25	35	O	necrotizing
6	37	44	O	myopathy
7	46	54	O	secondary
8	56	57	O	to
9	59	59	O	a
10	61	65	O	toxin
NULL

11197581.xml	DDI-MedLine.d25.s7	NO_SECTION	NO_SETID	19
The patient continued to receive intermittent hemodialysis until his death from infectious complications that occurred three months after admission.
1	0	2	O	The
2	4	10	O	patient
3	12	20	O	continued
4	22	23	O	to
5	25	31	O	receive
6	33	44	O	intermittent
7	46	57	O	hemodialysis
8	59	63	O	until
9	65	67	O	his
10	69	73	O	death
11	75	78	O	from
12	80	89	O	infectious
13	91	103	O	complications
14	105	108	O	that
15	110	117	O	occurred
16	119	123	O	three
17	125	130	O	months
18	132	136	O	after
19	138	146	O	admission
NULL

11197581.xml	DDI-MedLine.d25.s8	NO_SECTION	NO_SETID	18
There were several factors that could have increased his risk for developing rhabdomyolysis, including chronic renal failure.
1	0	4	O	There
2	6	9	O	were
3	11	17	O	several
4	19	25	O	factors
5	27	30	O	that
6	32	36	O	could
7	38	41	O	have
8	43	51	O	increased
9	53	55	O	his
10	57	60	O	risk
11	62	64	O	for
12	66	75	O	developing
13	77	90	O	rhabdomyolysis
14	91	91	O	,
15	93	101	O	including
16	103	109	O	chronic
17	111	115	O	renal
18	117	123	O	failure
NULL

11197581.xml	DDI-MedLine.d25.s9	NO_SECTION	NO_SETID	17
DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
1	0	9	O	DISCUSSION
2	10	10	O	:
3	12	25	U-UNK	Clarithromycin
4	27	28	O	is
5	30	30	O	a
6	32	37	O	potent
7	39	47	O	inhibitor
8	49	50	O	of
9	52	57	O	CYP3A4
10	58	58	O	,
11	60	62	O	the
12	64	68	O	major
13	70	75	O	enzyme
14	77	87	O	responsible
15	89	91	O	for
16	93	103	U-UNK	simvastatin
17	105	114	O	metabolism
NULL

11197581.xml	DDI-MedLine.d25.s10	NO_SECTION	NO_SETID	22
The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	42	B-UNK	macrolide
6	44	54	L-UNK	antibiotics
7	56	58	O	and
8	60	64	O	other
9	66	86	B-UNK	hydroxymethylglutaryl
10	88	95	I-UNK	coenzyme
11	97	97	I-UNK	A
12	100	102	I-UNK	HMG
13	104	106	I-UNK	CoA
14	109	117	I-UNK	reductase
15	119	128	L-UNK	inhibitors
16	130	133	O	have
17	135	142	O	resulted
18	144	145	O	in
19	147	154	O	previous
20	156	162	O	reports
21	164	165	O	of
22	167	180	O	rhabdomyolysis
NULL

11197581.xml	DDI-MedLine.d25.s11	NO_SECTION	NO_SETID	37
Other factors may increase the risk of this drug interaction, including the administration of other medications that are associated with myopathy, underlying renal insufficiency, and administration of high doses of HMG-CoA reductase inhibitors.
1	0	4	O	Other
2	6	12	O	factors
3	14	16	O	may
4	18	25	O	increase
5	27	29	O	the
6	31	34	O	risk
7	36	37	O	of
8	39	42	O	this
9	44	47	O	drug
10	49	59	O	interaction
11	60	60	O	,
12	62	70	O	including
13	72	74	O	the
14	76	89	O	administration
15	91	92	O	of
16	94	98	O	other
17	100	110	O	medications
18	112	115	O	that
19	117	119	O	are
20	121	130	O	associated
21	132	135	O	with
22	137	144	O	myopathy
23	145	145	O	,
24	147	156	O	underlying
25	158	162	O	renal
26	164	176	O	insufficiency
27	177	177	O	,
28	179	181	O	and
29	183	196	O	administration
30	198	199	O	of
31	201	204	O	high
32	206	210	O	doses
33	212	213	O	of
34	215	217	B-UNK	HMG
35	219	221	I-UNK	CoA
36	223	231	I-UNK	reductase
37	233	242	L-UNK	inhibitors
NULL

11197581.xml	DDI-MedLine.d25.s12	NO_SECTION	NO_SETID	26
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	21	B-UNK	Macrolide
4	23	33	L-UNK	antibiotics
5	35	41	O	inhibit
6	43	45	O	the
7	47	56	O	metabolism
8	58	59	O	of
9	61	63	B-UNK	HMG
10	65	67	I-UNK	CoA
11	69	77	I-UNK	reductase
12	79	88	L-UNK	inhibitors
13	90	93	O	that
14	95	97	O	are
15	99	109	O	metabolized
16	111	112	O	by
17	114	119	O	CYP3A4
18	122	124	O	i.e
19	126	126	O	,
20	128	139	U-UNK	atorvastatin
21	140	140	O	,
22	142	153	U-UNK	cerivastatin
23	154	154	O	,
24	156	165	U-UNK	lovastatin
25	166	166	O	,
26	168	178	U-UNK	simvastatin
NULL

11197581.xml	DDI-MedLine.d25.s13	NO_SECTION	NO_SETID	25
This interaction may result in myopathy and rhabdomyolysis, particularly in patients with renal insufficiency or those who are concurrently taking medications associated with myopathy.
1	0	3	O	This
2	5	15	O	interaction
3	17	19	O	may
4	21	26	O	result
5	28	29	O	in
6	31	38	O	myopathy
7	40	42	O	and
8	44	57	O	rhabdomyolysis
9	58	58	O	,
10	60	71	O	particularly
11	73	74	O	in
12	76	83	O	patients
13	85	88	O	with
14	90	94	O	renal
15	96	108	O	insufficiency
16	110	111	O	or
17	113	117	O	those
18	119	121	O	who
19	123	125	O	are
20	127	138	O	concurrently
21	140	145	O	taking
22	147	157	O	medications
23	159	168	O	associated
24	170	173	O	with
25	175	182	O	myopathy
NULL

11197767.xml	DDI-MedLine.d141.s0	NO_SECTION	NO_SETID	17
Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).
1	0	7	O	Toxicity
2	9	10	O	of
3	12	18	O	cadmium
4	20	22	O	and
5	24	27	U-UNK	zinc
6	29	30	O	to
7	32	41	O	encystment
8	43	45	O	and
9	47	48	O	in
10	50	54	O	vitro
11	56	65	O	excystment
12	67	68	O	of
13	70	78	O	Parorchis
14	80	87	O	acanthus
15	90	96	O	Digenea
16	97	97	O	:
17	99	114	O	Philophthalmidae
NULL

11197767.xml	DDI-MedLine.d141.s1	NO_SECTION	NO_SETID	37
The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.
1	0	2	O	The
2	4	11	O	toxicity
3	13	14	O	of
4	16	22	O	cadmium
5	23	23	O	,
6	25	28	U-UNK	zinc
7	30	32	O	and
8	34	40	O	cadmium
9	41	41	O	/
10	42	45	O	zinc
11	47	54	O	mixtures
12	56	57	O	at
13	59	72	O	concentrations
14	74	80	O	ranging
15	82	85	O	from
16	87	90	O	1000
17	92	93	O	to
18	95	99	O	50000
19	101	106	O	microg
20	107	107	O	/
21	108	108	O	l
22	110	113	O	were
23	115	126	O	investigated
24	128	134	O	against
25	136	144	O	cercariae
26	146	148	O	and
27	150	162	O	metacercariae
28	164	165	O	of
29	167	175	O	Parorchis
30	177	184	O	acanthus
31	186	193	O	obtained
32	195	198	O	from
33	200	202	O	the
34	204	206	O	dog
35	208	212	O	whelk
36	214	220	O	Nucella
37	222	229	O	lapillus
NULL

11197767.xml	DDI-MedLine.d141.s2	NO_SECTION	NO_SETID	18
Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals;
1	0	8	O	Cercarial
2	10	19	O	encystment
3	21	22	O	at
4	24	37	O	concentrations
5	39	40	O	of
6	42	46	O	25000
7	48	53	O	microg
8	54	54	O	/
9	55	55	O	l
10	57	58	O	or
11	60	65	O	higher
12	67	69	O	was
13	71	83	O	significantly
14	85	92	O	impaired
15	94	95	O	by
16	97	99	O	all
17	101	104	O	test
18	106	111	O	metals
NULL

11197767.xml	DDI-MedLine.d141.s3	NO_SECTION	NO_SETID	9
however, at lower concentrations only zinc demonstrated toxicity.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	at
4	12	16	O	lower
5	18	31	O	concentrations
6	33	36	O	only
7	38	41	U-UNK	zinc
8	43	54	O	demonstrated
9	56	63	O	toxicity
NULL

11197767.xml	DDI-MedLine.d141.s4	NO_SECTION	NO_SETID	21
Mixtures of cadmium and zinc had a synergistic effect compared with single metal toxicity but only at 50000 microg/l.
1	0	7	O	Mixtures
2	9	10	O	of
3	12	18	O	cadmium
4	20	22	O	and
5	24	27	U-UNK	zinc
6	29	31	O	had
7	33	33	O	a
8	35	45	O	synergistic
9	47	52	O	effect
10	54	61	O	compared
11	63	66	O	with
12	68	73	O	single
13	75	79	O	metal
14	81	88	O	toxicity
15	90	92	O	but
16	94	97	O	only
17	99	100	O	at
18	102	106	O	50000
19	108	113	O	microg
20	114	114	O	/
21	115	115	O	l
NULL

11197767.xml	DDI-MedLine.d141.s5	NO_SECTION	NO_SETID	17
Excystment in vitro was only significantly affected by cercariae exposed to cadmium/zinc mixtures whilst encysting.
1	0	9	O	Excystment
2	11	12	O	in
3	14	18	O	vitro
4	20	22	O	was
5	24	27	O	only
6	29	41	O	significantly
7	43	50	O	affected
8	52	53	O	by
9	55	63	O	cercariae
10	65	71	O	exposed
11	73	74	O	to
12	76	82	O	cadmium
13	83	83	O	/
14	84	87	O	zinc
15	89	96	O	mixtures
16	98	103	O	whilst
17	105	113	O	encysting
NULL

11197767.xml	DDI-MedLine.d141.s6	NO_SECTION	NO_SETID	15
Twenty-four h exposures of fully formed cysts had no effect on excystment in vitro.
1	0	5	O	Twenty
2	7	10	O	four
3	12	12	O	h
4	14	22	O	exposures
5	24	25	O	of
6	27	31	O	fully
7	33	38	O	formed
8	40	44	O	cysts
9	46	48	O	had
10	50	51	O	no
11	53	58	O	effect
12	60	61	O	on
13	63	72	O	excystment
14	74	75	O	in
15	77	81	O	vitro
NULL

11197767.xml	DDI-MedLine.d141.s7	NO_SECTION	NO_SETID	18
Effects on in vitro excystment rates over a 2 h period demonstrated widespread effects for cercariae-exposed P.
1	0	6	O	Effects
2	8	9	O	on
3	11	12	O	in
4	14	18	O	vitro
5	20	29	O	excystment
6	31	35	O	rates
7	37	40	O	over
8	42	42	O	a
9	44	44	O	2
10	46	46	O	h
11	48	53	O	period
12	55	66	O	demonstrated
13	68	77	O	widespread
14	79	85	O	effects
15	87	89	O	for
16	91	99	O	cercariae
17	101	107	O	exposed
18	109	109	O	P
NULL

11197767.xml	DDI-MedLine.d141.s9	NO_SECTION	NO_SETID	11
No effects were evident on excystment rates of cyst-exposed parasites.
1	0	1	O	No
2	3	9	O	effects
3	11	14	O	were
4	16	22	O	evident
5	24	25	O	on
6	27	36	O	excystment
7	38	42	O	rates
8	44	45	O	of
9	47	50	O	cyst
10	52	58	O	exposed
11	60	68	O	parasites
NULL

11197768.xml	DDI-MedLine.d70.s0	NO_SECTION	NO_SETID	10
Toxicity of cadmium and zinc to miracidia of Schistosoma mansoni.
1	0	7	O	Toxicity
2	9	10	O	of
3	12	18	O	cadmium
4	20	22	O	and
5	24	27	U-UNK	zinc
6	29	30	O	to
7	32	40	O	miracidia
8	42	43	O	of
9	45	55	O	Schistosoma
10	57	63	O	mansoni
NULL

11197768.xml	DDI-MedLine.d70.s1	NO_SECTION	NO_SETID	22
The specific objectives of this study were to elucidate metal toxicity to hatching, survival and avoidance behaviour of Schistosoma mansoni miracidia.
1	0	2	O	The
2	4	11	O	specific
3	13	22	O	objectives
4	24	25	O	of
5	27	30	O	this
6	32	36	O	study
7	38	41	O	were
8	43	44	O	to
9	46	54	O	elucidate
10	56	60	O	metal
11	62	69	O	toxicity
12	71	72	O	to
13	74	81	O	hatching
14	82	82	O	,
15	84	91	O	survival
16	93	95	O	and
17	97	105	O	avoidance
18	107	115	O	behaviour
19	117	118	O	of
20	120	130	O	Schistosoma
21	132	138	O	mansoni
22	140	148	O	miracidia
NULL

11197768.xml	DDI-MedLine.d70.s2	NO_SECTION	NO_SETID	24
The toxicity of cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l was investigated.
1	0	2	O	The
2	4	11	O	toxicity
3	13	14	O	of
4	16	22	O	cadmium
5	23	23	O	,
6	25	28	U-UNK	zinc
7	29	29	O	,
8	31	33	O	and
9	35	41	O	cadmium
10	42	42	O	/
11	43	46	O	zinc
12	48	55	O	mixtures
13	57	58	O	at
14	60	73	O	concentrations
15	75	81	O	ranging
16	83	86	O	from
17	88	92	O	10000
18	94	95	O	to
19	97	98	O	10
20	100	105	O	microg
21	106	106	O	/
22	107	107	O	l
23	109	111	O	was
24	113	124	O	investigated
NULL

11197768.xml	DDI-MedLine.d70.s3	NO_SECTION	NO_SETID	12
Metal mixture toxicity investigation was undertaken with equal concentrations of the metals.
1	0	4	O	Metal
2	6	12	O	mixture
3	14	21	O	toxicity
4	23	35	O	investigation
5	37	39	O	was
6	41	50	O	undertaken
7	52	55	O	with
8	57	61	O	equal
9	63	76	O	concentrations
10	78	79	O	of
11	81	83	O	the
12	85	90	O	metals
NULL

11197768.xml	DDI-MedLine.d70.s4	NO_SECTION	NO_SETID	19
The hatching of miracidia from eggs was inhibited by concentrations of 1000-10000 microg/l of single metals.
1	0	2	O	The
2	4	11	O	hatching
3	13	14	O	of
4	16	24	O	miracidia
5	26	29	O	from
6	31	34	O	eggs
7	36	38	O	was
8	40	48	O	inhibited
9	50	51	O	by
10	53	66	O	concentrations
11	68	69	O	of
12	71	74	O	1000
13	76	80	O	10000
14	82	87	O	microg
15	88	88	O	/
16	89	89	O	l
17	91	92	O	of
18	94	99	O	single
19	101	106	O	metals
NULL

11197768.xml	DDI-MedLine.d70.s5	NO_SECTION	NO_SETID	8
Metal mixtures had no effect on egg hatching.
1	0	4	O	Metal
2	6	13	O	mixtures
3	15	17	O	had
4	19	20	O	no
5	22	27	O	effect
6	29	30	O	on
7	32	34	U-UNK	egg
8	36	43	O	hatching
NULL

11197768.xml	DDI-MedLine.d70.s6	NO_SECTION	NO_SETID	28
Survival of miracidia was reduced by increasing metal concentration except at concentrations of 10 microg/l for single metal toxicity where survival was increased above the control.
1	0	7	O	Survival
2	9	10	O	of
3	12	20	O	miracidia
4	22	24	O	was
5	26	32	O	reduced
6	34	35	O	by
7	37	46	O	increasing
8	48	52	O	metal
9	54	66	O	concentration
10	68	73	O	except
11	75	76	O	at
12	78	91	O	concentrations
13	93	94	O	of
14	96	97	O	10
15	99	104	O	microg
16	105	105	O	/
17	106	106	O	l
18	108	110	O	for
19	112	117	O	single
20	119	123	O	metal
21	125	132	O	toxicity
22	134	138	O	where
23	140	147	O	survival
24	149	151	O	was
25	153	161	O	increased
26	163	167	O	above
27	169	171	O	the
28	173	179	O	control
NULL

11197768.xml	DDI-MedLine.d70.s7	NO_SECTION	NO_SETID	12
Miracidia demonstrated a rapid avoidance behaviour when briefly exposed to heavy metals.
1	0	8	O	Miracidia
2	10	21	O	demonstrated
3	23	23	O	a
4	25	29	O	rapid
5	31	39	O	avoidance
6	41	49	O	behaviour
7	51	54	O	when
8	56	62	O	briefly
9	64	70	O	exposed
10	72	73	O	to
11	75	79	O	heavy
12	81	86	O	metals
NULL

11197768.xml	DDI-MedLine.d70.s8	NO_SECTION	NO_SETID	10
The mechanisms of metal toxicity to miracidia are briefly discussed.
1	0	2	O	The
2	4	13	O	mechanisms
3	15	16	O	of
4	18	22	O	metal
5	24	31	O	toxicity
6	33	34	O	to
7	36	44	O	miracidia
8	46	48	O	are
9	50	56	O	briefly
10	58	66	O	discussed
NULL

11198959.xml	DDI-MedLine.d35.s1	NO_SECTION	NO_SETID	10
Differences can occur in therapeutic effect and in adverse events.
1	0	10	O	Differences
2	12	14	O	can
3	16	20	O	occur
4	22	23	O	in
5	25	35	O	therapeutic
6	37	42	O	effect
7	44	46	O	and
8	48	49	O	in
9	51	57	O	adverse
10	59	64	O	events
NULL

11198959.xml	DDI-MedLine.d35.s2	NO_SECTION	NO_SETID	32
Genetic variation in metabolism may result in high concentrations of drugs and an increased risk of adverse effects in slow metabolizers, which is important when using for example antidepressants or chemotherapy.
1	0	6	O	Genetic
2	8	16	O	variation
3	18	19	O	in
4	21	30	O	metabolism
5	32	34	O	may
6	36	41	O	result
7	43	44	O	in
8	46	49	O	high
9	51	64	O	concentrations
10	66	67	O	of
11	69	73	O	drugs
12	75	77	O	and
13	79	80	O	an
14	82	90	O	increased
15	92	95	O	risk
16	97	98	O	of
17	100	106	O	adverse
18	108	114	O	effects
19	116	117	O	in
20	119	122	O	slow
21	124	135	O	metabolizers
22	136	136	O	,
23	138	142	O	which
24	144	145	O	is
25	147	155	O	important
26	157	160	O	when
27	162	166	O	using
28	168	170	O	for
29	172	178	O	example
30	180	194	U-UNK	antidepressants
31	196	197	O	or
32	199	210	O	chemotherapy
NULL

11198959.xml	DDI-MedLine.d35.s3	NO_SECTION	NO_SETID	17
Genetic variation also occurs in proteins interacting with drugs, which may change the effect of e.g.
1	0	6	O	Genetic
2	8	16	O	variation
3	18	21	O	also
4	23	28	O	occurs
5	30	31	O	in
6	33	40	O	proteins
7	42	52	O	interacting
8	54	57	O	with
9	59	63	O	drugs
10	64	64	O	,
11	66	70	O	which
12	72	74	O	may
13	76	81	O	change
14	83	85	O	the
15	87	92	O	effect
16	94	95	O	of
17	97	99	O	e.g
NULL

11198959.xml	DDI-MedLine.d35.s4	NO_SECTION	NO_SETID	4
asthma drugs and antipsychotics.
1	0	5	O	asthma
2	7	11	O	drugs
3	13	15	O	and
4	17	30	U-UNK	antipsychotics
NULL

11198959.xml	DDI-MedLine.d35.s5	NO_SECTION	NO_SETID	21
The selection of drugs and their dosages may be improved, and the number of adverse effects reduced by pharmacogenetic investigations.
1	0	2	O	The
2	4	12	O	selection
3	14	15	O	of
4	17	21	O	drugs
5	23	25	O	and
6	27	31	O	their
7	33	39	O	dosages
8	41	43	O	may
9	45	46	O	be
10	48	55	O	improved
11	56	56	O	,
12	58	60	O	and
13	62	64	O	the
14	66	71	O	number
15	73	74	O	of
16	76	82	O	adverse
17	84	90	O	effects
18	92	98	O	reduced
19	100	101	O	by
20	103	117	O	pharmacogenetic
21	119	132	O	investigations
NULL

11198959.xml	DDI-MedLine.d35.s6	NO_SECTION	NO_SETID	36
However, it may be important also in case of medical examinations for insurances and job appointments, since some patients may turn out to need expensive drugs or to be susceptible to a certain disease.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	may
5	16	17	O	be
6	19	27	O	important
7	29	32	O	also
8	34	35	O	in
9	37	40	O	case
10	42	43	O	of
11	45	51	O	medical
12	53	64	O	examinations
13	66	68	O	for
14	70	79	O	insurances
15	81	83	O	and
16	85	87	O	job
17	89	100	O	appointments
18	101	101	O	,
19	103	107	O	since
20	109	112	O	some
21	114	121	O	patients
22	123	125	O	may
23	127	130	O	turn
24	132	134	O	out
25	136	137	O	to
26	139	142	O	need
27	144	152	O	expensive
28	154	158	O	drugs
29	160	161	O	or
30	163	164	O	to
31	166	167	O	be
32	169	179	O	susceptible
33	181	182	O	to
34	184	184	O	a
35	186	192	O	certain
36	194	200	O	disease
NULL

11198959.xml	DDI-MedLine.d35.s7	NO_SECTION	NO_SETID	14
Therefore, the use of genetic data in these instances has to be regulated.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	17	O	use
5	19	20	O	of
6	22	28	O	genetic
7	30	33	O	data
8	35	36	O	in
9	38	42	O	these
10	44	52	O	instances
11	54	56	O	has
12	58	59	O	to
13	61	62	O	be
14	64	72	O	regulated
NULL

11199955.xml	DDI-MedLine.d0.s0	NO_SECTION	NO_SETID	13
The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	concomitant
5	27	35	U-UNK	phenytoin
6	37	50	O	administration
7	52	53	O	on
8	55	57	O	the
9	59	64	O	steady
10	66	70	O	state
11	72	87	O	pharmacokinetics
12	89	90	O	of
13	92	101	U-UNK	quetiapine
NULL

11199955.xml	DDI-MedLine.d0.s1	NO_SECTION	NO_SETID	24
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
1	0	9	B-UNK	Quetiapine
2	11	18	L-UNK	fumarate
3	21	21	O	'
4	22	29	O	XXXXXXXX
5	30	30	O	'
6	33	34	O	is
7	36	36	O	a
8	38	42	O	newly
9	44	53	O	introduced
10	55	62	B-UNK	atypical
11	64	76	L-UNK	antipsychotic
12	78	81	O	with
13	83	94	O	demonstrated
14	96	103	O	efficacy
15	105	106	O	in
16	108	110	O	the
17	112	120	O	treatment
18	122	123	O	of
19	125	132	O	positive
20	134	136	O	and
21	138	145	O	negative
22	147	154	O	symptoms
23	156	157	O	of
24	159	171	O	schizophrenia
NULL

11199955.xml	DDI-MedLine.d0.s2	NO_SECTION	NO_SETID	10
It is extensively metabolized, predominantly by cytochrome P450 3A4.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	extensively
4	18	28	O	metabolized
5	29	29	O	,
6	31	43	O	predominantly
7	45	46	O	by
8	48	57	O	cytochrome
9	59	62	O	P450
10	64	66	O	3A4
NULL

11199955.xml	DDI-MedLine.d0.s3	NO_SECTION	NO_SETID	16
Therefore, concurrent administration of drugs that induce or inhibit this enzyme may affect quetiapine pharmacokinetics.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	concurrent
4	22	35	O	administration
5	37	38	O	of
6	40	44	O	drugs
7	46	49	O	that
8	51	56	O	induce
9	58	59	O	or
10	61	67	O	inhibit
11	69	72	O	this
12	74	79	O	enzyme
13	81	83	O	may
14	85	90	O	affect
15	92	101	U-UNK	quetiapine
16	103	118	O	pharmacokinetics
NULL

11199955.xml	DDI-MedLine.d0.s4	NO_SECTION	NO_SETID	48
This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
1	0	3	O	This
2	5	9	O	study
3	11	22	O	demonstrated
4	24	27	O	that
5	29	31	O	the
6	33	38	O	potent
7	40	49	O	cytochrome
8	51	54	O	P450
9	56	61	O	enzyme
10	63	69	O	inducer
11	71	79	U-UNK	phenytoin
12	81	83	O	did
13	85	90	O	indeed
14	92	95	O	have
15	97	97	O	a
16	99	104	O	marked
17	106	111	O	effect
18	113	114	O	on
19	116	118	O	the
20	120	129	O	metabolism
21	131	132	O	of
22	134	143	U-UNK	quetiapine
23	144	144	O	,
24	146	154	O	resulting
25	156	157	O	in
26	159	159	O	a
27	161	161	O	5
28	163	166	O	fold
29	168	175	O	increase
30	177	178	O	in
31	180	188	O	clearance
32	190	193	O	when
33	195	206	O	administered
34	208	220	O	concomitantly
35	222	223	O	to
36	225	232	O	patients
37	234	237	O	with
38	239	241	O	DSM
39	243	244	O	IV
40	246	254	O	diagnosed
41	256	268	O	schizophrenia
42	269	269	O	,
43	271	285	O	schizoaffective
44	287	294	O	disorder
45	295	295	O	,
46	297	298	O	or
47	300	306	O	bipolar
48	308	315	O	disorder
NULL

11199955.xml	DDI-MedLine.d0.s5	NO_SECTION	NO_SETID	37
These results indicate that dosage adjustment of quetiapine may be necessary when the two drugs are given concurrently and that caution may be required when administering other drugs that inhibit or induce cytochromes, particularly P450 3A4.
1	0	4	O	These
2	6	12	O	results
3	14	21	O	indicate
4	23	26	O	that
5	28	33	O	dosage
6	35	44	O	adjustment
7	46	47	O	of
8	49	58	U-UNK	quetiapine
9	60	62	O	may
10	64	65	O	be
11	67	75	O	necessary
12	77	80	O	when
13	82	84	O	the
14	86	88	O	two
15	90	94	O	drugs
16	96	98	O	are
17	100	104	O	given
18	106	117	O	concurrently
19	119	121	O	and
20	123	126	O	that
21	128	134	O	caution
22	136	138	O	may
23	140	141	O	be
24	143	150	O	required
25	152	155	O	when
26	157	169	O	administering
27	171	175	O	other
28	177	181	O	drugs
29	183	186	O	that
30	188	194	O	inhibit
31	196	197	O	or
32	199	204	O	induce
33	206	216	O	cytochromes
34	217	217	O	,
35	219	230	O	particularly
36	232	235	O	P450
37	237	239	O	3A4
NULL

11206047.xml	DDI-MedLine.d111.s0	NO_SECTION	NO_SETID	17
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.
1	0	5	O	Effect
2	7	8	O	of
3	10	23	O	coadministered
4	25	29	O	drugs
5	31	33	O	and
6	35	41	U-UNK	ethanol
7	43	44	O	on
8	46	48	O	the
9	50	56	O	binding
10	58	59	O	of
11	61	71	O	therapeutic
12	73	77	O	drugs
13	79	80	O	to
14	82	86	O	human
15	88	92	O	serum
16	94	95	O	in
17	97	101	O	vitro
NULL

11206047.xml	DDI-MedLine.d111.s1	NO_SECTION	NO_SETID	20
The effects of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro was investigated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	28	O	coadministered
5	30	34	O	drugs
6	36	38	O	and
7	40	46	U-UNK	ethanol
8	48	49	O	on
9	51	53	O	the
10	55	61	O	binding
11	63	64	O	of
12	66	76	O	therapeutic
13	78	82	O	drugs
14	84	85	O	to
15	87	91	O	human
16	93	97	O	serum
17	99	100	O	in
18	102	106	O	vitro
19	108	110	O	was
20	112	123	O	investigated
NULL

11206047.xml	DDI-MedLine.d111.s2	NO_SECTION	NO_SETID	22
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.
1	0	12	U-UNK	Acetaminophen
2	13	13	O	,
3	15	23	U-UNK	lidocaine
4	24	24	O	,
5	26	38	U-UNK	phenobarbital
6	39	39	O	,
7	41	49	U-UNK	quinidine
8	50	50	O	,
9	52	63	U-UNK	theophylline
10	64	64	O	,
11	66	68	O	and
12	70	77	B-UNK	valproic
13	79	82	L-UNK	acid
14	84	87	O	were
15	89	93	O	added
16	95	96	O	to
17	98	103	O	pooled
18	105	109	O	human
19	111	115	O	serum
20	117	118	O	at
21	120	130	O	therapeutic
22	132	145	O	concentrations
NULL

11206047.xml	DDI-MedLine.d111.s3	NO_SECTION	NO_SETID	16
To each preparation was added one additional drug at three concentrations ranging from therapeutic to toxic.
1	0	1	O	To
2	3	6	O	each
3	8	18	O	preparation
4	20	22	O	was
5	24	28	O	added
6	30	32	O	one
7	34	43	O	additional
8	45	48	O	drug
9	50	51	O	at
10	53	57	O	three
11	59	72	O	concentrations
12	74	80	O	ranging
13	82	85	O	from
14	87	97	O	therapeutic
15	99	100	O	to
16	102	106	O	toxic
NULL

11206047.xml	DDI-MedLine.d111.s4	NO_SECTION	NO_SETID	15
The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital.
1	0	2	O	The
2	4	12	O	following
3	14	18	O	eight
4	20	25	O	target
5	27	30	O	drug
6	31	31	O	/
7	32	36	O	added
8	38	41	O	drug
9	43	54	O	combinations
10	56	59	O	were
11	61	67	O	studied
12	68	68	O	:
13	70	82	U-UNK	acetaminophen
14	83	83	O	/
15	84	96	U-UNK	phenobarbital
NULL

11206047.xml	DDI-MedLine.d111.s5	NO_SECTION	NO_SETID	30
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
1	0	12	U-UNK	acetaminophen
2	13	13	O	/
3	14	25	U-UNK	theophylline
4	26	26	O	,
5	28	36	U-UNK	lidocaine
6	37	37	O	/
7	38	46	U-UNK	quinidine
8	47	47	O	,
9	49	61	U-UNK	phenobarbital
10	62	62	O	/
11	63	75	U-UNK	acetaminophen
12	76	76	O	,
13	78	90	U-UNK	phenobarbital
14	91	91	O	/
15	92	99	B-UNK	valproic
16	101	104	L-UNK	acid
17	105	105	O	,
18	107	115	U-UNK	quinidine
19	116	116	O	/
20	117	125	U-UNK	lidocaine
21	126	126	O	,
22	128	139	U-UNK	theophylline
23	140	140	O	/
24	141	153	U-UNK	acetaminophen
25	154	154	O	,
26	156	158	O	and
27	160	167	B-UNK	valproic
28	169	172	L-UNK	acid
29	173	173	O	/
30	174	186	U-UNK	phenobarbital
NULL

11206047.xml	DDI-MedLine.d111.s6	NO_SECTION	NO_SETID	26
Each serum without the other added drug as well as the serum supplemented with the other drug at the three concentrations was dialyzed against phosphate buffer.
1	0	3	O	Each
2	5	9	O	serum
3	11	17	O	without
4	19	21	O	the
5	23	27	O	other
6	29	33	O	added
7	35	38	O	drug
8	40	41	O	as
9	43	46	O	well
10	48	49	O	as
11	51	53	O	the
12	55	59	O	serum
13	61	72	O	supplemented
14	74	77	O	with
15	79	81	O	the
16	83	87	O	other
17	89	92	O	drug
18	94	95	O	at
19	97	99	O	the
20	101	105	O	three
21	107	120	O	concentrations
22	122	124	O	was
23	126	133	O	dialyzed
24	135	141	O	against
25	143	151	O	phosphate
26	153	158	O	buffer
NULL

11206047.xml	DDI-MedLine.d111.s7	NO_SECTION	NO_SETID	26
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.
1	0	8	O	Similarly
2	10	17	O	dialyzed
3	19	22	O	were
4	24	36	U-UNK	phenobarbital
5	37	37	O	,
6	39	47	U-UNK	quinidine
7	48	48	O	,
8	50	52	O	and
9	54	65	U-UNK	theophylline
10	66	66	O	,
11	68	71	O	both
12	73	77	O	alone
13	79	80	O	at
14	82	92	O	therapeutic
15	94	107	O	concentrations
16	109	110	O	in
17	112	116	O	serum
18	118	120	O	and
19	122	125	O	with
20	127	133	U-UNK	ethanol
21	135	136	O	at
22	138	142	O	three
23	144	152	O	different
24	154	167	O	concentrations
25	169	170	O	in
26	172	176	O	serum
NULL

11206047.xml	DDI-MedLine.d111.s8	NO_SECTION	NO_SETID	10
The percentage of drug binding in each preparation was calculated.
1	0	2	O	The
2	4	13	O	percentage
3	15	16	O	of
4	18	21	O	drug
5	23	29	O	binding
6	31	32	O	in
7	34	37	O	each
8	39	49	O	preparation
9	51	53	O	was
10	55	64	O	calculated
NULL

11206047.xml	DDI-MedLine.d111.s9	NO_SECTION	NO_SETID	47
Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
1	0	12	U-UNK	Acetaminophen
2	14	23	O	diminished
3	25	27	O	the
4	29	35	O	binding
5	37	38	O	of
6	40	51	U-UNK	theophylline
7	53	54	O	to
8	56	60	O	human
9	62	66	O	serum
10	68	69	O	by
11	71	71	O	a
12	73	75	O	net
13	77	82	O	change
14	84	85	O	of
15	87	90	O	5.7%
16	93	102	O	percentage
17	104	111	O	increase
18	113	114	O	in
19	116	119	O	free
20	121	124	O	drug
21	126	133	O	fraction
22	136	138	O	FDF
23	140	140	O	,
24	142	146	O	11.0%
25	149	150	O	at
26	152	154	O	662
27	156	163	O	micromol
28	164	164	O	/
29	165	165	O	L
30	167	169	O	and
31	171	172	O	by
32	174	174	O	a
33	176	178	O	net
34	180	185	O	change
35	187	188	O	of
36	190	193	O	7.1%
37	196	205	O	percentage
38	207	214	O	increase
39	216	217	O	in
40	219	221	O	FDF
41	222	222	O	,
42	224	228	O	13.7%
43	231	232	O	at
44	234	237	O	1324
45	239	246	O	micromol
46	247	247	O	/
47	248	248	O	L
NULL

11206047.xml	DDI-MedLine.d111.s10	NO_SECTION	NO_SETID	23
Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
1	0	11	U-UNK	Theophylline
2	13	21	O	decreased
3	23	25	O	the
4	27	33	O	binding
5	35	36	O	of
6	38	50	U-UNK	acetaminophen
7	52	53	O	by
8	55	55	O	a
9	57	59	O	net
10	61	66	O	change
11	68	69	O	of
12	71	74	O	6.8%
13	77	86	O	percentage
14	88	95	O	increase
15	97	98	O	in
16	100	102	O	FDF
17	103	103	O	,
18	105	108	O	8.8%
19	111	112	O	at
20	114	118	O	277.5
21	120	127	O	micromol
22	128	128	O	/
23	129	129	O	L
NULL

11206047.xml	DDI-MedLine.d111.s11	NO_SECTION	NO_SETID	20
phenobarbital reduced it by a net change of 6.6% (percentage increase in FDF, 8.5%) at 431 micromol/L.
1	0	12	U-UNK	phenobarbital
2	14	20	O	reduced
3	22	23	O	it
4	25	26	O	by
5	28	28	O	a
6	30	32	O	net
7	34	39	O	change
8	41	42	O	of
9	44	47	O	6.6%
10	50	59	O	percentage
11	61	68	O	increase
12	70	71	O	in
13	73	75	O	FDF
14	76	76	O	,
15	78	81	O	8.5%
16	84	85	O	at
17	87	89	O	431
18	91	98	O	micromol
19	99	99	O	/
20	100	100	O	L
NULL

11206047.xml	DDI-MedLine.d111.s12	NO_SECTION	NO_SETID	23
Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
1	0	7	B-UNK	Valproic
2	9	12	L-UNK	acid
3	14	23	O	diminished
4	25	31	O	binding
5	33	34	O	of
6	36	48	U-UNK	phenobarbital
7	50	51	O	by
8	53	53	O	a
9	55	57	O	net
10	59	64	O	change
11	66	67	O	of
12	69	72	O	9.9%
13	75	84	O	percentage
14	86	93	O	increase
15	95	96	O	in
16	98	100	O	FDF
17	101	101	O	,
18	103	107	O	21.2%
19	110	111	O	at
20	113	116	O	1732
21	118	125	O	micromol
22	126	126	O	/
23	127	127	O	L
NULL

11206047.xml	DDI-MedLine.d111.s13	NO_SECTION	NO_SETID	15
No significant effects were noted with other drug combinations or with the addition of ethanol.
1	0	1	O	No
2	3	13	O	significant
3	15	21	O	effects
4	23	26	O	were
5	28	32	O	noted
6	34	37	O	with
7	39	43	O	other
8	45	48	O	drug
9	50	61	O	combinations
10	63	64	O	or
11	66	69	O	with
12	71	73	O	the
13	75	82	O	addition
14	84	85	O	of
15	87	93	U-UNK	ethanol
NULL

11206047.xml	DDI-MedLine.d111.s14	NO_SECTION	NO_SETID	27
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
1	0	10	O	Coingestion
2	12	13	O	of
3	15	27	U-UNK	acetaminophen
4	29	32	O	with
5	34	45	U-UNK	theophylline
6	46	46	O	,
7	48	60	U-UNK	phenobarbital
8	62	65	O	with
9	67	79	U-UNK	acetaminophen
10	80	80	O	,
11	82	84	O	and
12	86	93	B-UNK	valproic
13	95	98	L-UNK	acid
14	100	103	O	with
15	105	117	U-UNK	phenobarbital
16	119	120	O	at
17	122	125	O	high
18	127	128	O	to
19	130	134	O	toxic
20	136	149	O	concentrations
21	151	159	O	decreases
22	161	163	O	the
23	165	171	O	binding
24	173	174	O	of
25	176	178	O	the
26	180	185	O	target
27	187	190	O	drug
NULL

11206047.xml	DDI-MedLine.d111.s15	NO_SECTION	NO_SETID	15
The resulting increase in free drug concentration may lead to enhanced drug effect in vivo.
1	0	2	O	The
2	4	12	O	resulting
3	14	21	O	increase
4	23	24	O	in
5	26	29	O	free
6	31	34	O	drug
7	36	48	O	concentration
8	50	52	O	may
9	54	57	O	lead
10	59	60	O	to
11	62	69	O	enhanced
12	71	74	O	drug
13	76	81	O	effect
14	83	84	O	in
15	86	89	O	vivo
NULL

11206048.xml	DDI-MedLine.d60.s0	NO_SECTION	NO_SETID	5
Phenytoin intoxication induced by fluvoxamine.
1	0	8	O	Phenytoin
2	10	21	O	intoxication
3	23	29	O	induced
4	31	32	O	by
5	34	44	U-UNK	fluvoxamine
NULL

11206048.xml	DDI-MedLine.d60.s1	NO_SECTION	NO_SETID	15
A patient had phenytoin intoxication after administration of fluvoxamine, a selective serotonin reuptake inhibitor.
1	0	0	O	A
2	2	8	O	patient
3	10	12	O	had
4	14	22	O	phenytoin
5	24	35	O	intoxication
6	37	41	O	after
7	43	56	O	administration
8	58	59	O	of
9	61	71	U-UNK	fluvoxamine
10	72	72	O	,
11	74	74	O	a
12	76	84	O	selective
13	86	94	O	serotonin
14	96	103	O	reuptake
15	105	113	O	inhibitor
NULL

11206048.xml	DDI-MedLine.d60.s2	NO_SECTION	NO_SETID	31
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
1	0	2	O	The
2	4	8	O	serum
3	10	22	O	concentration
4	24	25	O	of
5	27	35	U-UNK	phenytoin
6	37	45	O	increased
7	47	58	O	dramatically
8	60	63	O	from
9	65	68	O	16.6
10	70	71	O	to
11	73	76	O	49.1
12	78	83	O	microg
13	84	84	O	/
14	85	86	O	mL
15	88	91	O	when
16	93	103	U-UNK	fluvoxamine
17	105	107	O	was
18	109	122	O	coadministered
19	123	123	O	,
20	125	132	O	although
21	134	136	O	the
22	138	142	O	daily
23	144	149	O	dosage
24	151	152	O	of
25	154	162	U-UNK	phenytoin
26	164	166	O	and
27	168	172	O	other
28	174	178	U-UNK	drugs
29	180	182	O	had
30	184	186	O	not
31	188	194	O	changed
NULL

11206048.xml	DDI-MedLine.d60.s3	NO_SECTION	NO_SETID	17
During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed.
1	0	5	O	During
2	7	15	U-UNK	phenytoin
3	17	19	O	and
4	21	31	O	fluvoxamine
5	33	41	O	treatment
6	42	42	O	,
7	44	49	O	ataxia
8	50	50	O	,
9	52	52	O	a
10	54	60	O	typical
11	62	65	O	side
12	67	72	O	effect
13	74	75	O	of
14	77	85	U-UNK	phenytoin
15	86	86	O	,
16	88	90	O	was
17	92	99	O	observed
NULL

11206048.xml	DDI-MedLine.d60.s4	NO_SECTION	NO_SETID	28
The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1).
1	0	2	O	The
2	4	12	O	genotypes
3	14	15	O	of
4	17	22	U-UNK	CYP2C9
5	24	26	O	and
6	28	31	O	2C19
7	32	32	O	,
8	34	36	O	the
9	38	44	O	enzymes
10	46	56	O	responsible
11	58	60	O	for
12	62	70	O	phenytoin
13	72	81	O	metabolism
14	82	82	O	,
15	84	87	O	were
16	89	98	O	homozygous
17	100	102	O	for
18	104	106	O	the
19	108	111	O	wild
20	113	116	O	type
21	118	124	O	alleles
22	127	134	O	CYP2C9*1
23	135	135	O	/
24	136	137	O	1
25	139	141	O	and
26	143	148	O	2C19*1
27	149	149	O	/
28	151	152	O	1
NULL

11206048.xml	DDI-MedLine.d60.s5	NO_SECTION	NO_SETID	15
The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	may
4	20	21	O	be
5	23	23	O	a
6	25	30	O	result
7	32	33	O	of
8	35	44	O	inhibition
9	46	47	O	of
10	49	52	O	both
11	54	59	U-UNK	CYP2C9
12	61	63	O	and
13	65	68	O	2C19
14	70	71	O	by
15	73	83	U-UNK	fluvoxamine
NULL

11206187.xml	DDI-MedLine.d123.s0	NO_SECTION	NO_SETID	7
Vancomycin resistance reversal in enterococci by flavonoids.
1	0	9	O	Vancomycin
2	11	20	O	resistance
3	22	29	O	reversal
4	31	32	O	in
5	34	44	O	enterococci
6	46	47	O	by
7	49	58	O	flavonoids
NULL

11206187.xml	DDI-MedLine.d123.s1	NO_SECTION	NO_SETID	16
The development of clinical vancomycin-resistant strains of enterococci (VRE) is a major cause for concern.
1	0	2	O	The
2	4	14	O	development
3	16	17	O	of
4	19	26	O	clinical
5	28	37	O	vancomycin
6	39	47	O	resistant
7	49	55	O	strains
8	57	58	O	of
9	60	70	O	enterococci
10	73	75	O	VRE
11	78	79	O	is
12	81	81	O	a
13	83	87	O	major
14	89	93	O	cause
15	95	97	O	for
16	99	105	O	concern
NULL

11206187.xml	DDI-MedLine.d123.s2	NO_SECTION	NO_SETID	33
Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.
1	0	3	O	Here
2	5	6	O	we
3	8	11	O	show
4	13	16	O	that
5	18	18	O	a
6	20	30	O	combination
7	32	33	O	of
8	35	42	U-UNK	galangin
9	44	45	O	or
10	47	49	O	3,7
11	51	66	O	dihydroxyflavone
12	68	71	O	with
13	73	82	U-UNK	vancomycin
14	84	86	O	may
15	88	89	O	be
16	91	94	O	used
17	96	97	O	to
18	99	107	O	sensitize
19	109	117	O	resistant
20	119	125	O	strains
21	127	128	O	of
22	130	141	O	Enterococcus
23	143	150	O	faecalis
24	152	154	O	and
25	156	167	O	Enterococcus
26	169	175	O	faecium
27	177	178	O	to
28	180	182	O	the
29	184	188	O	level
30	190	191	O	of
31	193	202	O	vancomycin
32	204	212	O	sensitive
33	214	220	O	strains
NULL

11206187.xml	DDI-MedLine.d123.s3	NO_SECTION	NO_SETID	17
Minimum inhibitory concentrations (MICs) and viable counts were determined in Iso-sensitest broth using a microtitre method.
1	0	6	O	Minimum
2	8	17	O	inhibitory
3	19	32	O	concentrations
4	35	38	O	MICs
5	41	43	O	and
6	45	50	O	viable
7	52	57	O	counts
8	59	62	O	were
9	64	73	O	determined
10	75	76	O	in
11	78	80	O	Iso
12	82	90	O	sensitest
13	92	96	O	broth
14	98	102	O	using
15	104	104	O	a
16	106	115	O	microtitre
17	117	122	O	method
NULL

11206187.xml	DDI-MedLine.d123.s4	NO_SECTION	NO_SETID	25
MICs of vancomycin against 67% of resistant clinical isolates and a type strain of enterococci were lowered from > 250 microg mL(-1) to 1
1	0	3	O	MICs
2	5	6	O	of
3	8	17	U-UNK	vancomycin
4	19	25	O	against
5	27	29	O	67%
6	31	32	O	of
7	34	42	O	resistant
8	44	51	O	clinical
9	53	60	O	isolates
10	62	64	O	and
11	66	66	O	a
12	68	71	O	type
13	73	78	O	strain
14	80	81	O	of
15	83	93	O	enterococci
16	95	98	O	were
17	100	106	O	lowered
18	108	111	O	from
19	113	113	O	>
20	115	117	O	250
21	119	124	O	microg
22	126	127	O	mL
23	130	130	O	1
24	133	134	O	to
25	136	136	O	1
NULL

11206187.xml	DDI-MedLine.d123.s5	NO_SECTION	NO_SETID	20
4 microg mL(-1) in the presence of galangin (12.5 microg mL(-1)) or 3,7-dihydroxyflavone (6.25 microg mL(-1)).
1	0	0	O	4
2	2	7	O	microg
3	9	10	O	mL
4	13	13	O	1
5	16	17	O	in
6	19	21	O	the
7	23	30	O	presence
8	32	33	O	of
9	35	42	U-UNK	galangin
10	45	48	O	12.5
11	50	55	O	microg
12	57	58	O	mL
13	61	61	O	1
14	65	66	O	or
15	68	70	O	3,7
16	72	87	O	dihydroxyflavone
17	90	93	O	6.25
18	95	100	O	microg
19	102	103	O	mL
20	106	106	O	1
NULL

11206187.xml	DDI-MedLine.d123.s6	NO_SECTION	NO_SETID	6
Viable counts for type culture E.
1	0	5	O	Viable
2	7	12	O	counts
3	14	16	O	for
4	18	21	O	type
5	23	29	O	culture
6	31	31	O	E
NULL

11206187.xml	DDI-MedLine.d123.s7	NO_SECTION	NO_SETID	15
faecalis ATCC 51299 showed the flavonoids alone significantly lowered numbers of colony forming units (CFUs).
1	0	7	O	faecalis
2	9	12	O	ATCC
3	14	18	O	51299
4	20	25	O	showed
5	27	29	O	the
6	31	40	O	flavonoids
7	42	46	O	alone
8	48	60	O	significantly
9	62	68	O	lowered
10	70	76	O	numbers
11	78	79	O	of
12	81	86	O	colony
13	88	94	O	forming
14	96	100	O	units
15	103	106	O	CFUs
NULL

11206187.xml	DDI-MedLine.d123.s8	NO_SECTION	NO_SETID	18
CFUs were maintained at low levels (10(3) CFU mL(-1)) for 24 h by vancomycin/flavone combinations.
1	0	3	O	CFUs
2	5	8	O	were
3	10	19	O	maintained
4	21	22	O	at
5	24	26	O	low
6	28	33	O	levels
7	36	39	O	10(3
8	42	44	O	CFU
9	46	47	O	mL
10	50	50	O	1
11	54	56	O	for
12	58	59	O	24
13	61	61	O	h
14	63	64	O	by
15	66	75	U-UNK	vancomycin
16	76	76	O	/
17	77	83	O	flavone
18	85	96	O	combinations
NULL

11206187.xml	DDI-MedLine.d123.s9	NO_SECTION	NO_SETID	26
This combinational action in reversing vancomycin resistance of enterococci highlights novel drug targets and has importance in the design of new therapeutic regimes against resistant pathogens.
1	0	3	O	This
2	5	17	O	combinational
3	19	24	O	action
4	26	27	O	in
5	29	37	O	reversing
6	39	48	O	vancomycin
7	50	59	O	resistance
8	61	62	O	of
9	64	74	O	enterococci
10	76	85	O	highlights
11	87	91	O	novel
12	93	96	O	drug
13	98	104	O	targets
14	106	108	O	and
15	110	112	O	has
16	114	123	O	importance
17	125	126	O	in
18	128	130	O	the
19	132	137	O	design
20	139	140	O	of
21	142	144	O	new
22	146	156	O	therapeutic
23	158	164	O	regimes
24	166	172	O	against
25	174	182	O	resistant
26	184	192	O	pathogens
NULL

11206417.xml	DDI-MedLine.d137.s0	NO_SECTION	NO_SETID	13
Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
1	0	6	U-UNK	Glucose
2	8	10	O	and
3	12	18	U-UNK	insulin
4	20	24	O	exert
5	26	33	O	additive
6	35	40	O	ocular
7	42	44	O	and
8	46	50	O	renal
9	52	62	O	vasodilator
10	64	70	O	effects
11	72	73	O	on
12	75	81	O	healthy
13	83	88	O	humans
NULL

11206417.xml	DDI-MedLine.d137.s1	NO_SECTION	NO_SETID	16
AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.
1	0	3	O	AIMS
2	4	4	O	/
3	5	14	O	HYPOTHESIS
4	15	15	O	:
5	17	21	O	There
6	23	24	O	is
7	26	33	O	evidence
8	35	38	O	that
9	40	46	U-UNK	insulin
10	48	50	O	and
11	52	58	U-UNK	glucose
12	60	64	O	cause
13	66	70	O	renal
14	72	74	O	and
15	76	81	O	ocular
16	83	94	O	vasodilation
NULL

11206417.xml	DDI-MedLine.d137.s2	NO_SECTION	NO_SETID	30
There is, however, currently no data on the effect of combined hyperglycaemia and hyperinsulinaemia on the renal and ocular blood flow seen in diabetic patients on insulin therapy.
1	0	4	O	There
2	6	7	O	is
3	8	8	O	,
4	10	16	O	however
5	17	17	O	,
6	19	27	O	currently
7	29	30	O	no
8	32	35	O	data
9	37	38	O	on
10	40	42	O	the
11	44	49	O	effect
12	51	52	O	of
13	54	61	O	combined
14	63	76	O	hyperglycaemia
15	78	80	O	and
16	82	98	O	hyperinsulinaemia
17	100	101	O	on
18	103	105	O	the
19	107	111	O	renal
20	113	115	O	and
21	117	122	O	ocular
22	124	128	O	blood
23	130	133	O	flow
24	135	138	O	seen
25	140	141	O	in
26	143	150	O	diabetic
27	152	159	O	patients
28	161	162	O	on
29	164	170	O	insulin
30	172	178	O	therapy
NULL

11206417.xml	DDI-MedLine.d137.s3	NO_SECTION	NO_SETID	19
METHODS: We carried out two different 3-way crossover studies in healthy subjects (each, n = 9).
1	0	6	O	METHODS
2	7	7	O	:
3	9	10	O	We
4	12	18	O	carried
5	20	22	O	out
6	24	26	O	two
7	28	36	O	different
8	38	38	O	3
9	40	42	O	way
10	44	52	O	crossover
11	54	60	O	studies
12	62	63	O	in
13	65	71	O	healthy
14	73	80	O	subjects
15	83	86	O	each
16	87	87	O	,
17	89	89	O	n
18	91	91	O	=
19	93	93	O	9
NULL

11206417.xml	DDI-MedLine.d137.s4	NO_SECTION	NO_SETID	46
In study one, hyperglycaemic clamps (5.6 mmol/l, 11.1 mmol/ 1, 16.7 mmol/l) were carried out during placebo or insulin (dose 1: 1 mU/kg/min; dose 2: 2 mU/kg/min) infusion.
1	0	1	O	In
2	3	7	O	study
3	9	11	O	one
4	12	12	O	,
5	14	27	O	hyperglycaemic
6	29	34	O	clamps
7	37	39	O	5.6
8	41	44	O	mmol
9	45	45	O	/
10	46	46	O	l
11	47	47	O	,
12	49	52	O	11.1
13	54	57	O	mmol
14	58	58	O	/
15	60	60	O	1
16	61	61	O	,
17	63	66	O	16.7
18	68	71	O	mmol
19	72	72	O	/
20	73	73	O	l
21	76	79	O	were
22	81	87	O	carried
23	89	91	O	out
24	93	98	O	during
25	100	106	O	placebo
26	108	109	O	or
27	111	117	U-UNK	insulin
28	120	123	O	dose
29	125	125	O	1
30	126	126	O	:
31	128	128	O	1
32	130	131	O	mU
33	132	132	O	/
34	133	134	O	kg
35	135	135	O	/
36	136	138	O	min
37	141	144	O	dose
38	146	146	O	2
39	147	147	O	:
40	149	149	O	2
41	151	152	O	mU
42	153	153	O	/
43	154	155	O	kg
44	156	156	O	/
45	157	159	O	min
46	162	169	O	infusion
NULL

11206417.xml	DDI-MedLine.d137.s5	NO_SECTION	NO_SETID	13
The second study was identical but endogenous insulin secretion was blocked with somatostatin.
1	0	2	O	The
2	4	9	O	second
3	11	15	O	study
4	17	19	O	was
5	21	29	O	identical
6	31	33	O	but
7	35	44	O	endogenous
8	46	52	O	insulin
9	54	62	O	secretion
10	64	66	O	was
11	68	74	O	blocked
12	76	79	O	with
13	81	92	U-UNK	somatostatin
NULL

11206417.xml	DDI-MedLine.d137.s6	NO_SECTION	NO_SETID	34
The renal plasma flow, glomerular filtration rate and pulsatile choroidal blood flow were measured using the paraaminohippurate method, the inulin method and a laser interferometric measurement of fundus pulsation amplitude, respectively.
1	0	2	O	The
2	4	8	O	renal
3	10	15	O	plasma
4	17	20	O	flow
5	21	21	O	,
6	23	32	O	glomerular
7	34	43	O	filtration
8	45	48	O	rate
9	50	52	O	and
10	54	62	O	pulsatile
11	64	72	O	choroidal
12	74	78	O	blood
13	80	83	O	flow
14	85	88	O	were
15	90	97	O	measured
16	99	103	O	using
17	105	107	O	the
18	109	126	O	paraaminohippurate
19	128	133	O	method
20	134	134	O	,
21	136	138	O	the
22	140	145	O	inulin
23	147	152	O	method
24	154	156	O	and
25	158	158	O	a
26	160	164	O	laser
27	166	180	O	interferometric
28	182	192	O	measurement
29	194	195	O	of
30	197	202	O	fundus
31	204	212	O	pulsation
32	214	222	O	amplitude
33	223	223	O	,
34	225	236	O	respectively
NULL

11206417.xml	DDI-MedLine.d137.s7	NO_SECTION	NO_SETID	17
RESULTS: Insulin increased renal plasma flow and fundus pulsation amplitude but not the glomerular filtration rate.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	15	U-UNK	Insulin
4	17	25	O	increased
5	27	31	O	renal
6	33	38	O	plasma
7	40	43	O	flow
8	45	47	O	and
9	49	54	O	fundus
10	56	64	O	pulsation
11	66	74	O	amplitude
12	76	78	O	but
13	80	82	O	not
14	84	86	O	the
15	88	97	O	glomerular
16	99	108	O	filtration
17	110	113	O	rate
NULL

11206417.xml	DDI-MedLine.d137.s8	NO_SECTION	NO_SETID	9
Hyperglycaemia increased all the renal and ocular parameters studied.
1	0	13	O	Hyperglycaemia
2	15	23	O	increased
3	25	27	O	all
4	29	31	O	the
5	33	37	O	renal
6	39	41	O	and
7	43	48	O	ocular
8	50	59	O	parameters
9	61	67	O	studied
NULL

11206417.xml	DDI-MedLine.d137.s9	NO_SECTION	NO_SETID	18
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
1	0	11	O	Haemodynamic
2	13	19	O	effects
3	21	22	O	of
4	24	30	U-UNK	glucose
5	32	34	O	and
6	36	42	U-UNK	insulin
7	44	47	O	were
8	49	56	O	additive
9	58	61	O	when
10	63	74	U-UNK	somatostatin
11	76	78	O	was
12	80	81	O	co
13	83	94	O	administered
14	96	98	O	but
15	100	102	O	not
16	104	108	O	under
17	110	114	O	basal
18	116	125	O	conditions
NULL

11206417.xml	DDI-MedLine.d137.s10	NO_SECTION	NO_SETID	17
CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation.
1	0	10	O	CONCLUSIONS
2	11	11	O	/
3	12	25	O	INTERPRETATION
4	26	26	O	:
5	28	34	U-UNK	Glucose
6	36	38	O	and
7	40	46	U-UNK	insulin
8	48	50	O	can
9	52	56	O	exert
10	58	65	O	additive
11	67	77	O	vasodilator
12	79	88	O	properties
13	90	91	O	on
14	93	97	O	renal
15	99	101	O	and
16	103	108	O	ocular
17	110	120	O	circulation
NULL

11206417.xml	DDI-MedLine.d137.s11	NO_SECTION	NO_SETID	28
To find out whether this observation is related to the increased regional perfusion in diabetes longitudinal studies on patients with Type I (insulin-dependent) diabetes mellitus are needed.
1	0	1	O	To
2	3	6	O	find
3	8	10	O	out
4	12	18	O	whether
5	20	23	O	this
6	25	35	O	observation
7	37	38	O	is
8	40	46	O	related
9	48	49	O	to
10	51	53	O	the
11	55	63	O	increased
12	65	72	O	regional
13	74	82	O	perfusion
14	84	85	O	in
15	87	94	O	diabetes
16	96	107	O	longitudinal
17	109	115	O	studies
18	117	118	O	on
19	120	127	O	patients
20	129	132	O	with
21	134	137	O	Type
22	139	139	O	I
23	142	148	O	insulin
24	150	158	O	dependent
25	161	168	O	diabetes
26	170	177	O	mellitus
27	179	181	O	are
28	183	188	O	needed
NULL

11210403.xml	DDI-MedLine.d124.s0	NO_SECTION	NO_SETID	12
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
1	0	3	O	Lack
2	5	6	O	of
3	8	18	O	interaction
4	20	26	O	between
5	28	39	U-UNK	levofloxacin
6	41	43	O	and
7	45	53	U-UNK	oxycodone
8	54	54	O	:
9	56	71	O	pharmacokinetics
10	73	75	O	and
11	77	80	O	drug
12	82	92	O	disposition
NULL

11210403.xml	DDI-MedLine.d124.s1	NO_SECTION	NO_SETID	25
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
1	0	7	O	Previous
2	9	15	O	studies
3	17	20	O	have
4	22	33	O	demonstrated
5	35	35	O	a
6	37	47	O	significant
7	49	57	O	reduction
8	59	60	O	in
9	62	64	O	the
10	66	69	O	oral
11	71	85	O	bioavailability
12	87	88	O	of
13	90	102	U-UNK	trovafloxacin
14	104	106	O	and
15	108	120	U-UNK	ciprofloxacin
16	122	125	O	when
17	127	138	O	administered
18	140	152	O	concomitantly
19	154	157	O	with
20	159	160	O	an
21	162	172	O	intravenous
22	174	179	U-UNK	opiate
23	181	184	O	such
24	186	187	O	as
25	189	196	U-UNK	morphine
NULL

11210403.xml	DDI-MedLine.d124.s2	NO_SECTION	NO_SETID	24
This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures.
1	0	3	O	This
2	5	12	O	decrease
3	14	15	O	in
4	17	26	O	absorption
5	28	34	O	results
6	36	37	O	in
7	39	39	O	a
8	41	43	O	36%
9	45	47	O	and
10	49	51	O	50%
11	53	57	O	lower
12	59	61	O	AUC
13	63	65	O	for
14	67	79	U-UNK	trovafloxacin
15	81	83	O	and
16	85	97	U-UNK	ciprofloxacin
17	98	98	O	,
18	100	111	O	respectively
19	112	112	O	,
20	114	118	O	which
21	120	124	O	could
22	126	130	O	cause
23	132	139	O	clinical
24	141	148	O	failures
NULL

11210403.xml	DDI-MedLine.d124.s3	NO_SECTION	NO_SETID	13
The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin.
1	0	2	O	The
2	4	10	O	authors
3	12	23	O	investigated
4	25	27	O	the
5	29	39	O	possibility
6	41	42	O	of
7	44	44	O	a
8	46	52	O	similar
9	54	64	O	interaction
10	66	72	O	between
11	74	82	U-UNK	oxycodone
12	84	86	O	and
13	88	99	U-UNK	levofloxacin
NULL

11210403.xml	DDI-MedLine.d124.s4	NO_SECTION	NO_SETID	21
Eight healthy volunteers were randomized in an open-label, two-way crossover study to receive oxycodone, 5 mg p.o.
1	0	4	O	Eight
2	6	12	O	healthy
3	14	23	O	volunteers
4	25	28	O	were
5	30	39	O	randomized
6	41	42	O	in
7	44	45	O	an
8	47	50	O	open
9	52	56	O	label
10	57	57	O	,
11	59	61	O	two
12	63	65	O	way
13	67	75	O	crossover
14	77	81	O	study
15	83	84	O	to
16	86	92	O	receive
17	94	102	U-UNK	oxycodone
18	103	103	O	,
19	105	105	O	5
20	107	108	O	mg
21	110	112	O	p.o
NULL

11210403.xml	DDI-MedLine.d124.s5	NO_SECTION	NO_SETID	8
Q4H, and levofloxacin, 500 mg p.o.
1	0	2	O	Q4H
2	3	3	O	,
3	5	7	O	and
4	9	20	U-UNK	levofloxacin
5	21	21	O	,
6	23	25	O	500
7	27	28	O	mg
8	30	32	O	p.o
NULL

11210403.xml	DDI-MedLine.d124.s6	NO_SECTION	NO_SETID	11
1 hour after starting the oxycodone or levofloxacin 500 mg p.o.
1	0	0	O	1
2	2	5	O	hour
3	7	11	O	after
4	13	20	O	starting
5	22	24	O	the
6	26	34	U-UNK	oxycodone
7	36	37	O	or
8	39	50	U-UNK	levofloxacin
9	52	54	O	500
10	56	57	O	mg
11	59	61	O	p.o
NULL

11210403.xml	DDI-MedLine.d124.s8	NO_SECTION	NO_SETID	38
Blood samples were drawn at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours for Cmax, tmax, and AUC determinations.
1	0	4	O	Blood
2	6	12	O	samples
3	14	17	O	were
4	19	23	O	drawn
5	25	26	O	at
6	28	28	O	0
7	29	29	O	,
8	31	33	O	0.5
9	34	34	O	,
10	36	36	O	1
11	37	37	O	,
12	39	41	O	1.5
13	42	42	O	,
14	44	44	O	2
15	45	45	O	,
16	47	47	O	3
17	48	48	O	,
18	50	50	O	4
19	51	51	O	,
20	53	53	O	6
21	54	54	O	,
22	56	56	O	8
23	57	57	O	,
24	59	60	O	12
25	61	61	O	,
26	63	64	O	18
27	65	65	O	,
28	67	69	O	and
29	71	72	O	24
30	74	78	O	hours
31	80	82	O	for
32	84	87	O	Cmax
33	88	88	O	,
34	90	93	O	tmax
35	94	94	O	,
36	96	98	O	and
37	100	102	O	AUC
38	104	117	O	determinations
NULL

11210403.xml	DDI-MedLine.d124.s9	NO_SECTION	NO_SETID	50
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.
1	0	4	O	There
2	6	8	O	was
3	10	12	O	not
4	14	14	O	a
5	16	26	O	significant
6	28	37	O	difference
7	40	40	O	p
8	42	42	O	>
9	44	47	O	0.05
10	50	51	O	in
11	53	55	O	AUC
12	58	62	O	48.59
13	64	64	O	+
14	65	65	O	/
15	68	71	O	8.52
16	73	74	O	vs
17	77	80	O	49.9
18	82	82	O	+
19	83	83	O	/
20	86	89	O	9.93
21	91	91	O	,
22	93	96	O	Cmax
23	99	102	O	7.73
24	104	104	O	+
25	105	105	O	/
26	108	110	O	2.6
27	112	113	O	vs
28	116	118	O	6.6
29	120	120	O	+
30	121	121	O	/
31	124	126	O	2.0
32	128	128	O	,
33	130	132	O	and
34	134	137	O	tmax
35	140	142	O	1.1
36	144	144	O	+
37	145	145	O	/
38	148	150	O	0.6
39	152	153	O	vs
40	156	158	O	1.6
41	160	160	O	+
42	161	161	O	/
43	164	166	O	1.1
44	169	171	O	for
45	173	184	U-UNK	levofloxacin
46	186	191	O	versus
47	193	204	U-UNK	levofloxacin
48	205	205	O	/
49	206	214	U-UNK	oxycodone
50	216	223	O	regimens
NULL

11210403.xml	DDI-MedLine.d124.s10	NO_SECTION	NO_SETID	23
It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
1	0	1	O	It
2	3	5	O	was
3	7	15	O	concluded
4	17	20	O	that
5	22	25	O	oral
6	27	35	U-UNK	oxycodone
7	37	39	O	and
8	41	52	U-UNK	levofloxacin
9	54	56	O	can
10	58	59	O	be
11	61	72	O	administered
12	74	86	O	concomitantly
13	88	94	O	without
14	96	96	O	a
15	98	108	O	significant
16	110	117	O	decrease
17	119	120	O	in
18	122	124	O	AUC
19	125	125	O	,
20	127	130	O	Cmax
21	131	131	O	,
22	133	134	O	or
23	136	139	O	tmax
NULL

11210404.xml	DDI-MedLine.d105.s0	NO_SECTION	NO_SETID	17
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
1	0	3	O	Lack
2	5	6	O	of
3	8	9	O	an
4	11	16	O	effect
5	18	19	O	of
6	21	32	U-UNK	azithromycin
7	34	35	O	on
8	37	39	O	the
9	41	51	O	disposition
10	53	54	O	of
11	56	65	U-UNK	zidovudine
12	67	69	O	and
13	71	84	U-UNK	dideoxyinosine
14	86	87	O	in
15	89	91	O	HIV
16	93	100	O	infected
17	102	109	O	patients
NULL

11210404.xml	DDI-MedLine.d105.s1	NO_SECTION	NO_SETID	20
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine.
1	0	2	O	Two
2	4	10	O	studies
3	12	15	O	were
4	17	25	O	conducted
5	27	28	O	in
6	30	32	O	HIV
7	34	41	O	infected
8	43	50	O	subjects
9	52	53	O	to
10	55	60	O	assess
11	62	64	O	the
12	66	74	O	potential
13	76	78	O	for
14	80	91	U-UNK	azithromycin
15	93	94	O	to
16	96	103	O	interact
17	105	108	O	with
18	110	119	U-UNK	zidovudine
19	121	123	O	and
20	125	138	U-UNK	dideoxyinosine
NULL

11210404.xml	DDI-MedLine.d105.s2	NO_SECTION	NO_SETID	5
Both studies used 12 subjects.
1	0	3	O	Both
2	5	11	O	studies
3	13	16	O	used
4	18	19	O	12
5	21	28	O	subjects
NULL

11210404.xml	DDI-MedLine.d105.s3	NO_SECTION	NO_SETID	45
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.
1	0	2	O	The
2	4	13	U-UNK	zidovudine
3	15	19	O	study
4	21	25	O	dosed
5	27	34	O	subjects
6	36	39	O	with
7	41	44	O	1200
8	46	47	O	mg
9	48	48	O	/
10	49	51	O	day
11	53	54	O	of
12	56	67	U-UNK	azithromycin
13	70	70	O	n
14	72	72	O	=
15	74	74	O	7
16	78	82	O	later
17	84	90	O	changed
18	92	93	O	to
19	95	97	O	600
20	99	100	O	mg
21	101	101	O	/
22	102	104	O	day
23	107	107	O	n
24	109	109	O	=
25	111	111	O	5
26	115	117	O	for
27	119	122	O	Days
28	124	124	O	8
29	126	127	O	to
30	129	130	O	21
31	132	133	O	of
32	135	135	O	a
33	137	138	O	21
34	140	142	O	day
35	144	149	O	course
36	151	152	O	of
37	154	156	O	100
38	158	159	O	mg
39	160	160	O	,
40	162	165	O	five
41	167	171	O	times
42	172	172	O	/
43	173	175	O	day
44	177	178	O	of
45	180	189	U-UNK	zidovudine
NULL

11210404.xml	DDI-MedLine.d105.s4	NO_SECTION	NO_SETID	30
Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21.
1	0	7	O	Subjects
2	9	15	O	treated
3	17	20	O	with
4	22	24	O	200
5	26	27	O	mg
6	29	30	O	of
7	32	45	U-UNK	dideoxyinosine
8	47	51	O	twice
9	53	57	O	daily
10	59	61	O	for
11	63	64	O	21
12	66	69	O	days
13	71	78	O	received
14	80	83	O	1200
15	85	86	O	mg
16	88	89	O	of
17	91	102	U-UNK	azithromycin
18	104	105	O	or
19	107	108	O	an
20	110	119	O	equivalent
21	121	126	O	amount
22	128	129	O	of
23	131	137	O	placebo
24	138	138	O	/
25	139	141	O	day
26	143	145	O	for
27	147	150	O	Days
28	152	152	O	8
29	154	155	O	to
30	157	158	O	21
NULL

11210404.xml	DDI-MedLine.d105.s5	NO_SECTION	NO_SETID	25
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine.
1	0	13	U-UNK	Antiretroviral
2	15	20	O	plasma
3	22	24	O	and
4	26	30	O	urine
5	32	39	O	sampling
6	41	44	O	were
7	46	54	O	conducted
8	56	57	O	on
9	59	62	O	Days
10	64	64	O	1
11	65	65	O	,
12	67	67	O	7
13	68	68	O	,
14	70	72	O	and
15	74	75	O	21
16	77	79	O	for
17	81	90	U-UNK	zidovudine
18	92	94	O	and
19	96	97	O	on
20	99	102	O	Days
21	104	104	O	7
22	106	108	O	and
23	110	111	O	21
24	113	115	O	for
25	117	130	U-UNK	dideoxyinosine
NULL

11210404.xml	DDI-MedLine.d105.s6	NO_SECTION	NO_SETID	11
Peripheral mononuclear cells were also collected for quantitation of phosphorylated zidovudine.
1	0	9	O	Peripheral
2	11	21	O	mononuclear
3	23	27	O	cells
4	29	32	O	were
5	34	37	O	also
6	39	47	O	collected
7	49	51	O	for
8	53	64	O	quantitation
9	66	67	O	of
10	69	82	O	phosphorylated
11	84	93	U-UNK	zidovudine
NULL

11210404.xml	DDI-MedLine.d105.s7	NO_SECTION	NO_SETID	32
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
1	0	11	U-UNK	Azithromycin
2	13	15	O	had
3	17	18	O	no
4	20	30	O	significant
5	32	37	O	impact
6	39	40	O	on
7	42	44	O	the
8	46	49	O	Cmax
9	51	53	O	and
10	55	57	O	AUC
11	59	60	O	of
12	62	71	U-UNK	zidovudine
13	72	72	O	,
14	74	81	O	although
15	83	84	O	it
16	86	98	O	significantly
17	100	108	O	decreased
18	110	112	O	the
19	114	123	U-UNK	zidovudine
20	125	128	O	tmax
21	130	131	O	by
22	133	135	O	44%
23	137	139	O	and
24	141	149	O	increased
25	151	153	O	the
26	155	167	O	intracellular
27	169	176	O	exposure
28	178	179	O	to
29	181	194	O	phosphorylated
30	196	205	U-UNK	zidovudine
31	207	208	O	by
32	210	213	O	110%
NULL

11210404.xml	DDI-MedLine.d105.s8	NO_SECTION	NO_SETID	8
Azithromycin had no significant effect on dideoxyinosine pharmacokinetics.
1	0	11	U-UNK	Azithromycin
2	13	15	O	had
3	17	18	O	no
4	20	30	O	significant
5	32	37	O	effect
6	39	40	O	on
7	42	55	U-UNK	dideoxyinosine
8	57	72	O	pharmacokinetics
NULL

11210404.xml	DDI-MedLine.d105.s9	NO_SECTION	NO_SETID	22
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	19	O	results
5	21	22	O	of
6	24	28	O	these
7	30	36	O	studies
8	37	37	O	,
9	39	40	O	it
10	42	43	O	is
11	45	53	O	concluded
12	55	58	O	that
13	60	71	U-UNK	azithromycin
14	73	75	O	may
15	77	78	O	be
16	80	85	O	safely
17	87	100	O	coadministered
18	102	105	O	with
19	107	110	O	both
20	112	121	U-UNK	zidovudine
21	123	125	O	and
22	127	140	U-UNK	dideoxyinosine
NULL

11210678.xml	DDI-MedLine.d67.s0	NO_SECTION	NO_SETID	17
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
1	0	5	O	Effect
2	7	8	O	of
3	10	17	U-UNK	diazepam
4	19	21	O	and
5	23	31	U-UNK	midazolam
6	33	34	O	on
7	36	38	O	the
8	40	54	O	antinociceptive
9	56	61	O	effect
10	63	64	O	of
11	66	73	U-UNK	morphine
12	74	74	O	,
13	76	84	U-UNK	metamizol
14	86	88	O	and
15	90	101	U-UNK	indomethacin
16	103	104	O	in
17	106	109	O	mice
NULL

11210678.xml	DDI-MedLine.d67.s1	NO_SECTION	NO_SETID	41
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
1	0	2	O	The
2	4	12	O	influence
3	14	15	O	of
4	17	25	U-UNK	midazolam
5	27	29	O	and
6	31	38	U-UNK	diazepam
7	40	41	O	on
8	43	57	O	antinociceptive
9	59	64	O	effect
10	66	67	O	of
11	69	76	U-UNK	morphine
12	79	80	O	10
13	82	83	O	mg
14	84	84	O	/
15	85	86	O	kg
16	88	88	O	,
17	90	98	U-UNK	metamizol
18	101	103	O	500
19	105	106	O	mg
20	107	107	O	/
21	108	109	O	kg
22	112	114	O	and
23	116	127	U-UNK	indomethacin
24	130	131	O	10
25	133	134	O	mg
26	135	135	O	/
27	136	137	O	kg
28	140	142	O	was
29	144	155	O	investigated
30	157	158	O	in
31	160	160	O	a
32	162	166	O	mouse
33	168	172	O	model
34	174	178	O	using
35	180	182	O	the
36	184	187	O	tail
37	189	193	O	flick
38	195	197	O	and
39	199	201	O	hot
40	203	207	O	plate
41	209	213	O	tests
NULL

11210678.xml	DDI-MedLine.d67.s2	NO_SECTION	NO_SETID	5
All drugs were injected intraperitoneally.
1	0	2	O	All
2	4	8	O	drugs
3	10	13	O	were
4	15	22	O	injected
5	24	40	O	intraperitoneally
NULL

11210678.xml	DDI-MedLine.d67.s3	NO_SECTION	NO_SETID	12
Benzodiazepines were administered to mice 30 min before applying the analgesic drugs.
1	0	14	U-UNK	Benzodiazepines
2	16	19	O	were
3	21	32	O	administered
4	34	35	O	to
5	37	40	O	mice
6	42	43	O	30
7	45	47	O	min
8	49	54	O	before
9	56	63	O	applying
10	65	67	O	the
11	69	77	B-UNK	analgesic
12	79	83	L-UNK	drugs
NULL

11210678.xml	DDI-MedLine.d67.s4	NO_SECTION	NO_SETID	11
Measurement of nociception was performed within 2 h after benzodiazepine administration.
1	0	10	O	Measurement
2	12	13	O	of
3	15	25	O	nociception
4	27	29	O	was
5	31	39	O	performed
6	41	46	O	within
7	48	48	O	2
8	50	50	O	h
9	52	56	O	after
10	58	71	U-UNK	benzodiazepine
11	73	86	O	administration
NULL

11210678.xml	DDI-MedLine.d67.s5	NO_SECTION	NO_SETID	25
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
1	0	7	U-UNK	Diazepam
2	9	10	O	at
3	12	16	O	doses
4	18	19	O	of
5	21	24	O	0.25
6	26	27	O	mg
7	28	28	O	/
8	29	30	O	kg
9	32	34	O	and
10	36	38	O	2.5
11	40	41	O	mg
12	42	42	O	/
13	43	44	O	kg
14	46	53	O	injected
15	55	58	O	with
16	60	67	U-UNK	morphine
17	69	71	O	was
18	73	77	O	found
19	79	80	O	to
20	82	89	O	decrease
21	91	93	O	the
22	95	109	O	antinociceptive
23	111	116	O	effect
24	118	119	O	of
25	121	128	U-UNK	morphine
NULL

11210678.xml	DDI-MedLine.d67.s6	NO_SECTION	NO_SETID	17
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
1	0	8	O	Similarly
2	9	9	O	,
3	11	18	U-UNK	diazepam
4	20	28	O	decreased
5	30	32	O	the
6	34	48	O	antinociceptive
7	50	55	O	effect
8	57	58	O	of
9	60	68	U-UNK	metamizol
10	71	74	O	only
11	76	77	O	in
12	79	81	O	the
13	83	86	O	tail
14	88	92	O	flick
15	94	97	O	test
16	100	102	O	and
17	104	115	U-UNK	indomethacin
NULL

11210678.xml	DDI-MedLine.d67.s7	NO_SECTION	NO_SETID	30
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
1	0	8	U-UNK	Midazolam
2	10	13	O	used
3	15	16	O	at
4	18	22	O	doses
5	24	25	O	of
6	27	30	O	1.25
7	32	33	O	mg
8	34	34	O	/
9	35	36	O	kg
10	38	40	O	and
11	42	44	O	2.5
12	46	47	O	mg
13	48	48	O	/
14	49	50	O	kg
15	52	60	O	decreased
16	62	64	O	the
17	66	80	O	antinociceptive
18	82	87	O	effect
19	89	90	O	of
20	92	99	U-UNK	morphine
21	100	100	O	,
22	102	110	U-UNK	metamizol
23	113	116	O	only
24	118	119	O	in
25	121	123	O	the
26	125	128	O	tail
27	130	134	O	flick
28	136	139	O	test
29	142	144	O	and
30	146	157	U-UNK	indomethacin
NULL

11211460.xml	DDI-MedLine.d64.s0	NO_SECTION	NO_SETID	9
Pharmacological treatment of depression: the role of paroxetine.
1	0	14	O	Pharmacological
2	16	24	O	treatment
3	26	27	O	of
4	29	38	O	depression
5	39	39	O	:
6	41	43	O	the
7	45	48	O	role
8	50	51	O	of
9	53	62	U-UNK	paroxetine
NULL

11211460.xml	DDI-MedLine.d64.s1	NO_SECTION	NO_SETID	9
Depression is reaching epidemic proportions in the western world.
1	0	9	O	Depression
2	11	12	O	is
3	14	21	O	reaching
4	23	30	O	epidemic
5	32	42	O	proportions
6	44	45	O	in
7	47	49	O	the
8	51	57	O	western
9	59	63	O	world
NULL

11211460.xml	DDI-MedLine.d64.s2	NO_SECTION	NO_SETID	15
With each successive generation more people are becoming more severely depressed at a younger age.
1	0	3	O	With
2	5	8	O	each
3	10	19	O	successive
4	21	30	O	generation
5	32	35	O	more
6	37	42	O	people
7	44	46	O	are
8	48	55	O	becoming
9	57	60	O	more
10	62	69	O	severely
11	71	79	O	depressed
12	81	82	O	at
13	84	84	O	a
14	86	92	O	younger
15	94	96	O	age
NULL

11213358.xml	DDI-MedLine.d102.s0	NO_SECTION	NO_SETID	14
Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
1	0	8	O	Influence
2	10	11	O	of
3	13	21	U-UNK	estradiol
4	23	25	O	and
5	27	38	U-UNK	progesterone
6	40	41	O	on
7	43	45	O	the
8	47	57	O	sensitivity
9	59	60	O	of
10	62	64	O	rat
11	66	73	O	thoracic
12	75	79	O	aorta
13	81	82	O	to
14	84	96	U-UNK	noradrenaline
NULL

11213358.xml	DDI-MedLine.d102.s1	NO_SECTION	NO_SETID	30
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta.
1	0	2	O	The
2	4	6	O	aim
3	8	9	O	of
4	11	14	O	this
5	16	20	O	study
6	22	24	O	was
7	26	27	O	to
8	29	39	O	investigate
9	41	43	O	the
10	45	51	O	effects
11	53	54	O	of
12	56	58	O	low
13	60	62	O	and
14	64	67	O	high
15	69	73	O	doses
16	75	76	O	of
17	78	86	U-UNK	estradiol
18	87	87	O	,
19	89	91	O	and
20	93	94	O	of
21	96	107	U-UNK	progesterone
22	109	110	O	on
23	112	114	O	the
24	116	123	O	response
25	125	126	O	to
26	128	140	U-UNK	noradrenaline
27	142	143	O	in
28	145	147	O	rat
29	149	156	O	thoracic
30	158	162	O	aorta
NULL

11213358.xml	DDI-MedLine.d102.s2	NO_SECTION	NO_SETID	11
Two weeks after bilateral ovariectomy, female rats received a s.c.
1	0	2	O	Two
2	4	8	O	weeks
3	10	14	O	after
4	16	24	O	bilateral
5	26	36	O	ovariectomy
6	37	37	O	,
7	39	44	O	female
8	46	49	O	rats
9	51	58	O	received
10	60	60	O	a
11	62	64	O	s.c
NULL

11213358.xml	DDI-MedLine.d102.s3	NO_SECTION	NO_SETID	39
injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days.
1	0	8	O	injection
2	10	11	O	of
3	13	19	O	vehicle
4	22	25	O	corn
5	27	29	O	oil
6	30	30	O	,
7	32	34	O	0.1
8	36	37	O	mL
9	38	38	O	/
10	39	41	O	day
11	43	43	O	,
12	45	53	U-UNK	estradiol
13	56	57	O	10
14	59	64	O	microg
15	65	65	O	/
16	66	67	O	kg
17	68	68	O	/
18	69	71	O	day
19	73	74	O	or
20	76	76	O	4
21	78	79	O	mg
22	80	80	O	/
23	81	82	O	kg
24	83	83	O	/
25	84	86	O	day
26	89	91	O	and
27	92	92	O	/
28	93	94	O	or
29	96	107	U-UNK	progesterone
30	110	111	O	20
31	113	114	O	mg
32	115	115	O	/
33	116	117	O	kg
34	118	118	O	/
35	119	121	O	day
36	123	123	O	,
37	125	127	O	for
38	129	133	O	eight
39	135	138	O	days
NULL

11213358.xml	DDI-MedLine.d102.s4	NO_SECTION	NO_SETID	27
On the ninth day, the rats were sacrificed and aortic rings, with or without endothelium, were used to generate concentration-response curves to noradrenaline.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	ninth
4	13	15	O	day
5	16	16	O	,
6	18	20	O	the
7	22	25	O	rats
8	27	30	O	were
9	32	41	O	sacrificed
10	43	45	O	and
11	47	52	O	aortic
12	54	58	O	rings
13	59	59	O	,
14	61	64	O	with
15	66	67	O	or
16	69	75	O	without
17	77	87	O	endothelium
18	88	88	O	,
19	90	93	O	were
20	95	98	O	used
21	100	101	O	to
22	103	110	O	generate
23	112	124	O	concentration
24	126	133	O	response
25	135	140	O	curves
26	142	143	O	to
27	145	157	U-UNK	noradrenaline
NULL

11213358.xml	DDI-MedLine.d102.s5	NO_SECTION	NO_SETID	52
Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
1	0	5	O	Aortic
2	7	11	O	rings
3	13	16	O	with
4	18	23	O	intact
5	25	35	O	endothelium
6	37	40	O	from
7	42	44	O	the
8	46	49	O	high
9	51	54	O	dose
10	57	57	O	4
11	59	60	O	mg
12	61	61	O	/
13	62	63	O	kg
14	64	64	O	/
15	65	67	O	day
16	70	78	U-UNK	estradiol
17	80	84	O	group
18	86	89	O	were
19	91	104	O	supersensitive
20	106	107	O	to
21	109	121	U-UNK	noradrenaline
22	123	130	O	compared
23	132	133	O	to
24	135	137	O	the
25	139	145	O	vehicle
26	147	148	O	or
27	150	152	O	low
28	154	157	O	dose
29	160	161	O	10
30	163	168	O	microg
31	169	169	O	/
32	170	171	O	kg
33	172	172	O	/
34	173	175	O	day
35	178	186	O	estradiol
36	188	193	O	groups
37	196	198	O	pD2
38	200	205	O	values
39	207	207	O	=
40	209	213	O	7.86+
41	214	214	O	/
42	216	219	O	0.09
43	220	220	O	,
44	222	226	O	7.30+
45	227	227	O	/
46	229	232	O	0.11
47	234	236	O	and
48	238	242	O	7.35+
49	243	243	O	/
50	245	248	O	0.04
51	249	249	O	,
52	251	262	O	respectively
NULL

11213358.xml	DDI-MedLine.d102.s6	NO_SECTION	NO_SETID	45
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
1	0	10	O	Endothelium
2	12	17	O	intact
3	19	24	O	aortic
4	26	30	O	rings
5	32	35	O	from
6	37	40	O	high
7	42	50	U-UNK	estradiol
8	52	55	O	rats
9	57	60	O	were
10	62	75	O	supersensitive
11	77	78	O	to
12	80	92	U-UNK	noradrenaline
13	94	97	O	when
14	99	106	O	compared
15	108	109	O	to
16	111	117	O	vehicle
17	119	119	O	,
18	121	132	U-UNK	progesterone
19	135	137	O	and
20	139	150	U-UNK	progesterone
21	152	152	O	+
22	154	157	O	high
23	159	167	U-UNK	estradiol
24	169	175	O	treated
25	177	180	O	rats
26	183	185	O	pD2
27	187	192	O	values
28	194	194	O	=
29	196	200	O	7.77+
30	201	201	O	/
31	203	206	O	0.12
32	207	207	O	,
33	209	213	O	7.21+
34	214	214	O	/
35	216	219	O	0.13
36	220	220	O	,
37	222	226	O	6.93+
38	227	227	O	/
39	229	232	O	0.04
40	234	236	O	and
41	238	242	O	7.22+
42	243	243	O	/
43	245	248	O	0.18
44	249	249	O	,
45	251	262	O	respectively
NULL

11213358.xml	DDI-MedLine.d102.s7	NO_SECTION	NO_SETID	16
There were no significant differences among the pD2 values for noradrenaline in aortic rings without endothelium.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	24	O	significant
5	26	36	O	differences
6	38	42	O	among
7	44	46	O	the
8	48	50	O	pD2
9	52	57	O	values
10	59	61	O	for
11	63	75	U-UNK	noradrenaline
12	77	78	O	in
13	80	85	O	aortic
14	87	91	O	rings
15	93	99	O	without
16	101	111	O	endothelium
NULL

11213358.xml	DDI-MedLine.d102.s8	NO_SECTION	NO_SETID	7
Both of these effects were endothelium-dependent.
1	0	3	O	Both
2	5	6	O	of
3	8	12	O	these
4	14	20	O	effects
5	22	25	O	were
6	27	37	O	endothelium
7	39	47	O	dependent
NULL

11213561.xml	DDI-MedLine.d1.s1	NO_SECTION	NO_SETID	32
Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular.
1	0	4	O	Since
2	6	8	O	the
3	10	16	O	arrival
4	18	19	O	of
5	21	24	O	oral
6	26	33	B-UNK	erection
7	35	44	I-UNK	supporting
8	46	55	L-UNK	medication
9	56	56	O	,
10	58	65	O	patients
11	67	70	O	want
12	72	73	O	to
13	75	78	O	know
14	80	82	O	how
15	84	87	O	safe
16	89	94	O	sexual
17	96	103	O	activity
18	105	106	O	is
19	108	109	O	in
20	111	124	O	cardiovascular
21	126	132	O	disease
22	134	135	O	in
23	137	143	O	general
24	145	147	O	and
25	149	154	O	during
26	156	158	O	use
27	160	161	O	of
28	163	170	B-UNK	erection
29	172	181	I-UNK	supporting
30	183	192	L-UNK	medication
31	194	195	O	in
32	197	206	O	particular
NULL

11213561.xml	DDI-MedLine.d1.s2	NO_SECTION	NO_SETID	32
Sexual intercourse with a steady partner causes no more cardiovascular risk than normal daily activities such as ironing, 2 kilometers of walking without climbing, paperhanging, playing golf or gardening.
1	0	5	O	Sexual
2	7	17	O	intercourse
3	19	22	O	with
4	24	24	O	a
5	26	31	O	steady
6	33	39	O	partner
7	41	46	O	causes
8	48	49	O	no
9	51	54	O	more
10	56	69	O	cardiovascular
11	71	74	O	risk
12	76	79	O	than
13	81	86	O	normal
14	88	92	O	daily
15	94	103	O	activities
16	105	108	O	such
17	110	111	O	as
18	113	119	O	ironing
19	120	120	O	,
20	122	122	O	2
21	124	133	O	kilometers
22	135	136	O	of
23	138	144	O	walking
24	146	152	O	without
25	154	161	O	climbing
26	162	162	O	,
27	164	175	O	paperhanging
28	176	176	O	,
29	178	184	O	playing
30	186	189	O	golf
31	191	192	O	or
32	194	202	O	gardening
NULL

11213561.xml	DDI-MedLine.d1.s3	NO_SECTION	NO_SETID	17
The relative risk of myocardial infarction during sexual activity is not significantly higher than for healthy persons.
1	0	2	O	The
2	4	11	O	relative
3	13	16	O	risk
4	18	19	O	of
5	21	30	O	myocardial
6	32	41	O	infarction
7	43	48	O	during
8	50	55	O	sexual
9	57	64	O	activity
10	66	67	O	is
11	69	71	O	not
12	73	85	O	significantly
13	87	92	O	higher
14	94	97	O	than
15	99	101	O	for
16	103	109	O	healthy
17	111	117	O	persons
NULL

11213561.xml	DDI-MedLine.d1.s4	NO_SECTION	NO_SETID	14
The incidence of cardiovascular morbidity and mortality is not higher among users of sildenafil.
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	30	O	cardiovascular
5	32	40	O	morbidity
6	42	44	O	and
7	46	54	O	mortality
8	56	57	O	is
9	59	61	O	not
10	63	68	O	higher
11	70	74	O	among
12	76	80	O	users
13	82	83	O	of
14	85	94	U-UNK	sildenafil
NULL

11213561.xml	DDI-MedLine.d1.s5	NO_SECTION	NO_SETID	31
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
1	0	9	U-UNK	Sildenafil
2	11	12	O	is
3	14	28	O	contraindicated
4	30	31	O	in
5	33	40	O	patients
6	42	46	O	using
7	48	51	B-UNK	long
8	53	58	I-UNK	acting
9	60	67	L-UNK	nitrates
10	69	70	O	or
11	72	74	O	who
12	76	78	O	may
13	80	83	O	need
14	85	86	O	to
15	88	90	O	use
16	92	96	B-UNK	short
17	98	103	I-UNK	acting
18	105	112	L-UNK	nitrates
19	113	113	O	,
20	115	121	O	because
21	123	125	O	the
22	127	137	O	combination
23	139	141	O	may
24	143	147	O	cause
25	149	149	O	a
26	151	155	O	sharp
27	157	160	O	fall
28	162	163	O	of
29	165	167	O	the
30	169	173	O	blood
31	175	182	O	pressure
NULL

11213561.xml	DDI-MedLine.d1.s6	NO_SECTION	NO_SETID	20
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors.
1	0	1	O	No
2	3	14	O	interactions
3	16	19	O	have
4	21	24	O	been
5	26	33	O	observed
6	35	38	O	with
7	40	43	B-UNK	beta
8	45	52	I-UNK	receptor
9	54	61	L-UNK	blockers
10	62	62	O	,
11	64	70	B-UNK	calcium
12	72	82	L-UNK	antagonists
13	83	83	O	,
14	85	92	B-UNK	thiazide
15	94	96	I-UNK	and
16	98	101	I-UNK	loop
17	103	111	L-UNK	diuretics
18	113	115	O	and
19	117	119	B-UNK	ACE
20	121	130	L-UNK	inhibitors
NULL

11213561.xml	DDI-MedLine.d1.s7	NO_SECTION	NO_SETID	28
Before prescribing a symptomatic (pharmaceutical) treatment for patients with an erection disorder, attention should be given tot the sexological, psychological and medical backgrounds of the disorder.
1	0	5	O	Before
2	7	17	O	prescribing
3	19	19	O	a
4	21	31	O	symptomatic
5	34	47	O	pharmaceutical
6	50	58	O	treatment
7	60	62	O	for
8	64	71	O	patients
9	73	76	O	with
10	78	79	O	an
11	81	88	O	erection
12	90	97	O	disorder
13	98	98	O	,
14	100	108	O	attention
15	110	115	O	should
16	117	118	O	be
17	120	124	O	given
18	126	128	O	tot
19	130	132	O	the
20	134	144	O	sexological
21	145	145	O	,
22	147	159	O	psychological
23	161	163	O	and
24	165	171	O	medical
25	173	183	O	backgrounds
26	185	186	O	of
27	188	190	O	the
28	192	199	O	disorder
NULL

11213561.xml	DDI-MedLine.d1.s8	NO_SECTION	NO_SETID	41
Secondary prevention of atherosclerotic risk factors is also important: regulation of blood pressure and blood sugar level, hyperlipidaemia and obesity, as well as a change of lifestyle (giving up smoking, adapting of diet and more physical exertion).
1	0	8	O	Secondary
2	10	19	O	prevention
3	21	22	O	of
4	24	38	O	atherosclerotic
5	40	43	O	risk
6	45	51	O	factors
7	53	54	O	is
8	56	59	O	also
9	61	69	O	important
10	70	70	O	:
11	72	81	O	regulation
12	83	84	O	of
13	86	90	O	blood
14	92	99	O	pressure
15	101	103	O	and
16	105	109	O	blood
17	111	115	O	sugar
18	117	121	O	level
19	122	122	O	,
20	124	138	O	hyperlipidaemia
21	140	142	O	and
22	144	150	O	obesity
23	151	151	O	,
24	153	154	O	as
25	156	159	O	well
26	161	162	O	as
27	164	164	O	a
28	166	171	O	change
29	173	174	O	of
30	176	184	O	lifestyle
31	187	192	O	giving
32	194	195	O	up
33	197	203	O	smoking
34	204	204	O	,
35	206	213	O	adapting
36	215	216	O	of
37	218	221	O	diet
38	223	225	O	and
39	227	230	O	more
40	232	239	O	physical
41	241	248	O	exertion
NULL

11213561.xml	DDI-MedLine.d1.s9	NO_SECTION	NO_SETID	18
Patients with a very low cardiac capacity should be advised to refrain from treatment of the erection disorder.
1	0	7	O	Patients
2	9	12	O	with
3	14	14	O	a
4	16	19	O	very
5	21	23	O	low
6	25	31	O	cardiac
7	33	40	O	capacity
8	42	47	O	should
9	49	50	O	be
10	52	58	O	advised
11	60	61	O	to
12	63	69	O	refrain
13	71	74	O	from
14	76	84	O	treatment
15	86	87	O	of
16	89	91	O	the
17	93	100	O	erection
18	102	109	O	disorder
NULL

11213850.xml	DDI-MedLine.d46.s0	NO_SECTION	NO_SETID	14
Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
1	0	8	O	Influence
2	10	11	O	of
3	13	28	O	coadministration
4	30	31	O	of
5	33	42	U-UNK	fluoxetine
6	44	45	O	on
7	47	55	U-UNK	cisapride
8	57	72	O	pharmacokinetics
9	74	76	O	and
10	78	80	O	QTc
11	82	90	O	intervals
12	92	93	O	in
13	95	101	O	healthy
14	103	112	O	volunteers
NULL

11213850.xml	DDI-MedLine.d46.s1	NO_SECTION	NO_SETID	23
STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men.
1	0	4	O	STUDY
2	6	14	O	OBJECTIVE
3	15	15	O	:
4	17	18	O	To
5	20	27	O	evaluate
6	29	31	O	the
7	33	38	O	effect
8	40	41	O	of
9	43	52	U-UNK	fluoxetine
10	54	55	O	on
11	57	59	O	the
12	61	76	O	pharmacokinetics
13	78	80	O	and
14	82	95	O	cardiovascular
15	97	102	O	safety
16	104	105	O	of
17	107	115	U-UNK	cisapride
18	117	118	O	at
19	120	125	O	steady
20	127	131	O	state
21	133	134	O	in
22	136	142	O	healthy
23	144	146	O	men
NULL

11213850.xml	DDI-MedLine.d46.s2	NO_SECTION	NO_SETID	10
DESIGN: Open-label, three-phase, sequential study.
1	0	5	O	DESIGN
2	6	6	O	:
3	8	11	O	Open
4	13	17	O	label
5	18	18	O	,
6	20	24	O	three
7	26	30	O	phase
8	31	31	O	,
9	33	42	O	sequential
10	44	48	O	study
NULL

11213850.xml	DDI-MedLine.d46.s3	NO_SECTION	NO_SETID	5
SETTING: Clinical research center.
1	0	6	O	SETTING
2	7	7	O	:
3	9	16	O	Clinical
4	18	25	O	research
5	27	32	O	center
NULL

11213850.xml	DDI-MedLine.d46.s4	NO_SECTION	NO_SETID	4
SUBJECTS:Twelve healthy male volunteers.
1	0	14	O	SUBJECTS:Twelve
2	16	22	O	healthy
3	24	27	O	male
4	29	38	O	volunteers
NULL

11213850.xml	DDI-MedLine.d46.s5	NO_SECTION	NO_SETID	13
INTERVENTIONS: Each subject was treated according to the following sequence: baseline;
1	0	12	O	INTERVENTIONS
2	13	13	O	:
3	15	18	O	Each
4	20	26	O	subject
5	28	30	O	was
6	32	38	O	treated
7	40	48	O	according
8	50	51	O	to
9	53	55	O	the
10	57	65	O	following
11	67	74	O	sequence
12	75	75	O	:
13	77	84	O	baseline
NULL

11213850.xml	DDI-MedLine.d46.s6	NO_SECTION	NO_SETID	13
phase 1 (days 1-6): cisapride 10 mg 4 times/day;
1	0	4	O	phase
2	6	6	O	1
3	9	12	O	days
4	14	14	O	1
5	16	16	O	6
6	18	18	O	:
7	20	28	U-UNK	cisapride
8	30	31	O	10
9	33	34	O	mg
10	36	36	O	4
11	38	42	O	times
12	43	43	O	/
13	44	46	O	day
NULL

11213850.xml	DDI-MedLine.d46.s7	NO_SECTION	NO_SETID	4
washout (days 7-13);
1	0	6	O	washout
2	9	12	O	days
3	14	14	O	7
4	16	17	O	13
NULL

11213850.xml	DDI-MedLine.d46.s8	NO_SECTION	NO_SETID	11
phase 2 (days 14-44): fluoxetine 20 mg/day;
1	0	4	O	phase
2	6	6	O	2
3	9	12	O	days
4	14	15	O	14
5	17	18	O	44
6	20	20	O	:
7	22	31	U-UNK	fluoxetine
8	33	34	O	20
9	36	37	O	mg
10	38	38	O	/
11	39	41	O	day
NULL

11213850.xml	DDI-MedLine.d46.s9	NO_SECTION	NO_SETID	26
and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
1	0	2	O	and
2	4	8	O	phase
3	10	10	O	3
4	13	16	O	days
5	18	19	O	45
6	21	22	O	52
7	24	24	O	:
8	26	34	U-UNK	cisapride
9	36	37	O	10
10	39	40	O	mg
11	42	42	O	4
12	44	48	O	times
13	49	49	O	/
14	50	52	O	day
15	55	58	O	days
16	60	61	O	45
17	63	64	O	51
18	67	70	O	plus
19	72	81	U-UNK	fluoxetine
20	83	84	O	20
21	86	87	O	mg
22	88	88	O	/
23	89	91	O	day
24	94	97	O	days
25	99	100	O	45
26	102	103	O	52
NULL

11213850.xml	DDI-MedLine.d46.s10	NO_SECTION	NO_SETID	30
MEASUREMENTS and MAIN RESULTS: Blood samples were drawn and 12-lead electrocardiograms performed at specified time points after the last morning dose of cisapride in phases 1 and 3.
1	0	11	O	MEASUREMENTS
2	13	15	O	and
3	17	20	O	MAIN
4	22	28	O	RESULTS
5	29	29	O	:
6	31	35	O	Blood
7	37	43	O	samples
8	45	48	O	were
9	50	54	O	drawn
10	56	58	O	and
11	60	61	O	12
12	63	66	O	lead
13	68	85	O	electrocardiograms
14	87	95	O	performed
15	97	98	O	at
16	100	108	O	specified
17	110	113	O	time
18	115	120	O	points
19	122	126	O	after
20	128	130	O	the
21	132	135	O	last
22	137	143	O	morning
23	145	148	O	dose
24	150	151	O	of
25	153	161	U-UNK	cisapride
26	163	164	O	in
27	166	171	O	phases
28	173	173	O	1
29	175	177	O	and
30	179	179	O	3
NULL

11213850.xml	DDI-MedLine.d46.s11	NO_SECTION	NO_SETID	22
Blood samples also were taken before morning doses on the 3rd, 4th, and 5th days of phases 1 and 3.
1	0	4	O	Blood
2	6	12	O	samples
3	14	17	O	also
4	19	22	O	were
5	24	28	O	taken
6	30	35	O	before
7	37	43	O	morning
8	45	49	O	doses
9	51	52	O	on
10	54	56	O	the
11	58	60	O	3rd
12	61	61	O	,
13	63	65	O	4th
14	66	66	O	,
15	68	70	O	and
16	72	74	O	5th
17	76	79	O	days
18	81	82	O	of
19	84	89	O	phases
20	91	91	O	1
21	93	95	O	and
22	97	97	O	3
NULL

11213850.xml	DDI-MedLine.d46.s12	NO_SECTION	NO_SETID	17
Electrocardiograms were done at baseline and on the last day of the washout period and phase 2.
1	0	17	O	Electrocardiograms
2	19	22	O	were
3	24	27	O	done
4	29	30	O	at
5	32	39	O	baseline
6	41	43	O	and
7	45	46	O	on
8	48	50	O	the
9	52	55	O	last
10	57	59	O	day
11	61	62	O	of
12	64	66	O	the
13	68	74	O	washout
14	76	81	O	period
15	83	85	O	and
16	87	91	O	phase
17	93	93	O	2
NULL

11213850.xml	DDI-MedLine.d46.s13	NO_SECTION	NO_SETID	8
Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-UNK	fluoxetine
4	31	43	O	significantly
5	45	53	O	decreased
6	55	63	U-UNK	cisapride
7	65	70	O	plasma
8	72	85	O	concentrations
NULL

11213850.xml	DDI-MedLine.d46.s14	NO_SECTION	NO_SETID	18
There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	23	O	clinically
5	25	35	O	significant
6	37	43	O	changes
7	45	46	O	in
8	48	56	O	corrected
9	58	59	O	QT
10	61	69	O	intervals
11	71	76	O	during
12	78	91	O	administration
13	93	94	O	of
14	96	104	U-UNK	cisapride
15	106	110	O	alone
16	112	113	O	or
17	115	118	O	with
18	120	129	U-UNK	fluoxetine
NULL

11213850.xml	DDI-MedLine.d46.s15	NO_SECTION	NO_SETID	10
Cisapride was well tolerated when administered alone or with fluoxetine.
1	0	8	U-UNK	Cisapride
2	10	12	O	was
3	14	17	O	well
4	19	27	O	tolerated
5	29	32	O	when
6	34	45	O	administered
7	47	51	O	alone
8	53	54	O	or
9	56	59	O	with
10	61	70	U-UNK	fluoxetine
NULL

11213850.xml	DDI-MedLine.d46.s16	NO_SECTION	NO_SETID	15
CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.
1	0	9	O	CONCLUSION
2	10	10	O	:
3	12	20	U-UNK	Cisapride
4	22	24	O	can
5	26	27	O	be
6	29	40	O	administered
7	42	47	O	safely
8	49	50	O	to
9	52	59	O	patients
10	61	69	O	receiving
11	71	73	O	low
12	75	85	O	therapeutic
13	87	93	O	dosages
14	95	96	O	of
15	98	107	U-UNK	fluoxetine
NULL

11217867.xml	DDI-MedLine.d83.s0	NO_SECTION	NO_SETID	13
Olanzapine: an updated review of its use in the management of schizophrenia.
1	0	9	U-UNK	Olanzapine
2	10	10	O	:
3	12	13	O	an
4	15	21	O	updated
5	23	28	O	review
6	30	31	O	of
7	33	35	O	its
8	37	39	O	use
9	41	42	O	in
10	44	46	O	the
11	48	57	O	management
12	59	60	O	of
13	62	74	O	schizophrenia
NULL

11217867.xml	DDI-MedLine.d83.s1	NO_SECTION	NO_SETID	25
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia.
1	0	9	U-UNK	Olanzapine
2	10	10	O	,
3	12	12	O	a
4	14	33	B-UNK	thienobenzodiazepine
5	35	44	L-UNK	derivative
6	45	45	O	,
7	47	48	O	is
8	50	50	O	a
9	52	57	B-UNK	second
10	59	68	I-UNK	generation
11	71	78	I-UNK	atypical
12	81	93	I-UNK	antipsychotic
13	95	99	L-UNK	agent
14	101	105	O	which
15	107	109	O	has
16	111	116	O	proven
17	118	125	O	efficacy
18	127	133	O	against
19	135	137	O	the
20	139	146	O	positive
21	148	150	O	and
22	152	159	O	negative
23	161	168	O	symptoms
24	170	171	O	of
25	173	185	O	schizophrenia
NULL

11217867.xml	DDI-MedLine.d83.s2	NO_SECTION	NO_SETID	18
Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT2A than for dopamine D2 receptors.
1	0	7	O	Compared
2	9	12	O	with
3	14	25	B-UNK	conventional
4	27	40	L-UNK	antipsychotics
5	41	41	O	,
6	43	44	O	it
7	46	48	O	has
8	50	56	O	greater
9	58	65	O	affinity
10	67	69	O	for
11	71	79	O	serotonin
12	81	81	O	5
13	83	86	O	HT2A
14	88	91	O	than
15	93	95	O	for
16	97	104	O	dopamine
17	106	107	O	D2
18	109	117	O	receptors
NULL

11217867.xml	DDI-MedLine.d83.s3	NO_SECTION	NO_SETID	58
In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms.
1	0	1	O	In
2	3	7	O	large
3	8	8	O	,
4	10	13	O	well
5	15	24	O	controlled
6	26	31	O	trials
7	33	34	O	in
8	36	43	O	patients
9	45	48	O	with
10	50	62	O	schizophrenia
11	64	65	O	or
12	67	73	O	related
13	75	83	O	psychoses
14	84	84	O	,
15	86	95	U-UNK	olanzapine
16	97	97	O	5
17	99	100	O	to
18	102	103	O	20
19	105	106	O	mg
20	107	107	O	/
21	108	110	O	day
22	112	114	O	was
23	116	128	O	significantly
24	130	137	O	superior
25	139	140	O	to
26	142	152	U-UNK	haloperidol
27	154	154	O	5
28	156	157	O	to
29	159	160	O	20
30	162	163	O	mg
31	164	164	O	/
32	165	167	O	day
33	169	170	O	in
34	172	178	O	overall
35	180	191	O	improvements
36	193	194	O	in
37	196	210	O	psychopathology
38	212	217	O	rating
39	219	224	O	scales
40	226	228	O	and
41	230	231	O	in
42	233	235	O	the
43	237	245	O	treatment
44	247	248	O	of
45	250	259	O	depressive
46	261	263	O	and
47	265	272	O	negative
48	274	281	O	symptoms
49	282	282	O	,
50	284	286	O	and
51	288	290	O	was
52	292	301	O	comparable
53	303	304	O	in
54	306	312	O	effects
55	314	315	O	on
56	317	324	O	positive
57	326	334	O	psychotic
58	336	343	O	symptoms
NULL

11217867.xml	DDI-MedLine.d83.s4	NO_SECTION	NO_SETID	16
The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
1	0	2	O	The
2	4	4	O	1
3	6	9	O	year
4	11	14	O	risk
5	16	17	O	of
6	19	25	O	relapse
7	28	44	O	rehospitalisation
8	47	49	O	was
9	51	63	O	significantly
10	65	69	O	lower
11	71	74	O	with
12	76	85	U-UNK	olanzapine
13	87	90	O	than
14	92	95	O	with
15	97	107	U-UNK	haloperidol
16	109	117	O	treatment
NULL

11217867.xml	DDI-MedLine.d83.s5	NO_SECTION	NO_SETID	49
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	first
4	13	18	O	double
5	20	24	O	blind
6	26	36	O	comparative
7	38	42	O	study
8	45	46	O	28
9	48	51	O	week
10	54	55	O	of
11	57	66	U-UNK	olanzapine
12	68	70	O	and
13	72	82	U-UNK	risperidone
14	83	83	O	,
15	85	94	U-UNK	olanzapine
16	96	97	O	10
17	99	100	O	to
18	102	103	O	20
19	105	106	O	mg
20	107	107	O	/
21	108	110	O	day
22	112	117	O	proved
23	119	120	O	to
24	122	123	O	be
25	125	137	O	significantly
26	139	142	O	more
27	144	152	O	effective
28	154	157	O	than
29	159	169	U-UNK	risperidone
30	171	171	O	4
31	173	174	O	to
32	176	177	O	12
33	179	180	O	mg
34	181	181	O	/
35	182	184	O	day
36	186	187	O	in
37	189	191	O	the
38	193	201	O	treatment
39	203	204	O	of
40	206	213	O	negative
41	215	217	O	and
42	219	228	O	depressive
43	230	237	O	symptoms
44	239	241	O	but
45	243	245	O	not
46	247	248	O	on
47	250	256	O	overall
48	258	272	O	psychopathology
49	274	281	O	symptoms
NULL

11217867.xml	DDI-MedLine.d83.s6	NO_SECTION	NO_SETID	57
In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	23	O	preliminary
5	25	31	O	results
6	33	36	O	from
7	38	39	O	an
8	41	41	O	8
9	43	46	O	week
10	48	57	O	controlled
11	59	63	O	study
12	65	73	O	suggested
13	75	85	U-UNK	risperidone
14	87	87	O	2
15	89	90	O	to
16	92	92	O	6
17	94	95	O	mg
18	96	96	O	/
19	97	99	O	day
20	101	103	O	was
21	105	112	O	superior
22	114	115	O	to
23	117	126	U-UNK	olanzapine
24	128	128	O	5
25	130	131	O	to
26	133	134	O	20
27	136	137	O	mg
28	138	138	O	/
29	139	141	O	day
30	143	149	O	against
31	151	158	O	positive
32	160	162	O	and
33	164	170	O	anxiety
34	171	171	O	/
35	172	181	O	depressive
36	183	190	O	symptoms
37	193	193	O	p
38	195	195	O	<
39	197	200	O	0.05
40	202	202	O	,
41	204	211	O	although
42	213	222	O	consistent
43	224	227	O	with
44	229	231	O	the
45	233	237	O	first
46	239	243	O	study
47	244	244	O	,
48	246	249	O	both
49	251	256	O	agents
50	258	269	O	demonstrated
51	271	277	O	similar
52	279	286	O	efficacy
53	288	289	O	on
54	291	298	O	measures
55	300	301	O	of
56	303	309	O	overall
57	311	325	O	psychopathology
NULL

11217867.xml	DDI-MedLine.d83.s7	NO_SECTION	NO_SETID	33
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol.
1	0	11	O	Improvements
2	13	14	O	in
3	16	22	O	general
4	24	32	O	cognitive
5	34	41	O	function
6	43	46	O	seen
7	48	51	O	with
8	53	62	U-UNK	olanzapine
9	64	72	O	treatment
10	74	75	O	in
11	77	77	O	a
12	79	79	O	1
13	81	84	O	year
14	86	95	O	controlled
15	97	101	O	study
16	103	104	O	of
17	106	113	O	patients
18	115	118	O	with
19	120	124	O	early
20	126	130	O	phase
21	132	144	O	schizophrenia
22	145	145	O	,
23	147	150	O	were
24	152	164	O	significantly
25	166	172	O	greater
26	174	177	O	than
27	179	185	O	changes
28	187	190	O	seen
29	192	195	O	with
30	197	202	O	either
31	204	214	U-UNK	risperidone
32	216	217	O	or
33	219	229	U-UNK	haloperidol
NULL

11217867.xml	DDI-MedLine.d83.s8	NO_SECTION	NO_SETID	26
However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder.
1	0	6	O	However
2	7	7	O	,
3	9	19	O	preliminary
4	21	27	O	results
5	29	32	O	from
6	34	35	O	an
7	37	37	O	8
8	39	42	O	week
9	44	48	O	trial
10	50	55	O	showed
11	57	66	O	comparable
12	68	76	O	cognitive
13	78	86	O	enhancing
14	88	94	O	effects
15	96	97	O	of
16	99	108	U-UNK	olanzapine
17	110	112	O	and
18	114	124	U-UNK	risperidone
19	126	134	O	treatment
20	136	137	O	in
21	139	146	O	patients
22	148	151	O	with
23	153	165	O	schizophrenia
24	167	168	O	or
25	170	184	O	schizoaffective
26	186	193	O	disorder
NULL

11217867.xml	DDI-MedLine.d83.s9	NO_SECTION	NO_SETID	29
Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology.
1	0	6	O	Several
2	8	14	O	studies
3	16	23	O	indicate
4	25	28	O	that
5	30	39	U-UNK	olanzapine
6	41	43	O	has
7	45	52	O	benefits
8	54	60	O	against
9	62	69	O	symptoms
10	71	72	O	of
11	74	83	O	aggression
12	85	87	O	and
13	89	97	O	agitation
14	98	98	O	,
15	100	104	O	while
16	106	110	O	other
17	112	118	O	studies
18	120	127	O	strongly
19	129	135	O	support
20	137	139	O	the
21	141	153	O	effectiveness
22	155	156	O	of
23	158	167	U-UNK	olanzapine
24	169	170	O	in
25	172	174	O	the
26	176	184	O	treatment
27	186	187	O	of
28	189	198	O	depressive
29	200	213	O	symptomatology
NULL

11217867.xml	DDI-MedLine.d83.s10	NO_SECTION	NO_SETID	12
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone.
1	0	9	U-UNK	Olanzapine
2	11	12	O	is
3	14	23	O	associated
4	25	28	O	with
5	30	42	O	significantly
6	44	48	O	fewer
7	50	63	O	extrapyramidal
8	65	72	O	symptoms
9	74	77	O	than
10	79	89	U-UNK	haloperidol
11	91	93	O	and
12	95	105	U-UNK	risperidone
NULL

11217867.xml	DDI-MedLine.d83.s11	NO_SECTION	NO_SETID	30
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	22	U-UNK	olanzapine
5	24	25	O	is
6	27	29	O	not
7	31	40	O	associated
8	42	45	O	with
9	47	47	O	a
10	49	52	O	risk
11	54	55	O	of
12	57	71	O	agranulocytosis
13	73	74	O	as
14	76	79	O	seen
15	81	84	O	with
16	86	94	U-UNK	clozapine
17	96	97	O	or
18	99	108	O	clinically
19	110	120	O	significant
20	122	140	O	hyperprolactinaemia
21	142	143	O	as
22	145	148	O	seen
23	150	153	O	with
24	155	165	U-UNK	risperidone
25	167	168	O	or
26	170	181	O	prolongation
27	183	184	O	of
28	186	188	O	the
29	190	191	O	QT
30	193	200	O	interval
NULL

11217867.xml	DDI-MedLine.d83.s12	NO_SECTION	NO_SETID	28
The most common adverse effects reported with olanzapine are bodyweight gain, somnolence, dizziness, anticholinergic effects (constipation and dry mouth) and transient asymptomatic liver enzyme elevations.
1	0	2	O	The
2	4	7	O	most
3	9	14	O	common
4	16	22	O	adverse
5	24	30	O	effects
6	32	39	O	reported
7	41	44	O	with
8	46	55	U-UNK	olanzapine
9	57	59	O	are
10	61	70	O	bodyweight
11	72	75	O	gain
12	76	76	O	,
13	78	87	O	somnolence
14	88	88	O	,
15	90	98	O	dizziness
16	99	99	O	,
17	101	115	O	anticholinergic
18	117	123	O	effects
19	126	137	O	constipation
20	139	141	O	and
21	143	145	O	dry
22	147	151	O	mouth
23	154	156	O	and
24	158	166	O	transient
25	168	179	O	asymptomatic
26	181	185	O	liver
27	187	192	O	enzyme
28	194	203	O	elevations
NULL

11217867.xml	DDI-MedLine.d83.s13	NO_SECTION	NO_SETID	44
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine.
1	0	1	O	In
2	3	12	O	comparison
3	14	17	O	with
4	19	29	U-UNK	haloperidol
5	30	30	O	,
6	32	34	O	the
7	36	42	O	adverse
8	44	49	O	events
9	51	58	O	reported
10	60	72	O	significantly
11	74	77	O	more
12	79	88	O	frequently
13	90	93	O	with
14	95	104	U-UNK	olanzapine
15	106	107	O	in
16	109	109	O	>
17	111	112	O	or
18	114	114	O	=
19	116	119	O	3.5%
20	121	122	O	of
21	124	131	O	patients
22	133	136	O	were
23	138	140	O	dry
24	142	146	O	mouth
25	147	147	O	,
26	149	158	O	bodyweight
27	160	163	O	gain
28	165	167	O	and
29	169	177	O	increased
30	179	186	O	appetite
31	188	190	O	and
32	192	199	O	compared
33	201	204	O	with
34	206	216	U-UNK	risperidone
35	217	217	O	,
36	219	222	O	only
37	224	233	O	bodyweight
38	235	238	O	gain
39	240	247	O	occurred
40	249	261	O	significantly
41	263	266	O	more
42	268	277	O	frequently
43	279	282	O	with
44	284	293	U-UNK	olanzapine
NULL

11217867.xml	DDI-MedLine.d83.s14	NO_SECTION	NO_SETID	22
The high acquisition cost of olanzapine is offset by reductions in other treatment costs (inpatient and/or outpatient services) of schizophrenia.
1	0	2	O	The
2	4	7	O	high
3	9	19	O	acquisition
4	21	24	O	cost
5	26	27	O	of
6	29	38	U-UNK	olanzapine
7	40	41	O	is
8	43	48	O	offset
9	50	51	O	by
10	53	62	O	reductions
11	64	65	O	in
12	67	71	O	other
13	73	81	O	treatment
14	83	87	O	costs
15	90	98	O	inpatient
16	100	102	O	and
17	103	103	O	/
18	104	105	O	or
19	107	116	O	outpatient
20	118	125	O	services
21	128	129	O	of
22	131	143	O	schizophrenia
NULL

11217867.xml	DDI-MedLine.d83.s15	NO_SECTION	NO_SETID	26
Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol.
1	0	15	O	Pharmacoeconomic
2	17	24	O	analyses
3	26	33	O	indicate
4	35	38	O	that
5	40	49	U-UNK	olanzapine
6	51	54	O	does
7	56	58	O	not
8	60	72	O	significantly
9	74	81	O	increase
10	82	82	O	,
11	84	86	O	and
12	88	90	O	may
13	92	95	O	even
14	97	104	O	decrease
15	105	105	O	,
16	107	109	O	the
17	111	117	O	overall
18	119	124	O	direct
19	126	134	O	treatment
20	136	140	O	costs
21	142	143	O	of
22	145	157	O	schizophrenia
23	158	158	O	,
24	160	167	O	compared
25	169	172	O	with
26	174	184	U-UNK	haloperidol
NULL

11217867.xml	DDI-MedLine.d83.s16	NO_SECTION	NO_SETID	26
Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug.
1	0	7	O	Compared
2	9	12	O	with
3	14	24	U-UNK	risperidone
4	25	25	O	,
5	27	36	U-UNK	olanzapine
6	38	40	O	has
7	42	45	O	also
8	47	50	O	been
9	52	59	O	reported
10	61	62	O	to
11	64	71	O	decrease
12	73	79	O	overall
13	81	89	O	treatment
14	91	95	O	costs
15	96	96	O	,
16	98	104	O	despite
17	106	108	O	the
18	110	116	O	several
19	118	121	O	fold
20	123	128	O	higher
21	130	134	O	daily
22	136	146	O	acquisition
23	148	151	O	cost
24	153	154	O	of
25	156	158	O	the
26	160	163	O	drug
NULL

11217867.xml	DDI-MedLine.d83.s17	NO_SECTION	NO_SETID	28
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone.
1	0	9	U-UNK	Olanzapine
2	11	19	O	treatment
3	21	28	O	improves
4	30	36	O	quality
5	38	39	O	of
6	41	44	O	life
7	46	47	O	in
8	49	56	O	patients
9	58	61	O	with
10	63	75	O	schizophrenia
11	77	79	O	and
12	81	87	O	related
13	89	97	O	psychoses
14	99	100	O	to
15	102	102	O	a
16	104	110	O	greater
17	112	117	O	extent
18	119	122	O	than
19	124	134	U-UNK	haloperidol
20	135	135	O	,
21	137	139	O	and
22	141	142	O	to
23	144	150	O	broadly
24	152	154	O	the
25	156	159	O	same
26	161	166	O	extent
27	168	169	O	as
28	171	181	U-UNK	risperidone
NULL

11217867.xml	DDI-MedLine.d83.s18	NO_SECTION	NO_SETID	32
CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	22	U-UNK	Olanzapine
4	24	35	O	demonstrated
5	37	44	O	superior
6	46	58	O	antipsychotic
7	60	67	O	efficacy
8	69	76	O	compared
9	78	81	O	with
10	83	93	U-UNK	haloperidol
11	95	96	O	in
12	98	100	O	the
13	102	110	O	treatment
14	112	113	O	of
15	115	119	O	acute
16	121	125	O	phase
17	127	139	O	schizophrenia
18	140	140	O	,
19	142	144	O	and
20	146	147	O	in
21	149	151	O	the
22	153	161	O	treatment
23	163	164	O	of
24	166	169	O	some
25	171	178	O	patients
26	180	183	O	with
27	185	189	O	first
28	191	197	O	episode
29	199	200	O	or
30	202	210	O	treatment
31	212	220	O	resistant
32	222	234	O	schizophrenia
NULL

11217867.xml	DDI-MedLine.d83.s19	NO_SECTION	NO_SETID	48
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
1	0	2	O	The
2	4	10	O	reduced
3	12	15	O	risk
4	17	18	O	of
5	20	26	O	adverse
6	28	33	O	events
7	35	37	O	and
8	39	49	O	therapeutic
9	51	61	O	superiority
10	63	70	O	compared
11	72	75	O	with
12	77	87	U-UNK	haloperidol
13	89	91	O	and
14	93	103	U-UNK	risperidone
15	105	106	O	in
16	108	110	O	the
17	112	120	O	treatment
18	122	123	O	of
19	125	132	O	negative
20	134	136	O	and
21	138	147	O	depressive
22	149	156	O	symptoms
23	158	164	O	support
24	166	168	O	the
25	170	175	O	choice
26	177	178	O	of
27	180	189	U-UNK	olanzapine
28	191	192	O	as
29	194	194	O	a
30	196	200	O	first
31	202	205	O	line
32	207	212	O	option
33	214	215	O	in
34	217	219	O	the
35	221	230	O	management
36	232	233	O	of
37	235	247	O	schizophrenia
38	249	250	O	in
39	252	254	O	the
40	256	260	O	acute
41	262	266	O	phase
42	268	270	O	and
43	272	274	O	for
44	276	278	O	the
45	280	290	O	maintenance
46	292	293	O	of
47	295	303	O	treatment
48	305	312	O	response
NULL

11217868.xml	DDI-MedLine.d132.s0	NO_SECTION	NO_SETID	12
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
1	0	2	O	The
2	4	11	O	emerging
3	13	17	O	roles
4	19	20	O	of
5	22	24	B-UNK	non
6	26	35	I-UNK	nucleoside
7	37	43	I-UNK	reverse
8	45	57	I-UNK	transcriptase
9	59	68	L-UNK	inhibitors
10	70	71	O	in
11	73	86	U-UNK	antiretroviral
12	88	94	O	therapy
NULL

11217868.xml	DDI-MedLine.d132.s1	NO_SECTION	NO_SETID	35
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
1	0	2	O	The
2	4	15	O	availability
3	17	18	O	of
4	20	25	O	potent
5	27	29	B-UNK	non
6	31	40	I-UNK	nucleoside
7	42	48	I-UNK	reverse
8	50	62	I-UNK	transcriptase
9	64	72	L-UNK	inhibitor
10	75	79	U-UNK	NNRTI
11	82	86	O	based
12	88	95	O	regimens
13	97	99	O	for
14	101	114	U-UNK	antiretroviral
15	116	122	O	therapy
16	124	126	O	and
17	128	135	O	concerns
18	137	145	O	regarding
19	147	154	B-UNK	protease
20	156	164	L-UNK	inhibitor
21	167	168	U-UNK	PI
22	171	177	O	related
23	179	187	O	metabolic
24	189	200	O	disturbances
25	202	205	O	have
26	207	209	O	led
27	211	212	O	to
28	214	224	O	significant
29	226	231	O	shifts
30	233	234	O	in
31	236	244	O	treatment
32	246	254	O	practices
33	256	257	O	in
34	259	261	O	HIV
35	263	271	O	infection
NULL

11217868.xml	DDI-MedLine.d132.s2	NO_SECTION	NO_SETID	36
NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.
1	0	4	U-UNK	NNRTI
2	6	10	O	based
3	12	19	O	regimens
4	21	23	O	may
5	25	28	O	have
6	30	36	O	several
7	38	47	O	advantages
8	49	52	O	over
9	54	55	U-UNK	PI
10	57	61	O	based
11	63	69	O	therapy
12	71	73	O	for
13	75	81	O	initial
14	83	84	O	or
15	86	94	O	prolonged
16	96	102	O	therapy
17	103	103	O	,
18	105	113	O	including
19	115	118	O	more
20	120	129	O	convenient
21	131	144	O	administration
22	146	153	O	regimens
23	154	154	O	,
24	156	160	O	lower
25	162	167	O	tablet
26	169	174	O	volume
27	175	175	O	,
28	177	181	O	fewer
29	183	186	O	drug
30	188	199	O	interactions
31	200	200	O	,
32	202	204	O	and
33	206	212	O	central
34	214	220	O	nervous
35	222	227	O	system
36	229	239	O	penetration
NULL

11217868.xml	DDI-MedLine.d132.s3	NO_SECTION	NO_SETID	18
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine).
1	0	1	O	No
2	3	6	O	data
3	8	11	O	from
4	13	23	O	prospective
5	25	32	O	clinical
6	34	39	O	trials
7	41	49	O	currently
8	51	55	O	exist
9	57	65	O	comparing
10	67	69	O	the
11	71	71	O	3
12	73	80	O	approved
13	82	87	O	agents
14	90	98	U-UNK	efavirenz
15	99	99	O	,
16	101	110	U-UNK	nevirapine
17	112	113	O	or
18	115	125	U-UNK	delavirdine
NULL

11217868.xml	DDI-MedLine.d132.s4	NO_SECTION	NO_SETID	34
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.
1	0	3	O	Both
2	5	13	U-UNK	efavirenz
3	15	17	O	and
4	19	28	U-UNK	nevirapine
5	30	33	O	have
6	35	38	O	been
7	40	47	O	compared
8	49	50	O	to
9	52	57	O	triple
10	59	65	O	therapy
11	67	70	O	with
12	72	74	O	the
13	76	77	U-UNK	PI
14	79	87	U-UNK	indinavir
15	89	92	O	over
16	94	95	O	48
17	97	101	O	weeks
18	103	104	O	as
19	106	112	O	initial
20	114	120	O	therapy
21	121	121	O	,
22	123	126	O	with
23	128	134	O	similar
24	136	144	O	responses
25	146	150	O	being
26	152	159	O	observed
27	161	164	O	with
28	166	175	U-UNK	nevirapine
29	177	184	O	regimens
30	186	188	O	and
31	190	200	O	superiority
32	202	209	O	observed
33	211	214	O	with
34	216	224	U-UNK	efavirenz
NULL

11217868.xml	DDI-MedLine.d132.s5	NO_SECTION	NO_SETID	15
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir.
1	0	0	O	A
2	2	8	O	smaller
3	10	11	O	24
4	13	16	O	week
5	18	22	O	study
6	24	26	O	has
7	28	36	O	suggested
8	38	47	U-UNK	nevirapine
9	49	51	O	may
10	53	54	O	be
11	56	63	O	superior
12	65	66	O	to
13	68	70	O	the
14	72	73	U-UNK	PI
15	75	84	U-UNK	nelfinavir
NULL

11217868.xml	DDI-MedLine.d132.s6	NO_SECTION	NO_SETID	18
Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist.
1	0	6	O	Limited
2	8	18	O	comparative
3	20	23	O	data
4	25	26	O	in
5	28	35	O	patients
6	37	40	O	with
7	42	45	O	high
8	47	51	O	viral
9	53	57	O	loads
10	59	65	O	treated
11	67	70	O	with
12	72	81	U-UNK	nevirapine
13	84	85	O	or
14	87	97	U-UNK	delavirdine
15	99	103	O	based
16	105	112	O	regimens
17	114	122	O	currently
18	124	128	O	exist
NULL

11217868.xml	DDI-MedLine.d132.s7	NO_SECTION	NO_SETID	21
However, cohort data and selected patient data from clinical trials suggest comparable activity to PI-based regimens in these patients.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	cohort
4	16	19	O	data
5	21	23	O	and
6	25	32	O	selected
7	34	40	O	patient
8	42	45	O	data
9	47	50	O	from
10	52	59	O	clinical
11	61	66	O	trials
12	68	74	O	suggest
13	76	85	O	comparable
14	87	94	O	activity
15	96	97	O	to
16	99	100	U-UNK	PI
17	102	106	O	based
18	108	115	O	regimens
19	117	118	O	in
20	120	124	O	these
21	126	133	O	patients
NULL

11217868.xml	DDI-MedLine.d132.s8	NO_SECTION	NO_SETID	23
The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads.
1	0	2	O	The
2	4	14	O	superiority
3	16	17	O	of
4	19	27	U-UNK	efavirenz
5	29	32	O	over
6	34	42	U-UNK	indinavir
7	44	48	O	based
8	50	57	O	regimens
9	59	61	O	has
10	63	66	O	been
11	68	75	O	observed
12	77	78	O	in
13	80	90	O	comparative
14	92	95	O	data
15	97	98	O	in
16	100	100	O	a
17	102	107	O	subset
18	109	110	O	of
19	112	119	O	patients
20	121	124	O	with
21	126	129	O	high
22	131	135	O	viral
23	137	141	O	loads
NULL

11217868.xml	DDI-MedLine.d132.s9	NO_SECTION	NO_SETID	23
In treatment-experienced patients, available uncontrolled data suggest these agents contribute to regimen efficacy in NNRTI-na  ve, treatment-experienced patients.
1	0	1	O	In
2	3	11	O	treatment
3	13	23	O	experienced
4	25	32	O	patients
5	33	33	O	,
6	35	43	O	available
7	45	56	O	uncontrolled
8	58	61	O	data
9	63	69	O	suggest
10	71	75	O	these
11	77	82	O	agents
12	84	93	O	contribute
13	95	96	O	to
14	98	104	O	regimen
15	106	113	O	efficacy
16	115	116	O	in
17	118	122	U-UNK	NNRTI
18	124	125	O	na
19	128	129	O	ve
20	130	130	O	,
21	132	140	O	treatment
22	142	152	O	experienced
23	154	161	O	patients
NULL

11217868.xml	DDI-MedLine.d132.s10	NO_SECTION	NO_SETID	24
Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.
1	0	8	U-UNK	Efavirenz
2	10	12	O	has
3	14	25	O	demonstrated
4	27	37	O	superiority
5	39	42	O	over
6	44	53	U-UNK	nelfinavir
7	55	56	O	in
8	58	67	O	nucleoside
9	69	79	O	experienced
10	81	88	O	patients
11	89	89	O	,
12	91	98	O	although
13	100	108	O	combining
14	110	114	O	these
15	116	116	O	2
16	118	123	O	agents
17	125	127	O	may
18	129	137	O	represent
19	139	141	O	the
20	143	146	O	best
21	148	155	O	approach
22	157	158	O	in
23	160	164	O	these
24	166	178	O	circumstances
NULL

11217868.xml	DDI-MedLine.d132.s11	NO_SECTION	NO_SETID	21
The tolerability of NNRTIs appears generally good with few individuals discontinuing in clinical studies as a result of adverse drug events.
1	0	2	O	The
2	4	15	O	tolerability
3	17	18	O	of
4	20	25	U-UNK	NNRTIs
5	27	33	O	appears
6	35	43	O	generally
7	45	48	O	good
8	50	53	O	with
9	55	57	O	few
10	59	69	O	individuals
11	71	83	O	discontinuing
12	85	86	O	in
13	88	95	O	clinical
14	97	103	O	studies
15	105	106	O	as
16	108	108	O	a
17	110	115	O	result
18	117	118	O	of
19	120	126	O	adverse
20	128	131	O	drug
21	133	138	O	events
NULL

11217868.xml	DDI-MedLine.d132.s12	NO_SECTION	NO_SETID	21
The majority of adverse events with NNRTIs occur within the first month, and are predictable and manageable without therapy interruption.
1	0	2	O	The
2	4	11	O	majority
3	13	14	O	of
4	16	22	O	adverse
5	24	29	O	events
6	31	34	O	with
7	36	41	U-UNK	NNRTIs
8	43	47	O	occur
9	49	54	O	within
10	56	58	O	the
11	60	64	O	first
12	66	70	O	month
13	71	71	O	,
14	73	75	O	and
15	77	79	O	are
16	81	91	O	predictable
17	93	95	O	and
18	97	106	O	manageable
19	108	114	O	without
20	116	122	O	therapy
21	124	135	O	interruption
NULL

11218973.xml	DDI-MedLine.d72.s1	NO_SECTION	NO_SETID	6
DESIGN: Cross-sectional descriptive study.
1	0	5	O	DESIGN
2	6	6	O	:
3	8	12	O	Cross
4	14	22	O	sectional
5	24	34	O	descriptive
6	36	40	O	study
NULL

11218973.xml	DDI-MedLine.d72.s2	NO_SECTION	NO_SETID	6
SETTING: Rural primary care centre.
1	0	6	O	SETTING
2	7	7	O	:
3	9	13	O	Rural
4	15	21	O	primary
5	23	26	O	care
6	28	33	O	centre
NULL

11218973.xml	DDI-MedLine.d72.s3	NO_SECTION	NO_SETID	13
PATIENTS: Random sample of 626 MAC out of a total of 1306.
1	0	7	O	PATIENTS
2	8	8	O	:
3	10	15	O	Random
4	17	22	O	sample
5	24	25	O	of
6	27	29	O	626
7	31	33	O	MAC
8	35	37	O	out
9	39	40	O	of
10	42	42	O	a
11	44	48	O	total
12	50	51	O	of
13	53	56	O	1306
NULL

11218973.xml	DDI-MedLine.d72.s4	NO_SECTION	NO_SETID	56
MEASUREMENTS AND MAIN RESULTS: In December 1998, the following was gathered for every MAC with more than one drug treatment: age, sex, number of drugs, intrinsic value, drugs prescribed, daily dose and pharmacological interactions (PI), classified (using the scale of Hansten 1996) into light and clinically relevant.
1	0	11	O	MEASUREMENTS
2	13	15	O	AND
3	17	20	O	MAIN
4	22	28	O	RESULTS
5	29	29	O	:
6	31	32	O	In
7	34	41	O	December
8	43	46	O	1998
9	47	47	O	,
10	49	51	O	the
11	53	61	O	following
12	63	65	O	was
13	67	74	O	gathered
14	76	78	O	for
15	80	84	O	every
16	86	88	O	MAC
17	90	93	O	with
18	95	98	O	more
19	100	103	O	than
20	105	107	O	one
21	109	112	O	drug
22	114	122	O	treatment
23	123	123	O	:
24	125	127	O	age
25	128	128	O	,
26	130	132	O	sex
27	133	133	O	,
28	135	140	O	number
29	142	143	O	of
30	145	149	O	drugs
31	150	150	O	,
32	152	160	O	intrinsic
33	162	166	O	value
34	167	167	O	,
35	169	173	O	drugs
36	175	184	O	prescribed
37	185	185	O	,
38	187	191	O	daily
39	193	196	O	dose
40	198	200	O	and
41	202	216	O	pharmacological
42	218	229	O	interactions
43	232	233	O	PI
44	235	235	O	,
45	237	246	O	classified
46	249	253	O	using
47	255	257	O	the
48	259	263	O	scale
49	265	266	O	of
50	268	274	O	Hansten
51	276	279	O	1996
52	282	285	O	into
53	287	291	O	light
54	293	295	O	and
55	297	306	O	clinically
56	308	315	O	relevant
NULL

11218973.xml	DDI-MedLine.d72.s5	NO_SECTION	NO_SETID	8
Statistical analysis: Mantel-Haenszel (alpha = 0.05).
1	0	10	O	Statistical
2	12	19	O	analysis
3	20	20	O	:
4	22	27	O	Mantel
5	29	36	O	Haenszel
6	39	43	O	alpha
7	45	45	O	=
8	47	50	O	0.05
NULL

11218973.xml	DDI-MedLine.d72.s6	NO_SECTION	NO_SETID	11
Patients' mean age was 69.1 (95% CI, +/- 1.2).
1	0	8	O	Patients'
2	10	13	O	mean
3	15	17	O	age
4	19	21	O	was
5	23	26	O	69.1
6	29	31	O	95%
7	33	34	O	CI
8	35	35	O	,
9	37	37	O	+
10	38	38	O	/
11	41	43	O	1.2
NULL

11218973.xml	DDI-MedLine.d72.s7	NO_SECTION	NO_SETID	14
Mean number of drugs per MAC was 4 (95% CI, +/- 0.2).
1	0	3	O	Mean
2	5	10	O	number
3	12	13	O	of
4	15	19	O	drugs
5	21	23	O	per
6	25	27	O	MAC
7	29	31	O	was
8	33	33	O	4
9	36	38	O	95%
10	40	41	O	CI
11	42	42	O	,
12	44	44	O	+
13	45	45	O	/
14	48	50	O	0.2
NULL

11218973.xml	DDI-MedLine.d72.s8	NO_SECTION	NO_SETID	15
341 PI affecting 197 patients (31.5%, 95% CI, +/- 3.6) were identified.
1	0	2	O	341
2	4	5	O	PI
3	7	15	O	affecting
4	17	19	O	197
5	21	28	O	patients
6	31	35	O	31.5%
7	36	36	O	,
8	38	40	O	95%
9	42	43	O	CI
10	44	44	O	,
11	46	46	O	+
12	47	47	O	/
13	50	52	O	3.6
14	55	58	O	were
15	60	69	O	identified
NULL

11218973.xml	DDI-MedLine.d72.s9	NO_SECTION	NO_SETID	22
24.9% (95% CI, +/- 4.5) were PICR, detected in 11.7% (95% CI, +/- 2.5) of the MAC.
1	0	4	O	24.9%
2	7	9	O	95%
3	11	12	O	CI
4	13	13	O	,
5	15	15	O	+
6	16	16	O	/
7	19	21	O	4.5
8	24	27	O	were
9	29	32	O	PICR
10	33	33	O	,
11	35	42	O	detected
12	44	45	O	in
13	47	51	O	11.7%
14	54	56	O	95%
15	58	59	O	CI
16	60	60	O	,
17	62	62	O	+
18	63	63	O	/
19	66	68	O	2.5
20	71	72	O	of
21	74	76	O	the
22	78	80	O	MAC
NULL

11218973.xml	DDI-MedLine.d72.s10	NO_SECTION	NO_SETID	18
The existence of PI was related to the number of drugs prescribed to each patient (p < 0.01).
1	0	2	O	The
2	4	12	O	existence
3	14	15	O	of
4	17	18	O	PI
5	20	22	O	was
6	24	30	O	related
7	32	33	O	to
8	35	37	O	the
9	39	44	O	number
10	46	47	O	of
11	49	53	O	drugs
12	55	64	O	prescribed
13	66	67	O	to
14	69	72	O	each
15	74	80	O	patient
16	83	83	O	p
17	85	85	O	<
18	87	90	O	0.01
NULL

11218973.xml	DDI-MedLine.d72.s11	NO_SECTION	NO_SETID	17
There were 26 PI with drugs of low intrinsic value (7.6%; 95% CI, +/- 2.8).
1	0	4	O	There
2	6	9	O	were
3	11	12	O	26
4	14	15	O	PI
5	17	20	O	with
6	22	26	O	drugs
7	28	29	O	of
8	31	33	O	low
9	35	43	O	intrinsic
10	45	49	O	value
11	52	55	O	7.6%
12	58	60	O	95%
13	62	63	O	CI
14	64	64	O	,
15	66	66	O	+
16	67	67	O	/
17	70	72	O	2.8
NULL

11218973.xml	DDI-MedLine.d72.s12	NO_SECTION	NO_SETID	17
74.1% (95% CI, +/- 9.3) of the total PICR could be avoided by simple recommendations;
1	0	4	O	74.1%
2	7	9	O	95%
3	11	12	O	CI
4	13	13	O	,
5	15	15	O	+
6	16	16	O	/
7	19	21	O	9.3
8	24	25	O	of
9	27	29	O	the
10	31	35	O	total
11	37	40	O	PICR
12	42	46	O	could
13	48	49	O	be
14	51	57	O	avoided
15	59	60	O	by
16	62	67	O	simple
17	69	83	O	recommendations
NULL

11218973.xml	DDI-MedLine.d72.s13	NO_SECTION	NO_SETID	17
and the remaining 25.9% (95% CI, +/- 9.3) by monitoring and follow-up of patients.
1	0	2	O	and
2	4	6	O	the
3	8	16	O	remaining
4	18	22	O	25.9%
5	25	27	O	95%
6	29	30	O	CI
7	31	31	O	,
8	33	33	O	+
9	34	34	O	/
10	37	39	O	9.3
11	42	43	O	by
12	45	54	O	monitoring
13	56	58	O	and
14	60	65	O	follow
15	67	68	O	up
16	70	71	O	of
17	73	80	O	patients
NULL

11218973.xml	DDI-MedLine.d72.s14	NO_SECTION	NO_SETID	29
CONCLUSIONS: It is important to identify the medications most commonly involved in the PICR so as to establish corrective measures to minimise the risks arising from multiple medication.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	14	O	It
4	16	17	O	is
5	19	27	O	important
6	29	30	O	to
7	32	39	O	identify
8	41	43	O	the
9	45	55	O	medications
10	57	60	O	most
11	62	69	O	commonly
12	71	78	O	involved
13	80	81	O	in
14	83	85	O	the
15	87	90	O	PICR
16	92	93	O	so
17	95	96	O	as
18	98	99	O	to
19	101	109	O	establish
20	111	120	O	corrective
21	122	129	O	measures
22	131	132	O	to
23	134	141	O	minimise
24	143	145	O	the
25	147	151	O	risks
26	153	159	O	arising
27	161	164	O	from
28	166	173	O	multiple
29	175	184	O	medication
NULL

11218973.xml	DDI-MedLine.d72.s15	NO_SECTION	NO_SETID	11
Four educational messages advise on over 60% of the PICR detected.
1	0	3	O	Four
2	5	15	O	educational
3	17	24	O	messages
4	26	31	O	advise
5	33	34	O	on
6	36	39	O	over
7	41	43	O	60%
8	45	46	O	of
9	48	50	O	the
10	52	55	O	PICR
11	57	64	O	detected
NULL

11219023.xml	DDI-MedLine.d32.s1	NO_SECTION	NO_SETID	9
Keys to maximizing benefit while avoiding adverse drug effects.
1	0	3	O	Keys
2	5	6	O	to
3	8	17	O	maximizing
4	19	25	O	benefit
5	27	31	O	while
6	33	40	O	avoiding
7	42	48	O	adverse
8	50	53	O	drug
9	55	61	O	effects
NULL

11219023.xml	DDI-MedLine.d32.s2	NO_SECTION	NO_SETID	24
When prescribing for older patients, some physicians are overly cautious, and this strategy can result in a less than optimal treatment outcome.
1	0	3	O	When
2	5	15	O	prescribing
3	17	19	O	for
4	21	25	O	older
5	27	34	O	patients
6	35	35	O	,
7	37	40	O	some
8	42	51	O	physicians
9	53	55	O	are
10	57	62	O	overly
11	64	71	O	cautious
12	72	72	O	,
13	74	76	O	and
14	78	81	O	this
15	83	90	O	strategy
16	92	94	O	can
17	96	101	O	result
18	103	104	O	in
19	106	106	O	a
20	108	111	O	less
21	113	116	O	than
22	118	124	O	optimal
23	126	134	O	treatment
24	136	142	O	outcome
NULL

11219023.xml	DDI-MedLine.d32.s3	NO_SECTION	NO_SETID	17
The reluctance to treat aggressively is understandable because the geriatric population is susceptible to adverse drug reactions.
1	0	2	O	The
2	4	13	O	reluctance
3	15	16	O	to
4	18	22	O	treat
5	24	35	O	aggressively
6	37	38	O	is
7	40	53	O	understandable
8	55	61	O	because
9	63	65	O	the
10	67	75	O	geriatric
11	77	86	O	population
12	88	89	O	is
13	91	101	O	susceptible
14	103	104	O	to
15	106	112	O	adverse
16	114	117	O	drug
17	119	127	O	reactions
NULL

11219023.xml	DDI-MedLine.d32.s4	NO_SECTION	NO_SETID	13
The key to maximizing therapy lies in individualizing it as much as possible.
1	0	2	O	The
2	4	6	O	key
3	8	9	O	to
4	11	20	O	maximizing
5	22	28	O	therapy
6	30	33	O	lies
7	35	36	O	in
8	38	52	O	individualizing
9	54	55	O	it
10	57	58	O	as
11	60	63	O	much
12	65	66	O	as
13	68	75	O	possible
NULL

11219023.xml	DDI-MedLine.d32.s5	NO_SECTION	NO_SETID	18
There are a number of steps physicians can take to ensure that their patients are not being undertreated.
1	0	4	O	There
2	6	8	O	are
3	10	10	O	a
4	12	17	O	number
5	19	20	O	of
6	22	26	O	steps
7	28	37	O	physicians
8	39	41	O	can
9	43	46	O	take
10	48	49	O	to
11	51	56	O	ensure
12	58	61	O	that
13	63	67	O	their
14	69	76	O	patients
15	78	80	O	are
16	82	84	O	not
17	86	90	O	being
18	92	103	O	undertreated
NULL

11219023.xml	DDI-MedLine.d32.s6	NO_SECTION	NO_SETID	25
These steps include regular reevaluations of dosages and plasma drug concentrations, recognition and understanding of drug side effects, and avoidance of certain agents.
1	0	4	O	These
2	6	10	O	steps
3	12	18	O	include
4	20	26	O	regular
5	28	40	O	reevaluations
6	42	43	O	of
7	45	51	O	dosages
8	53	55	O	and
9	57	62	O	plasma
10	64	67	O	drug
11	69	82	O	concentrations
12	83	83	O	,
13	85	95	O	recognition
14	97	99	O	and
15	101	113	O	understanding
16	115	116	O	of
17	118	121	O	drug
18	123	126	O	side
19	128	134	O	effects
20	135	135	O	,
21	137	139	O	and
22	141	149	O	avoidance
23	151	152	O	of
24	154	160	O	certain
25	162	167	O	agents
NULL

11219023.xml	DDI-MedLine.d32.s7	NO_SECTION	NO_SETID	26
Close monitoring allows physicians to minimize risks, maximize benefits, and get the most out of what modern medications can do to help older patients.
1	0	4	O	Close
2	6	15	O	monitoring
3	17	22	O	allows
4	24	33	O	physicians
5	35	36	O	to
6	38	45	O	minimize
7	47	51	O	risks
8	52	52	O	,
9	54	61	O	maximize
10	63	70	O	benefits
11	71	71	O	,
12	73	75	O	and
13	77	79	O	get
14	81	83	O	the
15	85	88	O	most
16	90	92	O	out
17	94	95	O	of
18	97	100	O	what
19	102	107	O	modern
20	109	119	O	medications
21	121	123	O	can
22	125	126	O	do
23	128	129	O	to
24	131	134	O	help
25	136	140	O	older
26	142	149	O	patients
NULL

11219477.xml	DDI-MedLine.d42.s0	NO_SECTION	NO_SETID	6
Sildenafil citrate: a therapeutic update.
1	0	9	B-UNK	Sildenafil
2	11	17	L-UNK	citrate
3	18	18	O	:
4	20	20	O	a
5	22	32	O	therapeutic
6	34	39	O	update
NULL

11219477.xml	DDI-MedLine.d42.s1	NO_SECTION	NO_SETID	31
BACKGROUND: Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction.
1	0	9	O	BACKGROUND
2	10	10	O	:
3	12	16	O	Since
4	18	20	O	its
5	22	29	O	approval
6	31	32	O	by
7	34	36	O	the
8	38	39	O	US
9	41	44	O	Food
10	46	48	O	and
11	50	53	O	Drug
12	55	68	O	Administration
13	70	71	O	in
14	73	77	O	March
15	79	82	O	1998
16	83	83	O	,
17	85	94	B-UNK	sildenafil
18	96	102	L-UNK	citrate
19	104	106	O	has
20	108	111	O	been
21	113	116	O	used
22	118	119	O	by
23	121	128	O	millions
24	130	131	O	of
25	133	135	O	men
26	137	139	O	for
27	141	143	O	the
28	145	153	O	treatment
29	155	156	O	of
30	158	165	O	erectile
31	167	177	O	dysfunction
NULL

11219477.xml	DDI-MedLine.d42.s2	NO_SECTION	NO_SETID	20
Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions.
1	0	5	O	Recent
2	7	13	O	studies
3	15	17	O	and
4	19	27	O	consensus
5	29	35	O	reports
6	37	40	O	have
7	42	49	O	expanded
8	51	53	O	our
9	55	67	O	understanding
10	69	70	O	of
11	72	74	O	its
12	76	83	O	efficacy
13	84	84	O	,
14	86	91	O	safety
15	92	92	O	,
16	94	110	O	contraindications
17	111	111	O	,
18	113	115	O	and
19	117	120	O	drug
20	122	133	O	interactions
NULL

11219477.xml	DDI-MedLine.d42.s3	NO_SECTION	NO_SETID	51
OBJECTIVE: This paper reviews recent studies of the efficacy of sildenafil, its adverse effects and drug interactions, and socioeconomic factors involved in its use, with a focus on specific patient populations (prostate cancer, diabetes mellitus, ischemic heart disease, spinal cord injuries, neurologic disorders).
1	0	8	O	OBJECTIVE
2	9	9	O	:
3	11	14	O	This
4	16	20	O	paper
5	22	28	O	reviews
6	30	35	O	recent
7	37	43	O	studies
8	45	46	O	of
9	48	50	O	the
10	52	59	O	efficacy
11	61	62	O	of
12	64	73	U-UNK	sildenafil
13	74	74	O	,
14	76	78	O	its
15	80	86	O	adverse
16	88	94	O	effects
17	96	98	O	and
18	100	103	O	drug
19	105	116	O	interactions
20	117	117	O	,
21	119	121	O	and
22	123	135	O	socioeconomic
23	137	143	O	factors
24	145	152	O	involved
25	154	155	O	in
26	157	159	O	its
27	161	163	O	use
28	164	164	O	,
29	166	169	O	with
30	171	171	O	a
31	173	177	O	focus
32	179	180	O	on
33	182	189	O	specific
34	191	197	O	patient
35	199	209	O	populations
36	212	219	O	prostate
37	221	226	O	cancer
38	227	227	O	,
39	229	236	O	diabetes
40	238	245	O	mellitus
41	246	246	O	,
42	248	255	O	ischemic
43	257	261	O	heart
44	263	269	O	disease
45	270	270	O	,
46	272	277	O	spinal
47	279	282	O	cord
48	284	291	O	injuries
49	292	292	O	,
50	294	303	O	neurologic
51	305	313	O	disorders
NULL

11219477.xml	DDI-MedLine.d42.s4	NO_SECTION	NO_SETID	49
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction.
1	0	6	O	METHODS
2	7	7	O	:
3	9	16	O	Clinical
4	18	24	O	studies
5	25	25	O	,
6	27	30	O	case
7	32	38	O	reports
8	39	39	O	,
9	41	43	O	and
10	45	56	O	commentaries
11	58	60	O	and
12	62	71	O	editorials
13	73	82	O	concerning
14	84	93	U-UNK	sildenafil
15	95	103	O	published
16	105	106	O	in
17	108	110	O	the
18	112	124	O	international
19	126	135	O	literature
20	137	143	O	between
21	145	151	O	January
22	153	156	O	1999
23	158	160	O	and
24	162	167	O	August
25	169	172	O	2000
26	174	177	O	were
27	179	188	O	identified
28	190	196	O	through
29	198	205	O	searches
30	207	208	O	of
31	210	216	O	MEDLINE
32	217	217	O	,
33	219	228	O	PREMEDLINE
34	229	229	O	,
35	231	233	O	and
36	235	247	O	International
37	249	262	O	Pharmaceutical
38	264	272	O	Abstracts
39	273	273	O	,
40	275	279	O	using
41	281	283	O	the
42	285	289	O	terms
43	291	300	U-UNK	sildenafil
44	301	301	O	,
45	303	308	O	XXXXXXXX
46	309	309	O	,
47	311	313	O	and
48	315	322	O	erectile
49	324	334	O	dysfunction
NULL

11219477.xml	DDI-MedLine.d42.s5	NO_SECTION	NO_SETID	35
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]).
1	0	6	O	RESULTS
2	7	7	O	:
3	9	18	U-UNK	Sildenafil
4	20	22	O	has
5	24	35	O	demonstrated
6	37	49	O	effectiveness
7	51	52	O	in
8	54	56	O	men
9	58	61	O	with
10	63	70	O	erectile
11	72	82	O	dysfunction
12	84	93	O	associated
13	95	98	O	with
14	100	112	O	prostatectomy
15	113	113	O	,
16	115	123	O	radiation
17	125	131	O	therapy
18	132	132	O	,
19	134	141	O	diabetes
20	143	150	O	mellitus
21	151	151	O	,
22	153	159	O	certain
23	161	170	O	neurologic
24	172	180	O	disorders
25	181	181	O	,
26	183	185	O	and
27	187	190	O	drug
28	192	198	O	therapy
29	201	202	O	eg
30	203	203	O	,
31	205	213	B-UNK	selective
32	215	223	I-UNK	serotonin
33	225	232	I-UNK	reuptake
34	234	243	L-UNK	inhibitors
35	246	250	U-UNK	SSRIs
NULL

11219477.xml	DDI-MedLine.d42.s6	NO_SECTION	NO_SETID	20
It has not been as effective in women with sexual dysfunction, with the exception of SSRI-associated sexual dysfunction.
1	0	1	O	It
2	3	5	O	has
3	7	9	O	not
4	11	14	O	been
5	16	17	O	as
6	19	27	O	effective
7	29	30	O	in
8	32	36	O	women
9	38	41	O	with
10	43	48	O	sexual
11	50	60	O	dysfunction
12	61	61	O	,
13	63	66	O	with
14	68	70	O	the
15	72	80	O	exception
16	82	83	O	of
17	85	88	U-UNK	SSRI
18	90	99	O	associated
19	101	106	O	sexual
20	108	118	O	dysfunction
NULL

11219477.xml	DDI-MedLine.d42.s7	NO_SECTION	NO_SETID	16
Some disorders unrelated to sexual dysfunction (eg, esophageal motility dysfunction) may also respond to sildenafil.
1	0	3	O	Some
2	5	13	O	disorders
3	15	23	O	unrelated
4	25	26	O	to
5	28	33	O	sexual
6	35	45	O	dysfunction
7	48	49	O	eg
8	50	50	O	,
9	52	61	O	esophageal
10	63	70	O	motility
11	72	82	O	dysfunction
12	85	87	O	may
13	89	92	O	also
14	94	100	O	respond
15	102	103	O	to
16	105	114	U-UNK	sildenafil
NULL

11219477.xml	DDI-MedLine.d42.s8	NO_SECTION	NO_SETID	14
In the general population, sildenafil is considered to have an acceptable tolerability profile;
1	0	1	O	In
2	3	5	O	the
3	7	13	O	general
4	15	24	O	population
5	25	25	O	,
6	27	36	U-UNK	sildenafil
7	38	39	O	is
8	41	50	O	considered
9	52	53	O	to
10	55	58	O	have
11	60	61	O	an
12	63	72	O	acceptable
13	74	85	O	tolerability
14	87	93	O	profile
NULL

11219477.xml	DDI-MedLine.d42.s9	NO_SECTION	NO_SETID	27
however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
1	0	6	O	however
2	7	7	O	,
3	9	16	O	patients
4	18	21	O	with
5	23	30	O	moderate
6	32	33	O	to
7	35	40	O	severe
8	42	55	O	cardiovascular
9	57	63	O	disease
10	65	66	O	or
11	68	72	O	those
12	74	79	O	taking
13	81	87	U-UNK	nitrate
14	89	95	O	therapy
15	97	99	O	are
16	101	102	O	at
17	104	112	O	increased
18	114	117	O	risk
19	119	121	O	for
20	123	133	O	potentially
21	135	141	O	serious
22	143	156	O	cardiovascular
23	158	164	O	adverse
24	166	172	O	effects
25	174	177	O	with
26	179	188	U-UNK	sildenafil
27	190	196	O	therapy
NULL

11219477.xml	DDI-MedLine.d42.s10	NO_SECTION	NO_SETID	31
In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	20	O	patients
5	22	27	O	taking
6	29	33	O	drugs
7	35	38	O	that
8	40	46	O	inhibit
9	48	50	O	the
10	52	61	O	cytochrome
11	63	66	O	P450
12	68	70	O	3A4
13	72	78	O	isozyme
14	79	79	O	,
15	81	85	O	which
16	87	97	O	metabolizes
17	99	108	U-UNK	sildenafil
18	109	109	O	,
19	111	113	O	may
20	115	124	O	experience
21	126	134	O	increased
22	136	139	O	drug
23	141	154	O	concentrations
24	156	158	O	and
25	160	167	O	possible
26	169	176	O	toxicity
27	178	181	O	from
28	183	188	O	normal
29	190	194	O	doses
30	196	197	O	of
31	199	208	U-UNK	sildenafil
NULL

11219477.xml	DDI-MedLine.d42.s11	NO_SECTION	NO_SETID	14
CONCLUSIONS: Sildenafil is an effective first-line therapy for erectile dysfunction in men.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	22	U-UNK	Sildenafil
4	24	25	O	is
5	27	28	O	an
6	30	38	O	effective
7	40	44	O	first
8	46	49	O	line
9	51	57	O	therapy
10	59	61	O	for
11	63	70	O	erectile
12	72	82	O	dysfunction
13	84	85	O	in
14	87	89	O	men
NULL

11219477.xml	DDI-MedLine.d42.s12	NO_SECTION	NO_SETID	28
The decision to prescribe this agent should include such considerations as the cost-risk-benefit balance, patient access, drug distribution pathways, and prescription drug coverage.
1	0	2	O	The
2	4	11	O	decision
3	13	14	O	to
4	16	24	O	prescribe
5	26	29	O	this
6	31	35	O	agent
7	37	42	O	should
8	44	50	O	include
9	52	55	O	such
10	57	70	O	considerations
11	72	73	O	as
12	75	77	O	the
13	79	82	O	cost
14	84	87	O	risk
15	89	95	O	benefit
16	97	103	O	balance
17	104	104	O	,
18	106	112	O	patient
19	114	119	O	access
20	120	120	O	,
21	122	125	O	drug
22	127	138	O	distribution
23	140	147	O	pathways
24	148	148	O	,
25	150	152	O	and
26	154	165	O	prescription
27	167	170	O	drug
28	172	179	O	coverage
NULL

11271411.xml	DDI-MedLine.d38.s0	NO_SECTION	NO_SETID	13
Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
1	0	4	O	Acute
2	6	19	U-UNK	hydrocortisone
3	21	34	O	administration
4	36	39	O	does
5	41	43	O	not
6	45	50	O	affect
7	52	61	O	subjective
8	63	71	O	responses
9	73	74	O	to
10	76	76	B-UNK	d
11	78	88	L-UNK	amphetamine
12	90	91	O	in
13	93	98	O	humans
NULL

11271411.xml	DDI-MedLine.d38.s1	NO_SECTION	NO_SETID	13
RATIONALE: Stress and glucocorticoids facilitate and reinstate psychostimulant self-administration in rodents.
1	0	8	O	RATIONALE
2	9	9	O	:
3	11	16	O	Stress
4	18	20	O	and
5	22	36	U-UNK	glucocorticoids
6	38	47	O	facilitate
7	49	51	O	and
8	53	61	O	reinstate
9	63	77	O	psychostimulant
10	79	82	O	self
11	84	97	O	administration
12	99	100	O	in
13	102	108	O	rodents
NULL

11271411.xml	DDI-MedLine.d38.s2	NO_SECTION	NO_SETID	23
However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	19	O	effects
5	21	22	O	of
6	24	29	O	stress
7	31	33	O	and
8	35	49	U-UNK	glucocorticoids
9	51	52	O	on
10	54	56	O	the
11	58	67	O	subjective
12	69	71	O	and
13	73	82	O	behavioral
14	84	90	O	effects
15	92	93	O	of
16	95	110	U-UNK	psychostimulants
17	112	115	O	have
18	117	119	O	not
19	121	124	O	been
20	126	129	O	well
21	131	137	O	studied
22	139	140	O	in
23	142	147	O	humans
NULL

11271411.xml	DDI-MedLine.d38.s3	NO_SECTION	NO_SETID	19
OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine.
1	0	9	O	OBJECTIVES
2	10	10	O	:
3	12	13	O	To
4	15	21	O	examine
5	23	25	O	the
6	27	33	O	effects
7	35	36	O	of
8	38	42	O	acute
9	44	57	U-UNK	hydrocortisone
10	59	70	O	pretreatment
11	72	73	O	on
12	75	77	O	the
13	79	88	O	subjective
14	90	92	O	and
15	94	103	O	behavioral
16	105	111	O	effects
17	113	114	O	of
18	116	116	B-UNK	d
19	118	128	L-UNK	amphetamine
NULL

11271411.xml	DDI-MedLine.d38.s4	NO_SECTION	NO_SETID	33
METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design.
1	0	6	O	METHODS
2	7	7	O	:
3	9	22	U-UNK	Hydrocortisone
4	25	27	O	100
5	29	30	O	mg
6	33	35	O	and
7	37	37	B-UNK	d
8	39	49	L-UNK	amphetamine
9	52	53	O	20
10	55	56	O	mg
11	59	62	O	were
12	64	75	O	administered
13	77	82	O	orally
14	84	85	O	to
15	87	88	O	16
16	90	96	O	healthy
17	98	101	O	male
18	103	105	O	and
19	107	112	O	female
20	114	123	O	volunteers
21	125	126	O	in
22	128	128	O	a
23	130	133	O	four
24	135	141	O	session
25	142	142	O	,
26	144	150	O	placebo
27	152	161	O	controlled
28	162	162	O	,
29	164	169	O	within
30	171	177	O	subject
31	178	178	O	,
32	180	188	O	crossover
33	190	195	O	design
NULL

11271411.xml	DDI-MedLine.d38.s5	NO_SECTION	NO_SETID	13
To prevent stomach irritation, subjects received rantidine hydrochloride before each experimental session.
1	0	1	O	To
2	3	9	O	prevent
3	11	17	O	stomach
4	19	28	O	irritation
5	29	29	O	,
6	31	38	O	subjects
7	40	47	O	received
8	49	57	B-UNK	rantidine
9	59	71	L-UNK	hydrochloride
10	73	78	O	before
11	80	83	O	each
12	85	96	O	experimental
13	98	104	O	session
NULL

11271411.xml	DDI-MedLine.d38.s6	NO_SECTION	NO_SETID	37
Dependent measures included self-reported mood and subjective effects (Addiction Research Center inventory, the profile of mood states, and a series of visual analogue scales), vital signs, salivary cortisol, and psychomotor performance.
1	0	8	O	Dependent
2	10	17	O	measures
3	19	26	O	included
4	28	31	O	self
5	33	40	O	reported
6	42	45	O	mood
7	47	49	O	and
8	51	60	O	subjective
9	62	68	O	effects
10	71	79	O	Addiction
11	81	88	O	Research
12	90	95	O	Center
13	97	105	O	inventory
14	106	106	O	,
15	108	110	O	the
16	112	118	O	profile
17	120	121	O	of
18	123	126	O	mood
19	128	133	O	states
20	134	134	O	,
21	136	138	O	and
22	140	140	O	a
23	142	147	O	series
24	149	150	O	of
25	152	157	O	visual
26	159	166	O	analogue
27	168	173	O	scales
28	175	175	O	,
29	177	181	O	vital
30	183	187	O	signs
31	188	188	O	,
32	190	197	O	salivary
33	199	206	O	cortisol
34	207	207	O	,
35	209	211	O	and
36	213	223	O	psychomotor
37	225	235	O	performance
NULL

11271411.xml	DDI-MedLine.d38.s7	NO_SECTION	NO_SETID	20
RESULTS: Hydrocortisone elevated salivary cortisol levels, produced modest dysphoria, and reduced subjects' reports of wanting more drug.
1	0	6	O	RESULTS
2	7	7	O	:
3	9	22	U-UNK	Hydrocortisone
4	24	31	O	elevated
5	33	40	O	salivary
6	42	49	O	cortisol
7	51	56	O	levels
8	57	57	O	,
9	59	66	O	produced
10	68	73	O	modest
11	75	83	O	dysphoria
12	84	84	O	,
13	86	88	O	and
14	90	96	O	reduced
15	98	106	O	subjects'
16	108	114	O	reports
17	116	117	O	of
18	119	125	O	wanting
19	127	130	O	more
20	132	135	O	drug
NULL

11271411.xml	DDI-MedLine.d38.s8	NO_SECTION	NO_SETID	20
However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine.
1	0	6	O	However
2	7	7	O	,
3	9	22	U-UNK	hydrocortisone
4	24	35	O	pretreatment
5	37	39	O	did
6	41	43	O	not
7	45	50	O	affect
8	52	54	O	any
9	56	57	O	of
10	59	61	O	the
11	63	75	O	physiological
12	76	76	O	,
13	78	87	O	behavioral
14	88	88	O	,
15	90	91	O	or
16	93	102	O	subjective
17	104	110	O	effects
18	112	113	O	of
19	115	115	B-UNK	d
20	117	127	L-UNK	amphetamine
NULL

11271411.xml	DDI-MedLine.d38.s9	NO_SECTION	NO_SETID	33
CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.
1	0	10	O	CONCLUSIONS
2	11	11	O	:
3	13	14	O	In
4	16	23	O	contrast
5	25	26	O	to
6	28	30	O	the
7	32	38	O	effects
8	40	41	O	of
9	43	57	U-UNK	glucocorticoids
10	59	60	O	in
11	62	67	O	rodent
12	69	75	O	studies
13	76	76	O	,
14	78	82	O	these
15	84	90	O	results
16	92	99	O	indicate
17	101	104	O	that
18	106	107	O	an
19	109	113	O	acute
20	115	122	O	increase
21	124	125	O	in
22	127	134	O	cortisol
23	136	139	O	does
24	141	143	O	not
25	145	151	O	enhance
26	153	155	O	the
27	157	171	O	psychostimulant
28	173	179	O	effects
29	181	182	O	of
30	184	184	B-UNK	d
31	186	196	L-UNK	amphetamine
32	198	199	O	in
33	201	206	O	humans
NULL

1167743.xml	DDI-MedLine.d23.s0	NO_SECTION	NO_SETID	13
The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	22	U-UNK	ketamine
5	24	26	O	and
6	28	29	O	of
7	31	37	O	XXXXXXXX
8	39	48	O	anesthesia
9	50	51	O	on
10	53	61	U-UNK	digitalis
11	63	71	O	tolerance
12	73	74	O	in
13	76	79	O	dogs
NULL

1167743.xml	DDI-MedLine.d23.s1	NO_SECTION	NO_SETID	45
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
1	0	1	O	In
2	3	3	O	a
3	5	14	O	comparison
4	16	17	O	of
5	19	27	U-UNK	digitalis
6	29	37	O	tolerance
7	39	40	O	in
8	42	45	O	dogs
9	47	58	O	anesthetized
10	60	63	O	with
11	65	72	U-UNK	ketamine
12	73	73	O	,
13	75	81	O	XXXXXXXX
14	83	85	O	Vet
15	86	86	O	,
16	88	89	O	or
17	91	103	U-UNK	pentobarbital
18	104	104	O	,
19	106	108	O	the
20	110	115	O	dosage
21	117	118	O	of
22	120	126	U-DYN	ouabain
23	128	133	O	needed
24	135	136	O	to
25	138	142	O	cause
26	144	154	O	ventricular
27	156	166	O	tachycardia
28	168	170	O	was
29	172	184	O	significantly
30	186	191	O	higher
31	192	192	O	,
32	194	195	O	as
33	197	199	O	was
34	201	203	O	the
35	205	208	O	LD50
36	210	211	O	of
37	213	219	U-UNK	ouabain
38	220	220	O	,
39	222	225	O	with
40	227	234	U-UNK	ketamine
41	236	237	O	or
42	239	245	O	XXXXXXXX
43	247	250	O	than
44	252	255	O	with
45	257	269	U-UNK	pentobarbital
NULL

1167743.xml	DDI-MedLine.d23.s2	NO_SECTION	NO_SETID	30
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
1	0	10	O	Ventricular
2	12	22	O	tachycardia
3	24	30	O	induced
4	32	33	O	by
5	35	41	U-DYN	ouabain
6	43	45	O	was
7	47	55	O	generally
8	57	65	O	converted
9	67	68	O	to
10	70	74	O	sinus
11	76	81	O	rhythm
12	83	91	O	following
13	93	106	O	administration
14	108	109	O	of
15	111	117	O	XXXXXXXX
16	118	118	O	,
17	120	127	U-UNK	ketamine
18	128	128	O	,
19	130	131	O	or
20	133	142	U-UNK	droperidol
21	144	146	O	but
22	148	150	O	not
23	152	156	O	after
24	158	171	O	administration
25	173	174	O	of
26	176	182	U-UNK	fentayl
27	184	188	O	alone
28	190	191	O	or
29	193	197	O	after
30	199	211	U-UNK	pentobarbital
NULL

1167797.xml	DDI-MedLine.d138.s0	NO_SECTION	NO_SETID	22
Interaction between oxytocin and antidiuretic hormone and its effect on the milk secretion by alveoli of the mammary gland of lactating rats.
1	0	10	O	Interaction
2	12	18	O	between
3	20	27	U-UNK	oxytocin
4	29	31	O	and
5	33	44	O	antidiuretic
6	46	52	O	hormone
7	54	56	O	and
8	58	60	O	its
9	62	67	O	effect
10	69	70	O	on
11	72	74	O	the
12	76	79	O	milk
13	81	89	O	secretion
14	91	92	O	by
15	94	100	O	alveoli
16	102	103	O	of
17	105	107	O	the
18	109	115	O	mammary
19	117	121	O	gland
20	123	124	O	of
21	126	134	O	lactating
22	136	139	O	rats
NULL

1167797.xml	DDI-MedLine.d138.s1	NO_SECTION	NO_SETID	27
Interaction between exogenous and endogenous oxytocin and vasopressin was found to affect the mechanism of milk ejection by the alveoli of the mammary gland in lactating rats.
1	0	10	O	Interaction
2	12	18	O	between
3	20	28	O	exogenous
4	30	32	O	and
5	34	43	O	endogenous
6	45	52	U-UNK	oxytocin
7	54	56	O	and
8	58	68	O	vasopressin
9	70	72	O	was
10	74	78	O	found
11	80	81	O	to
12	83	88	O	affect
13	90	92	O	the
14	94	102	O	mechanism
15	104	105	O	of
16	107	110	O	milk
17	112	119	O	ejection
18	121	122	O	by
19	124	126	O	the
20	128	134	O	alveoli
21	136	137	O	of
22	139	141	O	the
23	143	149	O	mammary
24	151	155	O	gland
25	157	158	O	in
26	160	168	O	lactating
27	170	173	O	rats
NULL

1167797.xml	DDI-MedLine.d138.s2	NO_SECTION	NO_SETID	15
Inhibition and stimulation of the effect of oxytocin on milk ejection by vasopressin was demonstrated.
1	0	9	O	Inhibition
2	11	13	O	and
3	15	25	O	stimulation
4	27	28	O	of
5	30	32	O	the
6	34	39	O	effect
7	41	42	O	of
8	44	51	U-UNK	oxytocin
9	53	54	O	on
10	56	59	O	milk
11	61	68	O	ejection
12	70	71	O	by
13	73	83	O	vasopressin
14	85	87	O	was
15	89	100	O	demonstrated
NULL

1167797.xml	DDI-MedLine.d138.s3	NO_SECTION	NO_SETID	30
On the basis of the principles observed the concentrations fo these hormones were investigated in the plasma of dogs deprived of water for 3 days and then allowed to drink.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	18	O	the
6	20	29	O	principles
7	31	38	O	observed
8	40	42	O	the
9	44	57	O	concentrations
10	59	60	O	fo
11	62	66	O	these
12	68	75	O	hormones
13	77	80	O	were
14	82	93	O	investigated
15	95	96	O	in
16	98	100	O	the
17	102	107	O	plasma
18	109	110	O	of
19	112	115	O	dogs
20	117	124	O	deprived
21	126	127	O	of
22	129	133	O	water
23	135	137	O	for
24	139	139	O	3
25	141	144	O	days
26	146	148	O	and
27	150	153	O	then
28	155	161	O	allowed
29	163	164	O	to
30	166	170	O	drink
NULL

15825309.xml	DDI-MedLine.d49.s0	NO_SECTION	NO_SETID	7
Interaction of clindamycin and gentamicin in vitro.
1	0	10	O	Interaction
2	12	13	O	of
3	15	25	U-UNK	clindamycin
4	27	29	O	and
5	31	40	U-UNK	gentamicin
6	42	43	O	in
7	45	49	O	vitro
NULL

15825309.xml	DDI-MedLine.d49.s1	NO_SECTION	NO_SETID	28
The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates.
1	0	2	O	The
2	4	10	O	minimal
3	12	21	O	inhibitory
4	23	36	O	concentrations
5	38	39	O	of
6	41	51	U-UNK	clindamycin
7	53	55	O	and
8	57	66	U-UNK	gentamicin
9	68	72	O	alone
10	74	76	O	and
11	78	79	O	in
12	81	92	O	combinations
13	94	97	O	were
14	99	108	O	determined
15	110	111	O	by
16	113	113	O	a
17	115	127	O	microdilution
18	129	134	O	method
19	136	138	O	for
20	140	142	O	163
21	144	150	O	aerobic
22	151	151	O	,
23	153	163	O	facultative
24	164	164	O	,
25	166	168	O	and
26	170	178	O	anaerobic
27	180	187	O	clinical
28	189	196	O	isolates
NULL

15825309.xml	DDI-MedLine.d49.s2	NO_SECTION	NO_SETID	33
All 77 strains of Staphylococcus aureus, Diplococcus pneumoniae, Streptococcus pyogenes, and anaerobic bacteria (except for three strains of Clostridium) were inhibited by 1.6 mug or less of clindamycin per ml.
1	0	2	O	All
2	4	5	O	77
3	7	13	O	strains
4	15	16	O	of
5	18	31	O	Staphylococcus
6	33	38	O	aureus
7	39	39	O	,
8	41	51	O	Diplococcus
9	53	62	O	pneumoniae
10	63	63	O	,
11	65	77	O	Streptococcus
12	79	86	O	pyogenes
13	87	87	O	,
14	89	91	O	and
15	93	101	O	anaerobic
16	103	110	O	bacteria
17	113	118	O	except
18	120	122	O	for
19	124	128	O	three
20	130	136	O	strains
21	138	139	O	of
22	141	151	O	Clostridium
23	154	157	O	were
24	159	167	O	inhibited
25	169	170	O	by
26	172	174	O	1.6
27	176	178	O	mug
28	180	181	O	or
29	183	186	O	less
30	188	189	O	of
31	191	201	U-UNK	clindamycin
32	203	205	O	per
33	207	208	O	ml
NULL

15825309.xml	DDI-MedLine.d49.s3	NO_SECTION	NO_SETID	21
Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml);
1	0	9	U-UNK	Gentamicin
2	11	13	O	did
3	15	17	O	not
4	19	27	O	interfere
5	29	32	O	with
6	34	36	O	the
7	38	45	O	activity
8	47	48	O	of
9	50	60	U-UNK	clindamycin
10	62	67	O	within
11	69	71	O	the
12	73	77	O	range
13	79	80	O	of
14	82	95	O	concentrations
15	97	102	O	tested
16	105	107	O	0.1
17	109	110	O	to
18	112	114	O	100
19	116	118	O	mug
20	119	119	O	/
21	120	121	O	ml
NULL

15825309.xml	DDI-MedLine.d49.s4	NO_SECTION	NO_SETID	6
for some strains combinations were synergistic.
1	0	2	O	for
2	4	7	O	some
3	9	15	O	strains
4	17	28	O	combinations
5	30	33	O	were
6	35	45	O	synergistic
NULL

15825309.xml	DDI-MedLine.d49.s5	NO_SECTION	NO_SETID	22
Sixty-two (94%) of 66 strains of Enterobacteriaceae and Pseudomonas aeruginosa were inhibited by 6.2 mug or less of gentamicin per ml.
1	0	4	O	Sixty
2	6	8	O	two
3	11	13	O	94%
4	16	17	O	of
5	19	20	O	66
6	22	28	O	strains
7	30	31	O	of
8	33	50	O	Enterobacteriaceae
9	52	54	O	and
10	56	66	O	Pseudomonas
11	68	77	O	aeruginosa
12	79	82	O	were
13	84	92	O	inhibited
14	94	95	O	by
15	97	99	O	6.2
16	101	103	O	mug
17	105	106	O	or
18	108	111	O	less
19	113	114	O	of
20	116	125	U-UNK	gentamicin
21	127	129	O	per
22	131	132	O	ml
NULL

15825309.xml	DDI-MedLine.d49.s6	NO_SECTION	NO_SETID	15
Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
1	0	11	O	Combinations
2	13	14	O	of
3	16	26	U-UNK	clindamycin
4	28	30	O	and
5	32	41	U-UNK	gentamicin
6	43	46	O	were
7	48	58	O	indifferent
8	60	62	O	for
9	64	65	O	29
10	67	73	O	strains
11	75	77	O	and
12	79	89	O	synergistic
13	91	93	O	for
14	95	96	O	33
15	98	104	O	strains
NULL

15825309.xml	DDI-MedLine.d49.s7	NO_SECTION	NO_SETID	48
All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml).
1	0	2	O	All
2	4	5	O	20
3	7	13	O	strains
4	15	16	O	of
5	18	29	O	enterococcus
6	30	30	O	,
7	32	36	O	three
8	38	44	O	strains
9	46	47	O	of
10	49	59	O	Clostridium
11	60	60	O	,
12	62	66	O	three
13	68	74	O	strains
14	76	77	O	of
15	79	89	O	Escherichia
16	91	94	O	coli
17	95	95	O	,
18	97	99	O	and
19	101	103	O	one
20	105	110	O	strain
21	112	113	O	of
22	115	121	O	Proteus
23	123	130	O	rettgeri
24	132	135	O	were
25	137	145	O	resistant
26	147	148	O	to
27	150	153	O	both
28	155	165	U-UNK	clindamycin
29	168	174	O	minimal
30	176	185	O	inhibitory
31	187	199	O	concentration
32	201	207	O	greater
33	209	212	O	than
34	214	216	O	3.1
35	218	220	O	mug
36	221	221	O	/
37	222	223	O	ml
38	226	228	O	and
39	230	239	U-UNK	gentamicin
40	242	248	O	minimal
41	250	259	O	inhibitory
42	261	273	O	concentration
43	275	281	O	greater
44	283	286	O	than
45	288	290	O	6.2
46	292	294	O	mug
47	295	295	O	/
48	296	297	O	ml
NULL

15825309.xml	DDI-MedLine.d49.s8	NO_SECTION	NO_SETID	17
Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
1	0	11	O	Combinations
2	13	14	O	of
3	16	26	U-UNK	clindamycin
4	28	30	O	and
5	32	41	U-UNK	gentamicin
6	43	46	O	were
7	48	58	O	indifferent
8	60	62	O	for
9	64	65	O	16
10	67	69	O	and
11	71	81	O	synergistic
12	83	85	O	for
13	87	88	O	11
14	90	91	O	of
15	93	95	O	the
16	97	105	O	resistant
17	107	113	O	strains
NULL

15825309.xml	DDI-MedLine.d49.s9	NO_SECTION	NO_SETID	25
Except for clindamycin-sensitive isolates, synergy was usually observed only at concentrations of one or both drugs which are not readily obtainable in vivo.
1	0	5	O	Except
2	7	9	O	for
3	11	21	U-UNK	clindamycin
4	23	31	O	sensitive
5	33	40	O	isolates
6	41	41	O	,
7	43	49	O	synergy
8	51	53	O	was
9	55	61	O	usually
10	63	70	O	observed
11	72	75	O	only
12	77	78	O	at
13	80	93	O	concentrations
14	95	96	O	of
15	98	100	O	one
16	102	103	O	or
17	105	108	O	both
18	110	114	O	drugs
19	116	120	O	which
20	122	124	O	are
21	126	128	O	not
22	130	136	O	readily
23	138	147	O	obtainable
24	149	150	O	in
25	152	155	O	vivo
NULL

15825309.xml	DDI-MedLine.d49.s10	NO_SECTION	NO_SETID	4
Antagonism was never observed.
1	0	9	O	Antagonism
2	11	13	O	was
3	15	19	O	never
4	21	28	O	observed
NULL

15825391.xml	DDI-MedLine.d120.s0	NO_SECTION	NO_SETID	16
Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.
1	0	8	O	Molecular
2	10	14	O	basis
3	16	18	O	for
4	20	22	O	the
5	24	32	O	selective
6	34	41	O	toxicity
7	43	44	O	of
8	46	57	B-UNK	amphotericin
9	59	59	L-UNK	B
10	61	63	O	for
11	65	69	O	yeast
12	71	73	O	and
13	75	81	U-UNK	filipin
14	83	85	O	for
15	87	92	O	animal
16	94	98	O	cells
NULL

15825391.xml	DDI-MedLine.d120.s1	NO_SECTION	NO_SETID	18
Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic;
1	0	4	O	Among
2	6	8	O	the
3	10	16	B-UNK	polyene
4	18	28	L-UNK	antibiotics
5	29	29	O	,
6	31	34	O	many
7	35	35	O	,
8	37	40	O	like
9	42	48	U-UNK	filipin
10	49	49	O	,
11	51	56	O	cannot
12	58	59	O	be
13	61	64	O	used
14	66	75	O	clinically
15	77	83	O	because
16	85	88	O	they
17	90	92	O	are
18	94	98	O	toxic
NULL

15825391.xml	DDI-MedLine.d120.s2	NO_SECTION	NO_SETID	18
amphotericin B, however, is useful in therapy of human fungal infections because it is less toxic.
1	0	11	B-UNK	amphotericin
2	13	13	L-UNK	B
3	14	14	O	,
4	16	22	O	however
5	23	23	O	,
6	25	26	O	is
7	28	33	O	useful
8	35	36	O	in
9	38	44	O	therapy
10	46	47	O	of
11	49	53	O	human
12	55	60	O	fungal
13	62	71	O	infections
14	73	79	O	because
15	81	82	O	it
16	84	85	O	is
17	87	90	O	less
18	92	96	O	toxic
NULL

15825391.xml	DDI-MedLine.d120.s3	NO_SECTION	NO_SETID	35
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;
1	0	3	O	Both
2	5	7	O	the
3	9	16	O	toxicity
4	18	19	O	of
5	21	27	U-UNK	filipin
6	29	31	O	and
7	33	35	O	the
8	37	47	O	therapeutic
9	49	53	O	value
10	55	56	O	of
11	58	69	B-UNK	amphotericin
12	71	71	L-UNK	B
13	73	75	O	can
14	77	78	O	be
15	80	91	O	rationalized
16	93	94	O	at
17	96	98	O	the
18	100	107	O	cellular
19	109	111	O	and
20	113	121	O	molecular
21	123	127	O	level
22	129	130	O	by
23	132	134	O	the
24	136	144	O	following
25	146	157	O	observations
26	158	158	O	:
27	161	161	O	i
28	164	168	O	these
29	170	176	B-UNK	polyene
30	178	188	L-UNK	antibiotics
31	190	195	O	showed
32	197	208	O	differential
33	210	216	O	effects
34	218	219	O	on
35	221	225	O	cells
NULL

15825391.xml	DDI-MedLine.d120.s4	NO_SECTION	NO_SETID	22
filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth;
1	0	6	U-UNK	filipin
2	8	10	O	was
3	12	15	O	more
4	17	22	O	potent
5	24	25	O	in
6	27	32	O	lysing
7	34	38	O	human
8	40	42	O	red
9	44	48	O	blood
10	50	54	O	cells
11	55	55	O	,
12	57	63	O	whereas
13	65	76	B-UNK	amphotericin
14	78	78	L-UNK	B
15	80	82	O	was
16	84	87	O	more
17	89	94	O	potent
18	96	97	O	in
19	99	108	O	inhibiting
20	110	114	O	yeast
21	116	119	O	cell
22	121	126	O	growth
NULL

15825391.xml	DDI-MedLine.d120.s5	NO_SECTION	NO_SETID	41
and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.
1	0	2	O	and
2	5	6	O	ii
3	9	11	O	the
4	13	19	O	effects
5	21	22	O	of
6	24	30	U-UNK	filipin
7	32	35	O	were
8	37	40	O	more
9	42	52	O	efficiently
10	54	62	O	inhibited
11	64	65	O	by
12	67	71	O	added
13	73	83	O	cholesterol
14	84	84	O	,
15	86	88	O	the
16	90	94	O	major
17	96	103	O	membrane
18	105	110	O	sterol
19	112	113	O	in
20	115	119	O	human
21	121	125	O	cells
22	126	126	O	,
23	128	134	O	whereas
24	136	138	O	the
25	140	146	O	effects
26	148	149	O	of
27	151	162	B-UNK	amphotericin
28	164	164	L-UNK	B
29	166	169	O	were
30	171	174	O	more
31	176	186	O	efficiently
32	188	196	O	inhibited
33	198	199	O	by
34	201	210	O	ergosterol
35	211	211	O	,
36	213	215	O	the
37	217	221	O	major
38	223	230	O	membrane
39	232	237	O	sterol
40	239	240	O	in
41	242	246	O	yeast
NULL

15825391.xml	DDI-MedLine.d120.s6	NO_SECTION	NO_SETID	24
The simplest inference is that the toxicity and effectiveness of polyenes are determined by their relative avidities for the predominant sterol in cell membranes.
1	0	2	O	The
2	4	11	O	simplest
3	13	21	O	inference
4	23	24	O	is
5	26	29	O	that
6	31	33	O	the
7	35	42	O	toxicity
8	44	46	O	and
9	48	60	O	effectiveness
10	62	63	O	of
11	65	72	O	polyenes
12	74	76	O	are
13	78	87	O	determined
14	89	90	O	by
15	92	96	O	their
16	98	105	O	relative
17	107	115	O	avidities
18	117	119	O	for
19	121	123	O	the
20	125	135	O	predominant
21	137	142	O	sterol
22	144	145	O	in
23	147	150	O	cell
24	152	160	O	membranes
NULL

15825399.xml	DDI-MedLine.d40.s0	NO_SECTION	NO_SETID	20
Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
1	0	6	O	Studies
2	8	9	O	on
3	11	13	O	the
4	15	23	O	mechanism
5	25	26	O	of
6	28	33	O	action
7	35	36	O	of
8	38	47	U-UNK	miconazole
9	48	48	O	:
10	50	55	O	effect
11	57	58	O	of
12	60	69	U-UNK	miconazole
13	71	72	O	on
14	74	84	O	respiration
15	86	88	O	and
16	90	93	O	cell
17	95	106	O	permeability
18	108	109	O	of
19	111	117	O	Candida
20	119	126	O	albicans
NULL

15825399.xml	DDI-MedLine.d40.s1	NO_SECTION	NO_SETID	15
The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida.
1	0	2	O	The
2	4	13	B-UNK	antifungal
3	15	18	L-UNK	drug
4	19	19	O	,
5	21	30	B-UNK	miconazole
6	32	38	L-UNK	nitrate
7	39	39	O	,
8	41	48	O	inhibits
9	50	52	O	the
10	54	59	O	growth
11	61	62	O	of
12	64	70	O	several
13	72	78	O	species
14	80	81	O	of
15	83	89	O	Candida
NULL

15825399.xml	DDI-MedLine.d40.s2	NO_SECTION	NO_SETID	21
Candida albicans, one of the pathogenic species, was totally inhibited at a concentration of approximately 10 mug/ml.
1	0	6	O	Candida
2	8	15	O	albicans
3	16	16	O	,
4	18	20	O	one
5	22	23	O	of
6	25	27	O	the
7	29	38	O	pathogenic
8	40	46	O	species
9	47	47	O	,
10	49	51	O	was
11	53	59	O	totally
12	61	69	O	inhibited
13	71	72	O	at
14	74	74	O	a
15	76	88	O	concentration
16	90	91	O	of
17	93	105	O	approximately
18	107	108	O	10
19	110	112	O	mug
20	113	113	O	/
21	114	115	O	ml
NULL

15825399.xml	DDI-MedLine.d40.s3	NO_SECTION	NO_SETID	31
Endogenous respiration was unaffected by the drug at a concentration as high as 100 mug/ml, whereas exogenous respiration was markedly sensitive and inhibited to an extent of 85%.
1	0	9	O	Endogenous
2	11	21	O	respiration
3	23	25	O	was
4	27	36	O	unaffected
5	38	39	O	by
6	41	43	O	the
7	45	48	O	drug
8	50	51	O	at
9	53	53	O	a
10	55	67	O	concentration
11	69	70	O	as
12	72	75	O	high
13	77	78	O	as
14	80	82	O	100
15	84	86	O	mug
16	87	87	O	/
17	88	89	O	ml
18	90	90	O	,
19	92	98	O	whereas
20	100	108	O	exogenous
21	110	120	O	respiration
22	122	124	O	was
23	126	133	O	markedly
24	135	143	O	sensitive
25	145	147	O	and
26	149	157	O	inhibited
27	159	160	O	to
28	162	163	O	an
29	165	170	O	extent
30	172	173	O	of
31	175	177	O	85%
NULL

15825399.xml	DDI-MedLine.d40.s4	NO_SECTION	NO_SETID	27
The permeability of the cell membrane was changed as evidenced by the leakage of 260-nm absorbing materials, amino acids, proteins, and inorganic cations.
1	0	2	O	The
2	4	15	O	permeability
3	17	18	O	of
4	20	22	O	the
5	24	27	O	cell
6	29	36	O	membrane
7	38	40	O	was
8	42	48	O	changed
9	50	51	O	as
10	53	61	O	evidenced
11	63	64	O	by
12	66	68	O	the
13	70	76	O	leakage
14	78	79	O	of
15	81	83	O	260
16	85	86	O	nm
17	88	96	O	absorbing
18	98	106	O	materials
19	107	107	O	,
20	109	113	O	amino
21	115	119	O	acids
22	120	120	O	,
23	122	129	O	proteins
24	130	130	O	,
25	132	134	O	and
26	136	144	O	inorganic
27	146	152	O	cations
NULL

15825399.xml	DDI-MedLine.d40.s5	NO_SECTION	NO_SETID	24
The results we present clearly show that the drug alters the cellular permeability, and thus the exogenous respiration becomes sensitive to the drug.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	we
4	15	21	O	present
5	23	29	O	clearly
6	31	34	O	show
7	36	39	O	that
8	41	43	O	the
9	45	48	O	drug
10	50	55	O	alters
11	57	59	O	the
12	61	68	O	cellular
13	70	81	O	permeability
14	82	82	O	,
15	84	86	O	and
16	88	91	O	thus
17	93	95	O	the
18	97	105	O	exogenous
19	107	117	O	respiration
20	119	125	O	becomes
21	127	135	O	sensitive
22	137	138	O	to
23	140	142	O	the
24	144	147	O	drug
NULL

15830476.xml	DDI-MedLine.d29.s0	NO_SECTION	NO_SETID	13
Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
1	0	5	O	Effect
2	7	8	O	of
3	10	19	U-UNK	probenecid
4	21	22	O	on
5	24	26	O	the
6	28	35	O	apparent
7	37	42	O	volume
8	44	45	O	of
9	47	58	O	distribution
10	60	62	O	and
11	64	74	O	elimination
12	76	77	O	of
13	79	89	U-UNK	cloxacillin
NULL

15830476.xml	DDI-MedLine.d29.s1	NO_SECTION	NO_SETID	5
According to Gibaldi et al.
1	0	8	O	According
2	10	11	O	to
3	13	19	O	Gibaldi
4	21	22	O	et
5	24	25	O	al
NULL

15830476.xml	DDI-MedLine.d29.s2	NO_SECTION	NO_SETID	34
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
1	1	4	O	1968
2	5	5	O	,
3	7	10	O	1970
4	12	12	O	,
5	14	16	O	the
6	18	23	O	higher
7	25	29	O	serum
8	31	44	O	concentrations
9	46	47	O	of
10	49	59	U-UNK	penicillins
11	61	63	O	and
12	65	77	U-UNK	cephaloridine
13	79	85	O	reached
14	87	91	O	after
15	93	106	O	administration
16	108	109	O	of
17	111	120	U-UNK	probenecid
18	122	124	O	are
19	126	128	O	due
20	130	132	O	not
21	134	137	O	only
22	139	140	O	to
23	142	147	O	slower
24	149	153	O	renal
25	155	165	O	elimination
26	167	169	O	but
27	171	174	O	also
28	176	177	O	to
29	179	180	O	an
30	182	188	O	altered
31	190	201	O	distribution
32	203	204	O	in
33	206	208	O	the
34	210	213	O	body
NULL

15830476.xml	DDI-MedLine.d29.s3	NO_SECTION	NO_SETID	46
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.
1	0	1	O	To
2	3	11	O	determine
3	13	19	O	whether
4	21	30	U-UNK	probenecid
5	32	34	O	has
6	36	36	O	a
7	38	43	O	direct
8	45	50	O	effect
9	52	53	O	on
10	55	57	O	the
11	59	70	O	distribution
12	72	73	O	of
13	75	85	U-UNK	cloxacillin
14	86	86	O	,
15	88	90	O	the
16	92	102	O	elimination
17	104	106	O	and
18	108	119	O	distribution
19	121	122	O	of
20	124	134	U-UNK	cloxacillin
21	136	138	O	was
22	140	146	O	studied
23	148	149	O	in
24	151	153	O	six
25	155	162	O	patients
26	163	163	O	,
27	165	168	O	five
28	170	176	O	lacking
29	178	183	O	kidney
30	185	192	O	function
31	194	196	O	and
32	198	200	O	one
33	202	205	O	with
34	207	207	O	a
35	209	217	O	partially
36	219	226	O	impaired
37	228	232	O	renal
38	234	241	O	function
39	242	242	O	,
40	244	245	O	in
41	247	249	O	the
42	251	258	O	presence
43	260	261	O	or
44	263	269	O	absence
45	271	272	O	of
46	274	283	U-UNK	probenecid
NULL

15830476.xml	DDI-MedLine.d29.s4	NO_SECTION	NO_SETID	26
No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively).
1	0	1	O	No
2	3	13	O	significant
3	15	24	O	difference
4	26	28	O	was
5	30	34	O	found
6	36	42	O	between
7	44	46	O	the
8	48	51	O	mean
9	53	58	O	values
10	60	61	O	of
11	63	65	O	the
12	67	72	O	volume
13	74	75	O	of
14	77	88	O	distribution
15	90	91	O	of
16	93	103	U-UNK	cloxacillin
17	105	108	O	with
18	110	112	O	and
19	114	120	O	without
20	122	131	U-UNK	probenecid
21	134	137	O	13.0
22	139	141	O	and
23	143	146	O	12.6
24	148	153	O	liters
25	154	154	O	,
26	156	167	O	respectively
NULL

15830476.xml	DDI-MedLine.d29.s5	NO_SECTION	NO_SETID	8
Thus, the hypothesis of Gibaldi et al.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	19	O	hypothesis
5	21	22	O	of
6	24	30	O	Gibaldi
7	32	33	O	et
8	35	36	O	al
NULL

15830476.xml	DDI-MedLine.d29.s6	NO_SECTION	NO_SETID	11
could not be confirmed for cloxacillin in patients lacking kidney function.
1	0	4	O	could
2	6	8	O	not
3	10	11	O	be
4	13	21	O	confirmed
5	23	25	O	for
6	27	37	U-UNK	cloxacillin
7	39	40	O	in
8	42	49	O	patients
9	51	57	O	lacking
10	59	64	O	kidney
11	66	73	O	function
NULL

15830476.xml	DDI-MedLine.d29.s7	NO_SECTION	NO_SETID	30
In spite of the absence of kidney function, the value of the elimination rate constant was significantly decreased in the presence of probenecid (from 0.326 to 0.263/h).
1	0	1	O	In
2	3	7	O	spite
3	9	10	O	of
4	12	14	O	the
5	16	22	O	absence
6	24	25	O	of
7	27	32	O	kidney
8	34	41	O	function
9	42	42	O	,
10	44	46	O	the
11	48	52	O	value
12	54	55	O	of
13	57	59	O	the
14	61	71	O	elimination
15	73	76	O	rate
16	78	85	O	constant
17	87	89	O	was
18	91	103	O	significantly
19	105	113	O	decreased
20	115	116	O	in
21	118	120	O	the
22	122	129	O	presence
23	131	132	O	of
24	134	143	U-UNK	probenecid
25	146	149	O	from
26	151	155	O	0.326
27	157	158	O	to
28	160	164	O	0.263
29	165	165	O	/
30	166	166	O	h
NULL

15830476.xml	DDI-MedLine.d29.s8	NO_SECTION	NO_SETID	17
This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
1	0	3	O	This
2	5	9	O	might
3	11	12	O	be
4	14	22	O	explained
5	24	25	O	by
6	27	27	O	a
7	29	36	O	blockade
8	38	39	O	by
9	41	50	U-UNK	probenecid
10	52	53	O	of
11	55	57	O	the
12	59	69	O	elimination
13	71	72	O	of
14	74	84	U-UNK	cloxacillin
15	86	87	O	by
16	89	91	O	the
17	93	97	O	liver
NULL

15986716.xml	DDI-MedLine.d122.s0	NO_SECTION	NO_SETID	9
Behavioral mechanisms underlying the link between smoking and drinking.
1	0	9	O	Behavioral
2	11	20	O	mechanisms
3	22	31	O	underlying
4	33	35	O	the
5	37	40	O	link
6	42	48	O	between
7	50	56	O	smoking
8	58	60	O	and
9	62	69	O	drinking
NULL

15986716.xml	DDI-MedLine.d122.s1	NO_SECTION	NO_SETID	14
Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products).
1	0	3	O	Many
2	5	10	O	people
3	12	14	O	use
4	16	19	O	both
5	21	27	U-UNK	alcohol
6	29	31	O	and
7	33	40	U-UNK	nicotine
8	43	45	O	i.e
9	47	47	O	,
10	49	58	O	cigarettes
11	60	62	O	and
12	64	68	O	other
13	70	76	O	tobacco
14	78	85	O	products
NULL

15986716.xml	DDI-MedLine.d122.s2	NO_SECTION	NO_SETID	34
The behavioral effects of these two drugs differ, and they do not act on the same target sites in the brain, although they may share, or partly share, certain properties.
1	0	2	O	The
2	4	13	O	behavioral
3	15	21	O	effects
4	23	24	O	of
5	26	30	O	these
6	32	34	O	two
7	36	40	O	drugs
8	42	47	O	differ
9	48	48	O	,
10	50	52	O	and
11	54	57	O	they
12	59	60	O	do
13	62	64	O	not
14	66	68	O	act
15	70	71	O	on
16	73	75	O	the
17	77	80	O	same
18	82	87	O	target
19	89	93	O	sites
20	95	96	O	in
21	98	100	O	the
22	102	106	O	brain
23	107	107	O	,
24	109	116	O	although
25	118	121	O	they
26	123	125	O	may
27	127	131	O	share
28	132	132	O	,
29	134	135	O	or
30	137	142	O	partly
31	144	148	O	share
32	149	149	O	,
33	151	157	O	certain
34	159	168	O	properties
NULL

15986716.xml	DDI-MedLine.d122.s3	NO_SECTION	NO_SETID	24
The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.
1	0	2	O	The
2	4	13	O	initiation
3	15	16	O	of
4	18	24	U-UNK	alcohol
5	26	27	O	or
6	29	36	U-UNK	nicotine
7	38	40	O	use
8	42	44	O	may
9	46	47	O	be
10	49	60	O	precipitated
11	62	63	O	by
12	65	71	O	similar
13	73	83	O	personality
14	85	99	O	characteristics
15	101	102	O	in
16	104	106	O	the
17	108	111	O	user
18	112	112	O	,
19	114	117	O	such
20	119	120	O	as
21	122	132	O	impulsivity
22	134	136	O	and
23	138	146	O	sensation
24	148	154	O	seeking
NULL

15986716.xml	DDI-MedLine.d122.s4	NO_SECTION	NO_SETID	16
Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine.
1	0	7	O	Moreover
2	8	8	O	,
3	10	12	O	the
4	14	23	O	mechanisms
5	25	34	O	underlying
6	36	38	O	the
7	40	50	O	development
8	52	53	O	of
9	55	64	O	dependence
10	66	68	O	may
11	70	71	O	be
12	73	79	O	similar
13	81	83	O	for
14	85	91	U-UNK	alcohol
15	93	95	O	and
16	97	104	U-UNK	nicotine
NULL

15986716.xml	DDI-MedLine.d122.s5	NO_SECTION	NO_SETID	29
Thus, certain factors, such as reinforcing drug effects, conditioning processes, automatic behavior, and stress, may influence the development of dependence on both drugs.
1	0	3	O	Thus
2	4	4	O	,
3	6	12	O	certain
4	14	20	O	factors
5	21	21	O	,
6	23	26	O	such
7	28	29	O	as
8	31	41	O	reinforcing
9	43	46	O	drug
10	48	54	O	effects
11	55	55	O	,
12	57	68	O	conditioning
13	70	78	O	processes
14	79	79	O	,
15	81	89	O	automatic
16	91	98	O	behavior
17	99	99	O	,
18	101	103	O	and
19	105	110	O	stress
20	111	111	O	,
21	113	115	O	may
22	117	125	O	influence
23	127	129	O	the
24	131	141	O	development
25	143	144	O	of
26	146	155	O	dependence
27	157	158	O	on
28	160	163	O	both
29	165	169	O	drugs
NULL

15986716.xml	DDI-MedLine.d122.s6	NO_SECTION	NO_SETID	24
Other factors, such as tolerance and sensitization to the drugs' actions and the development of withdrawal symptoms, may also contribute to dependence.
1	0	4	O	Other
2	6	12	O	factors
3	13	13	O	,
4	15	18	O	such
5	20	21	O	as
6	23	31	O	tolerance
7	33	35	O	and
8	37	49	O	sensitization
9	51	52	O	to
10	54	56	O	the
11	58	63	O	drugs'
12	65	71	O	actions
13	73	75	O	and
14	77	79	O	the
15	81	91	O	development
16	93	94	O	of
17	96	105	O	withdrawal
18	107	114	O	symptoms
19	115	115	O	,
20	117	119	O	may
21	121	124	O	also
22	126	135	O	contribute
23	137	138	O	to
24	140	149	O	dependence
NULL

15986716.xml	DDI-MedLine.d122.s7	NO_SECTION	NO_SETID	30
This review discusses the actions of the two drugs on certain brain chemical (i.e., neurotransmitter) systems and the extent to which the effects of the two drugs may interact.
1	0	3	O	This
2	5	10	O	review
3	12	20	O	discusses
4	22	24	O	the
5	26	32	O	actions
6	34	35	O	of
7	37	39	O	the
8	41	43	O	two
9	45	49	O	drugs
10	51	52	O	on
11	54	60	O	certain
12	62	66	O	brain
13	68	75	O	chemical
14	78	80	O	i.e
15	82	82	O	,
16	84	99	O	neurotransmitter
17	102	108	O	systems
18	110	112	O	and
19	114	116	O	the
20	118	123	O	extent
21	125	126	O	to
22	128	132	O	which
23	134	136	O	the
24	138	144	O	effects
25	146	147	O	of
26	149	151	O	the
27	153	155	O	two
28	157	161	O	drugs
29	163	165	O	may
30	167	174	O	interact
NULL

163470.xml	DDI-MedLine.d134.s1	NO_SECTION	NO_SETID	38
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.
1	0	1	O	An
2	3	13	O	intravenous
3	15	18	O	dose
4	20	21	O	of
5	23	24	O	50
6	26	27	O	mg
7	29	39	U-UNK	perchlorate
8	41	43	O	was
9	45	46	O	in
10	48	54	O	respect
11	56	57	O	of
12	59	69	O	competitive
13	71	81	O	suppression
14	83	84	O	of
15	86	91	O	organs
16	93	100	O	actively
17	102	114	O	concentrating
18	116	128	U-UNK	pertechnetate
19	130	131	O	as
20	133	141	O	effective
21	143	144	O	as
22	146	156	O	intravenous
23	158	161	O	1000
24	163	164	O	mg
25	166	168	O	ClO
26	170	170	O	4
27	173	186	O	simultaneously
28	188	189	O	or
29	191	194	O	1000
30	196	197	O	mg
31	199	204	O	orally
32	206	207	O	30
33	209	211	O	min
34	213	218	O	before
35	220	222	O	the
36	224	232	O	injection
37	234	235	O	of
38	237	254	U-UNK	radiopertechnetate
NULL

163470.xml	DDI-MedLine.d134.s2	NO_SECTION	NO_SETID	41
An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
1	0	1	O	An
2	3	13	O	intravenous
3	15	23	O	injection
4	25	26	O	of
5	28	38	U-UNK	perchlorate
6	40	44	O	given
7	46	50	O	later
8	52	55	O	also
9	57	64	O	produces
10	66	66	O	a
11	68	75	O	complete
12	77	79	O	and
13	81	91	O	immediately
14	93	101	O	beginning
15	103	111	O	depletion
16	113	114	O	of
17	116	128	U-UNK	pertechnetate
18	130	136	O	already
19	138	148	O	accumulated
20	150	151	O	in
21	153	155	O	the
22	157	163	O	thyroid
23	164	164	O	,
24	166	171	O	within
25	173	173	O	a
26	175	180	O	period
27	182	183	O	of
28	185	187	O	195
29	189	191	O	min
30	193	197	O	after
31	199	201	O	99m
32	203	205	O	TcO
33	207	207	O	4
34	209	217	O	injection
35	219	222	O	with
36	224	224	O	a
37	226	238	O	corresponding
38	240	247	O	increase
39	249	250	O	in
40	252	256	O	blood
41	258	263	O	levels
NULL

163470.xml	DDI-MedLine.d134.s3	NO_SECTION	NO_SETID	14
20 mg result in incomplete depletion which becomes complete after a second additional dose.
1	0	1	O	20
2	3	4	O	mg
3	6	11	O	result
4	13	14	O	in
5	16	25	O	incomplete
6	27	35	O	depletion
7	37	41	O	which
8	43	49	O	becomes
9	51	58	O	complete
10	60	64	O	after
11	66	66	O	a
12	68	73	O	second
13	75	84	O	additional
14	86	89	O	dose
NULL

163470.xml	DDI-MedLine.d134.s4	NO_SECTION	NO_SETID	10
The intravenous application of perchlorate offers advantages in clinical use.
1	0	2	O	The
2	4	14	O	intravenous
3	16	26	O	application
4	28	29	O	of
5	31	41	U-UNK	perchlorate
6	43	48	O	offers
7	50	59	O	advantages
8	61	62	O	in
9	64	71	O	clinical
10	73	75	O	use
NULL

16649322.xml	DDI-MedLine.d10.s0	NO_SECTION	NO_SETID	8
Herbal remedies, nephropathies, and renal disease.
1	0	5	O	Herbal
2	7	14	O	remedies
3	15	15	O	,
4	17	29	O	nephropathies
5	30	30	O	,
6	32	34	O	and
7	36	40	O	renal
8	42	48	O	disease
NULL

16649322.xml	DDI-MedLine.d10.s1	NO_SECTION	NO_SETID	13
The use of herbal remedies is becoming increasingly popular in the United States.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	16	O	herbal
5	18	25	O	remedies
6	27	28	O	is
7	30	37	O	becoming
8	39	50	O	increasingly
9	52	58	O	popular
10	60	61	O	in
11	63	65	O	the
12	67	72	O	United
13	74	79	O	States
NULL

16649322.xml	DDI-MedLine.d10.s2	NO_SECTION	NO_SETID	14
Research has shown that herbal remedy use may be associated with acute renal failure.
1	0	7	O	Research
2	9	11	O	has
3	13	17	O	shown
4	19	22	O	that
5	24	29	O	herbal
6	31	36	O	remedy
7	38	40	O	use
8	42	44	O	may
9	46	47	O	be
10	49	58	O	associated
11	60	63	O	with
12	65	69	O	acute
13	71	75	O	renal
14	77	83	O	failure
NULL

16649322.xml	DDI-MedLine.d10.s3	NO_SECTION	NO_SETID	18
In addition, the use of herbal remedies may be detrimental for the patient with compromised renal function.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	19	O	use
6	21	22	O	of
7	24	29	O	herbal
8	31	38	O	remedies
9	40	42	O	may
10	44	45	O	be
11	47	57	O	detrimental
12	59	61	O	for
13	63	65	O	the
14	67	73	O	patient
15	75	78	O	with
16	80	90	O	compromised
17	92	96	O	renal
18	98	105	O	function
NULL

16649322.xml	DDI-MedLine.d10.s4	NO_SECTION	NO_SETID	30
Patients with renal insufficiency or renal failure may be at risk for further kidney damage as well as complications related to interactions of herbal remedies with complex renal therapy regimens.
1	0	7	O	Patients
2	9	12	O	with
3	14	18	O	renal
4	20	32	O	insufficiency
5	34	35	O	or
6	37	41	O	renal
7	43	49	O	failure
8	51	53	O	may
9	55	56	O	be
10	58	59	O	at
11	61	64	O	risk
12	66	68	O	for
13	70	76	O	further
14	78	83	O	kidney
15	85	90	O	damage
16	92	93	O	as
17	95	98	O	well
18	100	101	O	as
19	103	115	O	complications
20	117	123	O	related
21	125	126	O	to
22	128	139	O	interactions
23	141	142	O	of
24	144	149	O	herbal
25	151	158	O	remedies
26	160	163	O	with
27	165	171	O	complex
28	173	177	O	renal
29	179	185	O	therapy
30	187	194	O	regimens
NULL

16649322.xml	DDI-MedLine.d10.s5	NO_SECTION	NO_SETID	19
This article will describe the escalating use of herbal therapy and the hazards of herbal remedy use among patients.
1	0	3	O	This
2	5	11	O	article
3	13	16	O	will
4	18	25	O	describe
5	27	29	O	the
6	31	40	O	escalating
7	42	44	O	use
8	46	47	O	of
9	49	54	O	herbal
10	56	62	O	therapy
11	64	66	O	and
12	68	70	O	the
13	72	78	O	hazards
14	80	81	O	of
15	83	88	O	herbal
16	90	95	O	remedy
17	97	99	O	use
18	101	105	O	among
19	107	114	O	patients
NULL

16649344.xml	DDI-MedLine.d118.s0	NO_SECTION	NO_SETID	11
Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
1	0	8	U-UNK	Sirolimus
2	9	9	O	:
3	11	19	O	mammalian
4	21	26	O	target
5	28	29	O	of
6	31	39	U-UNK	rapamycin
7	41	49	O	inhibitor
8	51	52	O	to
9	54	60	O	prevent
10	62	67	O	kidney
11	69	77	O	rejection
NULL

16649344.xml	DDI-MedLine.d118.s1	NO_SECTION	NO_SETID	13
Current immunosuppressive therapies are effective but can be associated with significant adverse reactions.
1	0	6	O	Current
2	8	24	O	immunosuppressive
3	26	34	O	therapies
4	36	38	O	are
5	40	48	O	effective
6	50	52	O	but
7	54	56	O	can
8	58	59	O	be
9	61	70	O	associated
10	72	75	O	with
11	77	87	O	significant
12	89	95	O	adverse
13	97	105	O	reactions
NULL

16649344.xml	DDI-MedLine.d118.s2	NO_SECTION	NO_SETID	38
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.
1	0	8	U-UNK	Sirolimus
2	10	14	O	works
3	16	26	O	differently
4	28	31	O	from
5	33	35	O	the
6	37	54	U-UNK	immunosuppressants
7	56	64	O	currently
8	66	74	O	available
9	75	75	O	,
10	77	79	O	and
11	81	86	O	except
12	88	90	O	for
13	92	100	O	increased
14	102	106	O	lipid
15	108	113	O	levels
16	114	114	O	,
17	116	118	O	the
18	120	126	O	adverse
19	128	135	O	reaction
20	137	143	O	profile
21	145	146	O	of
22	148	156	U-UNK	sirolimus
23	158	161	O	does
24	163	165	O	not
25	167	172	O	appear
26	174	175	O	to
27	177	183	O	overlap
28	185	186	O	to
29	188	190	O	any
30	192	196	O	great
31	198	203	O	extent
32	205	208	O	with
33	210	213	O	that
34	215	224	O	associated
35	226	229	O	with
36	231	242	U-UNK	cyclosporine
37	244	245	O	or
38	247	256	U-UNK	tacrolimus
NULL

16649344.xml	DDI-MedLine.d118.s3	NO_SECTION	NO_SETID	51
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
1	0	4	O	While
2	6	15	O	additional
3	17	24	O	research
4	26	27	O	is
5	29	34	O	needed
6	35	35	O	,
7	37	39	O	the
8	41	47	O	initial
9	49	56	O	clinical
10	58	61	O	data
11	63	64	O	in
12	66	71	O	kidney
13	73	82	O	recipients
14	84	90	O	suggest
15	92	95	O	that
16	97	105	U-UNK	sirolimus
17	106	106	O	,
18	108	109	O	in
19	111	121	O	combination
20	123	126	O	with
21	128	139	U-UNK	cyclosporine
22	141	142	O	or
23	144	153	U-UNK	tacrolimus
24	154	154	O	,
25	156	160	O	might
26	162	165	O	have
27	167	169	O	the
28	171	179	O	potential
29	181	182	O	to
30	184	189	O	reduce
31	191	193	O	the
32	195	203	O	frequency
33	205	206	O	of
34	208	216	O	rejection
35	218	225	O	episodes
36	226	226	O	,
37	228	233	O	permit
38	235	244	O	reductions
39	246	247	O	in
40	249	260	U-UNK	cyclosporine
41	262	263	O	or
42	265	274	U-UNK	tacrolimus
43	276	281	O	dosage
44	282	282	O	,
45	284	286	O	and
46	288	293	O	permit
47	295	301	O	steroid
48	303	312	O	withdrawal
49	315	319	O	Kelly
50	320	320	O	,
51	322	325	O	1999
NULL

17894105.xml	DDI-MedLine.d88.s0	NO_SECTION	NO_SETID	18
The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	30	U-UNK	chlordiazepoxide
5	31	31	O	,
6	33	43	U-UNK	amphetamine
7	45	47	O	and
8	49	55	U-UNK	cocaine
9	57	58	O	on
10	60	62	O	bar
11	64	68	O	press
12	70	77	O	behavior
13	79	80	O	in
14	82	87	O	normal
15	89	91	O	and
16	93	103	O	genetically
17	105	111	O	nervous
18	113	116	O	dogs
NULL

17894105.xml	DDI-MedLine.d88.s1	NO_SECTION	NO_SETID	24
Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in "genetically nervous"
1	0	6	O	Studies
2	8	9	O	on
3	11	13	O	two
4	15	21	O	strains
5	23	24	O	of
6	26	32	O	pointer
7	34	37	O	dogs
8	39	42	O	have
9	44	55	O	demonstrated
10	57	60	O	that
11	62	75	O	administration
12	77	78	O	of
13	80	80	O	a
14	82	95	U-UNK	benzodiazepine
15	98	113	U-UNK	chlordiazepoxide
16	116	126	O	facilitates
17	128	138	O	acquisition
18	140	141	O	of
19	143	146	O	goal
20	148	155	O	directed
21	157	164	O	behavior
22	166	167	O	in
23	169	180	O	"genetically
24	182	189	O	nervous"
NULL

17894105.xml	DDI-MedLine.d88.s3	NO_SECTION	NO_SETID	16
Continued admistration of the drug is required to maintain barpress response in this strain of dogs.
1	0	8	O	Continued
2	10	21	O	admistration
3	23	24	O	of
4	26	28	O	the
5	30	33	O	drug
6	35	36	O	is
7	38	45	O	required
8	47	48	O	to
9	50	57	O	maintain
10	59	66	O	barpress
11	68	75	O	response
12	77	78	O	in
13	80	83	O	this
14	85	90	O	strain
15	92	93	O	of
16	95	98	O	dogs
NULL

17894105.xml	DDI-MedLine.d88.s4	NO_SECTION	NO_SETID	39
The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	39	O	either
6	41	47	U-UNK	cocaine
7	49	50	O	or
8	52	62	U-UNK	amphetamine
9	63	63	O	,
10	65	73	O	compounds
11	75	79	O	which
12	81	87	O	inhibit
13	89	96	O	neuronal
14	98	105	O	reuptake
15	107	108	O	of
16	110	123	O	norepinephrine
17	124	124	O	,
18	126	133	O	disrupts
19	135	137	O	the
20	139	148	O	behavioral
21	150	157	O	response
22	159	160	O	of
23	162	164	O	the
24	166	176	O	genetically
25	178	184	O	nervous
26	186	186	O	E
27	188	193	O	strain
28	195	202	O	subjects
29	204	205	O	to
30	207	207	O	a
31	209	211	O	far
32	213	219	O	greater
33	221	226	O	extent
34	228	231	O	than
35	233	235	O	the
36	237	242	O	stable
37	244	244	O	A
38	246	251	O	strain
39	253	260	O	subjects
NULL

17894105.xml	DDI-MedLine.d88.s5	NO_SECTION	NO_SETID	53
It is also shown that after 14 days of daily administration of chlordiazepoxide, withdrawal of the drug not only re-results in almost complete loss of bar-press response in the E-strain subjects but also results in a temporary decrease in the acquired behavioral response of the stable A-strain subjects.
1	0	1	O	It
2	3	4	O	is
3	6	9	O	also
4	11	15	O	shown
5	17	20	O	that
6	22	26	O	after
7	28	29	O	14
8	31	34	O	days
9	36	37	O	of
10	39	43	O	daily
11	45	58	O	administration
12	60	61	O	of
13	63	78	U-UNK	chlordiazepoxide
14	79	79	O	,
15	81	90	O	withdrawal
16	92	93	O	of
17	95	97	O	the
18	99	102	O	drug
19	104	106	O	not
20	108	111	O	only
21	113	114	O	re
22	116	122	O	results
23	124	125	O	in
24	127	132	O	almost
25	134	141	O	complete
26	143	146	O	loss
27	148	149	O	of
28	151	153	O	bar
29	155	159	O	press
30	161	168	O	response
31	170	171	O	in
32	173	175	O	the
33	177	177	O	E
34	179	184	O	strain
35	186	193	O	subjects
36	195	197	O	but
37	199	202	O	also
38	204	210	O	results
39	212	213	O	in
40	215	215	O	a
41	217	225	O	temporary
42	227	234	O	decrease
43	236	237	O	in
44	239	241	O	the
45	243	250	O	acquired
46	252	261	O	behavioral
47	263	270	O	response
48	272	273	O	of
49	275	277	O	the
50	279	284	O	stable
51	286	286	O	A
52	288	293	O	strain
53	295	302	O	subjects
NULL

19489169.xml	DDI-MedLine.d119.s0	NO_SECTION	NO_SETID	5
Development and pharmacology of fluvastatin.
1	0	10	O	Development
2	12	14	O	and
3	16	27	O	pharmacology
4	29	30	O	of
5	32	42	U-UNK	fluvastatin
NULL

19489169.xml	DDI-MedLine.d119.s1	NO_SECTION	NO_SETID	30
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986.
1	0	10	U-UNK	Fluvastatin
2	12	13	O	is
3	15	17	O	the
4	19	23	O	first
5	25	33	B-UNK	synthetic
6	35	35	I-UNK	3
7	37	43	I-UNK	hydroxy
8	45	45	I-UNK	3
9	47	60	I-UNK	methylglutaryl
10	62	69	I-UNK	coenzyme
11	71	71	I-UNK	A
12	74	79	I-UNK	HMGCoA
13	82	90	I-UNK	reductase
14	92	100	L-UNK	inhibitor
15	102	103	O	to
16	105	106	O	be
17	108	115	O	approved
18	117	119	O	for
19	121	128	O	clinical
20	130	132	O	use
21	133	133	O	,
22	135	137	O	and
23	139	141	O	has
24	143	146	O	been
25	148	154	O	studied
26	156	166	O	extensively
27	168	169	O	in
28	171	176	O	humans
29	178	182	O	since
30	184	187	O	1986
NULL

19489169.xml	DDI-MedLine.d119.s2	NO_SECTION	NO_SETID	32
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.
1	0	1	O	It
2	3	4	O	is
3	6	17	O	structurally
4	19	26	O	distinct
5	28	31	O	from
6	33	35	O	the
7	37	41	O	other
8	43	51	O	currently
9	53	61	O	available
10	63	68	B-UNK	HMGCoA
11	70	78	I-UNK	reductase
12	80	89	L-UNK	inhibitors
13	92	101	U-UNK	lovastatin
14	102	102	O	,
15	104	114	U-UNK	simvastatin
16	115	115	O	,
17	117	119	O	and
18	121	131	U-UNK	pravastatin
19	133	133	O	,
20	135	141	O	leading
21	143	144	O	to
22	146	151	O	unique
23	153	169	O	biopharmaceutical
24	171	180	O	properties
25	182	189	O	relative
26	191	192	O	to
27	194	196	O	the
28	198	202	O	other
29	204	209	O	agents
30	211	212	O	of
31	214	217	O	this
32	219	223	O	class
NULL

19489169.xml	DDI-MedLine.d119.s3	NO_SECTION	NO_SETID	22
Absorption of fluvastatin is virtually complete across all species, including man, and is not affected by the presence of food.
1	0	9	O	Absorption
2	11	12	O	of
3	14	24	U-UNK	fluvastatin
4	26	27	O	is
5	29	37	O	virtually
6	39	46	O	complete
7	48	53	O	across
8	55	57	O	all
9	59	65	O	species
10	66	66	O	,
11	68	76	O	including
12	78	80	O	man
13	81	81	O	,
14	83	85	O	and
15	87	88	O	is
16	90	92	O	not
17	94	101	O	affected
18	103	104	O	by
19	106	108	O	the
20	110	117	O	presence
21	119	120	O	of
22	122	125	O	food
NULL

19489169.xml	DDI-MedLine.d119.s4	NO_SECTION	NO_SETID	26
Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	is
4	21	27	O	limited
5	28	28	O	,
6	30	31	O	as
7	33	43	U-UNK	fluvastatin
8	45	46	O	is
9	48	54	O	subject
10	56	57	O	to
11	59	63	O	first
12	65	68	O	pass
13	70	79	O	metabolism
14	80	80	O	,
15	82	84	O	and
16	86	88	O	the
17	90	95	O	plasma
18	97	100	O	half
19	102	105	O	life
20	107	108	O	of
21	110	112	O	the
22	114	117	O	drug
23	119	120	O	is
24	122	134	O	approximately
25	136	137	O	30
26	139	145	O	minutes
NULL

19489169.xml	DDI-MedLine.d119.s5	NO_SECTION	NO_SETID	25
Some 95% of a single dosage of fluvastatin is excreted via the biliary route, with less than 2% of this being the parent compound.
1	0	3	O	Some
2	5	7	O	95%
3	9	10	O	of
4	12	12	O	a
5	14	19	O	single
6	21	26	O	dosage
7	28	29	O	of
8	31	41	U-UNK	fluvastatin
9	43	44	O	is
10	46	53	O	excreted
11	55	57	O	via
12	59	61	O	the
13	63	69	O	biliary
14	71	75	O	route
15	76	76	O	,
16	78	81	O	with
17	83	86	O	less
18	88	91	O	than
19	93	94	O	2%
20	96	97	O	of
21	99	102	O	this
22	104	108	O	being
23	110	112	O	the
24	114	119	O	parent
25	121	128	O	compound
NULL

19489169.xml	DDI-MedLine.d119.s6	NO_SECTION	NO_SETID	15
Additionally, there is no evidence of circulating active metabolites or accumulation during chronic dosing.
1	0	11	O	Additionally
2	12	12	O	,
3	14	18	O	there
4	20	21	O	is
5	23	24	O	no
6	26	33	O	evidence
7	35	36	O	of
8	38	48	O	circulating
9	50	55	O	active
10	57	67	O	metabolites
11	69	70	O	or
12	72	83	O	accumulation
13	85	90	O	during
14	92	98	O	chronic
15	100	105	O	dosing
NULL

19489169.xml	DDI-MedLine.d119.s7	NO_SECTION	NO_SETID	24
Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%;
1	0	6	O	Studies
2	8	9	O	of
3	11	13	O	the
4	15	20	O	effect
5	22	23	O	of
6	25	28	O	food
7	30	31	O	on
8	33	35	O	the
9	37	52	O	pharmacokinetics
10	54	55	O	of
11	57	67	U-UNK	fluvastatin
12	69	72	O	have
13	74	85	O	demonstrated
14	87	92	O	marked
15	94	103	O	reductions
16	105	106	O	in
17	108	110	O	the
18	112	115	O	rate
19	117	118	O	of
20	120	134	O	bioavailability
21	137	140	O	from
22	142	144	O	40%
23	146	147	O	to
24	149	151	O	60%
NULL

19489169.xml	DDI-MedLine.d119.s8	NO_SECTION	NO_SETID	32
however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.
1	0	6	O	however
2	7	7	O	,
3	9	9	O	a
4	11	20	O	comparison
5	22	23	O	of
6	25	35	U-UNK	fluvastatin
7	37	50	O	administration
8	52	55	O	with
9	57	59	O	the
10	61	67	O	evening
11	69	72	O	meal
12	74	75	O	or
13	77	78	O	at
14	80	86	O	bedtime
15	88	90	O	has
16	92	99	O	revealed
17	101	102	O	no
18	104	114	O	significant
19	116	126	O	differences
20	128	129	O	in
21	131	133	O	the
22	135	140	O	extent
23	142	143	O	of
24	145	159	O	bioavailability
25	162	165	O	area
26	167	171	O	under
27	173	175	O	the
28	177	181	O	curve
29	184	185	O	of
30	187	191	O	these
31	193	195	O	two
32	197	204	O	regimens
NULL

19489169.xml	DDI-MedLine.d119.s9	NO_SECTION	NO_SETID	24
Furthermore, no significant difference in pharmacodynamic effect (reduction in low-density lipoprotein cholesterol levels) could be ascertained between mealtime dosing and bedtime dosing.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	14	O	no
4	16	26	O	significant
5	28	37	O	difference
6	39	40	O	in
7	42	56	O	pharmacodynamic
8	58	63	O	effect
9	66	74	O	reduction
10	76	77	O	in
11	79	81	O	low
12	83	89	O	density
13	91	101	O	lipoprotein
14	103	113	O	cholesterol
15	115	120	O	levels
16	123	127	O	could
17	129	130	O	be
18	132	142	O	ascertained
19	144	150	O	between
20	152	159	O	mealtime
21	161	166	O	dosing
22	168	170	O	and
23	172	178	O	bedtime
24	180	185	O	dosing
NULL

19489169.xml	DDI-MedLine.d119.s10	NO_SECTION	NO_SETID	12
The pharmacokinetics of fluvastatin have also been assessed in various demographic groups.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	U-UNK	fluvastatin
5	36	39	O	have
6	41	44	O	also
7	46	49	O	been
8	51	58	O	assessed
9	60	61	O	in
10	63	69	O	various
11	71	81	O	demographic
12	83	88	O	groups
NULL

19489169.xml	DDI-MedLine.d119.s11	NO_SECTION	NO_SETID	21
Relative to the general population, plasma concentrations of fluvastatin do not vary as a function of either age or gender.
1	0	7	O	Relative
2	9	10	O	to
3	12	14	O	the
4	16	22	O	general
5	24	33	O	population
6	34	34	O	,
7	36	41	O	plasma
8	43	56	O	concentrations
9	58	59	O	of
10	61	71	U-UNK	fluvastatin
11	73	74	O	do
12	76	78	O	not
13	80	83	O	vary
14	85	86	O	as
15	88	88	O	a
16	90	97	O	function
17	99	100	O	of
18	102	107	O	either
19	109	111	O	age
20	113	114	O	or
21	116	121	O	gender
NULL

19489169.xml	DDI-MedLine.d119.s12	NO_SECTION	NO_SETID	28
In addition, administration to a patient population with hepatic insufficiency resulted in a 2.5-fold increase in both the rate and extent of bioavailability relative to controls.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	26	O	administration
5	28	29	O	to
6	31	31	O	a
7	33	39	O	patient
8	41	50	O	population
9	52	55	O	with
10	57	63	O	hepatic
11	65	77	O	insufficiency
12	79	86	O	resulted
13	88	89	O	in
14	91	91	O	a
15	93	95	O	2.5
16	97	100	O	fold
17	102	109	O	increase
18	111	112	O	in
19	114	117	O	both
20	119	121	O	the
21	123	126	O	rate
22	128	130	O	and
23	132	137	O	extent
24	139	140	O	of
25	142	156	O	bioavailability
26	158	165	O	relative
27	167	168	O	to
28	170	177	O	controls
NULL

19489169.xml	DDI-MedLine.d119.s13	NO_SECTION	NO_SETID	35
Also, although minimal alterations of fluvastatin clearance in patients with renal insufficiency are anticipated due to limited renal excretion (5%), a study in this patient group is currently underway to examine this further.
1	0	3	O	Also
2	4	4	O	,
3	6	13	O	although
4	15	21	O	minimal
5	23	33	O	alterations
6	35	36	O	of
7	38	48	U-UNK	fluvastatin
8	50	58	O	clearance
9	60	61	O	in
10	63	70	O	patients
11	72	75	O	with
12	77	81	O	renal
13	83	95	O	insufficiency
14	97	99	O	are
15	101	111	O	anticipated
16	113	115	O	due
17	117	118	O	to
18	120	126	O	limited
19	128	132	O	renal
20	134	142	O	excretion
21	145	146	O	5%
22	148	148	O	,
23	150	150	O	a
24	152	156	O	study
25	158	159	O	in
26	161	164	O	this
27	166	172	O	patient
28	174	178	O	group
29	180	181	O	is
30	183	191	O	currently
31	193	200	O	underway
32	202	203	O	to
33	205	211	O	examine
34	213	216	O	this
35	218	224	O	further
NULL

19489169.xml	DDI-MedLine.d119.s14	NO_SECTION	NO_SETID	16
Interaction studies have been performed with fluvastatin and several drugs with which it might be coadministered.
1	0	10	O	Interaction
2	12	18	O	studies
3	20	23	O	have
4	25	28	O	been
5	30	38	O	performed
6	40	43	O	with
7	45	55	U-UNK	fluvastatin
8	57	59	O	and
9	61	67	O	several
10	69	73	O	drugs
11	75	78	O	with
12	80	84	O	which
13	86	87	O	it
14	89	93	O	might
15	95	96	O	be
16	98	111	O	coadministered
NULL

19489169.xml	DDI-MedLine.d119.s15	NO_SECTION	NO_SETID	20
Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
1	0	13	U-UNK	Cholestyramine
2	14	14	O	,
3	16	17	O	an
4	19	25	O	anionic
5	27	33	O	binding
6	35	39	O	resin
7	40	40	O	,
8	42	44	O	has
9	46	46	O	a
10	48	59	O	considerable
11	61	66	O	effect
12	68	69	O	in
13	71	78	O	lowering
14	80	82	O	the
15	84	87	O	rate
16	89	91	O	and
17	93	98	O	extent
18	100	101	O	of
19	103	113	U-UNK	fluvastatin
20	115	129	O	bioavailability
NULL

19489169.xml	DDI-MedLine.d119.s16	NO_SECTION	NO_SETID	24
Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
1	0	7	O	Although
2	9	12	O	this
3	14	19	O	effect
4	21	23	O	was
5	25	29	O	noted
6	31	34	O	even
7	36	39	O	when
8	41	54	U-UNK	cholestyramine
9	56	58	O	was
10	60	64	O	given
11	66	66	O	4
12	68	72	O	hours
13	74	78	O	prior
14	80	81	O	to
15	83	93	U-UNK	fluvastatin
16	94	94	O	,
17	96	99	O	this
18	101	107	O	regimen
19	109	111	O	did
20	113	115	O	not
21	117	122	O	result
22	124	125	O	in
23	127	136	O	diminished
24	138	145	O	efficacy
NULL

19489169.xml	DDI-MedLine.d119.s17	NO_SECTION	NO_SETID	23
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin.
1	0	6	O	Further
2	7	7	O	,
3	9	10	O	no
4	12	18	O	effects
5	20	21	O	on
6	23	28	O	either
7	30	37	U-UNK	warfarin
8	39	44	O	levels
9	46	47	O	or
10	49	59	O	prothrombin
11	61	65	O	times
12	67	70	O	were
13	72	79	O	observed
14	81	82	O	in
15	84	84	O	a
16	86	90	O	study
17	92	100	O	involving
18	102	112	O	concomitant
19	114	127	O	administration
20	129	130	O	of
21	132	139	U-UNK	warfarin
22	141	143	O	and
23	145	155	U-UNK	fluvastatin
NULL

19489169.xml	DDI-MedLine.d119.s18	NO_SECTION	NO_SETID	43
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.
1	0	7	O	Moreover
2	8	8	O	,
3	10	19	O	additional
4	21	31	O	interaction
5	33	39	O	studies
6	41	44	O	with
7	46	51	U-UNK	niacin
8	53	55	O	and
9	57	67	U-UNK	propranolol
10	69	72	O	have
11	74	76	O	not
12	78	89	O	demonstrated
13	91	93	O	any
14	95	100	O	effect
15	102	103	O	on
16	105	115	U-UNK	fluvastatin
17	117	122	O	plasma
18	124	129	O	levels
19	130	130	O	,
20	132	134	O	and
21	136	149	O	administration
22	151	152	O	to
23	154	154	O	a
24	156	162	O	patient
25	164	173	O	population
26	175	185	O	chronically
27	187	195	O	receiving
28	197	203	U-UNK	digoxin
29	205	212	O	resulted
30	214	215	O	in
31	217	218	O	no
32	220	229	O	difference
33	231	232	O	in
34	234	236	O	the
35	238	243	O	extent
36	245	246	O	of
37	248	262	O	bioavailability
38	264	265	O	of
39	267	273	U-UNK	digoxin
40	275	282	O	relative
41	284	285	O	to
42	287	293	O	control
43	295	298	O	data
NULL

19489169.xml	DDI-MedLine.d119.s19	NO_SECTION	NO_SETID	22
The results generated to date in clinical pharmacokinetic studies with fluvastatin thus support its use in a broad population of hypercholesterolaemic patients.
1	0	2	O	The
2	4	10	O	results
3	12	20	O	generated
4	22	23	O	to
5	25	28	O	date
6	30	31	O	in
7	33	40	O	clinical
8	42	56	O	pharmacokinetic
9	58	64	O	studies
10	66	69	O	with
11	71	81	U-UNK	fluvastatin
12	83	86	O	thus
13	88	94	O	support
14	96	98	O	its
15	100	102	O	use
16	104	105	O	in
17	107	107	O	a
18	109	113	O	broad
19	115	124	O	population
20	126	127	O	of
21	129	149	O	hypercholesterolaemic
22	151	158	O	patients
NULL

2578306.xml	DDI-MedLine.d43.s0	NO_SECTION	NO_SETID	15
Tumor phenotype and susceptibility to progression as an expression of subpopulations of initiated murine cells.
1	0	4	O	Tumor
2	6	14	O	phenotype
3	16	18	O	and
4	20	33	O	susceptibility
5	35	36	O	to
6	38	48	O	progression
7	50	51	O	as
8	53	54	O	an
9	56	65	O	expression
10	67	68	O	of
11	70	83	O	subpopulations
12	85	86	O	of
13	88	96	O	initiated
14	98	103	O	murine
15	105	109	O	cells
NULL

2578306.xml	DDI-MedLine.d43.s1	NO_SECTION	NO_SETID	24
Currently, it is conceived that a number of events, or hits, are required for the induction of tumors by chemical agents.
1	0	8	O	Currently
2	9	9	O	,
3	11	12	O	it
4	14	15	O	is
5	17	25	O	conceived
6	27	30	O	that
7	32	32	O	a
8	34	39	O	number
9	41	42	O	of
10	44	49	O	events
11	50	50	O	,
12	52	53	O	or
13	55	58	O	hits
14	59	59	O	,
15	61	63	O	are
16	65	72	O	required
17	74	76	O	for
18	78	80	O	the
19	82	90	O	induction
20	92	93	O	of
21	95	100	O	tumors
22	102	103	O	by
23	105	112	O	chemical
24	114	119	O	agents
NULL

2578306.xml	DDI-MedLine.d43.s2	NO_SECTION	NO_SETID	22
The first phase of this sequence, initiation, is considered to result from at least one event in the genetic apparatus.
1	0	2	O	The
2	4	8	O	first
3	10	14	O	phase
4	16	17	O	of
5	19	22	O	this
6	24	31	O	sequence
7	32	32	O	,
8	34	43	O	initiation
9	44	44	O	,
10	46	47	O	is
11	49	58	O	considered
12	60	61	O	to
13	63	68	O	result
14	70	73	O	from
15	75	76	O	at
16	78	82	O	least
17	84	86	O	one
18	88	92	O	event
19	94	95	O	in
20	97	99	O	the
21	101	107	O	genetic
22	109	117	O	apparatus
NULL

2578306.xml	DDI-MedLine.d43.s3	NO_SECTION	NO_SETID	26
Analyses of this sequence, however, usually give little consideration to the nature of the target cell or to the characteristics of the resultant tumors.
1	0	7	O	Analyses
2	9	10	O	of
3	12	15	O	this
4	17	24	O	sequence
5	25	25	O	,
6	27	33	O	however
7	34	34	O	,
8	36	42	O	usually
9	44	47	O	give
10	49	54	O	little
11	56	68	O	consideration
12	70	71	O	to
13	73	75	O	the
14	77	82	O	nature
15	84	85	O	of
16	87	89	O	the
17	91	96	O	target
18	98	101	O	cell
19	103	104	O	or
20	106	107	O	to
21	109	111	O	the
22	113	127	O	characteristics
23	129	130	O	of
24	132	134	O	the
25	136	144	O	resultant
26	146	151	O	tumors
NULL

2578306.xml	DDI-MedLine.d43.s4	NO_SECTION	NO_SETID	3
Vesselinovitch et al.
1	0	13	O	Vesselinovitch
2	15	16	O	et
3	18	19	O	al
NULL

2578306.xml	DDI-MedLine.d43.s5	NO_SECTION	NO_SETID	37
(Cancer Res., 38: 2003-2010, 1978) have reported that a single, small pulse of carcinogen can induce early and numerous liver tumors when administered neonatally to mice with a genetic predisposition to hepatotumorigenesis.
1	1	6	O	Cancer
2	8	10	O	Res
3	12	12	O	,
4	14	15	O	38
5	16	16	O	:
6	18	21	O	2003
7	23	26	O	2010
8	27	27	O	,
9	29	32	O	1978
10	35	38	O	have
11	40	47	O	reported
12	49	52	O	that
13	54	54	O	a
14	56	61	O	single
15	62	62	O	,
16	64	68	O	small
17	70	74	O	pulse
18	76	77	O	of
19	79	88	O	carcinogen
20	90	92	O	can
21	94	99	O	induce
22	101	105	O	early
23	107	109	O	and
24	111	118	O	numerous
25	120	124	O	liver
26	126	131	O	tumors
27	133	136	O	when
28	138	149	O	administered
29	151	160	O	neonatally
30	162	163	O	to
31	165	168	O	mice
32	170	173	O	with
33	175	175	O	a
34	177	183	O	genetic
35	185	198	O	predisposition
36	200	201	O	to
37	203	221	O	hepatotumorigenesis
NULL

2578306.xml	DDI-MedLine.d43.s6	NO_SECTION	NO_SETID	24
In the current study, the nonpredisposed strain C57BL/6N was also shown to be highly susceptible to diethylnitrosamine during the neonatal period.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	current
4	15	19	O	study
5	20	20	O	,
6	22	24	O	the
7	26	39	O	nonpredisposed
8	41	46	O	strain
9	48	52	O	C57BL
10	53	53	O	/
11	54	55	O	6N
12	57	59	O	was
13	61	64	O	also
14	66	70	O	shown
15	72	73	O	to
16	75	76	O	be
17	78	83	O	highly
18	85	95	O	susceptible
19	97	98	O	to
20	100	117	O	diethylnitrosamine
21	119	124	O	during
22	126	128	O	the
23	130	137	O	neonatal
24	139	144	O	period
NULL

2578306.xml	DDI-MedLine.d43.s7	NO_SECTION	NO_SETID	35
C57BL/6N demonstrated large numbers of two of the three types of liver tumors seen in livers of genetically predisposed mice, one of which required the additional stimulus of dietary phenobarbital for growth.
1	0	4	O	C57BL
2	5	5	O	/
3	6	7	O	6N
4	9	20	O	demonstrated
5	22	26	O	large
6	28	34	O	numbers
7	36	37	O	of
8	39	41	O	two
9	43	44	O	of
10	46	48	O	the
11	50	54	O	three
12	56	60	O	types
13	62	63	O	of
14	65	69	O	liver
15	71	76	O	tumors
16	78	81	O	seen
17	83	84	O	in
18	86	91	O	livers
19	93	94	O	of
20	96	106	O	genetically
21	108	118	O	predisposed
22	120	123	O	mice
23	124	124	O	,
24	126	128	O	one
25	130	131	O	of
26	133	137	O	which
27	139	146	O	required
28	148	150	O	the
29	152	161	O	additional
30	163	170	O	stimulus
31	172	173	O	of
32	175	181	O	dietary
33	183	195	U-UNK	phenobarbital
34	197	199	O	for
35	201	206	O	growth
NULL

2578306.xml	DDI-MedLine.d43.s8	NO_SECTION	NO_SETID	26
Tumors of more malignant phenotype were demonstrated only in genetically predisposed mice (C57BL/6N X C3H/HeN F1) that received one dose of carcinogen.
1	0	5	O	Tumors
2	7	8	O	of
3	10	13	O	more
4	15	23	O	malignant
5	25	33	O	phenotype
6	35	38	O	were
7	40	51	O	demonstrated
8	53	56	O	only
9	58	59	O	in
10	61	71	O	genetically
11	73	83	O	predisposed
12	85	88	O	mice
13	91	95	O	C57BL
14	96	96	O	/
15	97	98	O	6N
16	100	100	O	XXXXXXXX
17	102	104	O	C3H
18	105	105	O	/
19	106	108	O	HeN
20	110	111	O	F1
21	114	117	O	that
22	119	126	O	received
23	128	130	O	one
24	132	135	O	dose
25	137	138	O	of
26	140	149	O	carcinogen
NULL

2578306.xml	DDI-MedLine.d43.s9	NO_SECTION	NO_SETID	24
These findings suggest that the phenotype of a tumor that results from a pulse of a chemical carcinogen may depend upon the target cell.
1	0	4	O	These
2	6	13	O	findings
3	15	21	O	suggest
4	23	26	O	that
5	28	30	O	the
6	32	40	O	phenotype
7	42	43	O	of
8	45	45	O	a
9	47	51	O	tumor
10	53	56	O	that
11	58	64	O	results
12	66	69	O	from
13	71	71	O	a
14	73	77	O	pulse
15	79	80	O	of
16	82	82	O	a
17	84	91	O	chemical
18	93	102	O	carcinogen
19	104	106	O	may
20	108	113	O	depend
21	115	118	O	upon
22	120	122	O	the
23	124	129	O	target
24	131	134	O	cell
NULL

2578306.xml	DDI-MedLine.d43.s10	NO_SECTION	NO_SETID	41
The initiated cells that result from this hit may vary from those that demonstrate very little progression in cell type and may or may not require exogenous enhancement of growth to those that can progress very rapidly to fully malignant behavior.
1	0	2	O	The
2	4	12	O	initiated
3	14	18	O	cells
4	20	23	O	that
5	25	30	O	result
6	32	35	O	from
7	37	40	O	this
8	42	44	O	hit
9	46	48	O	may
10	50	53	O	vary
11	55	58	O	from
12	60	64	O	those
13	66	69	O	that
14	71	81	O	demonstrate
15	83	86	O	very
16	88	93	O	little
17	95	105	O	progression
18	107	108	O	in
19	110	113	O	cell
20	115	118	O	type
21	120	122	O	and
22	124	126	O	may
23	128	129	O	or
24	131	133	O	may
25	135	137	O	not
26	139	145	O	require
27	147	155	O	exogenous
28	157	167	O	enhancement
29	169	170	O	of
30	172	177	O	growth
31	179	180	O	to
32	182	186	O	those
33	188	191	O	that
34	193	195	O	can
35	197	204	O	progress
36	206	209	O	very
37	211	217	O	rapidly
38	219	220	O	to
39	222	226	O	fully
40	228	236	O	malignant
41	238	245	O	behavior
NULL

2578306.xml	DDI-MedLine.d43.s11	NO_SECTION	NO_SETID	25
The latter might arise from a hit in a genetically initiated cell, the result of which is a more rapid progression in tumor type.
1	0	2	O	The
2	4	9	O	latter
3	11	15	O	might
4	17	21	O	arise
5	23	26	O	from
6	28	28	O	a
7	30	32	O	hit
8	34	35	O	in
9	37	37	O	a
10	39	49	O	genetically
11	51	59	O	initiated
12	61	64	O	cell
13	65	65	O	,
14	67	69	O	the
15	71	76	O	result
16	78	79	O	of
17	81	85	O	which
18	87	88	O	is
19	90	90	O	a
20	92	95	O	more
21	97	101	O	rapid
22	103	113	O	progression
23	115	116	O	in
24	118	122	O	tumor
25	124	127	O	type
NULL

2578597.xml	DDI-MedLine.d57.s0	NO_SECTION	NO_SETID	4
Analgesic effects of antihistaminics.
1	0	8	O	Analgesic
2	10	16	O	effects
3	18	19	O	of
4	21	35	U-UNK	antihistaminics
NULL

2578597.xml	DDI-MedLine.d57.s1	NO_SECTION	NO_SETID	25
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.
1	0	2	O	The
2	4	13	O	literature
3	15	22	O	provides
4	24	35	O	considerable
5	37	44	O	evidence
6	46	55	O	indicating
7	57	60	O	that
8	62	68	O	several
9	69	69	O	,
10	71	73	O	but
11	75	77	O	not
12	79	81	O	all
13	83	97	U-UNK	antihistaminics
14	98	98	O	,
15	100	102	O	are
16	104	109	O	indeed
17	111	119	B-UNK	analgesic
18	121	126	L-UNK	agents
19	128	130	O	and
20	132	135	O	some
21	137	139	O	are
22	141	149	B-UNK	analgesic
23	151	159	L-UNK	adjuvants
24	161	162	O	as
25	164	167	O	well
NULL

2578597.xml	DDI-MedLine.d57.s2	NO_SECTION	NO_SETID	23
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
1	0	4	O	Those
2	6	8	O	for
3	10	14	O	which
4	16	28	O	effectiveness
5	30	31	O	is
6	33	40	O	reported
7	42	49	O	includes
8	51	65	U-UNK	diphenhydramine
9	66	66	O	,
10	68	78	U-UNK	hydroxyzine
11	79	79	O	,
12	81	92	U-UNK	orphenadrine
13	93	93	O	,
14	95	104	U-UNK	pyrilamine
15	105	105	O	,
16	107	122	U-UNK	phenyltoloxamine
17	123	123	O	,
18	125	136	U-UNK	promethazine
19	137	137	O	,
20	139	150	U-UNK	methdilazine
21	151	151	O	,
22	153	155	O	and
23	157	170	U-UNK	tripelennamine
NULL

2578597.xml	DDI-MedLine.d57.s3	NO_SECTION	NO_SETID	12
The proposed mechanisms of analgesic action of antihistaminics are reviewed and discussed.
1	0	2	O	The
2	4	11	O	proposed
3	13	22	O	mechanisms
4	24	25	O	of
5	27	35	O	analgesic
6	37	42	O	action
7	44	45	O	of
8	47	61	U-UNK	antihistaminics
9	63	65	O	are
10	67	74	O	reviewed
11	76	78	O	and
12	80	88	O	discussed
NULL

2578597.xml	DDI-MedLine.d57.s4	NO_SECTION	NO_SETID	13
The literature suggests that more than one mechanism of action exists for them.
1	0	2	O	The
2	4	13	O	literature
3	15	22	O	suggests
4	24	27	O	that
5	29	32	O	more
6	34	37	O	than
7	39	41	O	one
8	43	51	O	mechanism
9	53	54	O	of
10	56	61	O	action
11	63	68	O	exists
12	70	72	O	for
13	74	77	O	them
NULL

2578597.xml	DDI-MedLine.d57.s5	NO_SECTION	NO_SETID	24
There is considerable evidence suggesting that histaminergic and serotoninergic central pathways are involved in nociception and that antihistaminic drugs can modulate their responses (1).
1	0	4	O	There
2	6	7	O	is
3	9	20	O	considerable
4	22	29	O	evidence
5	31	40	O	suggesting
6	42	45	O	that
7	47	59	O	histaminergic
8	61	63	O	and
9	65	78	O	serotoninergic
10	80	86	O	central
11	88	95	O	pathways
12	97	99	O	are
13	101	108	O	involved
14	110	111	O	in
15	113	123	O	nociception
16	125	127	O	and
17	129	132	O	that
18	134	147	U-UNK	antihistaminic
19	149	153	O	drugs
20	155	157	O	can
21	159	166	O	modulate
22	168	172	O	their
23	174	182	O	responses
24	185	185	O	1
NULL

2578597.xml	DDI-MedLine.d57.s6	NO_SECTION	NO_SETID	20
The evidence for a role for norepinephrine and dopamine and the effects of antihistaminics on them are less well established.
1	0	2	O	The
2	4	11	O	evidence
3	13	15	O	for
4	17	17	O	a
5	19	22	O	role
6	24	26	O	for
7	28	41	O	norepinephrine
8	43	45	O	and
9	47	54	O	dopamine
10	56	58	O	and
11	60	62	O	the
12	64	70	O	effects
13	72	73	O	of
14	75	89	U-UNK	antihistaminics
15	91	92	O	on
16	94	97	O	them
17	99	101	O	are
18	103	106	O	less
19	108	111	O	well
20	113	123	O	established
NULL

2578597.xml	DDI-MedLine.d57.s7	NO_SECTION	NO_SETID	6
Still other pathways have been proposed.
1	0	4	O	Still
2	6	10	O	other
3	12	19	O	pathways
4	21	24	O	have
5	26	29	O	been
6	31	38	O	proposed
NULL

2578597.xml	DDI-MedLine.d57.s8	NO_SECTION	NO_SETID	16
A greater understanding of pain mechanisms will aid in elucidating the role of antihistaminics in analgesia.
1	0	0	O	A
2	2	8	O	greater
3	10	22	O	understanding
4	24	25	O	of
5	27	30	O	pain
6	32	41	O	mechanisms
7	43	46	O	will
8	48	50	O	aid
9	52	53	O	in
10	55	65	O	elucidating
11	67	69	O	the
12	71	74	O	role
13	76	77	O	of
14	79	93	U-UNK	antihistaminics
15	95	96	O	in
16	98	106	O	analgesia
NULL

2857099.xml	DDI-MedLine.d27.s1	NO_SECTION	NO_SETID	18
When the dose of picrotoxin is minimized to 0.5 mg/kg such an effect is not observed.
1	0	3	O	When
2	5	7	O	the
3	9	12	O	dose
4	14	15	O	of
5	17	26	U-UNK	picrotoxin
6	28	29	O	is
7	31	39	O	minimized
8	41	42	O	to
9	44	46	O	0.5
10	48	49	O	mg
11	50	50	O	/
12	51	52	O	kg
13	54	57	O	such
14	59	60	O	an
15	62	67	O	effect
16	69	70	O	is
17	72	74	O	not
18	76	83	O	observed
NULL

2857099.xml	DDI-MedLine.d27.s2	NO_SECTION	NO_SETID	20
Prolonged daily administration of picrotoxin in a dose of 1 mg/kg results in the development of brain edema.
1	0	8	O	Prolonged
2	10	14	O	daily
3	16	29	O	administration
4	31	32	O	of
5	34	43	U-UNK	picrotoxin
6	45	46	O	in
7	48	48	O	a
8	50	53	O	dose
9	55	56	O	of
10	58	58	O	1
11	60	61	O	mg
12	62	62	O	/
13	63	64	O	kg
14	66	72	O	results
15	74	75	O	in
16	77	79	O	the
17	81	91	O	development
18	93	94	O	of
19	96	100	O	brain
20	102	106	O	edema
NULL

2857099.xml	DDI-MedLine.d27.s3	NO_SECTION	NO_SETID	17
It is recommended that GABA-positive drugs be included into a complex of treatment measures for edema.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	26	O	GABA
6	28	35	O	positive
7	37	41	O	drugs
8	43	44	O	be
9	46	53	O	included
10	55	58	O	into
11	60	60	O	a
12	62	68	O	complex
13	70	71	O	of
14	73	81	O	treatment
15	83	90	O	measures
16	92	94	O	for
17	96	100	O	edema
NULL

2857100.xml	DDI-MedLine.d15.s1	NO_SECTION	NO_SETID	27
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
1	0	4	O	After
2	6	14	O	prolonged
3	16	29	O	administration
4	31	32	O	of
5	34	45	U-UNK	neuroleptics
6	47	49	O	the
7	51	60	O	displacing
8	62	67	O	effect
9	69	70	O	of
10	72	79	U-UNK	cerulein
11	80	80	O	,
12	82	83	O	an
13	85	90	O	analog
14	92	93	O	of
15	95	109	O	cholecystokinin
16	111	121	O	octapeptide
17	122	122	O	,
18	124	126	O	was
19	128	135	O	replaced
20	137	138	O	by
21	140	142	O	the
22	144	152	O	stimulant
23	154	159	O	action
24	161	162	O	on
25	164	165	B-UNK	3H
26	167	178	L-UNK	spiroperidol
27	180	186	O	binding
NULL

2857100.xml	DDI-MedLine.d15.s2	NO_SECTION	NO_SETID	31
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	assumed
4	14	17	O	that
5	19	27	O	increased
6	29	39	O	interaction
7	41	47	O	between
8	49	50	B-UNK	3H
9	52	63	L-UNK	spiroperidol
10	65	67	O	and
11	69	72	O	high
12	74	81	O	affinity
13	83	89	O	binding
14	91	95	O	sites
15	97	99	O	for
16	101	111	U-UNK	apomorphine
17	113	114	O	on
18	116	124	O	dopamine2
19	127	129	O	and
20	131	140	O	serotonin2
21	142	150	O	receptors
22	152	160	O	underlies
23	162	164	O	the
24	166	178	O	antipsychotic
25	180	185	O	action
26	187	188	O	of
27	190	201	U-UNK	neuroleptics
28	203	207	O	after
29	209	213	O	their
30	215	223	O	prolonged
31	225	238	O	administration
NULL

2857100.xml	DDI-MedLine.d15.s3	NO_SECTION	NO_SETID	13
Cholecystokinin octapeptide is a necessary factor for realization of this action of neuroleptics.
1	0	14	O	Cholecystokinin
2	16	26	O	octapeptide
3	28	29	O	is
4	31	31	O	a
5	33	41	O	necessary
6	43	48	O	factor
7	50	52	O	for
8	54	64	O	realization
9	66	67	O	of
10	69	72	O	this
11	74	79	O	action
12	81	82	O	of
13	84	95	U-UNK	neuroleptics
NULL

2857198.xml	DDI-MedLine.d56.s0	NO_SECTION	NO_SETID	18
Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.
1	0	3	O	Dual
2	5	10	O	effect
3	12	13	O	of
4	15	21	U-UNK	ouabain
5	23	24	O	on
6	26	28	O	the
7	30	38	U-UNK	palytoxin
8	40	46	O	induced
9	48	58	O	contraction
10	60	62	O	and
11	64	77	O	norepinephrine
12	79	85	O	release
13	87	88	O	in
14	90	92	O	the
15	94	99	O	guinea
16	101	103	O	pig
17	105	107	O	vas
18	109	116	O	deferens
NULL

2857198.xml	DDI-MedLine.d56.s1	NO_SECTION	NO_SETID	29
Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.
1	0	8	U-UNK	Palytoxin
2	11	13	U-UNK	PTX
3	15	15	O	,
4	17	29	O	C129H223N3O54
5	30	30	O	,
6	32	39	O	isolated
7	41	44	O	from
8	46	51	O	marine
9	53	65	O	coelenterates
10	67	68	O	of
11	70	77	O	Palythoa
12	79	89	O	tuberculosa
13	90	90	O	,
14	92	97	O	caused
15	99	99	O	a
16	101	105	O	first
17	107	111	O	rapid
18	113	123	O	contraction
19	125	132	O	followed
20	134	135	O	by
21	137	139	O	the
22	141	144	O	slow
23	146	151	O	phasic
24	153	163	O	contraction
25	165	166	O	of
26	168	173	O	guinea
27	175	177	O	pig
28	179	181	O	vas
29	183	190	O	deferens
NULL

2857198.xml	DDI-MedLine.d56.s2	NO_SECTION	NO_SETID	19
In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	25	U-UNK	ouabain
6	28	29	O	10
7	32	32	O	5
8	35	35	O	M
9	37	37	O	,
10	39	41	U-UNK	PTX
11	44	45	O	10
12	48	48	O	8
13	51	51	O	M
14	54	59	O	failed
15	61	62	O	to
16	64	68	O	cause
17	70	72	O	the
18	74	78	O	first
19	80	90	O	contraction
NULL

2857198.xml	DDI-MedLine.d56.s3	NO_SECTION	NO_SETID	7
however, the second contraction was potentiated.
1	0	6	O	however
2	7	7	O	,
3	9	11	O	the
4	13	18	O	second
5	20	30	O	contraction
6	32	34	O	was
7	36	46	O	potentiated
NULL

2857198.xml	DDI-MedLine.d56.s4	NO_SECTION	NO_SETID	15
In the presence of phentolamine (10(-6) M), the second contraction was inhibited selectively.
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	30	U-UNK	phentolamine
6	33	34	O	10
7	37	37	O	6
8	40	40	O	M
9	42	42	O	,
10	44	46	O	the
11	48	53	O	second
12	55	65	O	contraction
13	67	69	O	was
14	71	79	O	inhibited
15	81	91	O	selectively
NULL

2857198.xml	DDI-MedLine.d56.s5	NO_SECTION	NO_SETID	23
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
1	0	3	O	When
2	5	11	U-UNK	ouabain
3	13	15	O	was
4	17	23	O	applied
5	25	26	O	to
6	28	30	O	the
7	32	37	O	muscle
8	39	40	O	in
9	42	44	O	the
10	46	53	O	presence
11	55	56	O	of
12	58	69	U-UNK	phentolamine
13	70	70	O	,
14	72	75	O	both
15	77	81	O	first
16	83	85	O	and
17	87	92	O	second
18	94	104	O	contractile
19	106	114	O	responses
20	116	117	O	to
21	119	121	U-UNK	PTX
22	123	126	O	were
23	128	136	O	abolished
NULL

2857198.xml	DDI-MedLine.d56.s6	NO_SECTION	NO_SETID	20
When the muscle was exposed to the potassium-depleted solution, the first contractile response to PTX was rather potentiated.
1	0	3	O	When
2	5	7	O	the
3	9	14	O	muscle
4	16	18	O	was
5	20	26	O	exposed
6	28	29	O	to
7	31	33	O	the
8	35	43	O	potassium
9	45	52	O	depleted
10	54	61	O	solution
11	62	62	O	,
12	64	66	O	the
13	68	72	O	first
14	74	84	O	contractile
15	86	93	O	response
16	95	96	O	to
17	98	100	U-UNK	PTX
18	102	104	O	was
19	106	111	O	rather
20	113	123	O	potentiated
NULL

2857198.xml	DDI-MedLine.d56.s7	NO_SECTION	NO_SETID	9
PTX caused the release of norepinephrine from the muscle.
1	0	2	U-UNK	PTX
2	4	9	O	caused
3	11	13	O	the
4	15	21	O	release
5	23	24	O	of
6	26	39	O	norepinephrine
7	41	44	O	from
8	46	48	O	the
9	50	55	O	muscle
NULL

2857198.xml	DDI-MedLine.d56.s8	NO_SECTION	NO_SETID	15
Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
1	0	7	O	Exposure
2	9	10	O	of
3	12	14	O	the
4	16	21	O	muscle
5	23	24	O	to
6	26	32	U-UNK	ouabain
7	35	36	O	10
8	39	39	O	5
9	42	42	O	M
10	45	52	O	markedly
11	54	62	O	increased
12	64	66	O	the
13	68	70	U-UNK	PTX
14	72	78	O	induced
15	80	86	O	release
NULL

2857198.xml	DDI-MedLine.d56.s9	NO_SECTION	NO_SETID	16
It is indicated that the first and second contractile responses to PTX have entirely different properties.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	indicated
4	16	19	O	that
5	21	23	O	the
6	25	29	O	first
7	31	33	O	and
8	35	40	O	second
9	42	52	O	contractile
10	54	62	O	responses
11	64	65	O	to
12	67	69	U-UNK	PTX
13	71	74	O	have
14	76	83	O	entirely
15	85	93	O	different
16	95	104	O	properties
NULL

2857198.xml	DDI-MedLine.d56.s10	NO_SECTION	NO_SETID	51
The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain.
1	0	2	O	The
2	4	9	O	second
3	11	18	O	response
4	20	21	O	is
5	23	25	O	due
6	27	28	O	to
7	30	30	O	a
8	32	38	O	release
9	40	41	O	of
10	43	56	O	norepinephrine
11	58	61	O	from
12	63	68	O	nerves
13	70	72	O	and
14	74	76	O	was
15	78	88	O	potentiated
16	90	91	O	by
17	93	99	U-UNK	ouabain
18	101	107	O	through
19	109	111	O	the
20	113	120	O	increase
21	122	123	O	in
22	125	127	O	the
23	129	142	O	norepinephrine
24	144	150	O	release
25	151	151	O	,
26	153	159	O	whereas
27	161	163	O	the
28	165	169	O	first
29	171	178	O	response
30	180	182	O	was
31	184	186	O	not
32	188	190	O	due
33	192	193	O	to
34	195	197	O	the
35	199	212	O	norepinephrine
36	214	220	O	release
37	222	224	O	but
38	226	235	O	presumably
39	237	238	O	to
40	240	240	O	a
41	242	247	O	direct
42	249	254	O	action
43	256	257	O	on
44	259	264	O	smooth
45	266	271	O	muscle
46	273	276	O	cell
47	278	280	O	and
48	282	284	O	was
49	286	294	O	inhibited
50	296	297	O	by
51	299	305	U-UNK	ouabain
NULL

2857198.xml	DDI-MedLine.d56.s11	NO_SECTION	NO_SETID	15
The mechanism of the action of PTX was discussed in the relation with Na,K-ATPase.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	19	O	the
5	21	26	O	action
6	28	29	O	of
7	31	33	U-UNK	PTX
8	35	37	O	was
9	39	47	O	discussed
10	49	50	O	in
11	52	54	O	the
12	56	63	O	relation
13	65	68	O	with
14	70	73	O	Na,K
15	75	80	O	ATPase
NULL

2857499.xml	DDI-MedLine.d139.s0	NO_SECTION	NO_SETID	29
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports.
1	1	12	O	Quantitative
2	14	21	O	approach
3	23	24	O	to
4	26	34	O	treatment
5	36	39	O	with
6	41	48	O	incisive
7	50	61	U-UNK	neuroleptics
8	63	64	O	by
9	66	76	O	therapeutic
10	78	87	O	monitoring
11	91	93	O	The
12	95	102	O	problems
13	104	114	O	encountered
14	116	121	O	during
15	123	125	O	the
16	127	134	O	longterm
17	136	144	O	treatment
18	146	147	O	of
19	149	157	O	psychotic
20	159	166	O	patients
21	168	171	O	with
22	173	184	U-UNK	neuroleptics
23	186	188	O	are
24	190	200	O	illustrated
25	202	203	O	by
26	205	207	O	six
27	209	215	O	typical
28	217	220	O	case
29	222	228	O	reports
NULL

2857499.xml	DDI-MedLine.d139.s1	NO_SECTION	NO_SETID	17
A group of patients who had had a new acute episode despite seemingly adequate treatment were selected.
1	0	0	O	A
2	2	6	O	group
3	8	9	O	of
4	11	18	O	patients
5	20	22	O	who
6	24	26	O	had
7	28	30	O	had
8	32	32	O	a
9	34	36	O	new
10	38	42	O	acute
11	44	50	O	episode
12	52	58	O	despite
13	60	68	O	seemingly
14	70	77	O	adequate
15	79	87	O	treatment
16	89	92	O	were
17	94	101	O	selected
NULL

2857499.xml	DDI-MedLine.d139.s2	NO_SECTION	NO_SETID	27
In these six cases it was demonstrated that the neuroleptics dosage was inappropriate, being either too high or too low as judged from the plasma concentrations.
1	0	1	O	In
2	3	7	O	these
3	9	11	O	six
4	13	17	O	cases
5	19	20	O	it
6	22	24	O	was
7	26	37	O	demonstrated
8	39	42	O	that
9	44	46	O	the
10	48	59	U-UNK	neuroleptics
11	61	66	O	dosage
12	68	70	O	was
13	72	84	O	inappropriate
14	85	85	O	,
15	87	91	O	being
16	93	98	O	either
17	100	102	O	too
18	104	107	O	high
19	109	110	O	or
20	112	114	O	too
21	116	118	O	low
22	120	121	O	as
23	123	128	O	judged
24	130	133	O	from
25	135	137	O	the
26	139	144	O	plasma
27	146	159	O	concentrations
NULL

2857499.xml	DDI-MedLine.d139.s3	NO_SECTION	NO_SETID	15
Ways of improving the adequacy of the treatment of psychotic patients with neuroleptics are discussed.
1	0	3	O	Ways
2	5	6	O	of
3	8	16	O	improving
4	18	20	O	the
5	22	29	O	adequacy
6	31	32	O	of
7	34	36	O	the
8	38	46	O	treatment
9	48	49	O	of
10	51	59	O	psychotic
11	61	68	O	patients
12	70	73	O	with
13	75	86	U-UNK	neuroleptics
14	88	90	O	are
15	92	100	O	discussed
NULL

2981680.xml	DDI-MedLine.d82.s0	NO_SECTION	NO_SETID	7
Intestinal absorption of arsenate in the chick.
1	0	9	O	Intestinal
2	11	20	O	absorption
3	22	23	O	of
4	25	32	U-UNK	arsenate
5	34	35	O	in
6	37	39	O	the
7	41	45	O	chick
NULL

2981680.xml	DDI-MedLine.d82.s1	NO_SECTION	NO_SETID	21
The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique.
1	0	2	O	The
2	4	13	O	intestinal
3	15	24	O	absorption
4	26	27	O	of
5	29	41	O	arsenate(As(V
6	45	47	O	has
7	49	52	O	been
8	54	65	O	investigated
9	67	68	O	in
10	70	72	O	the
11	74	78	O	chick
12	80	81	O	by
13	83	87	O	means
14	89	90	O	of
15	92	94	O	the
16	96	97	O	in
17	99	102	O	situ
18	104	110	O	ligated
19	112	119	O	duodenal
20	121	124	O	loop
21	126	134	O	technique
NULL

2981680.xml	DDI-MedLine.d82.s2	NO_SECTION	NO_SETID	36
By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM.
1	0	1	O	By
2	3	6	O	this
3	8	16	O	procedure
4	17	17	O	,
5	19	20	O	it
6	22	24	O	was
7	26	33	O	observed
8	35	38	O	that
9	40	47	U-UNK	arsenate
10	49	50	O	is
11	52	58	O	rapidly
12	60	62	O	and
13	64	74	O	essentially
14	76	85	O	completely
15	87	94	O	absorbed
16	97	98	O	80
17	100	102	O	95%
18	105	108	O	from
19	110	112	O	the
20	114	118	O	lumen
21	120	121	O	at
22	123	126	U-UNK	As(V
23	129	142	O	concentrations
24	144	145	O	up
25	147	148	O	to
26	150	150	O	5
27	152	153	O	mM
28	154	154	O	,
29	156	164	O	declining
30	166	167	O	to
31	169	173	O	about
32	175	177	O	50%
33	179	188	O	absorption
34	190	191	O	at
35	193	194	O	50
36	196	197	O	mM
NULL

2981680.xml	DDI-MedLine.d82.s3	NO_SECTION	NO_SETID	30
Transfer from the intestinal lumen to the mucosal cells at low As(V) concentration (0.1 mM) is rapid, while transfer from the mucosal cells to the body occurs more slowly.
1	0	7	O	Transfer
2	9	12	O	from
3	14	16	O	the
4	18	27	O	intestinal
5	29	33	O	lumen
6	35	36	O	to
7	38	40	O	the
8	42	48	O	mucosal
9	50	54	O	cells
10	56	57	O	at
11	59	61	O	low
12	63	66	U-UNK	As(V
13	69	81	O	concentration
14	84	86	O	0.1
15	88	89	O	mM
16	92	93	O	is
17	95	99	O	rapid
18	100	100	O	,
19	102	106	O	while
20	108	115	O	transfer
21	117	120	O	from
22	122	124	O	the
23	126	132	O	mucosal
24	134	138	O	cells
25	140	141	O	to
26	143	145	O	the
27	147	150	O	body
28	152	157	O	occurs
29	159	162	O	more
30	164	169	O	slowly
NULL

2981680.xml	DDI-MedLine.d82.s4	NO_SECTION	NO_SETID	25
At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines.
1	0	1	O	At
2	3	8	O	stable
3	10	13	U-UNK	As(V
4	16	29	O	concentrations
5	31	37	O	greater
6	39	42	O	than
7	44	44	O	1
8	46	47	O	mM
9	48	48	O	,
10	50	59	O	fractional
11	61	67	O	mucosal
12	69	72	O	cell
13	74	85	O	accumulation
14	87	88	O	of
15	90	93	U-UNK	As(V
16	96	102	O	remains
17	104	111	O	constant
18	112	112	O	,
19	114	118	O	while
20	120	129	O	fractional
21	131	138	O	transfer
22	140	141	O	to
23	143	145	O	the
24	147	150	O	body
25	152	159	O	declines
NULL

2981680.xml	DDI-MedLine.d82.s5	NO_SECTION	NO_SETID	25
However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V).
1	0	6	O	However
2	7	7	O	,
3	9	13	O	total
4	15	21	O	mucosal
5	23	34	O	accumulation
6	36	37	O	of
7	39	42	U-UNK	As(V
8	45	47	O	and
9	49	52	O	that
10	54	64	O	transferred
11	66	67	O	to
12	69	71	O	the
13	73	76	O	body
14	78	85	O	increase
15	87	88	O	in
16	90	90	O	a
17	92	97	O	linear
18	99	109	O	logarithmic
19	111	117	O	fashion
20	119	122	O	from
21	124	127	O	0.05
22	129	130	O	to
23	132	132	O	5
24	134	135	O	mm
25	137	140	U-UNK	As(V
NULL

2981680.xml	DDI-MedLine.d82.s6	NO_SECTION	NO_SETID	17
The results indicate that As(V) readily penetrates both the mucosal and serosal surfaces of the epithelial membrane.
1	0	2	O	The
2	4	10	O	results
3	12	19	O	indicate
4	21	24	O	that
5	26	29	U-UNK	As(V
6	32	38	O	readily
7	40	49	O	penetrates
8	51	54	O	both
9	56	58	O	the
10	60	66	O	mucosal
11	68	70	O	and
12	72	78	O	serosal
13	80	87	O	surfaces
14	89	90	O	of
15	92	94	O	the
16	96	105	O	epithelial
17	107	114	O	membrane
NULL

2981680.xml	DDI-MedLine.d82.s7	NO_SECTION	NO_SETID	31
Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	U-UNK	arsenate
4	22	24	O	and
5	26	34	U-UNK	phosphate
6	36	37	O	do
7	39	41	O	not
8	43	48	O	appear
9	50	51	O	to
10	53	57	O	share
11	59	59	O	a
12	61	66	O	common
13	68	76	O	transport
14	78	84	O	pathway
15	86	87	O	in
16	89	91	O	the
17	93	100	O	duodenum
18	102	104	O	and
19	106	107	O	no
20	109	116	O	evidence
21	118	120	O	was
22	122	129	O	obtained
23	131	133	O	for
24	135	137	O	any
25	139	149	O	interaction
26	151	157	O	between
27	159	161	O	the
28	163	165	O	two
29	167	168	O	at
30	170	173	O	this
31	175	179	O	level
NULL

2981680.xml	DDI-MedLine.d82.s8	NO_SECTION	NO_SETID	21
Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
1	0	6	B-UNK	Vitamin
2	8	9	L-UNK	D3
3	11	24	O	administration
4	26	27	O	to
5	29	36	O	rachitic
6	38	43	O	chicks
7	45	47	O	was
8	49	57	O	effective
9	59	60	O	in
10	62	74	O	significantly
11	76	84	O	elevating
12	86	93	O	duodenal
13	95	102	U-UNK	arsenate
14	104	113	O	absorption
15	114	114	O	,
16	116	121	O	acting
17	123	131	O	primarily
18	133	134	O	to
19	136	142	O	enhance
20	144	150	O	serosal
21	152	160	O	transport
NULL

2981704.xml	DDI-MedLine.d22.s0	NO_SECTION	NO_SETID	27
Spermine promotes the translocation of phosphatidate phosphohydrolase from the cytosol to the microsomal fraction of rat liver and it enhances the effects of oleate in this respect.
1	0	7	U-UNK	Spermine
2	9	16	O	promotes
3	18	20	O	the
4	22	34	O	translocation
5	36	37	O	of
6	39	51	O	phosphatidate
7	53	68	O	phosphohydrolase
8	70	73	O	from
9	75	77	O	the
10	79	85	O	cytosol
11	87	88	O	to
12	90	92	O	the
13	94	103	O	microsomal
14	105	112	O	fraction
15	114	115	O	of
16	117	119	O	rat
17	121	125	O	liver
18	127	129	O	and
19	131	132	O	it
20	134	141	O	enhances
21	143	145	O	the
22	147	153	O	effects
23	155	156	O	of
24	158	163	O	oleate
25	165	166	O	in
26	168	171	O	this
27	173	179	O	respect
NULL

2981704.xml	DDI-MedLine.d22.s1	NO_SECTION	NO_SETID	26
Spermine (0.5-2 mM) promoted the translocation of phosphatidate phosphohydrolase from the soluble to the microsomal fraction in a cell-free system derived from rat liver.
1	0	7	U-UNK	Spermine
2	10	12	O	0.5
3	14	14	O	2
4	16	17	O	mM
5	20	27	O	promoted
6	29	31	O	the
7	33	45	O	translocation
8	47	48	O	of
9	50	62	O	phosphatidate
10	64	79	O	phosphohydrolase
11	81	84	O	from
12	86	88	O	the
13	90	96	O	soluble
14	98	99	O	to
15	101	103	O	the
16	105	114	O	microsomal
17	116	123	O	fraction
18	125	126	O	in
19	128	128	O	a
20	130	133	O	cell
21	135	138	O	free
22	140	145	O	system
23	147	153	O	derived
24	155	158	O	from
25	160	162	O	rat
26	164	168	O	liver
NULL

2981704.xml	DDI-MedLine.d22.s2	NO_SECTION	NO_SETID	20
By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone.
1	0	1	O	By
2	3	10	O	contrast
3	11	11	O	,
4	13	22	U-UNK	spermidine
5	25	25	O	1
6	27	28	O	mM
7	31	33	O	and
8	35	44	U-UNK	putrescine
9	47	47	O	1
10	49	50	O	mM
11	53	55	O	had
12	57	58	O	no
13	60	70	O	significant
14	72	77	O	effect
15	79	80	O	on
16	82	84	O	the
17	86	98	O	translocation
18	100	103	O	when
19	105	109	O	added
20	111	115	O	alone
NULL

2981704.xml	DDI-MedLine.d22.s3	NO_SECTION	NO_SETID	31
Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.
1	0	7	U-UNK	Spermine
2	8	8	O	,
3	10	12	O	and
4	14	15	O	to
5	17	17	O	a
6	19	24	O	lesser
7	26	31	O	extent
8	32	32	O	,
9	34	43	U-UNK	spermidine
10	44	44	O	,
11	46	53	O	enhanced
12	55	57	O	the
13	59	71	O	translocating
14	73	78	O	action
15	80	81	O	of
16	83	88	O	oleate
17	90	92	O	and
18	94	102	O	increased
19	104	106	O	its
20	108	120	O	effectiveness
21	122	123	O	in
22	125	136	O	transferring
23	138	140	O	the
24	142	157	O	phosphohydrolase
25	159	162	O	from
26	164	166	O	the
27	168	174	O	soluble
28	176	177	O	to
29	179	181	O	the
30	183	192	O	microsomal
31	194	201	O	fraction
NULL

2981704.xml	DDI-MedLine.d22.s4	NO_SECTION	NO_SETID	23
It is proposed that the phosphohydrolase becomes metabolically active when it combines with membranes and that polyamines might help to regulate this interaction.
1	0	1	O	It
2	3	4	O	is
3	6	13	O	proposed
4	15	18	O	that
5	20	22	O	the
6	24	39	O	phosphohydrolase
7	41	47	O	becomes
8	49	61	O	metabolically
9	63	68	O	active
10	70	73	O	when
11	75	76	O	it
12	78	85	O	combines
13	87	90	O	with
14	92	100	O	membranes
15	102	104	O	and
16	106	109	O	that
17	111	120	O	polyamines
18	122	126	O	might
19	128	131	O	help
20	133	134	O	to
21	136	143	O	regulate
22	145	148	O	this
23	150	160	O	interaction
NULL

2981704.xml	DDI-MedLine.d22.s5	NO_SECTION	NO_SETID	26
This could facilitate the action of fatty acids and enable cells to increase their capacity for triacylglycerol synthesis to match an increased availability of fatty acids.
1	0	3	O	This
2	5	9	O	could
3	11	20	O	facilitate
4	22	24	O	the
5	26	31	O	action
6	33	34	O	of
7	36	40	O	fatty
8	42	46	O	acids
9	48	50	O	and
10	52	57	O	enable
11	59	63	O	cells
12	65	66	O	to
13	68	75	O	increase
14	77	81	O	their
15	83	90	O	capacity
16	92	94	O	for
17	96	110	O	triacylglycerol
18	112	120	O	synthesis
19	122	123	O	to
20	125	129	O	match
21	131	132	O	an
22	134	142	O	increased
23	144	155	O	availability
24	157	158	O	of
25	160	164	O	fatty
26	166	170	O	acids
NULL

2982252.xml	DDI-MedLine.d100.s0	NO_SECTION	NO_SETID	12
Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.
1	0	8	O	Influence
2	10	11	O	of
3	13	19	B-UNK	calcium
4	21	27	I-UNK	channel
5	29	36	L-UNK	blockers
6	38	39	O	on
7	41	48	O	platelet
8	50	57	O	function
9	59	61	O	and
10	63	73	O	arachidonic
11	75	78	O	acid
12	80	89	O	metabolism
NULL

2982252.xml	DDI-MedLine.d100.s1	NO_SECTION	NO_SETID	20
Available data indicate that platelet function and arachidonic acid metabolism are important factors in hemostasis and regulation of vascular tone.
1	0	8	O	Available
2	10	13	O	data
3	15	22	O	indicate
4	24	27	O	that
5	29	36	O	platelet
6	38	45	O	function
7	47	49	O	and
8	51	61	O	arachidonic
9	63	66	O	acid
10	68	77	O	metabolism
11	79	81	O	are
12	83	91	O	important
13	93	99	O	factors
14	101	102	O	in
15	104	113	O	hemostasis
16	115	117	O	and
17	119	128	O	regulation
18	130	131	O	of
19	133	140	O	vascular
20	142	145	O	tone
NULL

2982252.xml	DDI-MedLine.d100.s2	NO_SECTION	NO_SETID	19
Plasma membrane and intracellular mobilization of calcium ions are intimately related to platelet activation and release of platelet contents.
1	0	5	O	Plasma
2	7	14	O	membrane
3	16	18	O	and
4	20	32	O	intracellular
5	34	45	O	mobilization
6	47	48	O	of
7	50	56	O	calcium
8	58	61	O	ions
9	63	65	O	are
10	67	76	O	intimately
11	78	84	O	related
12	86	87	O	to
13	89	96	O	platelet
14	98	107	O	activation
15	109	111	O	and
16	113	119	O	release
17	121	122	O	of
18	124	131	O	platelet
19	133	140	O	contents
NULL

2982252.xml	DDI-MedLine.d100.s3	NO_SECTION	NO_SETID	26
Release of arachidonic acid from membrane phospholipids as well as subsequent synthesis and release of vasoconstrictor thromboxane A2 are also regulated by movement of calcium ions.
1	0	6	O	Release
2	8	9	O	of
3	11	21	O	arachidonic
4	23	26	O	acid
5	28	31	O	from
6	33	40	O	membrane
7	42	54	O	phospholipids
8	56	57	O	as
9	59	62	O	well
10	64	65	O	as
11	67	76	O	subsequent
12	78	86	O	synthesis
13	88	90	O	and
14	92	98	O	release
15	100	101	O	of
16	103	117	O	vasoconstrictor
17	119	129	O	thromboxane
18	131	132	O	A2
19	134	136	O	are
20	138	141	O	also
21	143	151	O	regulated
22	153	154	O	by
23	156	163	O	movement
24	165	166	O	of
25	168	174	O	calcium
26	176	179	O	ions
NULL

2982252.xml	DDI-MedLine.d100.s4	NO_SECTION	NO_SETID	19
Adenosine 3':5'-cyclic phosphate in turn controls levels of free calcium ions in platelets and regulates calcium-dependent reactions.
1	0	8	O	Adenosine
2	10	14	O	3':5'
3	16	21	O	cyclic
4	23	31	O	phosphate
5	33	34	O	in
6	36	39	O	turn
7	41	48	O	controls
8	50	55	O	levels
9	57	58	O	of
10	60	63	O	free
11	65	71	O	calcium
12	73	76	O	ions
13	78	79	O	in
14	81	89	O	platelets
15	91	93	O	and
16	95	103	O	regulates
17	105	111	O	calcium
18	113	121	O	dependent
19	123	131	O	reactions
NULL

2982252.xml	DDI-MedLine.d100.s5	NO_SECTION	NO_SETID	24
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.
1	0	3	B-UNK	Slow
2	5	11	I-UNK	channel
3	13	19	I-UNK	calcium
4	21	28	L-UNK	blockers
5	29	29	O	,
6	31	34	O	such
7	36	37	O	as
8	39	47	U-UNK	verapamil
9	48	48	O	,
10	50	58	U-UNK	diltiazem
11	60	62	O	and
12	64	73	U-UNK	nifedipine
13	74	74	O	,
14	76	82	O	inhibit
15	84	91	O	platelet
16	93	102	O	activation
17	104	105	O	in
18	107	111	O	vitro
19	112	112	O	,
20	114	116	O	and
21	118	125	O	decrease
22	127	134	O	platelet
23	136	143	O	adhesion
24	145	159	O	intravascularly
NULL

2982252.xml	DDI-MedLine.d100.s6	NO_SECTION	NO_SETID	15
These agents have also been shown to decrease platelet nucleotide release and thromboxane A2 generation.
1	0	4	O	These
2	6	11	O	agents
3	13	16	O	have
4	18	21	O	also
5	23	26	O	been
6	28	32	O	shown
7	34	35	O	to
8	37	44	O	decrease
9	46	53	O	platelet
10	55	64	O	nucleotide
11	66	72	O	release
12	74	76	O	and
13	78	88	O	thromboxane
14	90	91	O	A2
15	93	102	O	generation
NULL

2982252.xml	DDI-MedLine.d100.s7	NO_SECTION	NO_SETID	25
Some preliminary data suggest that calcium blockers also increase generation of vasodilator and platelet antiaggregant prostacyclin, which could contribute to decrease in platelet function.
1	0	3	O	Some
2	5	15	O	preliminary
3	17	20	O	data
4	22	28	O	suggest
5	30	33	O	that
6	35	41	B-UNK	calcium
7	43	50	L-UNK	blockers
8	52	55	O	also
9	57	64	O	increase
10	66	75	O	generation
11	77	78	O	of
12	80	90	O	vasodilator
13	92	94	O	and
14	96	103	O	platelet
15	105	117	O	antiaggregant
16	119	130	O	prostacyclin
17	131	131	O	,
18	133	137	O	which
19	139	143	O	could
20	145	154	O	contribute
21	156	157	O	to
22	159	166	O	decrease
23	168	169	O	in
24	171	178	O	platelet
25	180	187	O	function
NULL

2982252.xml	DDI-MedLine.d100.s8	NO_SECTION	NO_SETID	25
These effects of calcium blockers on platelet function and arachidonic acid metabolism could contribute in part to their efficacy in patients with ischemic heart disease.
1	0	4	O	These
2	6	12	O	effects
3	14	15	O	of
4	17	23	B-UNK	calcium
5	25	32	L-UNK	blockers
6	34	35	O	on
7	37	44	O	platelet
8	46	53	O	function
9	55	57	O	and
10	59	69	O	arachidonic
11	71	74	O	acid
12	76	85	O	metabolism
13	87	91	O	could
14	93	102	O	contribute
15	104	105	O	in
16	107	110	O	part
17	112	113	O	to
18	115	119	O	their
19	121	128	O	efficacy
20	130	131	O	in
21	133	140	O	patients
22	142	145	O	with
23	147	154	O	ischemic
24	156	160	O	heart
25	162	168	O	disease
NULL

3155550.xml	DDI-MedLine.d63.s0	NO_SECTION	NO_SETID	20
Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
1	0	11	O	Differential
2	13	19	O	actions
3	21	22	O	of
4	24	34	O	intrathecal
5	36	43	U-UNK	naloxone
6	45	46	O	on
7	48	55	O	blocking
8	57	59	O	the
9	61	64	O	tail
10	66	70	O	flick
11	72	81	O	inhibition
12	83	89	O	induced
13	91	92	O	by
14	94	109	O	intraventricular
15	111	114	B-UNK	beta
16	116	124	L-UNK	endorphin
17	126	128	O	and
18	130	137	U-UNK	morphine
19	139	140	O	in
20	142	145	O	rats
NULL

3155550.xml	DDI-MedLine.d63.s1	NO_SECTION	NO_SETID	29
In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	present
4	15	19	O	study
5	20	20	O	,
6	22	23	O	it
7	25	26	O	is
8	28	35	O	proposed
9	37	40	O	that
10	42	44	O	the
11	46	52	U-UNK	opioids
12	54	60	O	applied
13	62	63	O	to
14	65	75	O	supraspinal
15	77	81	O	brain
16	83	87	O	sites
17	89	96	O	produced
18	98	102	O	their
19	104	112	O	analgesic
20	114	120	O	effects
21	122	123	O	by
22	125	127	O	the
23	129	138	O	activation
24	140	141	O	of
25	143	151	O	different
26	153	162	O	descending
27	164	167	O	pain
28	169	178	O	inhibitory
29	180	186	O	systems
NULL

3155550.xml	DDI-MedLine.d63.s2	NO_SECTION	NO_SETID	27
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied.
1	0	2	O	The
2	4	11	O	blockade
3	13	14	O	of
4	16	18	O	the
5	20	25	O	spinal
6	27	40	O	endorphinergic
7	42	47	O	system
8	49	50	O	by
9	52	62	O	intrathecal
10	64	71	U-UNK	naloxone
11	73	74	O	on
12	76	78	O	the
13	80	89	O	production
14	91	92	O	of
15	94	97	O	tail
16	99	103	O	flick
17	105	114	O	inhibition
18	116	122	O	induced
19	124	125	O	by
20	127	142	O	intraventricular
21	144	147	B-UNK	beta
22	149	157	L-UNK	endorphin
23	159	161	O	and
24	163	170	U-UNK	morphine
25	172	174	O	was
26	176	179	O	then
27	181	187	O	studied
NULL

3155550.xml	DDI-MedLine.d63.s3	NO_SECTION	NO_SETID	21
Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats.
1	0	15	O	Intraventricular
2	17	25	O	injection
3	27	28	O	of
4	30	33	B-UNK	beta
5	35	43	L-UNK	endorphin
6	45	47	O	and
7	49	56	U-UNK	morphine
8	58	65	O	produced
9	67	68	O	an
10	70	79	O	inhibition
11	81	82	O	of
12	84	86	O	the
13	88	91	O	tail
14	93	97	O	flick
15	99	106	O	response
16	108	109	O	to
17	111	113	O	the
18	115	118	O	heat
19	120	127	O	stimulus
20	129	130	O	in
21	132	135	O	rats
NULL

3155550.xml	DDI-MedLine.d63.s4	NO_SECTION	NO_SETID	53
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
1	0	10	O	Intrathecal
2	12	20	O	injection
3	22	23	O	of
4	25	32	U-UNK	naloxone
5	34	35	O	at
6	37	41	O	doses
7	43	44	O	of
8	46	48	O	0.4
9	50	51	O	to
10	53	54	O	40
11	56	65	O	micrograms
12	67	72	O	caused
13	74	74	O	a
14	76	79	O	dose
15	81	87	O	related
16	89	96	O	blockade
17	98	99	O	of
18	101	103	O	the
19	105	114	O	inhibition
20	116	117	O	of
21	119	121	O	the
22	123	126	O	tail
23	128	132	O	flick
24	134	141	O	response
25	143	149	O	induced
26	151	152	O	by
27	154	169	O	intraventricular
28	171	179	O	injection
29	181	182	O	of
30	184	187	B-UNK	beta
31	189	197	L-UNK	endorphin
32	198	198	O	,
33	200	202	O	and
34	204	204	O	a
35	206	209	O	high
36	211	214	O	dose
37	216	217	O	of
38	219	226	U-UNK	naloxone
39	229	230	O	40
40	232	241	O	micrograms
41	244	253	O	completely
42	255	261	O	blocked
43	263	265	O	the
44	267	270	O	tail
45	272	276	O	flick
46	278	287	O	inhibition
47	289	295	O	induced
48	297	298	O	by
49	300	315	O	intraventricular
50	317	320	B-UNK	beta
51	322	330	L-UNK	endorphin
52	333	334	O	16
53	336	345	O	micrograms
NULL

3155550.xml	DDI-MedLine.d63.s5	NO_SECTION	NO_SETID	27
On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
1	0	1	O	On
2	3	5	O	the
3	7	11	O	other
4	13	16	O	hand
5	17	17	O	,
6	19	29	O	intrathecal
7	31	38	U-UNK	naloxone
8	41	42	O	12
9	44	46	O	120
10	48	57	O	micrograms
11	60	62	O	had
12	64	67	O	only
13	69	69	O	a
14	71	74	O	very
15	76	79	O	weak
16	81	86	O	effect
17	88	89	O	on
18	91	93	O	the
19	95	98	O	tail
20	100	104	O	flick
21	106	115	O	inhibition
22	117	123	O	induced
23	125	126	O	by
24	128	143	O	intraventricular
25	145	152	U-UNK	morphine
26	155	156	O	40
27	158	167	O	micrograms
NULL

3155550.xml	DDI-MedLine.d63.s6	NO_SECTION	NO_SETID	29
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
1	0	15	O	Intraventricular
2	17	25	O	injection
3	27	28	O	of
4	30	37	U-UNK	naloxone
5	39	40	O	at
6	42	46	O	doses
7	48	49	O	of
8	51	53	O	1.2
9	55	56	O	to
10	58	59	O	12
11	61	70	O	micrograms
12	72	78	O	equally
13	80	90	O	antagonized
14	92	93	O	in
15	95	95	O	a
16	97	100	O	dose
17	102	110	O	dependent
18	112	117	O	manner
19	119	121	O	the
20	123	126	O	tail
21	128	132	O	flick
22	134	143	O	inhibition
23	145	151	O	induced
24	153	154	O	by
25	156	171	O	intraventricular
26	173	176	B-UNK	beta
27	178	186	L-UNK	endorphin
28	188	190	O	and
29	192	199	U-UNK	morphine
NULL

3155550.xml	DDI-MedLine.d63.s7	NO_SECTION	NO_SETID	47
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems;
1	0	2	O	The
2	4	10	O	results
3	12	19	O	indicate
4	21	24	O	that
5	26	26	O	a
6	28	33	O	spinal
7	35	42	U-UNK	naloxone
8	44	52	O	sensitive
9	54	67	O	endorphinergic
10	69	74	O	system
11	76	77	O	is
12	79	86	O	involved
13	88	89	O	in
14	91	93	O	the
15	95	104	O	production
16	106	107	O	of
17	109	112	B-UNK	beta
18	114	122	L-UNK	endorphin
19	124	126	O	but
20	128	130	O	not
21	132	139	U-UNK	morphine
22	141	147	O	induced
23	149	152	O	tail
24	154	158	O	flick
25	160	169	O	inhibition
26	170	170	O	,
27	172	174	O	and
28	176	182	O	suggest
29	184	187	O	that
30	189	204	O	intraventricular
31	206	209	B-UNK	beta
32	211	219	L-UNK	endorphin
33	221	223	O	and
34	225	232	U-UNK	morphine
35	234	239	O	elicit
36	241	245	O	their
37	247	261	O	pharmacological
38	263	269	O	actions
39	271	273	O	via
40	275	277	O	the
41	279	288	O	activation
42	290	291	O	of
43	293	301	O	different
44	303	312	O	descending
45	314	317	O	pain
46	319	328	O	inhibitory
47	330	336	O	systems
NULL

3155550.xml	DDI-MedLine.d63.s8	NO_SECTION	NO_SETID	15
descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
1	0	9	O	descending
2	11	17	O	epsilon
3	19	21	O	and
4	23	24	O	mu
5	26	32	O	systems
6	34	36	O	for
7	38	41	B-UNK	beta
8	43	51	L-UNK	endorphin
9	53	55	O	and
10	57	64	U-UNK	morphine
11	65	65	O	,
12	67	78	O	respectively
13	79	79	O	,
14	81	83	O	are
15	85	92	O	proposed
NULL

3871245.xml	DDI-MedLine.d73.s0	NO_SECTION	NO_SETID	14
Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
1	0	12	O	Neurochemical
2	14	16	O	and
3	18	27	O	functional
4	29	40	O	consequences
5	42	50	O	following
6	52	52	B-UNK	1
7	54	59	I-UNK	methyl
8	61	61	I-UNK	4
9	63	68	I-UNK	phenyl
10	70	76	I-UNK	1,2,5,6
11	78	95	L-UNK	tetrahydropyridine
12	98	101	U-UNK	MPTP
13	104	106	O	and
14	108	122	U-UNK	methamphetamine
NULL

3871245.xml	DDI-MedLine.d73.s1	NO_SECTION	NO_SETID	21
The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration.
1	0	2	O	The
2	4	16	O	neurochemical
3	18	20	O	and
4	22	31	O	functional
5	33	44	O	consequences
6	46	54	O	following
7	56	59	U-UNK	MPTP
8	61	74	O	administration
9	76	77	O	to
10	79	81	O	the
11	83	85	O	rat
12	87	90	O	were
13	92	100	O	evaluated
14	102	104	O	and
15	106	113	O	compared
16	115	116	O	to
17	118	124	O	similar
18	126	132	O	effects
19	134	142	O	following
20	144	158	U-UNK	methamphetamine
21	160	173	O	administration
NULL

3871245.xml	DDI-MedLine.d73.s2	NO_SECTION	NO_SETID	23
It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
1	0	1	O	It
2	3	5	O	was
3	7	14	O	observed
4	16	19	O	that
5	21	24	U-UNK	MPTP
6	26	32	O	induced
7	34	37	O	long
8	39	45	O	lasting
9	47	56	O	depletions
10	58	59	O	of
11	61	68	O	striatal
12	70	77	O	dopamine
13	79	92	O	concentrations
14	94	96	O	and
15	98	101	O	this
16	103	112	O	neurotoxic
17	114	119	O	effect
18	121	125	O	could
19	127	128	O	be
20	130	138	O	prevented
21	140	141	O	by
22	143	151	U-UNK	pargyline
23	153	164	O	pretreatment
NULL

3871245.xml	DDI-MedLine.d73.s3	NO_SECTION	NO_SETID	31
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
1	0	2	O	The
2	4	7	U-UNK	MPTP
3	9	15	O	induced
4	17	24	O	neuronal
5	26	31	O	damage
6	33	40	O	produced
7	42	42	O	a
8	44	52	O	tolerance
9	54	55	O	to
10	57	59	O	the
11	61	70	O	disruptive
12	72	78	O	effects
13	80	81	O	of
14	83	93	U-UNK	amphetamine
15	95	97	O	and
16	99	99	O	a
17	101	116	O	supersensitivity
18	118	119	O	to
19	121	123	O	the
20	125	134	O	disruptive
21	136	142	O	effects
22	144	145	O	of
23	147	157	U-UNK	apomorphine
24	159	160	O	in
25	162	165	O	rats
26	167	176	O	responding
27	178	179	O	in
28	181	181	O	a
29	183	190	O	schedule
30	192	201	O	controlled
31	203	210	O	paradigm
NULL

3871245.xml	DDI-MedLine.d73.s4	NO_SECTION	NO_SETID	18
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
1	0	14	U-UNK	Methamphetamine
2	15	15	O	,
3	17	20	O	like
4	22	25	U-UNK	MPTP
5	26	26	O	,
6	28	35	O	produced
7	37	46	O	depletions
8	48	49	O	of
9	51	58	O	striatal
10	60	67	O	dopamine
11	69	71	O	but
12	73	77	O	these
13	79	85	O	actions
14	87	90	O	were
15	92	102	O	potentiated
16	104	105	O	by
17	107	115	U-UNK	pargyline
18	117	128	O	pretreatment
NULL

3871245.xml	DDI-MedLine.d73.s5	NO_SECTION	NO_SETID	20
These observations are discussed in reference to possible deleterious effects following the administration of pargyline to patients with Parkinson's Disease.
1	0	4	O	These
2	6	17	O	observations
3	19	21	O	are
4	23	31	O	discussed
5	33	34	O	in
6	36	44	O	reference
7	46	47	O	to
8	49	56	O	possible
9	58	68	O	deleterious
10	70	76	O	effects
11	78	86	O	following
12	88	90	O	the
13	92	105	O	administration
14	107	108	O	of
15	110	118	U-UNK	pargyline
16	120	121	O	to
17	123	130	O	patients
18	132	135	O	with
19	137	147	O	Parkinson's
20	149	155	O	Disease
NULL

3871459.xml	DDI-MedLine.d96.s0	NO_SECTION	NO_SETID	6
Jacalin: an IgA-binding lectin.
1	0	6	U-UNK	Jacalin
2	7	7	O	:
3	9	10	O	an
4	12	14	O	IgA
5	16	22	O	binding
6	24	29	O	lectin
NULL

3871459.xml	DDI-MedLine.d96.s1	NO_SECTION	NO_SETID	42
We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins.
1	0	1	O	We
2	3	12	O	previously
3	14	21	O	reported
4	23	26	O	that
5	28	32	O	seeds
6	34	35	O	of
7	37	46	O	Artocarpus
8	48	59	O	integrifolia
9	62	70	O	jackfruit
10	73	79	O	contain
11	81	81	O	a
12	83	88	O	lectin
13	89	89	O	,
14	91	95	O	which
15	97	98	O	we
16	100	103	O	call
17	105	111	U-UNK	jacalin
18	112	112	O	,
19	114	117	O	that
20	119	120	O	is
21	122	125	O	both
22	127	127	O	a
23	129	134	O	potent
24	136	136	O	T
25	138	141	O	cell
26	143	149	O	mitogen
27	151	153	O	and
28	155	156	O	an
29	158	167	O	apparently
30	169	169	O	T
31	171	174	O	cell
32	176	186	O	independent
33	188	196	O	activator
34	198	199	O	of
35	201	205	O	human
36	207	207	O	B
37	209	213	O	cells
38	215	217	O	for
39	219	221	O	the
40	223	231	O	secretion
41	233	234	O	of
42	236	250	O	immunoglobulins
NULL

3871459.xml	DDI-MedLine.d96.s2	NO_SECTION	NO_SETID	23
During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin.
1	0	5	O	During
2	7	9	O	the
3	11	15	O	above
4	17	27	O	experiments
5	29	30	O	we
6	32	36	O	noted
7	38	38	O	a
8	40	46	O	massive
9	48	60	O	precipitation
10	62	63	O	in
11	65	68	O	cell
12	70	77	O	cultures
13	79	88	O	stimulated
14	90	93	O	with
15	95	101	O	greater
16	103	106	O	than
17	108	109	O	or
18	111	115	O	equal
19	117	118	O	to
20	120	122	O	100
21	124	133	O	micrograms
22	135	136	O	of
23	138	143	O	lectin
NULL

3871459.xml	DDI-MedLine.d96.s3	NO_SECTION	NO_SETID	25
In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	paper
4	13	13	O	,
5	15	16	O	we
6	18	21	O	show
7	23	26	O	that
8	28	30	O	the
9	32	42	O	precipitate
10	44	45	O	is
11	47	52	O	formed
12	54	58	O	after
13	60	62	O	the
14	64	74	O	interaction
15	76	77	O	of
16	79	85	U-UNK	jacalin
17	87	89	O	and
18	91	93	O	the
19	95	99	O	serum
20	101	107	O	protein
21	109	113	O	added
22	115	116	O	to
23	118	120	O	the
24	122	128	O	culture
25	130	135	O	medium
NULL

3871459.xml	DDI-MedLine.d96.s4	NO_SECTION	NO_SETID	29
More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates.
1	0	3	O	More
2	5	15	O	importantly
3	16	16	O	,
4	18	19	O	we
5	21	31	O	demonstrate
6	33	36	O	that
7	38	40	O	IgA
8	42	43	O	is
9	45	52	O	probably
10	54	56	O	the
11	58	62	O	major
12	64	68	O	serum
13	70	80	O	constituent
14	82	93	O	precipitated
15	95	96	O	by
16	98	100	O	the
17	102	107	O	lectin
18	109	111	O	and
19	113	116	O	that
20	118	119	O	no
21	121	123	O	IgG
22	125	126	O	or
23	128	130	O	IgM
24	132	134	O	can
25	136	137	O	be
26	139	146	O	detected
27	148	149	O	in
28	151	153	O	the
29	155	166	O	precipitates
NULL

3871459.xml	DDI-MedLine.d96.s5	NO_SECTION	NO_SETID	14
In secretions such as colostrum, IgA is the only protein precipitated by jacalin.
1	0	1	O	In
2	3	12	O	secretions
3	14	17	O	such
4	19	20	O	as
5	22	30	O	colostrum
6	31	31	O	,
7	33	35	O	IgA
8	37	38	O	is
9	40	42	O	the
10	44	47	O	only
11	49	55	O	protein
12	57	68	O	precipitated
13	70	71	O	by
14	73	79	U-UNK	jacalin
NULL

3871459.xml	DDI-MedLine.d96.s6	NO_SECTION	NO_SETID	25
On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	19	O	this
6	21	31	O	specificity
7	33	34	O	we
8	36	43	O	describe
9	45	45	O	a
10	47	52	O	simple
11	54	56	O	and
12	58	65	O	reliable
13	67	74	O	affinity
14	76	89	O	chromatography
15	91	99	O	procedure
16	101	103	O	for
17	105	107	O	the
18	109	120	O	purification
19	122	123	O	of
20	125	128	O	both
21	130	134	O	human
22	136	140	O	serum
23	142	144	O	and
24	146	154	O	colostrum
25	156	158	O	IgA
NULL

3871459.xml	DDI-MedLine.d96.s7	NO_SECTION	NO_SETID	20
Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.
1	0	6	U-UNK	Jacalin
2	8	9	O	is
3	11	11	O	a
4	13	13	O	D
5	15	17	O	Gal
6	19	25	O	binding
7	27	32	O	lectin
8	34	36	O	and
9	38	43	O	should
10	45	46	O	be
11	48	48	O	a
12	50	55	O	useful
13	57	60	O	tool
14	62	64	O	for
15	66	73	O	studying
16	75	76	O	of
17	78	82	O	serum
18	84	86	O	and
19	88	96	O	secretory
20	98	100	O	IgA
NULL

3881076.xml	DDI-MedLine.d31.s0	NO_SECTION	NO_SETID	10
Cancer in the elderly: basic science and clinical aspects.
1	0	5	O	Cancer
2	7	8	O	in
3	10	12	O	the
4	14	20	O	elderly
5	21	21	O	:
6	23	27	O	basic
7	29	35	O	science
8	37	39	O	and
9	41	48	O	clinical
10	50	56	O	aspects
NULL

3881076.xml	DDI-MedLine.d31.s1	NO_SECTION	NO_SETID	8
The incidence of cancer increases progressively with age.
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	22	O	cancer
5	24	32	O	increases
6	34	46	O	progressively
7	48	51	O	with
8	53	55	O	age
NULL

3881076.xml	DDI-MedLine.d31.s2	NO_SECTION	NO_SETID	10
Rearrangements of genomes have been found to accompany cellular aging.
1	0	13	O	Rearrangements
2	15	16	O	of
3	18	24	O	genomes
4	26	29	O	have
5	31	34	O	been
6	36	40	O	found
7	42	43	O	to
8	45	53	O	accompany
9	55	62	O	cellular
10	64	68	O	aging
NULL

3881076.xml	DDI-MedLine.d31.s3	NO_SECTION	NO_SETID	29
These factors, in concert with age-dependent alterations in immune function and host defense, may help to explain the increased risk of malignant disease in aged persons.
1	0	4	O	These
2	6	12	O	factors
3	13	13	O	,
4	15	16	O	in
5	18	24	O	concert
6	26	29	O	with
7	31	33	O	age
8	35	43	O	dependent
9	45	55	O	alterations
10	57	58	O	in
11	60	65	O	immune
12	67	74	O	function
13	76	78	O	and
14	80	83	O	host
15	85	91	O	defense
16	92	92	O	,
17	94	96	O	may
18	98	101	O	help
19	103	104	O	to
20	106	112	O	explain
21	114	116	O	the
22	118	126	O	increased
23	128	131	O	risk
24	133	134	O	of
25	136	144	O	malignant
26	146	152	O	disease
27	154	155	O	in
28	157	160	O	aged
29	162	168	O	persons
NULL

3881076.xml	DDI-MedLine.d31.s4	NO_SECTION	NO_SETID	13
The clinical presentation and natural history of neoplasia are also affected by aging.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	presentation
4	26	28	O	and
5	30	36	O	natural
6	38	44	O	history
7	46	47	O	of
8	49	57	O	neoplasia
9	59	61	O	are
10	63	66	O	also
11	68	75	O	affected
12	77	78	O	by
13	80	84	O	aging
NULL

3881076.xml	DDI-MedLine.d31.s5	NO_SECTION	NO_SETID	38
This conference reviews recent developments in these areas, examines the effects of drug use in the elderly and implications for management, and discusses current information on how age may influence the response of cancer to therapy.
1	0	3	O	This
2	5	14	O	conference
3	16	22	O	reviews
4	24	29	O	recent
5	31	42	O	developments
6	44	45	O	in
7	47	51	O	these
8	53	57	O	areas
9	58	58	O	,
10	60	67	O	examines
11	69	71	O	the
12	73	79	O	effects
13	81	82	O	of
14	84	87	O	drug
15	89	91	O	use
16	93	94	O	in
17	96	98	O	the
18	100	106	O	elderly
19	108	110	O	and
20	112	123	O	implications
21	125	127	O	for
22	129	138	O	management
23	139	139	O	,
24	141	143	O	and
25	145	153	O	discusses
26	155	161	O	current
27	163	173	O	information
28	175	176	O	on
29	178	180	O	how
30	182	184	O	age
31	186	188	O	may
32	190	198	O	influence
33	200	202	O	the
34	204	211	O	response
35	213	214	O	of
36	216	221	O	cancer
37	223	224	O	to
38	226	232	O	therapy
NULL

3881461.xml	DDI-MedLine.d12.s0	NO_SECTION	NO_SETID	16
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
1	0	12	U-UNK	Dexamethasone
2	14	16	O	and
3	18	24	B-UNK	retinyl
4	26	32	L-UNK	acetate
5	34	42	O	similarly
6	44	50	O	inhibit
7	52	54	O	and
8	56	64	O	stimulate
9	66	68	U-UNK	EGF
10	71	72	O	or
11	74	80	U-UNK	insulin
12	82	88	O	induced
13	90	102	O	proliferation
14	104	105	O	of
15	107	115	O	prostatic
16	117	126	O	epithelium
NULL

3881461.xml	DDI-MedLine.d12.s1	NO_SECTION	NO_SETID	36
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).
1	0	8	O	Prostatic
2	10	19	O	epithelium
3	21	32	O	proliferates
4	34	35	O	in
5	37	37	O	a
6	39	45	O	defined
7	47	52	O	medium
8	54	63	O	consisting
9	65	66	O	of
10	68	72	O	basal
11	74	79	O	medium
12	81	88	O	RPMI1640
13	90	99	O	containing
14	101	111	U-UNK	transferrin
15	114	114	O	1
16	116	124	O	microgram
17	125	125	O	/
18	126	127	O	ml
19	129	129	O	,
20	131	133	U-UNK	EGF
21	136	137	O	10
22	139	140	O	ng
23	141	141	O	/
24	142	143	O	ml
25	145	145	O	,
26	147	149	O	and
27	151	157	U-UNK	insulin
28	160	162	O	3.7
29	164	173	O	micrograms
30	174	174	O	/
31	175	176	O	ml
32	178	179	O	or
33	181	183	O	0.1
34	185	186	O	IU
35	187	187	O	/
36	188	189	O	ml
NULL

3881461.xml	DDI-MedLine.d12.s2	NO_SECTION	NO_SETID	27
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
1	0	7	O	Although
2	9	15	O	neither
3	17	29	U-UNK	dexamethasone
4	31	33	O	nor
5	35	41	B-UNK	retinyl
6	43	49	L-UNK	acetate
7	51	58	O	affected
8	60	62	O	the
9	64	76	O	proliferation
10	78	79	O	of
11	81	89	O	prostatic
12	91	100	O	epithelium
13	102	103	O	in
14	105	112	O	RPMI1640
15	114	123	O	containing
16	125	135	U-UNK	transferrin
17	137	141	O	alone
18	142	142	O	,
19	144	147	O	they
20	149	154	O	modify
21	156	158	O	the
22	160	168	O	mitogenic
23	170	175	O	effect
24	177	178	O	of
25	180	182	U-UNK	EGF
26	184	186	O	and
27	188	194	U-UNK	insulin
NULL

3881461.xml	DDI-MedLine.d12.s3	NO_SECTION	NO_SETID	20
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
1	0	12	U-UNK	Dexamethasone
2	14	15	O	at
3	17	18	O	10
4	21	22	O	10
5	25	25	O	M
6	27	28	O	or
7	30	36	B-UNK	retinyl
8	38	44	L-UNK	acetate
9	46	47	O	at
10	49	53	O	about
11	55	55	O	3
12	57	57	O	XXXXXXXX
13	59	60	O	10
14	63	63	O	9
15	66	66	O	M
16	68	75	O	inhibits
17	77	89	O	proliferation
18	91	100	O	stimulated
19	102	103	O	by
20	105	107	U-UNK	EGF
NULL

3881461.xml	DDI-MedLine.d12.s4	NO_SECTION	NO_SETID	25
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
1	0	5	O	Higher
2	7	20	O	concentrations
3	22	23	O	of
4	25	37	U-UNK	dexamethasone
5	40	41	O	10
6	44	44	O	8
7	49	50	O	10
8	53	53	O	6
9	56	56	O	M
10	59	60	O	or
11	62	68	B-UNK	retinyl
12	70	76	L-UNK	acetate
13	79	79	O	3
14	81	81	O	XXXXXXXX
15	83	84	O	10
16	87	87	O	8
17	92	93	O	10
18	96	96	O	7
19	99	99	O	M
20	102	108	O	enhance
21	110	112	O	the
22	114	122	O	mitogenic
23	124	131	O	activity
24	133	134	O	of
25	136	138	U-UNK	EGF
NULL

3881461.xml	DDI-MedLine.d12.s5	NO_SECTION	NO_SETID	10
Dexamethasone had a similar effect in the presence of insulin.
1	0	12	U-UNK	Dexamethasone
2	14	16	O	had
3	18	18	O	a
4	20	26	O	similar
5	28	33	O	effect
6	35	36	O	in
7	38	40	O	the
8	42	49	O	presence
9	51	52	O	of
10	54	60	U-UNK	insulin
NULL

3881461.xml	DDI-MedLine.d12.s6	NO_SECTION	NO_SETID	18
However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
1	0	6	O	However
2	7	7	O	,
3	9	15	B-UNK	retinyl
4	17	23	L-UNK	acetate
5	25	34	O	stimulated
6	35	35	O	,
7	37	39	O	but
8	41	43	O	did
9	45	47	O	not
10	49	61	O	significantly
11	63	69	O	inhibit
12	70	70	O	,
13	72	84	O	proliferation
14	86	87	O	in
15	89	91	O	the
16	93	100	O	presence
17	102	103	O	of
18	105	111	U-UNK	insulin
NULL

3881461.xml	DDI-MedLine.d12.s7	NO_SECTION	NO_SETID	36
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	30	O	both
6	32	44	U-UNK	dexamethasone
7	46	48	O	and
8	50	56	B-UNK	retinyl
9	58	64	L-UNK	acetate
10	65	65	O	,
11	67	69	O	and
12	71	78	O	possibly
13	80	84	O	other
14	86	100	U-UNK	glucocorticoids
15	102	104	O	and
16	106	114	U-UNK	retinoids
17	115	115	O	,
18	117	119	O	may
19	121	128	O	regulate
20	130	132	O	the
21	134	146	O	proliferation
22	148	149	O	of
23	151	158	O	prostate
24	160	169	O	epithelium
25	171	172	O	by
26	174	174	O	a
27	176	179	O	dose
28	181	189	O	dependent
29	191	202	O	modification
30	204	205	O	of
31	207	209	O	the
32	211	218	O	activity
33	220	221	O	of
34	223	229	U-UNK	insulin
35	231	233	O	and
36	235	237	U-UNK	EGF
NULL

3881917.xml	DDI-MedLine.d9.s0	NO_SECTION	NO_SETID	5
Pharmacokinetics of calcium-entry blockers.
1	0	15	O	Pharmacokinetics
2	17	18	O	of
3	20	26	B-UNK	calcium
4	28	32	I-UNK	entry
5	34	41	L-UNK	blockers
NULL

3881917.xml	DDI-MedLine.d9.s1	NO_SECTION	NO_SETID	23
Effective use of drugs in therapy depends not only on clinical acumen but also on the availability of relevant pharmacokinetic and pharmacodynamic data.
1	0	8	O	Effective
2	10	12	O	use
3	14	15	O	of
4	17	21	O	drugs
5	23	24	O	in
6	26	32	O	therapy
7	34	40	O	depends
8	42	44	O	not
9	46	49	O	only
10	51	52	O	on
11	54	61	O	clinical
12	63	68	O	acumen
13	70	72	O	but
14	74	77	O	also
15	79	80	O	on
16	82	84	O	the
17	86	97	O	availability
18	99	100	O	of
19	102	109	O	relevant
20	111	125	O	pharmacokinetic
21	127	129	O	and
22	131	145	O	pharmacodynamic
23	147	150	O	data
NULL

3881917.xml	DDI-MedLine.d9.s2	NO_SECTION	NO_SETID	27
Such information assists in development of safe dosing regimens, prediction of abnormal handling of drugs in states of disease and disorder and anticipation of drug interactions.
1	0	3	O	Such
2	5	15	O	information
3	17	23	O	assists
4	25	26	O	in
5	28	38	O	development
6	40	41	O	of
7	43	46	O	safe
8	48	53	O	dosing
9	55	62	O	regimens
10	63	63	O	,
11	65	74	O	prediction
12	76	77	O	of
13	79	86	O	abnormal
14	88	95	O	handling
15	97	98	O	of
16	100	104	O	drugs
17	106	107	O	in
18	109	114	O	states
19	116	117	O	of
20	119	125	O	disease
21	127	129	O	and
22	131	138	O	disorder
23	140	142	O	and
24	144	155	O	anticipation
25	157	158	O	of
26	160	163	O	drug
27	165	176	O	interactions
NULL

3881917.xml	DDI-MedLine.d9.s3	NO_SECTION	NO_SETID	28
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved.
1	0	2	O	For
2	4	6	O	the
3	8	14	B-UNK	calcium
4	16	20	I-UNK	entry
5	22	29	I-UNK	blocking
6	31	36	L-UNK	agents
7	38	40	O	now
8	42	50	O	available
9	52	53	O	in
10	55	57	O	the
11	59	64	O	United
12	66	71	O	States
13	74	82	U-UNK	verapamil
14	83	83	O	,
15	85	94	U-UNK	nifedipine
16	96	98	O	and
17	100	108	U-UNK	diltiazem
18	110	110	O	,
19	112	116	O	these
20	118	121	O	data
21	123	130	O	appeared
22	132	135	O	well
23	137	141	O	after
24	143	150	O	clinical
25	152	159	O	patterns
26	161	162	O	of
27	164	166	O	use
28	168	174	O	evolved
NULL

3881917.xml	DDI-MedLine.d9.s4	NO_SECTION	NO_SETID	26
Nonetheless, their relevance continues to be demonstrated by the dependence of each agent on intact liver blood flow and function for normal rates of elimination;
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	17	O	their
4	19	27	O	relevance
5	29	37	O	continues
6	39	40	O	to
7	42	43	O	be
8	45	56	O	demonstrated
9	58	59	O	by
10	61	63	O	the
11	65	74	O	dependence
12	76	77	O	of
13	79	82	O	each
14	84	88	O	agent
15	90	91	O	on
16	93	98	O	intact
17	100	104	O	liver
18	106	110	O	blood
19	112	115	O	flow
20	117	119	O	and
21	121	128	O	function
22	130	132	O	for
23	134	139	O	normal
24	141	145	O	rates
25	147	148	O	of
26	150	160	O	elimination
NULL

3881917.xml	DDI-MedLine.d9.s5	NO_SECTION	NO_SETID	25
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements;
1	0	1	O	by
2	3	5	O	the
3	7	15	O	nonlinear
4	17	23	O	kinetic
5	25	39	O	characteristics
6	41	43	O	for
7	45	53	U-UNK	verapamil
8	55	57	O	and
9	59	67	U-UNK	diltiazem
10	70	72	O	and
11	74	81	O	probably
12	83	85	O	for
13	87	96	U-UNK	nifedipine
14	97	97	O	,
15	99	100	O	as
16	102	105	O	well
17	108	110	O	and
18	112	114	O	the
19	116	125	O	derivative
20	127	138	O	implications
21	140	142	O	for
22	144	152	O	decreased
23	154	159	O	dosing
24	161	169	O	frequency
25	171	182	O	requirements
NULL

3881917.xml	DDI-MedLine.d9.s6	NO_SECTION	NO_SETID	20
and by observations now appearing on the relation between plasma drug levels and drug effects, both therapeutic and toxic.
1	0	2	O	and
2	4	5	O	by
3	7	18	O	observations
4	20	22	O	now
5	24	32	O	appearing
6	34	35	O	on
7	37	39	O	the
8	41	48	O	relation
9	50	56	O	between
10	58	63	O	plasma
11	65	68	O	drug
12	70	75	O	levels
13	77	79	O	and
14	81	84	O	drug
15	86	92	O	effects
16	93	93	O	,
17	95	98	O	both
18	100	110	O	therapeutic
19	112	114	O	and
20	116	120	O	toxic
NULL

3881917.xml	DDI-MedLine.d9.s7	NO_SECTION	NO_SETID	22
Such data are discussed herein, with emphasis on those aspects that impact on the clinical use of the calcium-entry antagonists.
1	0	3	O	Such
2	5	8	O	data
3	10	12	O	are
4	14	22	O	discussed
5	24	29	O	herein
6	30	30	O	,
7	32	35	O	with
8	37	44	O	emphasis
9	46	47	O	on
10	49	53	O	those
11	55	61	O	aspects
12	63	66	O	that
13	68	73	O	impact
14	75	76	O	on
15	78	80	O	the
16	82	89	O	clinical
17	91	93	O	use
18	95	96	O	of
19	98	100	O	the
20	102	108	B-UNK	calcium
21	110	114	I-UNK	entry
22	116	126	L-UNK	antagonists
NULL

3918122.xml	DDI-MedLine.d45.s0	NO_SECTION	NO_SETID	14
Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
1	0	8	O	Selective
2	10	17	O	survival
3	19	20	O	in
4	22	32	U-UNK	pentazocine
5	34	36	O	and
6	38	51	U-UNK	tripelennamine
7	53	54	O	of
8	56	66	O	Pseudomonas
9	68	77	O	aeruginosa
10	79	86	O	serotype
11	88	90	O	O11
12	92	95	O	from
13	97	100	O	drug
14	102	108	O	addicts
NULL

3918122.xml	DDI-MedLine.d45.s1	NO_SECTION	NO_SETID	14
The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine
1	0	2	O	The
2	4	9	O	growth
3	11	12	O	of
4	14	24	O	Pseudomonas
5	26	35	O	aeruginosa
6	36	36	O	,
7	38	49	O	particularly
8	51	58	O	serotype
9	60	62	O	O11
10	63	63	O	,
11	65	66	O	in
12	68	78	U-UNK	pentazocine
13	80	82	O	and
14	84	97	U-UNK	tripelennamine
NULL

3918122.xml	DDI-MedLine.d45.s2	NO_SECTION	NO_SETID	21
was evaluated as a possible explanation for the association of deep-seated infection with this organism and abuse of these drugs.
1	0	2	O	was
2	4	12	O	evaluated
3	14	15	O	as
4	17	17	O	a
5	19	26	O	possible
6	28	38	O	explanation
7	40	42	O	for
8	44	46	O	the
9	48	58	O	association
10	60	61	O	of
11	63	66	O	deep
12	68	73	O	seated
13	75	83	O	infection
14	85	88	O	with
15	90	93	O	this
16	95	102	O	organism
17	104	106	O	and
18	108	112	O	abuse
19	114	115	O	of
20	117	121	O	these
21	123	127	O	drugs
NULL

3918122.xml	DDI-MedLine.d45.s3	NO_SECTION	NO_SETID	41
The mean reduction of growth caused by the drugs was 1,000-fold greater for 49 Pseudomonas strains from normal subjects than for 32 strains from drug addicts (4.2 vs. 1.3 logs of reduction at 2 hr, P less than .0005).
1	0	2	O	The
2	4	7	O	mean
3	9	17	O	reduction
4	19	20	O	of
5	22	27	O	growth
6	29	34	O	caused
7	36	37	O	by
8	39	41	O	the
9	43	47	O	drugs
10	49	51	O	was
11	53	57	O	1,000
12	59	62	O	fold
13	64	70	O	greater
14	72	74	O	for
15	76	77	O	49
16	79	89	O	Pseudomonas
17	91	97	O	strains
18	99	102	O	from
19	104	109	O	normal
20	111	118	O	subjects
21	120	123	O	than
22	125	127	O	for
23	129	130	O	32
24	132	138	O	strains
25	140	143	O	from
26	145	148	O	drug
27	150	156	O	addicts
28	159	161	O	4.2
29	163	164	O	vs
30	167	169	O	1.3
31	171	174	O	logs
32	176	177	O	of
33	179	187	O	reduction
34	189	190	O	at
35	192	192	O	2
36	194	195	O	hr
37	196	196	O	,
38	198	198	O	P
39	200	203	O	less
40	205	208	O	than
41	211	214	O	0005
NULL

3918122.xml	DDI-MedLine.d45.s4	NO_SECTION	NO_SETID	19
A common phenotypic subset of the serotype O11 strains from drug addicts was especially resistant to the inhibitory effects.
1	0	0	O	A
2	2	7	O	common
3	9	18	O	phenotypic
4	20	25	O	subset
5	27	28	O	of
6	30	32	O	the
7	34	41	O	serotype
8	43	45	O	O11
9	47	53	O	strains
10	55	58	O	from
11	60	63	O	drug
12	65	71	O	addicts
13	73	75	O	was
14	77	86	O	especially
15	88	96	O	resistant
16	98	99	O	to
17	101	103	O	the
18	105	114	O	inhibitory
19	116	122	O	effects
NULL

3918122.xml	DDI-MedLine.d45.s5	NO_SECTION	NO_SETID	28
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
1	0	5	O	Twelve
2	7	13	O	strains
3	15	16	O	of
4	18	31	O	Staphylococcus
5	33	38	O	aureus
6	41	41	O	a
7	43	50	O	frequent
8	52	56	O	cause
9	58	59	O	of
10	61	69	O	infection
11	71	72	O	in
12	74	79	U-UNK	heroin
13	80	80	O	,
14	82	84	O	but
15	86	88	O	not
16	90	91	O	in
17	93	103	U-UNK	pentazocine
18	105	107	O	and
19	109	122	U-UNK	tripelennamine
20	123	123	O	,
21	125	131	O	addicts
22	134	137	O	were
23	139	148	O	completely
24	150	158	O	inhibited
25	160	161	O	by
26	163	165	O	the
27	167	170	O	drug
28	172	182	O	combination
NULL

3918122.xml	DDI-MedLine.d45.s6	NO_SECTION	NO_SETID	32
Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
1	0	3	O	Dose
2	5	12	O	response
3	14	19	O	curves
4	22	28	O	derived
5	30	33	O	from
6	35	37	O	the
7	39	45	O	results
8	47	48	O	of
9	50	54	O	using
10	56	58	O	the
11	60	66	O	tablets
12	68	69	O	as
13	71	74	O	well
14	76	77	O	as
15	79	82	O	pure
16	84	90	O	powders
17	93	98	O	showed
18	100	103	O	that
19	105	118	U-UNK	tripelennamine
20	120	122	O	was
21	124	134	O	responsible
22	136	138	O	for
23	140	142	O	the
24	144	153	O	inhibitory
25	155	162	O	activity
26	163	163	O	,
27	165	169	O	which
28	171	173	O	was
29	175	183	O	partially
30	185	195	O	antagonized
31	197	198	O	by
32	200	210	U-UNK	pentazocine
NULL

3918122.xml	DDI-MedLine.d45.s7	NO_SECTION	NO_SETID	8
We conclude that an ability of some P.
1	0	1	O	We
2	3	10	O	conclude
3	12	15	O	that
4	17	18	O	an
5	20	26	O	ability
6	28	29	O	of
7	31	34	O	some
8	36	36	O	P
NULL

3918122.xml	DDI-MedLine.d45.s8	NO_SECTION	NO_SETID	8
aeruginosa serotype O11 strains, but not S.
1	0	9	O	aeruginosa
2	11	18	O	serotype
3	20	22	O	O11
4	24	30	O	strains
5	31	31	O	,
6	33	35	O	but
7	37	39	O	not
8	41	41	O	S
NULL

3918122.xml	DDI-MedLine.d45.s9	NO_SECTION	NO_SETID	16
aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S.
1	0	5	O	aureus
2	6	6	O	,
3	8	9	O	to
4	11	17	O	survive
5	19	20	O	in
6	22	32	U-UNK	pentazocine
7	34	36	O	and
8	38	51	U-UNK	tripelennamine
9	53	55	O	may
10	57	63	O	explain
11	65	66	O	in
12	68	71	O	part
13	73	73	O	a
14	75	79	O	shift
15	81	84	O	from
16	86	86	O	S
NULL

3918122.xml	DDI-MedLine.d45.s11	NO_SECTION	NO_SETID	18
aeruginosa as common pathogens of drug addicts in areas where abuse of this combination of drugs has increased.
1	0	9	O	aeruginosa
2	11	12	O	as
3	14	19	O	common
4	21	29	O	pathogens
5	31	32	O	of
6	34	37	O	drug
7	39	45	O	addicts
8	47	48	O	in
9	50	54	O	areas
10	56	60	O	where
11	62	66	O	abuse
12	68	69	O	of
13	71	74	O	this
14	76	86	O	combination
15	88	89	O	of
16	91	95	O	drugs
17	97	99	O	has
18	101	109	O	increased
NULL

3964797.xml	DDI-MedLine.d61.s0	NO_SECTION	NO_SETID	7
Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
1	0	14	O	Pharmacokinetic
2	16	25	O	evaluation
3	27	28	O	of
4	30	32	O	the
5	34	40	U-UNK	digoxin
6	42	51	U-UNK	amiodarone
7	53	63	O	interaction
NULL

3964797.xml	DDI-MedLine.d61.s1	NO_SECTION	NO_SETID	8
Amiodarone is known to raise serum digoxin levels.
1	0	9	U-UNK	Amiodarone
2	11	12	O	is
3	14	18	O	known
4	20	21	O	to
5	23	27	O	raise
6	29	33	O	serum
7	35	41	U-UNK	digoxin
8	43	48	O	levels
NULL

3964797.xml	DDI-MedLine.d61.s2	NO_SECTION	NO_SETID	16
This study was designed to evaluate the pharmacokinetic basis of this interaction in 10 normal subjects.
1	0	3	O	This
2	5	9	O	study
3	11	13	O	was
4	15	22	O	designed
5	24	25	O	to
6	27	34	O	evaluate
7	36	38	O	the
8	40	54	O	pharmacokinetic
9	56	60	O	basis
10	62	63	O	of
11	65	68	O	this
12	70	80	O	interaction
13	82	83	O	in
14	85	86	O	10
15	88	93	O	normal
16	95	102	O	subjects
NULL

3964797.xml	DDI-MedLine.d61.s3	NO_SECTION	NO_SETID	31
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.
1	0	2	O	The
2	4	18	O	pharmacokinetic
3	20	28	O	variables
4	30	32	O	for
5	34	40	U-UNK	digoxin
6	42	45	O	were
7	47	56	O	determined
8	58	62	O	after
9	64	64	O	a
10	66	68	O	1.0
11	70	71	O	mg
12	73	83	O	intravenous
13	85	88	O	dose
14	90	91	O	of
15	93	99	U-UNK	digoxin
16	101	102	O	in
17	104	107	O	each
18	109	115	O	subject
19	116	116	O	,
20	118	123	O	before
21	125	127	O	and
22	129	133	O	after
23	135	138	O	oral
24	140	149	U-UNK	amiodarone
25	150	150	O	,
26	152	154	O	400
27	156	157	O	mg
28	159	163	O	daily
29	165	167	O	for
30	169	169	O	3
31	171	175	O	weeks
NULL

3964797.xml	DDI-MedLine.d61.s4	NO_SECTION	NO_SETID	35
During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
1	0	5	O	During
2	7	16	U-UNK	amiodarone
3	18	31	O	administration
4	32	32	O	,
5	34	41	O	systemic
6	43	51	O	clearance
7	53	54	O	of
8	56	62	U-UNK	digoxin
9	64	66	O	was
10	68	74	O	reduced
11	76	79	O	from
12	81	83	O	234
13	85	85	O	+
14	86	86	O	/
15	89	90	O	72
16	92	93	O	ml
17	94	94	O	/
18	95	97	O	min
19	100	103	O	mean
20	105	105	O	+
21	106	106	O	/
22	109	116	O	standard
23	118	126	O	deviation
24	129	130	O	to
25	132	134	O	172
26	136	136	O	+
27	137	137	O	/
28	140	141	O	33
29	143	144	O	ml
30	145	145	O	/
31	146	148	O	min
32	151	151	O	p
33	153	156	O	less
34	158	161	O	than
35	163	166	O	0.01
NULL

3964797.xml	DDI-MedLine.d61.s5	NO_SECTION	NO_SETID	46
This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).
1	0	3	O	This
2	5	7	O	was
3	9	11	O	due
4	13	14	O	to
5	16	25	O	reductions
6	27	28	O	in
7	30	33	O	both
8	35	39	O	renal
9	41	49	O	clearance
10	52	55	O	from
11	57	59	O	105
12	61	61	O	+
13	62	62	O	/
14	65	66	O	39
15	68	69	O	to
16	71	72	O	84
17	74	74	O	+
18	75	75	O	/
19	78	79	O	15
20	81	82	O	ml
21	83	83	O	/
22	84	86	O	min
23	90	90	O	p
24	92	95	O	less
25	97	100	O	than
26	102	105	O	0.05
27	108	110	O	and
28	112	119	O	nonrenal
29	121	129	O	clearance
30	132	135	O	from
31	137	139	O	130
32	141	141	O	+
33	142	142	O	/
34	145	146	O	38
35	148	149	O	to
36	151	152	O	88
37	154	154	O	+
38	155	155	O	/
39	158	159	O	20
40	161	162	O	ml
41	163	163	O	/
42	164	166	O	min
43	170	170	O	p
44	172	175	O	less
45	177	180	O	than
46	182	185	O	0.01
NULL

3964797.xml	DDI-MedLine.d61.s6	NO_SECTION	NO_SETID	22
Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).
1	0	6	U-UNK	Digoxin
2	8	11	O	half
3	13	16	O	life
4	18	19	O	of
5	21	31	O	elimination
6	33	35	O	was
7	37	45	O	prolonged
8	47	50	O	from
9	52	53	O	34
10	55	55	O	+
11	56	56	O	/
12	59	60	O	13
13	62	63	O	to
14	65	66	O	40
15	68	68	O	+
16	69	69	O	/
17	72	73	O	16
18	75	79	O	hours
19	82	82	O	p
20	84	87	O	less
21	89	92	O	than
22	94	97	O	0.05
NULL

3964797.xml	DDI-MedLine.d61.s7	NO_SECTION	NO_SETID	8
Digoxin volume of distribution was not significantly changed.
1	0	6	U-UNK	Digoxin
2	8	13	O	volume
3	15	16	O	of
4	18	29	O	distribution
5	31	33	O	was
6	35	37	O	not
7	39	51	O	significantly
8	53	59	O	changed
NULL

3964797.xml	DDI-MedLine.d61.s8	NO_SECTION	NO_SETID	28
Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics.
1	0	9	U-UNK	Amiodarone
2	11	16	O	caused
3	18	18	O	a
4	20	24	O	three
5	27	28	O	to
6	30	37	O	fivefold
7	39	46	O	increase
8	48	49	O	in
9	51	55	O	serum
10	57	63	O	reverse
11	65	80	O	triiodothyronine
12	82	87	O	levels
13	88	88	O	,
14	90	92	O	but
15	94	100	O	changes
16	102	103	O	in
17	105	111	O	thyroid
18	113	120	O	function
19	122	125	O	were
20	127	129	O	not
21	131	144	O	quantitatively
22	146	152	O	related
23	154	155	O	to
24	157	159	O	the
25	161	167	O	changes
26	169	170	O	in
27	172	178	U-UNK	digoxin
28	180	195	O	pharmacokinetics
NULL

3964797.xml	DDI-MedLine.d61.s9	NO_SECTION	NO_SETID	27
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
1	0	4	O	These
2	6	16	O	alterations
3	18	19	O	in
4	21	27	U-UNK	digoxin
5	29	44	O	pharmacokinetics
6	46	53	O	produced
7	55	56	O	by
8	58	67	U-UNK	amiodarone
9	69	75	O	explain
10	77	79	O	the
11	81	88	O	increase
12	90	91	O	in
13	93	97	O	serum
14	99	105	U-UNK	digoxin
15	107	111	O	level
16	113	116	O	that
17	118	120	O	has
18	122	125	O	been
19	127	134	O	observed
20	136	139	O	when
21	141	144	O	this
22	146	149	O	drug
23	151	161	O	combination
24	163	165	O	has
25	167	170	O	been
26	172	175	O	used
27	177	186	O	clinically
NULL

3966974.xml	DDI-MedLine.d85.s0	NO_SECTION	NO_SETID	13
Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
1	0	11	U-UNK	Misonidazole
2	13	20	O	protects
3	22	26	O	mouse
4	28	33	O	tumour
5	35	37	O	and
6	39	44	O	normal
7	46	52	O	tissues
8	54	57	O	from
9	59	61	O	the
10	63	70	O	toxicity
11	72	73	O	of
12	75	78	O	oral
13	80	83	U-UNK	CCNU
NULL

3966974.xml	DDI-MedLine.d85.s1	NO_SECTION	NO_SETID	43
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole.
1	0	6	O	Because
2	8	10	O	the
3	12	22	U-UNK	nitrosourea
4	24	27	U-UNK	CCNU
5	29	30	O	is
6	32	36	O	given
7	38	48	O	exclusively
8	50	51	O	by
9	53	55	O	the
10	57	60	O	oral
11	62	66	O	route
12	68	69	O	in
13	71	73	O	man
14	74	74	O	,
15	76	77	O	we
16	79	82	O	have
17	84	90	O	carried
18	92	94	O	out
19	96	102	O	studies
20	104	105	O	in
21	107	110	O	mice
22	112	113	O	on
23	115	117	O	the
24	119	128	O	antitumour
25	130	137	O	activity
26	138	138	O	,
27	140	144	O	acute
28	146	153	O	toxicity
29	155	157	O	and
30	159	174	O	pharmacokinetics
31	176	177	O	of
32	179	182	O	oral
33	184	187	U-UNK	CCNU
34	188	188	O	,
35	190	195	O	either
36	197	201	O	alone
37	203	204	O	or
38	206	207	O	in
39	209	219	O	combination
40	221	224	O	with
41	226	228	O	the
42	230	244	O	chemosensitizer
43	246	257	U-UNK	misonidazole
NULL

3966974.xml	DDI-MedLine.d85.s2	NO_SECTION	NO_SETID	11
In both plasma and KHT tumour the peak concentration and "early"
1	0	1	O	In
2	3	6	O	both
3	8	13	O	plasma
4	15	17	O	and
5	19	21	O	KHT
6	23	28	O	tumour
7	30	32	O	the
8	34	37	O	peak
9	39	51	O	concentration
10	53	55	O	and
11	57	63	O	"early"
NULL

3966974.xml	DDI-MedLine.d85.s3	NO_SECTION	NO_SETID	17
AUC for total nitrosoureas were about 1.4-1.5 fold greater for the oral compared to the i.p.
1	0	2	O	AUC
2	4	6	O	for
3	8	12	O	total
4	14	25	U-UNK	nitrosoureas
5	27	30	O	were
6	32	36	O	about
7	38	40	O	1.4
8	42	44	O	1.5
9	46	49	O	fold
10	51	57	O	greater
11	59	61	O	for
12	63	65	O	the
13	67	70	O	oral
14	72	79	O	compared
15	81	82	O	to
16	84	86	O	the
17	88	90	O	i.p
NULL

3966974.xml	DDI-MedLine.d85.s5	NO_SECTION	NO_SETID	15
These differences were reflected in the roughly twofold greater antitumour activity for the oral route.
1	0	4	O	These
2	6	16	O	differences
3	18	21	O	were
4	23	31	O	reflected
5	33	34	O	in
6	36	38	O	the
7	40	46	O	roughly
8	48	54	O	twofold
9	56	62	O	greater
10	64	73	O	antitumour
11	75	82	O	activity
12	84	86	O	for
13	88	90	O	the
14	92	95	O	oral
15	97	101	O	route
NULL

3966974.xml	DDI-MedLine.d85.s6	NO_SECTION	NO_SETID	31
In contrast, acute toxicity tests showed that oral CCNU was 1.45 times less toxic to normal tissue, although the dose-limiting organ may be different for the two routes.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	17	O	acute
5	19	26	O	toxicity
6	28	32	O	tests
7	34	39	O	showed
8	41	44	O	that
9	46	49	O	oral
10	51	54	U-UNK	CCNU
11	56	58	O	was
12	60	63	O	1.45
13	65	69	O	times
14	71	74	O	less
15	76	80	O	toxic
16	82	83	O	to
17	85	90	O	normal
18	92	97	O	tissue
19	98	98	O	,
20	100	107	O	although
21	109	111	O	the
22	113	116	O	dose
23	118	125	O	limiting
24	127	131	O	organ
25	133	135	O	may
26	137	138	O	be
27	140	148	O	different
28	150	152	O	for
29	154	156	O	the
30	158	160	O	two
31	162	167	O	routes
NULL

3966974.xml	DDI-MedLine.d85.s7	NO_SECTION	NO_SETID	16
Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
1	0	11	U-UNK	Misonidazole
2	13	19	O	reduced
3	21	23	O	the
4	25	34	O	antitumour
5	36	43	O	activity
6	45	46	O	of
7	48	51	O	oral
8	53	56	U-UNK	CCNU
9	58	59	O	by
10	61	64	O	dose
11	66	74	O	modifying
12	76	82	O	factors
13	85	87	O	DMF
14	90	91	O	of
15	93	96	O	0.58
16	98	101	O	0.71
NULL

3966974.xml	DDI-MedLine.d85.s8	NO_SECTION	NO_SETID	13
Similarly, the acute toxicity was also diminished by a DMF of 0.74.
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	the
4	15	19	O	acute
5	21	28	O	toxicity
6	30	32	O	was
7	34	37	O	also
8	39	48	O	diminished
9	50	51	O	by
10	53	53	O	a
11	55	57	O	DMF
12	59	60	O	of
13	62	65	O	0.74
NULL

3966974.xml	DDI-MedLine.d85.s9	NO_SECTION	NO_SETID	9
Misonidazole has a complex effect on oral CCNU pharmacokinetics.
1	0	11	U-UNK	Misonidazole
2	13	15	O	has
3	17	17	O	a
4	19	25	O	complex
5	27	32	O	effect
6	34	35	O	on
7	37	40	O	oral
8	42	45	U-UNK	CCNU
9	47	62	O	pharmacokinetics
NULL

3966974.xml	DDI-MedLine.d85.s10	NO_SECTION	NO_SETID	16
The plasma and tumour total nitrosourea peak concentrations were reduced by 1.5 and 1.7 fold respectively.
1	0	2	O	The
2	4	9	O	plasma
3	11	13	O	and
4	15	20	O	tumour
5	22	26	O	total
6	28	38	U-UNK	nitrosourea
7	40	43	O	peak
8	45	58	O	concentrations
9	60	63	O	were
10	65	71	O	reduced
11	73	74	O	by
12	76	78	O	1.5
13	80	82	O	and
14	84	86	O	1.7
15	88	91	O	fold
16	93	104	O	respectively
NULL

3966974.xml	DDI-MedLine.d85.s11	NO_SECTION	NO_SETID	5
Misonidazole also reduced the "early"
1	0	11	U-UNK	Misonidazole
2	13	16	O	also
3	18	24	O	reduced
4	26	28	O	the
5	30	36	O	"early"
NULL

3966974.xml	DDI-MedLine.d85.s12	NO_SECTION	NO_SETID	17
nitrosourea AUC, with the extent of the reduction depending on the minimum effective concentration (MEC) chosen.
1	0	10	U-UNK	nitrosourea
2	12	14	O	AUC
3	15	15	O	,
4	17	20	O	with
5	22	24	O	the
6	26	31	O	extent
7	33	34	O	of
8	36	38	O	the
9	40	48	O	reduction
10	50	58	O	depending
11	60	61	O	on
12	63	65	O	the
13	67	73	O	minimum
14	75	83	O	effective
15	85	97	O	concentration
16	100	102	O	MEC
17	105	110	O	chosen
NULL

3966974.xml	DDI-MedLine.d85.s13	NO_SECTION	NO_SETID	26
For example, the plasma nitrosourea AUC was reduced by factors of 1.05 and 9.6 for MEC values of 1 and 2 micrograms ml-1 respectively.
1	0	2	O	For
2	4	10	O	example
3	11	11	O	,
4	13	15	O	the
5	17	22	O	plasma
6	24	34	U-UNK	nitrosourea
7	36	38	O	AUC
8	40	42	O	was
9	44	50	O	reduced
10	52	53	O	by
11	55	61	O	factors
12	63	64	O	of
13	66	69	O	1.05
14	71	73	O	and
15	75	77	O	9.6
16	79	81	O	for
17	83	85	O	MEC
18	87	92	O	values
19	94	95	O	of
20	97	97	O	1
21	99	101	O	and
22	103	103	O	2
23	105	114	O	micrograms
24	116	117	O	ml
25	119	119	O	1
26	121	132	O	respectively
NULL

3966974.xml	DDI-MedLine.d85.s14	NO_SECTION	NO_SETID	19
We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
1	0	1	O	We
2	3	9	O	propose
3	11	15	O	these
4	17	31	O	pharmacokinetic
5	33	39	O	changes
6	41	42	O	to
7	44	45	O	be
8	47	49	O	the
9	51	60	O	underlying
10	62	70	O	mechanism
11	72	74	O	for
12	76	78	O	the
13	80	88	O	reduction
14	90	91	O	of
15	93	96	O	oral
16	98	101	U-UNK	CCNU
17	103	114	O	cytotoxicity
18	116	117	O	by
19	119	130	U-UNK	misonidazole
NULL

3966974.xml	DDI-MedLine.d85.s15	NO_SECTION	NO_SETID	12
Clinical trials of such combinations should be accompanied by detailed pharmacokinetic evaluation.
1	0	7	O	Clinical
2	9	14	O	trials
3	16	17	O	of
4	19	22	O	such
5	24	35	O	combinations
6	37	42	O	should
7	44	45	O	be
8	47	57	O	accompanied
9	59	60	O	by
10	62	69	O	detailed
11	71	85	O	pharmacokinetic
12	87	96	O	evaluation
NULL

3967572.xml	DDI-MedLine.d7.s0	NO_SECTION	NO_SETID	7
Enhanced theophylline clearance secondary to phenytoin therapy.
1	0	7	O	Enhanced
2	9	20	U-UNK	theophylline
3	22	30	O	clearance
4	32	40	O	secondary
5	42	43	O	to
6	45	53	U-UNK	phenytoin
7	55	61	O	therapy
NULL

3967572.xml	DDI-MedLine.d7.s1	NO_SECTION	NO_SETID	15
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
1	0	3	O	This
2	5	10	O	report
3	12	20	O	describes
4	22	24	O	two
5	26	30	O	cases
6	32	33	O	in
7	35	39	O	which
8	41	52	U-UNK	theophylline
9	54	62	O	clearance
10	64	74	O	accelerated
11	76	83	O	markedly
12	85	88	O	with
13	90	100	O	concomitant
14	102	110	U-UNK	phenytoin
15	112	125	O	administration
NULL

3967572.xml	DDI-MedLine.d7.s2	NO_SECTION	NO_SETID	17
Maximum calculated theophylline clearance ranged from 2 1/2 to 3 1/2 times baseline.
1	0	6	O	Maximum
2	8	17	O	calculated
3	19	30	U-UNK	theophylline
4	32	40	O	clearance
5	42	47	O	ranged
6	49	52	O	from
7	54	54	O	2
8	56	56	O	1
9	57	57	O	/
10	58	58	O	2
11	60	61	O	to
12	63	63	O	3
13	65	65	O	1
14	66	66	O	/
15	67	67	O	2
16	69	73	O	times
17	75	82	O	baseline
NULL

3967572.xml	DDI-MedLine.d7.s3	NO_SECTION	NO_SETID	12
Onset of the interaction began within five days of beginning concurrent therapy.
1	0	4	O	Onset
2	6	7	O	of
3	9	11	O	the
4	13	23	O	interaction
5	25	29	O	began
6	31	36	O	within
7	38	41	O	five
8	43	46	O	days
9	48	49	O	of
10	51	59	O	beginning
11	61	70	O	concurrent
12	72	78	O	therapy
NULL

3967572.xml	DDI-MedLine.d7.s4	NO_SECTION	NO_SETID	28
With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
1	0	3	O	With
2	5	12	O	combined
3	14	16	O	use
4	17	17	O	,
5	19	28	O	clinicians
6	30	35	O	should
7	37	38	O	be
8	40	44	O	aware
9	45	45	O	,
10	47	50	O	when
11	52	60	U-UNK	phenytoin
12	62	63	O	is
13	65	69	O	added
14	70	70	O	,
15	72	73	O	of
16	75	77	O	the
17	79	87	O	potential
18	89	91	O	for
19	93	106	O	reexacerbation
20	108	109	O	of
21	111	119	O	pulmonary
22	121	134	O	symptomatology
23	136	138	O	due
24	140	141	O	to
25	143	149	O	lowered
26	151	155	O	serum
27	157	168	U-UNK	theophylline
28	170	183	O	concentrations
NULL

3968644.xml	DDI-MedLine.d30.s0	NO_SECTION	NO_SETID	11
Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys.
1	0	14	O	Stereoselective
2	16	25	O	behavioral
3	27	33	O	effects
4	35	36	O	of
5	38	38	B-UNK	N
6	40	57	L-UNK	allylnormetazocine
7	59	60	O	in
8	62	68	O	pigeons
9	70	72	O	and
10	74	81	O	squirrel
11	83	89	O	monkeys
NULL

3968644.xml	DDI-MedLine.d30.s1	NO_SECTION	NO_SETID	36
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.
1	0	2	O	The
2	4	13	O	behavioral
3	15	21	O	effects
4	23	24	O	of
5	26	28	O	the
6	30	42	O	stereoisomers
7	44	45	O	of
8	47	47	B-UNK	N
9	49	66	L-UNK	allylnormetazocine
10	69	72	U-UNK	NANM
11	75	78	O	were
12	80	87	O	compared
13	89	92	O	with
14	94	98	O	those
15	100	101	O	of
16	103	115	U-UNK	phencyclidine
17	118	120	U-UNK	PCP
18	123	124	O	in
19	126	132	O	pigeons
20	134	136	O	and
21	138	145	O	squirrel
22	147	153	O	monkeys
23	155	164	O	responding
24	166	170	O	under
25	172	172	O	a
26	174	181	O	multiple
27	183	187	O	fixed
28	189	196	O	interval
29	198	202	O	fixed
30	204	208	O	ratio
31	211	212	O	FI
32	214	215	O	FR
33	218	225	O	schedule
34	227	228	O	of
35	230	233	O	food
36	235	246	O	presentation
NULL

3968644.xml	DDI-MedLine.d30.s2	NO_SECTION	NO_SETID	23
Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;
1	0	11	O	Intermediate
2	13	17	O	doses
3	19	20	O	of
4	23	23	B-UNK	+
5	26	29	L-UNK	NANM
6	31	32	O	or
7	34	36	U-UNK	PCP
8	38	45	O	produced
9	47	55	O	transient
10	57	65	O	increases
11	67	68	O	in
12	70	71	O	FI
13	73	82	O	responding
14	84	85	O	in
15	87	93	O	monkeys
16	95	97	O	and
17	99	107	O	sustained
18	109	117	O	increases
19	119	120	O	in
20	122	123	O	FI
21	125	134	O	responding
22	136	137	O	in
23	139	145	O	pigeons
NULL

3968644.xml	DDI-MedLine.d30.s3	NO_SECTION	NO_SETID	10
higher doses decreased FI and FR responding in both species.
1	0	5	O	higher
2	7	11	O	doses
3	13	21	O	decreased
4	23	24	O	FI
5	26	28	O	and
6	30	31	O	FR
7	33	42	O	responding
8	44	45	O	in
9	47	50	O	both
10	52	58	O	species
NULL

3968644.xml	DDI-MedLine.d30.s4	NO_SECTION	NO_SETID	16
In contrast to its enantiomer, (-)-NANM failed to increase FI responding significantly in either species;
1	0	1	O	In
2	3	10	O	contrast
3	12	13	O	to
4	15	17	O	its
5	19	28	O	enantiomer
6	29	29	O	,
7	35	38	U-UNK	NANM
8	40	45	O	failed
9	47	48	O	to
10	50	57	O	increase
11	59	60	O	FI
12	62	71	O	responding
13	73	85	O	significantly
14	87	88	O	in
15	90	95	O	either
16	97	103	O	species
NULL

3968644.xml	DDI-MedLine.d30.s5	NO_SECTION	NO_SETID	10
at high doses, (-)-NANM decreased FI and FR responding.
1	0	1	O	at
2	3	6	O	high
3	8	12	O	doses
4	13	13	O	,
5	19	22	U-UNK	NANM
6	24	32	O	decreased
7	34	35	O	FI
8	37	39	O	and
9	41	42	O	FR
10	44	53	O	responding
NULL

3968644.xml	DDI-MedLine.d30.s6	NO_SECTION	NO_SETID	27
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.
1	0	1	O	In
2	3	9	O	monkeys
3	10	10	O	,
4	16	19	U-UNK	NANM
5	21	23	O	was
6	25	29	O	about
7	31	32	O	10
8	34	38	O	times
9	40	43	O	more
10	45	50	O	potent
11	52	55	O	than
12	58	58	B-UNK	+
13	61	64	L-UNK	NANM
14	66	67	O	in
15	69	78	O	decreasing
16	80	89	O	responding
17	90	90	O	,
18	92	98	O	whereas
19	100	101	O	in
20	103	109	O	pigeons
21	115	118	U-UNK	NANM
22	120	122	O	was
23	124	128	O	about
24	130	139	O	equipotent
25	141	144	O	with
26	147	147	B-UNK	+
27	150	153	L-UNK	NANM
NULL

3968644.xml	DDI-MedLine.d30.s7	NO_SECTION	NO_SETID	23
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	species
4	15	15	O	,
5	21	24	U-UNK	NANM
6	25	25	O	,
7	27	29	O	but
8	31	33	O	not
9	36	36	B-UNK	+
10	39	42	L-UNK	NANM
11	43	43	O	,
12	45	55	O	antagonized
13	57	59	O	the
14	61	64	O	rate
15	66	75	O	decreasing
16	77	83	O	effects
17	85	86	O	of
18	88	95	U-UNK	morphine
19	97	98	O	on
20	100	101	O	FI
21	103	105	O	and
22	107	108	O	FR
23	110	119	O	responding
NULL

3968644.xml	DDI-MedLine.d30.s8	NO_SECTION	NO_SETID	19
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
1	0	1	O	In
2	3	9	O	monkeys
3	10	10	O	,
4	12	14	O	the
5	16	22	O	effects
6	24	25	O	of
7	31	34	U-UNK	NANM
8	35	35	O	,
9	37	39	O	but
10	41	43	O	not
11	46	46	B-UNK	+
12	49	52	L-UNK	NANM
13	54	55	O	or
14	57	59	U-UNK	PCP
15	60	60	O	,
16	62	65	O	were
17	67	77	O	antagonized
18	79	80	O	by
19	82	89	U-UNK	naloxone
NULL

3968644.xml	DDI-MedLine.d30.s9	NO_SECTION	NO_SETID	26
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
1	0	2	O	the
2	4	8	O	doses
3	10	11	O	of
4	13	20	U-UNK	naloxone
5	22	29	O	required
6	31	32	O	to
7	34	43	O	antagonize
8	45	47	O	the
9	49	55	O	effects
10	57	58	O	of
11	64	67	U-UNK	NANM
12	69	72	O	were
13	74	77	O	more
14	79	82	O	than
15	84	86	O	100
16	88	92	O	times
17	94	99	O	higher
18	101	104	O	than
19	106	110	O	those
20	112	119	O	required
21	121	122	O	to
22	124	133	O	antagonize
23	135	137	O	the
24	139	145	O	effects
25	147	148	O	of
26	150	157	U-UNK	morphine
NULL

3968644.xml	DDI-MedLine.d30.s10	NO_SECTION	NO_SETID	17
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP.
1	0	1	O	In
2	3	9	O	pigeons
3	10	10	O	,
4	12	19	U-UNK	naloxone
5	21	23	O	did
6	25	27	O	not
7	29	42	O	systematically
8	44	48	O	alter
9	50	52	O	the
10	54	60	O	effects
11	62	63	O	of
12	69	72	U-UNK	NANM
13	73	73	O	,
14	76	76	B-UNK	+
15	79	82	L-UNK	NANM
16	84	85	O	or
17	87	89	U-UNK	PCP
NULL

3968644.xml	DDI-MedLine.d30.s11	NO_SECTION	NO_SETID	44
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
1	0	10	U-UNK	Haloperidol
2	12	18	O	reduced
3	20	21	O	or
4	23	32	O	eliminated
5	34	36	O	the
6	38	46	O	increases
7	48	49	O	in
8	51	52	O	FI
9	54	63	O	responding
10	65	72	O	produced
11	74	75	O	by
12	77	88	O	intermediate
13	90	94	O	doses
14	96	97	O	of
15	99	104	O	either
16	107	107	B-UNK	+
17	110	113	L-UNK	NANM
18	115	116	O	or
19	118	120	U-UNK	PCP
20	122	123	O	in
21	125	131	O	pigeons
22	132	132	O	,
23	134	136	O	but
24	138	140	O	did
25	142	144	O	not
26	146	155	O	antagonize
27	157	159	O	the
28	161	169	O	decreases
29	171	172	O	in
30	174	175	O	FI
31	177	178	O	or
32	180	181	O	FR
33	183	192	O	responding
34	194	201	O	produced
35	203	204	O	by
36	206	209	O	high
37	211	215	O	doses
38	217	218	O	of
39	220	222	O	PCP
40	224	225	O	or
41	227	232	O	either
42	234	245	O	stereoisomer
43	247	248	O	of
44	250	253	U-UNK	NANM
NULL

3968644.xml	DDI-MedLine.d30.s12	NO_SECTION	NO_SETID	14
The results demonstrate a high degree of stereoselectivity in the behavioral effects of NANM.
1	0	2	O	The
2	4	10	O	results
3	12	22	O	demonstrate
4	24	24	O	a
5	26	29	O	high
6	31	36	O	degree
7	38	39	O	of
8	41	57	O	stereoselectivity
9	59	60	O	in
10	62	64	O	the
11	66	75	O	behavioral
12	77	83	O	effects
13	85	86	O	of
14	88	91	U-UNK	NANM
NULL

3968644.xml	DDI-MedLine.d30.s13	NO_SECTION	NO_SETID	21
The levorotatory isomer had opioid-antagonist and non-opioid agonist effects in pigeons and mixed opioid agonist-antagonist effects in monkeys.
1	0	2	O	The
2	4	15	O	levorotatory
3	17	22	O	isomer
4	24	26	O	had
5	28	33	O	opioid
6	35	44	O	antagonist
7	46	48	O	and
8	50	52	O	non
9	54	59	O	opioid
10	61	67	O	agonist
11	69	75	O	effects
12	77	78	O	in
13	80	86	O	pigeons
14	88	90	O	and
15	92	96	O	mixed
16	98	103	O	opioid
17	105	111	O	agonist
18	113	122	O	antagonist
19	124	130	O	effects
20	132	133	O	in
21	135	141	O	monkeys
NULL

3968644.xml	DDI-MedLine.d30.s14	NO_SECTION	NO_SETID	19
The dextrorotatory isomer, on the other hand, had effects similar to those of PCP in both species.
1	0	2	O	The
2	4	17	O	dextrorotatory
3	19	24	O	isomer
4	25	25	O	,
5	27	28	O	on
6	30	32	O	the
7	34	38	O	other
8	40	43	O	hand
9	44	44	O	,
10	46	48	O	had
11	50	56	O	effects
12	58	64	O	similar
13	66	67	O	to
14	69	73	O	those
15	75	76	O	of
16	78	80	U-UNK	PCP
17	82	83	O	in
18	85	88	O	both
19	90	96	O	species
NULL

3969689.xml	DDI-MedLine.d55.s0	NO_SECTION	NO_SETID	12
Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
1	0	8	O	Increased
2	10	23	O	hepatotoxicity
3	25	26	O	of
4	28	40	U-UNK	acetaminophen
5	42	43	O	by
6	45	55	O	concomitant
7	57	70	O	administration
8	72	73	O	of
9	75	82	U-UNK	caffeine
10	84	85	O	in
11	87	89	O	the
12	91	93	O	rat
NULL

3969689.xml	DDI-MedLine.d55.s1	NO_SECTION	NO_SETID	25
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
1	0	4	O	Since
2	6	13	U-UNK	caffeine
3	15	16	O	is
4	18	27	O	frequently
5	29	30	O	co
6	32	43	O	administered
7	45	48	O	with
8	50	62	U-UNK	acetaminophen
9	63	63	O	,
10	65	66	O	it
11	68	69	O	is
12	71	72	O	of
13	74	81	O	clinical
14	83	90	O	interest
15	92	93	O	to
16	95	99	O	study
17	101	103	O	the
18	105	110	O	effect
19	112	113	O	of
20	115	122	U-UNK	caffeine
21	124	125	O	on
22	127	129	O	the
23	131	144	O	hepatotoxicity
24	146	147	O	of
25	149	161	U-UNK	acetaminophen
NULL

3969689.xml	DDI-MedLine.d55.s2	NO_SECTION	NO_SETID	20
In male Sprague-Dawley rats fasted for 18 h, concomitant administration of caffeine (0.1 g/kg, i.p.)
1	0	1	O	In
2	3	6	O	male
3	8	14	O	Sprague
4	16	21	O	Dawley
5	23	26	O	rats
6	28	33	O	fasted
7	35	37	O	for
8	39	40	O	18
9	42	42	O	h
10	43	43	O	,
11	45	55	O	concomitant
12	57	70	O	administration
13	72	73	O	of
14	75	82	U-UNK	caffeine
15	85	87	O	0.1
16	89	89	O	g
17	90	90	O	/
18	91	92	O	kg
19	93	93	O	,
20	95	97	O	i.p
NULL

3969689.xml	DDI-MedLine.d55.s3	NO_SECTION	NO_SETID	13
as judged by increased serum enzyme activities and increased incidence of hepatic necrosis.
1	0	1	O	as
2	3	8	O	judged
3	10	11	O	by
4	13	21	O	increased
5	23	27	O	serum
6	29	34	O	enzyme
7	36	45	O	activities
8	47	49	O	and
9	51	59	O	increased
10	61	69	O	incidence
11	71	72	O	of
12	74	80	O	hepatic
13	82	89	O	necrosis
NULL

3969689.xml	DDI-MedLine.d55.s4	NO_SECTION	NO_SETID	12
Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
1	0	6	O	Careful
2	8	19	O	observations
3	21	22	O	on
4	24	37	O	hepatotoxicity
5	39	41	O	are
6	43	51	O	suggested
7	53	56	O	when
8	58	70	U-UNK	acetaminophen
9	72	73	O	is
10	75	84	O	prescribed
11	86	89	O	with
12	91	98	U-UNK	caffeine
NULL

4038510.xml	DDI-MedLine.d130.s0	NO_SECTION	NO_SETID	7
High-dose cisplatin with sodium thiosulfate protection.
1	0	3	O	High
2	5	8	O	dose
3	10	18	U-UNK	cisplatin
4	20	23	O	with
5	25	30	B-UNK	sodium
6	32	42	L-UNK	thiosulfate
7	44	53	O	protection
NULL

4038510.xml	DDI-MedLine.d130.s1	NO_SECTION	NO_SETID	16
Nephrotoxicity frequently limits the dose of cisplatin to less than 120 mg/m2 per injection.
1	0	13	O	Nephrotoxicity
2	15	24	O	frequently
3	26	31	O	limits
4	33	35	O	the
5	37	40	O	dose
6	42	43	O	of
7	45	53	U-UNK	cisplatin
8	55	56	O	to
9	58	61	O	less
10	63	66	O	than
11	68	70	O	120
12	72	73	O	mg
13	74	74	O	/
14	75	76	O	m2
15	78	80	O	per
16	82	90	O	injection
NULL

4038510.xml	DDI-MedLine.d130.s2	NO_SECTION	NO_SETID	13
Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
1	0	5	B-UNK	Sodium
2	7	17	L-UNK	thiosulfate
3	19	20	O	is
4	22	22	O	a
5	24	35	O	neutralizing
6	37	41	O	agent
7	43	45	O	for
8	47	55	U-UNK	cisplatin
9	57	60	O	that
10	62	69	O	protects
11	71	77	O	against
12	79	83	O	renal
13	85	90	O	damage
NULL

4038510.xml	DDI-MedLine.d130.s3	NO_SECTION	NO_SETID	37
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.
1	0	1	O	To
2	3	11	O	determine
3	13	19	O	whether
4	21	29	O	injection
5	31	32	O	of
6	34	44	U-UNK	thiosulfate
7	46	50	O	would
8	52	57	O	permit
9	59	64	O	larger
10	66	70	O	doses
11	72	73	O	of
12	75	83	U-UNK	cisplatin
13	85	86	O	to
14	88	89	O	be
15	91	102	O	administered
16	103	103	O	,
17	105	105	O	a
18	107	111	O	fixed
19	113	115	O	9.9
20	117	117	O	g
21	118	118	O	/
22	119	120	O	m2
23	122	125	O	dose
24	127	128	O	of
25	130	140	U-UNK	thiosulfate
26	142	144	O	was
27	146	150	O	given
28	152	164	O	intravenously
29	166	169	O	over
30	171	175	O	three
31	177	181	O	hours
32	183	194	O	concurrently
33	196	199	O	with
34	201	210	O	escalating
35	212	216	O	doses
36	218	219	O	of
37	221	229	U-UNK	cisplatin
NULL

4038510.xml	DDI-MedLine.d130.s4	NO_SECTION	NO_SETID	12
Cisplatin was administered over the last two hours of the thiosulfate infusion.
1	0	8	U-UNK	Cisplatin
2	10	12	O	was
3	14	25	O	administered
4	27	30	O	over
5	32	34	O	the
6	36	39	O	last
7	41	43	O	two
8	45	49	O	hours
9	51	52	O	of
10	54	56	O	the
11	58	68	U-UNK	thiosulfate
12	70	77	O	infusion
NULL

4038510.xml	DDI-MedLine.d130.s5	NO_SECTION	NO_SETID	23
Using this technique, it was possible to escalate the cisplatin dose to 225 mg/m2 before dose-limiting toxicities were encountered.
1	0	4	O	Using
2	6	9	O	this
3	11	19	O	technique
4	20	20	O	,
5	22	23	O	it
6	25	27	O	was
7	29	36	O	possible
8	38	39	O	to
9	41	48	O	escalate
10	50	52	O	the
11	54	62	U-UNK	cisplatin
12	64	67	O	dose
13	69	70	O	to
14	72	74	O	225
15	76	77	O	mg
16	78	78	O	/
17	79	80	O	m2
18	82	87	O	before
19	89	92	O	dose
20	94	101	O	limiting
21	103	112	O	toxicities
22	114	117	O	were
23	119	129	O	encountered
NULL

4038510.xml	DDI-MedLine.d130.s6	NO_SECTION	NO_SETID	48
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.
1	0	9	O	Comparison
2	11	12	O	of
3	14	22	U-UNK	cisplatin
4	24	39	O	pharmacokinetics
5	41	42	O	in
6	44	51	O	patients
7	53	59	O	treated
8	61	64	O	with
9	66	70	O	202.5
10	72	73	O	mg
11	74	74	O	/
12	75	76	O	m2
13	78	81	O	plus
14	83	93	U-UNK	thiosulfate
15	95	96	O	to
16	98	102	O	those
17	104	105	O	in
18	107	114	O	patients
19	116	122	O	treated
20	124	127	O	with
21	129	131	O	100
22	133	134	O	mg
23	135	135	O	/
24	136	137	O	m2
25	139	145	O	without
26	147	157	U-UNK	thiosulfate
27	159	167	O	indicated
28	169	172	O	that
29	174	178	O	there
30	180	183	O	were
31	185	186	O	no
32	188	194	O	changes
33	196	197	O	in
34	199	201	O	the
35	203	213	O	elimination
36	215	218	O	rate
37	220	227	O	constant
38	228	228	O	,
39	230	235	O	volume
40	237	238	O	of
41	240	251	O	distribution
42	252	252	O	,
43	254	255	O	or
44	257	261	O	total
45	263	266	O	body
46	268	276	O	clearance
47	278	279	O	of
48	281	289	U-UNK	cisplatin
NULL

4038510.xml	DDI-MedLine.d130.s7	NO_SECTION	NO_SETID	15
The total drug exposure for the plasma was approximately twofold at the higher cisplatin dose.
1	0	2	O	The
2	4	8	O	total
3	10	13	O	drug
4	15	22	O	exposure
5	24	26	O	for
6	28	30	O	the
7	32	37	O	plasma
8	39	41	O	was
9	43	55	O	approximately
10	57	63	O	twofold
11	65	66	O	at
12	68	70	O	the
13	72	77	O	higher
14	79	87	U-UNK	cisplatin
15	89	92	O	dose
NULL

4038510.xml	DDI-MedLine.d130.s8	NO_SECTION	NO_SETID	21
This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
1	0	3	O	This
2	5	9	O	study
3	11	22	O	demonstrates
4	24	27	O	that
5	29	38	O	concurrent
6	40	53	O	administration
7	55	56	O	of
8	58	68	U-UNK	thiosulfate
9	70	76	O	permits
10	78	79	O	at
11	81	85	O	least
12	87	87	O	a
13	89	95	O	twofold
14	97	104	O	increase
15	106	107	O	in
16	109	112	O	dose
17	114	116	O	and
18	118	122	O	total
19	124	131	O	exposure
20	133	134	O	to
21	136	144	U-UNK	cisplatin
NULL

4469683.xml	DDI-MedLine.d41.s0	NO_SECTION	NO_SETID	9
Interferon induction: tool for establishing interactions among homopolyribonucleotides.
1	0	9	O	Interferon
2	11	19	O	induction
3	20	20	O	:
4	22	25	O	tool
5	27	29	O	for
6	31	42	O	establishing
7	44	55	O	interactions
8	57	61	O	among
9	63	85	O	homopolyribonucleotides
NULL

4469683.xml	DDI-MedLine.d41.s1	NO_SECTION	NO_SETID	31
Hitherto unrecognized interactions between homopolyribonucleotides and complexes thereof are suggested by interferon induction data obtained in a highly sensitive assay system of primary rabbit kidney cell cultures superinduced by metabolic inhibitors.
1	0	7	O	Hitherto
2	9	20	O	unrecognized
3	22	33	O	interactions
4	35	41	O	between
5	43	65	O	homopolyribonucleotides
6	67	69	O	and
7	71	79	O	complexes
8	81	87	O	thereof
9	89	91	O	are
10	93	101	O	suggested
11	103	104	O	by
12	106	115	O	interferon
13	117	125	O	induction
14	127	130	O	data
15	132	139	O	obtained
16	141	142	O	in
17	144	144	O	a
18	146	151	O	highly
19	153	161	O	sensitive
20	163	167	O	assay
21	169	174	O	system
22	176	177	O	of
23	179	185	O	primary
24	187	192	O	rabbit
25	194	199	O	kidney
26	201	204	O	cell
27	206	213	O	cultures
28	215	226	O	superinduced
29	228	229	O	by
30	231	239	O	metabolic
31	241	250	O	inhibitors
NULL

46730.xml	DDI-MedLine.d5.s0	NO_SECTION	NO_SETID	19
Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
1	0	7	O	Repeated
2	9	12	O	oral
3	14	27	O	administration
4	29	30	O	of
5	32	40	U-UNK	coumaphos
6	42	43	O	in
7	45	49	O	sheep
8	50	50	O	:
9	52	63	O	interactions
10	65	66	O	of
11	68	76	U-UNK	coumaphos
12	78	81	O	with
13	83	100	U-UNK	bishydroxycoumarin
14	101	101	O	,
15	103	113	U-UNK	trichlorfon
16	114	114	O	,
17	116	118	O	and
18	120	132	B-UNK	phenobarbital
19	134	139	L-UNK	sodium
NULL

46730.xml	DDI-MedLine.d5.s1	NO_SECTION	NO_SETID	27
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.
1	0	11	O	Interactions
2	13	19	O	between
3	21	30	O	treatments
4	32	35	O	with
5	37	45	U-UNK	coumaphos
6	46	46	O	,
7	48	65	U-UNK	bishydroxycoumarin
8	68	69	O	an
9	71	83	U-UNK	anticoagulant
10	85	85	O	,
11	87	97	U-UNK	trichlorfon
12	100	101	O	an
13	103	119	B-UNK	organophosphorous
14	121	128	L-UNK	compound
15	130	130	O	,
16	132	134	O	and
17	136	148	B-UNK	phenobarbital
18	150	155	L-UNK	sodium
19	158	159	O	an
20	161	167	O	inducer
21	169	170	O	of
22	172	181	O	microsomal
23	183	189	O	enzymes
24	192	195	O	were
25	197	208	O	investigated
26	210	211	O	in
27	213	217	O	sheep
NULL

46730.xml	DDI-MedLine.d5.s2	NO_SECTION	NO_SETID	31
A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
1	0	0	O	A
2	2	6	O	daily
3	8	11	O	dose
4	13	14	O	of
5	16	16	O	2
6	18	19	O	mg
7	21	22	O	of
8	24	32	U-UNK	coumaphos
9	33	33	O	/
10	34	35	O	kg
11	37	38	O	of
12	40	43	O	body
13	45	50	O	weight
14	52	54	O	for
15	56	56	O	6
16	58	61	O	days
17	63	65	O	did
18	67	69	O	not
19	71	76	O	affect
20	78	80	O	the
21	82	87	O	plasma
22	89	95	O	enzymes
23	97	98	O	or
24	100	102	O	the
25	104	122	O	antiprothrombinemic
26	124	129	O	effect
27	131	132	O	of
28	134	143	B-UNK	bishydroxy
29	145	152	L-UNK	coumarin
30	154	155	O	in
31	157	163	O	wethers
NULL

46730.xml	DDI-MedLine.d5.s3	NO_SECTION	NO_SETID	43
The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
1	0	2	O	The
2	4	12	O	treatment
3	14	15	O	of
4	17	20	O	ewes
5	22	25	O	with
6	27	28	O	an
7	30	40	O	intravenous
8	43	44	O	IV
9	47	55	O	injection
10	57	58	O	of
11	60	70	U-UNK	trichlorfon
12	71	71	O	,
13	73	84	O	insufficient
14	86	87	O	to
15	89	95	O	produce
16	97	107	O	significant
17	109	118	O	inhibition
18	120	121	O	of
19	123	133	O	erythrocyte
20	135	154	O	acetylcholinesterase
21	157	160	O	AChE
22	163	170	O	activity
23	171	171	O	,
24	173	180	O	appeared
25	182	183	O	to
26	185	191	O	produce
27	193	200	O	additive
28	202	208	O	effects
29	210	213	O	with
30	215	219	O	those
31	221	228	O	produced
32	230	231	O	by
33	233	242	O	subsequent
34	244	252	O	treatment
35	254	257	O	with
36	259	259	O	4
37	261	262	O	mg
38	264	265	O	of
39	267	275	U-UNK	coumaphos
40	276	276	O	/
41	277	278	O	kg
42	279	279	O	/
43	280	282	O	day
NULL

46730.xml	DDI-MedLine.d5.s4	NO_SECTION	NO_SETID	36
In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
1	0	1	O	In
2	3	6	O	ewes
3	8	12	O	given
4	14	15	O	40
5	17	18	O	mg
6	20	21	O	of
7	23	35	B-UNK	phenobarbital
8	37	42	L-UNK	sodium
9	43	43	O	/
10	44	45	O	kg
11	47	49	O	for
12	51	51	O	5
13	53	56	O	days
14	58	74	O	intraperitoneally
15	77	78	O	IP
16	80	80	O	,
17	82	84	O	the
18	86	103	O	anticholinesterase
19	105	110	O	effect
20	112	113	O	of
21	115	115	O	4
22	117	118	O	mg
23	120	121	O	of
24	123	131	U-UNK	coumaphos
25	132	132	O	/
26	133	134	O	kg
27	136	138	O	was
28	140	152	O	significantly
29	154	160	O	reduced
30	162	164	O	and
31	166	170	O	signs
32	172	173	O	of
33	175	182	O	toxicity
34	184	187	O	were
35	189	191	O	not
36	193	199	O	present
NULL

46730.xml	DDI-MedLine.d5.s5	NO_SECTION	NO_SETID	30
Treatment with daily doses of 2 mg of coumaphos/kg for 6 days did not modify the anticholinesterase effect of a 2nd series of treatments given 6 weeks later.
1	0	8	O	Treatment
2	10	13	O	with
3	15	19	O	daily
4	21	25	O	doses
5	27	28	O	of
6	30	30	O	2
7	32	33	O	mg
8	35	36	O	of
9	38	46	U-UNK	coumaphos
10	47	47	O	/
11	48	49	O	kg
12	51	53	O	for
13	55	55	O	6
14	57	60	O	days
15	62	64	O	did
16	66	68	O	not
17	70	75	O	modify
18	77	79	O	the
19	81	98	O	anticholinesterase
20	100	105	O	effect
21	107	108	O	of
22	110	110	O	a
23	112	114	O	2nd
24	116	121	O	series
25	123	124	O	of
26	126	135	O	treatments
27	137	141	O	given
28	143	143	O	6
29	145	149	O	weeks
30	151	155	O	later
NULL

6100190.xml	DDI-MedLine.d91.s0	NO_SECTION	NO_SETID	9
Diagnostic, treatment and aftercare approaches to cocaine abuse.
1	0	9	O	Diagnostic
2	10	10	O	,
3	12	20	O	treatment
4	22	24	O	and
5	26	34	O	aftercare
6	36	45	O	approaches
7	47	48	O	to
8	50	56	U-UNK	cocaine
9	58	62	O	abuse
NULL

6100190.xml	DDI-MedLine.d91.s1	NO_SECTION	NO_SETID	23
The general public feels that cocaine is not particularly dangerous because it does not produce a well defined physical dependency and abstinence syndrome.
1	0	2	O	The
2	4	10	O	general
3	12	17	O	public
4	19	23	O	feels
5	25	28	O	that
6	30	36	U-UNK	cocaine
7	38	39	O	is
8	41	43	O	not
9	45	56	O	particularly
10	58	66	O	dangerous
11	68	74	O	because
12	76	77	O	it
13	79	82	O	does
14	84	86	O	not
15	88	94	O	produce
16	96	96	O	a
17	98	101	O	well
18	103	109	O	defined
19	111	118	O	physical
20	120	129	O	dependency
21	131	133	O	and
22	135	144	O	abstinence
23	146	153	O	syndrome
NULL

6100190.xml	DDI-MedLine.d91.s2	NO_SECTION	NO_SETID	33
However, when addiction is defined as compulsion, loss of control and continued use in spite of adverse consequences, cocaine drug hunger can be seen as an agent of addictive disease.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	when
4	14	22	O	addiction
5	24	25	O	is
6	27	33	O	defined
7	35	36	O	as
8	38	47	O	compulsion
9	48	48	O	,
10	50	53	O	loss
11	55	56	O	of
12	58	64	O	control
13	66	68	O	and
14	70	78	O	continued
15	80	82	O	use
16	84	85	O	in
17	87	91	O	spite
18	93	94	O	of
19	96	102	O	adverse
20	104	115	O	consequences
21	116	116	O	,
22	118	124	U-UNK	cocaine
23	126	129	O	drug
24	131	136	O	hunger
25	138	140	O	can
26	142	143	O	be
27	145	148	O	seen
28	150	151	O	as
29	153	154	O	an
30	156	160	O	agent
31	162	163	O	of
32	165	173	O	addictive
33	175	181	O	disease
NULL

6100190.xml	DDI-MedLine.d91.s3	NO_SECTION	NO_SETID	11
Withdrawal from cocaine dependence usually involves depression, anxiety and lethargy.
1	0	9	O	Withdrawal
2	11	14	O	from
3	16	22	U-UNK	cocaine
4	24	33	O	dependence
5	35	41	O	usually
6	43	50	O	involves
7	52	61	O	depression
8	62	62	O	,
9	64	70	O	anxiety
10	72	74	O	and
11	76	83	O	lethargy
NULL

6100190.xml	DDI-MedLine.d91.s4	NO_SECTION	NO_SETID	12
These usually clear within a week, leaving only the "drug hunger"
1	0	4	O	These
2	6	12	O	usually
3	14	18	O	clear
4	20	25	O	within
5	27	27	O	a
6	29	32	O	week
7	33	33	O	,
8	35	41	O	leaving
9	43	46	O	only
10	48	50	O	the
11	52	56	O	"drug
12	58	64	O	hunger"
NULL

6100190.xml	DDI-MedLine.d91.s6	NO_SECTION	NO_SETID	4
Medication is rarely needed.
1	0	9	O	Medication
2	11	12	O	is
3	14	19	O	rarely
4	21	26	O	needed
NULL

6100190.xml	DDI-MedLine.d91.s7	NO_SECTION	NO_SETID	21
When cocaine is the primary addiction, after withdrawal the most effective treatment is group therapy with other recovering cocaine abusers.
1	0	3	O	When
2	5	11	U-UNK	cocaine
3	13	14	O	is
4	16	18	O	the
5	20	26	O	primary
6	28	36	O	addiction
7	37	37	O	,
8	39	43	O	after
9	45	54	O	withdrawal
10	56	58	O	the
11	60	63	O	most
12	65	73	O	effective
13	75	83	O	treatment
14	85	86	O	is
15	88	92	O	group
16	94	100	O	therapy
17	102	105	O	with
18	107	111	O	other
19	113	122	O	recovering
20	124	130	O	cocaine
21	132	138	O	abusers
NULL

6100190.xml	DDI-MedLine.d91.s8	NO_SECTION	NO_SETID	17
We incorporate the principles of recovery and define positive and constructive alternatives in dealing with cocaine hunger.
1	0	1	O	We
2	3	13	O	incorporate
3	15	17	O	the
4	19	28	O	principles
5	30	31	O	of
6	33	40	O	recovery
7	42	44	O	and
8	46	51	O	define
9	53	60	O	positive
10	62	64	O	and
11	66	77	O	constructive
12	79	90	O	alternatives
13	92	93	O	in
14	95	101	O	dealing
15	103	106	O	with
16	108	114	O	cocaine
17	116	121	O	hunger
NULL

6100190.xml	DDI-MedLine.d91.s9	NO_SECTION	NO_SETID	19
Recovery programs should be flexible and involve individual and family education on recovery and the nature of addictive disease.
1	0	7	O	Recovery
2	9	16	O	programs
3	18	23	O	should
4	25	26	O	be
5	28	35	O	flexible
6	37	39	O	and
7	41	47	O	involve
8	49	58	O	individual
9	60	62	O	and
10	64	69	O	family
11	71	79	O	education
12	81	82	O	on
13	84	91	O	recovery
14	93	95	O	and
15	97	99	O	the
16	101	106	O	nature
17	108	109	O	of
18	111	119	O	addictive
19	121	127	O	disease
NULL

6100190.xml	DDI-MedLine.d91.s10	NO_SECTION	NO_SETID	18
Exercise that produces cardiopulmonary stimulation is a helpful means of reducing drug hunger and anxiety during recovery therapy.
1	0	7	O	Exercise
2	9	12	O	that
3	14	21	O	produces
4	23	37	O	cardiopulmonary
5	39	49	O	stimulation
6	51	52	O	is
7	54	54	O	a
8	56	62	O	helpful
9	64	68	O	means
10	70	71	O	of
11	73	80	O	reducing
12	82	85	O	drug
13	87	92	O	hunger
14	94	96	O	and
15	98	104	O	anxiety
16	106	111	O	during
17	113	120	O	recovery
18	122	128	O	therapy
NULL

6100240.xml	DDI-MedLine.d2.s0	NO_SECTION	NO_SETID	10
Failure of neomycin to modify ACTH induced hypertension in sheep.
1	0	6	O	Failure
2	8	9	O	of
3	11	18	U-UNK	neomycin
4	20	21	O	to
5	23	28	O	modify
6	30	33	U-UNK	ACTH
7	35	41	O	induced
8	43	54	O	hypertension
9	56	57	O	in
10	59	63	O	sheep
NULL

6100240.xml	DDI-MedLine.d2.s1	NO_SECTION	NO_SETID	20
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
1	0	6	O	Studies
2	8	9	O	in
3	11	14	O	rats
4	16	19	O	have
5	21	25	O	shown
6	27	30	O	that
7	32	39	U-UNK	neomycin
8	41	54	O	administration
9	56	65	O	attenuates
10	67	73	O	certain
11	75	79	O	types
12	81	82	O	of
13	84	97	B-UNK	adrenocortical
14	99	105	L-UNK	steroid
15	107	115	O	dependent
16	117	128	O	hypertension
17	129	129	O	,
18	131	139	O	including
19	141	144	U-UNK	ACTH
20	146	157	O	hypertension
NULL

6100240.xml	DDI-MedLine.d2.s2	NO_SECTION	NO_SETID	14
The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	18	O	oral
5	20	27	U-UNK	neomycin
6	29	30	O	on
7	32	35	U-UNK	ACTH
8	37	43	O	induced
9	45	56	O	hypertension
10	58	61	O	were
11	63	70	O	examined
12	72	73	O	in
13	75	83	O	conscious
14	85	89	O	sheep
NULL

6100240.xml	DDI-MedLine.d2.s3	NO_SECTION	NO_SETID	15
Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.
1	0	7	U-UNK	Neomycin
2	9	11	O	has
3	13	14	O	no
4	16	21	O	effect
5	23	24	O	on
6	26	28	O	the
7	30	34	O	blood
8	36	43	O	pressure
9	45	46	O	or
10	48	56	O	metabolic
11	58	66	O	responses
12	68	69	O	to
13	71	74	U-UNK	ACTH
14	76	77	O	in
15	79	83	O	sheep
NULL

6443625.xml	DDI-MedLine.d66.s0	NO_SECTION	NO_SETID	13
Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.
1	0	6	O	Changes
2	8	9	O	in
3	11	17	O	urinary
4	19	30	O	homocysteine
5	32	40	O	following
6	42	50	B-UNK	synthetic
7	52	60	I-UNK	steroidal
8	62	69	L-UNK	estrogen
9	71	73	B-UNK	and
10	75	85	L-UNK	progestogen
11	87	100	O	administration
12	102	103	O	to
13	105	108	O	rats
NULL

6443625.xml	DDI-MedLine.d66.s1	NO_SECTION	NO_SETID	27
The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine.
1	0	2	O	The
2	4	10	O	present
3	12	15	O	work
4	17	24	O	involved
5	26	28	O	the
6	30	43	O	administration
7	45	46	O	of
8	48	51	O	both
9	53	59	B-UNK	ethynyl
10	61	69	L-UNK	estradiol
11	71	73	O	and
12	75	88	U-UNK	levonorgestrel
13	90	91	O	to
14	93	98	O	groups
15	100	101	O	of
16	103	106	O	rats
17	107	107	O	,
18	109	116	O	followed
19	118	119	O	by
20	121	133	O	determination
21	135	136	O	of
22	138	140	O	the
23	142	153	O	homocysteine
24	155	163	O	excretion
25	165	168	O	rate
26	170	171	O	in
27	173	177	O	urine
NULL

6443625.xml	DDI-MedLine.d66.s2	NO_SECTION	NO_SETID	35
The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol.
1	0	2	O	The
2	4	10	O	results
3	12	19	O	indicate
4	21	24	O	that
5	26	26	O	a
6	28	40	O	statistically
7	42	52	O	significant
8	54	63	O	difference
9	65	70	O	exists
10	72	78	O	between
11	80	82	O	the
12	84	91	O	excreted
13	93	98	O	levels
14	100	101	O	of
15	103	114	O	homocysteine
16	116	117	O	in
17	119	121	O	the
18	123	127	O	urine
19	129	130	O	of
20	132	135	O	both
21	137	143	O	control
22	145	147	O	and
23	149	162	U-UNK	levonorgestrel
24	164	170	O	treated
25	172	175	O	rats
26	177	179	O	and
27	181	183	O	the
28	185	190	O	levels
29	192	196	O	shown
30	198	199	O	by
31	201	204	O	rats
32	206	212	O	treated
33	214	217	O	with
34	219	225	B-UNK	ethynyl
35	227	235	L-UNK	estradiol
NULL

6443625.xml	DDI-MedLine.d66.s3	NO_SECTION	NO_SETID	27
The implications of these results are discussed, especially with respect to observations which indicate that homocysteine may be a precipitating factor in the development of thrombosis.
1	0	2	O	The
2	4	15	O	implications
3	17	18	O	of
4	20	24	O	these
5	26	32	O	results
6	34	36	O	are
7	38	46	O	discussed
8	47	47	O	,
9	49	58	O	especially
10	60	63	O	with
11	65	71	O	respect
12	73	74	O	to
13	76	87	O	observations
14	89	93	O	which
15	95	102	O	indicate
16	104	107	O	that
17	109	120	O	homocysteine
18	122	124	O	may
19	126	127	O	be
20	129	129	O	a
21	131	143	O	precipitating
22	145	150	O	factor
23	152	153	O	in
24	155	157	O	the
25	159	169	O	development
26	171	172	O	of
27	174	183	O	thrombosis
NULL

6443625.xml	DDI-MedLine.d66.s4	NO_SECTION	NO_SETID	40
Also included in this paper is a study which confirms the identity of the HPLC peak as being homocysteine by forming a radioactive derivative of this particular sulphydryl-containing amino acid, and then analysing the resulting mixture by TLC.
1	0	3	O	Also
2	5	12	O	included
3	14	15	O	in
4	17	20	O	this
5	22	26	O	paper
6	28	29	O	is
7	31	31	O	a
8	33	37	O	study
9	39	43	O	which
10	45	52	O	confirms
11	54	56	O	the
12	58	65	O	identity
13	67	68	O	of
14	70	72	O	the
15	74	77	O	HPLC
16	79	82	O	peak
17	84	85	O	as
18	87	91	O	being
19	93	104	O	homocysteine
20	106	107	O	by
21	109	115	O	forming
22	117	117	O	a
23	119	129	O	radioactive
24	131	140	O	derivative
25	142	143	O	of
26	145	148	O	this
27	150	159	O	particular
28	161	170	O	sulphydryl
29	172	181	O	containing
30	183	187	O	amino
31	189	192	O	acid
32	193	193	O	,
33	195	197	O	and
34	199	202	O	then
35	204	212	O	analysing
36	214	216	O	the
37	218	226	O	resulting
38	228	234	O	mixture
39	236	237	O	by
40	239	241	O	TLC
NULL

6536282.xml	DDI-MedLine.d93.s0	NO_SECTION	NO_SETID	9
Altered responsiveness to alcohol after exposure to organic lead.
1	0	6	O	Altered
2	8	21	O	responsiveness
3	23	24	O	to
4	26	32	U-UNK	alcohol
5	34	38	O	after
6	40	47	O	exposure
7	49	50	O	to
8	52	58	O	organic
9	60	63	O	lead
NULL

6536282.xml	DDI-MedLine.d93.s1	NO_SECTION	NO_SETID	31
Ethyl alcohol is known to effect the functional integrity of the limbic system, particularly the hippocampus, and to alter behaviors which are thought to be mediated through limbic function.
1	0	4	B-UNK	Ethyl
2	6	12	L-UNK	alcohol
3	14	15	O	is
4	17	21	O	known
5	23	24	O	to
6	26	31	O	effect
7	33	35	O	the
8	37	46	O	functional
9	48	56	O	integrity
10	58	59	O	of
11	61	63	O	the
12	65	70	O	limbic
13	72	77	O	system
14	78	78	O	,
15	80	91	O	particularly
16	93	95	O	the
17	97	107	O	hippocampus
18	108	108	O	,
19	110	112	O	and
20	114	115	O	to
21	117	121	O	alter
22	123	131	O	behaviors
23	133	137	O	which
24	139	141	O	are
25	143	149	O	thought
26	151	152	O	to
27	154	155	O	be
28	157	164	O	mediated
29	166	172	O	through
30	174	179	O	limbic
31	181	188	O	function
NULL

6536282.xml	DDI-MedLine.d93.s2	NO_SECTION	NO_SETID	14
Organometals also compromise the limbic system and result in deficits in learning and memory.
1	0	11	O	Organometals
2	13	16	O	also
3	18	27	O	compromise
4	29	31	O	the
5	33	38	O	limbic
6	40	45	O	system
7	47	49	O	and
8	51	56	O	result
9	58	59	O	in
10	61	68	O	deficits
11	70	71	O	in
12	73	80	O	learning
13	82	84	O	and
14	86	91	O	memory
NULL

6536282.xml	DDI-MedLine.d93.s3	NO_SECTION	NO_SETID	29
Since both alcohol and organoleads are present in the environment and seem to influence limbic integration, the interaction of these two compounds was assessed in the present experiment.
1	0	4	O	Since
2	6	9	O	both
3	11	17	U-UNK	alcohol
4	19	21	O	and
5	23	33	O	organoleads
6	35	37	O	are
7	39	45	O	present
8	47	48	O	in
9	50	52	O	the
10	54	64	O	environment
11	66	68	O	and
12	70	73	O	seem
13	75	76	O	to
14	78	86	O	influence
15	88	93	O	limbic
16	95	105	O	integration
17	106	106	O	,
18	108	110	O	the
19	112	122	O	interaction
20	124	125	O	of
21	127	131	O	these
22	133	135	O	two
23	137	145	O	compounds
24	147	149	O	was
25	151	158	O	assessed
26	160	161	O	in
27	163	165	O	the
28	167	173	O	present
29	175	184	O	experiment
NULL

6536282.xml	DDI-MedLine.d93.s4	NO_SECTION	NO_SETID	35
Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle.
1	0	5	O	Thirty
2	7	10	O	male
3	12	15	O	rats
4	17	18	O	of
5	20	22	O	the
6	24	30	O	Fischer
7	32	34	O	344
8	36	41	O	strain
9	43	46	O	were
10	48	54	O	divided
11	56	59	O	into
12	61	65	O	three
13	67	71	O	equal
14	73	78	O	groups
15	80	82	O	and
16	84	87	O	were
17	89	93	O	given
18	95	104	O	injections
19	106	107	O	of
20	109	117	B-UNK	trimethyl
21	119	122	L-UNK	lead
22	125	127	U-UNK	TML
23	131	133	O	8.0
24	135	136	O	or
25	138	141	O	17.0
26	143	144	O	mg
27	145	145	O	/
28	146	147	O	kg
29	148	148	O	/
30	149	150	O	ml
31	152	153	O	SC
32	156	157	O	or
33	159	161	O	the
34	163	168	O	saline
35	170	176	O	vehicle
NULL

6536282.xml	DDI-MedLine.d93.s5	NO_SECTION	NO_SETID	20
Fourteen days later, all animals were challenged with a single hypnotic dose of ethanol (3.5 g/kg IP).
1	0	7	O	Fourteen
2	9	12	O	days
3	14	18	O	later
4	19	19	O	,
5	21	23	O	all
6	25	31	O	animals
7	33	36	O	were
8	38	47	O	challenged
9	49	52	O	with
10	54	54	O	a
11	56	61	O	single
12	63	70	O	hypnotic
13	72	75	O	dose
14	77	78	O	of
15	80	86	U-UNK	ethanol
16	89	91	O	3.5
17	93	93	O	g
18	94	94	O	/
19	95	96	O	kg
20	98	99	O	IP
NULL

6536282.xml	DDI-MedLine.d93.s6	NO_SECTION	NO_SETID	19
The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol.
1	0	2	O	The
2	4	6	O	20%
3	8	8	O	v
4	9	9	O	/
5	10	10	O	v
6	12	19	O	solution
7	21	22	O	of
8	24	30	U-UNK	alcohol
9	32	34	O	was
10	36	43	O	prepared
11	45	46	O	in
12	48	52	O	water
13	54	57	O	from
14	59	59	O	a
15	61	65	O	stock
16	67	74	O	solution
17	76	77	O	of
18	79	81	O	95%
19	83	89	U-UNK	ethanol
NULL

6536282.xml	DDI-MedLine.d93.s7	NO_SECTION	NO_SETID	24
The latency to loss of the righting reflex and duration of sleep time were recorded while the rats were kept in sound-attenuating chambers.
1	0	2	O	The
2	4	10	O	latency
3	12	13	O	to
4	15	18	O	loss
5	20	21	O	of
6	23	25	O	the
7	27	34	O	righting
8	36	41	O	reflex
9	43	45	O	and
10	47	54	O	duration
11	56	57	O	of
12	59	63	O	sleep
13	65	68	O	time
14	70	73	O	were
15	75	82	O	recorded
16	84	88	O	while
17	90	92	O	the
18	94	97	O	rats
19	99	102	O	were
20	104	107	O	kept
21	109	110	O	in
22	112	116	O	sound
23	118	128	O	attenuating
24	130	137	O	chambers
NULL

6536282.xml	DDI-MedLine.d93.s8	NO_SECTION	NO_SETID	26
The rats treated with the highest dose of TML manifested significantly longer latencies to lose the righting reflex and shorter durations of sleep than did controls.
1	0	2	O	The
2	4	7	O	rats
3	9	15	O	treated
4	17	20	O	with
5	22	24	O	the
6	26	32	O	highest
7	34	37	O	dose
8	39	40	O	of
9	42	44	U-UNK	TML
10	46	55	O	manifested
11	57	69	O	significantly
12	71	76	O	longer
13	78	86	O	latencies
14	88	89	O	to
15	91	94	O	lose
16	96	98	O	the
17	100	107	O	righting
18	109	114	O	reflex
19	116	118	O	and
20	120	126	O	shorter
21	128	136	O	durations
22	138	139	O	of
23	141	145	O	sleep
24	147	150	O	than
25	152	154	O	did
26	156	163	O	controls
NULL

6536282.xml	DDI-MedLine.d93.s9	NO_SECTION	NO_SETID	20
These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	34	O	exposure
6	36	37	O	to
7	39	51	O	environmental
8	53	56	U-UNK	lead
9	58	60	O	may
10	62	66	O	alter
11	68	70	O	the
12	72	81	O	biological
13	83	85	O	and
14	87	96	O	behavioral
15	98	111	O	responsiveness
16	113	114	O	of
17	116	117	O	an
18	119	124	O	animal
19	126	127	O	to
20	129	135	U-UNK	alcohol
NULL

6536292.xml	DDI-MedLine.d54.s0	NO_SECTION	NO_SETID	15
Cholinergic role in alcohol's effects on evoked potentials in visual cortex of the albino rat.
1	0	10	O	Cholinergic
2	12	15	O	role
3	17	18	O	in
4	20	28	O	alcohol's
5	30	36	O	effects
6	38	39	O	on
7	41	46	O	evoked
8	48	57	O	potentials
9	59	60	O	in
10	62	67	O	visual
11	69	74	O	cortex
12	76	77	O	of
13	79	81	O	the
14	83	88	O	albino
15	90	92	O	rat
NULL

6536292.xml	DDI-MedLine.d54.s1	NO_SECTION	NO_SETID	14
Photic evoked potentials were recorded from the visual cortex of chronically implanted albino rats.
1	0	5	O	Photic
2	7	12	O	evoked
3	14	23	O	potentials
4	25	28	O	were
5	30	37	O	recorded
6	39	42	O	from
7	44	46	O	the
8	48	53	O	visual
9	55	60	O	cortex
10	62	63	O	of
11	65	75	O	chronically
12	77	85	O	implanted
13	87	92	O	albino
14	94	97	O	rats
NULL

6536292.xml	DDI-MedLine.d54.s2	NO_SECTION	NO_SETID	36
Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol.
1	0	4	O	Since
2	6	11	O	photic
3	13	18	O	evoked
4	20	28	O	potential
5	30	39	O	components
6	41	43	O	are
7	45	59	O	representations
8	61	62	O	of
9	64	69	O	neural
10	71	78	O	pathways
11	80	84	O	which
12	86	88	O	are
13	90	98	O	activated
14	100	105	O	during
15	107	112	O	photic
16	114	124	O	stimulation
17	125	125	O	,
18	127	131	O	study
19	133	134	O	of
20	136	138	O	the
21	140	146	O	effects
22	148	149	O	of
23	151	157	U-UNK	alcohol
24	159	160	O	on
25	162	166	O	these
26	168	177	O	components
27	179	181	O	may
28	183	186	O	help
29	188	189	O	to
30	191	195	O	trace
31	197	204	O	pathways
32	206	210	O	which
33	212	214	O	are
34	216	223	O	affected
35	225	226	O	by
36	228	234	U-UNK	alcohol
NULL

6536292.xml	DDI-MedLine.d54.s3	NO_SECTION	NO_SETID	43
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	present
4	15	19	O	study
5	20	20	O	,
6	22	27	O	evoked
7	29	38	O	potentials
8	40	43	O	were
9	45	52	O	recorded
10	54	55	O	at
11	57	57	O	5
12	58	58	O	,
13	60	61	O	20
14	62	62	O	,
15	64	66	O	and
16	68	69	O	40
17	71	73	O	min
18	75	83	O	following
19	85	86	O	IP
20	88	97	O	injections
21	99	100	O	of
22	102	107	O	saline
23	108	108	O	,
24	110	116	U-UNK	ethanol
25	119	121	O	2.0
26	123	123	O	g
27	124	124	O	/
28	125	126	O	kg
29	128	128	O	,
30	130	142	U-UNK	physostigmine
31	145	147	O	0.6
32	149	150	O	mg
33	151	151	O	/
34	152	153	O	kg
35	156	157	O	or
36	159	166	U-UNK	atropine
37	169	172	O	15.0
38	174	175	O	mg
39	176	176	O	/
40	177	178	O	kg
41	181	182	O	on
42	184	191	O	separate
43	193	196	O	days
NULL

6536292.xml	DDI-MedLine.d54.s4	NO_SECTION	NO_SETID	14
Ethanol depressed the amplitudes of most evoked potential components in comparison to saline administration.
1	0	6	U-UNK	Ethanol
2	8	16	O	depressed
3	18	20	O	the
4	22	31	O	amplitudes
5	33	34	O	of
6	36	39	O	most
7	41	46	O	evoked
8	48	56	O	potential
9	58	67	O	components
10	69	70	O	in
11	72	81	O	comparison
12	83	84	O	to
13	86	91	O	saline
14	93	106	O	administration
NULL

6536292.xml	DDI-MedLine.d54.s5	NO_SECTION	NO_SETID	9
Component P2, however, was increased in amplitude.
1	0	8	O	Component
2	10	11	O	P2
3	12	12	O	,
4	14	20	O	however
5	21	21	O	,
6	23	25	O	was
7	27	35	O	increased
8	37	38	O	in
9	40	48	O	amplitude
NULL

6536292.xml	DDI-MedLine.d54.s6	NO_SECTION	NO_SETID	11
Physostigmine briefly reduced the amplitude of most components, including P2.
1	0	12	U-UNK	Physostigmine
2	14	20	O	briefly
3	22	28	O	reduced
4	30	32	O	the
5	34	42	O	amplitude
6	44	45	O	of
7	47	50	O	most
8	52	61	O	components
9	62	62	O	,
10	64	72	O	including
11	74	75	O	P2
NULL

6536292.xml	DDI-MedLine.d54.s7	NO_SECTION	NO_SETID	26
In contrast, atropine increased the amplitudes of components P1 and P2, while decreasing components N1, N2 and N3 for varying durations of time.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	20	U-UNK	atropine
5	22	30	O	increased
6	32	34	O	the
7	36	45	O	amplitudes
8	47	48	O	of
9	50	59	O	components
10	61	62	O	P1
11	64	66	O	and
12	68	69	O	P2
13	70	70	O	,
14	72	76	O	while
15	78	87	O	decreasing
16	89	98	O	components
17	100	101	O	N1
18	102	102	O	,
19	104	105	O	N2
20	107	109	O	and
21	111	112	O	N3
22	114	116	O	for
23	118	124	O	varying
24	126	134	O	durations
25	136	137	O	of
26	139	142	O	time
NULL

6536292.xml	DDI-MedLine.d54.s8	NO_SECTION	NO_SETID	25
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
1	0	12	U-UNK	Physostigmine
2	14	25	O	pretreatment
3	27	35	O	augmented
4	37	39	O	the
5	41	50	O	depressant
6	52	57	O	effect
7	59	60	O	of
8	62	68	U-UNK	alcohol
9	70	71	O	on
10	73	75	O	the
11	77	81	O	early
12	83	92	O	components
13	94	95	O	P1
14	97	99	O	and
15	101	102	O	N1
16	103	103	O	,
17	105	109	O	while
18	111	121	O	attenuating
19	123	131	O	alcohol's
20	133	141	O	influence
21	143	144	O	on
22	146	155	O	components
23	157	158	O	P2
24	160	162	O	and
25	164	165	O	P3
NULL

6536292.xml	DDI-MedLine.d54.s9	NO_SECTION	NO_SETID	22
Pretreatment with atropine likewise further reduced the amplitudes of components P1 and N1, and produced a similar effect on component N3.
1	0	11	O	Pretreatment
2	13	16	O	with
3	18	25	U-UNK	atropine
4	27	34	O	likewise
5	36	42	O	further
6	44	50	O	reduced
7	52	54	O	the
8	56	65	O	amplitudes
9	67	68	O	of
10	70	79	O	components
11	81	82	O	P1
12	84	86	O	and
13	88	89	O	N1
14	90	90	O	,
15	92	94	O	and
16	96	103	O	produced
17	105	105	O	a
18	107	113	O	similar
19	115	120	O	effect
20	122	123	O	on
21	125	133	O	component
22	135	136	O	N3
NULL

6536292.xml	DDI-MedLine.d54.s10	NO_SECTION	NO_SETID	20
Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2.
1	0	7	U-UNK	Atropine
2	8	8	O	,
3	10	15	O	either
4	17	21	O	alone
5	23	24	O	or
6	26	27	O	in
7	29	39	O	combination
8	41	44	O	with
9	46	52	U-UNK	alcohol
10	53	53	O	,
11	55	62	O	produced
12	64	76	O	approximately
13	78	80	O	the
14	82	85	O	same
15	87	92	O	degree
16	94	95	O	of
17	97	107	O	enhancement
18	109	110	O	of
19	112	120	O	component
20	122	123	O	P2
NULL

6536292.xml	DDI-MedLine.d54.s11	NO_SECTION	NO_SETID	27
In comparison to saline values, all three agents produced reliable increases in peak latency for most of the components, with only N3 showing no effects.
1	0	1	O	In
2	3	12	O	comparison
3	14	15	O	to
4	17	22	O	saline
5	24	29	O	values
6	30	30	O	,
7	32	34	O	all
8	36	40	O	three
9	42	47	O	agents
10	49	56	O	produced
11	58	65	O	reliable
12	67	75	O	increases
13	77	78	O	in
14	80	83	O	peak
15	85	91	O	latency
16	93	95	O	for
17	97	100	O	most
18	102	103	O	of
19	105	107	O	the
20	109	118	O	components
21	119	119	O	,
22	121	124	O	with
23	126	129	O	only
24	131	132	O	N3
25	134	140	O	showing
26	142	143	O	no
27	145	151	O	effects
NULL

6536292.xml	DDI-MedLine.d54.s12	NO_SECTION	NO_SETID	26
The amplitude data from this study suggest that ethanol's augmentation of component P2 may result, at least in part, from alterations in cholinergic functions.
1	0	2	O	The
2	4	12	O	amplitude
3	14	17	O	data
4	19	22	O	from
5	24	27	O	this
6	29	33	O	study
7	35	41	O	suggest
8	43	46	O	that
9	48	56	O	ethanol's
10	58	69	O	augmentation
11	71	72	O	of
12	74	82	O	component
13	84	85	O	P2
14	87	89	O	may
15	91	96	O	result
16	97	97	O	,
17	99	100	O	at
18	102	106	O	least
19	108	109	O	in
20	111	114	O	part
21	115	115	O	,
22	117	120	O	from
23	122	132	O	alterations
24	134	135	O	in
25	137	147	O	cholinergic
26	149	157	O	functions
NULL

6537219.xml	DDI-MedLine.d81.s0	NO_SECTION	NO_SETID	12
Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
1	0	10	O	Hypothermia
2	12	13	O	as
3	15	16	O	an
4	18	22	O	index
5	24	25	O	of
6	27	29	O	the
7	31	40	U-UNK	disulfiram
8	42	48	U-UNK	ethanol
9	50	57	O	reaction
10	59	60	O	in
11	62	64	O	the
12	66	68	O	rat
NULL

6537219.xml	DDI-MedLine.d81.s1	NO_SECTION	NO_SETID	18
Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER).
1	0	8	O	Decreased
2	10	13	O	core
3	15	25	O	temperature
4	27	28	O	in
5	30	35	O	female
6	37	40	O	rats
7	42	44	O	was
8	46	57	O	investigated
9	59	60	O	as
10	62	64	O	one
11	66	73	O	possible
12	75	79	O	index
13	81	82	O	of
14	84	86	O	the
15	88	97	U-UNK	disulfiram
16	99	105	U-UNK	ethanol
17	107	114	O	reaction
18	117	119	O	DER
NULL

6537219.xml	DDI-MedLine.d81.s2	NO_SECTION	NO_SETID	26
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
1	0	3	O	Core
2	5	15	O	temperature
3	17	19	O	was
4	21	29	O	decreased
5	31	32	O	in
6	34	37	O	rats
7	39	40	O	in
8	42	42	O	a
9	44	47	O	dose
10	49	57	O	dependent
11	59	64	O	manner
12	66	69	O	when
13	71	77	U-UNK	ethanol
14	79	81	O	was
15	83	94	O	administered
16	96	97	O	to
17	99	102	O	rats
18	104	110	O	treated
19	112	115	O	with
20	117	126	U-UNK	disulfiram
21	128	128	O	8
22	130	134	O	hours
23	136	141	O	before
24	143	145	O	the
25	147	153	U-UNK	ethanol
26	155	163	O	challenge
NULL

6537219.xml	DDI-MedLine.d81.s3	NO_SECTION	NO_SETID	23
The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol.
1	0	2	O	The
2	4	11	O	decrease
3	13	14	O	in
4	16	26	O	temperature
5	28	32	O	began
6	34	39	O	within
7	41	42	O	20
8	44	50	O	minutes
9	52	56	O	after
10	58	64	U-UNK	ethanol
11	66	79	O	administration
12	80	80	O	,
13	82	89	O	reaching
14	91	91	O	a
15	93	99	O	maximal
16	101	108	O	decrease
17	110	116	O	between
18	118	119	O	60
19	121	123	O	and
20	125	127	O	120
21	129	135	O	minutes
22	137	140	O	post
23	142	148	U-UNK	ethanol
NULL

6537219.xml	DDI-MedLine.d81.s4	NO_SECTION	NO_SETID	10
The core temperature returned to normal 300 minutes after ethanol.
1	0	2	O	The
2	4	7	O	core
3	9	19	O	temperature
4	21	28	O	returned
5	30	31	O	to
6	33	38	O	normal
7	40	42	O	300
8	44	50	O	minutes
9	52	56	O	after
10	58	64	U-UNK	ethanol
NULL

6537219.xml	DDI-MedLine.d81.s5	NO_SECTION	NO_SETID	11
The blood pressure (carotid cannulation) decreased along with the core temperature.
1	0	2	O	The
2	4	8	O	blood
3	10	17	O	pressure
4	20	26	O	carotid
5	28	38	O	cannulation
6	41	49	O	decreased
7	51	55	O	along
8	57	60	O	with
9	62	64	O	the
10	66	69	O	core
11	71	81	O	temperature
NULL

6537219.xml	DDI-MedLine.d81.s6	NO_SECTION	NO_SETID	17
Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol.
1	0	6	O	Maximal
2	8	18	O	hypotension
3	20	22	O	was
4	24	28	O	found
5	30	32	O	120
6	34	40	O	minutes
7	42	45	O	post
8	47	53	U-UNK	ethanol
9	54	54	O	,
10	56	58	O	and
11	60	67	O	returned
12	69	70	O	to
13	72	77	O	normal
14	79	81	O	300
15	83	89	O	minutes
16	91	95	O	after
17	97	103	U-UNK	ethanol
NULL

6537219.xml	DDI-MedLine.d81.s7	NO_SECTION	NO_SETID	13
Heart rate increased initially and returned to normal 40 minutes after ethanol challenge.
1	0	4	O	Heart
2	6	9	O	rate
3	11	19	O	increased
4	21	29	O	initially
5	31	33	O	and
6	35	42	O	returned
7	44	45	O	to
8	47	52	O	normal
9	54	55	O	40
10	57	63	O	minutes
11	65	69	O	after
12	71	77	U-UNK	ethanol
13	79	87	O	challenge
NULL

6545279.xml	DDI-MedLine.d24.s0	NO_SECTION	NO_SETID	10
Excretion of thioethers in urine after exposure to electrophilic chemicals.
1	0	8	O	Excretion
2	10	11	O	of
3	13	22	O	thioethers
4	24	25	O	in
5	27	31	O	urine
6	33	37	O	after
7	39	46	O	exposure
8	48	49	O	to
9	51	63	O	electrophilic
10	65	73	O	chemicals
NULL

6545279.xml	DDI-MedLine.d24.s1	NO_SECTION	NO_SETID	23
Electrophilic agents--a class of chemicals that includes most genotoxic compounds--can be inactivated by reaction with glutathione or other SH-bearing molecules.
1	0	12	O	Electrophilic
2	14	19	O	agents
3	22	22	O	a
4	24	28	O	class
5	30	31	O	of
6	33	41	O	chemicals
7	43	46	O	that
8	48	55	O	includes
9	57	60	O	most
10	62	70	O	genotoxic
11	72	80	O	compounds
12	83	85	O	can
13	87	88	O	be
14	90	100	O	inactivated
15	102	103	O	by
16	105	112	O	reaction
17	114	117	O	with
18	119	129	O	glutathione
19	131	132	O	or
20	134	138	O	other
21	140	141	O	SH
22	143	149	O	bearing
23	151	159	O	molecules
NULL

6545279.xml	DDI-MedLine.d24.s2	NO_SECTION	NO_SETID	16
The conjugates so formed often appear in the urine as mercapturic acids or other thioether products.
1	0	2	O	The
2	4	13	O	conjugates
3	15	16	O	so
4	18	23	O	formed
5	25	29	O	often
6	31	36	O	appear
7	38	39	O	in
8	41	43	O	the
9	45	49	O	urine
10	51	52	O	as
11	54	64	O	mercapturic
12	66	70	O	acids
13	72	73	O	or
14	75	79	O	other
15	81	89	O	thioether
16	91	98	O	products
NULL

6545279.xml	DDI-MedLine.d24.s3	NO_SECTION	NO_SETID	25
This paper critically reviews the suitability of the urinary thioether assay as a method for the detection of exposure to electrophilic agents or their precursors.
1	0	3	O	This
2	5	9	O	paper
3	11	20	O	critically
4	22	28	O	reviews
5	30	32	O	the
6	34	44	O	suitability
7	46	47	O	of
8	49	51	O	the
9	53	59	O	urinary
10	61	69	O	thioether
11	71	75	O	assay
12	77	78	O	as
13	80	80	O	a
14	82	87	O	method
15	89	91	O	for
16	93	95	O	the
17	97	105	O	detection
18	107	108	O	of
19	110	117	O	exposure
20	119	120	O	to
21	122	134	O	electrophilic
22	136	141	O	agents
23	143	144	O	or
24	146	150	O	their
25	152	161	O	precursors
NULL

6545279.xml	DDI-MedLine.d24.s4	NO_SECTION	NO_SETID	17
In practice, the greatest value of the thioether assay appears to lie in its signal function.
1	0	1	O	In
2	3	10	O	practice
3	11	11	O	,
4	13	15	O	the
5	17	24	O	greatest
6	26	30	O	value
7	32	33	O	of
8	35	37	O	the
9	39	47	O	thioether
10	49	53	O	assay
11	55	61	O	appears
12	63	64	O	to
13	66	68	O	lie
14	70	71	O	in
15	73	75	O	its
16	77	82	O	signal
17	84	91	O	function
NULL

6545279.xml	DDI-MedLine.d24.s5	NO_SECTION	NO_SETID	14
This is demonstrated for cigarette smokers and industrial workers involved in chemical waste incineration.
1	0	3	O	This
2	5	6	O	is
3	8	19	O	demonstrated
4	21	23	O	for
5	25	33	O	cigarette
6	35	41	O	smokers
7	43	45	O	and
8	47	56	O	industrial
9	58	64	O	workers
10	66	73	O	involved
11	75	76	O	in
12	78	85	O	chemical
13	87	91	O	waste
14	93	104	O	incineration
NULL

6545279.xml	DDI-MedLine.d24.s6	NO_SECTION	NO_SETID	21
Whenever increased thioether excretion is observed, it is likely to be due to exposure to one or more suspect compounds.
1	0	7	O	Whenever
2	9	17	O	increased
3	19	27	O	thioether
4	29	37	O	excretion
5	39	40	O	is
6	42	49	O	observed
7	50	50	O	,
8	52	53	O	it
9	55	56	O	is
10	58	63	O	likely
11	65	66	O	to
12	68	69	O	be
13	71	73	O	due
14	75	76	O	to
15	78	85	O	exposure
16	87	88	O	to
17	90	92	O	one
18	94	95	O	or
19	97	100	O	more
20	102	108	O	suspect
21	110	118	O	compounds
NULL

6545279.xml	DDI-MedLine.d24.s7	NO_SECTION	NO_SETID	28
However, when the thioether concentration ranges within the limits of the normal value, one must not conclude that there is no, or negligible, exposure.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	when
4	14	16	O	the
5	18	26	O	thioether
6	28	40	O	concentration
7	42	47	O	ranges
8	49	54	O	within
9	56	58	O	the
10	60	65	O	limits
11	67	68	O	of
12	70	72	O	the
13	74	79	O	normal
14	81	85	O	value
15	86	86	O	,
16	88	90	O	one
17	92	95	O	must
18	97	99	O	not
19	101	108	O	conclude
20	110	113	O	that
21	115	119	O	there
22	121	122	O	is
23	124	125	O	no
24	126	126	O	,
25	128	129	O	or
26	131	140	O	negligible
27	141	141	O	,
28	143	150	O	exposure
NULL

6545279.xml	DDI-MedLine.d24.s8	NO_SECTION	NO_SETID	23
More specific applications of the assay of thio compounds in urine allow development of selective methods that may be useful for biological monitoring.
1	0	3	O	More
2	5	12	O	specific
3	14	25	O	applications
4	27	28	O	of
5	30	32	O	the
6	34	38	O	assay
7	40	41	O	of
8	43	46	O	thio
9	48	56	O	compounds
10	58	59	O	in
11	61	65	O	urine
12	67	71	O	allow
13	73	83	O	development
14	85	86	O	of
15	88	96	O	selective
16	98	104	O	methods
17	106	109	O	that
18	111	113	O	may
19	115	116	O	be
20	118	123	O	useful
21	125	127	O	for
22	129	138	O	biological
23	140	149	O	monitoring
NULL

6545985.xml	DDI-MedLine.d131.s0	NO_SECTION	NO_SETID	11
Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
1	0	10	O	Interaction
2	12	13	O	on
3	15	17	O	the
4	19	33	O	antinociceptive
5	35	40	O	effect
6	42	48	O	between
7	50	60	U-UNK	neurotensin
8	62	64	O	and
9	66	76	U-UNK	enkephalins
10	78	79	O	or
11	81	87	U-UNK	tuftsin
NULL

6545985.xml	DDI-MedLine.d131.s1	NO_SECTION	NO_SETID	38
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.
1	0	2	O	The
2	4	6	O	aim
3	8	9	O	of
4	11	14	O	this
5	16	20	O	paper
6	22	24	O	was
7	26	27	O	to
8	29	33	O	study
9	35	37	O	the
10	39	49	O	interaction
11	51	57	O	between
12	59	69	U-UNK	neurotensin
13	71	73	O	and
14	75	78	O	both
15	80	90	U-UNK	enkephalins
16	92	93	O	or
17	95	97	O	its
18	99	107	O	synthetic
19	109	116	O	analogue
20	118	118	B-UNK	D
21	120	123	I-UNK	Ala2
22	125	142	L-UNK	metenkephalinamide
23	143	143	O	,
24	145	146	O	or
25	148	154	U-UNK	tuftsin
26	155	155	O	,
27	157	158	O	on
28	160	162	O	the
29	164	179	O	antinonciceptive
30	181	186	O	effect
31	188	189	O	of
32	191	195	O	these
33	197	204	O	peptides
34	206	207	O	in
35	209	212	O	mice
36	214	218	O	after
37	220	233	O	intracisternal
38	235	243	O	injection
NULL

6545985.xml	DDI-MedLine.d131.s2	NO_SECTION	NO_SETID	8
Antinociception was measured by the hot-plate method.
1	0	14	O	Antinociception
2	16	18	O	was
3	20	27	O	measured
4	29	30	O	by
5	32	34	O	the
6	36	38	O	hot
7	40	44	O	plate
8	46	51	O	method
NULL

6545985.xml	DDI-MedLine.d131.s3	NO_SECTION	NO_SETID	15
It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
1	0	1	O	It
2	3	5	O	was
3	7	11	O	shown
4	13	16	O	that
5	18	28	U-UNK	neurotensin
6	30	40	O	antagonized
7	42	50	O	evidently
8	52	54	O	the
9	56	70	O	antinociceptive
10	72	77	O	effect
11	79	80	O	of
12	82	92	U-UNK	enkephalins
13	94	96	O	and
14	98	102	O	their
15	104	111	O	analogue
NULL

6545985.xml	DDI-MedLine.d131.s4	NO_SECTION	NO_SETID	13
On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
1	0	1	O	On
2	3	5	O	the
3	7	14	O	contrary
4	15	15	O	,
5	17	27	U-UNK	neurotensin
6	29	31	O	and
7	33	39	U-UNK	tuftsin
8	41	44	O	were
9	46	53	O	agonists
10	55	56	O	in
11	58	66	O	induction
12	68	69	O	of
13	71	79	O	analgesia
NULL

6545985.xml	DDI-MedLine.d131.s5	NO_SECTION	NO_SETID	22
It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	concluded
4	16	19	O	that
5	21	31	U-UNK	neurotensin
6	33	41	O	modulates
7	43	44	O	in
8	46	47	O	an
9	49	56	O	opposite
10	58	60	O	way
11	62	64	O	the
12	66	73	O	function
13	75	76	O	of
14	78	80	O	the
15	82	96	O	enkephalinergic
16	98	104	O	neurons
17	106	108	O	and
18	110	112	O	the
19	114	120	O	central
20	122	127	O	action
21	129	130	O	of
22	132	138	U-UNK	tuftsin
NULL

7476793.xml	DDI-MedLine.d71.s0	NO_SECTION	NO_SETID	8
Drug-lab interactions: implications for nutrition support.
1	0	3	O	Drug
2	5	7	O	lab
3	9	20	O	interactions
4	21	21	O	:
5	23	34	O	implications
6	36	38	O	for
7	40	48	O	nutrition
8	50	56	O	support
NULL

7476793.xml	DDI-MedLine.d71.s1	NO_SECTION	NO_SETID	6
Acetylcysteine interference with urine ketone test.
1	0	13	U-UNK	Acetylcysteine
2	15	26	O	interference
3	28	31	O	with
4	33	37	O	urine
5	39	44	O	ketone
6	46	49	O	test
NULL

7476793.xml	DDI-MedLine.d71.s2	NO_SECTION	NO_SETID	20
It is important that health care professionals be aware of the potential for medications to interfere with clinical laboratory tests.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	important
4	16	19	O	that
5	21	26	O	health
6	28	31	O	care
7	33	45	O	professionals
8	47	48	O	be
9	50	54	O	aware
10	56	57	O	of
11	59	61	O	the
12	63	71	O	potential
13	73	75	O	for
14	77	87	O	medications
15	89	90	O	to
16	92	100	O	interfere
17	102	105	O	with
18	107	114	O	clinical
19	116	125	O	laboratory
20	127	131	O	tests
NULL

7476793.xml	DDI-MedLine.d71.s3	NO_SECTION	NO_SETID	28
Medications can cause in vivo effects when the concentration or activity of the analyte is altered before the analysis and therefore the assay result is true and accurate.
1	0	10	O	Medications
2	12	14	O	can
3	16	20	O	cause
4	22	23	O	in
5	25	28	O	vivo
6	30	36	O	effects
7	38	41	O	when
8	43	45	O	the
9	47	59	O	concentration
10	61	62	O	or
11	64	71	O	activity
12	73	74	O	of
13	76	78	O	the
14	80	86	O	analyte
15	88	89	O	is
16	91	97	O	altered
17	99	104	O	before
18	106	108	O	the
19	110	117	O	analysis
20	119	121	O	and
21	123	131	O	therefore
22	133	135	O	the
23	137	141	O	assay
24	143	148	O	result
25	150	151	O	is
26	153	156	O	true
27	158	160	O	and
28	162	169	O	accurate
NULL

7476793.xml	DDI-MedLine.d71.s4	NO_SECTION	NO_SETID	22
An in vitro effect occurs when the medication interferes with the assay, and the result is erroneous and cannot be interpreted.
1	0	1	O	An
2	3	4	O	in
3	6	10	O	vitro
4	12	17	O	effect
5	19	24	O	occurs
6	26	29	O	when
7	31	33	O	the
8	35	44	O	medication
9	46	55	O	interferes
10	57	60	O	with
11	62	64	O	the
12	66	70	O	assay
13	71	71	O	,
14	73	75	O	and
15	77	79	O	the
16	81	86	O	result
17	88	89	O	is
18	91	99	O	erroneous
19	101	103	O	and
20	105	110	O	cannot
21	112	113	O	be
22	115	125	O	interpreted
NULL

7476793.xml	DDI-MedLine.d71.s5	NO_SECTION	NO_SETID	31
This report describes a recently identified case of interference of acetylcysteine with the urine test for ketones and demonstrates the importance of a thorough medication review in evaluating abnormal laboratory tests.
1	0	3	O	This
2	5	10	O	report
3	12	20	O	describes
4	22	22	O	a
5	24	31	O	recently
6	33	42	O	identified
7	44	47	O	case
8	49	50	O	of
9	52	63	O	interference
10	65	66	O	of
11	68	81	U-UNK	acetylcysteine
12	83	86	O	with
13	88	90	O	the
14	92	96	O	urine
15	98	101	O	test
16	103	105	O	for
17	107	113	O	ketones
18	115	117	O	and
19	119	130	O	demonstrates
20	132	134	O	the
21	136	145	O	importance
22	147	148	O	of
23	150	150	O	a
24	152	159	O	thorough
25	161	170	O	medication
26	172	177	O	review
27	179	180	O	in
28	182	191	O	evaluating
29	193	200	O	abnormal
30	202	211	O	laboratory
31	213	217	O	tests
NULL

7496198.xml	DDI-MedLine.d97.s1	NO_SECTION	NO_SETID	13
Between 1988 and 1993, more than 7,000 patients were diagnosed and treated.
1	0	6	O	Between
2	8	11	O	1988
3	13	15	O	and
4	17	20	O	1993
5	21	21	O	,
6	23	26	O	more
7	28	31	O	than
8	33	37	O	7,000
9	39	46	O	patients
10	48	51	O	were
11	53	61	O	diagnosed
12	63	65	O	and
13	67	73	O	treated
NULL

7496198.xml	DDI-MedLine.d97.s2	NO_SECTION	NO_SETID	27
Since 1988, it has been noted that incidence of melarsoprol reaction had increased systematically between June and October of each year, indicating strong seasonal variation.
1	0	4	O	Since
2	6	9	O	1988
3	10	10	O	,
4	12	13	O	it
5	15	17	O	has
6	19	22	O	been
7	24	28	O	noted
8	30	33	O	that
9	35	43	O	incidence
10	45	46	O	of
11	48	58	U-UNK	melarsoprol
12	60	67	O	reaction
13	69	71	O	had
14	73	81	O	increased
15	83	96	O	systematically
16	98	104	O	between
17	106	109	O	June
18	111	113	O	and
19	115	121	O	October
20	123	124	O	of
21	126	129	O	each
22	131	134	O	year
23	135	135	O	,
24	137	146	O	indicating
25	148	153	O	strong
26	155	162	O	seasonal
27	164	172	O	variation
NULL

7496198.xml	DDI-MedLine.d97.s3	NO_SECTION	NO_SETID	20
In 1992 and 1993, two outbreaks of arsenical reactive encephalopathy (ARE) occurred in the sleeping sickness center of Adjumani.
1	0	1	O	In
2	3	6	O	1992
3	8	10	O	and
4	12	15	O	1993
5	16	16	O	,
6	18	20	O	two
7	22	30	O	outbreaks
8	32	33	O	of
9	35	43	O	arsenical
10	45	52	O	reactive
11	54	67	O	encephalopathy
12	70	72	O	ARE
13	75	82	O	occurred
14	84	85	O	in
15	87	89	O	the
16	91	98	O	sleeping
17	100	107	O	sickness
18	109	114	O	center
19	116	117	O	of
20	119	126	O	Adjumani
NULL

7496198.xml	DDI-MedLine.d97.s4	NO_SECTION	NO_SETID	19
The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993.
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	19	O	ARE
5	21	28	O	suddenly
6	30	37	O	exceeded
7	39	41	O	10%
8	43	44	O	of
9	46	48	O	the
10	50	57	O	patients
11	59	65	O	treated
12	67	68	O	by
13	70	80	U-UNK	melarsoprol
14	82	87	O	during
15	89	94	O	August
16	96	99	O	1992
17	101	103	O	and
18	105	113	O	September
19	115	118	O	1993
NULL

7496198.xml	DDI-MedLine.d97.s5	NO_SECTION	NO_SETID	7
The onset of 80% of those "epidemic"
1	0	2	O	The
2	4	8	O	onset
3	10	11	O	of
4	13	15	O	80%
5	17	18	O	of
6	20	24	O	those
7	26	35	O	"epidemic"
NULL

7496198.xml	DDI-MedLine.d97.s6	NO_SECTION	NO_SETID	12
cases, occurred between the 5th and the 11th day of treatment.
1	0	4	O	cases
2	5	5	O	,
3	7	14	O	occurred
4	16	22	O	between
5	24	26	O	the
6	28	30	O	5th
7	32	34	O	and
8	36	38	O	the
9	40	43	O	11th
10	45	47	O	day
11	49	50	O	of
12	52	60	O	treatment
NULL

7496198.xml	DDI-MedLine.d97.s7	NO_SECTION	NO_SETID	14
Two retrospective studies were conducted in 1992 (75 cases) and in 1993 (51 cases).
1	0	2	O	Two
2	4	16	O	retrospective
3	18	24	O	studies
4	26	29	O	were
5	31	39	O	conducted
6	41	42	O	in
7	44	47	O	1992
8	50	51	O	75
9	53	57	O	cases
10	60	62	O	and
11	64	65	O	in
12	67	70	O	1993
13	73	74	O	51
14	76	80	O	cases
NULL

7496198.xml	DDI-MedLine.d97.s8	NO_SECTION	NO_SETID	34
Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
1	0	4	O	Among
2	6	8	O	the
3	10	13	O	risk
4	15	21	O	factors
5	23	29	O	studied
6	30	30	O	,
7	32	34	O	two
8	36	41	O	appear
9	43	44	O	to
10	46	53	O	increase
11	55	57	O	the
12	59	62	O	risk
13	64	65	O	of
14	67	69	O	ARE
15	70	70	O	:
16	72	74	O	the
17	76	87	O	prescription
18	89	90	O	of
19	92	104	U-UNK	thiabendazole
20	106	107	O	to
21	109	113	O	treat
22	115	130	O	strongyloidiasis
23	132	137	O	during
24	139	141	O	the
25	143	153	U-UNK	melarsoprol
26	155	158	O	cure
27	160	162	O	and
28	164	166	O	the
29	168	170	O	bad
30	172	178	O	general
31	180	187	O	clinical
32	189	198	O	conditions
33	200	201	O	of
34	203	210	O	patients
NULL

7496198.xml	DDI-MedLine.d97.s9	NO_SECTION	NO_SETID	15
These observations suggest that exogenous co-factors could be involved in the occurrence of ARE.
1	0	4	O	These
2	6	17	O	observations
3	19	25	O	suggest
4	27	30	O	that
5	32	40	O	exogenous
6	42	43	O	co
7	45	51	O	factors
8	53	57	O	could
9	59	60	O	be
10	62	69	O	involved
11	71	72	O	in
12	74	76	O	the
13	78	87	O	occurrence
14	89	90	O	of
15	92	94	O	ARE
NULL

7496198.xml	DDI-MedLine.d97.s10	NO_SECTION	NO_SETID	27
Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.
1	0	14	O	Recommendations
2	16	19	O	were
3	21	22	O	to
4	24	28	O	avoid
5	30	43	O	administration
6	45	46	O	of
7	48	57	O	diffusible
8	59	62	B-UNK	anti
9	64	73	L-UNK	helminthic
10	75	83	O	treatment
11	85	90	O	during
12	92	94	O	the
13	96	99	O	cure
14	100	100	O	,
15	102	104	O	and
16	106	107	O	to
17	109	115	O	improve
18	117	119	O	the
19	121	127	O	general
20	129	138	O	conditions
21	140	141	O	of
22	143	150	O	patients
23	152	157	O	before
24	159	161	O	the
25	163	166	O	cure
26	168	169	O	of
27	171	181	U-UNK	melarsoprol
NULL

7599505.xml	DDI-MedLine.d34.s0	NO_SECTION	NO_SETID	9
Interactions of cobalt and iron in absorption and retention.
1	0	11	O	Interactions
2	13	14	O	of
3	16	21	U-UNK	cobalt
4	23	25	O	and
5	27	30	U-UNK	iron
6	32	33	O	in
7	35	44	O	absorption
8	46	48	O	and
9	50	58	O	retention
NULL

7599505.xml	DDI-MedLine.d34.s1	NO_SECTION	NO_SETID	71
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	27	O	supplementary
5	29	32	O	oral
6	34	39	U-UNK	cobalt
7	41	43	O	and
8	45	48	U-UNK	iron
9	49	49	O	,
10	51	52	O	as
11	54	57	O	well
12	59	60	O	as
13	62	64	O	the
14	66	76	O	interaction
15	78	84	O	between
16	86	89	O	both
17	91	92	O	at
18	94	96	O	the
19	98	107	O	absorption
20	109	112	O	site
21	113	113	O	,
22	115	119	O	fecal
23	121	123	O	and
24	125	131	O	urinary
25	133	141	O	excretion
26	143	144	O	as
27	146	149	O	well
28	151	152	O	as
29	154	156	O	the
30	158	166	O	retention
31	168	169	O	of
32	171	175	O	these
33	177	181	O	trace
34	183	190	O	elements
35	192	195	O	were
36	197	206	O	determined
37	208	209	O	by
38	211	215	O	using
39	217	220	O	four
40	222	226	O	diets
41	228	237	O	containing
42	239	244	O	either
43	246	246	O	9
44	248	249	O	or
45	251	252	O	63
46	254	263	O	micrograms
47	264	264	O	/
48	265	266	O	kg
49	268	269	O	of
50	271	272	U-UNK	Co
51	274	276	O	and
52	278	279	O	48
53	281	282	O	or
54	284	286	O	446
55	288	289	O	mg
56	290	290	O	/
57	291	292	O	kg
58	294	295	O	of
59	297	298	U-UNK	Fe
60	300	303	O	over
61	305	305	O	a
62	307	312	O	period
63	314	315	O	of
64	317	318	O	19
65	320	323	O	days
66	325	326	O	in
67	328	328	O	a
68	330	334	O	total
69	336	337	O	of
70	339	340	O	24
71	342	345	O	rats
NULL

7599505.xml	DDI-MedLine.d34.s2	NO_SECTION	NO_SETID	13
Retention was calculated by the balance technique and by the comparative slaughter technique.
1	0	8	O	Retention
2	10	12	O	was
3	14	23	O	calculated
4	25	26	O	by
5	28	30	O	the
6	32	38	O	balance
7	40	48	O	technique
8	50	52	O	and
9	54	55	O	by
10	57	59	O	the
11	61	71	O	comparative
12	73	81	O	slaughter
13	83	91	O	technique
NULL

7599505.xml	DDI-MedLine.d34.s3	NO_SECTION	NO_SETID	30
After one day, fecal as well as urinary excretion of both elements had already responded to the dietary treatments, with constant values being reached after approximately three days.
1	0	4	O	After
2	6	8	O	one
3	10	12	O	day
4	13	13	O	,
5	15	19	O	fecal
6	21	22	O	as
7	24	27	O	well
8	29	30	O	as
9	32	38	O	urinary
10	40	48	O	excretion
11	50	51	O	of
12	53	56	O	both
13	58	65	O	elements
14	67	69	O	had
15	71	77	O	already
16	79	87	O	responded
17	89	90	O	to
18	92	94	O	the
19	96	102	O	dietary
20	104	113	O	treatments
21	114	114	O	,
22	116	119	O	with
23	121	128	O	constant
24	130	135	O	values
25	137	141	O	being
26	143	149	O	reached
27	151	155	O	after
28	157	169	O	approximately
29	171	175	O	three
30	177	180	O	days
NULL

7599505.xml	DDI-MedLine.d34.s4	NO_SECTION	NO_SETID	7
Cobalt excretion was enhanced by supplementary cobalt;
1	0	5	U-UNK	Cobalt
2	7	15	O	excretion
3	17	19	O	was
4	21	28	O	enhanced
5	30	31	O	by
6	33	45	O	supplementary
7	47	52	U-UNK	cobalt
NULL

7599505.xml	DDI-MedLine.d34.s5	NO_SECTION	NO_SETID	10
fecal excretion, too, was increased by supplementary iron;
1	0	4	O	fecal
2	6	14	O	excretion
3	15	15	O	,
4	17	19	O	too
5	20	20	O	,
6	22	24	O	was
7	26	34	O	increased
8	36	37	O	by
9	39	51	O	supplementary
10	53	56	U-UNK	iron
NULL

7599505.xml	DDI-MedLine.d34.s6	NO_SECTION	NO_SETID	8
whereas urinary excretion was decreased in both cases.
1	0	6	O	whereas
2	8	14	O	urinary
3	16	24	O	excretion
4	26	28	O	was
5	30	38	O	decreased
6	40	41	O	in
7	43	46	O	both
8	48	52	O	cases
NULL

7599505.xml	DDI-MedLine.d34.s7	NO_SECTION	NO_SETID	13
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
1	0	9	O	Additional
2	11	14	U-UNK	iron
3	16	28	O	significantly
4	30	38	O	inhibited
5	40	42	O	the
6	44	53	O	absorption
7	55	56	O	of
8	58	63	U-UNK	cobalt
9	65	66	O	in
10	68	71	O	both
11	73	79	O	dietary
12	81	86	U-UNK	cobalt
13	88	97	O	treatments
NULL

7599505.xml	DDI-MedLine.d34.s8	NO_SECTION	NO_SETID	29
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
1	0	2	O	The
2	4	8	O	lower
3	10	13	O	rate
4	15	16	O	of
5	18	27	O	absorption
6	29	30	O	in
7	32	34	O	the
8	36	41	O	groups
9	43	51	O	receiving
10	53	55	O	446
11	57	58	O	mg
12	60	61	U-UNK	Fe
13	63	69	O	instead
14	71	72	O	of
15	74	75	O	48
16	77	78	O	mg
17	80	81	O	of
18	83	84	U-UNK	Fe
19	86	88	O	per
20	90	91	O	kg
21	93	96	O	diet
22	98	105	O	resulted
23	107	108	O	in
24	110	110	O	a
25	112	120	O	decreased
26	122	126	O	renal
27	128	136	O	excretion
28	138	139	O	of
29	141	146	U-UNK	cobalt
NULL

7599505.xml	DDI-MedLine.d34.s9	NO_SECTION	NO_SETID	16
Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	the
4	18	23	O	effect
5	25	26	O	of
6	28	31	U-UNK	iron
7	33	34	O	on
8	36	38	O	the
9	40	48	O	retention
10	50	51	O	of
11	53	58	U-UNK	cobalt
12	60	62	O	was
13	64	68	O	lower
14	70	73	O	than
15	75	76	O	on
16	78	87	O	absorption
NULL

7599505.xml	DDI-MedLine.d34.s10	NO_SECTION	NO_SETID	16
This suggests that interactions between the two elements only take place at the site of absorption.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	30	O	interactions
5	32	38	O	between
6	40	42	O	the
7	44	46	O	two
8	48	55	O	elements
9	57	60	O	only
10	62	65	O	take
11	67	71	O	place
12	73	74	O	at
13	76	78	O	the
14	80	83	O	site
15	85	86	O	of
16	88	97	O	absorption
NULL

7599505.xml	DDI-MedLine.d34.s11	NO_SECTION	NO_SETID	27
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	17	O	low
5	19	25	O	dietary
6	27	32	U-UNK	cobalt
7	34	46	O	concentration
8	48	49	O	as
9	51	58	O	compared
10	60	61	O	to
11	63	65	O	the
12	67	70	U-UNK	iron
13	72	79	O	contents
14	81	82	O	of
15	84	86	O	the
16	88	92	O	diets
17	93	93	O	,
18	95	96	O	no
19	98	103	O	effect
20	105	106	O	of
21	108	113	U-UNK	cobalt
22	115	116	O	on
23	118	121	U-UNK	iron
24	123	132	O	absorption
25	134	136	O	and
26	138	146	O	excretion
27	148	155	O	occurred
NULL

7599505.xml	DDI-MedLine.d34.s12	NO_SECTION	NO_SETID	35
Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)
1	0	10	O	Differences
2	12	13	O	in
3	15	18	U-UNK	iron
4	20	26	O	balance
5	28	31	O	were
6	33	36	O	only
7	38	45	O	observed
8	47	53	O	between
9	55	58	O	both
10	60	66	O	dietary
11	68	81	O	concentrations
12	82	82	O	,
13	84	90	O	showing
14	92	92	O	a
15	94	99	O	higher
16	101	108	O	absolute
17	110	112	O	but
18	114	114	O	a
19	116	120	O	lower
20	122	129	O	relative
21	131	140	O	absorption
22	142	143	O	as
23	145	148	O	well
24	150	151	O	as
25	153	161	O	retention
26	163	164	O	in
27	166	168	O	the
28	170	175	O	groups
29	177	179	O	fed
30	181	187	O	further
31	189	200	O	Fe.(ABSTRACT
32	202	210	O	TRUNCATED
33	212	213	O	AT
34	215	217	O	250
35	219	223	O	WORDS
NULL

7600639.xml	DDI-MedLine.d39.s0	NO_SECTION	NO_SETID	16
Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.
1	0	5	O	Effect
2	7	8	O	of
3	10	18	U-UNK	estradiol
4	20	21	O	on
5	23	31	U-UNK	endotoxin
6	33	39	O	induced
7	41	47	O	changes
8	49	50	O	in
9	52	58	O	steroid
10	60	66	O	hormone
11	68	73	O	levels
12	75	77	O	and
13	79	87	O	lethality
14	89	90	O	in
15	92	95	O	male
16	97	100	O	rats
NULL

7600639.xml	DDI-MedLine.d39.s1	NO_SECTION	NO_SETID	38
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
1	0	1	O	We
2	3	10	O	examined
3	12	14	O	the
4	16	21	O	effect
5	23	24	O	of
6	26	34	O	exogenous
7	36	44	U-UNK	estradiol
8	46	47	O	on
9	49	51	O	the
10	53	59	O	changes
11	61	62	O	in
12	64	68	O	serum
13	70	76	O	steroid
14	78	84	O	hormone
15	86	91	O	levels
16	93	99	O	induced
17	101	102	O	by
18	104	104	O	a
19	106	114	O	nonlethal
20	116	119	O	dose
21	121	122	O	of
22	124	134	O	Escherichia
23	136	139	O	coli
24	141	149	U-UNK	endotoxin
25	151	152	O	in
26	154	157	O	male
27	159	162	O	rats
28	164	166	O	and
29	168	170	O	the
30	172	177	O	deaths
31	179	181	O	due
32	183	184	O	to
33	186	194	O	nonlethal
34	196	198	O	and
35	200	205	O	lethal
36	207	211	O	doses
37	213	214	O	of
38	216	224	U-UNK	endotoxin
NULL

7600639.xml	DDI-MedLine.d39.s2	NO_SECTION	NO_SETID	23
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
1	0	8	O	Injection
2	10	11	O	of
3	13	21	U-UNK	estradiol
4	23	23	O	5
5	25	27	O	min
6	29	34	O	before
7	36	36	O	a
8	38	46	O	nonlethal
9	48	51	O	dose
10	53	54	O	of
11	56	64	U-UNK	endotoxin
12	66	72	O	changed
13	74	76	O	the
14	78	82	O	serum
15	84	86	O	sex
16	88	94	O	steroid
17	96	102	O	hormone
18	104	111	O	response
19	113	114	O	of
20	116	119	O	male
21	121	124	O	rats
22	126	127	O	to
23	129	137	U-UNK	endotoxin
NULL

7600639.xml	DDI-MedLine.d39.s3	NO_SECTION	NO_SETID	26
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
1	0	2	O	The
2	4	8	O	serum
3	10	17	O	estrogen
4	19	32	O	concentrations
5	34	35	O	of
6	37	45	U-UNK	estradiol
7	47	47	O	+
8	49	57	U-UNK	endotoxin
9	59	65	O	treated
10	67	70	O	rats
11	72	80	O	decreased
12	82	83	O	by
13	85	87	O	50%
14	88	88	O	,
15	90	94	O	while
16	96	100	O	those
17	102	103	O	of
18	105	107	O	the
19	109	117	U-UNK	endotoxin
20	119	125	O	treated
21	127	130	O	rats
22	132	140	O	increased
23	143	143	O	2
24	146	147	O	to
25	149	149	O	5
26	151	154	O	fold
NULL

7600639.xml	DDI-MedLine.d39.s4	NO_SECTION	NO_SETID	25
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
1	0	2	O	The
2	4	8	O	serum
3	10	17	O	androgen
4	19	32	O	concentrations
5	34	35	O	of
6	37	45	U-UNK	estradiol
7	47	47	O	+
8	49	57	U-UNK	endotoxin
9	59	65	O	treated
10	67	70	O	rats
11	72	74	O	did
12	76	78	O	not
13	80	85	O	change
14	87	99	O	significantly
15	100	100	O	,
16	102	106	O	while
17	108	112	O	those
18	114	115	O	of
19	117	125	U-UNK	endotoxin
20	127	133	O	treated
21	135	138	O	rats
22	140	146	O	dropped
23	148	149	O	to
24	151	152	O	30
25	154	156	O	40%
NULL

7600639.xml	DDI-MedLine.d39.s6	NO_SECTION	NO_SETID	17
Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
1	0	8	O	Exogenous
2	10	18	U-UNK	estradiol
3	20	23	O	also
4	25	32	O	appeared
5	34	35	O	to
6	37	45	O	influence
7	47	49	O	the
8	51	60	O	percentage
9	62	63	O	of
10	65	73	U-UNK	endotoxin
11	75	81	O	induced
12	83	88	O	deaths
13	90	91	O	in
14	93	93	O	a
15	95	98	O	dose
16	100	108	O	dependent
17	110	115	O	manner
NULL

7600639.xml	DDI-MedLine.d39.s7	NO_SECTION	NO_SETID	32
It reduced the number of deaths induced by nonlethal (2 mg/kg) dose of endotoxin but increased the number of deaths induced by a highly lethal dose (8 mg/kg).
1	0	1	O	It
2	3	9	O	reduced
3	11	13	O	the
4	15	20	O	number
5	22	23	O	of
6	25	30	O	deaths
7	32	38	O	induced
8	40	41	O	by
9	43	51	O	nonlethal
10	54	54	O	2
11	56	57	O	mg
12	58	58	O	/
13	59	60	O	kg
14	63	66	O	dose
15	68	69	O	of
16	71	79	U-UNK	endotoxin
17	81	83	O	but
18	85	93	O	increased
19	95	97	O	the
20	99	104	O	number
21	106	107	O	of
22	109	114	O	deaths
23	116	122	O	induced
24	124	125	O	by
25	127	127	O	a
26	129	134	O	highly
27	136	141	O	lethal
28	143	146	O	dose
29	149	149	O	8
30	151	152	O	mg
31	153	153	O	/
32	154	155	O	kg
NULL

7600639.xml	DDI-MedLine.d39.s8	NO_SECTION	NO_SETID	36
These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.
1	0	4	O	These
2	6	12	O	results
3	13	13	O	,
4	15	22	O	together
5	24	27	O	with
6	29	31	O	the
7	33	37	O	known
8	39	51	O	relationships
9	53	59	O	between
10	61	68	U-UNK	estrogen
11	70	72	O	and
12	74	76	O	the
13	78	83	O	immune
14	85	92	O	response
15	93	93	O	,
16	95	101	O	suggest
17	103	106	O	that
18	108	116	U-UNK	estrogens
19	118	123	O	affect
20	125	127	O	the
21	129	134	O	course
22	136	137	O	of
23	139	144	O	septic
24	146	150	O	shock
25	152	153	O	in
26	155	155	O	a
27	157	163	O	complex
28	165	171	O	fashion
29	173	175	O	and
30	177	179	O	may
31	181	184	O	have
32	186	191	O	either
33	193	202	O	protective
34	204	205	O	or
35	207	217	O	deleterious
36	219	224	O	effect
NULL

7625885.xml	DDI-MedLine.d128.s0	NO_SECTION	NO_SETID	10
Analysis of 16,16-dimethylprostaglandin E2-induced diarrhea in cecectomized rats.
1	0	7	O	Analysis
2	9	10	O	of
3	12	16	B-UNK	16,16
4	18	38	I-UNK	dimethylprostaglandin
5	40	41	L-UNK	E2
6	43	49	O	induced
7	51	58	O	diarrhea
8	60	61	O	in
9	63	74	O	cecectomized
10	76	79	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s1	NO_SECTION	NO_SETID	25
The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction.
1	0	2	O	The
2	4	8	B-UNK	16,16
3	10	30	I-UNK	dimethylprostaglandin
4	32	33	L-UNK	E2
5	36	41	U-UNK	dmPGE2
6	44	50	O	induced
7	52	59	O	diarrhea
8	61	63	O	was
9	65	72	O	analyzed
10	74	75	O	in
11	77	88	O	cecectomized
12	90	93	O	rats
13	95	102	O	prepared
14	104	105	O	by
15	107	115	O	resecting
16	117	119	O	the
17	121	125	O	cecum
18	127	129	O	and
19	131	133	O	its
20	135	145	O	vasculature
21	147	153	O	without
22	155	164	O	disturbing
23	166	168	O	the
24	170	178	O	ileocecal
25	180	187	O	junction
NULL

7625885.xml	DDI-MedLine.d128.s2	NO_SECTION	NO_SETID	8
dmPGE2 (0.1-1.0 mg/kg, p.o.)
1	0	5	U-UNK	dmPGE2
2	8	10	O	0.1
3	12	14	O	1.0
4	16	17	O	mg
5	18	18	O	/
6	19	20	O	kg
7	21	21	O	,
8	23	25	O	p.o
NULL

7625885.xml	DDI-MedLine.d128.s3	NO_SECTION	NO_SETID	18
dose-dependently increased the number of defecation episodes and induced a soft and watery stool in cecectomized rats.
1	0	3	O	dose
2	5	15	O	dependently
3	17	25	O	increased
4	27	29	O	the
5	31	36	O	number
6	38	39	O	of
7	41	50	O	defecation
8	52	59	O	episodes
9	61	63	O	and
10	65	71	O	induced
11	73	73	O	a
12	75	78	O	soft
13	80	82	O	and
14	84	89	O	watery
15	91	95	O	stool
16	97	98	O	in
17	100	111	O	cecectomized
18	113	116	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s4	NO_SECTION	NO_SETID	21
At 0.3 mg/kg, the diarrhea-inducing effects of dmPGE2 were more pronounced in cecectomized than in control rats.
1	0	1	O	At
2	3	5	O	0.3
3	7	8	O	mg
4	9	9	O	/
5	10	11	O	kg
6	12	12	O	,
7	14	16	O	the
8	18	25	O	diarrhea
9	27	34	O	inducing
10	36	42	O	effects
11	44	45	O	of
12	47	52	U-UNK	dmPGE2
13	54	57	O	were
14	59	62	O	more
15	64	73	O	pronounced
16	75	76	O	in
17	78	89	O	cecectomized
18	91	94	O	than
19	96	97	O	in
20	99	105	O	control
21	107	110	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s5	NO_SECTION	NO_SETID	34
When given i.p., dmPGE2 (0.3 mg/kg) induced a watery stool in cecectomized and control rats with the same efficacy, although these effects were short-lasting as compared to oral administration.
1	0	3	O	When
2	5	9	O	given
3	11	13	O	i.p
4	15	15	O	,
5	17	22	U-UNK	dmPGE2
6	25	27	O	0.3
7	29	30	O	mg
8	31	31	O	/
9	32	33	O	kg
10	36	42	O	induced
11	44	44	O	a
12	46	51	O	watery
13	53	57	O	stool
14	59	60	O	in
15	62	73	O	cecectomized
16	75	77	O	and
17	79	85	O	control
18	87	90	O	rats
19	92	95	O	with
20	97	99	O	the
21	101	104	O	same
22	106	113	O	efficacy
23	114	114	O	,
24	116	123	O	although
25	125	129	O	these
26	131	137	O	effects
27	139	142	O	were
28	144	148	O	short
29	150	156	O	lasting
30	158	159	O	as
31	161	168	O	compared
32	170	171	O	to
33	173	176	O	oral
34	178	191	O	administration
NULL

7625885.xml	DDI-MedLine.d128.s6	NO_SECTION	NO_SETID	8
Castor oil (4 ml/kg, p.o.)
1	0	5	B-UNK	Castor
2	7	9	L-UNK	oil
3	12	12	O	4
4	14	15	O	ml
5	16	16	O	/
6	17	18	O	kg
7	19	19	O	,
8	21	23	O	p.o
NULL

7625885.xml	DDI-MedLine.d128.s7	NO_SECTION	NO_SETID	14
also induced diarrhea, but did not produce a watery stool in cecectomized rats.
1	0	3	O	also
2	5	11	O	induced
3	13	20	O	diarrhea
4	21	21	O	,
5	23	25	O	but
6	27	29	O	did
7	31	33	O	not
8	35	41	O	produce
9	43	43	O	a
10	45	50	O	watery
11	52	56	O	stool
12	58	59	O	in
13	61	72	O	cecectomized
14	74	77	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s8	NO_SECTION	NO_SETID	25
There were no differences between cecectomized and control rats in basal small intestinal transits or in dmPGE2 (0.3 mg/kg, p.o.)-induced enhancements.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	24	O	differences
5	26	32	O	between
6	34	45	O	cecectomized
7	47	49	O	and
8	51	57	O	control
9	59	62	O	rats
10	64	65	O	in
11	67	71	O	basal
12	73	77	O	small
13	79	88	O	intestinal
14	90	97	O	transits
15	99	100	O	or
16	102	103	O	in
17	105	110	U-UNK	dmPGE2
18	113	115	O	0.3
19	117	118	O	mg
20	119	119	O	/
21	120	121	O	kg
22	122	122	O	,
23	124	126	O	p.o
24	130	136	O	induced
25	138	149	O	enhancements
NULL

7625885.xml	DDI-MedLine.d128.s9	NO_SECTION	NO_SETID	20
Moreover, the basal and dmPGE2-induced jejunal net fluid transfers were the same in cecectomized and in control rats.
1	0	7	O	Moreover
2	8	8	O	,
3	10	12	O	the
4	14	18	O	basal
5	20	22	O	and
6	24	29	U-UNK	dmPGE2
7	31	37	O	induced
8	39	45	O	jejunal
9	47	49	O	net
10	51	55	O	fluid
11	57	65	O	transfers
12	67	70	O	were
13	72	74	O	the
14	76	79	O	same
15	81	82	O	in
16	84	95	O	cecectomized
17	97	99	O	and
18	101	102	O	in
19	104	110	O	control
20	112	115	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s10	NO_SECTION	NO_SETID	54
On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	other
4	13	16	O	hand
5	17	17	O	,
6	19	21	O	the
7	23	30	O	enhanced
8	32	40	O	secretion
9	42	43	O	of
10	45	51	O	colonic
11	53	57	O	fluid
12	59	60	O	by
13	62	67	U-UNK	dmPGE2
14	68	68	O	,
15	70	74	O	given
16	76	89	O	intraluminally
17	90	90	O	,
18	92	94	O	was
19	96	99	O	only
20	101	104	O	half
21	106	107	O	of
22	109	112	O	that
23	114	115	O	in
24	117	123	O	control
25	125	128	O	rats
26	129	129	O	,
27	131	137	O	whereas
28	139	141	O	the
29	143	149	O	colonic
30	151	157	O	transit
31	159	167	O	enhancing
32	169	174	O	effect
33	176	177	O	of
34	179	184	U-UNK	dmPGE2
35	186	187	O	in
36	189	200	O	cecectomized
37	202	205	O	rats
38	207	209	O	was
39	211	214	O	more
40	216	225	O	pronounced
41	227	230	O	than
42	232	233	O	in
43	235	241	O	control
44	243	246	O	rats
45	248	249	O	at
46	251	252	O	15
47	254	256	O	but
48	258	260	O	not
49	262	263	O	at
50	265	266	O	30
51	268	270	O	min
52	272	276	O	after
53	278	280	O	its
54	282	295	O	administration
NULL

7625885.xml	DDI-MedLine.d128.s11	NO_SECTION	NO_SETID	16
The basal colonic fluid contents and transits were the same in cecectomized and in control rats.
1	0	2	O	The
2	4	8	O	basal
3	10	16	O	colonic
4	18	22	O	fluid
5	24	31	O	contents
6	33	35	O	and
7	37	44	O	transits
8	46	49	O	were
9	51	53	O	the
10	55	58	O	same
11	60	61	O	in
12	63	74	O	cecectomized
13	76	78	O	and
14	80	81	O	in
15	83	89	O	control
16	91	94	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s12	NO_SECTION	NO_SETID	11
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.)
1	0	9	U-UNK	Loperamide
2	11	13	O	and
3	15	22	U-UNK	morphine
4	25	27	O	0.1
5	29	31	O	and
6	33	35	O	1.0
7	37	38	O	mg
8	39	39	O	/
9	40	41	O	kg
10	42	42	O	,
11	44	46	O	s.c
NULL

7625885.xml	DDI-MedLine.d128.s13	NO_SECTION	NO_SETID	25
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
1	0	9	U-UNK	Loperamide
2	11	13	O	and
3	15	22	U-UNK	morphine
4	25	27	O	0.1
5	29	31	O	and
6	33	35	O	1.0
7	37	38	O	mg
8	39	39	O	/
9	40	41	O	kg
10	42	42	O	,
11	44	46	O	s.c
12	50	58	O	inhibited
13	60	62	O	the
14	64	69	U-UNK	dmPGE2
15	72	74	O	0.3
16	76	77	O	mg
17	78	78	O	/
18	79	80	O	kg
19	81	81	O	,
20	83	85	O	p.o
21	89	95	O	induced
22	97	104	O	diarrhea
23	106	107	O	in
24	109	120	O	cecectomized
25	122	125	O	rats
NULL

7625885.xml	DDI-MedLine.d128.s14	NO_SECTION	NO_SETID	8
N-methyllevallorphan (5 mg/kg, s.c.)
1	0	0	B-UNK	N
2	2	19	L-UNK	methyllevallorphan
3	22	22	O	5
4	24	25	O	mg
5	26	26	O	/
6	27	28	O	kg
7	29	29	O	,
8	31	33	O	s.c
NULL

7625885.xml	DDI-MedLine.d128.s15	NO_SECTION	NO_SETID	22
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
1	0	0	B-UNK	N
2	2	19	L-UNK	methyllevallorphan
3	22	22	O	5
4	24	25	O	mg
5	26	26	O	/
6	27	28	O	kg
7	29	29	O	,
8	31	33	O	s.c
9	37	46	O	completely
10	48	58	O	antagonized
11	60	62	O	the
12	64	73	O	inhibitory
13	75	80	O	effect
14	82	83	O	of
15	85	94	U-UNK	loperamide
16	96	98	O	and
17	100	105	O	partly
18	107	117	O	antagonized
19	119	121	O	the
20	123	128	O	effect
21	130	131	O	of
22	133	140	U-UNK	morphine
NULL

7625885.xml	DDI-MedLine.d128.s16	NO_SECTION	NO_SETID	37
These results suggest that oral administration of dmPGE2 induces a more pronounced secretory diarrhea in cecectomized than in control rats, probably due to the lack of the reservoir function of the cecum in the operated animals.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	30	O	oral
6	32	45	O	administration
7	47	48	O	of
8	50	55	U-UNK	dmPGE2
9	57	63	O	induces
10	65	65	O	a
11	67	70	O	more
12	72	81	O	pronounced
13	83	91	O	secretory
14	93	100	O	diarrhea
15	102	103	O	in
16	105	116	O	cecectomized
17	118	121	O	than
18	123	124	O	in
19	126	132	O	control
20	134	137	O	rats
21	138	138	O	,
22	140	147	O	probably
23	149	151	O	due
24	153	154	O	to
25	156	158	O	the
26	160	163	O	lack
27	165	166	O	of
28	168	170	O	the
29	172	180	O	reservoir
30	182	189	O	function
31	191	192	O	of
32	194	196	O	the
33	198	202	O	cecum
34	204	205	O	in
35	207	209	O	the
36	211	218	O	operated
37	220	226	O	animals
NULL

7625885.xml	DDI-MedLine.d128.s17	NO_SECTION	NO_SETID	13
This secretory diarrhea model is suitable for evaluating the antidiarrheal activity of drugs.
1	0	3	O	This
2	5	13	O	secretory
3	15	22	O	diarrhea
4	24	28	O	model
5	30	31	O	is
6	33	40	O	suitable
7	42	44	O	for
8	46	55	O	evaluating
9	57	59	O	the
10	61	73	O	antidiarrheal
11	75	82	O	activity
12	84	85	O	of
13	87	91	O	drugs
NULL

7632757.xml	DDI-MedLine.d89.s0	NO_SECTION	NO_SETID	15
Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
1	0	10	O	Therapeutic
2	12	15	O	drug
3	17	26	O	monitoring
4	28	30	O	can
5	32	36	O	avoid
6	38	47	O	iatrogenic
7	49	59	O	alterations
8	61	66	O	caused
9	68	69	O	by
10	71	75	B-UNK	99mTc
11	77	85	I-UNK	methylene
12	87	99	L-UNK	diphosphonate
13	102	104	O	MDP
14	107	116	U-UNK	gentamicin
15	118	128	O	interaction
NULL

7632757.xml	DDI-MedLine.d89.s1	NO_SECTION	NO_SETID	27
Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys.
1	0	9	U-UNK	Gentamicin
2	11	12	O	is
3	14	15	O	an
4	17	30	B-UNK	aminoglycoside
5	32	41	L-UNK	antibiotic
6	43	46	O	used
7	48	49	O	to
8	51	55	O	treat
9	57	57	O	a
10	59	62	O	wide
11	64	70	O	variety
12	72	73	O	of
13	75	84	O	infections
14	86	91	O	caused
15	93	94	O	by
16	96	99	O	gram
17	101	108	O	negative
18	110	118	O	organisms
19	119	119	O	,
20	121	123	O	but
21	125	126	O	it
22	128	129	O	is
23	131	141	O	potentially
24	143	147	O	toxic
25	149	150	O	to
26	152	154	O	the
27	156	162	O	kidneys
NULL

7632757.xml	DDI-MedLine.d89.s2	NO_SECTION	NO_SETID	19
Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	its
4	11	24	O	nephrotoxicity
5	25	25	O	,
6	27	36	U-UNK	gentamicin
7	38	40	O	may
8	42	46	O	cause
9	48	55	O	abnormal
10	57	61	O	renal
11	63	68	O	uptake
12	70	71	O	to
13	73	74	O	be
14	76	79	O	seen
15	81	82	O	on
16	84	88	B-UNK	99mTc
17	90	92	L-UNK	MDP
18	94	97	O	bone
19	99	110	O	scintigraphy
NULL

7632757.xml	DDI-MedLine.d89.s3	NO_SECTION	NO_SETID	43
The presence of the radiopharmaceutical in the kidneys, along with an increase in renal retention, tend to produce scintigraphic results that falsely identify characteristics related to diseases such as renal vascular, or urinary tract obstruction, and even renal cancer.
1	0	2	O	The
2	4	11	O	presence
3	13	14	O	of
4	16	18	O	the
5	20	38	U-UNK	radiopharmaceutical
6	40	41	O	in
7	43	45	O	the
8	47	53	O	kidneys
9	54	54	O	,
10	56	60	O	along
11	62	65	O	with
12	67	68	O	an
13	70	77	O	increase
14	79	80	O	in
15	82	86	O	renal
16	88	96	O	retention
17	97	97	O	,
18	99	102	O	tend
19	104	105	O	to
20	107	113	O	produce
21	115	127	O	scintigraphic
22	129	135	O	results
23	137	140	O	that
24	142	148	O	falsely
25	150	157	O	identify
26	159	173	O	characteristics
27	175	181	O	related
28	183	184	O	to
29	186	193	O	diseases
30	195	198	O	such
31	200	201	O	as
32	203	207	O	renal
33	209	216	O	vascular
34	217	217	O	,
35	219	220	O	or
36	222	228	O	urinary
37	230	234	O	tract
38	236	246	O	obstruction
39	247	247	O	,
40	249	251	O	and
41	253	256	O	even
42	258	262	O	renal
43	264	269	O	cancer
NULL

7632757.xml	DDI-MedLine.d89.s4	NO_SECTION	NO_SETID	16
An altered biodistribution may provide misleading information that can either mask or mimic certain disease symptoms.
1	0	1	O	An
2	3	9	O	altered
3	11	25	O	biodistribution
4	27	29	O	may
5	31	37	O	provide
6	39	48	O	misleading
7	50	60	O	information
8	62	65	O	that
9	67	69	O	can
10	71	76	O	either
11	78	81	O	mask
12	83	84	O	or
13	86	90	O	mimic
14	92	98	O	certain
15	100	106	O	disease
16	108	115	O	symptoms
NULL

7632757.xml	DDI-MedLine.d89.s5	NO_SECTION	NO_SETID	26
A method to maximize the therapeutic benefit of gentamicin while minimizing the risk of nephrotoxicity and the appearance of a hot kidney on scintigraphy is desirable.
1	0	0	O	A
2	2	7	O	method
3	9	10	O	to
4	12	19	O	maximize
5	21	23	O	the
6	25	35	O	therapeutic
7	37	43	O	benefit
8	45	46	O	of
9	48	57	U-UNK	gentamicin
10	59	63	O	while
11	65	74	O	minimizing
12	76	78	O	the
13	80	83	O	risk
14	85	86	O	of
15	88	101	O	nephrotoxicity
16	103	105	O	and
17	107	109	O	the
18	111	120	O	appearance
19	122	123	O	of
20	125	125	O	a
21	127	129	O	hot
22	131	136	O	kidney
23	138	139	O	on
24	141	152	O	scintigraphy
25	154	155	O	is
26	157	165	O	desirable
NULL

7632757.xml	DDI-MedLine.d89.s6	NO_SECTION	NO_SETID	13
Serial pharmacokinetic dosing has been proposed as a method to accomplish this goal.
1	0	5	O	Serial
2	7	21	O	pharmacokinetic
3	23	28	O	dosing
4	30	32	O	has
5	34	37	O	been
6	39	46	O	proposed
7	48	49	O	as
8	51	51	O	a
9	53	58	O	method
10	60	61	O	to
11	63	72	O	accomplish
12	74	77	O	this
13	79	82	O	goal
NULL

7632757.xml	DDI-MedLine.d89.s7	NO_SECTION	NO_SETID	23
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients.
1	0	10	O	Therapeutic
2	12	15	O	drug
3	17	26	O	monitoring
4	29	31	O	TDM
5	34	35	O	of
6	37	46	U-UNK	gentamicin
7	48	54	O	therapy
8	55	55	O	,
9	57	59	O	and
10	61	64	O	bone
11	66	77	O	scintigraphy
12	79	87	O	employing
13	89	93	B-UNK	99mTc
14	95	97	L-UNK	MDP
15	99	100	O	as
16	102	104	O	the
17	106	124	U-UNK	radiopharmaceutical
18	126	128	O	was
19	130	136	O	carried
20	138	140	O	out
21	142	143	O	in
22	145	146	O	22
23	148	155	O	patients
NULL

7632757.xml	DDI-MedLine.d89.s8	NO_SECTION	NO_SETID	23
The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.
1	0	2	O	The
2	4	7	O	data
3	9	17	O	presented
4	19	22	O	here
5	24	34	O	demonstrate
6	36	39	O	that
7	41	44	O	with
8	46	51	O	serial
9	53	67	O	pharmacokinetic
10	69	74	O	dosing
11	76	77	O	of
12	79	88	U-UNK	gentamicin
13	89	89	O	,
14	91	93	O	the
15	95	104	O	iatrogenic
16	106	115	O	alteration
17	117	122	O	caused
18	124	125	O	by
19	127	136	U-UNK	gentamicin
20	138	144	O	therapy
21	146	148	O	can
22	150	151	O	be
23	153	159	O	avoided
NULL

7635041.xml	DDI-MedLine.d11.s0	NO_SECTION	NO_SETID	5
Immunosuppressive drugs and their complications.
1	0	16	B-UNK	Immunosuppressive
2	18	22	L-UNK	drugs
3	24	26	O	and
4	28	32	O	their
5	34	46	O	complications
NULL

7635041.xml	DDI-MedLine.d11.s1	NO_SECTION	NO_SETID	9
Drugs that suppress the immune system are widely used.
1	0	4	O	Drugs
2	6	9	O	that
3	11	18	O	suppress
4	20	22	O	the
5	24	29	O	immune
6	31	36	O	system
7	38	40	O	are
8	42	47	O	widely
9	49	52	O	used
NULL

7635041.xml	DDI-MedLine.d11.s2	NO_SECTION	NO_SETID	38
They are part of the treatment of patients with organ transplants, malignancy, and increasingly those with conditions such as psoriasis, rheumatoid arthritis, and liver and bowel disease in which inflammation is an aetiological factor.
1	0	3	O	They
2	5	7	O	are
3	9	12	O	part
4	14	15	O	of
5	17	19	O	the
6	21	29	O	treatment
7	31	32	O	of
8	34	41	O	patients
9	43	46	O	with
10	48	52	O	organ
11	54	64	O	transplants
12	65	65	O	,
13	67	76	O	malignancy
14	77	77	O	,
15	79	81	O	and
16	83	94	O	increasingly
17	96	100	O	those
18	102	105	O	with
19	107	116	O	conditions
20	118	121	O	such
21	123	124	O	as
22	126	134	O	psoriasis
23	135	135	O	,
24	137	146	O	rheumatoid
25	148	156	O	arthritis
26	157	157	O	,
27	159	161	O	and
28	163	167	O	liver
29	169	171	O	and
30	173	177	O	bowel
31	179	185	O	disease
32	187	188	O	in
33	190	194	O	which
34	196	207	O	inflammation
35	209	210	O	is
36	212	213	O	an
37	215	226	O	aetiological
38	228	233	O	factor
NULL

7635041.xml	DDI-MedLine.d11.s3	NO_SECTION	NO_SETID	47
Because of the broadening indications for immunosuppressive drugs, and the prolonged survival in conditions for which they are being used, many patients on immunosuppression are now cared for in the community or seen in non-specialist hospitals, usually in close collaboration with a specialist.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	24	O	broadening
5	26	36	O	indications
6	38	40	O	for
7	42	58	B-UNK	immunosuppressive
8	60	64	L-UNK	drugs
9	65	65	O	,
10	67	69	O	and
11	71	73	O	the
12	75	83	O	prolonged
13	85	92	O	survival
14	94	95	O	in
15	97	106	O	conditions
16	108	110	O	for
17	112	116	O	which
18	118	121	O	they
19	123	125	O	are
20	127	131	O	being
21	133	136	O	used
22	137	137	O	,
23	139	142	O	many
24	144	151	O	patients
25	153	154	O	on
26	156	172	O	immunosuppression
27	174	176	O	are
28	178	180	O	now
29	182	186	O	cared
30	188	190	O	for
31	192	193	O	in
32	195	197	O	the
33	199	207	O	community
34	209	210	O	or
35	212	215	O	seen
36	217	218	O	in
37	220	222	O	non
38	224	233	O	specialist
39	235	243	O	hospitals
40	244	244	O	,
41	246	252	O	usually
42	254	255	O	in
43	257	261	O	close
44	263	275	O	collaboration
45	277	280	O	with
46	282	282	O	a
47	284	293	O	specialist
NULL

7635041.xml	DDI-MedLine.d11.s4	NO_SECTION	NO_SETID	42
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
1	0	3	O	This
2	5	11	O	article
3	13	17	O	looks
4	19	20	O	at
5	22	25	O	five
6	27	34	O	commonly
7	36	39	O	used
8	41	57	B-UNK	immunosuppressive
9	59	63	L-UNK	drugs
10	65	66	O	in
11	68	71	O	turn
12	74	88	U-UNK	corticosteroids
13	89	89	O	,
14	91	101	U-UNK	cyclosporin
15	102	102	O	,
16	104	115	U-UNK	azathioprine
17	116	116	O	,
18	118	129	U-UNK	methotrexate
19	130	130	O	,
20	132	147	U-UNK	cyclophosphamide
21	149	149	O	,
22	151	160	O	discussing
23	162	164	O	the
24	166	169	O	main
25	170	170	O	,
26	172	174	O	non
27	176	184	O	infection
28	185	185	O	,
29	187	194	O	unwanted
30	196	202	O	effects
31	203	203	O	,
32	205	208	O	ways
33	210	211	O	to
34	213	217	O	avoid
35	219	222	O	them
36	224	226	O	and
37	228	231	O	what
38	233	234	O	to
39	236	237	O	do
40	239	240	O	if
41	242	249	O	problems
42	251	255	O	arise
NULL

7635041.xml	DDI-MedLine.d11.s5	NO_SECTION	NO_SETID	11
The management of infection is dealt with as a separate section.
1	0	2	O	The
2	4	13	O	management
3	15	16	O	of
4	18	26	O	infection
5	28	29	O	is
6	31	35	O	dealt
7	37	40	O	with
8	42	43	O	as
9	45	45	O	a
10	47	54	O	separate
11	56	62	O	section
NULL

7653281.xml	DDI-MedLine.d107.s0	NO_SECTION	NO_SETID	13
Interaction of the constituents of alcoholic beverages in the promotion of liver damage.
1	0	10	O	Interaction
2	12	13	O	of
3	15	17	O	the
4	19	30	O	constituents
5	32	33	O	of
6	35	43	O	alcoholic
7	45	53	O	beverages
8	55	56	O	in
9	58	60	O	the
10	62	70	O	promotion
11	72	73	O	of
12	75	79	O	liver
13	81	86	O	damage
NULL

7653281.xml	DDI-MedLine.d107.s1	NO_SECTION	NO_SETID	32
Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.
1	0	5	O	Little
2	7	9	O	has
3	11	14	O	been
4	16	22	O	studied
5	24	25	O	of
6	27	29	O	the
7	31	37	O	adverse
8	39	45	O	effects
9	47	48	O	of
10	50	52	O	the
11	54	61	O	exposure
12	63	64	O	of
13	66	68	O	the
14	70	74	O	liver
15	76	77	O	to
16	79	81	O	the
17	83	93	O	interaction
18	95	96	O	of
19	98	104	U-UNK	ethanol
20	106	109	O	with
21	111	113	O	its
22	115	123	O	congeners
23	125	127	O	and
24	129	140	U-UNK	acetaldehyde
25	141	141	O	,
26	143	152	O	coexisting
27	154	155	O	in
28	157	159	O	the
29	161	168	O	contents
30	170	171	O	of
31	173	181	O	alcoholic
32	183	191	O	beverages
NULL

7653281.xml	DDI-MedLine.d107.s2	NO_SECTION	NO_SETID	10
Twenty four male Wistar rats were divided into four groups.
1	0	5	O	Twenty
2	7	10	O	four
3	12	15	O	male
4	17	22	O	Wistar
5	24	27	O	rats
6	29	32	O	were
7	34	40	O	divided
8	42	45	O	into
9	47	50	O	four
10	52	57	O	groups
NULL

7653281.xml	DDI-MedLine.d107.s3	NO_SECTION	NO_SETID	41
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;
1	0	2	O	Two
2	4	9	O	groups
3	12	13	O	SH
4	14	14	O	/
5	15	16	O	DA
6	19	20	O	SH
7	21	21	O	/
8	22	23	O	FA
9	26	29	O	were
10	31	39	O	submitted
11	41	42	O	to
12	44	48	O	daily
13	50	58	O	treatment
14	60	63	O	with
15	65	73	O	synthetic
16	75	88	O	hydroalcoholic
17	90	98	O	solutions
18	100	109	O	containing
19	111	117	U-UNK	ethanol
20	118	118	O	,
21	120	127	U-UNK	methanol
22	128	128	O	,
23	130	135	O	higher
24	137	144	U-UNK	alcohols
25	146	148	O	and
26	150	161	U-UNK	acetaldehyde
27	163	164	O	in
28	166	168	O	the
29	170	173	O	same
30	175	185	O	proportions
31	187	188	O	as
32	190	194	O	those
33	196	200	O	found
34	202	203	O	in
35	205	208	O	most
36	210	215	O	common
37	217	225	O	distilled
38	227	229	O	and
39	231	239	O	fermented
40	241	249	O	alcoholic
41	251	259	O	beverages
NULL

7653281.xml	DDI-MedLine.d107.s4	NO_SECTION	NO_SETID	14
the third group (SH/EA) was treated with a hydroalcoholic solution of ethanol;
1	0	2	O	the
2	4	8	O	third
3	10	14	O	group
4	17	18	O	SH
5	19	19	O	/
6	20	21	O	EA
7	24	26	O	was
8	28	34	O	treated
9	36	39	O	with
10	41	41	O	a
11	43	56	O	hydroalcoholic
12	58	65	O	solution
13	67	68	O	of
14	70	76	U-UNK	ethanol
NULL

7653281.xml	DDI-MedLine.d107.s5	NO_SECTION	NO_SETID	17
the fourth group served as control and received an equivalent volume of an isocaloric solution of dextrose.
1	0	2	O	the
2	4	9	O	fourth
3	11	15	O	group
4	17	22	O	served
5	24	25	O	as
6	27	33	O	control
7	35	37	O	and
8	39	46	O	received
9	48	49	O	an
10	51	60	O	equivalent
11	62	67	O	volume
12	69	70	O	of
13	72	73	O	an
14	75	84	O	isocaloric
15	86	93	O	solution
16	95	96	O	of
17	98	105	U-UNK	dextrose
NULL

7653281.xml	DDI-MedLine.d107.s6	NO_SECTION	NO_SETID	15
All the animals were killed at the end of the 9th week of the experiment.
1	0	2	O	All
2	4	6	O	the
3	8	14	O	animals
4	16	19	O	were
5	21	26	O	killed
6	28	29	O	at
7	31	33	O	the
8	35	37	O	end
9	39	40	O	of
10	42	44	O	the
11	46	48	O	9th
12	50	53	O	week
13	55	56	O	of
14	58	60	O	the
15	62	71	O	experiment
NULL

7653281.xml	DDI-MedLine.d107.s7	NO_SECTION	NO_SETID	23
The ratio between the liver weight and body weight was found to be lower in the treated animals than in the control group.
1	0	2	O	The
2	4	8	O	ratio
3	10	16	O	between
4	18	20	O	the
5	22	26	O	liver
6	28	33	O	weight
7	35	37	O	and
8	39	42	O	body
9	44	49	O	weight
10	51	53	O	was
11	55	59	O	found
12	61	62	O	to
13	64	65	O	be
14	67	71	O	lower
15	73	74	O	in
16	76	78	O	the
17	80	86	O	treated
18	88	94	O	animals
19	96	99	O	than
20	101	102	O	in
21	104	106	O	the
22	108	114	O	control
23	116	120	O	group
NULL

7653281.xml	DDI-MedLine.d107.s8	NO_SECTION	NO_SETID	29
The histology of the liver was altered in the three groups which were submitted to treatment with the hydroalcoholic solutions, with quantitative and qualitative differences between the groups.
1	0	2	O	The
2	4	12	O	histology
3	14	15	O	of
4	17	19	O	the
5	21	25	O	liver
6	27	29	O	was
7	31	37	O	altered
8	39	40	O	in
9	42	44	O	the
10	46	50	O	three
11	52	57	O	groups
12	59	63	O	which
13	65	68	O	were
14	70	78	O	submitted
15	80	81	O	to
16	83	91	O	treatment
17	93	96	O	with
18	98	100	O	the
19	102	115	O	hydroalcoholic
20	117	125	O	solutions
21	126	126	O	,
22	128	131	O	with
23	133	144	O	quantitative
24	146	148	O	and
25	150	160	O	qualitative
26	162	172	O	differences
27	174	180	O	between
28	182	184	O	the
29	186	191	O	groups
NULL

7653281.xml	DDI-MedLine.d107.s9	NO_SECTION	NO_SETID	20
These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	29	O	the
6	31	42	O	hepatoxicity
7	44	45	O	of
8	47	53	U-UNK	ethanol
9	55	56	O	in
10	58	66	O	alcoholic
11	68	76	O	beverages
12	78	79	O	is
13	81	88	O	enhanced
14	90	91	O	by
15	93	103	O	interaction
16	105	108	O	with
17	110	112	O	its
18	114	122	O	congeners
19	124	126	O	and
20	128	139	U-UNK	acetaldehyde
NULL

7653281.xml	DDI-MedLine.d107.s10	NO_SECTION	NO_SETID	16
they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage.
1	0	3	O	they
2	5	8	O	also
3	10	16	O	suggest
4	18	21	O	that
5	23	31	O	alcoholic
6	33	41	O	beverages
7	43	45	O	are
8	47	49	O	not
9	51	60	O	equivalent
10	62	63	O	in
11	65	69	O	their
12	71	79	O	potential
13	81	82	O	to
14	84	88	O	cause
15	90	94	O	liver
16	96	101	O	damage
NULL

7654327.xml	DDI-MedLine.d53.s0	NO_SECTION	NO_SETID	14
Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
1	0	8	O	Induction
2	10	11	O	of
3	13	21	O	apoptosis
4	23	24	O	in
5	26	31	O	breast
6	33	38	O	cancer
7	40	44	O	cells
8	46	47	O	in
9	49	56	O	response
10	58	59	O	to
11	61	67	B-UNK	vitamin
12	69	69	L-UNK	D
13	71	73	O	and
14	75	87	U-UNK	antiestrogens
NULL

7654327.xml	DDI-MedLine.d53.s1	NO_SECTION	NO_SETID	27
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro.
1	0	3	O	1,25
2	5	28	B-UNK	Dihydroxycholecalciferol
3	30	31	L-UNK	D3
4	34	44	U-UNK	1,25(OH)2D3
5	46	46	O	,
6	48	50	O	the
7	52	57	O	active
8	59	68	O	metabolite
9	70	71	O	of
10	73	79	B-UNK	vitamin
11	81	81	L-UNK	D
12	82	82	O	,
13	84	85	O	is
14	87	87	O	a
15	89	94	O	potent
16	96	104	O	inhibitor
17	106	107	O	of
18	109	114	O	breast
19	116	121	O	cancer
20	123	126	O	cell
21	128	133	O	growth
22	135	138	O	both
23	140	141	O	in
24	143	146	O	vivo
25	148	150	O	and
26	152	153	O	in
27	155	159	O	vitro
NULL

7654327.xml	DDI-MedLine.d53.s2	NO_SECTION	NO_SETID	31
We have shown that MCF-7 cells treated with 100 nM 1,25(OH)2D3 exhibit characteristic apoptotic morphology (pyknotic nuclei, chromatin and cytoplasmic condensation, nuclear matrix protein reorganization) within 48 h.
1	0	1	O	We
2	3	6	O	have
3	8	12	O	shown
4	14	17	O	that
5	19	21	O	MCF
6	23	23	O	7
7	25	29	O	cells
8	31	37	O	treated
9	39	42	O	with
10	44	46	O	100
11	48	49	O	nM
12	51	61	U-UNK	1,25(OH)2D3
13	63	69	O	exhibit
14	71	84	O	characteristic
15	86	94	O	apoptotic
16	96	105	O	morphology
17	108	115	O	pyknotic
18	117	122	O	nuclei
19	123	123	O	,
20	125	133	O	chromatin
21	135	137	O	and
22	139	149	O	cytoplasmic
23	151	162	O	condensation
24	163	163	O	,
25	165	171	O	nuclear
26	173	178	O	matrix
27	180	186	O	protein
28	188	201	O	reorganization
29	204	209	O	within
30	211	212	O	48
31	214	214	O	h
NULL

7654327.xml	DDI-MedLine.d53.s3	NO_SECTION	NO_SETID	27
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
1	0	1	O	In
2	3	5	O	the
3	7	17	O	experiments
4	19	26	O	reported
5	28	31	O	here
6	32	32	O	,
7	34	35	O	we
8	37	44	O	examined
9	46	48	O	the
10	50	61	O	interactions
11	63	69	O	between
12	71	81	U-UNK	1,25(OH)2D3
13	83	85	O	and
14	87	89	O	the
15	91	102	U-UNK	antiestrogen
16	104	104	B-UNK	4
17	106	121	L-UNK	hydroxytamoxifen
18	124	126	U-UNK	TAM
19	128	128	O	,
20	130	134	O	which
21	136	139	O	also
22	141	147	O	induces
23	149	157	O	apoptosis
24	159	160	O	in
25	162	164	O	MCF
26	166	166	O	7
27	168	172	O	cells
NULL

7654327.xml	DDI-MedLine.d53.s4	NO_SECTION	NO_SETID	16
Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
1	0	2	O	Our
2	4	7	O	data
3	9	15	O	suggest
4	17	20	O	that
5	22	24	U-UNK	TAM
6	26	38	O	significantly
7	40	50	O	potentiates
8	52	54	O	the
9	56	64	O	reduction
10	66	67	O	in
11	69	72	O	cell
12	74	79	O	number
13	81	87	O	induced
14	89	90	O	by
15	92	102	U-UNK	1,25(OH)2D3
16	104	108	O	alone
NULL

7654327.xml	DDI-MedLine.d53.s5	NO_SECTION	NO_SETID	23
Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
1	0	7	O	Combined
2	9	17	O	treatment
3	19	22	O	with
4	24	34	U-UNK	1,25(OH)2D3
5	36	38	O	and
6	40	42	U-UNK	TAM
7	44	51	O	enhances
8	53	55	O	the
9	57	62	O	degree
10	64	65	O	of
11	67	75	O	apoptosis
12	77	84	O	assessed
13	86	90	O	using
14	92	104	O	morphological
15	106	112	O	markers
16	114	117	O	that
17	119	126	O	identify
18	128	136	O	chromatin
19	138	140	O	and
20	142	148	O	nuclear
21	150	155	O	matrix
22	157	163	O	protein
23	165	176	O	condensation
NULL

7654327.xml	DDI-MedLine.d53.s6	NO_SECTION	NO_SETID	14
We have selected a subclone of MCF-7 cells resistant to 1,25(OH)2D3 (MCF-7D3Res).
1	0	1	O	We
2	3	6	O	have
3	8	15	O	selected
4	17	17	O	a
5	19	26	O	subclone
6	28	29	O	of
7	31	33	O	MCF
8	35	35	O	7
9	37	41	O	cells
10	43	51	O	resistant
11	53	54	O	to
12	56	66	U-UNK	1,25(OH)2D3
13	69	71	O	MCF
14	73	78	O	7D3Res
NULL

7654327.xml	DDI-MedLine.d53.s7	NO_SECTION	NO_SETID	26
These cells express the vitamin D receptor and exhibit doubling times comparable to the parental MCF-7 cells, even when grown in 100 mM 1,25(OH)2D3.
1	0	4	O	These
2	6	10	O	cells
3	12	18	O	express
4	20	22	O	the
5	24	30	O	vitamin
6	32	32	O	D
7	34	41	O	receptor
8	43	45	O	and
9	47	53	O	exhibit
10	55	62	O	doubling
11	64	68	O	times
12	70	79	O	comparable
13	81	82	O	to
14	84	86	O	the
15	88	95	O	parental
16	97	99	O	MCF
17	101	101	O	7
18	103	107	O	cells
19	108	108	O	,
20	110	113	O	even
21	115	118	O	when
22	120	124	O	grown
23	126	127	O	in
24	129	131	O	100
25	133	134	O	mM
26	136	146	U-UNK	1,25(OH)2D3
NULL

7654327.xml	DDI-MedLine.d53.s8	NO_SECTION	NO_SETID	15
Treatment of both parental and resistant MCF-7 cells with TAM induces apoptosis and clusterin.
1	0	8	O	Treatment
2	10	11	O	of
3	13	16	O	both
4	18	25	O	parental
5	27	29	O	and
6	31	39	O	resistant
7	41	43	O	MCF
8	45	45	O	7
9	47	51	O	cells
10	53	56	O	with
11	58	60	U-UNK	TAM
12	62	68	O	induces
13	70	78	O	apoptosis
14	80	82	O	and
15	84	92	O	clusterin
NULL

7654327.xml	DDI-MedLine.d53.s9	NO_SECTION	NO_SETID	26
These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.
1	0	4	O	These
2	6	9	O	data
3	11	19	O	emphasize
4	21	24	O	that
5	26	34	O	apoptosis
6	36	38	O	can
7	40	41	O	be
8	43	49	O	induced
9	51	52	O	in
10	54	56	O	MCF
11	58	58	O	7
12	60	64	O	cells
13	66	71	O	either
14	73	74	O	by
15	76	85	O	activation
16	87	88	O	of
17	90	96	B-UNK	vitamin
18	98	98	L-UNK	D
19	100	107	O	mediated
20	109	118	O	signalling
21	120	121	O	or
22	123	132	O	disruption
23	134	135	O	of
24	137	144	U-UNK	estrogen
25	146	154	O	dependent
26	156	165	O	signalling
NULL

7744123.xml	DDI-MedLine.d6.s0	NO_SECTION	NO_SETID	7
Pharmacokinetic profile of etodolac in special populations.
1	0	14	O	Pharmacokinetic
2	16	22	O	profile
3	24	25	O	of
4	27	34	U-UNK	etodolac
5	36	37	O	in
6	39	45	O	special
7	47	57	O	populations
NULL

7744123.xml	DDI-MedLine.d6.s1	NO_SECTION	NO_SETID	16
The pharmacokinetics of etodolac in healthy normal volunteers has been extensively studied and is well described.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	31	U-UNK	etodolac
5	33	34	O	in
6	36	42	O	healthy
7	44	49	O	normal
8	51	60	O	volunteers
9	62	64	O	has
10	66	69	O	been
11	71	81	O	extensively
12	83	89	O	studied
13	91	93	O	and
14	95	96	O	is
15	98	101	O	well
16	103	111	O	described
NULL

7744123.xml	DDI-MedLine.d6.s2	NO_SECTION	NO_SETID	24
Etodolac is characterised by a high oral bioavailability, low clearance, a small volume of distribution, and a 7-hour half-life.
1	0	7	U-UNK	Etodolac
2	9	10	O	is
3	12	24	O	characterised
4	26	27	O	by
5	29	29	O	a
6	31	34	O	high
7	36	39	O	oral
8	41	55	O	bioavailability
9	56	56	O	,
10	58	60	O	low
11	62	70	O	clearance
12	71	71	O	,
13	73	73	O	a
14	75	79	O	small
15	81	86	O	volume
16	88	89	O	of
17	91	102	O	distribution
18	103	103	O	,
19	105	107	O	and
20	109	109	O	a
21	111	111	O	7
22	113	116	O	hour
23	118	121	O	half
24	123	126	O	life
NULL

7744123.xml	DDI-MedLine.d6.s3	NO_SECTION	NO_SETID	11
It is essentially completely metabolised, therefore little is excreted unchanged.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	essentially
4	18	27	O	completely
5	29	39	O	metabolised
6	40	40	O	,
7	42	50	O	therefore
8	52	57	O	little
9	59	60	O	is
10	62	69	O	excreted
11	71	79	O	unchanged
NULL

7744123.xml	DDI-MedLine.d6.s4	NO_SECTION	NO_SETID	5
Etodolac is highly protein bound.
1	0	7	U-UNK	Etodolac
2	9	10	O	is
3	12	17	O	highly
4	19	25	O	protein
5	27	31	O	bound
NULL

7744123.xml	DDI-MedLine.d6.s5	NO_SECTION	NO_SETID	27
To investigate the effect of disease states or concomitant drug administration on a patient's response to etodolac, additional pharmacokinetic studies were carried out in special populations.
1	0	1	O	To
2	3	13	O	investigate
3	15	17	O	the
4	19	24	O	effect
5	26	27	O	of
6	29	35	O	disease
7	37	42	O	states
8	44	45	O	or
9	47	57	O	concomitant
10	59	62	O	drug
11	64	77	O	administration
12	79	80	O	on
13	82	82	O	a
14	84	92	O	patient's
15	94	101	O	response
16	103	104	O	to
17	106	113	U-UNK	etodolac
18	114	114	O	,
19	116	125	O	additional
20	127	141	O	pharmacokinetic
21	143	149	O	studies
22	151	154	O	were
23	156	162	O	carried
24	164	166	O	out
25	168	169	O	in
26	171	177	O	special
27	179	189	O	populations
NULL

7744123.xml	DDI-MedLine.d6.s6	NO_SECTION	NO_SETID	17
Since etodolac has a well-defined pharmacokinetic-pharmacodynamic relationship, measurement of pharmacokinetic parameters is clinically relevant.
1	0	4	O	Since
2	6	13	U-UNK	etodolac
3	15	17	O	has
4	19	19	O	a
5	21	24	O	well
6	26	32	O	defined
7	34	48	O	pharmacokinetic
8	50	64	O	pharmacodynamic
9	66	77	O	relationship
10	78	78	O	,
11	80	90	O	measurement
12	92	93	O	of
13	95	109	O	pharmacokinetic
14	111	120	O	parameters
15	122	123	O	is
16	125	134	O	clinically
17	136	143	O	relevant
NULL

7744123.xml	DDI-MedLine.d6.s7	NO_SECTION	NO_SETID	27
Data from studies to date show that disease states, underlying conditions, and concomitantly administered highly protein-bound drugs have essentially no effect on etodolac pharmacokinetics.
1	0	3	O	Data
2	5	8	O	from
3	10	16	O	studies
4	18	19	O	to
5	21	24	O	date
6	26	29	O	show
7	31	34	O	that
8	36	42	O	disease
9	44	49	O	states
10	50	50	O	,
11	52	61	O	underlying
12	63	72	O	conditions
13	73	73	O	,
14	75	77	O	and
15	79	91	O	concomitantly
16	93	104	O	administered
17	106	111	O	highly
18	113	119	O	protein
19	121	125	O	bound
20	127	131	O	drugs
21	133	136	O	have
22	138	148	O	essentially
23	150	151	O	no
24	153	158	O	effect
25	160	161	O	on
26	163	170	U-UNK	etodolac
27	172	187	O	pharmacokinetics
NULL

7744123.xml	DDI-MedLine.d6.s8	NO_SECTION	NO_SETID	34
Therefore, etodolac can generally be given without the need for dosage modifications in special populations such as uncompromised elderly patients, those with moderate renal impairment, and patients with stable hepatic disease.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	U-UNK	etodolac
4	20	22	O	can
5	24	32	O	generally
6	34	35	O	be
7	37	41	O	given
8	43	49	O	without
9	51	53	O	the
10	55	58	O	need
11	60	62	O	for
12	64	69	O	dosage
13	71	83	O	modifications
14	85	86	O	in
15	88	94	O	special
16	96	106	O	populations
17	108	111	O	such
18	113	114	O	as
19	116	128	O	uncompromised
20	130	136	O	elderly
21	138	145	O	patients
22	146	146	O	,
23	148	152	O	those
24	154	157	O	with
25	159	166	O	moderate
26	168	172	O	renal
27	174	183	O	impairment
28	184	184	O	,
29	186	188	O	and
30	190	197	O	patients
31	199	202	O	with
32	204	209	O	stable
33	211	217	O	hepatic
34	219	225	O	disease
NULL

7746025.xml	DDI-MedLine.d51.s0	NO_SECTION	NO_SETID	18
Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors.
1	0	6	O	Effects
2	8	9	O	of
3	11	18	B-UNK	xanthine
4	20	30	L-UNK	derivatives
5	32	33	O	in
6	35	35	O	a
7	37	41	O	light
8	42	42	O	/
9	43	46	O	dark
10	48	51	O	test
11	53	54	O	in
12	56	59	O	mice
13	61	63	O	and
14	65	67	O	the
15	69	80	O	contribution
16	82	83	O	of
17	85	93	O	adenosine
18	95	103	O	receptors
NULL

7746025.xml	DDI-MedLine.d51.s1	NO_SECTION	NO_SETID	31
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
1	0	1	O	We
2	3	14	O	investigated
3	16	18	O	the
4	20	26	O	effects
5	28	29	O	of
6	31	39	O	adenosine
7	41	48	O	receptor
8	50	60	O	antagonists
9	61	61	O	,
10	63	70	U-UNK	caffeine
11	71	71	O	,
12	73	84	U-UNK	theophylline
13	85	85	O	,
14	87	87	B-UNK	8
15	89	106	L-UNK	phenyltheophylline
16	107	107	O	,
17	109	111	O	and
18	113	113	B-UNK	8
19	115	125	I-UNK	cyclopentyl
20	127	129	I-UNK	1,3
21	131	146	L-UNK	dipropylxanthine
22	149	153	U-UNK	DPCPX
23	155	155	O	,
24	157	158	O	in
25	160	160	O	a
26	162	166	O	light
27	167	167	O	/
28	168	171	O	dark
29	173	176	O	test
30	178	179	O	in
31	181	184	O	mice
NULL

7746025.xml	DDI-MedLine.d51.s2	NO_SECTION	NO_SETID	22
All antagonists decreased the time spent in the light zone in this test, which suggested that these compounds have anxiogenic effects.
1	0	2	O	All
2	4	14	O	antagonists
3	16	24	O	decreased
4	26	28	O	the
5	30	33	O	time
6	35	39	O	spent
7	41	42	O	in
8	44	46	O	the
9	48	52	O	light
10	54	57	O	zone
11	59	60	O	in
12	62	65	O	this
13	67	70	O	test
14	71	71	O	,
15	73	77	O	which
16	79	87	O	suggested
17	89	92	O	that
18	94	98	O	these
19	100	108	O	compounds
20	110	113	O	have
21	115	124	O	anxiogenic
22	126	132	O	effects
NULL

7746025.xml	DDI-MedLine.d51.s3	NO_SECTION	NO_SETID	29
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
1	0	2	O	The
2	4	13	O	anxiogenic
3	15	21	O	effects
4	23	24	O	of
5	26	37	U-UNK	theophylline
6	39	42	O	were
7	44	50	O	reduced
8	52	53	O	by
9	55	66	O	pretreatment
10	68	71	O	with
11	73	75	B-UNK	CGS
12	77	81	L-UNK	21680
13	82	82	O	,
14	84	85	O	an
15	87	88	O	A2
16	90	98	O	selective
17	100	106	O	agonist
18	107	107	O	,
19	109	111	O	but
20	113	115	O	not
21	117	118	O	by
22	120	121	B-UNK	N6
23	123	142	L-UNK	cyclopentyladenosine
24	145	147	U-UNK	CPA
25	149	149	O	,
26	151	152	O	an
27	154	155	O	A1
28	157	165	O	selective
29	167	173	O	agonist
NULL

7746025.xml	DDI-MedLine.d51.s4	NO_SECTION	NO_SETID	38
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	22	O	antagonism
5	24	25	O	of
6	27	29	O	the
7	31	42	U-UNK	theophylline
8	44	50	O	induced
9	52	61	O	anxiogenic
10	63	69	O	effects
11	71	72	O	by
12	74	81	U-UNK	CGS21680
13	83	85	O	was
14	87	90	O	only
15	92	99	O	observed
16	101	102	O	in
17	104	106	O	the
18	108	111	O	time
19	113	117	O	spent
20	119	120	O	in
21	122	124	O	the
22	126	130	O	light
23	132	135	O	zone
24	136	136	O	,
25	138	140	O	and
26	142	146	U-UNK	DPCPX
27	148	154	O	induced
28	156	165	O	anxiogenic
29	167	173	O	effects
30	175	178	O	were
31	180	186	O	neither
32	188	195	O	reversed
33	197	198	O	by
34	200	202	B-UNK	CGS
35	204	208	L-UNK	21680
36	210	212	O	nor
37	214	215	O	by
38	217	219	U-UNK	CPA
NULL

7746025.xml	DDI-MedLine.d51.s5	NO_SECTION	NO_SETID	24
Finally, it is notable that xanthine-derived adenosine antagonists tested here commonly showed anxiogenic effects in the light/dark test in mice.
1	0	6	O	Finally
2	7	7	O	,
3	9	10	O	it
4	12	13	O	is
5	15	21	O	notable
6	23	26	O	that
7	28	35	O	xanthine
8	37	43	O	derived
9	45	53	O	adenosine
10	55	65	O	antagonists
11	67	72	O	tested
12	74	77	O	here
13	79	86	O	commonly
14	88	93	O	showed
15	95	104	O	anxiogenic
16	106	112	O	effects
17	114	115	O	in
18	117	119	O	the
19	121	125	O	light
20	126	126	O	/
21	127	130	O	dark
22	132	135	O	test
23	137	138	O	in
24	140	143	O	mice
NULL

7746025.xml	DDI-MedLine.d51.s6	NO_SECTION	NO_SETID	28
It is suggested that there is a minor contribution of adenosine receptors to these effects, although theophylline-induced anxiogenic effects were antagonized by an A2 receptor agonist.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	suggested
4	16	19	O	that
5	21	25	O	there
6	27	28	O	is
7	30	30	O	a
8	32	36	O	minor
9	38	49	O	contribution
10	51	52	O	of
11	54	62	O	adenosine
12	64	72	O	receptors
13	74	75	O	to
14	77	81	O	these
15	83	89	O	effects
16	90	90	O	,
17	92	99	O	although
18	101	112	U-UNK	theophylline
19	114	120	O	induced
20	122	131	O	anxiogenic
21	133	139	O	effects
22	141	144	O	were
23	146	156	O	antagonized
24	158	159	O	by
25	161	162	O	an
26	164	165	O	A2
27	167	174	O	receptor
28	176	182	O	agonist
NULL

7756960.xml	DDI-MedLine.d4.s1	NO_SECTION	NO_SETID	25
The agent was found to produce some inhibiting activity against hepatic microsomal 7-ethoxycoumarine deethylase in male Wistar rats in vitro and in vivo experiments.
1	0	2	O	The
2	4	8	O	agent
3	10	12	O	was
4	14	18	O	found
5	20	21	O	to
6	23	29	O	produce
7	31	34	O	some
8	36	45	O	inhibiting
9	47	54	O	activity
10	56	62	O	against
11	64	70	O	hepatic
12	72	81	O	microsomal
13	83	83	O	7
14	85	99	O	ethoxycoumarine
15	101	110	O	deethylase
16	112	113	O	in
17	115	118	O	male
18	120	125	O	Wistar
19	127	130	O	rats
20	132	133	O	in
21	135	139	O	vitro
22	141	143	O	and
23	145	146	O	in
24	148	151	O	vivo
25	153	163	O	experiments
NULL

7756960.xml	DDI-MedLine.d4.s2	NO_SECTION	NO_SETID	26
When given in a dose of 50 mg/kg, sandimmune produced no statistically significant effect on the duration of hexanal-induced sleep in mice.
1	0	3	O	When
2	5	9	O	given
3	11	12	O	in
4	14	14	O	a
5	16	19	O	dose
6	21	22	O	of
7	24	25	O	50
8	27	28	O	mg
9	29	29	O	/
10	30	31	O	kg
11	32	32	O	,
12	34	43	O	XXXXXXXX
13	45	52	O	produced
14	54	55	O	no
15	57	69	O	statistically
16	71	81	O	significant
17	83	88	O	effect
18	90	91	O	on
19	93	95	O	the
20	97	104	O	duration
21	106	107	O	of
22	109	115	O	hexanal
23	117	123	O	induced
24	125	129	O	sleep
25	131	132	O	in
26	134	137	O	mice
NULL

7756960.xml	DDI-MedLine.d4.s3	NO_SECTION	NO_SETID	13
The findings suggest that the agent has slight effects on the tested activities.
1	0	2	O	The
2	4	11	O	findings
3	13	19	O	suggest
4	21	24	O	that
5	26	28	O	the
6	30	34	O	agent
7	36	38	O	has
8	40	45	O	slight
9	47	53	O	effects
10	55	56	O	on
11	58	60	O	the
12	62	67	O	tested
13	69	78	O	activities
NULL

7756965.xml	DDI-MedLine.d68.s1	NO_SECTION	NO_SETID	14
The higher verografine and iodamide excretion was due to their increased renal tubular secretion.
1	0	2	O	The
2	4	9	O	higher
3	11	21	U-UNK	verografine
4	23	25	O	and
5	27	34	U-UNK	iodamide
6	36	44	O	excretion
7	46	48	O	was
8	50	52	O	due
9	54	55	O	to
10	57	61	O	their
11	63	71	O	increased
12	73	77	O	renal
13	79	85	O	tubular
14	87	95	O	secretion
NULL

7756965.xml	DDI-MedLine.d68.s2	NO_SECTION	NO_SETID	16
In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport.
1	0	1	O	In
2	3	6	O	dogs
3	7	7	O	,
4	9	18	U-UNK	cimetidine
5	20	28	O	unchanged
6	30	32	O	the
7	34	42	O	secretion
8	44	45	O	of
9	47	57	U-UNK	cardiotrast
10	58	58	O	,
11	60	60	O	a
12	62	65	O	test
13	67	71	O	agent
14	73	75	O	for
15	77	83	O	anionic
16	85	93	O	transport
NULL

7756965.xml	DDI-MedLine.d68.s3	NO_SECTION	NO_SETID	15
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.
1	0	7	O	Possible
2	9	18	O	extrarenal
3	20	29	O	mechanisms
4	31	32	O	of
5	34	39	O	action
6	41	42	O	of
7	44	53	U-UNK	cimetidine
8	55	56	O	on
9	58	68	U-UNK	verografine
10	70	72	O	and
11	74	81	U-UNK	iodamide
12	83	91	O	transport
13	93	96	O	were
14	98	101	O	also
15	103	110	O	examined
NULL

7780789.xml	DDI-MedLine.d121.s1	NO_SECTION	NO_SETID	20
Animals studies on the various dual-memory theories have been carried out mainly on the basis of hippocampal system function.
1	0	6	O	Animals
2	8	14	O	studies
3	16	17	O	on
4	19	21	O	the
5	23	29	O	various
6	31	34	O	dual
7	36	41	O	memory
8	43	50	O	theories
9	52	55	O	have
10	57	60	O	been
11	62	68	O	carried
12	70	72	O	out
13	74	79	O	mainly
14	81	82	O	on
15	84	86	O	the
16	88	92	O	basis
17	94	95	O	of
18	97	107	O	hippocampal
19	109	114	O	system
20	116	123	O	function
NULL

7780789.xml	DDI-MedLine.d121.s2	NO_SECTION	NO_SETID	22
Specifically, they have focused on aspects of learning and memory that are impaired (vs. spared) by lesions of the hippocampal formation.
1	0	11	O	Specifically
2	12	12	O	,
3	14	17	O	they
4	19	22	O	have
5	24	30	O	focused
6	32	33	O	on
7	35	41	O	aspects
8	43	44	O	of
9	46	53	O	learning
10	55	57	O	and
11	59	64	O	memory
12	66	69	O	that
13	71	73	O	are
14	75	82	O	impaired
15	85	86	O	vs
16	89	94	O	spared
17	97	98	O	by
18	100	106	O	lesions
19	108	109	O	of
20	111	113	O	the
21	115	125	O	hippocampal
22	127	135	O	formation
NULL

7780789.xml	DDI-MedLine.d121.s3	NO_SECTION	NO_SETID	21
However, there are several instances in the animal literature showing that hippocampal lesions actually produced enhanced learning and memory function.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	17	O	are
5	19	25	O	several
6	27	35	O	instances
7	37	38	O	in
8	40	42	O	the
9	44	49	O	animal
10	51	60	O	literature
11	62	68	O	showing
12	70	73	O	that
13	75	85	O	hippocampal
14	87	93	O	lesions
15	95	102	O	actually
16	104	111	O	produced
17	113	120	O	enhanced
18	122	129	O	learning
19	131	133	O	and
20	135	140	O	memory
21	142	149	O	function
NULL

7780789.xml	DDI-MedLine.d121.s4	NO_SECTION	NO_SETID	29
Moreover, the acquisition of tasks that are facilitated by hippocampal lesions (or dysfunction) is nevertheless associated, in intact subjects, with specific neurobiological alterations in the hippocampus.
1	0	7	O	Moreover
2	8	8	O	,
3	10	12	O	the
4	14	24	O	acquisition
5	26	27	O	of
6	29	33	O	tasks
7	35	38	O	that
8	40	42	O	are
9	44	54	O	facilitated
10	56	57	O	by
11	59	69	O	hippocampal
12	71	77	O	lesions
13	80	81	O	or
14	83	93	O	dysfunction
15	96	97	O	is
16	99	110	O	nevertheless
17	112	121	O	associated
18	122	122	O	,
19	124	125	O	in
20	127	132	O	intact
21	134	141	O	subjects
22	142	142	O	,
23	144	147	O	with
24	149	156	O	specific
25	158	172	O	neurobiological
26	174	184	O	alterations
27	186	187	O	in
28	189	191	O	the
29	193	203	O	hippocampus
NULL

7780789.xml	DDI-MedLine.d121.s5	NO_SECTION	NO_SETID	21
This problem has been analysed using two different tasks in mice: a bar-press conditioning and a spatial discrimination task.
1	0	3	O	This
2	5	11	O	problem
3	13	15	O	has
4	17	20	O	been
5	22	29	O	analysed
6	31	35	O	using
7	37	39	O	two
8	41	49	O	different
9	51	55	O	tasks
10	57	58	O	in
11	60	63	O	mice
12	64	64	O	:
13	66	66	O	a
14	68	70	O	bar
15	72	76	O	press
16	78	89	O	conditioning
17	91	93	O	and
18	95	95	O	a
19	97	103	O	spatial
20	105	118	O	discrimination
21	120	123	O	task
NULL

7780789.xml	DDI-MedLine.d121.s6	NO_SECTION	NO_SETID	23
Results showed that, depending on the task considered, the same pharmacological treatment produced either a facilitation or an impairment of acquisition.
1	0	6	O	Results
2	8	13	O	showed
3	15	18	O	that
4	19	19	O	,
5	21	29	O	depending
6	31	32	O	on
7	34	36	O	the
8	38	41	O	task
9	43	52	O	considered
10	53	53	O	,
11	55	57	O	the
12	59	62	O	same
13	64	78	O	pharmacological
14	80	88	O	treatment
15	90	97	O	produced
16	99	104	O	either
17	106	106	O	a
18	108	119	O	facilitation
19	121	122	O	or
20	124	125	O	an
21	127	136	O	impairment
22	138	139	O	of
23	141	151	O	acquisition
NULL

7780789.xml	DDI-MedLine.d121.s7	NO_SECTION	NO_SETID	16
Moreover, each task induced significant alterations in hippocampal adenylate cyclase activity but in opposite directions.
1	0	7	O	Moreover
2	8	8	O	,
3	10	13	O	each
4	15	18	O	task
5	20	26	O	induced
6	28	38	O	significant
7	40	50	O	alterations
8	52	53	O	in
9	55	65	O	hippocampal
10	67	75	O	adenylate
11	77	83	O	cyclase
12	85	92	O	activity
13	94	96	O	but
14	98	99	O	in
15	101	108	O	opposite
16	110	119	O	directions
NULL

7780789.xml	DDI-MedLine.d121.s8	NO_SECTION	NO_SETID	20
Together with previous findings, these results suggest that the hippocampus is involved in both the so-called "hippocampal-dependent"
1	0	7	O	Together
2	9	12	O	with
3	14	21	O	previous
4	23	30	O	findings
5	31	31	O	,
6	33	37	O	these
7	39	45	O	results
8	47	53	O	suggest
9	55	58	O	that
10	60	62	O	the
11	64	74	O	hippocampus
12	76	77	O	is
13	79	86	O	involved
14	88	89	O	in
15	91	94	O	both
16	96	98	O	the
17	100	101	O	so
18	103	108	O	called
19	110	121	O	"hippocampal
20	123	132	O	dependent"
NULL

7780789.xml	DDI-MedLine.d121.s9	NO_SECTION	NO_SETID	2
"hippocampal-independent"
1	0	11	O	"hippocampal
2	13	24	O	independent"
NULL

7780789.xml	DDI-MedLine.d121.s11	NO_SECTION	NO_SETID	27
It is postulated that some of the observed training-induced neurobiological alterations might reflect the interaction between two (or more) competing memory systems at the hippocampal level.
1	0	1	O	It
2	3	4	O	is
3	6	15	O	postulated
4	17	20	O	that
5	22	25	O	some
6	27	28	O	of
7	30	32	O	the
8	34	41	O	observed
9	43	50	O	training
10	52	58	O	induced
11	60	74	O	neurobiological
12	76	86	O	alterations
13	88	92	O	might
14	94	100	O	reflect
15	102	104	O	the
16	106	116	O	interaction
17	118	124	O	between
18	126	128	O	two
19	131	132	O	or
20	134	137	O	more
21	140	148	O	competing
22	150	155	O	memory
23	157	163	O	systems
24	165	166	O	at
25	168	170	O	the
26	172	182	O	hippocampal
27	184	188	O	level
NULL

7780789.xml	DDI-MedLine.d121.s12	NO_SECTION	NO_SETID	45
Thus, in addition to its proposed specific information processing functions (i.e., relational), the hippocampus would play a role in addressing information to the brain memory system that, in a given situation, has the best adaptive value.(ABSTRACT TRUNCATED AT 250 WORDS)
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	in
4	9	16	O	addition
5	18	19	O	to
6	21	23	O	its
7	25	32	O	proposed
8	34	41	O	specific
9	43	53	O	information
10	55	64	O	processing
11	66	74	O	functions
12	77	79	O	i.e
13	81	81	O	,
14	83	92	O	relational
15	94	94	O	,
16	96	98	O	the
17	100	110	O	hippocampus
18	112	116	O	would
19	118	121	O	play
20	123	123	O	a
21	125	128	O	role
22	130	131	O	in
23	133	142	O	addressing
24	144	154	O	information
25	156	157	O	to
26	159	161	O	the
27	163	167	O	brain
28	169	174	O	memory
29	176	181	O	system
30	183	186	O	that
31	187	187	O	,
32	189	190	O	in
33	192	192	O	a
34	194	198	O	given
35	200	208	O	situation
36	209	209	O	,
37	211	213	O	has
38	215	217	O	the
39	219	222	O	best
40	224	231	O	adaptive
41	233	247	O	value.(ABSTRACT
42	249	257	O	TRUNCATED
43	259	260	O	AT
44	262	264	O	250
45	266	270	O	WORDS
NULL

7786695.xml	DDI-MedLine.d103.s0	NO_SECTION	NO_SETID	3
Magnesium and therapeutics.
1	0	8	U-UNK	Magnesium
2	10	12	O	and
3	14	25	O	therapeutics
NULL

7786695.xml	DDI-MedLine.d103.s1	NO_SECTION	NO_SETID	43
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
1	0	2	O	Two
2	4	12	O	different
3	14	18	O	types
4	20	21	O	of
5	23	29	O	therapy
6	31	34	O	with
7	36	44	U-UNK	magnesium
8	46	48	O	are
9	50	53	O	used
10	54	54	O	:
11	56	68	O	physiological
12	70	73	O	oral
13	75	83	U-UNK	magnesium
14	85	99	O	supplementation
15	101	105	O	which
16	107	108	O	is
17	110	116	O	totally
18	118	123	O	atoxic
19	125	129	O	since
20	131	132	O	it
21	134	142	O	palliates
22	144	152	U-UNK	magnesium
23	154	165	O	deficiencies
24	167	168	O	by
25	170	175	O	simply
26	177	187	O	normalizing
27	189	191	O	the
28	193	201	U-UNK	magnesium
29	203	208	O	intake
30	210	212	O	and
31	214	228	O	pharmacological
32	230	238	U-UNK	magnesium
33	240	246	O	therapy
34	248	252	O	which
35	254	256	O	may
36	258	263	O	induce
37	265	272	O	toxicity
38	274	278	O	since
39	280	281	O	it
40	283	289	O	creates
41	291	300	O	iatrogenic
42	302	310	U-UNK	magnesium
43	312	319	O	overload
NULL

7786695.xml	DDI-MedLine.d103.s2	NO_SECTION	NO_SETID	14
Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy.
1	0	6	O	Primary
2	8	10	O	and
3	12	20	O	secondary
4	22	30	U-UNK	magnesium
5	32	43	O	deficiencies
6	45	54	O	constitute
7	56	58	O	the
8	60	63	O	sole
9	65	74	O	indication
10	76	77	O	of
11	79	91	O	physiological
12	93	96	O	oral
13	98	106	U-UNK	magnesium
14	108	114	O	therapy
NULL

7786695.xml	DDI-MedLine.d103.s3	NO_SECTION	NO_SETID	60
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	therefore
4	16	24	O	necessary
5	26	27	O	to
6	29	30	O	be
7	32	35	O	well
8	37	46	O	acquainted
9	48	51	O	with
10	53	55	O	the
11	57	64	O	clinical
12	66	68	O	and
13	70	81	O	paraclinical
14	83	89	O	pattern
15	91	92	O	of
16	94	102	U-UNK	magnesium
17	104	110	O	deficit
18	112	114	O	and
19	116	117	O	to
20	119	130	O	discriminate
21	132	138	O	between
22	140	148	U-UNK	magnesium
23	150	159	O	deficiency
24	161	163	O	due
25	165	166	O	to
26	168	169	O	an
27	171	182	O	insufficient
28	184	192	U-UNK	magnesium
29	194	199	O	intake
30	201	205	O	which
31	207	210	O	only
32	212	219	O	requires
33	221	224	O	oral
34	226	238	O	physiological
35	240	254	O	supplementation
36	256	258	O	and
37	260	268	U-UNK	magnesium
38	270	278	O	depletion
39	280	286	O	related
40	288	289	O	to
41	291	291	O	a
42	293	305	O	dysregulation
43	307	308	O	of
44	310	312	O	the
45	314	320	O	control
46	322	331	O	mechanisms
47	333	334	O	of
48	336	344	U-UNK	magnesium
49	346	351	O	status
50	353	357	O	which
51	359	366	O	requires
52	368	371	O	more
53	373	374	O	or
54	376	379	O	less
55	381	388	O	specific
56	390	399	O	regulation
57	401	402	O	of
58	404	406	O	its
59	408	413	O	causal
60	415	427	O	dysregulation
NULL

7786695.xml	DDI-MedLine.d103.s4	NO_SECTION	NO_SETID	20
Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment.
1	0	12	O	Physiological
2	14	17	O	oral
3	19	27	U-UNK	magnesium
4	29	32	O	load
5	34	44	O	constitutes
6	46	48	O	the
7	50	53	O	best
8	55	58	O	tool
9	60	62	O	for
10	64	72	O	diagnosis
11	74	75	O	of
12	77	85	U-UNK	magnesium
13	87	96	O	deficiency
14	98	100	O	and
15	102	104	O	the
16	106	110	O	first
17	112	115	O	step
18	117	118	O	of
19	120	122	O	its
20	124	132	O	treatment
NULL

7786695.xml	DDI-MedLine.d103.s5	NO_SECTION	NO_SETID	35
Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure.
1	0	12	O	Physiological
2	14	17	O	oral
3	19	27	U-UNK	magnesium
4	29	43	O	supplementation
5	46	46	O	5
6	48	49	O	mg
7	50	50	O	/
8	51	52	O	kg
9	53	53	O	/
10	54	56	O	day
11	59	60	O	is
12	62	65	O	easy
13	67	69	O	and
14	71	73	O	can
15	75	76	O	be
16	78	84	O	carried
17	86	88	O	out
18	90	91	O	in
19	93	95	O	the
20	97	100	O	diet
21	102	103	O	or
22	105	108	O	with
23	110	118	U-UNK	magnesium
24	120	124	O	salts
25	125	125	O	,
26	127	130	O	with
27	132	142	O	practically
28	144	147	O	only
29	149	151	O	one
30	153	158	O	contra
31	160	169	O	indication
32	170	170	O	:
33	172	176	O	overt
34	178	182	O	renal
35	184	190	O	failure
NULL

7786695.xml	DDI-MedLine.d103.s6	NO_SECTION	NO_SETID	30
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.
1	0	7	O	Specific
2	9	11	O	and
3	13	21	O	aspecific
4	23	32	O	treatments
5	34	35	O	of
6	37	45	U-UNK	magnesium
7	47	55	O	depletion
8	57	59	O	are
9	61	66	O	tricky
10	68	72	O	using
11	74	76	O	for
12	78	84	O	example
13	86	94	B-UNK	magnesium
14	96	102	I-UNK	sparing
15	104	112	L-UNK	diuretics
16	113	113	O	,
17	115	129	O	pharmacological
18	131	135	O	doses
19	137	138	O	of
20	140	146	B-UNK	vitamin
21	148	149	L-UNK	B6
22	150	150	O	,
23	152	164	O	physiological
24	166	170	O	doses
25	172	173	O	of
26	175	181	B-UNK	vitamin
27	183	183	L-UNK	D
28	185	187	O	and
29	189	190	O	of
30	192	199	U-UNK	selenium
NULL

7786695.xml	DDI-MedLine.d103.s7	NO_SECTION	NO_SETID	38
In order to use the pharmacological properties of induced therapeutic hypermagnesaemia, high oral doses of magnesium (> 10 mg/kg/day) are advisable for chronic indications and the parenteral route is suitable for acute indications.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	14	O	use
5	16	18	O	the
6	20	34	O	pharmacological
7	36	45	O	properties
8	47	48	O	of
9	50	56	O	induced
10	58	68	O	therapeutic
11	70	85	O	hypermagnesaemia
12	86	86	O	,
13	88	91	O	high
14	93	96	O	oral
15	98	102	O	doses
16	104	105	O	of
17	107	115	U-UNK	magnesium
18	118	118	O	>
19	120	121	O	10
20	123	124	O	mg
21	125	125	O	/
22	126	127	O	kg
23	128	128	O	/
24	129	131	O	day
25	134	136	O	are
26	138	146	O	advisable
27	148	150	O	for
28	152	158	O	chronic
29	160	170	O	indications
30	172	174	O	and
31	176	178	O	the
32	180	189	O	parenteral
33	191	195	O	route
34	197	198	O	is
35	200	207	O	suitable
36	209	211	O	for
37	213	217	O	acute
38	219	229	O	indications
NULL

7786695.xml	DDI-MedLine.d103.s8	NO_SECTION	NO_SETID	38
There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).
1	0	4	O	There
2	6	8	O	are
3	10	10	O	3
4	12	16	O	types
5	18	19	O	of
6	21	31	O	indications
7	32	32	O	:
8	34	41	O	specific
9	44	46	O	for
10	48	50	O	the
11	52	60	O	treatment
12	62	63	O	of
13	65	68	O	some
14	70	74	O	forms
15	76	77	O	of
16	79	87	U-UNK	magnesium
17	89	95	O	deficit
18	97	99	O	i.e
19	102	106	O	acute
20	108	108	O	,
21	110	124	O	pharmacological
22	127	129	O	i.e
23	132	138	O	without
24	140	150	O	alterations
25	152	153	O	of
26	155	163	U-UNK	magnesium
27	165	170	O	status
28	173	175	O	and
29	177	181	O	mixed
30	184	198	O	pharmacological
31	200	202	O	and
32	204	218	O	aetiopathogenic
33	222	224	O	for
34	226	232	O	example
35	234	246	O	complications
36	248	249	O	of
37	251	257	O	chronic
38	259	268	O	alcoholism
NULL

7786695.xml	DDI-MedLine.d103.s9	NO_SECTION	NO_SETID	13
Today pharmacological magnesium therapy mainly concerns the obstetrical, cardiological and anaesthesiological fields.
1	0	4	O	Today
2	6	20	O	pharmacological
3	22	30	U-UNK	magnesium
4	32	38	O	therapy
5	40	45	O	mainly
6	47	54	O	concerns
7	56	58	O	the
8	60	70	O	obstetrical
9	71	71	O	,
10	73	85	O	cardiological
11	87	89	O	and
12	91	108	O	anaesthesiological
13	110	115	O	fields
NULL

7786695.xml	DDI-MedLine.d103.s10	NO_SECTION	NO_SETID	15
The main indications are eclampsia, some dysrhythmias (torsades de pointe particularly) and myocardial ischaemias.
1	0	2	O	The
2	4	7	O	main
3	9	19	O	indications
4	21	23	O	are
5	25	33	O	eclampsia
6	34	34	O	,
7	36	39	O	some
8	41	52	O	dysrhythmias
9	55	62	O	torsades
10	64	65	O	de
11	67	72	O	pointe
12	74	85	O	particularly
13	88	90	O	and
14	92	101	O	myocardial
15	103	112	O	ischaemias
NULL

7786695.xml	DDI-MedLine.d103.s11	NO_SECTION	NO_SETID	16
But it is now difficult to situate the exact place of the pharmacological indications of magnesium.
1	0	2	O	But
2	4	5	O	it
3	7	8	O	is
4	10	12	O	now
5	14	22	O	difficult
6	24	25	O	to
7	27	33	O	situate
8	35	37	O	the
9	39	43	O	exact
10	45	49	O	place
11	51	52	O	of
12	54	56	O	the
13	58	72	O	pharmacological
14	74	84	O	indications
15	86	87	O	of
16	89	97	U-UNK	magnesium
NULL

7786695.xml	DDI-MedLine.d103.s12	NO_SECTION	NO_SETID	30
Magnesium infusions can only be envisaged in intensive care units with careful monitoring of pulse, arterial pressure, deep tendon reflexes, hourly diuresis, electrocardiogram and respiratory recordings.
1	0	8	U-UNK	Magnesium
2	10	18	O	infusions
3	20	22	O	can
4	24	27	O	only
5	29	30	O	be
6	32	40	O	envisaged
7	42	43	O	in
8	45	53	O	intensive
9	55	58	O	care
10	60	64	O	units
11	66	69	O	with
12	71	77	O	careful
13	79	88	O	monitoring
14	90	91	O	of
15	93	97	O	pulse
16	98	98	O	,
17	100	107	O	arterial
18	109	116	O	pressure
19	117	117	O	,
20	119	122	O	deep
21	124	129	O	tendon
22	131	138	O	reflexes
23	139	139	O	,
24	141	146	O	hourly
25	148	155	O	diuresis
26	156	156	O	,
27	158	174	O	electrocardiogram
28	176	178	O	and
29	180	190	O	respiratory
30	192	201	O	recordings
NULL

7786695.xml	DDI-MedLine.d103.s13	NO_SECTION	NO_SETID	16
High oral magnesium doses besides their laxative action may bring latent complications which may reduce lifespan.
1	0	3	O	High
2	5	8	O	oral
3	10	18	U-UNK	magnesium
4	20	24	O	doses
5	26	32	O	besides
6	34	38	O	their
7	40	47	O	laxative
8	49	54	O	action
9	56	58	O	may
10	60	64	O	bring
11	66	71	O	latent
12	73	85	O	complications
13	87	91	O	which
14	93	95	O	may
15	97	102	O	reduce
16	104	111	O	lifespan
NULL

7786695.xml	DDI-MedLine.d103.s14	NO_SECTION	NO_SETID	20
There may remain some indications of the laxative and antacid properties of non soluble magnesium, particularly during intermittent haemodialysis.
1	0	4	O	There
2	6	8	O	may
3	10	15	O	remain
4	17	20	O	some
5	22	32	O	indications
6	34	35	O	of
7	37	39	O	the
8	41	48	O	laxative
9	50	52	O	and
10	54	60	O	antacid
11	62	71	O	properties
12	73	74	O	of
13	76	78	O	non
14	80	86	O	soluble
15	88	96	U-UNK	magnesium
16	97	97	O	,
17	99	110	O	particularly
18	112	117	O	during
19	119	130	O	intermittent
20	132	144	O	haemodialysis
NULL

7786695.xml	DDI-MedLine.d103.s15	NO_SECTION	NO_SETID	24
Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.
1	0	5	O	Lastly
2	7	11	O	local
3	13	15	O	use
4	17	18	O	of
5	20	22	O	the
6	24	36	O	mucocutaneous
7	38	40	O	and
8	42	55	O	cytoprotective
9	57	66	O	properties
10	68	69	O	of
11	71	79	U-UNK	magnesium
12	81	82	O	is
13	84	88	O	still
14	90	94	O	valid
15	95	95	O	,
16	97	98	O	in
17	100	111	B-UNK	cardioplegic
18	113	121	L-UNK	solutions
19	123	125	O	and
20	127	129	O	for
21	131	142	O	preservation
22	144	145	O	of
23	147	157	O	transplants
24	159	170	O	particularly
NULL

7794883.xml	DDI-MedLine.d20.s0	NO_SECTION	NO_SETID	14
Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
1	0	10	O	Interaction
2	12	18	O	between
3	20	26	U-UNK	glycine
4	28	30	O	and
5	32	40	U-UNK	glutamate
6	42	43	O	in
7	45	47	O	the
8	49	59	O	development
9	61	62	O	of
10	64	74	O	spontaneous
11	76	83	O	motility
12	85	86	O	in
13	88	92	O	chick
14	94	100	O	embryos
NULL

7794883.xml	DDI-MedLine.d20.s1	NO_SECTION	NO_SETID	30
In this study we investigated whether also glycine fulfils the function as co-activator in glutamatergic activation of NMDA receptors in the neuronal apparatus of spontaneous motility in chick embryos.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	14	15	O	we
5	17	28	O	investigated
6	30	36	O	whether
7	38	41	O	also
8	43	49	U-UNK	glycine
9	51	57	O	fulfils
10	59	61	O	the
11	63	70	O	function
12	72	73	O	as
13	75	76	O	co
14	78	86	O	activator
15	88	89	O	in
16	91	103	O	glutamatergic
17	105	114	O	activation
18	116	117	O	of
19	119	122	O	NMDA
20	124	132	O	receptors
21	134	135	O	in
22	137	139	O	the
23	141	148	O	neuronal
24	150	158	O	apparatus
25	160	161	O	of
26	163	173	O	spontaneous
27	175	182	O	motility
28	184	185	O	in
29	187	191	O	chick
30	193	199	O	embryos
NULL

7794883.xml	DDI-MedLine.d20.s2	NO_SECTION	NO_SETID	14
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.)
1	0	2	O	The
2	4	13	O	successive
3	15	25	O	application
4	27	28	O	of
5	30	36	U-UNK	glycine
6	39	39	O	5
7	41	42	O	or
8	44	45	O	10
9	47	48	O	mg
10	49	49	O	/
11	50	51	O	kg
12	53	55	O	egg
13	57	62	O	weight
14	65	67	O	e.w
NULL

7794883.xml	DDI-MedLine.d20.s3	NO_SECTION	NO_SETID	7
and glutamate (15 mg/kg e.w.)
1	0	2	O	and
2	4	12	U-UNK	glutamate
3	15	16	O	15
4	18	19	O	mg
5	20	20	O	/
6	21	22	O	kg
7	24	26	O	e.w
NULL

7794883.xml	DDI-MedLine.d20.s4	NO_SECTION	NO_SETID	47
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
1	0	2	O	The
2	4	13	O	successive
3	15	25	O	application
4	27	28	O	of
5	30	36	U-UNK	glycine
6	39	39	O	5
7	41	42	O	or
8	44	45	O	10
9	47	48	O	mg
10	49	49	O	/
11	50	51	O	kg
12	53	55	O	egg
13	57	62	O	weight
14	65	67	O	e.w
15	71	73	O	and
16	75	83	U-UNK	glutamate
17	86	87	O	15
18	89	90	O	mg
19	91	91	O	/
20	92	93	O	kg
21	95	97	O	e.w
22	101	102	O	in
23	104	104	O	a
24	106	107	O	10
25	109	111	O	min
26	113	120	O	interval
27	122	134	O	significantly
28	136	144	O	increased
29	146	148	O	the
30	150	159	O	activation
31	161	162	O	of
32	164	174	O	spontaneous
33	176	183	O	motility
34	185	186	O	of
35	188	189	O	17
36	191	193	O	day
37	195	197	O	old
38	199	203	O	chick
39	205	211	O	embryos
40	213	214	O	in
41	216	225	O	comparison
42	227	230	O	with
43	232	234	O	the
44	236	241	O	effect
45	243	244	O	of
46	246	254	U-UNK	glutamate
47	256	260	O	alone
NULL

7794883.xml	DDI-MedLine.d20.s5	NO_SECTION	NO_SETID	13
This effect did not depend on the order of application of the drugs.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	did
4	16	18	O	not
5	20	25	O	depend
6	27	28	O	on
7	30	32	O	the
8	34	38	O	order
9	40	41	O	of
10	43	53	O	application
11	55	56	O	of
12	58	60	O	the
13	62	66	O	drugs
NULL

7794883.xml	DDI-MedLine.d20.s6	NO_SECTION	NO_SETID	12
In 13-day-old embryos, glycine was ineffective in both doses.
1	0	1	O	In
2	3	4	O	13
3	6	8	O	day
4	10	12	O	old
5	14	20	O	embryos
6	21	21	O	,
7	23	29	U-UNK	glycine
8	31	33	O	was
9	35	45	O	ineffective
10	47	48	O	in
11	50	53	O	both
12	55	59	O	doses
NULL

7794883.xml	DDI-MedLine.d20.s7	NO_SECTION	NO_SETID	40
It is concluded from these results that the modulatory effect of glycine is evidently a later developmental acquisition (after day 15 of incubation) in the embryogenesis of NMDA-ergic activation of spontaneous motility in chick embryos similarly as glycinergic inhibition.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	concluded
4	16	19	O	from
5	21	25	O	these
6	27	33	O	results
7	35	38	O	that
8	40	42	O	the
9	44	53	O	modulatory
10	55	60	O	effect
11	62	63	O	of
12	65	71	U-UNK	glycine
13	73	74	O	is
14	76	84	O	evidently
15	86	86	O	a
16	88	92	O	later
17	94	106	O	developmental
18	108	118	O	acquisition
19	121	125	O	after
20	127	129	O	day
21	131	132	O	15
22	134	135	O	of
23	137	146	O	incubation
24	149	150	O	in
25	152	154	O	the
26	156	168	O	embryogenesis
27	170	171	O	of
28	173	176	O	NMDA
29	178	182	O	ergic
30	184	193	O	activation
31	195	196	O	of
32	198	208	O	spontaneous
33	210	217	O	motility
34	219	220	O	in
35	222	226	O	chick
36	228	234	O	embryos
37	236	244	O	similarly
38	246	247	O	as
39	249	259	O	glycinergic
40	261	270	O	inhibition
NULL

7798493.xml	DDI-MedLine.d94.s0	NO_SECTION	NO_SETID	12
Evidence for reduction of norepinephrine uptake sites in the failing human heart.
1	0	7	O	Evidence
2	9	11	O	for
3	13	21	O	reduction
4	23	24	O	of
5	26	39	U-UNK	norepinephrine
6	41	46	O	uptake
7	48	52	O	sites
8	54	55	O	in
9	57	59	O	the
10	61	67	O	failing
11	69	73	O	human
12	75	79	O	heart
NULL

7798493.xml	DDI-MedLine.d94.s2	NO_SECTION	NO_SETID	30
This study investigated the role of neuronal uptake of norepinephrine (uptake-1) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes.
1	0	3	O	This
2	5	9	O	study
3	11	22	O	investigated
4	24	26	O	the
5	28	31	O	role
6	33	34	O	of
7	36	43	O	neuronal
8	45	50	O	uptake
9	52	53	O	of
10	55	68	U-UNK	norepinephrine
11	71	76	O	uptake
12	78	78	O	1
13	81	82	O	in
14	84	88	O	human
15	90	94	O	heart
16	96	102	O	failure
17	104	105	O	as
18	107	107	O	a
19	109	113	O	local
20	115	120	O	factor
21	122	124	O	for
22	126	133	O	altering
23	135	148	O	concentrations
24	150	151	O	of
25	153	166	O	norepinephrine
26	168	169	O	at
27	171	173	O	the
28	175	181	O	cardiac
29	183	189	O	myocyte
30	191	199	O	membranes
NULL

7798493.xml	DDI-MedLine.d94.s4	NO_SECTION	NO_SETID	9
Several beta-adrenergic neuroeffector defects occur in heart failure.
1	0	6	O	Several
2	8	11	O	beta
3	13	22	O	adrenergic
4	24	36	O	neuroeffector
5	38	44	O	defects
6	46	50	O	occur
7	52	53	O	in
8	55	59	O	heart
9	61	67	O	failure
NULL

7798493.xml	DDI-MedLine.d94.s5	NO_SECTION	NO_SETID	11
Whether an alteration in norepinephrine uptake-1 occurs is still unresolved.
1	0	6	O	Whether
2	8	9	O	an
3	11	20	O	alteration
4	22	23	O	in
5	25	38	U-UNK	norepinephrine
6	40	45	O	uptake
7	47	47	O	1
8	49	54	O	occurs
9	56	57	O	is
10	59	63	O	still
11	65	74	O	unresolved
NULL

7798493.xml	DDI-MedLine.d94.s7	NO_SECTION	NO_SETID	25
The role of norepinephrine uptake-1 was studied in electrically stimulated (1 Hz, 37 degrees C) human ventricular cardiac preparations and isolated myocardial membranes.
1	0	2	O	The
2	4	7	O	role
3	9	10	O	of
4	12	25	U-UNK	norepinephrine
5	27	32	O	uptake
6	34	34	O	1
7	36	38	O	was
8	40	46	O	studied
9	48	49	O	in
10	51	62	O	electrically
11	64	73	O	stimulated
12	76	76	O	1
13	78	79	O	Hz
14	80	80	O	,
15	82	83	O	37
16	85	91	O	degrees
17	93	93	O	C
18	96	100	O	human
19	102	112	O	ventricular
20	114	120	O	cardiac
21	122	133	O	preparations
22	135	137	O	and
23	139	146	O	isolated
24	148	157	O	myocardial
25	159	167	O	membranes
NULL

7798493.xml	DDI-MedLine.d94.s9	NO_SECTION	NO_SETID	20
The effectiveness of norepinephrine in increasing the force of contraction was decreased in relation to the degree of heart failure.
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	34	U-UNK	norepinephrine
5	36	37	O	in
6	39	48	O	increasing
7	50	52	O	the
8	54	58	O	force
9	60	61	O	of
10	63	73	O	contraction
11	75	77	O	was
12	79	87	O	decreased
13	89	90	O	in
14	92	99	O	relation
15	101	102	O	to
16	104	106	O	the
17	108	113	O	degree
18	115	116	O	of
19	118	122	O	heart
20	124	130	O	failure
NULL

7798493.xml	DDI-MedLine.d94.s10	NO_SECTION	NO_SETID	31
In contrast, the potency of norepinephrine was increased in failing hearts (New York Heart Association functional class IV) in relation to the concentrations producing 50% of the maximal effect (EC50).
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	15	O	the
5	17	23	O	potency
6	25	26	O	of
7	28	41	U-UNK	norepinephrine
8	43	45	O	was
9	47	55	O	increased
10	57	58	O	in
11	60	66	O	failing
12	68	73	O	hearts
13	76	78	O	New
14	80	83	O	York
15	85	89	O	Heart
16	91	101	O	Association
17	103	112	O	functional
18	114	118	O	class
19	120	121	O	IV
20	124	125	O	in
21	127	134	O	relation
22	136	137	O	to
23	139	141	O	the
24	143	156	O	concentrations
25	158	166	O	producing
26	168	170	O	50%
27	172	173	O	of
28	175	177	O	the
29	179	185	O	maximal
30	187	192	O	effect
31	195	198	O	EC50
NULL

7798493.xml	DDI-MedLine.d94.s11	NO_SECTION	NO_SETID	34
The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium.
1	0	2	O	The
2	4	7	O	EC50
3	9	14	O	values
4	16	18	O	for
5	20	32	U-UNK	isoproterenol
6	33	33	O	,
7	35	39	O	which
8	41	42	O	is
9	44	46	O	not
10	48	48	O	a
11	50	58	O	substrate
12	60	62	O	for
13	64	77	U-UNK	norepinephrine
14	79	84	O	uptake
15	86	86	O	1
16	87	87	O	,
17	89	92	O	were
18	94	100	O	reduced
19	102	103	O	in
20	105	114	O	myocardium
21	116	117	O	in
22	119	128	O	functional
23	130	136	O	classes
24	138	139	O	II
25	141	142	O	to
26	144	146	O	III
27	148	150	O	and
28	152	153	O	IV
29	155	162	O	compared
30	164	167	O	with
31	169	173	O	those
32	175	176	O	in
33	178	187	O	nonfailing
34	189	198	O	myocardium
NULL

7798493.xml	DDI-MedLine.d94.s12	NO_SECTION	NO_SETID	30
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
1	0	2	O	The
2	4	9	O	uptake
3	11	20	O	inhibitors
4	22	28	U-UNK	cocaine
5	30	32	O	and
6	34	44	U-UNK	desipramine
7	47	47	O	3
8	49	53	O	mumol
9	54	54	O	/
10	55	59	O	liter
11	62	72	O	potentiated
12	74	76	O	the
13	78	85	O	positive
14	87	95	O	inotropic
15	97	103	O	effects
16	105	106	O	of
17	108	121	U-UNK	norepinephrine
18	123	124	O	in
19	126	135	O	nonfailing
20	137	146	O	myocardium
21	149	149	O	p
22	151	151	O	<
23	153	156	O	0.05
24	159	161	O	but
25	163	165	O	not
26	167	168	O	in
27	170	179	O	functional
28	181	185	O	class
29	187	188	O	IV
30	190	199	O	myocardium
NULL

7798493.xml	DDI-MedLine.d94.s13	NO_SECTION	NO_SETID	38
Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
1	0	10	O	Radioligand
2	12	18	O	binding
3	20	30	O	experiments
4	32	36	O	using
5	38	40	O	the
6	42	47	O	uptake
7	49	57	O	inhibitor
8	59	66	O	hydrogen
9	68	68	O	3
10	70	77	U-UNK	mazindol
11	79	86	O	revealed
12	88	88	O	a
13	90	100	O	significant
14	102	109	O	decrease
15	111	112	O	by
16	114	126	O	approximately
17	128	130	O	30%
18	132	133	O	in
19	135	148	U-UNK	norepinephrine
20	150	155	O	uptake
21	157	157	O	1
22	159	165	O	carrier
23	167	173	O	density
24	175	176	O	in
25	178	187	O	functional
26	189	195	O	classes
27	197	198	O	II
28	200	201	O	to
29	203	205	O	III
30	207	209	O	and
31	211	212	O	IV
32	214	223	O	myocardium
33	225	230	O	versus
34	232	241	O	nonfailing
35	243	252	O	myocardium
36	255	255	O	p
37	257	257	O	<
38	259	262	O	0.05
NULL

7798493.xml	DDI-MedLine.d94.s15	NO_SECTION	NO_SETID	22
In human heart failure, there is a presynaptic defect in the sympathetic nervous system, leading to reduced uptake-1 activity.
1	0	1	O	In
2	3	7	O	human
3	9	13	O	heart
4	15	21	O	failure
5	22	22	O	,
6	24	28	O	there
7	30	31	O	is
8	33	33	O	a
9	35	45	O	presynaptic
10	47	52	O	defect
11	54	55	O	in
12	57	59	O	the
13	61	71	O	sympathetic
14	73	79	O	nervous
15	81	86	O	system
16	87	87	O	,
17	89	95	O	leading
18	97	98	O	to
19	100	106	O	reduced
20	108	113	O	uptake
21	115	115	O	1
22	117	124	O	activity
NULL

7798493.xml	DDI-MedLine.d94.s16	NO_SECTION	NO_SETID	28
This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only.
1	0	3	O	This
2	5	10	O	defect
3	12	13	O	in
4	15	17	O	the
5	19	25	O	failing
6	27	31	O	heart
7	33	35	O	can
8	37	38	O	be
9	40	47	O	mimicked
10	49	50	O	by
11	52	54	O	the
12	56	62	O	effects
13	64	65	O	of
14	67	72	O	uptake
15	74	81	O	blocking
16	83	88	O	agents
17	89	89	O	,
18	91	94	O	such
19	96	97	O	as
20	99	105	U-UNK	cocaine
21	107	109	O	and
22	111	121	U-UNK	desipramine
23	122	122	O	,
24	124	125	O	in
25	127	129	O	the
26	131	140	O	nonfailing
27	142	146	O	heart
28	148	151	O	only
NULL

7798493.xml	DDI-MedLine.d94.s17	NO_SECTION	NO_SETID	16
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
1	0	10	O	Compromised
2	12	25	U-UNK	norepinephrine
3	27	32	O	uptake
4	34	34	O	1
5	36	37	O	in
6	39	48	O	functional
7	50	54	O	class
8	56	57	O	IV
9	59	64	O	cannot
10	66	67	O	be
11	69	75	O	further
12	77	85	O	increased
13	87	88	O	by
14	90	96	U-UNK	cocaine
15	98	100	O	and
16	102	112	U-UNK	desipramine
NULL

7798493.xml	DDI-MedLine.d94.s18	NO_SECTION	NO_SETID	16
The pathophysiologic consequences could be an increased synaptic concentration of norepinephrine predisposing to adenylyl cyclase desensitization.
1	0	2	O	The
2	4	19	O	pathophysiologic
3	21	32	O	consequences
4	34	38	O	could
5	40	41	O	be
6	43	44	O	an
7	46	54	O	increased
8	56	63	O	synaptic
9	65	77	O	concentration
10	79	80	O	of
11	82	95	U-UNK	norepinephrine
12	97	108	O	predisposing
13	110	111	O	to
14	113	120	O	adenylyl
15	122	128	O	cyclase
16	130	144	O	desensitization
NULL

8521984.xml	DDI-MedLine.d14.s1	NO_SECTION	NO_SETID	17
It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine.
1	0	1	O	It
2	3	5	O	was
3	7	17	O	established
4	19	22	O	that
5	24	27	O	both
6	29	40	O	angiotensins
7	42	50	O	inhibited
8	52	58	O	gastric
9	60	63	O	acid
10	65	73	O	secretion
11	75	84	O	stimulated
12	86	87	O	by
13	89	100	U-UNK	pentagastrin
14	102	104	O	but
15	106	108	O	not
16	110	111	O	by
17	113	121	U-UNK	histamine
NULL

8521984.xml	DDI-MedLine.d14.s2	NO_SECTION	NO_SETID	37
Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.
1	0	10	O	Comparative
2	12	19	O	analysis
3	21	22	O	of
4	24	26	O	the
5	28	34	O	effects
6	36	37	O	of
7	39	49	O	stimulation
8	51	53	O	and
9	55	64	O	inhibition
10	66	67	O	of
11	69	75	O	cholino
12	78	80	O	and
13	82	96	O	adrenoreceptors
14	98	99	O	on
15	101	104	O	this
16	106	115	O	inhibitory
17	117	122	O	action
18	124	125	O	of
19	127	138	U-UNK	angiotensins
20	140	148	O	suggested
21	150	152	O	the
22	154	162	O	mediation
23	164	165	O	of
24	167	177	U-UNK	angiotensin
25	179	187	O	influence
26	189	195	O	through
27	197	199	O	the
28	201	210	O	modulation
29	212	213	O	of
30	215	225	O	cholinergic
31	227	235	O	reactions
32	237	238	O	of
33	240	247	O	parietal
34	249	253	O	cells
35	255	256	O	in
36	258	260	O	the
37	262	268	O	stomach
NULL

8542840.xml	DDI-MedLine.d90.s0	NO_SECTION	NO_SETID	8
Interaction of gentamycin and atracurium in anaesthetised horses.
1	0	10	O	Interaction
2	12	13	O	of
3	15	24	U-UNK	gentamycin
4	26	28	O	and
5	30	39	U-UNK	atracurium
6	41	42	O	in
7	44	56	O	anaesthetised
8	58	63	O	horses
NULL

8542840.xml	DDI-MedLine.d90.s1	NO_SECTION	NO_SETID	26
Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane.
1	0	5	O	Evoked
2	7	10	O	hind
3	12	15	O	limb
4	17	23	O	digital
5	25	32	O	extensor
6	34	40	O	tension
7	43	46	O	hoof
8	48	53	O	twitch
9	56	58	O	was
10	60	69	O	maintained
11	71	72	O	at
12	74	76	O	40%
13	78	79	O	of
14	81	88	O	baseline
15	90	92	O	for
16	94	94	O	1
17	96	96	O	h
18	98	99	O	by
19	101	110	U-UNK	atracurium
20	112	119	O	infusion
21	121	122	O	in
22	124	124	O	7
23	126	131	O	horses
24	133	145	O	anaesthetised
25	147	150	O	with
26	152	160	U-UNK	halothane
NULL

8542840.xml	DDI-MedLine.d90.s2	NO_SECTION	NO_SETID	15
After 1 h, atracurium was discontinued and hoof twitch allowed to recover to 75%.
1	0	4	O	After
2	6	6	O	1
3	8	8	O	h
4	9	9	O	,
5	11	20	U-UNK	atracurium
6	22	24	O	was
7	26	37	O	discontinued
8	39	41	O	and
9	43	46	O	hoof
10	48	53	O	twitch
11	55	61	O	allowed
12	63	64	O	to
13	66	72	O	recover
14	74	75	O	to
15	77	79	O	75%
NULL

8542840.xml	DDI-MedLine.d90.s3	NO_SECTION	NO_SETID	25
Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v.
1	0	9	U-UNK	Atracurium
2	11	13	O	was
3	15	19	O	again
4	21	25	O	given
5	27	28	O	by
6	30	37	O	infusion
7	39	40	O	to
8	42	49	O	maintain
9	51	53	O	40%
10	55	60	O	twitch
11	62	64	O	for
12	66	66	O	a
13	68	73	O	second
14	75	78	O	hour
15	79	79	O	,
16	81	84	O	then
17	86	86	O	2
18	88	89	O	mg
19	91	100	U-UNK	gentamycin
20	101	101	O	/
21	102	103	O	kg
22	105	107	O	bwt
23	109	112	O	were
24	114	118	O	given
25	120	122	O	i.v
NULL

8542840.xml	DDI-MedLine.d90.s4	NO_SECTION	NO_SETID	21
Atracurium infusion was continued for a third hour, and then hoof twitch was again allowed to recover spontaneously to 75%.
1	0	9	U-UNK	Atracurium
2	11	18	O	infusion
3	20	22	O	was
4	24	32	O	continued
5	34	36	O	for
6	38	38	O	a
7	40	44	O	third
8	46	49	O	hour
9	50	50	O	,
10	52	54	O	and
11	56	59	O	then
12	61	64	O	hoof
13	66	71	O	twitch
14	73	75	O	was
15	77	81	O	again
16	83	89	O	allowed
17	91	92	O	to
18	94	100	O	recover
19	102	114	O	spontaneously
20	116	117	O	to
21	119	121	O	75%
NULL

8542840.xml	DDI-MedLine.d90.s5	NO_SECTION	NO_SETID	27
Gentamycin reduced twitch strength from 40 +/- 1% (mean +/- sem) to 29 +/- 4% within 7.0 +/- 1.5 min (P = 0.02).
1	0	9	U-UNK	Gentamycin
2	11	17	O	reduced
3	19	24	O	twitch
4	26	33	O	strength
5	35	38	O	from
6	40	41	O	40
7	43	43	O	+
8	44	44	O	/
9	47	48	O	1%
10	51	54	O	mean
11	56	56	O	+
12	57	57	O	/
13	60	62	O	sem
14	65	66	O	to
15	68	69	O	29
16	71	71	O	+
17	72	72	O	/
18	75	76	O	4%
19	78	83	O	within
20	85	87	O	7.0
21	89	89	O	+
22	90	90	O	/
23	93	95	O	1.5
24	97	99	O	min
25	102	102	O	P
26	104	104	O	=
27	106	109	O	0.02
NULL

8542840.xml	DDI-MedLine.d90.s6	NO_SECTION	NO_SETID	14
Twitch gradually returned to pre-gentamycin strength over the course of the next hour.
1	0	5	O	Twitch
2	7	15	O	gradually
3	17	24	O	returned
4	26	27	O	to
5	29	31	O	pre
6	33	42	U-UNK	gentamycin
7	44	51	O	strength
8	53	56	O	over
9	58	60	O	the
10	62	67	O	course
11	69	70	O	of
12	72	74	O	the
13	76	79	O	next
14	81	84	O	hour
NULL

8542840.xml	DDI-MedLine.d90.s7	NO_SECTION	NO_SETID	30
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
1	0	7	O	Recovery
2	9	10	O	of
3	12	15	O	hoof
4	17	22	O	twitch
5	24	27	O	from
6	29	31	O	50%
7	33	34	O	to
8	36	38	O	75%
9	40	43	O	took
10	45	47	O	7.7
11	49	49	O	+
12	50	50	O	/
13	53	55	O	0.7
14	57	59	O	min
15	61	63	O	for
16	65	74	U-UNK	atracurium
17	76	80	O	alone
18	82	84	O	and
19	86	89	O	11.5
20	91	91	O	+
21	92	92	O	/
22	95	97	O	2.7
23	99	101	O	min
24	103	105	O	for
25	107	116	U-UNK	atracurium
26	118	121	O	plus
27	123	132	U-UNK	gentamycin
28	135	135	O	P
29	137	137	O	=
30	139	142	O	0.03
NULL

8542840.xml	DDI-MedLine.d90.s8	NO_SECTION	NO_SETID	27
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
1	0	7	O	Recovery
2	9	12	O	from
3	14	16	O	50%
4	18	23	O	twitch
5	25	26	O	to
6	28	30	O	75%
7	32	35	O	fade
8	37	44	O	recovery
9	46	49	O	took
10	51	54	O	13.8
11	56	56	O	+
12	57	57	O	/
13	60	62	O	0.8
14	64	66	O	min
15	68	70	O	for
16	72	81	U-UNK	atracurium
17	83	87	O	alone
18	89	91	O	and
19	93	96	O	13.7
20	98	98	O	+
21	99	99	O	/
22	102	104	O	1.2
23	106	108	O	min
24	110	112	O	for
25	114	123	U-UNK	atracurium
26	125	128	O	plus
27	130	139	U-UNK	gentamycin
NULL

8542840.xml	DDI-MedLine.d90.s9	NO_SECTION	NO_SETID	25
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
1	0	1	O	At
2	3	5	O	75%
3	7	14	O	recovery
4	16	17	O	of
5	19	22	O	fade
6	23	23	O	,
7	25	28	O	hoof
8	30	35	O	twitch
9	37	39	O	was
10	41	42	O	87
11	44	44	O	+
12	45	45	O	/
13	48	49	O	3%
14	51	53	O	for
15	55	64	U-UNK	atracurium
16	66	70	O	alone
17	72	74	O	and
18	76	77	O	82
19	79	79	O	+
20	80	80	O	/
21	83	84	O	4%
22	86	88	O	for
23	90	99	U-UNK	atracurium
24	101	104	O	plus
25	106	115	U-UNK	gentamycin
NULL

8542840.xml	DDI-MedLine.d90.s10	NO_SECTION	NO_SETID	16
Reversal of the block with edrophonium and subsequent recovery of the horses from anaesthesia were uneventful.
1	0	7	O	Reversal
2	9	10	O	of
3	12	14	O	the
4	16	20	O	block
5	22	25	O	with
6	27	37	U-UNK	edrophonium
7	39	41	O	and
8	43	52	O	subsequent
9	54	61	O	recovery
10	63	64	O	of
11	66	68	O	the
12	70	75	O	horses
13	77	80	O	from
14	82	92	O	anaesthesia
15	94	97	O	were
16	99	108	O	uneventful
NULL

8542840.xml	DDI-MedLine.d90.s11	NO_SECTION	NO_SETID	19
It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
1	0	1	O	It
2	3	5	O	was
3	7	15	O	concluded
4	17	20	O	that
5	21	21	O	,
6	23	30	O	although
7	32	41	U-UNK	gentamycin
8	43	45	O	did
9	47	53	O	augment
10	55	57	O	the
11	59	71	O	neuromuscular
12	73	80	O	blockade
13	82	83	O	of
14	85	94	U-UNK	atracurium
15	95	95	O	,
16	97	99	O	the
17	101	106	O	effect
18	108	110	O	was
19	112	118	O	minimal
NULL

8619063.xml	DDI-MedLine.d37.s1	NO_SECTION	NO_SETID	9
Treatment plans for patients taking anticoagulants can become complicated.
1	0	8	O	Treatment
2	10	14	O	plans
3	16	18	O	for
4	20	27	O	patients
5	29	34	O	taking
6	36	49	U-UNK	anticoagulants
7	51	53	O	can
8	55	60	O	become
9	62	72	O	complicated
NULL

8619063.xml	DDI-MedLine.d37.s2	NO_SECTION	NO_SETID	7
Anticoagulants predispose a patient to bleeding problems.
1	0	13	U-UNK	Anticoagulants
2	15	24	O	predispose
3	26	26	O	a
4	28	34	O	patient
5	36	37	O	to
6	39	46	O	bleeding
7	48	55	O	problems
NULL

8619063.xml	DDI-MedLine.d37.s3	NO_SECTION	NO_SETID	12
Many drugs used in dentistry cannot be taken concomitantly with these medications.
1	0	3	O	Many
2	5	9	O	drugs
3	11	14	O	used
4	16	17	O	in
5	19	27	O	dentistry
6	29	34	O	cannot
7	36	37	O	be
8	39	43	O	taken
9	45	57	O	concomitantly
10	59	62	O	with
11	64	68	O	these
12	70	80	O	medications
NULL

8640374.xml	DDI-MedLine.d108.s0	NO_SECTION	NO_SETID	4
Administration of lithium prophylaxis.
1	0	13	O	Administration
2	15	16	O	of
3	18	24	U-UNK	lithium
4	26	36	O	prophylaxis
NULL

8640374.xml	DDI-MedLine.d108.s1	NO_SECTION	NO_SETID	14
Successful prophylaxis of manic-depressive disorder requires more than the prescription of lithium carbonate.
1	0	9	O	Successful
2	11	21	O	prophylaxis
3	23	24	O	of
4	26	30	O	manic
5	32	41	O	depressive
6	43	50	O	disorder
7	52	59	O	requires
8	61	64	O	more
9	66	69	O	than
10	71	73	O	the
11	75	86	O	prescription
12	88	89	O	of
13	91	97	B-UNK	lithium
14	99	107	L-UNK	carbonate
NULL

8640374.xml	DDI-MedLine.d108.s2	NO_SECTION	NO_SETID	36
The administrative arrangements in an area of Scotland were accompanied by a 300% increase in the frequency of admissions for mania, whereas in an area of the West Midlands, a large decrease was achieved.
1	0	2	O	The
2	4	17	O	administrative
3	19	30	O	arrangements
4	32	33	O	in
5	35	36	O	an
6	38	41	O	area
7	43	44	O	of
8	46	53	O	Scotland
9	55	58	O	were
10	60	70	O	accompanied
11	72	73	O	by
12	75	75	O	a
13	77	80	O	300%
14	82	89	O	increase
15	91	92	O	in
16	94	96	O	the
17	98	106	O	frequency
18	108	109	O	of
19	111	120	O	admissions
20	122	124	O	for
21	126	130	O	mania
22	131	131	O	,
23	133	139	O	whereas
24	141	142	O	in
25	144	145	O	an
26	147	150	O	area
27	152	153	O	of
28	155	157	O	the
29	159	162	O	West
30	164	171	O	Midlands
31	172	172	O	,
32	174	174	O	a
33	176	180	O	large
34	182	189	O	decrease
35	191	193	O	was
36	195	202	O	achieved
NULL

8682269.xml	DDI-MedLine.d136.s1	NO_SECTION	NO_SETID	23
At low-levels of exposure the toxicokinetic interferences between solvents have generally not been observed in man and presumably a threshold limit exists.
1	0	1	O	At
2	3	5	O	low
3	7	12	O	levels
4	14	15	O	of
5	17	24	O	exposure
6	26	28	O	the
7	30	42	O	toxicokinetic
8	44	56	O	interferences
9	58	64	O	between
10	66	73	O	solvents
11	75	78	O	have
12	80	88	O	generally
13	90	92	O	not
14	94	97	O	been
15	99	106	O	observed
16	108	109	O	in
17	111	113	O	man
18	115	117	O	and
19	119	128	O	presumably
20	130	130	O	a
21	132	140	O	threshold
22	142	146	O	limit
23	148	153	O	exists
NULL

8682269.xml	DDI-MedLine.d136.s2	NO_SECTION	NO_SETID	10
Conversely, at exposure levels close to the "limit values"
1	0	9	O	Conversely
2	10	10	O	,
3	12	13	O	at
4	15	22	O	exposure
5	24	29	O	levels
6	31	35	O	close
7	37	38	O	to
8	40	42	O	the
9	44	49	O	"limit
10	51	57	O	values"
NULL

8682269.xml	DDI-MedLine.d136.s3	NO_SECTION	NO_SETID	19
metabolic interference has sometimes been observed and the behaviour of the biological indicators differs from what would be expected.
1	0	8	O	metabolic
2	10	21	O	interference
3	23	25	O	has
4	27	35	O	sometimes
5	37	40	O	been
6	42	49	O	observed
7	51	53	O	and
8	55	57	O	the
9	59	67	O	behaviour
10	69	70	O	of
11	72	74	O	the
12	76	85	O	biological
13	87	96	O	indicators
14	98	104	O	differs
15	106	109	O	from
16	111	114	O	what
17	116	120	O	would
18	122	123	O	be
19	125	132	O	expected
NULL

8682269.xml	DDI-MedLine.d136.s4	NO_SECTION	NO_SETID	16
Toxicodynamic interference between solvents can give rise to additive, potentiation, synergistic, antagonistic effects.
1	0	12	O	Toxicodynamic
2	14	25	O	interference
3	27	33	O	between
4	35	42	O	solvents
5	44	46	O	can
6	48	51	O	give
7	53	56	O	rise
8	58	59	O	to
9	61	68	O	additive
10	69	69	O	,
11	71	82	O	potentiation
12	83	83	O	,
13	85	95	O	synergistic
14	96	96	O	,
15	98	109	O	antagonistic
16	111	117	O	effects
NULL

8682269.xml	DDI-MedLine.d136.s5	NO_SECTION	NO_SETID	27
For the identification of "limit values", it has generally been suggested in the literature that the possible effects deriving from multiple exposure be considered as additive.
1	0	2	O	For
2	4	6	O	the
3	8	21	O	identification
4	23	24	O	of
5	26	31	O	"limit
6	33	39	O	values"
7	40	40	O	,
8	42	43	O	it
9	45	47	O	has
10	49	57	O	generally
11	59	62	O	been
12	64	72	O	suggested
13	74	75	O	in
14	77	79	O	the
15	81	90	O	literature
16	92	95	O	that
17	97	99	O	the
18	101	108	O	possible
19	110	116	O	effects
20	118	125	O	deriving
21	127	130	O	from
22	132	139	O	multiple
23	141	148	O	exposure
24	150	151	O	be
25	153	162	O	considered
26	164	165	O	as
27	167	174	O	additive
NULL

8682269.xml	DDI-MedLine.d136.s6	NO_SECTION	NO_SETID	17
However, numerous potentiation effects have frequently been reported for combined exposure to substances of widespread use.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	numerous
4	18	29	O	potentiation
5	31	37	O	effects
6	39	42	O	have
7	44	53	O	frequently
8	55	58	O	been
9	60	67	O	reported
10	69	71	O	for
11	73	80	O	combined
12	82	89	O	exposure
13	91	92	O	to
14	94	103	O	substances
15	105	106	O	of
16	108	117	O	widespread
17	119	121	O	use
NULL

8682269.xml	DDI-MedLine.d136.s7	NO_SECTION	NO_SETID	38
In this paper lists of multiple exposure in which the doses of the substances, the types of interferences and the behaviour of the biological levels have been drawn up and proposed as a tool for easy consultation.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	paper
4	14	18	O	lists
5	20	21	O	of
6	23	30	O	multiple
7	32	39	O	exposure
8	41	42	O	in
9	44	48	O	which
10	50	52	O	the
11	54	58	O	doses
12	60	61	O	of
13	63	65	O	the
14	67	76	O	substances
15	77	77	O	,
16	79	81	O	the
17	83	87	O	types
18	89	90	O	of
19	92	104	O	interferences
20	106	108	O	and
21	110	112	O	the
22	114	122	O	behaviour
23	124	125	O	of
24	127	129	O	the
25	131	140	O	biological
26	142	147	O	levels
27	149	152	O	have
28	154	157	O	been
29	159	163	O	drawn
30	165	166	O	up
31	168	170	O	and
32	172	179	O	proposed
33	181	182	O	as
34	184	184	O	a
35	186	189	O	tool
36	191	193	O	for
37	195	198	O	easy
38	200	211	O	consultation
NULL

8996605.xml	DDI-MedLine.d33.s0	NO_SECTION	NO_SETID	9
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.
1	0	11	O	Determinants
2	13	14	O	of
3	16	23	O	cellular
4	25	35	O	sensitivity
5	37	38	O	to
6	40	52	B-UNK	topoisomerase
7	54	62	I-UNK	targeting
8	64	72	I-UNK	antitumor
9	74	78	L-UNK	drugs
NULL

8996605.xml	DDI-MedLine.d33.s1	NO_SECTION	NO_SETID	17
It is now clear that topoisomerase activity level is an important determinant of sensitivity to topo drugs.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	now
4	10	14	O	clear
5	16	19	O	that
6	21	33	O	topoisomerase
7	35	42	O	activity
8	44	48	O	level
9	50	51	O	is
10	53	54	O	an
11	56	64	O	important
12	66	76	O	determinant
13	78	79	O	of
14	81	91	O	sensitivity
15	93	94	O	to
16	96	99	O	topo
17	101	105	O	drugs
NULL

8996605.xml	DDI-MedLine.d33.s2	NO_SECTION	NO_SETID	20
The regulation of topoisomerases is no doubt complex and multifaceted and is probably accomplished through redundancy at many control levels.
1	0	2	O	The
2	4	13	O	regulation
3	15	16	O	of
4	18	31	O	topoisomerases
5	33	34	O	is
6	36	37	O	no
7	39	43	O	doubt
8	45	51	O	complex
9	53	55	O	and
10	57	68	O	multifaceted
11	70	72	O	and
12	74	75	O	is
13	77	84	O	probably
14	86	97	O	accomplished
15	99	105	O	through
16	107	116	O	redundancy
17	118	119	O	at
18	121	124	O	many
19	126	132	O	control
20	134	139	O	levels
NULL

8996605.xml	DDI-MedLine.d33.s3	NO_SECTION	NO_SETID	50
The mechanism(s) of altered topo I expression in certain tumor types is unknown, but may be related to the central importance of topoisomerases in proliferating cell functions (transcription, replication, etc.), and the aberrant and chronic activation of these functions as a result of specific tumorigenic alterations.
1	0	2	O	The
2	4	14	O	mechanism(s
3	17	18	O	of
4	20	26	O	altered
5	28	31	O	topo
6	33	33	O	I
7	35	44	O	expression
8	46	47	O	in
9	49	55	O	certain
10	57	61	O	tumor
11	63	67	O	types
12	69	70	O	is
13	72	78	O	unknown
14	79	79	O	,
15	81	83	O	but
16	85	87	O	may
17	89	90	O	be
18	92	98	O	related
19	100	101	O	to
20	103	105	O	the
21	107	113	O	central
22	115	124	O	importance
23	126	127	O	of
24	129	142	O	topoisomerases
25	144	145	O	in
26	147	159	O	proliferating
27	161	164	O	cell
28	166	174	O	functions
29	177	189	O	transcription
30	190	190	O	,
31	192	202	O	replication
32	203	203	O	,
33	205	207	O	etc
34	210	210	O	,
35	212	214	O	and
36	216	218	O	the
37	220	227	O	aberrant
38	229	231	O	and
39	233	239	O	chronic
40	241	250	O	activation
41	252	253	O	of
42	255	259	O	these
43	261	269	O	functions
44	271	272	O	as
45	274	274	O	a
46	276	281	O	result
47	283	284	O	of
48	286	293	O	specific
49	295	305	O	tumorigenic
50	307	317	O	alterations
NULL

8996605.xml	DDI-MedLine.d33.s4	NO_SECTION	NO_SETID	29
Small differences in sensitivity to chemotherapy can have a dramatic effect on cure rates, and therefore subtle cell type-specific differences may be important determinants of drug sensitivity.
1	0	4	O	Small
2	6	16	O	differences
3	18	19	O	in
4	21	31	O	sensitivity
5	33	34	O	to
6	36	47	O	chemotherapy
7	49	51	O	can
8	53	56	O	have
9	58	58	O	a
10	60	67	O	dramatic
11	69	74	O	effect
12	76	77	O	on
13	79	82	O	cure
14	84	88	O	rates
15	89	89	O	,
16	91	93	O	and
17	95	103	O	therefore
18	105	110	O	subtle
19	112	115	O	cell
20	117	120	O	type
21	122	129	O	specific
22	131	141	O	differences
23	143	145	O	may
24	147	148	O	be
25	150	158	O	important
26	160	171	O	determinants
27	173	174	O	of
28	176	179	O	drug
29	181	191	O	sensitivity
NULL

8996605.xml	DDI-MedLine.d33.s5	NO_SECTION	NO_SETID	24
Whether abnormal topoisomerase quantity and specific activity are associated with resistance or sensitivity to topoisomerase-targeted chemotherapy in the clinic is now being studied.
1	0	6	O	Whether
2	8	15	O	abnormal
3	17	29	O	topoisomerase
4	31	38	O	quantity
5	40	42	O	and
6	44	51	O	specific
7	53	60	O	activity
8	62	64	O	are
9	66	75	O	associated
10	77	80	O	with
11	82	91	O	resistance
12	93	94	O	or
13	96	106	O	sensitivity
14	108	109	O	to
15	111	123	O	topoisomerase
16	125	132	O	targeted
17	134	145	O	chemotherapy
18	147	148	O	in
19	150	152	O	the
20	154	159	O	clinic
21	161	162	O	is
22	164	166	O	now
23	168	172	O	being
24	174	180	O	studied
NULL

8996605.xml	DDI-MedLine.d33.s6	NO_SECTION	NO_SETID	29
Determinants downstream of cleavable complex formation that affect the sensitivity of tumor versus normal cells to topo drugs in particular and DNA-damaging agents in general are little known.
1	0	11	O	Determinants
2	13	22	O	downstream
3	24	25	O	of
4	27	35	O	cleavable
5	37	43	O	complex
6	45	53	O	formation
7	55	58	O	that
8	60	65	O	affect
9	67	69	O	the
10	71	81	O	sensitivity
11	83	84	O	of
12	86	90	O	tumor
13	92	97	O	versus
14	99	104	O	normal
15	106	110	O	cells
16	112	113	O	to
17	115	118	O	topo
18	120	124	O	drugs
19	126	127	O	in
20	129	138	O	particular
21	140	142	O	and
22	144	146	O	DNA
23	148	155	O	damaging
24	157	162	O	agents
25	164	165	O	in
26	167	173	O	general
27	175	177	O	are
28	179	184	O	little
29	186	190	O	known
NULL

8996605.xml	DDI-MedLine.d33.s7	NO_SECTION	NO_SETID	31
The goal of enhancing selective tumor cell killing relative to the normal cells that are dose limiting may be achieved either by overcoming tumor cell resistance or by protecting normal cells.
1	0	2	O	The
2	4	7	O	goal
3	9	10	O	of
4	12	20	O	enhancing
5	22	30	O	selective
6	32	36	O	tumor
7	38	41	O	cell
8	43	49	O	killing
9	51	58	O	relative
10	60	61	O	to
11	63	65	O	the
12	67	72	O	normal
13	74	78	O	cells
14	80	83	O	that
15	85	87	O	are
16	89	92	O	dose
17	94	101	O	limiting
18	103	105	O	may
19	107	108	O	be
20	110	117	O	achieved
21	119	124	O	either
22	126	127	O	by
23	129	138	O	overcoming
24	140	144	O	tumor
25	146	149	O	cell
26	151	160	O	resistance
27	162	163	O	or
28	165	166	O	by
29	168	177	O	protecting
30	179	184	O	normal
31	186	190	O	cells
NULL

8996605.xml	DDI-MedLine.d33.s8	NO_SECTION	NO_SETID	36
Both of these strategies will become more feasible as specific molecular differences between tumor and normal cells are being rapidly identified and new combination therapies that take advantage of these differences are being designed and tested.
1	0	3	O	Both
2	5	6	O	of
3	8	12	O	these
4	14	23	O	strategies
5	25	28	O	will
6	30	35	O	become
7	37	40	O	more
8	42	49	O	feasible
9	51	52	O	as
10	54	61	O	specific
11	63	71	O	molecular
12	73	83	O	differences
13	85	91	O	between
14	93	97	O	tumor
15	99	101	O	and
16	103	108	O	normal
17	110	114	O	cells
18	116	118	O	are
19	120	124	O	being
20	126	132	O	rapidly
21	134	143	O	identified
22	145	147	O	and
23	149	151	O	new
24	153	163	O	combination
25	165	173	O	therapies
26	175	178	O	that
27	180	183	O	take
28	185	193	O	advantage
29	195	196	O	of
30	198	202	O	these
31	204	214	O	differences
32	216	218	O	are
33	220	224	O	being
34	226	233	O	designed
35	235	237	O	and
36	239	244	O	tested
NULL

9120829.xml	DDI-MedLine.d113.s0	NO_SECTION	NO_SETID	11
Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
1	0	3	O	Acid
2	5	13	O	catalyzed
3	15	25	O	ethanolysis
4	27	28	O	of
5	30	38	U-UNK	temazepam
6	40	41	O	in
7	43	51	O	anhydrous
8	53	55	O	and
9	57	63	O	aqueous
10	65	71	U-UNK	ethanol
11	73	81	O	solutions
NULL

9120829.xml	DDI-MedLine.d113.s1	NO_SECTION	NO_SETID	10
The benzodiazepines are a family of anxiolytic and hypnotic drugs.
1	0	2	O	The
2	4	18	U-UNK	benzodiazepines
3	20	22	O	are
4	24	24	O	a
5	26	31	O	family
6	33	34	O	of
7	36	45	U-UNK	anxiolytic
8	47	49	O	and
9	51	58	B-UNK	hypnotic
10	60	64	L-UNK	drugs
NULL

9120829.xml	DDI-MedLine.d113.s2	NO_SECTION	NO_SETID	22
When taken concurrently with ethanol, a pharmacological interaction may occur, potentiating the central nervous system depression produced by either drug.
1	0	3	O	When
2	5	9	O	taken
3	11	22	O	concurrently
4	24	27	O	with
5	29	35	U-UNK	ethanol
6	36	36	O	,
7	38	38	O	a
8	40	54	O	pharmacological
9	56	66	O	interaction
10	68	70	O	may
11	72	76	O	occur
12	77	77	O	,
13	79	90	O	potentiating
14	92	94	O	the
15	96	102	O	central
16	104	110	O	nervous
17	112	117	O	system
18	119	128	O	depression
19	130	137	O	produced
20	139	140	O	by
21	142	147	O	either
22	149	152	O	drug
NULL

9120829.xml	DDI-MedLine.d113.s3	NO_SECTION	NO_SETID	36
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	18	O	this
5	20	34	O	pharmacological
6	36	46	O	interaction
7	47	47	O	,
8	49	52	O	this
9	54	59	O	report
10	61	69	O	describes
11	71	71	O	a
12	73	77	O	novel
13	79	86	O	chemical
14	88	95	O	reaction
15	97	103	O	between
16	105	113	U-UNK	temazepam
17	116	116	O	a
18	118	131	U-UNK	benzodiazepine
19	134	136	O	and
20	138	144	U-UNK	ethanol
21	146	150	O	under
22	152	157	O	acidic
23	159	168	O	conditions
24	170	176	O	similar
25	178	179	O	to
26	181	185	O	those
27	187	191	O	found
28	193	194	O	in
29	196	199	O	vivo
30	200	200	O	,
31	202	210	O	resulting
32	212	213	O	in
33	215	215	O	a
34	217	217	O	3
35	219	229	O	ethoxylated
36	231	237	O	product
NULL

9120829.xml	DDI-MedLine.d113.s4	NO_SECTION	NO_SETID	17
Optimal conditions, kinetics, equilibrium, and the mechanism of this acid-catalyzed ethanolysis are reported.
1	0	6	O	Optimal
2	8	17	O	conditions
3	18	18	O	,
4	20	27	O	kinetics
5	28	28	O	,
6	30	40	O	equilibrium
7	41	41	O	,
8	43	45	O	and
9	47	49	O	the
10	51	59	O	mechanism
11	61	62	O	of
12	64	67	O	this
13	69	72	O	acid
14	74	82	O	catalyzed
15	84	94	O	ethanolysis
16	96	98	O	are
17	100	107	O	reported
NULL

9120829.xml	DDI-MedLine.d113.s5	NO_SECTION	NO_SETID	28
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
1	0	2	O	The
2	4	10	O	results
3	12	16	O	raise
4	18	20	O	the
5	22	32	O	possibility
6	34	37	O	that
7	39	41	O	the
8	43	53	O	ethanolysis
9	55	62	O	reaction
10	64	66	O	may
11	68	72	O	occur
12	74	75	O	in
13	77	79	O	the
14	81	87	O	stomach
15	89	90	O	of
16	92	97	O	people
17	99	101	O	who
18	103	109	O	consume
19	111	117	U-UNK	alcohol
20	119	121	O	and
21	123	123	B-UNK	3
22	125	131	I-UNK	hydroxy
23	133	135	I-UNK	1,4
24	137	150	L-UNK	benzodiazepine
25	152	153	O	on
26	155	155	O	a
27	157	163	O	regular
28	165	169	O	basis
NULL

9120829.xml	DDI-MedLine.d113.s6	NO_SECTION	NO_SETID	20
The acid-catalyzed ethanol-drug reaction is a relatively unexplored area and may alter the pharmacological action of some drugs.
1	0	2	O	The
2	4	7	O	acid
3	9	17	O	catalyzed
4	19	25	U-UNK	ethanol
5	27	30	O	drug
6	32	39	O	reaction
7	41	42	O	is
8	44	44	O	a
9	46	55	O	relatively
10	57	66	O	unexplored
11	68	71	O	area
12	73	75	O	and
13	77	79	O	may
14	81	85	O	alter
15	87	89	O	the
16	91	105	O	pharmacological
17	107	112	O	action
18	114	115	O	of
19	117	120	O	some
20	122	126	O	drugs
NULL

